FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Bilimoria, KY
Liu, YM
Paruch, JL
Zhou, L
Kmiecik, TE
Ko, CY
Cohen, ME
AF Bilimoria, Karl Y.
Liu, Yaoming
Paruch, Jennifer L.
Zhou, Lynn
Kmiecik, Thomas E.
Ko, Clifford Y.
Cohen, Mark E.
TI Development and Evaluation of the Universal ACS NSQIP Surgical Risk
Calculator: A Decision Aid and Informed Consent Tool for Patients and
Surgeons
SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
LA English
DT Article; Proceedings Paper
CT Annual ACS NSQIP Conference
CY JUL, 2013
CL San Diego, CA
SP ACS
ID QUALITY IMPROVEMENT PROGRAM; AMERICAN-COLLEGE; COMPLICATIONS;
ADJUSTMENT; PREDICTION; HOSPITALS; MORTALITY; MODELS
AB BACKGROUND: Accurately estimating surgical risks is critical for shared decision making and informed consent. The Centers for Medicare and Medicaid Services may soon put forth a measure requiring surgeons to provide patients with patient-specific, empirically derived estimates of postoperative complications. Our objectives were to develop a universal surgical risk estimation tool, to compare performance of the universal vs previous procedure-specific surgical risk calculators, and to allow surgeons to empirically adjust the estimates of risk.
STUDY DESIGN: Using standardized clinical data from 393 ACS NSQIP hospitals, a web-based tool was developed to allow surgeons to easily enter 21 preoperative factors (demographics, comorbidities, procedure). Regression models were developed to predict 8 outcomes based on the preoperative risk factors. The universal model was compared with procedure-specific models. To incorporate surgeon input, a subjective surgeon adjustment score, allowing risk estimates to vary within the estimate's confidence interval, was introduced and tested with 80 surgeons using 10 case scenarios.
RESULTS: Based on 1,414,006 patients encompassing 1,557 unique CPT codes, a universal surgical risk calculator model was developed that had excellent performance for mortality (c-statistic = 0.944; Brier score = 0.011 [where scores approaching 0 are better]), morbidity (c-statistic = 0.816, Brier score = 0.069), and 6 additional complications (c-statistics > 0.8). Predictions were similarly robust for the universal calculator vs procedure-specific calculators (eg, colorectal). Surgeons demonstrated considerable agreement on the case scenario scoring (80% to 100% agreement), suggesting reliable score assignment between surgeons.
CONCLUSIONS: The ACS NSQIP surgical risk calculator is a decision-support tool based on reliable multi-institutional clinical data, which can be used to estimate the risks of most operations. The ACS NSQIP surgical risk calculator will allow clinicians and patients to make decisions using empirically derived, patient-specific postoperative risks. ((C) 2013 by the American College of Surgeons)
C1 [Bilimoria, Karl Y.; Liu, Yaoming; Paruch, Jennifer L.; Zhou, Lynn; Ko, Clifford Y.; Cohen, Mark E.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA.
[Bilimoria, Karl Y.; Kmiecik, Thomas E.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Surg Outcomes & Qual Improvement Ctr, Chicago, IL 60611 USA.
[Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA.
[Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Bilimoria, KY (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair St,22nd Floor, Chicago, IL 60611 USA.
EM kbilimoria@facs.org
FU NCATS NIH HHS [L30 TR000300]
NR 24
TC 151
Z9 151
U1 1
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1072-7515
EI 1879-1190
J9 J AM COLL SURGEONS
JI J. Am. Coll. Surg.
PD NOV
PY 2013
VL 217
IS 5
BP 833
EP +
DI 10.1016/j.jamcollsurg.2013.07.385
PG 13
WC Surgery
SC Surgery
GA 235YO
UT WOS:000325759500011
PM 24055383
ER
PT J
AU Raposo, RAS
Abdel-Mohsen, M
Bilska, M
Montefiori, DC
Nixon, DF
Pillai, SK
AF Raposo, Rui Andre Saraiva
Abdel-Mohsen, Mohamed
Bilska, Miroslawa
Montefiori, David C.
Nixon, Douglas F.
Pillai, Satish K.
TI Effects of Cellular Activation on Anti-HIV-1 Restriction Factor
Expression Profile in Primary Cells
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1 IN-VIVO; ANTIRETROVIRAL FACTOR;
TYPE-1 HIV-1; PROTEIN; INFECTION; REPLICATION; INHIBITION; RELEASE;
SAMHD1
AB Expression of cell-intrinsic antiviral factors suppresses HIV-1 replication. We hypothesized that cellular activation modulates host restriction and susceptibility to HIV-1 infection. We measured the gene expression of 34 antiviral factors in healthy peripheral blood mononuclear cells (PBMC). Cellular activation induced expression of interferon-stimulated gene 15 (ISG15), tripartite motif 5 alpha (TRIM5 alpha), bone marrow stromal cell antigen 2 (BST-2)/tetherin, and certain apolipoprotein B mRNA editing enzyme 3 (APOBEC3) family members. Expression of RTF1, RNA polymerase II-associated factor 1 (PAF1), TRIM11, TRIM26, and BST-2/tetherin correlated with decreased HIV-1 infectivity. This report demonstrates synchronous effects of activation-induced antiviral genes on HIV-1 infectivity, providing candidates for pharmacological manipulation.
C1 [Raposo, Rui Andre Saraiva; Nixon, Douglas F.] Univ Calif San Francisco, Div Expt Med, San Francisco, CA 94143 USA.
[Abdel-Mohsen, Mohamed; Pillai, Satish K.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Bilska, Miroslawa; Montefiori, David C.] Duke Univ, Med Ctr, Dept Surg, Lab AIDS Vaccine Res & Dev, Durham, NC 27710 USA.
[Pillai, Satish K.] Blood Syst Res Inst, San Francisco, CA USA.
[Pillai, Satish K.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA.
RP Raposo, RAS (reprint author), Univ Calif San Francisco, Div Expt Med, San Francisco, CA 94143 USA.
EM Andre.Raposo@ucsf.edu
OI Raposo, R. Andre/0000-0001-5435-0290; Nixon, Douglas/0000-0002-2801-1786
FU National Institutes of Health [AI093179, 1K01DA024654]; Peter and
Shelagh Godsoe Family Foundation through the AIDS Research Institute at
UCSF; UCSF-Gladstone Institute of Virology & Immunology Center for AIDS
Research [P30-AI027763]; Academic Senate under the UCSF RAP awards
program
FX This work was supported by grants from the National Institutes of Health
(AI093179 to D.F.N. and 1K01DA024654 to S. K. P.), the Peter and Shelagh
Godsoe Family Foundation through the AIDS Research Institute at UCSF (to
D.F.N.), and the UCSF-Gladstone Institute of Virology & Immunology
Center for AIDS Research (P30-AI027763 to R. A. S. R.) and in part by a
grant provided by the Academic Senate under the UCSF RAP awards program
(to D.F.N.).
NR 45
TC 17
Z9 17
U1 0
U2 7
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD NOV
PY 2013
VL 87
IS 21
BP 11924
EP 11929
DI 10.1128/JVI.02128-13
PG 6
WC Virology
SC Virology
GA 237IR
UT WOS:000325863400055
PM 23966394
ER
PT J
AU Amstadter, AB
Sumner, JA
Acierno, R
Ruggiero, KJ
Koenen, KC
Kilpatrick, DG
Galea, S
Gelernter, J
AF Amstadter, A. B.
Sumner, J. A.
Acierno, R.
Ruggiero, K. J.
Koenen, K. C.
Kilpatrick, D. G.
Galea, S.
Gelernter, J.
TI Support for association of RORA variant and post traumatic stress
symptoms in a population-based study of hurricane exposed adults
SO MOLECULAR PSYCHIATRY
LA English
DT Letter
ID GENOME-WIDE ASSOCIATION; POSTTRAUMATIC-STRESS; DISORDER; RISK
C1 [Amstadter, A. B.] Virginia Commonwealth Univ, Virginia Inst Psychiat & Behav Genet, Richmond, VA 23284 USA.
[Sumner, J. A.; Acierno, R.; Ruggiero, K. J.; Kilpatrick, D. G.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Acierno, R.; Ruggiero, K. J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
[Koenen, K. C.; Galea, S.] Columbia Univ, Dept Epidemiol, New York, NY USA.
[Gelernter, J.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
[Gelernter, J.] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA.
[Gelernter, J.] Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT USA.
[Gelernter, J.] VA CT Healthcare Ctr, West Haven, CT USA.
RP Amstadter, AB (reprint author), Virginia Commonwealth Univ, Virginia Inst Psychiat & Behav Genet, Richmond, VA 23284 USA.
EM abamstadter@vcu.edu
FU NIMH NIH HHS [R21 MH074469]
NR 10
TC 11
Z9 12
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1359-4184
EI 1476-5578
J9 MOL PSYCHIATR
JI Mol. Psychiatr.
PD NOV
PY 2013
VL 18
IS 11
BP 1148
EP 1149
DI 10.1038/mp.2012.189
PG 2
WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry
SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry
GA 240KN
UT WOS:000326094800001
PM 23319003
ER
PT J
AU Lam, TI
Bingham, D
Chang, TJ
Lee, CC
Shi, J
Wang, DM
Massa, S
Swanson, RA
Liu, JL
AF Lam, Tina I.
Bingham, Deborah
Chang, Ting Ju
Lee, Chih Cheng
Shi, Jian
Wang, Dongmin
Massa, Stephen
Swanson, Raymond A.
Liu, Jialing
TI Beneficial Effects of Minocycline and Botulinum Toxin-Induced Constraint
Physical Therapy Following Experimental Traumatic Brain Injury
SO NEUROREHABILITATION AND NEURAL REPAIR
LA English
DT Article
DE controlled cortical impact; constraint-induced movement therapy (CIMT);
botox; rehabilitation; microglia; glial fibrillary acidic protein (GFAP)
ID INDUCED MOVEMENT THERAPY; MICROGLIAL ACTIVATION; ANIMAL-MODELS; STROKE;
METAANALYSIS; CNS; MECHANISMS; PLASTICITY; DISORDERS; CHILDREN
AB Background. Effective recovery from functional impairments caused by traumatic brain injury (TBI) requires appropriate rehabilitation therapy. Multiple pathways are involved in secondary injury and recovery suggesting a role for multimodal approaches. Objective. Here, we examined the efficacy of the anti-inflammatory agent minocycline and botulinum toxin (botox)-induced limb constraint with structured physical therapy, delivered alone or in combination, after a severe TBI produced by a controlled cortical impact in rats. Methods. Minocycline was administered at 25 mg/kg daily for 2 weeks beginning 1 day after TBI or sham surgery. For constraint/physical therapy, botox-type A was injected into the nonaffected forearm muscle 1 day after injury and 2 weeks of physical therapy commenced at 5 days after injury. Functional evaluations were conducted 8 weeks after injury. Results. Minocycline, either as a monotherapy or as combination treatment with botox/physical therapy significantly reduced impairments of spatial learning and memory in the water maze test, whereas botox/physical therapy reduced forelimb motor asymmetry and improved manual dexterity in the cylinder and vermicelli handling tests, A synergistic effect between the 2 treatments was observed when rats performed tasks requiring dexterity. Inflammation was attenuated in the peri-contusion cortex and hippocampus in all TBI groups receiving mono or combination therapies, though there was no significant difference in lesion size among groups. Conclusion. These data provide a rationale for incorporating anti-inflammatory treatment during rehabilitation therapy.
C1 [Lam, Tina I.; Bingham, Deborah; Chang, Ting Ju; Lee, Chih Cheng; Shi, Jian; Wang, Dongmin; Massa, Stephen; Swanson, Raymond A.; Liu, Jialing] San Francisco VA Med Ctr, San Francisco, CA USA.
[Lam, Tina I.; Shi, Jian; Wang, Dongmin; Massa, Stephen; Swanson, Raymond A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
[Lam, Tina I.] USDA, Foodborne Contaminants Res Unit, Western Reg Res Ctr, Res Serv, Albany, CA USA.
[Bingham, Deborah; Chang, Ting Ju; Lee, Chih Cheng; Liu, Jialing] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA.
RP Liu, JL (reprint author), Univ Calif San Francisco, Dept Neurol Surg 112C, 4150 Clement St, San Francisco, CA 94121 USA.
EM jialing.liu@ucsf.edu
RI Liu, Jialing/A-8627-2012
OI Liu, Jialing/0000-0003-4420-4382; Swanson, Raymond/0000-0002-3664-5359
FU Veterans Affairs Research Enhancement Award; Veterans Affairs merit
awards
FX The author(s) disclosed receipt of the following financial support for
the research, authorship, and/or publication of this article: This work
was supported by a Veterans Affairs Research Enhancement Award (RAS),
and Veterans Affairs merit awards (JL, SM).].
NR 41
TC 14
Z9 14
U1 1
U2 12
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1545-9683
EI 1552-6844
J9 NEUROREHAB NEURAL RE
JI Neurorehabil. Neural Repair
PD NOV
PY 2013
VL 27
IS 9
BP 889
EP 899
DI 10.1177/1545968313491003
PG 11
WC Clinical Neurology; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA 229IL
UT WOS:000325256000013
PM 23778701
ER
PT J
AU Reis, JP
Launer, LJ
Terry, JG
Loria, CM
Al Hazzouri, AZ
Sidney, S
Yaffe, K
Jacobs, DR
Whitlow, CT
Zhu, N
Carr, JJ
AF Reis, Jared P.
Launer, Lenore J.
Terry, James G.
Loria, Catherine M.
Al Hazzouri, Adina Zeki
Sidney, Stephen
Yaffe, Kristine
Jacobs, David R., Jr.
Whitlow, Christopher T.
Zhu, Na
Carr, J. Jeffrey
TI Subclinical atherosclerotic calcification and cognitive functioning in
middle-aged adults: The CARDIA study
SO ATHEROSCLEROSIS
LA English
DT Article
DE Atherosclerosis; Cognition; Subclinical disease; Risk factors
ID CORONARY-ARTERY CALCIUM; DIABETES-MELLITUS; BLOOD-PRESSURE; DEMENTIA;
ASSOCIATION; IMPAIRMENT; MIDLIFE; HEALTH; RISK
AB Objective: Cardiovascular risk factors in middle-age are associated with cognitive impairment and dementia in older age. Less is known about the burden of calcified subclinical atherosclerosis and cognition, especially in midlife. We examined the association of coronary artery and abdominal aortic calcified plaque (CAC and AAC, respectively) with cognitive functioning in middle-aged adults.
Methods: This cross-sectional study included 2510 black and white adults (age: 43-55 years) without heart disease or stroke who completed a year 25 follow-up exam (2010-11) as part of the Coronary Artery Risk Development in Young Adults Study. CAC and AAC were measured with non-contrast computed tomography. Cognition was assessed with the Digit Symbol Substitution Test (DSST) (psychomotor speed), Stroop Test (executive function), and Rey Auditory Verbal Learning Test (RAVLT) (verbal memory).
Results: A greater amount of CAC and AAC was associated with worse performance on each test of cognitive function after adjustment for age, sex, race, education, and study center. Associations were attenuated, but remained significant for the DSST and RAVLT following additional adjustment for vascular risk factors, including adiposity, smoking, alcohol use, dyslipidemia, hypertension, and diabetes. Compared to participants without CAC or AAC, those with both CAC and AAC, but not CAC or AAC alone was associated with lower DSST scores (p < 0.05).
Conclusions: In this community-based sample, greater subclinical atherosclerotic calcification was associated with worse psychomotor speed and memory in midlife. These findings underscore the importance of a life course approach to the study of cognitive impairment with aging. Published by Elsevier Ireland Ltd.
C1 [Reis, Jared P.; Loria, Catherine M.] NHLBI, Div Cardiovasc Sci, Bethesda, MD 20892 USA.
[Launer, Lenore J.] NIA, Lab Epidemiol Demog & Biometry, Bethesda, MD 20892 USA.
[Terry, James G.; Whitlow, Christopher T.; Carr, J. Jeffrey] Wake Forest Univ, Bowman Gray Sch Med, Dept Radiol, Winston Salem, NC USA.
[Al Hazzouri, Adina Zeki; Yaffe, Kristine] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA.
[Sidney, Stephen] Kaiser Permanente No Calif, Div Res, Oakland, CA USA.
[Jacobs, David R., Jr.; Zhu, Na] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA.
[Jacobs, David R., Jr.] Univ Oslo, Dept Nutr, Oslo, Norway.
RP Reis, JP (reprint author), NHLBI, Div Cardiovasc Sci, 6701 Rockledge Dr,Suite 10197, Bethesda, MD 20892 USA.
EM reisjp@mail.nih.gov
RI Carr, John/A-1938-2012
OI Carr, John/0000-0002-4398-8237
FU National Heart, Lung, and Blood Institute [N01-HC95095, N01-HC48047,
N01-HC48050, N01-HC48049, N01-HC48048, R01-HL098445]
FX The Coronary Risk Development in Young Adults Study is conducted and
supported by the National Heart, Lung, and Blood Institute (N01-HC95095,
N01-HC48047, N01-HC48050, N01-HC48049, N01-HC48048, R01-HL098445).
NR 29
TC 13
Z9 13
U1 0
U2 10
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD NOV
PY 2013
VL 231
IS 1
BP 72
EP 77
DI 10.1016/j.atherosclerosis.2013.08.038
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 235XH
UT WOS:000325755300014
PM 24125414
ER
PT J
AU Millett, F
Havens, J
Rajagukguk, S
Durham, B
AF Millett, Francis
Havens, Jeffrey
Rajagukguk, Sany
Durham, Bill
TI Design and use of photoactive ruthenium complexes to study electron
transfer within cytochrome bc(1) and from cytochrome bc(1) to cytochrome
c
SO BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS
LA English
DT Review
DE Cytochrome bc(1); Cytochrome c; Electron transfer; Ruthenium
ID IRON-SULFUR PROTEIN; FE-S PROTEIN; PHOTOSYNTHETIC REACTION-CENTER;
QUINOL OXIDATION SITE; PROTONMOTIVE Q-CYCLE; DOMAIN MOVEMENT; Q(O) SITE;
RHODOBACTER-SPHAEROIDES; PARACOCCUS-DENITRIFICANS; BC1 COMPLEX
AB The cytochrome bc(1) complex (ubiquinone:cytochrome c oxidoreductase) is the central integral membrane protein in the mitochondrial respiratory chain as well as the electron-transfer chains of many respiratory and photosynthetic prokaryotes. Based on X-ray crystallographic studies of cytochrome bc(1), a mechanism has been proposed in which the extrinsic domain of the iron-sulfur protein first binds to cytochrome b where it accepts an electron from ubiquinol in the Q(o) site, and then rotates by 57 degrees to a position close to cytochrome c(1) where it transfers an electron to cytochrome c(1). This review describes the development of a ruthenium photooxidation technique to measure key electron transfer steps in cytochrome bc(1), including rapid electron transfer from the iron-sulfur protein to cytochrome c(1). It was discovered that this reaction is rate-limited by the rotational dynamics of the iron-sulfur protein rather than true electron transfer. A conformational linkage between the occupant of the Q(o) ubiquinol binding site and the rotational dynamics of the iron-sulfur protein was discovered which could play a role in the bifurcated oxidation of ubiquinol. A ruthenium photoexcitation method is also described for the measurement of electron transfer from cytochrome c(1) to cytochrome c. This article is part of a Special Issue entitled: Respiratory Complex III and related bc complexes. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Millett, Francis; Havens, Jeffrey; Durham, Bill] Univ Arkansas, Dept Chem & Biochem, Fayetteville, AR 72701 USA.
[Rajagukguk, Sany] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
RP Millett, F (reprint author), Univ Arkansas, Dept Chem & Biochem, Fayetteville, AR 72701 USA.
EM millett@uark.edu; jahavens@uark.edu; sany.rajagukguk@gmail.com;
bdurham@uark.edu
FU NIH [GM20488, 8P30GM103450]
FX This work was supported in part by NIH grants GM20488 and 8P30GM103450.
NR 112
TC 10
Z9 10
U1 9
U2 50
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0005-2728
EI 0006-3002
J9 BBA-BIOENERGETICS
JI Biochim. Biophys. Acta-Bioenerg.
PD NOV-DEC
PY 2013
VL 1827
IS 11-12
SI SI
BP 1309
EP 1319
DI 10.1016/j.bbabio.2012.09.002
PG 11
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 232RA
UT WOS:000325510500005
PM 22985600
ER
PT J
AU Felts, AS
Rodriguez, AL
Morrison, RD
Venable, DF
Manka, JT
Bates, BS
Blobaum, AL
Byers, FW
Daniels, JS
Niswender, CM
Jones, CK
Conn, PJ
Lindsley, CW
Emmitte, KA
AF Felts, Andrew S.
Rodriguez, Alice L.
Morrison, Ryan D.
Venable, Daryl F.
Manka, Jason T.
Bates, Brittney S.
Blobaum, Anna L.
Byers, Frank W.
Daniels, J. Scott
Niswender, Colleen M.
Jones, Carrie K.
Conn, P. Jeffrey
Lindsley, Craig W.
Emmitte, Kyle A.
TI Discovery of VU0409106: A negative allosteric modulator of mGlu(5) with
activity in a mouse model of anxiety
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Glutamate; CNS; mGlu(5); Allosteric modulator; Anxiety
ID MGLUR5 ANTAGONIST MPEP; METABOTROPIC GLUTAMATE-RECEPTOR-5 ANTAGONIST;
ESOPHAGEAL SPHINCTER RELAXATIONS; CUE-INDUCED REINSTATEMENT; RECEPTOR
SUBTYPE 5; GLUTAMATE RECEPTORS; GASTROESOPHAGEAL-REFLUX;
NUCLEUS-ACCUMBENS; SQUIRREL-MONKEYS; SEEKING BEHAVIOR
AB Development of SAR in an aryl ether series of mGlu(5) NAMs leading to the identification of tool compound VU0409106 is described in this Letter. VU0409106 is a potent and selective negative allosteric modulator of mGlu5 that binds at the known allosteric binding site and demonstrates good CNS exposure following intraperitoneal dosing in mice. VU0409106 also proved efficacious in a mouse marble burying model of anxiety, an assay known to be sensitive to mGlu(5) antagonists as well as clinically efficacious anxiolytics. (c) 2013 Elsevier Ltd. All rights reserved.
C1 [Felts, Andrew S.; Rodriguez, Alice L.; Morrison, Ryan D.; Venable, Daryl F.; Manka, Jason T.; Bates, Brittney S.; Blobaum, Anna L.; Byers, Frank W.; Daniels, J. Scott; Niswender, Colleen M.; Jones, Carrie K.; Conn, P. Jeffrey; Lindsley, Craig W.; Emmitte, Kyle A.] Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Neurosci Drug Discovery, Nashville, TN 37232 USA.
[Felts, Andrew S.; Rodriguez, Alice L.; Morrison, Ryan D.; Venable, Daryl F.; Manka, Jason T.; Bates, Brittney S.; Blobaum, Anna L.; Byers, Frank W.; Daniels, J. Scott; Niswender, Colleen M.; Jones, Carrie K.; Conn, P. Jeffrey; Lindsley, Craig W.; Emmitte, Kyle A.] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA.
[Lindsley, Craig W.; Emmitte, Kyle A.] Vanderbilt Univ, Dept Chem, Nashville, TN 37232 USA.
[Jones, Carrie K.] US Dept Vet Affairs, Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA.
RP Emmitte, KA (reprint author), Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Neurosci Drug Discovery, Nashville, TN 37232 USA.
EM kyle.a.emmitte@Vanderbilt.edu
FU NIDA [RO1 DA023947]; Seaside Therapeutics [VUMC33842]
FX We thank NIDA (RO1 DA023947) and Seaside Therapeutics (VUMC33842) for
their support of our programs in the development of noncompetitive
antagonist of mGlu5. We also thank Tammy S. Santomango for
technical contributions with the protein binding assays.
NR 71
TC 12
Z9 12
U1 0
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
EI 1464-3405
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD NOV 1
PY 2013
VL 23
IS 21
BP 5779
EP 5785
DI 10.1016/j.bmcl.2013.09.001
PG 7
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 232HH
UT WOS:000325483000003
PM 24074843
ER
PT J
AU Musher, DM
Sandvall, BP
Rueda, AM
AF Musher, Daniel M.
Sandvall, Barcleigh P.
Rueda, Adriana M.
TI Long-term Survival in Community-Acquired Pneumonia Caused by Other
Bacteria Than Pneumococci Is Impaired More Than in Pneumococcal
Pneumonia: Effect of Underlying Disease? Reply
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Letter
C1 [Musher, Daniel M.; Rueda, Adriana M.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Musher, Daniel M.; Sandvall, Barcleigh P.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
RP Musher, DM (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
NR 1
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD NOV 1
PY 2013
VL 57
IS 9
BP 1371
EP 1371
DI 10.1093/cid/cit509
PG 1
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 235ZM
UT WOS:000325762500035
PM 23929888
ER
PT J
AU Lu, ZY
Li, YC
Samuvel, DJ
Jin, JF
Zhang, XM
Lopes-Virella, MF
Huang, Y
AF Lu, Zhongyang
Li, Yanchun
Samuvel, Devadoss J.
Jin, Junfei
Zhang, Xiaoming
Lopes-Virella, Maria F.
Huang, Yan
TI MD-2 is involved in the stimulation of matrix metalloproteinase-1
expression by interferon-gamma and high glucose in mononuclear cells - a
potential role of MD-2 in Toll-like receptor 4-independent signalling
SO IMMUNOLOGY
LA English
DT Article
DE inflammation; interferon-; MD-2; mononuclear cells; Toll-like receptor
ID GRAM-NEGATIVE BACTERIA; NECROSIS-FACTOR-ALPHA; E-DEFICIENT MICE;
LIPOPOLYSACCHARIDE-RECOGNITION; TRANSCRIPTION FACTOR; MMP-1 EXPRESSION;
IFN-GAMMA; LPS; ACTIVATION; TLR4
AB We reported recently that treatment of diabetic apolipoprotein E-deficient mice with the Toll-like receptor 4 (TLR4) antagonist Rs-LPS, a lipopolysaccharide isolated from Rhodobacter sphaeroides, inhibited atherosclerosis. Since it is known that Rs-LPS antagonizes TLR4 by targeting TLR4 co-receptor MD-2, this finding indicates that MD-2 is a potential target for the treatment of atherosclerosis. In this study, we determined if MD-2 is involved in the gene expression regulated by signalling pathways independent of TLR4. Given that interferon- (IFN) and hyperglycaemia play key roles in atherosclerosis, we determined if MD-2 is involved in IFN- and high-glucose-regulated gene expression in mononuclear cells. Results showed that IFN- and high glucose synergistically stimulated matrix metalloproteinase 1 (MMP-1), a proteinase essential for vascular tissue remodelling and atherosclerosis, in U937 mononuclear cells, but Rs-LPS inhibited the MMP-1 stimulation. To provide more evidence for a role of MD-2 in IFN--stimulated MMP-1, studies using antibodies and small interfering RNA demonstrated that MD-2 blockade or knockdown attenuated the effect of IFN- on MMP-1. Furthermore, studies using PCR arrays showed that MD-2 blockade had a similar effect as IFN- receptor blockade on the inhibition of IFN--stimulated pro-inflammatory molecules. Although these findings indicate the involvement of MD-2 in IFN- signalling, we also observed that MD-2 was up-regulated by IFN- and high glucose. We found that MD-2 up-regulation by IFN- played an essential role in the synergistic effect of IFN- and LPS on MMP-1 expression. Taken together, these findings indicate that MD-2 is involved in IFN- signalling and IFN--augmented MMP-1 up-regulation by LPS.
C1 [Lu, Zhongyang; Li, Yanchun; Samuvel, Devadoss J.; Jin, Junfei; Zhang, Xiaoming; Lopes-Virella, Maria F.; Huang, Yan] Med Univ S Carolina, Coll Med, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29403 USA.
[Lopes-Virella, Maria F.; Huang, Yan] Ralph H Johnson Vet Affairs Med Ctr, Dept Vet Affairs, Charleston, SC USA.
RP Huang, Y (reprint author), Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, 114 Doughty St, Charleston, SC 29403 USA.
EM huangyan@musc.edu
FU Biomedical Laboratory Research and Development Program of the Department
of Veterans Affairs; NIH [DE016353]
FX This work was supported by the Biomedical Laboratory Research and
Development Program of the Department of Veterans Affairs and by NIH
grant DE016353 (to Y.H.). This study was presented as an abstract at the
72nd American Diabetes Association Scientific Sessions, in Philadelphia,
PA, 8 12 June 2012.
NR 42
TC 3
Z9 3
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0019-2805
EI 1365-2567
J9 IMMUNOLOGY
JI Immunology
PD NOV
PY 2013
VL 140
IS 3
BP 301
EP 313
DI 10.1111/imm.12138
PG 13
WC Immunology
SC Immunology
GA 229JN
UT WOS:000325259200003
PM 23800176
ER
PT J
AU Teodorescu, M
Polomis, DA
Gangnon, RE
Consens, FB
Chervin, RD
Teodorescu, MC
AF Teodorescu, Mihaela
Polomis, David A.
Gangnon, Ronald E.
Consens, Flavia B.
Chervin, Ronald D.
Teodorescu, Mihai C.
TI Sleep duration, asthma and obesity
SO JOURNAL OF ASTHMA
LA English
DT Article
DE Obesity; mechanisms
ID WEIGHT-GAIN; PROSPECTIVE COMMUNITY; UNITED-STATES; LEPTIN LEVELS;
YOUNG-ADULTS; ASSOCIATION; WOMEN; QUALITY; RISK; CHILDREN
AB Background: Obesity is more prevalent in asthmatics. Sleep duration is a novel risk factor for obesity in general populations. Objective: We tested the association of sleep duration and asthma characteristics with obesity. Methods: Adults at tertiary clinics were surveyed on asthma symptoms and habitual sleep duration. Medical records were used to assess asthma severity step (1-4), extract height and weight, current medications and diagnosed comorbid conditions. BMI >= 30 kg/m(2) defined obesity. Habitual sleep was categorized as <6 (very short), 6 to <7 h (short), 7-8 h (normal), >8 to <= 9 h (long) and >9 h (very long). Inhaled corticosteroid doses were categorized as low, moderate and high. Results: Among 611 participants (mean BMI 30 +/- 8), 249 (41%) were obese. After adjustment for covariates, obesity was associated with short and very long sleep: as compared to normal sleepers, the odds of being obese were on an average 66% higher ([95% CI: 1.07-2.57], p = 0.02) among short and 124% higher ([1.08-1.65], p = 0.03) among very long sleepers, and the association with very short sleep approached significance (1.74 [0.96-3.14], p = 0.06). Obesity was also significantly related to highest asthma step (1.87 [1.09-3.21], p = 0.02) and psychopathology (1.64 [1.08-2.48], p = 0.02), and a trend was seen with high-dose inhaled corticosteroids (1.82 [0.93-3.56], p = 0.08). Conclusions: Obesity in asthmatics is associated with shorter and very long sleep duration, worse asthma severity, psychopathology and high-dose inhaled corticosteroids. Although this cross-sectional study cannot prove causality, we speculate that further investigation of sleep may provide new opportunities to reduce the rising prevalence of obesity among asthmatics.
C1 [Teodorescu, Mihaela] William S Middleton Mem Vet Adm Med Ctr, Med Serv, James B Skatrud Pulm Sleep Res Lab, Madison, WI USA.
[Teodorescu, Mihaela; Polomis, David A.] Univ Wisconsin, Sch Med & Publ Hlth, Div Allergy Pulm & Crit Care Med, Madison, WI 53792 USA.
[Teodorescu, Mihaela; Teodorescu, Mihai C.] Univ Wisconsin, Sch Med & Publ Hlth, Ctr Sleep Med & Sleep Res Wisconsin Sleep, Madison, WI 53792 USA.
[Gangnon, Ronald E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI 53792 USA.
[Gangnon, Ronald E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI 53792 USA.
[Consens, Flavia B.; Chervin, Ronald D.] Univ Michigan Hlth Syst, Dept Neurol, Ann Arbor, MI USA.
[Consens, Flavia B.; Chervin, Ronald D.] Univ Michigan Hlth Syst, Sleep Disorders Ctr, Ann Arbor, MI USA.
[Teodorescu, Mihai C.] Univ Wisconsin, Sch Med & Publ Hlth, Div Geriatr & Gerontol, Madison, WI 53792 USA.
RP Teodorescu, M (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Div Allergy Pulm & Crit Care Med, K4-910 CSC 9988,600 Highland Ave, Madison, WI 53792 USA.
EM mt3@medicine.wisc.edu
FU University of Wisconsin School of Medicine and Public Health, Department
of Medicine and Medical Education and Research Committee - New
Investigator Award; Clinical and Translational Science Award (CTSA)
program of the National Center for Research Resources, National
Institutes of Health for asthma- sleep apnea research [1UL1RR025011];
National Institutes of Health; Fox Foundation; Philips Respironics,
Inc.; Fisher Paykel, Inc.
FX MT received funding from the University of Wisconsin School of Medicine
and Public Health, Department of Medicine and Medical Education and
Research Committee - New Investigator Award, and 1UL1RR025011 from the
Clinical and Translational Science Award (CTSA) program of the National
Center for Research Resources, National Institutes of Health for asthma-
sleep apnea research. DAP, REG, FBC and MCT have no relationships to
disclose. RDC has received research support from the National Institutes
of Health and Fox Foundation; has served on advisory boards for Pavad
Medical, not-for-profit Sweet Dreamzzz, and the NHLBI (Sleep Disorders
Research Advisory Board); is a section editor for UpToDate, Inc.;
received support for educational purposes from Philips Respironics, Inc.
and Fisher Paykel, Inc.; has consulted for Arena Pharmaceuticals,
Proctor & Gamble, and Zansors; serves on boards of directors for the
American Academy of Sleep Medicine and the International Pediatric Sleep
Association and is named in University of Michigan patents for
algorithms and devices to facilitate diagnosis and treatment of sleep
disorders. No scientific writing assistance was used for this article.
The contents of this article do not represent the views of the
Department of Veterans Affairs or the United States Government.
NR 50
TC 4
Z9 4
U1 2
U2 8
PU INFORMA HEALTHCARE
PI NEW YORK
PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA
SN 0277-0903
EI 1532-4303
J9 J ASTHMA
JI J. Asthma
PD NOV
PY 2013
VL 50
IS 9
BP 945
EP 953
DI 10.3109/02770903.2013.831871
PG 9
WC Allergy; Respiratory System
SC Allergy; Respiratory System
GA 236AS
UT WOS:000325766500005
PM 23923994
ER
PT J
AU Chapman, EN
Kaatz, A
Carnes, M
AF Chapman, Elizabeth N.
Kaatz, Anna
Carnes, Molly
TI Physicians and Implicit Bias: How Doctors May Unwittingly Perpetuate
Health Care Disparities
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE implicit bias; health care disparities; physicians
ID ACUTE MYOCARDIAL-INFARCTION; EMERGENCY-DEPARTMENT; KNEE ARTHROPLASTY;
MEDICAL-STUDENTS; ASSOCIATION TEST; BLACK PATIENTS; GENDER BIAS; RACE;
ATTITUDES; PAIN
AB Although the medical profession strives for equal treatment of all patients, disparities in health care are prevalent. Cultural stereotypes may not be consciously endorsed, but their mere existence influences how information about an individual is processed and leads to unintended biases in decision-making, so called "implicit bias". All of society is susceptible to these biases, including physicians. Research suggests that implicit bias may contribute to health care disparities by shaping physician behavior and producing differences in medical treatment along the lines of race, ethnicity, gender or other characteristics. We review the origins of implicit bias, cite research documenting the existence of implicit bias among physicians, and describe studies that demonstrate implicit bias in clinical decision-making. We then present the bias-reducing strategies of consciously taking patients' perspectives and intentionally focusing on individual patients' information apart from their social group. We conclude that the contribution of implicit bias to health care disparities could decrease if all physicians acknowledged their susceptibility to it, and deliberately practiced perspective-taking and individuation when providing patient care. We further conclude that increasing the number of African American/Black physicians could reduce the impact of implicit bias on health care disparities because they exhibit significantly less implicit race bias.
C1 [Chapman, Elizabeth N.; Carnes, Molly] Univ Wisconsin, Dept Med, Madison, WI USA.
[Carnes, Molly] Univ Wisconsin, Dept Psychiat, Madison, WI 53706 USA.
[Carnes, Molly] Univ Wisconsin, Madison, WI 53706 USA.
[Kaatz, Anna; Carnes, Molly] Univ Wisconsin, Ctr Womens Hlth Res, Madison, WI 53706 USA.
[Chapman, Elizabeth N.; Carnes, Molly] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI 53705 USA.
RP Chapman, EN (reprint author), William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison VA GRECC, 2500 Overlook Terrace, Madison, WI 53705 USA.
EM echapman@uwhealth.org
FU NIH [R01 GM088477, DP4 GM096822]
FX Dr. Chapman is a Geriatric Fellow at the Madison GRECC and Dr. Kaatz is
a postdoctoral fellow at the Center for Women's Health Research. This is
GRECC Manuscript No. 2013-14. Dr. Carnes's research on implicit bias is
supported by NIH grant no. R01 GM088477 and DP4 GM096822.
NR 61
TC 52
Z9 52
U1 13
U2 48
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD NOV
PY 2013
VL 28
IS 11
BP 1504
EP 1510
DI 10.1007/s11606-013-2441-1
PG 7
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 236DQ
UT WOS:000325774800026
PM 23576243
ER
PT J
AU Bayrak, OF
Gulluoglu, S
Aydemir, E
Ture, U
Acar, H
Atalay, B
Demir, Z
Sevli, S
Creighton, CJ
Ittmann, M
Sahin, F
Ozen, M
AF Bayrak, Omer Faruk
Gulluoglu, Sukru
Aydemir, Esra
Ture, Ugur
Acar, Hasan
Atalay, Basar
Demir, Zeynel
Sevli, Serhat
Creighton, Chad J.
Ittmann, Michael
Sahin, Fikrettin
Ozen, Mustafa
TI MicroRNA expression profiling reveals the potential function of
microRNA-31 in chordomas
SO JOURNAL OF NEURO-ONCOLOGY
LA English
DT Article
DE Chordoma; hsa-miR-31; Microarray; miRNA; Nucleus pulposus; Skull base
ID MET; PROLIFERATION; CANCER; CELLS; DIFFERENTIATION; MIGRATION; SURVIVAL;
RADIXIN; MIR-31; TUMORS
AB Chordomas are rare bone tumors arising from remnants of the notochord. Molecular studies to determine the pathways involved in their pathogenesis and develop better treatments are limited. Alterations in microRNAs (miRNAs) play important roles in cancer. miRNAs are small RNA sequences that affect transcriptional and post-transcriptional regulation of gene expression in most eukaryotic organisms. Studies show that miRNA dysregulation is important for tumor initiation and progression. We compared the expression profile of miRNAs in chordomas to that of healthy nucleus pulposus samples to gain insight into the molecular pathogenesis of chordomas. Results of functional studies on one of the altered miRNAs, miR-31, are presented. The comparison between the miRNA profile of chordoma samples and the profile of normal nucleus pulposus samples suggests dysregulation of 53 miRNAs. Thirty miRNAs were upregulated in our tumor samples, while 23 were downregulated. Notably, hsa-miR-140-3p and hsa-miR-148a were upregulated in most chordomas relative to levels in nucleus pulposus cells. Two other miRNAs, hsa-miR-31 and hsa-miR-222, were downregulated in chordomas compared with the control group. Quantification with real-time polymerase chain reaction confirmed up or downregulation of these miRNAs among all samples. Functional analyses showed that hsa-miR-31 has an apoptotic effect on chordoma cells and downregulates the expression of c-MET and radixin. miRNA profiling showed that hsa-miR-31, hsa-miR-222, hsa-miR-140-3p and hsa-miR-148a are differentially expressed in chordomas compared with healthy nucleus pulposus. Our profiling may be the first step toward delineating the differential regulation of cancer-related genes in chordomas, helping to reveal the mechanisms of initiation and progression.
C1 [Bayrak, Omer Faruk; Gulluoglu, Sukru; Aydemir, Esra] Yeditepe Univ, Sch Med, Dept Med Genet, Istanbul, Turkey.
[Bayrak, Omer Faruk; Gulluoglu, Sukru; Aydemir, Esra] Yeditepe Univ Hosp, Istanbul, Turkey.
[Gulluoglu, Sukru; Aydemir, Esra; Sevli, Serhat; Sahin, Fikrettin] Yeditepe Univ, Inst Sci, Dept Biotechnol, Istanbul, Turkey.
[Ture, Ugur; Atalay, Basar] Yeditepe Univ Hosp, Dept Neurosurg, Istanbul, Turkey.
[Acar, Hasan] Selcuklu Med Sch, Dept Med Genet, Konya, Turkey.
[Creighton, Chad J.; Ittmann, Michael; Ozen, Mustafa] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA.
[Creighton, Chad J.; Ittmann, Michael; Ozen, Mustafa] Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA.
[Creighton, Chad J.; Ittmann, Michael; Ozen, Mustafa] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA.
[Ittmann, Michael] Michael E DeBakey Dept Vet Affairs Med Ctr, Houston, TX USA.
[Ozen, Mustafa] Istanbul Univ, Cerrahpasa Med Sch, Dept Med Genet, TR-3409 Istanbul, Turkey.
RP Ozen, M (reprint author), Istanbul Univ, Cerrahpasa Med Sch, Dept Med Genet, TR-3409 Istanbul, Turkey.
EM mozen@bcm.edu
OI Bayrak, Omer Faruk/0000-0001-7562-6604
NR 28
TC 14
Z9 15
U1 0
U2 14
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-594X
EI 1573-7373
J9 J NEURO-ONCOL
JI J. Neuro-Oncol.
PD NOV
PY 2013
VL 115
IS 2
BP 143
EP 151
DI 10.1007/s11060-013-1211-6
PG 9
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 236TJ
UT WOS:000325821900002
PM 23912551
ER
PT J
AU Wang, HW
Xu, JJ
Grindle, G
Vazquez, J
Salatin, B
Kelleher, A
Ding, D
Collins, DM
Cooper, RA
AF Wang, Hongwu
Xu, Jijie
Grindle, Garrett
Vazquez, Juan
Salatin, Ben
Kelleher, Annmarie
Ding, Dan
Collins, Diane M.
Cooper, Rory A.
TI Performance evaluation of The Personal Mobility and Manipulation
Appliance (PerMMA)
SO MEDICAL ENGINEERING & PHYSICS
LA English
DT Article
DE Assistive robot; Powered mobility; Wheelchair mounted robotic arm;
Remote operator; Cooperative control; Performance evaluation; Personal
assistance
ID MOUNTED ROBOTIC ARM; WHEELCHAIR; INTERFACE; DESIGN; MANUS
AB The Personal Mobility and Manipulation Appliance (PerMMA) is a recently developed personal assistance robot created to provide people with severe physical disabilities enhanced assistance in both mobility and manipulation. PerMMA aims to improve functional independence when a personal care attendant is not available on site. PerMMA integrates both a smart powered wheelchair and two dexterous robotic arms to assist its users in completing essential mobility and manipulation tasks during basic and instrumental activities of daily living (ADL). Two user interfaces were developed: a local control interface and a remote operator controller. This paper reports on the evaluation of PerMMA with end users completing basic ADL tasks. Participants with both lower and upper extremity impairments (N = 15) were recruited to operate PerMMA and complete up to five ADL tasks in a single session of no more than two hours (to avoid fatigue or frustration of the participants). The performance of PerMMA was evaluated by participants completing ADL tasks with two different control modes: local mode and cooperative control. The users' task completion performance and answers on pre/post-evaluation questionnaires demonstrated not only the ease in learning and usefulness of PerMMA, but also their attitudes toward assistance from advanced technology like PerMMA. As a part of the iterative development process, results of this work will serve as supporting evidence to identify design criteria and other areas for improvement of PerMMA. (C) 2013 IPEM. Published by Elsevier Ltd. All rights reserved.
C1 [Wang, Hongwu; Xu, Jijie; Grindle, Garrett; Vazquez, Juan; Salatin, Ben; Kelleher, Annmarie; Ding, Dan; Cooper, Rory A.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA.
[Wang, Hongwu; Xu, Jijie; Grindle, Garrett; Vazquez, Juan; Salatin, Ben; Kelleher, Annmarie; Ding, Dan; Collins, Diane M.; Cooper, Rory A.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA.
[Kelleher, Annmarie] Univ Pittsburgh, Med Ctr, Ctr Assist Technol, Pittsburgh, PA USA.
RP Wang, HW (reprint author), Human Engn Res Labs, 6425 Penn Ave,Suite 400, Pittsburgh, PA 15206 USA.
EM how11@pitt.edu
FU National Science Foundation [EEC-540865]; Office of Research and
Development, Rehabilitation Research & Development Service, Department
of Veterans Affairs [B3142C, B6789C]; National Institute for Disability
and Rehabilitation Research [H133P09001002]
FX This material is based upon work supported in part by the National
Science Foundation Grant#EEC-540865, Office of Research and Development,
Rehabilitation Research & Development Service, Department of Veterans
Affairs, Grant#B3142C and #B6789C, and National Institute for Disability
and Rehabilitation Research Grant# H133P09001002.
NR 28
TC 5
Z9 5
U1 1
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1350-4533
EI 1873-4030
J9 MED ENG PHYS
JI Med. Eng. Phys.
PD NOV
PY 2013
VL 35
IS 11
BP 1613
EP 1619
DI 10.1016/j.medengphy.2013.05.008
PG 7
WC Engineering, Biomedical
SC Engineering
GA 233SV
UT WOS:000325590700009
PM 23769146
ER
PT J
AU Carrion, I
Nedjat-Haiem, F
Macip-Billbe, M
AF Carrion, Iraida
Nedjat-Haiem, Frances
Macip-Billbe, Melania
TI Coping Strategies Among Latino Men and Women With a Cancer Diagnosis
Living in the U.S
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Carrion, Iraida; Macip-Billbe, Melania] Univ S Florida, Tampa, FL USA.
[Nedjat-Haiem, Frances] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD NOV
PY 2013
VL 22
SU 3
SI SI
BP 43
EP 44
PG 2
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA 235AS
UT WOS:000325687200065
ER
PT J
AU Horan, WP
Hajcak, G
Wynn, JK
Green, MF
AF Horan, W. P.
Hajcak, G.
Wynn, J. K.
Green, M. F.
TI Impaired emotion regulation in schizophrenia: evidence from
event-related potentials
SO PSYCHOLOGICAL MEDICINE
LA English
DT Article
DE Emotion regulation; event-related potentials (ERPs); late positive
potential; schizophrenia
ID PSYCHIATRIC RATING-SCALE; QUALITY-ASSURANCE; CONTEXT; REAPPRAISAL;
PICTURES; DEFICITS; CONSEQUENCES; INTELLIGENCE; NEUROLEPTICS;
DYSFUNCTION
AB Background. Although several aspects of emotion seem to be intact in schizophrenia, there is emerging evidence that patients show an impaired ability to adaptively regulate their emotions. This event-related potential (ERP) study examined whether schizophrenia is associated with impaired neural responses to appraisal frames, that is when negative stimuli are presented in a less negative context.
Method. Thirty-one schizophrenia out-patients and 27 healthy controls completed a validated picture-viewing task with three conditions: (1) neutral pictures preceded by neutral descriptions ('Neutral'), (2) unpleasant pictures preceded by negative descriptions ('Preappraised negative'), and (3) unpleasant pictures preceded by more neutral descriptions ('Preappraised neutral' Analyses focused on the late positive potential (LPP), an index of facilitated attention to emotional stimuli that is reduced following cognitive emotion regulation strategies, during four time windows from 300 to 2000 ms post-picture onset.
Results. Replicating prior studies, controls showed smaller LPP in Preappraised neutral and Neutral versus Preappraised negative conditions throughout the 300-2000-ms time period. By contrast, patients showed (a) larger LPP in Preappraised neutral and Preappraised negative versus Neutral conditions in the initial period (300-600 ms) and (b) an atypical pattern of larger LPP to Preappraised neutral versus Preappraised negative and Neutral conditions in the 600-1500-ms epochs.
Conclusions. Modulation of neural responses by a cognitive emotion regulation strategy seems to be impaired in schizophrenia during the first 2 s after exposure to unpleasant stimuli.
C1 [Horan, W. P.; Wynn, J. K.; Green, M. F.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Hajcak, G.] SUNY Stony Brook, Stony Brook, NY 11794 USA.
RP Horan, WP (reprint author), Univ Calif Los Angeles, MIRECC 210A,Bldg 210,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM horan@ucla.edu
RI Wynn, Jonathan/H-3749-2014
OI Wynn, Jonathan/0000-0002-1763-8540
FU Veteran Affairs (VA) Career Development Award; National Institute of
Mental Health (NIMH) [MH065707, MH43292]
FX Support for this study came from a Veteran Affairs (VA) Career
Development Award (PI: W. P. Horan) and National Institute of Mental
Health (NIMH) Grants MH065707 and MH43292 (PI: M. F. Green). We thank J.
Lee, A. Bender, M. Dolinsky, C. Gibson, C. Tripp and K. Weiner for
assistance in data collection.
NR 62
TC 18
Z9 19
U1 5
U2 31
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0033-2917
EI 1469-8978
J9 PSYCHOL MED
JI Psychol. Med.
PD NOV
PY 2013
VL 43
IS 11
BP 2377
EP 2391
DI 10.1017/S0033291713000019
PG 15
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA 234KB
UT WOS:000325641200014
PM 23360592
ER
PT J
AU Han, JH
Bilker, WB
Nachamkin, I
Zaoutis, TE
Coffin, SE
Linkin, DR
Hu, BF
Tolomeo, P
Fishman, NO
Lautenbach, E
AF Han, Jennifer H.
Bilker, Warren B.
Nachamkin, Irving
Zaoutis, Theoklis E.
Coffin, Susan E.
Linkin, Darren R.
Hu, Baofeng
Tolomeo, Pam
Fishman, Neil O.
Lautenbach, Ebbing
TI The Effect of a Hospital-Wide Urine Culture Screening Intervention on
the Incidence of Extended-Spectrum beta-Lactamase-Producing Escherichia
coli and Klebsiella Species
SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
LA English
DT Article
ID INFECTION-CONTROL MEASURES; TO-PATIENT TRANSMISSION;
ANTIBIOTIC-RESISTANCE; UNITED-STATES; ENTEROBACTERIACEAE; COMMUNITY;
IMPACT; ORGANISMS; ACQUISITION; PREVALENCE
AB Objective.Optimal strategies for limiting the transmission of extended-spectrum -lactamase-producing Escherichia coli and Klebsiella spp (ESBL-EK) in the hospital setting remain unclear. The objective of this study was to evaluate the impact of a urine culture screening strategy on the incidence of ESBL-EK.Design.Prospective quasi-experimental study.Setting.Two intervention hospitals and one control hospital within a university health system from 2005 to 2009.Patients and Intervention.All clinical urine cultures with E. coli or Klebsiella spp were screened for ESBL-EK. Patients determined to be colonized or infected with ESBL-EK were placed in a private room with contact precautions. The primary outcome of interest was nosocomial ESBL-EK incidence in nonurinary clinical cultures (cases occurring more than 48 hours after admission). Changes in monthly ESBL-EK incidence rates were evaluated with mixed-effects Poisson regression models, with adjustment for institution-level characteristics (eg, total admissions).Results.The overall incidence of ESBL-EK increased from 1.42/10,000 patient-days to 2.16/10,000 patient-days during the study period. The incidence of community-acquired ESBL-EK increased nearly 3-fold, from 0.33/10,000 patient-days to 0.92/10,000 patient-days (P < .001). On multivariable analysis, the intervention was not significantly associated with a reduction in nosocomial ESBL-EK incidence (incidence rate ratio, 1.38 [95% confidence interval, 0.83 2.31]; P = .21).Conclusions.Universal screening of clinical urine cultures for ESBL-EK did not result in a reduction in nosocomial ESBL-EK incidence rates, most likely because of increases in importation of ESBL-EK cases from the community. Further studies are needed on elucidating optimal infection control interventions to limit spread of ESBL-producing organisms in the hospital setting.
C1 [Han, Jennifer H.; Linkin, Darren R.; Fishman, Neil O.; Lautenbach, Ebbing] Univ Penn, Sch Med, Dept Med, Div Infect Dis, Philadelphia, PA 19104 USA.
[Han, Jennifer H.; Bilker, Warren B.; Zaoutis, Theoklis E.; Tolomeo, Pam; Lautenbach, Ebbing] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
[Han, Jennifer H.; Bilker, Warren B.; Zaoutis, Theoklis E.; Coffin, Susan E.; Linkin, Darren R.; Tolomeo, Pam; Lautenbach, Ebbing] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
[Nachamkin, Irving; Hu, Baofeng] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
[Zaoutis, Theoklis E.; Coffin, Susan E.] Childrens Hosp Philadelphia, Div Infect Dis, Philadelphia, PA 19104 USA.
[Zaoutis, Theoklis E.; Coffin, Susan E.] Childrens Hosp Philadelphia, Ctr Pediat Clin Effectiveness, Philadelphia, PA 19104 USA.
[Linkin, Darren R.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Han, JH (reprint author), Hosp Univ Penn, Dept Med, Div Infect Dis, 811 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM jennifer.han@uphs.upenn.edu
FU Centers for Disease Control and Prevention (CDC) [R01-CI000389]; CDC
Prevention Epicenters Program [U54-CK000163]; National Institutes of
Health [K24 AI080942]; Commonwealth Universal Research Enhancement
Program from the Pennsylvania State Department of Health
FX This work was supported by the Centers for Disease Control and
Prevention (CDC; grant R01-CI000389 to E. L.). This study was also
supported, in part, by the CDC Prevention Epicenters Program (grant
U54-CK000163 to E. L.), the National Institutes of Health (grant K24
AI080942 to E. L.), and a Commonwealth Universal Research Enhancement
Program grant from the Pennsylvania State Department of Health (to E.
L.). The funding agencies had no role in the design and conduct of the
study; collection, management, analysis, and interpretation of the data;
or preparation, review, or approval of the manuscript.
NR 28
TC 4
Z9 7
U1 0
U2 7
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0899-823X
J9 INFECT CONT HOSP EP
JI Infect. Control Hosp. Epidemiol.
PD NOV 1
PY 2013
VL 34
IS 11
BP 1160
EP 1166
DI 10.1086/673453
PG 7
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 232KB
UT WOS:000325491500005
PM 24113599
ER
PT J
AU Grossbard, JR
Hawkins, EJ
Lapham, GT
Williams, EC
Rubinsky, AD
Simpson, TL
Seal, KH
Kivlahan, DR
Bradley, KA
AF Grossbard, Joel R.
Hawkins, Eric J.
Lapham, Gwen T.
Williams, Emily C.
Rubinsky, Anna D.
Simpson, Tracy L.
Seal, Karen H.
Kivlahan, Daniel R.
Bradley, Katharine A.
TI Follow-up care for alcohol misuse among OEF/OIF veterans with and
without alcohol use disorders and posttraumatic stress disorder
SO JOURNAL OF SUBSTANCE ABUSE TREATMENT
LA English
DT Article
DE Alcohol misuse; PTSD; OEF/OIF veterans; Brief alcohol interventions;
Referral to treatment
ID SUBSTANCE USE DISORDERS; AFFAIRS HEALTH-CARE; IDENTIFICATION TEST AUDIT;
MENTAL-HEALTH; AFGHANISTAN VETERANS; BRIEF INTERVENTIONS; RETURNING
VETERANS; MILITARY PERSONNEL; SEEKING SAFETY; UNITED-STATES
AB Little is known about follow-up care for alcohol misuse in the Veterans Affairs (VA) health care system among Operations Enduring and Iraqi Freedom (OEF/OIF) veterans with and without alcohol use disorders (AUD) and/or posttraumatic stress disorder (PTSD). Using data from 4725 OEF/OIF VA outpatients with alcohol screening (2006-2010), we compared the prevalence of follow-up for alcohol misuse brief intervention (BI) or referral to treatment among patients with and without AUD and/or PTSD. Among 933 (19.7%) patients with alcohol misuse (AUDIT-C >= 5), 77.0% had AUD and/or PTSD. Rates of BI or referral for alcohol misuse were higher among patients with AUD (76.9%) and both AUD and PTSD (70.1%) compared to those with PTSD only (53.1%) and neither AUD nor PTSD (52.3%). Among OEF/OIF VA outpatients with alcohol misuse, those with AUD had higher rates of follow-up for alcohol misuse than those without, but PTSD was not associated with differential follow-up. Published by Elsevier Inc.
C1 [Grossbard, Joel R.; Hawkins, Eric J.; Lapham, Gwen T.; Williams, Emily C.; Rubinsky, Anna D.; Kivlahan, Daniel R.; Bradley, Katharine A.] Vet Affairs VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev HSR&D, Seattle, WA 98101 USA.
[Hawkins, Eric J.; Simpson, Tracy L.; Kivlahan, Daniel R.; Bradley, Katharine A.] Vet Affairs VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98101 USA.
[Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA USA.
[Grossbard, Joel R.; Lapham, Gwen T.; Williams, Emily C.; Rubinsky, Anna D.; Bradley, Katharine A.] Univ Washington, Hlth Serv, Seattle, WA 98195 USA.
[Hawkins, Eric J.; Simpson, Tracy L.; Kivlahan, Daniel R.] Univ Washington, Seattle, WA 98195 USA.
[Bradley, Katharine A.] Grp Hlth Res Inst, Seattle, WA USA.
[Seal, Karen H.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Grossbard, JR (reprint author), VA Puget Sound Hlth Care Syst, Seattle, WA 98101 USA.
EM Joel.Grossbard@va.gov
FU HSRD VA [IK2 HX001161]
NR 57
TC 6
Z9 6
U1 2
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0740-5472
J9 J SUBST ABUSE TREAT
JI J. Subst. Abus. Treat.
PD NOV-DEC
PY 2013
VL 45
IS 5
BP 409
EP 415
DI 10.1016/j.jsat.2013.04.007
PG 7
WC Psychology, Clinical; Substance Abuse
SC Psychology; Substance Abuse
GA 224PK
UT WOS:000324900400004
PM 23906670
ER
PT J
AU Valente, AJ
Sakamuri, SSVP
Siddesha, JM
Yoshida, T
Gardner, JD
Prabhu, R
Siebenlist, U
Chandrasekar, B
AF Valente, Anthony J.
Sakamuri, Siva S. V. P.
Siddesha, Jalahalli M.
Yoshida, Tadashi
Gardner, Jason D.
Prabhu, Ramesh
Siebenlist, Ulrich
Chandrasekar, Bysani
TI TRAF3IP2 mediates interleukin-18-induced cardiac fibroblast migration
and differentiation
SO CELLULAR SIGNALLING
LA English
DT Article
DE RNA interference; Cardiac fibroblasts; Migration; TRAF3IP2; Cardiac
fibrosis; Remodeling
ID NF-KAPPA-B; GROWTH-FACTOR; TRANSCRIPTION FACTORS; CIKS ACT1; IN-VIVO;
EXPRESSION; CELL; PROTEIN; INFLAMMATION; ACTIVATION
AB TRAF3IP2 is a cytoplasmic adapter protein and an upstream regulator of IKK/NF-kappa B and JNK/AP-1. Here we demonstrate for the first time that the proinflammatory cytokine interleukin (IL)-18 induces TRAF3IP2 expression in primary cardiac fibroblasts (CF) in a Nox4/hydrogen peroxide-dependent manner. Silencing TRAF3IP2 using a phosphorothioated, 2'-O-methyl modified, cholesterol-tagged TRAF3IP2 siRNA duplex markedly attenuated IL-18-induced NF-kappa B and AP-1 activation and CF migration. Using co-IP/IB and co-localization experiments, we show that Nox4 physically associates with IL-18 receptor proteins, and IL-18 enhances their binding. Further, IL-18 promotes fibroblast to myofibroblast transition, as evidenced by enhanced a-smooth muscle actin expression, types 1 and 3 collagen induction, and soluble collagen secretion, via TRAF3IP2. These results indicate that TRAF3IP2 is a critical intermediate in IL-18-induced CF migration and differentiation in vitro. TRAF3IP2 could serve as a potential therapeutic target in cardiac fibrosis and adverse remodeling in vivo. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Valente, Anthony J.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Valente, Anthony J.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
[Sakamuri, Siva S. V. P.; Siddesha, Jalahalli M.; Yoshida, Tadashi; Chandrasekar, Bysani] Tulane Univ, Sch Med, Inst Heart & Vasc, New Orleans, LA 70112 USA.
[Gardner, Jason D.] Louisiana State Univ, Hlth Sci Ctr, New Orleans, LA 70112 USA.
[Prabhu, Ramesh] Tulane Univ, Sch Med, New Orleans, LA 70112 USA.
[Siebenlist, Ulrich] NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA.
[Chandrasekar, Bysani] Southeast Louisiana Vet Hlth Care Syst, Res Serv, New Orleans, LA 70161 USA.
RP Chandrasekar, B (reprint author), Tulane Univ, Sch Med, Inst Heart & Vasc, 1430 Tulane Ave, New Orleans, LA 70112 USA.
EM bchandra@tulane.edu
OI Yoshida, Tadashi/0000-0002-4544-1497
FU Department of Veterans Affairs Research Career Scientist award; VA
Office of Research and Development Biomedical Laboratory Research and
Development Service Award [1IO1BX000246]; NIH/NHLBI [HL-86787]
FX BC is a recipient of the Department of Veterans Affairs Research Career
Scientist award, and is supported by VA Office of Research and
Development Biomedical Laboratory Research and Development Service Award
1IO1BX000246 and the NIH/NHLBI grant HL-86787. The contents of this
report do not represent the views of the Department of Veterans Affairs
or the United States Government
NR 30
TC 18
Z9 19
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0898-6568
J9 CELL SIGNAL
JI Cell. Signal.
PD NOV
PY 2013
VL 25
IS 11
BP 2176
EP 2184
DI 10.1016/j.cellsig.2013.07.013
PG 9
WC Cell Biology
SC Cell Biology
GA 225OI
UT WOS:000324971800011
PM 23872479
ER
PT J
AU Brashers, DE
Hogan, TP
AF Brashers, Dale E.
Hogan, Timothy P.
TI The appraisal and management of uncertainty: Implications for
information-retrieval systems
SO INFORMATION PROCESSING & MANAGEMENT
LA English
DT Article
DE Uncertainty; Information retrieval; Appraisal; Anxiety; Hope
ID HUNTINGTONS-DISEASE; BRCA2 MUTATIONS; IR TOOL; SEEKING; BEHAVIOR;
COMMUNICATION; NEED; AIDS; HIV; PEOPLE
AB Uncertainty is an important idea in information-retrieval (IR) research, but the concept has yet to be fully elaborated and explored. Common assumptions about uncertainty are (a) that it is a negative (anxiety-producing) state and (b) that it will be reduced through information search and retrieval. Research in the domain of uncertainty in illness, however, has demonstrated that uncertainty is a complex phenomenon that shares a complicated relationship with information. Past research on people living with HIV and individuals who have tested positive for genetic risk for different illnesses has revealed that information and the reduction of uncertainty can, in fact, produce anxiety, and that maintaining uncertainty can be associated with optimism and hope. We review the theory of communication and uncertainty management and offer nine principles based on that theoretical work that can be used to influence IR system design. The principles reflect a view of uncertainty as a multi-faceted and dynamic experience, one subject to ongoing appraisal and management efforts that include interaction with and use of information in a variety of forms. Published by Elsevier Ltd.
C1 [Brashers, Dale E.] Univ Illinois, Coll Liberal Arts & Sci, Dept Commun, Urbana, IL 61801 USA.
[Hogan, Timothy P.] US Dept Vet Affairs, Ctr Hlth Qual Outcomes & Econ Res, eHlth Qual Enhancement Res Initiat, Natl eHlth QUERI Coordinating Ctr,Edith Nourse Ro, Bedford, MA 01730 USA.
[Hogan, Timothy P.] Univ Massachusetts, Sch Med, Div Hlth Informat & Implementat Sci, Dept Quantitat Hlth Sci,Albert Sherman Ctr, Worcester, MA 01605 USA.
RP Hogan, TP (reprint author), US Dept Vet Affairs, Ctr Hlth Qual Outcomes & Econ Res, eHlth Qual Enhancement Res Initiat, Natl eHlth QUERI Coordinating Ctr,Edith Nourse Ro, 200 Springs Rd Bldg 70 152, Bedford, MA 01730 USA.
EM timothy.hogan@va.gov
NR 71
TC 6
Z9 6
U1 8
U2 55
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0306-4573
J9 INFORM PROCESS MANAG
JI Inf. Process. Manage.
PD NOV
PY 2013
VL 49
IS 6
BP 1241
EP 1249
DI 10.1016/j.ipm.2013.06.002
PG 9
WC Computer Science, Information Systems; Information Science & Library
Science
SC Computer Science; Information Science & Library Science
GA 217JA
UT WOS:000324354600004
ER
PT J
AU Kubota, T
Elalieh, HZ
Saless, N
Fong, C
Wang, YM
Babey, M
Cheng, ZQ
Bikle, DD
AF Kubota, Takuo
Elalieh, Hashem Z.
Saless, Neema
Fong, Chak
Wang, Yongmei
Babey, Muriel
Cheng, Zhiqiang
Bikle, Daniel D.
TI Insulin-like growth factor-1 receptor in mature osteoblasts is required
for periosteal bone formation induced by reloading
SO ACTA ASTRONAUTICA
LA English
DT Article; Proceedings Paper
CT 18th Humans in Space (HIS) Symposium of the
International-Academy-of-Astronautics (IAA)
CY APR 11-15, 2011
CL Houston, TX
SP Int Acad Astronaut
DE Insulin-like growth factor 1 receptor; Osteoblasts; Unloading;
Reloading; Periosteal bone formation
ID LONG-DURATION SPACEFLIGHT; GENE-EXPRESSION; SPACE-FLIGHT; IGF-I;
RECOVERY; HORMONE; PERIOD; MICE
AB Skeletal loading and unloading has a pronounced impact on bone remodeling, a process also regulated by insulin-like growth factor-1 (IGF-1) signaling. Skeletal unloading leads to resistance to the anabolic effect of IGF-1, while reloading after unloading restores responsiveness to IGF-1. However, a direct study of the importance of IGF-1 signaling in the skeletal response to mechanical loading remains to be tested. In this study, we assessed the skeletal response of osteoblast-specific Igf-1 receptor deficient (Igf-1r(-/-)) mice to unloading and reloading. The mice were hindlimb unloaded for 14 days and then reloaded for 16 days. Igf-1r(-/-) mice displayed smaller cortical bone and diminished periosteal and endosteal bone formation at baseline. Periosteal and endosteal bone formation decreased with unloading in Igf-1r(+/+) mice. However, the recovery of periosteal bone formation with reloading was completely inhibited in Igf-1r(-/-) mice, although reloading-induced endosteal bone formation was not hampered. These changes in bone formation resulted in the abolishment of the expected increase in total cross-sectional area with reloading in Igf-1r(-/-) mice compared to the control mice. These results suggest that the Igf-1r in mature osteoblasts has a critical role in periosteal bone formation in the skeletal response to mechanical loading. Published by Elsevier Ltd. on behalf of IAA.
C1 [Bikle, Daniel D.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA.
San Francisco VA Med Ctr, Endocrine Res Unit, San Francisco, CA 94121 USA.
RP Bikle, DD (reprint author), Univ Calif San Francisco, Dept Med, 4150 Clement St,111N, San Francisco, CA 94121 USA.
EM daniel.bikle@ucsf.edu
FU BLRD VA [IP1 BX001599]; NIAMS NIH HHS [R01 AR055924, R01 AR050023];
NIDDK NIH HHS [R01 DK054793]
NR 29
TC 8
Z9 8
U1 0
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0094-5765
J9 ACTA ASTRONAUT
JI Acta Astronaut.
PD NOV
PY 2013
VL 92
IS 1
SI SI
BP 73
EP 78
DI 10.1016/j.actaastro.2012.08.007
PG 6
WC Engineering, Aerospace
SC Engineering
GA 212VX
UT WOS:000324012000011
PM 23976802
ER
PT J
AU Johnson, MS
Mitchell, T
Moore, DR
Lei, XY
Barnes, S
Zhang, JH
Koizumi, A
Ramanadham, S
Darley-Usmar, VM
AF Johnson, Michelle S.
Mitchell, Tanecia
Moore, D. Ray
Lei, Xiaoyong
Barnes, Stephen
Zhang, Jianhua
Koizumi, Akio
Ramanadham, Sasanka
Darley-Usmar, Victor M.
TI The Voltage-Dependant Anion Channel (VDAC) is S-Glutathionylated in
Ins(2Akita) Derived B-Cells
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Meeting Abstract
C1 [Johnson, Michelle S.; Mitchell, Tanecia; Darley-Usmar, Victor M.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
[Johnson, Michelle S.; Mitchell, Tanecia; Barnes, Stephen; Zhang, Jianhua; Darley-Usmar, Victor M.] Univ Alabama Birmingham, Ctr Free Radical Biol, Birmingham, AL USA.
[Zhang, Jianhua] Univ Alabama Birmingham, Birmingham VA Med Ctr, Birmingham, AL USA.
[Koizumi, Akio] Kyoto Grad Sch Med, Dept Hlth & Environm Sci, Kyoto, Japan.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD NOV 1
PY 2013
VL 65
SU 2
MA 102
BP S54
EP S55
DI 10.1016/j.freeradbiomed.2013.10.519
PG 2
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA V40JU
UT WOS:000209475700121
ER
PT J
AU Oates, JC
Mashmoushi, AK
AF Oates, Jim C.
Mashmoushi, Ahmad K.
TI Nitric Oxide and Not Superoxide Production by Inducible Nitric Oxide
Synthase Leads to Podocyte Dysfunction that is Seen in Lupus Nephritis
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Meeting Abstract
C1 [Oates, Jim C.; Mashmoushi, Ahmad K.] Med Univ S Carolina, Charleston, SC USA.
[Oates, Jim C.] Ralph H Johnson VAMC, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD NOV 1
PY 2013
VL 65
SU 2
MA 62
BP S38
EP S38
DI 10.1016/j.freeradbiomed.2013.10.477
PG 1
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA V40JU
UT WOS:000209475700081
ER
PT J
AU Oates, JC
Mashmoushi, AK
Hofbauer, AF
Gilkeson, GS
AF Oates, Jim C.
Mashmoushi, Ahmad K.
Hofbauer, Ann F.
Gilkeson, Gary S.
TI Nitric Oxide Modulation of Redox-Modulated Cytokines in Lupus Nephritis
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Meeting Abstract
C1 [Oates, Jim C.; Mashmoushi, Ahmad K.; Gilkeson, Gary S.] Med Univ S Carolina, Charleston, SC USA.
[Oates, Jim C.; Hofbauer, Ann F.; Gilkeson, Gary S.] Ralph H Johnson VAMC, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD NOV 1
PY 2013
VL 65
SU 2
MA 61
BP S37
EP S38
DI 10.1016/j.freeradbiomed.2013.10.476
PG 2
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA V40JU
UT WOS:000209475700080
ER
PT J
AU Tsui, I
Sarraf, D
AF Tsui, Irena
Sarraf, David
TI Paracentral Acute Middle Maculopathy and Acute Macular Neuroretinopathy
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
AB Type 1 acute macular neuroretinopathy (AMN), also known as paracentral acute middle maculopathy (PAMM), is a novel form of AMN in which spectral-domain optical coherence tomography (SD-OCT) demonstrates a characteristic hyper-reflective band-like lesion at the level of the inner nuclear layer. This form of AMN has only recently been described in five patients who were predominantly older men with vasculopathy. Herein, we describe a young, healthy female patient with classic features of type 1 AMN or PAMM with SD-OCT.
C1 [Tsui, Irena] Univ Calif Los Angeles, Jules Stein Eye Inst, Retina Div, Los Angeles, CA 90024 USA.
[Tsui, Irena; Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA.
[Sarraf, David] Univ Calif Los Angeles, Jules Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, Los Angeles, CA 90024 USA.
RP Sarraf, D (reprint author), Univ Calif Los Angeles, Jules Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, 100 Stein Plaza, Los Angeles, CA 90024 USA.
EM dsarraf@ucla.edu
NR 6
TC 13
Z9 13
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD NOV-DEC
PY 2013
VL 44
IS 6
SU S
BP S33
EP S35
DI 10.3928/23258160-20131101-06
PG 3
WC Ophthalmology; Surgery
SC Ophthalmology; Surgery
GA V37XT
UT WOS:000209309200006
PM 24220881
ER
PT J
AU Meinzer, M
Beeson, PM
Cappa, S
Crinion, J
Kiran, S
Saur, D
Parrish, T
Crosson, B
Thompson, CK
AF Meinzer, Marcus
Beeson, Pelagie M.
Cappa, Stefano
Crinion, Jenny
Kiran, Swathi
Saur, Dorothee
Parrish, Todd
Crosson, Bruce
Thompson, Cynthia K.
TI Neuroimaging in aphasia treatment research: Consensus and practical
guidelines for data analysis (vol 73, pg 215, 2013)
SO NEUROIMAGE
LA English
DT Correction
C1 [Meinzer, Marcus] Charite, Dept Neurol, Ctr Stroke Res Berlin, D-13353 Berlin, Germany.
[Meinzer, Marcus] Cluster Excellence NeuroCure, D-13353 Berlin, Germany.
[Meinzer, Marcus; Crosson, Bruce] Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL USA.
[Beeson, Pelagie M.] Univ Arizona, Dept Speech Language & Hearing Sci, Tucson, AZ USA.
[Cappa, Stefano] Univ Vita Salute San Raffaele, Dept Clin Neurosci, Milan, Italy.
[Crinion, Jenny] UCL, Inst Cognit Neurosci, London, England.
[Kiran, Swathi] Boston Univ, Sargent Coll Hlth & Rehabil Sci, Boston, MA 02215 USA.
[Saur, Dorothee] Univ Leipzig, Dept Neurol, Language & Aphasia Lab, D-04109 Leipzig, Germany.
[Parrish, Todd] Northwestern Univ, Dept Radiol, Chicago, IL 60611 USA.
[Crosson, Bruce] US Dept Vet Affairs, Brain Rehabil Res Ctr Excellence, Gainesville, FL USA.
[Thompson, Cynthia K.] Northwestern Univ, Dept Commun Sci & Disorders, Evanston, IL USA.
[Thompson, Cynthia K.] Northwestern Univ, Dept Neurol, Evanston, IL USA.
RP Meinzer, M (reprint author), Charite, Dept Neurol, Ctr Stroke Res Berlin, D-13353 Berlin, Germany.
EM marcus.meinzer@charite.de
RI Crosson, Bruce/L-3128-2013
NR 1
TC 0
Z9 0
U1 0
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
J9 NEUROIMAGE
JI Neuroimage
PD NOV 1
PY 2013
VL 81
BP 507
EP 507
DI 10.1016/j.neuroimage.2013.05.059
PG 1
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 198PI
UT WOS:000322934400052
ER
PT J
AU McGregor, KM
Nocera, JR
Sudhyadhom, A
Patten, C
Manini, TM
Kleim, JA
Crosson, B
Butler, AJ
AF McGregor, Keith M.
Nocera, Joe R.
Sudhyadhom, Atchar
Patten, Carolynn
Manini, Todd M.
Kleim, Jeffrey A.
Crosson, Bruce
Butler, Andrew J.
TI Effects of aerobic fitness on aging-related changes of interhemispheric
inhibition and motor performance
SO FRONTIERS IN AGING NEUROSCIENCE
LA English
DT Article
DE agingneuroscience; aging; fMRI; TMS; physicalfitness;
interhemisphericcommunication; negative BOLD; dexterity
ID PRIMARY SOMATOSENSORY CORTEX; AGE-RELATED DIFFERENCES; TRANSCRANIAL
MAGNETIC STIMULATION; UNILATERAL HAND MOVEMENTS; BOLD SIGNAL CHANGES;
CORPUS-CALLOSUM; MULTIPLE-SCLEROSIS; CARDIOVASCULAR FITNESS; NEURONAL
INHIBITION; PHYSICAL-ACTIVITY
AB Physical Fitness has been long associated with maintenance and improvement of motor performance as we age. In particular, measures of psychomotor speed and motor dexterity tend to be higher in physically fit aging adults as compared to their sedentary counterparts. Using functional magnetic resonance imaging and transcranial magnetic stimulation, we explored the patterns of neural activity that may, in part, account for differences between individuals of varying physical fitness levels. In this study, we enrolled both sedentary and physically fit middle age (40-60) and younger (18-30) adults and measured upper extremity motor performance during behavioral testing. In a follow-up session, we employed TMS and fMRI to assess levels of interhemispheric communication during unimanual tasks. Results show that increased physical fitness is associated with better upper extremity motor performance on distal dexterity assessments and increased levels of interhemispheric inhibition in middle-age adults. Further, the functional correlates of changes of ipsilateral activity appears to be restricted to the aging process as younger adults of varying fitness levels do not differ in hemispheric patterns of activity or motor performance. We conclude that sedentary aging confers a loss of interhemispheric inhibition that is deleterious to some aspects of motor function, as early as midlife, but these changes can be mediated by chronic engagement in aerobic exercise
C1 [McGregor, Keith M.; Nocera, Joe R.; Crosson, Bruce; Butler, Andrew J.] US Dept Vet Affairs, Ctr Visual & Neurocognit Rehabil, Decatur, GA USA.
[McGregor, Keith M.; Nocera, Joe R.; Crosson, Bruce] Emory Univ, Dept Neurol, Atlanta, GA USA.
[Sudhyadhom, Atchar; Patten, Carolynn] VA Ctr Excellence, Gainesville, FL USA.
[Sudhyadhom, Atchar] Univ Florida, Dept Neurosurg, Gainesville, FL USA.
[Patten, Carolynn] Univ Florida, Dept Phys Therapy, Gainesville, FL USA.
[Manini, Todd M.] Univ Florida, Dept Geriatr, Gainesville, FL USA.
[Kleim, Jeffrey A.] Arizona State Univ, Sch Biol & Hlth Syst Engn, Tempe, AZ USA.
[Butler, Andrew J.] Georgia State Univ, Dept Phys Therapy, Atlanta, GA 30303 USA.
RP McGregor, KM (reprint author), Emory Univ, Dept Neurol, 1518 Clifton Rd NE, Decatur, GA 30033 USA.
EM keith.mcgregor@emory.edu
RI Patten, Carolynn/B-4804-2009
OI Patten, Carolynn/0000-0002-9948-0045; McGregor,
Keith/0000-0003-3654-351X
FU NIA NIH HHS [P30 AG028740]
NR 92
TC 11
Z9 11
U1 2
U2 19
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND
SN 1663-4365
J9 FRONT AGING NEUROSCI
JI Front. Aging Neurosci.
PD OCT 30
PY 2013
VL 5
DI 10.3389/fnagi.2013.00066
PG 14
WC Geriatrics & Gerontology; Neurosciences
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 242UA
UT WOS:000326266700001
PM 24198784
ER
PT J
AU Hill, SY
Jones, BL
Holmes, B
Steinhauer, SR
Zezza, N
Stiffler, S
AF Hill, Shirley Y.
Jones, Bobby L.
Holmes, Brian
Steinhauer, Stuart R.
Zezza, Nicholas
Stiffler, Scott
TI Cholinergic receptor gene (CHRM2) variation and familial loading for
alcohol dependence predict childhood developmental trajectories of P300
SO PSYCHIATRY RESEARCH
LA English
DT Article
DE P300; CHRM2; High-risk; Alcohol dependence; Offspring; ERP; Childhood
ID EVENT-RELATED POTENTIALS; SUBSTANCE USE DISORDERS; LINKAGE-PHYSICAL MAP;
HIGH-RISK; EXTERNALIZING PSYCHOPATHOLOGY; AMPLITUDE DEVELOPMENT;
DRUG-DEPENDENCE; SAS PROCEDURE; HUMAN GENOME; ASSOCIATION
AB P300 amplitude in childhood predicts substance use disorders by young adulthood. Trajectories of visual P300 amplitude show an association between low amplitude P300 and familial risk for alcohol dependence (AD). Variation in the cholinergic muscarinic receptor gene (CHRM2) has previously been associated with P300 amplitude and AD. The present study used group based trajectory modeling of auditory P300 data collected longitudinally from offspring in families with and without familial loading for AD to determine if specific trajectories would be associated with familial risk and CHRM2 variation. Trajectory modeling confirms previous reports of an association between the low visual P300 trajectory with high familial risk in male offspring. This association was detected in offspring in the 8-12 age range, but not in 13-18 or 19-29 year olds or in high-risk female offspring. CHRM2 association analysis with P300 finds 8-12 year olds who are homozygous for the T allele of rs1824024 are 2.6 times more likely to follow a P300 trajectory characterized by lower and slower change regardless of familial loading. Combining the odds for being male and having a TT genotype results in odds of 6.5 that individuals will follow the low P300 trajectory. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 [Hill, Shirley Y.; Jones, Bobby L.; Holmes, Brian; Zezza, Nicholas; Stiffler, Scott] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA.
[Steinhauer, Stuart R.] VA Pittsburgh Healthcare Syst, Biometr Res, Pittsburgh, PA 15206 USA.
RP Hill, SY (reprint author), Univ Pittsburgh, Med Ctr, Dept Psychiat, 3811 OHara, St Pittsburgh, PA 15213 USA.
EM syh50@pitt.edu
FU NIAAA [AA018289, AA005909, AA 008082, AA015168]
FX This research was supported by NIAAA Grants AA018289, AA005909, AA
008082, and AA015168 to SYH.
NR 57
TC 6
Z9 7
U1 2
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0165-1781
J9 PSYCHIAT RES
JI Psychiatry Res.
PD OCT 30
PY 2013
VL 209
IS 3
BP 504
EP 511
DI 10.1016/j.psychres.2013.04.027
PG 8
WC Psychiatry
SC Psychiatry
GA 249GS
UT WOS:000326766300039
PM 23747232
ER
PT J
AU Ganguly, K
Poo, MM
AF Ganguly, Karunesh
Poo, Mu-ming
TI Activity-Dependent Neural Plasticity from Bench to Bedside
SO NEURON
LA English
DT Review
ID TRANSCRANIAL MAGNETIC STIMULATION; PRIMARY SOMATOSENSORY CORTEX; CA1
PYRAMIDAL NEURONS; OCULAR DOMINANCE PLASTICITY; TERM SYNAPTIC
PLASTICITY; INDUCED MOVEMENT THERAPY; DEEP-BRAIN-STIMULATION; PRIMARY
VISUAL-CORTEX; PRIMARY MOTOR CORTEX; FOCAL HAND DYSTONIA
AB Much progress has been made in understanding how behavioral experience and neural activity can modify the structure and function of neural circuits during development and in the adult brain. Studies of physiological and molecular mechanisms underlying activity-dependent plasticity in animal models have suggested potential therapeutic approaches for a wide range of brain disorders in humans. Physiological and electrical stimulations as well as plasticity-modifying molecular agents may facilitate functional recovery by selectively enhancing existing neural circuits or promoting the formation of new functional circuits. Here, we review the advances in basic studies of neural plasticity mechanisms in developing and adult nervous systems and current clinical treatments that harness neural plasticity, and we offer perspectives on future development of plasticity-based therapy.
C1 [Ganguly, Karunesh] San Francisco VA Med Ctr, Dept Neurol & Rehabil, San Francisco, CA 94121 USA.
[Ganguly, Karunesh] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94122 USA.
[Poo, Mu-ming] Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.
[Poo, Mu-ming] Chinese Acad Sci, Inst Neurosci, Shanghai 200031, Peoples R China.
RP Ganguly, K (reprint author), San Francisco VA Med Ctr, Dept Neurol & Rehabil, San Francisco, CA 94121 USA.
EM karunesh.ganguly@ucsf.edu; mpoo@berkeley.edu
FU Department of Veterans Affairs [B6674W]; American Heart Association
[0875016N]; Doris Duke Charitable Foundation [2013101]; Burroughs
Wellcome Fund [1009855]; NIH [NS36999]
FX This work is supported by grants to K.G. from the Department of Veterans
Affairs (B6674W), American Heart Association (0875016N), Doris Duke
Charitable Foundation (2013101), and Burroughs Wellcome Fund (1009855);
and to M.M.P. from the NIH (NS36999).
NR 173
TC 35
Z9 37
U1 1
U2 38
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0896-6273
EI 1097-4199
J9 NEURON
JI Neuron
PD OCT 30
PY 2013
VL 80
IS 3
BP 729
EP 741
DI 10.1016/j.neuron.2013.10.028
PG 13
WC Neurosciences
SC Neurosciences & Neurology
GA 247IA
UT WOS:000326609900017
PM 24183023
ER
PT J
AU Sun, CR
Sun, H
Wu, S
Lee, CC
Akamatsu, Y
Wang, RKK
Kernie, SG
Liu, JL
AF Sun, Chongran
Sun, Hui
Wu, Steven
Lee, Chih Cheng
Akamatsu, Yosuke
Wang, Ruikang K.
Kernie, Steven G.
Liu, Jialing
TI Conditional Ablation of Neuroprogenitor Cells in Adult Mice Impedes
Recovery of Poststroke Cognitive Function and Reduces Synaptic
Connectivity in the Perforant Pathway
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID TRAUMATIC BRAIN-INJURY; FOCAL CEREBRAL-ISCHEMIA; HIPPOCAMPAL
NEUROGENESIS; PATTERN SEPARATION; PSEUDORABIES VIRUS; EXPERIMENTAL
STROKE; GENERATED NEURONS; PROGENITOR CELLS; GAIT IMPAIRMENT; DENTATE
GYRUS
AB The causal relationship between neurogenesis and the recovery of poststroke cognitive function has not been properly explored. The current study aimed to determine whether depleting neuroprogenitor cells (NPCs) affects poststroke functional outcome in nestin-delta-HSV-TK-EGFP transgenic mice, in which the expression of a truncated viral thymidine kinase gene and EGFP was restricted to nestin-expressing NPCs. Ganciclovir (GCV; 200 mg/kg/d) or saline was continuously administered via osmotic pumps in mice for 4 weeks before the induction of experimental stroke. Both baseline and stroke-induced type 1 and type 2 NPCs were conditionally ablated. GCV eliminated NPCs in a duration-dependent fashion, but it did not attenuate the genesis of astroglia or oligodendrocytes in the peri-infarct cortex, nor did it affect infarct size or cerebral blood reperfusion after stroke. Transgenic stroke mice given GCV displayed impaired spatial learning and memory in the Barnes maze test compared with saline control or wild-type stroke mice given GCV, suggesting a contributing role of stroke-induced neurogenesis in the recovery of cognitive function. However, there was no significant difference in poststroke motor function between transgenic mice treated with GCV and those treated with vehicle, despite a significant ablation of NPCs in the subventricular zone of the former. Furthermore, nestin-delta-HSV-TK-EGFP mice treated with GCV had fewer retrogradely labeled neurons in the entorhinal cortex (EC) when injected with the polysynaptic viral marker PRV614 in the dentate gyrus (DG), suggesting that there might be reduced synaptic connectivity between the DG and EC following ablation of NPCs, which may contribute to impaired poststroke memory function.
C1 [Sun, Chongran; Sun, Hui; Wu, Steven; Lee, Chih Cheng; Akamatsu, Yosuke; Liu, Jialing] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94121 USA.
[Sun, Chongran; Sun, Hui; Wu, Steven; Lee, Chih Cheng; Akamatsu, Yosuke; Liu, Jialing] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Sun, Chongran] Zhejiang Univ, Coll Med, Affiliated Hosp 2, Dept Neurol Surg, Hangzhou 310009, Zhejiang, Peoples R China.
[Sun, Hui] Shanghai Jiao Tong Univ, Xinhua Hosp, Dept Neurol Surg, Shanghai 201101, Peoples R China.
[Akamatsu, Yosuke] Tohoku Univ, Grad Sch Med, Dept Neurol Surg, Aoba Ku, Sendai, Miyagi 9808574, Japan.
[Wang, Ruikang K.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.
[Wang, Ruikang K.] Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA.
[Kernie, Steven G.] Columbia Univ, Dept Pediat, New York, NY 10032 USA.
[Kernie, Steven G.] Columbia Univ, Dept Pathol, New York, NY 10032 USA.
[Kernie, Steven G.] Columbia Univ, Dept Cell Biol, New York, NY 10032 USA.
RP Liu, JL (reprint author), Univ Calif San Francisco, Dept Neurol Surg 112C, 4150 Clement St, San Francisco, CA 94121 USA.
EM jialing.liu@ucsf.edu
RI Liu, Jialing/A-8627-2012
OI Liu, Jialing/0000-0003-4420-4382
FU National Institutes of Health [R01 NS071050]; AHA EIA [0940065N]
FX This work was supported by National Institutes of Health Grants R01
NS071050 (J.L.) and AHA EIA 0940065N (J.L.). We thank Dr. Lin An for his
technical assistance in the analysis of blood perfusion by optical
coherence tomography.
NR 37
TC 21
Z9 21
U1 3
U2 11
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD OCT 30
PY 2013
VL 33
IS 44
BP 17314
EP 17325
DI 10.1523/JNEUROSCI.2129-13.2013
PG 12
WC Neurosciences
SC Neurosciences & Neurology
GA 246BB
UT WOS:000326509800009
PM 24174664
ER
PT J
AU Singh, GD
Amsterdam, EA
Armstrong, EJ
Barsness, G
Chan, K
Chiam, JR
Chua, K
Hou, KC
Low, R
Mahmud, E
McCabe, JM
Nishimura, M
Rogers, JH
Shunk, K
Waldo, S
Yap, J
Yeo, KK
AF Singh, Gagan D.
Amsterdam, Ezra A.
Armstrong, Ehrin J.
Barsness, Gregory
Chan, Krystal
Chiam, Jenn R.
Chua, Kelvin
Hou, Koh C.
Low, Reginald
Mahmud, Ehtisham
McCabe, James M.
Nishimura, Marin
Rogers, Jason H.
Shunk, Kendrick
Waldo, Stephen
Yap, Jonathan
Yeo, Khung Keong
TI ECG Findings in ST-Elevation Myocardial Infarction from Culprit Left
Main Coronary Artery Disease: A Multicenter Registry Study
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Meeting Abstract
CT 25th Annual Symposium on Transcatheter Cardiovascular Therapeutics (TCT)
CY OCT 27-NOV 01, 2013
CL San Francisco, CA
C1 [Singh, Gagan D.] UC Davis Med Ctr, Sacramento, CA USA.
[Amsterdam, Ezra A.; Chan, Krystal; Nishimura, Marin; Rogers, Jason H.] Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA.
[Armstrong, Ehrin J.] Univ Calif Davis, Sacramento, CA USA.
[Barsness, Gregory] Mayo, Rochester, MN USA.
[Chiam, Jenn R.; Chua, Kelvin; Hou, Koh C.] Natl Heart Ctr, Singapore, Singapore.
[Low, Reginald] Univ Calif Davis, Sacramento, CA 95817 USA.
[Mahmud, Ehtisham] Univ Calif San Diego, San Diego, CA 92103 USA.
[McCabe, James M.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Shunk, Kendrick] San Francisco VA Med Ctr, San Francisco, CA USA.
[Waldo, Stephen] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Yap, Jonathan; Yeo, Khung Keong] Natl Heart Ctr Singapore, Singapore, Singapore.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
EI 1558-3597
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD OCT 29
PY 2013
VL 62
IS 18
SU 1
BP B82
EP B82
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 291RA
UT WOS:000329845600248
ER
PT J
AU Wang, TY
Zettler, M
Effron, MB
McCoy, L
Anstrom, K
Fonarow, GC
Messenger, JC
Stone, G
Cohen, D
Henry, TD
Peterson, E
AF Wang, Tracy Y.
Zettler, Marjorie
Effron, Mark B.
McCoy, Lisa
Anstrom, Kevin
Fonarow, Gregg C.
Messenger, John C.
Stone, Gregg
Cohen, David
Henry, Timothy D.
Peterson, Eric
TI Comparative Effectiveness of Prasugrel vs. Clopidogrel Among Acute
Myocardial Infarction Patients Treated With Percutaneous Coronary
Intervention: 30-Day Outcomes from the TRANSLATE-ACS Observational Study
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Meeting Abstract
CT 25th Annual Symposium on Transcatheter Cardiovascular Therapeutics (TCT)
CY OCT 27-NOV 01, 2013
CL San Francisco, CA
C1 [Wang, Tracy Y.] Duke Univ, Durham, NC 27705 USA.
[Zettler, Marjorie] Lilly Inc, Indianapolis, IN USA.
[Effron, Mark B.] Eli Lilly & Co, Indianapolis, IN 46285 USA.
[McCoy, Lisa; Anstrom, Kevin] Duke Clin Res Inst, Durham, NC USA.
[Fonarow, Gregg C.] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA.
[Messenger, John C.] Denver VA Med Ctr, Denver, CO USA.
[Stone, Gregg] Columbia Univ, Med Ctr, New York, NY USA.
[Stone, Gregg] Cardiovasc Res Fdn, New York, NY USA.
[Cohen, David] St Lukes Mid Amer Heart Inst, Kansas City, KS USA.
[Henry, Timothy D.] Abbott NW Hosp, Minneapolis Heart Inst Fdn, Minneapolis, MN 55407 USA.
[Peterson, Eric] NA, Durham, NC USA.
RI Effron, Mark/P-9300-2015
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
EI 1558-3597
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD OCT 29
PY 2013
VL 62
IS 18
SU 1
BP B1
EP B1
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 291RA
UT WOS:000329845600003
ER
PT J
AU Studenski, S
AF Studenski, Stephanie
TI Prognosis for Recovery After Injurious Falls Clinical and Policy
Implications of Varying Definitions of Recovery
SO JAMA INTERNAL MEDICINE
LA English
DT Editorial Material
C1 [Studenski, Stephanie] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr & Gerontol, Pittsburgh, PA 15213 USA.
[Studenski, Stephanie] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Studenski, S (reprint author), Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr & Gerontol, 3471 Fifth Ave,Ste 500, Pittsburgh, PA 15213 USA.
EM sas33@pitt.edu
FU NIA NIH HHS [P30 AG024827, AG024827]
NR 6
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD OCT 28
PY 2013
VL 173
IS 19
BP 1786
EP 1787
DI 10.1001/jamainternmed.2013.8252
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 302EO
UT WOS:000330584900007
PM 23959545
ER
PT J
AU Grande, D
Mitra, N
Shah, A
Wan, F
Asch, DA
AF Grande, David
Mitra, Nandita
Shah, Anand
Wan, Fei
Asch, David A.
TI Public Preferences About Secondary Uses of Electronic Health Information
SO JAMA INTERNAL MEDICINE
LA English
DT Article
ID MEDICAL-RESEARCH; PERSONAL INFORMATION; AFRICAN-AMERICANS;
CONJOINT-ANALYSIS; ATTITUDES; PRIVACY; WILLINGNESS; PARTICIPATE;
DISTRUST; CONSENT
AB IMPORTANCE As health information technology grows, secondary uses of personal health information offer promise in advancing research, public health, and health care. Public perceptions about sharing personal health data are important for establishing and evaluating ethical and regulatory structures to oversee the use of these data.
OBJECTIVE To measure patient preferences about sharing their electronic health information for secondary purposes (other than their own health care).
DESIGN. SETTING, AND PARTICIPANTS In this conjoint analysis study, we surveyed 3336 adults (568 Hispanic, 500 non-Hispanic African American, and 2268 non-Hispanic white); participants were randomized to 6 of 18 scenarios describing secondary uses of electronic health information, constructed with 3 attributes: uses (research, quality improvement, or commercial marketing), users (university hospitals, commercial enterprises, or public health departments), and data sensitivity (whether it included genetic information about their own cancer risk). This design enabled participants to reveal their preferences for secondary uses of their personal health information.
MAIN OUTCOMES AND MEASURES Participants responded to each conjoint scenario by rating their willingness to share their electronic personal health information on a 1 to 10 scale (1 represents low willingness; 10, high willingness). Conjoint analysis yields importance weights reflecting the contribution of a dimension (use, user, or sensitivity) to willingness to share personal health information.
RESULTS The use of data was a more important factor in the conjoint analysis (importance weight, 64.3%) than the user (importance weight, 32.6%) and data sensitivity (importance weight, 3.1%). In unadjusted linear regression models, marketing uses (beta = -1.55), quality improvement uses (beta = -0.51), drug company users (beta = -0.80), and public health department users (beta = -0.52) were associated with less willingness to share health information than research uses and university hospital users (all P < .001). Hispanics and African Americans differentiated less than whites between uses.
CONCLUSIONS AND RELEVANCE Participants cared most about the specific purpose for using their health information, although differences were smaller among racial and ethnic minorities. The user of the information was of secondary importance, and the sensitivity was not a significant factor. These preferences should be considered in policies governing secondary uses of health information.
C1 [Grande, David; Asch, David A.] Univ Penn, Perelman Sch Med, Dept Med, Div Gen Internal Med, Philadelphia, PA 19014 USA.
[Grande, David; Asch, David A.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19014 USA.
[Mitra, Nandita; Wan, Fei] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19014 USA.
[Shah, Anand] Univ Texas SW Med Ctr Dallas, Div Emergency Med, Dallas, TX 75390 USA.
[Asch, David A.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
RP Grande, D (reprint author), Univ Penn, Perelman Sch Med, Dept Med, Div Gen Internal Med, 3641 Locust Walk,Colonial Penn Ctr 407, Philadelphia, PA 19014 USA.
EM dgrande@wharton.upenn.edu
OI Asch, David/0000-0002-7970-286X
FU National Human Genome Research Institute [5R21HG006047-02]
FX This research was supported by grant 5R21HG006047-02 from the National
Human Genome Research Institute.
NR 44
TC 26
Z9 26
U1 3
U2 11
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD OCT 28
PY 2013
VL 173
IS 19
BP 1798
EP 1806
DI 10.1001/jamainternmed.2013.9166
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 302EO
UT WOS:000330584900010
PM 23958803
ER
PT J
AU Brown, RT
Kiely, DK
Bharel, M
Grande, LJ
Mitchell, SL
AF Brown, Rebecca T.
Kiely, Dan K.
Bharel, Monica
Grande, Laura J.
Mitchell, Susan L.
TI Use of Acute Care Services Among Older Homeless Adults
SO JAMA INTERNAL MEDICINE
LA English
DT Letter
C1 [Brown, Rebecca T.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA.
[Kiely, Dan K.; Mitchell, Susan L.] Hebrew SeniorLife Inst Aging Res, Boston, MA USA.
[Bharel, Monica] Boston Hlth Care Homeless Program, Boston, MA USA.
[Grande, Laura J.] Vet Affairs Boston Healthcare Syst, Psychol Serv, Boston, MA USA.
RP Brown, RT (reprint author), San Francisco VA Med Ctr, 4150 Clement St,181G, San Francisco, CA 94122 USA.
EM rebecca.brown@ucsf.edu
FU NIA NIH HHS [K24 AG033640, P30 AG044281, T32 AG000212]
NR 9
TC 4
Z9 4
U1 1
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD OCT 28
PY 2013
VL 173
IS 19
BP 1831
EP 1834
DI 10.1001/jamainternmed.2013.6627
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 302EO
UT WOS:000330584900017
PM 23752708
ER
PT J
AU Dubin, RF
Li, YM
He, J
Jaar, BG
Kallem, R
Lash, JP
Makos, G
Rosas, SE
Soliman, EZ
Townsend, RR
Yang, W
Go, AS
Keane, M
deFilippi, C
Mishra, R
Wolf, M
Shlipak, MG
AF Dubin, Ruth F.
Li, Yongmei
He, Jiang
Jaar, Bernard G.
Kallem, Radhakrishna
Lash, James P.
Makos, Gail
Rosas, Sylvia E.
Soliman, Elsayed Z.
Townsend, Ray R.
Yang, Wei
Go, Alan S.
Keane, Martin
deFilippi, Christopher
Mishra, Rakesh
Wolf, Myles
Shlipak, Michael G.
CA CRIC Study Investigators
TI Predictors of high sensitivity cardiac troponin T in chronic kidney
disease patients: a cross-sectional study in the chronic renal
insufficiency cohort (CRIC)
SO BMC NEPHROLOGY
LA English
DT Article
DE Troponin T; Chronic kidney disease; Cardiovascular disease
ID LEFT-VENTRICULAR HYPERTROPHY; GROWTH-FACTOR 23; CYSTATIN-C
CONCENTRATION; CORONARY-ARTERY-DISEASE; CARDIOVASCULAR EVENTS;
HEART-FAILURE; HEMODIALYSIS-PATIENTS; GENERAL-POPULATION; MORTALITY
RISK; ESTIMATED GFR
AB Background: Cardiac troponin T is independently associated with cardiovascular events and mortality in patients with chronic kidney disease (CKD). Serum levels of high sensitivity cardiac troponin T (hs-TnT) reflect subclinical myocardial injury in ambulatory patients. We sought to determine the distribution and predictors of hs-TnT in CKD patients without overt cardiovascular disease (CVD).
Methods: We studied 2464 participants within the multi-ethnic Chronic Renal Insufficiency Cohort (CRIC) who did not have self-reported CVD. We considered renal and non-renal factors as potential determinants of hs-TnT, including demographics, comorbidities, left ventricular (LV) mass, serologic factors, estimated glomerular filtration rate (eGFR) and albumin to creatinine ratio.
Results: Hs-TnT was detectable in 81% of subjects, and the median (IQR) hs-TnT was 9.4 pg/ml (4.3-18.3). Analysis was performed using Tobit regression, adjusting for renal and non-renal factors. After adjustment, lower eGFR was associated with higher expected hs-TnT; participants with eGFR <30 ml/min/1.73m(2) had 3-fold higher expected hs-TnT compared to subjects with eGFR >60. Older age, male gender, black race, LV mass, diabetes and higher blood pressure all had strong, independent associations with higher expected hs-TnT.
Conclusions: Knowledge of the determinants of hs-TnT in this cohort may guide further research on the pathology of heart disease in patients with CKD and help to stratify sub-groups of CKD patients at higher cardiovascular risk.
C1 [Dubin, Ruth F.; Li, Yongmei; Mishra, Rakesh; Shlipak, Michael G.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[He, Jiang] Tulane Univ, Sch Publ Hlth & Trop Med, New Orleans, LA USA.
[Jaar, Bernard G.] Johns Hopkins Univ, Baltimore, MD USA.
[Kallem, Radhakrishna; Rosas, Sylvia E.; Townsend, Ray R.; Keane, Martin] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Lash, James P.] Univ Illinois, Chicago, IL USA.
[Makos, Gail] St Johns Hlth Syst, Detroit, MI USA.
[Soliman, Elsayed Z.] Wake Forest Sch Med, Epidemiol Cardiol Res Ctr EPICARE, Dept Epidemiol, Winston Salem, NC USA.
[Soliman, Elsayed Z.] Wake Forest Sch Med, Dept Internal Med, Cardiol Sect, Winston Salem, NC USA.
[Yang, Wei] Univ Penn, Sci & Data Coordinating Ctr, Philadelphia, PA 19104 USA.
[Go, Alan S.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA.
[deFilippi, Christopher] Univ Maryland, Med Ctr, Baltimore, MD 21201 USA.
[Wolf, Myles] Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
RP Dubin, RF (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, 4150 Clement St,Box 111A1, San Francisco, CA 94121 USA.
EM ruth.dubin@ucsf.edu
FU National Institute of Diabetes and Digestive and Kidney Diseases
[U01DK060990, U01DK060984, U01DK061022, U01DK061021, U01DK061028,
U01DK060980, U01DK060963, U01DK060902]; University of Pennsylvania CTRC
CTSA [UL1 RR-024134]; Johns Hopkins University [UL1 RR-025005];
University of Maryland GCRC [M01 RR-16500]; Clinical and Translational
Science Collaborative of Cleveland; National Center for Advancing
Translational Sciences (NCATS) component of the National Institutes of
Health [UL1TR000439]; NIH roadmap for Medical Research; Michigan
Institute for Clinical and Health Research (MICHR) [UL1RR024986];
University of Illinois at Chicago CTSA [UL1RR029879]; Tulane University
Translational Research in Hypertension and Renal Biology [P30GM103337];
Kaiser Permanente Northern California NIH/NCRR UCSF-CTSI [UL1
RR-024131]; [R01 DK066488]; [K23 DK092354]
FX Support Funding for the CRIC Study was obtained under a cooperative
agreement from National Institute of Diabetes and Digestive and Kidney
Diseases (U01DK060990, U01DK060984, U01DK061022, U01DK061021,
U01DK061028, U01DK060980, U01DK060963, and U01DK060902). This project
was supported by M.S.'s R01 DK066488 award (principal investigator M.
S.). R. D. is supported by K23 DK092354. In addition, this work was
supported in part by: the University of Pennsylvania CTRC CTSA UL1
RR-024134, Johns Hopkins University UL1 RR-025005, University of
Maryland GCRC M01 RR-16500, Clinical and Translational Science
Collaborative of Cleveland, UL1TR000439 from the National Center for
Advancing Translational Sciences (NCATS) component of the National
Institutes of Health and NIH roadmap for Medical Research, Michigan
Institute for Clinical and Health Research (MICHR) UL1RR024986,
University of Illinois at Chicago CTSA UL1RR029879, Tulane University
Translational Research in Hypertension and Renal Biology P30GM103337,
Kaiser Permanente Northern California NIH/NCRR UCSF-CTSI UL1 RR-024131.
NR 37
TC 20
Z9 21
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2369
J9 BMC NEPHROL
JI BMC Nephrol.
PD OCT 22
PY 2013
VL 14
AR 229
DI 10.1186/1471-2369-14-229
PG 8
WC Urology & Nephrology
SC Urology & Nephrology
GA 258TX
UT WOS:000327482700002
PM 24148285
ER
PT J
AU Pulliam, DA
Bhattacharya, A
Van Remmen, H
AF Pulliam, Daniel A.
Bhattacharya, Arunabh
Van Remmen, Holly
TI Mitochondrial Dysfunction in Aging and Longevity: A Causal or Protective
Role?
SO ANTIOXIDANTS & REDOX SIGNALING
LA English
DT Review
ID AGE-RELATED-CHANGES; SKELETAL-MUSCLE MITOCHONDRIA; OXYGEN SPECIES
PRODUCTION; FREE-RADICAL GENERATION; RAT-LIVER MITOCHONDRIA; LIFE-SPAN;
CAENORHABDITIS-ELEGANS; OXIDATIVE DAMAGE; SUPEROXIDE-DISMUTASE; CALORIC
RESTRICTION
AB Significance: Among the most highly investigated theories of aging is the mitochondrial theory of aging. The basis of this theory includes a central role for altered or compromised mitochondrial function in the pathophysiologic declines associated with aging. In general, studies in various organisms, including nematodes, rodents, and humans, have largely upheld that aging is associated with mitochondrial dysfunction. However, results from a number of studies directly testing the mitochondrial theory of aging by modulating oxidant production or scavenging in vivo in rodents have generally been inconsistent with predictions of the theory. Recent Advances: Interestingly, electron transport chain mutations or deletions in invertebrates and mice that causes mitochondrial dysfunction paradoxically leads to enhanced longevity, further challenging the mitochondrial theory of aging. Critical Issues: How can mitochondrial dysfunction contribute to lifespan extension in the mitochondrial mutants, and what does it mean for the mitochondrial theory of aging? Future Directions: It will be important to determine the potential mechanisms that lead to enhanced longevity in the mammalian mitochondrial mutants. Antioxid. Redox Signal. 19, 1373-1387.
C1 [Pulliam, Daniel A.; Bhattacharya, Arunabh; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA.
[Pulliam, Daniel A.; Bhattacharya, Arunabh] Univ Texas San Antonio, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78284 USA.
[Van Remmen, Holly] South Texas Vet Hlth Care Syst, GRECC, San Antonio, TX USA.
RP Van Remmen, H (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, 15355 Lambda Dr,Mail Code 5577, San Antonio, TX 78245 USA.
EM vanremmen@uthscsa.edu
FU Ellison Medical Foundation
FX This work was supported by a Senior Scholar Award to Dr. Van Remmen by
the Ellison Medical Foundation.
NR 97
TC 9
Z9 10
U1 1
U2 17
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1523-0864
EI 1557-7716
J9 ANTIOXID REDOX SIGN
JI Antioxid. Redox Signal.
PD OCT 20
PY 2013
VL 19
IS 12
BP 1373
EP 1387
DI 10.1089/ars.2012.4950
PG 15
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 229LX
UT WOS:000325267800006
PM 23025472
ER
PT J
AU Wang, RY
Brewster, LP
Gleason, RL
AF Wang, Ruoya
Brewster, Luke P.
Gleason, Rudolph L., Jr.
TI In-situ characterization of the uncrimping process of arterial collagen
fibers using two-photon confocal microscopy and digital image
correlation
SO JOURNAL OF BIOMECHANICS
LA English
DT Article
DE Adventitia; Digital image correlation; Two-photon excitation microscopy;
Deformation; Arterial mechanics
ID CAROTID ARTERIES; WALL MECHANICS; DEVICE
AB Uncrimping of collagen fibers in the arterial wall is an integral process in regulating the macro-level mechanical response of arteries. Uncrimping of collagen fibers leads to a gradual, but significant strain-stiffening response of the artery at physiological pressures and prevents overdistention at elevated pressures. In this study, we imaged adventitial collagen fibers from fresh primate arteries using two-photon excitation microscopy while subjecting the arteries to physiological inflation pressures and axial stretches. The imaging focal plane was fixed at a constant radial location in the adventitial wall by adjusting the focal distance as the arteries inflated, allowing for the continuously monitoring of the uncrimping process of a single region of collagen fibers. Digital image correlation was then applied to the sequential images to assess and correlate the local displacements to manual traces of selected reference fibers and their engagements. We found that the collagen fibers of interest became fully engaged at a luminal pressure of 20 mmHg, this was then followed by rotation of these fibers as the bulk artery continued to dilate. This technique helps to further the understanding of the uncrimping process of collagen fibers under physiological loads, which can aid in the development of more accurate microstructural constitutive models. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Wang, Ruoya; Gleason, Rudolph L., Jr.] George W Woodruff Sch Mech Engn, Atlanta, GA USA.
[Gleason, Rudolph L., Jr.] Wallace H Coulter Dept Biomed Engn, Atlanta, GA USA.
[Brewster, Luke P.; Gleason, Rudolph L., Jr.] Georgia Inst Technol, Parker H Petit Inst Bioengn & Biosci, Atlanta, GA 30332 USA.
[Wang, Ruoya; Brewster, Luke P.] Emory Univ, Sch Med, Dept Surg, Div Vasc Surg, Atlanta, GA 30322 USA.
[Brewster, Luke P.] US Dept Vet Affairs, Atlanta VA Med Ctr, Surg Serv, Atlanta, GA USA.
[Brewster, Luke P.] US Dept Vet Affairs, Atlanta VA Med Ctr, Res Serv, Atlanta, GA USA.
RP Wang, RY (reprint author), Emory Univ, Sch Med, Dept Vasc Surg, 101 Woodruff Circle,5211 WMB, Atlanta, GA 30322 USA.
EM r.wang@gatech.edu
FU Yerkes National Primate Center [P51OD11132]; Vascular Surgery Startup
Grant; Georgia Tech IBB Microscopy Core Facility
FX The authors would like to thank the Yerkes National Primate Center
(Grant P51OD11132) for providing the primate tissues, Georgia Tech IBB
Microscopy Core Facility and manager Andrew Shaw and the Vascular
Surgery Startup Grant for funding. A portion of this study was presented
at the Biomedical Engineering Society conference in Atlanta, GA on
October 27, 2012.
NR 10
TC 7
Z9 7
U1 0
U2 13
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0021-9290
EI 1873-2380
J9 J BIOMECH
JI J. Biomech.
PD OCT 18
PY 2013
VL 46
IS 15
BP 2726
EP 2729
DI 10.1016/j.jbiomech.2013.08.001
PG 4
WC Biophysics; Engineering, Biomedical
SC Biophysics; Engineering
GA 249IV
UT WOS:000326771800022
PM 24050510
ER
PT J
AU Wise, RA
Anzueto, A
Cotton, D
Dahl, R
Devins, T
Disse, B
Dusser, D
Joseph, E
Kattenbeck, S
Koenen-Bergmann, M
Pledger, G
Calverley, P
AF Wise, Robert A.
Anzueto, Antonio
Cotton, Daniel
Dahl, Ronald
Devins, Theresa
Disse, Bernd
Dusser, Daniel
Joseph, Elizabeth
Kattenbeck, Sabine
Koenen-Bergmann, Michael
Pledger, Gordon
Calverley, Peter
CA TIOSPIR Investigators
TI Tiotropium Respimat Inhaler and the Risk of Death in COPD
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID OBSTRUCTIVE PULMONARY-DISEASE; RANDOMIZED CONTROLLED-TRIALS; SAFETY;
METAANALYSIS; MEDICATIONS; SALMETEROL; EFFICACY
AB BackgroundTiotropium delivered at a dose of 5 g with the Respimat inhaler showed efficacy similar to that of 18 g of tiotropium delivered with the HandiHaler inhalation device in placebo-controlled trials involving patients with chronic obstructive pulmonary disease (COPD). Although tiotropium HandiHaler was associated with reduced mortality, as compared with placebo, more deaths were reported with tiotropium Respimat than with placebo.
MethodsIn this randomized, double-blind, parallel-group trial involving 17,135 patients with COPD, we evaluated the safety and efficacy of tiotropium Respimat at a once-daily dose of 2.5 g or 5 g, as compared with tiotropium HandiHaler at a once-daily dose of 18 g. Primary end points were the risk of death (noninferiority study, Respimat at a dose of 5 g or 2.5 g vs. HandiHaler) and the risk of the first COPD exacerbation (superiority study, Respimat at a dose of 5 g vs. HandiHaler). We also assessed cardiovascular safety, including safety in patients with stable cardiac disease.
ResultsDuring a mean follow-up of 2.3 years, Respimat was noninferior to HandiHaler with respect to the risk of death (Respimat at a dose of 5 g vs. HandiHaler: hazard ratio, 0.96; 95% confidence interval [CI], 0.84 to 1.09; Respimat at a dose of 2.5 g vs. HandiHaler: hazard ratio, 1.00; 95% CI, 0.87 to 1.14) and not superior to HandiHaler with respect to the risk of the first exacerbation (Respimat at a dose of 5 g vs. HandiHaler: hazard ratio, 0.98; 95% CI, 0.93 to 1.03). Causes of death and incidences of major cardiovascular adverse events were similar in the three groups.
ConclusionsTiotropium Respimat at a dose of 5 g or 2.5 g had a safety profile and exacerbation efficacy similar to those of tiotropium HandiHaler at a dose of 18 g in patients with COPD. (Funded by Boehringer Ingelheim; TIOSPIR ClinicalTrials.gov number, NCT01126437.)
C1 [Wise, Robert A.] Johns Hopkins Univ, Sch Med, Baltimore, MD 21224 USA.
[Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Anzueto, Antonio] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Cotton, Daniel; Devins, Theresa; Joseph, Elizabeth] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA.
[Dahl, Ronald] Odense Univ Hosp, DK-5000 Odense, Denmark.
[Disse, Bernd; Kattenbeck, Sabine; Koenen-Bergmann, Michael] Boehringer Ingelheim KG, Ingelheim, Germany.
[Dusser, Daniel] Univ Paris 05, Hop Cochin, AP HP, Serv Pneumol,Sorbonne Paris Cite, Paris, France.
[Calverley, Peter] Univ Liverpool, Inst Ageing & Chron Dis, Liverpool L69 3BX, Merseyside, England.
RP Wise, RA (reprint author), Johns Hopkins Univ, Sch Med, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.
EM rwise@jhmi.edu
RI Wiemer, Stefan/E-5033-2015; Vrbica, Zarko/Q-2705-2015; Cilli,
Aykut/C-7681-2016; Zadionchenko, Vladimir/A-7445-2016; POLATLI,
MEHMET/A-3516-2017
OI Zadionchenko, Vladimir/0000-0003-2377-5266; Van de Werf,
Frans/0000-0001-9479-7767; Field, Stephen/0000-0002-6682-4155
FU Boehringer Ingelheim
FX Funded by Boehringer Ingelheim; TIOSPIR ClinicalTrials.gov number,
NCT01126437.
NR 26
TC 139
Z9 146
U1 4
U2 34
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD OCT 17
PY 2013
VL 369
IS 16
BP 1491
EP 1501
DI 10.1056/NEJMoa1303342
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA 267MJ
UT WOS:000328101700006
PM 23992515
ER
PT J
AU Goswami, ND
Pfeiffer, CD
Horton, JR
Chiswell, K
Tasneem, A
Tsalik, EL
AF Goswami, Neela D.
Pfeiffer, Christopher D.
Horton, John R.
Chiswell, Karen
Tasneem, Asba
Tsalik, Ephraim L.
TI The State of Infectious Diseases Clinical Trials: A Systematic Review of
ClinicalTrials.gov
SO PLOS ONE
LA English
DT Article
ID PRACTICE GUIDELINES; REGISTRATION; SOCIETY; ISSUES
AB Background: There is a paucity of clinical trials informing specific questions faced by infectious diseases (ID) specialists. The ClinicalTrials.gov registry offers an opportunity to evaluate the ID clinical trials portfolio.
Methods: We examined 40,970 interventional trials registered with ClinicalTrials.gov from 2007-2010, focusing on study conditions and interventions to identify ID-related trials. Relevance to ID was manually confirmed for each programmatically identified trial, yielding 3570 ID trials and 37,400 non-ID trials for analysis.
Results: The number of ID trials was similar to the number of trials identified as belonging to cardiovascular medicine (n = 3437) or mental health (n = 3695) specialties. Slightly over half of ID trials were treatment-oriented trials (53%, vs. 77% for non-ID trials) followed by prevention (38%, vs. 8% in non-ID trials). ID trials tended to be larger than those of other specialties, with a median enrollment of 125 subjects (interquartile range [IQR], 45-400) vs. 60 (IQR, 30-160) for non-ID trials. Most ID studies are randomized (73%) but nonblinded (56%). Industry was the funding source in 51% of ID trials vs. 10% that were primarily NIH-funded. HIV-AIDS trials constitute the largest subset of ID trials (n = 815 [23%]), followed by influenza vaccine (n = 375 [11%]), and hepatitis C (n = 339 [9%]) trials. Relative to U. S. and global mortality rates, HIV-AIDS and hepatitis C virus trials are over-represented, whereas lower respiratory tract infection trials are under-represented in this large sample of ID clinical trials.
Conclusions: This work is the first to characterize ID clinical trials registered in ClinicalTrials.gov, providing a framework to discuss prioritization, methodology, and policy.
C1 [Goswami, Neela D.; Tsalik, Ephraim L.] Duke Univ, Sch Med, Dept Med, Div Infect Dis & Int Hlth, Durham, NC 27706 USA.
[Pfeiffer, Christopher D.] Portland VA Med Ctr, Dept Hosp & Specialty Med, Portland, OR USA.
[Pfeiffer, Christopher D.] Oregon Hlth & Sci Univ, Div Infect Dis, Portland, OR 97201 USA.
[Horton, John R.; Chiswell, Karen; Tasneem, Asba] Duke Clin Res Inst, Durham, NC USA.
[Tsalik, Ephraim L.] Durham VA Med Ctr, Emergency Med Serv, Durham, NC USA.
RP Tsalik, EL (reprint author), Duke Univ, Sch Med, Dept Med, Div Infect Dis & Int Hlth, Durham, NC 27706 USA.
EM e.t@duke.edu
FU US Food and Drug Administration [U19FD003800]; Clinical Science Research
and Development Service of the Veterans Health Administration Office of
Research and Development [1IK2CX000530]
FX This work was supported by grant U19FD003800 from the US Food and Drug
Administration awarded to Duke University for the Clinical Trials
Transformation Initiative. Dr. Tsalik's efforts were also supported by
Award Number 1IK2CX000530 from the Clinical Science Research and
Development Service of the Veterans Health Administration Office of
Research and Development. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 19
TC 4
Z9 4
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 16
PY 2013
VL 8
IS 10
AR e77086
DI 10.1371/journal.pone.0077086
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 239JR
UT WOS:000326019400093
PM 24146958
ER
PT J
AU Abdel-Mohsen, M
Raposo, RAS
Deng, XT
Li, MQ
Liegler, T
Sinclair, E
Salama, MS
Ghanem, HEDA
Hoh, R
Wong, JK
David, M
Nixon, DF
Deeks, SG
Pillai, SK
AF Abdel-Mohsen, Mohamed
Raposo, Rui Andre Saraiva
Deng, Xutao
Li, Manqing
Liegler, Teri
Sinclair, Elizabeth
Salama, Mohamed S.
Ghanem, Hussam El-Din A.
Hoh, Rebecca
Wong, Joseph K.
David, Michael
Nixon, Douglas F.
Deeks, Steven G.
Pillai, Satish K.
TI Expression profile of host restriction factors in HIV-1 elite
controllers
SO RETROVIROLOGY
LA English
DT Article
DE Elite controllers; Intrinsic immunity; Retroviral restriction factors;
APOBEC3; BST2/tetherin; TRIM; schlafen 11; p21; T cell activation
ID IMMUNODEFICIENCY-VIRUS TYPE-1; CD4(+) T-CELLS; INFECTION; REPLICATION;
PROTEIN; ACTIVATION; MACROPHAGES; SUPPRESSORS; INHIBITION; RESPONSES
AB Background: Several host-encoded antiviral factors suppress HIV-1 replication in a cell-autonomous fashion in vitro. The relevance of these defenses to the control of HIV-1 in vivo remains to be elucidated. We hypothesized that cellular restriction of HIV-1 replication plays a significant role in the observed suppression of HIV-1 in "elite controllers", individuals who maintain undetectable levels of viremia in the absence of antiretroviral therapy (ART). We comprehensively compared the expression levels of 34 host restriction factors and cellular activation levels in CD4+ T cells and sorted T cell subsets between elite controllers, HIV-1-infected (untreated) non-controllers, ART-suppressed, and uninfected individuals.
Results: Expression of schlafen 11, a codon usage-based inhibitor of HIV-1 protein synthesis, was significantly elevated in CD4+ T cells from elite controllers as compared to both non-controllers (p=0.048) and ART-suppressed individuals (p=0.024), with this effect most apparent in central memory CD4+ T cells. Schlafen 11 expression levels were comparable between controllers and uninfected individuals. Cumulative restriction factor expression was positively correlated with CD4+ T cell activation (r(2)=0.597, p<0.0001), viral load (r(2)=0.34, p=0.015), and expression of ISG15 (r(2)=0.73, p<0.0001), a marker of interferon exposure. APOBEC3C, APOBEC3D, CTR9, TRIM26, and TRIM32 were elevated in elite controllers with respect to ART-suppressed individuals, while levels were comparable to uninfected individuals and non-controllers.
Conclusions: Host restriction factor expression typically scales with cellular activation levels. However, the elevated mRNA and protein expression of schlafen 11, despite low activation and viral load, violates the global pattern and may be a signature characteristic of HIV-1 elite control.
C1 [Abdel-Mohsen, Mohamed; Liegler, Teri; Sinclair, Elizabeth; Hoh, Rebecca; Wong, Joseph K.; Deeks, Steven G.; Pillai, Satish K.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
[Raposo, Rui Andre Saraiva; Nixon, Douglas F.] Univ Calif San Francisco, Dept Expt Med, San Francisco, CA USA.
[Deng, Xutao; Pillai, Satish K.] Blood Syst Res Inst, San Francisco, CA USA.
[Li, Manqing; David, Michael] Univ Calif San Diego, Mol Biol Sect, Div Biol Sci, La Jolla, CA 92093 USA.
[Abdel-Mohsen, Mohamed; Salama, Mohamed S.; Ghanem, Hussam El-Din A.] Ain Shams Univ, Fac Sci, Cairo, Egypt.
[Wong, Joseph K.; Pillai, Satish K.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA 94118 USA.
RP Pillai, SK (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
EM satish.pillai@ucsf.edu
RI Salama, Mohamed/P-7169-2016
OI Raposo, R. Andre/0000-0001-5435-0290; Nixon, Douglas/0000-0002-2801-1786
FU National Institutes of Health [1K01DA024654, R01 AI087145, K24 AI069994,
R21 AI93179]; University of California, San Francisco-Gladstone
Institute of Virology & Immunology Center for AIDS Research [P30
AI027763]; DARE: Delaney AIDS Research Enterprise (DARE) [U19AI096109];
American Foundation for AIDS Research [106710-40-RGRL]; UCSF Clinical
and Translational Research Institute Clinical Research Center [UL1
RR024131]; Center for AIDS Prevention Studies [P30 MH62246]; CFAR
Network of Integrated Systems [R24 AI067039]
FX We thank all UCSF SCOPE Cohort patients who participated in our study,
the physicians and study nurses for excellent patient care, Dr. John
Guatelli for helpful discussion and suggestions regarding the panel of
restriction factors analyzed, and the UCSF CFAR Core Virology Lab and
Core Immunology Lab staff for processing and storage of the samples:
Alex Carvidi, Christina Gonzaga, David Chung, Khooshbu Shah, Lorrie
Epling, Maudi Killian, Montha Pao, Sophie Stephenson, Timothy Ryner, and
Timothy Schmidt. This study was supported by grants from the National
Institutes of Health (1K01DA024654, R01 AI087145, K24 AI069994, R21
AI93179), the University of California, San Francisco-Gladstone
Institute of Virology & Immunology Center for AIDS Research (grant
number P30 AI027763), the DARE: Delaney AIDS Research Enterprise (DARE;
U19AI096109), the American Foundation for AIDS Research (grant number
106710-40-RGRL), the UCSF Clinical and Translational Research Institute
Clinical Research Center (UL1 RR024131), the Center for AIDS Prevention
Studies (P30 MH62246), and the CFAR Network of Integrated Systems (R24
AI067039).
NR 55
TC 32
Z9 33
U1 0
U2 7
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD OCT 16
PY 2013
VL 10
AR 106
DI 10.1186/1742-4690-10-106
PG 13
WC Virology
SC Virology
GA 280PH
UT WOS:000329042700001
PM 24131498
ER
PT J
AU Shah, NR
Chokshi, DA
AF Shah, Nirav R.
Chokshi, Dave A.
TI Should Health Care Systems Become Insurers?
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
ID ORGANIZATIONS
C1 [Shah, Nirav R.] New York State Dept Hlth, Albany, NY USA.
[Chokshi, Dave A.] US Dept Vet Affairs, Washington, DC USA.
RP Chokshi, DA (reprint author), Dept Vet Affairs, 810 Vermont Ave NW, Washington, DC 20006 USA.
EM dave.chokshi@alumni.duke.edu
OI Shah, Nirav/0000-0003-2044-7865; Chokshi, Dave/0000-0001-7467-4591
NR 6
TC 2
Z9 2
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD OCT 16
PY 2013
VL 310
IS 15
BP 1561
EP 1562
DI 10.1001/jama.2013.280015
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 234EP
UT WOS:000325624800015
PM 24129460
ER
PT J
AU Smucny, J
Tregellas, J
AF Smucny, Jason
Tregellas, Jason
TI Nicotinic modulation of intrinsic brain networks in Schizophrenia
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Review
DE Schizophrenia; Nicotinic; Salience network; Default network; Small-world
network
ID ANTERIOR CINGULATE CIRCUITS; RESTING-STATE NETWORKS; DEFAULT MODE
NETWORK; SMALL-WORLD NETWORKS; SUBUNIT GENE CHRNA7;
ACETYLCHOLINE-RECEPTOR; FUNCTIONAL CONNECTIVITY; ALLOSTERIC MODULATORS;
PARTIAL DUPLICATION; CIGARETTE-SMOKING
AB The nicotinic receptor is a promising drug target currently being investigated for the treatment of cognitive symptoms in schizophrenia. A key step in this process is the development of noninvasive functional neuroimaging biomarkers that can be used to determine if nicotinic agents are eliciting their targeted biological effect, ideally through modulation of a fundamental aspect of neuronal function. To that end, neuroimaging researchers are beginning to understand how nicotinic modulation affects "intrinsic" brain networks to elicit potentially therapeutic effects. An intrinsic network is a functionally and (often) structurally connected network of brain areas whose activity reflects a fundamental neurobiological organizational principle of the brain. This review summarizes findings of the effects of nicotinic drugs on three topics related to intrinsic brain network activity: (1) the default mode network, a group of brain areas for which activity is maximal at rest and reduced during cognitive tasks, (2) the salience network, which integrates incoming sensory data with prior internal representations to guide future actions and change predictive values, and (3) multi-scale complex network dynamics, which describe these brain's ability to efficiency integrate information while preserving local functional specialization. These early findings can be used to inform future neuroimaging studies that examine the network effects of nicotinic agents. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Smucny, Jason; Tregellas, Jason] Univ Colorado, Neurosci Program, Aurora, CO 80045 USA.
[Smucny, Jason; Tregellas, Jason] Univ Colorado, Dept Psychiat, Aurora, CO 80045 USA.
[Smucny, Jason; Tregellas, Jason] Denver VA Med Ctr, Res Serv, Denver, CO 80220 USA.
RP Smucny, J (reprint author), Univ Colorado, Neurosci Program, Anschutz Med Campus, Aurora, CO 80045 USA.
EM Jason.smucny@ucdenver.edu; Jason.tregellas@ucdenver.edu
RI Tregellas, Jason/J-3637-2015
OI Smucny, Jason/0000-0001-5656-7987
FU NIMH NIH HHS [F31 MH102879]
NR 124
TC 7
Z9 7
U1 3
U2 16
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006-2952
EI 1873-2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD OCT 15
PY 2013
VL 86
IS 8
SI SI
BP 1163
EP 1172
DI 10.1016/j.bcp.2013.06.011
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 239FC
UT WOS:000326007000015
PM 23796751
ER
PT J
AU Fetterman, JL
Zelickson, BR
Johnson, LW
Moellering, DR
Westbrook, DG
Pompilius, M
Sammy, MJ
Johnson, M
Dunham-Snary, KJ
Cao, XM
Bradley, WE
Zhang, JJ
Wei, CC
Chacko, B
Schurr, TG
Kesterson, RA
Dell'Italia, LJ
Darley-Usmar, VM
Welch, DR
Ballinger, SW
AF Fetterman, Jessica L.
Zelickson, Blake R.
Johnson, Larry W.
Moellering, Douglas R.
Westbrook, David G.
Pompilius, Melissa
Sammy, Melissa J.
Johnson, Michelle
Dunham-Snary, Kimberly J.
Cao, Xuemei
Bradley, Wayne E.
Zhang, Jinju
Wei, Chih-Chang
Chacko, Balu
Schurr, Theodore G.
Kesterson, Robert A.
Dell'Italia, Louis J.
Darley-Usmar, Victor M.
Welch, Danny R.
Ballinger, Scott W.
TI Mitochondrial genetic background modulates bioenergetics and
susceptibility to acute cardiac volume overload
SO BIOCHEMICAL JOURNAL
LA English
DT Article
DE bioenergetics; disease susceptibility; mitochondria; mtDNA; oxidative
stress
ID NICOTINAMIDE NUCLEOTIDE TRANSHYDROGENASE; OXYGEN SPECIES PRODUCTION;
CORONARY-HEART-DISEASE; CARDIOVASCULAR-DISEASE; SMOKE EXPOSURE;
ATHEROSCLEROSIS SUSCEPTIBILITY; C57BL/6J MICE; MOUSE; DNA; NUCLEAR
AB Dysfunctional bioenergetics has emerged as a key feature in many chronic pathologies such as diabetes and cardiovascular disease. This has led to the mitochondrial paradigm in which it has been proposed that mtDNA sequence variation contributes to disease susceptibility. In the present study we show a novel animal model of mtDNA polymorphisms, the MNX (mitochondrial nuclear exchange) mouse, in which the mtDNA from the C3H/HeN mouse has been inserted on to the C57/BL6 nuclear background and vice versa to test this concept. Our data show a major contribution of the C57/BL6 mtDNA to the susceptibility to the pathological stress of cardiac volume overload which is independent of the nuclear background. Mitochondria harbouring the C57/BL6J mtDNA generate more ROS (reactive oxygen species) and have a higher mitochondrial membrane potential relative to those with C3H/HeN mtDNA, independent of nuclear background. We propose this is the primary mechanism associated with increased bioenergetic dysfunction in response to volume overload. In summary, these studies support the 'mitochondrial paradigm' for the development of disease susceptibility, and show that the mtDNA modulates cellular bioenergetics, mitochondrial ROS generation and susceptibility to cardiac stress.
C1 [Fetterman, Jessica L.; Zelickson, Blake R.; Westbrook, David G.; Pompilius, Melissa; Sammy, Melissa J.; Johnson, Michelle; Dunham-Snary, Kimberly J.; Chacko, Balu; Darley-Usmar, Victor M.; Ballinger, Scott W.] Univ Alabama Birmingham, Div Mol & Cellular Pathol, Birmingham, AL 35294 USA.
[Fetterman, Jessica L.; Zelickson, Blake R.; Moellering, Douglas R.; Sammy, Melissa J.; Dunham-Snary, Kimberly J.; Chacko, Balu; Dell'Italia, Louis J.; Darley-Usmar, Victor M.; Ballinger, Scott W.] Univ Alabama Birmingham, Ctr Free Rad Biol, Birmingham, AL 35294 USA.
[Johnson, Larry W.; Zhang, Jinju; Kesterson, Robert A.] Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA.
[Moellering, Douglas R.] Univ Alabama Birmingham, Birmingham, AL 35294 USA.
[Cao, Xuemei; Welch, Danny R.] Univ Kansas, Ctr Canc, Dept Canc Biol, Kansas City, KS 66160 USA.
[Bradley, Wayne E.; Wei, Chih-Chang; Dell'Italia, Louis J.] Univ Alabama Birmingham, Div Cardiol, Birmingham, AL 35294 USA.
[Schurr, Theodore G.] Univ Penn, Dept Anthropol, Philadelphia, PA 19104 USA.
[Dell'Italia, Louis J.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA.
RP Welch, DR (reprint author), Univ Kansas, Ctr Canc, Dept Canc Biol, Kansas City, KS 66160 USA.
EM dwelch@kumc.edu; sballing@uab.edu
OI Sammy, Melissa/0000-0002-5460-0963
FU National Institutes for Health [RO1 94518, RO1 103859]; National
Foundation for Cancer Research; Susan G. Komen for the Cure [SAC111370];
U.S. Army Medical Research & Material Command [W81XWH-07-1-0540d];
University of Alabama at Birmingham Comprehensive Cancer Center
[CA013148]; National Institutes of Health [RO1 HL109785, P30 CA13148,
P30 AR048311, P30 DK074038, P30 DK05336, P60 DK079626]; a National
Institutes of Health predoctoral training programme in cardiovascular
pathophysiology [T32 HL007918]; American Heart Association
[09PRE2240046, 11PRE7650033]; Diabetes Research Center Bioanalytical
Redox Biology Core [P60 DK079626]
FX This work was funded by the National Institutes for Health [grant
numbers RO1 94518 and RO1 103859 (to S.W.B.)], the National Foundation
for Cancer Research (to D.R.W.), Susan G. Komen for the Cure [grant
number SAC111370 (to D.R.W.)], U.S. Army Medical Research & Material
Command [grant number W81XWH-07-1-0540d (to S.W.B.)] and a pilot grant
from the University of Alabama at Birmingham Comprehensive Cancer Center
[grant number CA013148 (to D.R.W. and S.W.B.)]. Additional support was
received from the National Institutes of Health [grant number RO1
HL109785 (to L.J.D.)), a National Institutes of Health predoctoral
training programme in cardiovascular pathophysiology [grant number T32
HL007918 (to J.L.F.)], American Heart Association predoctoral
fellowships [numbers 09PRE2240046 (to J.L.F.) and 11PRE7650033 (to
K.J.D.)). The University of Alabama at Birmingham Transgenic Mouse
Facility (RAK) is supported by the National Institutes of Health [grant
numbers P30 CA13148, P30 AR048311, P30 DK074038, P30 DK05336 and P60
DK079626] and by the National Institutes of Health-funded Diabetes
Research Center Bioanalytical Redox Biology Core [grant number P60
DK079626) located at the University of Alabama at Birmingham.
NR 66
TC 22
Z9 22
U1 2
U2 12
PU PORTLAND PRESS LTD
PI LONDON
PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND
SN 0264-6021
EI 1470-8728
J9 BIOCHEM J
JI Biochem. J.
PD OCT 15
PY 2013
VL 455
BP 157
EP 167
DI 10.1042/BJ20130029
PN 2
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 243ZV
UT WOS:000326357800003
PM 23924350
ER
PT J
AU McCarthy, AM
Bristol, M
Fredricks, T
Wilkins, L
Roelfsema, I
Liao, KJ
Shea, JA
Groeneveld, P
Domchek, SM
Armstrong, K
AF McCarthy, Anne Marie
Bristol, Mirar
Fredricks, Tracey
Wilkins, Lache
Roelfsema, Irene
Liao, Kaijun
Shea, Judy A.
Groeneveld, Peter
Domchek, Susan M.
Armstrong, Katrina
TI Are Physician Recommendations for BRCA1/2 Testing in Patients With
Breast Cancer Appropriate? A Population-Based Study
SO CANCER
LA English
DT Article
DE breast cancer; genetic testing; BRCA1; 2; physician recommendations;
cancer registry
ID MUTATION CARRIERS; WOMEN; RISK; DECISIONS; KNOWLEDGE; ATTITUDES;
FAMILIES; COVERAGE; SURGERY
AB BACKGROUNDTo the best of the authors' knowledge, few population-based studies to date have examined the use of BRCA1/2 testing or patterns of physician recommendations for genetic testing among women diagnosed with breast cancer. The objective of the current study was to evaluate the rates and predictors of physician recommendation for BRCA1/2 testing among patients with breast cancer.
METHODSWomen aged 18 years to 64 years who were diagnosed with invasive breast cancer in 2007 were identified from the Pennsylvania Cancer Registry and mailed a survey regarding their family history of cancer, physician treatment recommendations, and BRCA1/2 testing. Of the 4009 women who were sent surveys, 2258 responded (56%). Based on age at diagnosis and family history, women were categorized as being at high, moderate, or low risk of BRCA1/2 mutations.
RESULTSNearly 25% of the participants were classified as being at high risk of carrying a BRCA1/2 mutation based on their age at the time of breast cancer diagnosis and family history of breast and/or ovarian cancer. Physician recommendations for BRCA1/2 testing were found to be strongly associated with risk of carrying a mutation, with 53% of high-risk women reporting a testing recommendation compared with 9% of low-risk women. In addition, physician recommendations were strongly correlated with the use of testing in all risk groups. Among high-risk women, the lack of a recommendation for BRCA1/2 testing was more common among older, low-income, and employed women.
CONCLUSIONSAlthough BRCA1/2 testing recommendations appear to be appropriately correlated with mutation risk, a significant percentage of patients with breast cancer who meet criteria for BRCA1/2 testing may not receive a recommendation for such testing from their health care providers. Cancer 2013;119:3596-3603. (c) 2013 American Cancer Society.
C1 [McCarthy, Anne Marie; Bristol, Mirar; Fredricks, Tracey; Wilkins, Lache; Roelfsema, Irene; Liao, Kaijun; Shea, Judy A.; Groeneveld, Peter; Domchek, Susan M.; Armstrong, Katrina] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Groeneveld, Peter] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Domchek, Susan M.; Armstrong, Katrina] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
RP McCarthy, AM (reprint author), Univ Penn, 423 Guardian Dr,Room 1009, Philadelphia, PA 19104 USA.
EM annemcc@mail.med.upenn.edu
FU National Institutes of Health grant from the National Cancer Institute
[5-R01-CA133004-3]
FX Supported by a National Institutes of Health grant from the National
Cancer Institute (5-R01-CA133004-3).
NR 25
TC 8
Z9 8
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD OCT 15
PY 2013
VL 119
IS 20
BP 3596
EP 3603
DI 10.1002/cncr.28268
PG 8
WC Oncology
SC Oncology
GA 230WJ
UT WOS:000325373700039
PM 23861169
ER
PT J
AU Skolarus, TA
Chan, S
Shelton, JB
Antonio, AL
Sales, AE
Malin, JL
Saigal, CS
AF Skolarus, Ted A.
Chan, Stephanie
Shelton, Jeremy B.
Antonio, Anna Liza
Sales, Anne E.
Malin, Jennifer L.
Saigal, Christopher S.
TI Quality of Prostate Cancer Care Among Rural Men in the Veterans Health
Administration
SO CANCER
LA English
DT Article
DE prostate cancer; quality; rural; integrated delivery system; access
ID RADIATION-THERAPY; ANDROGEN SUPPRESSION; ACCESS; ADENOCARCINOMA;
BARRIERS; TRIAL; RISK; TERM; VA
AB BACKGROUNDPatient travel distances, coupled with variation in facility-level resources, create barriers for prostate cancer care in the Veterans Health Administration integrated delivery system. For these reasons, the authors investigated the degree to which these barriers impact the quality of prostate cancer care.
METHODSThe Veterans Affairs Central Cancer Registry was used to identify all men who were diagnosed with prostate cancer in 2008. Patient residence was characterized using Rural Urban Commuting Area codes. The authors then examined whether rural residence, compared with urban residence, was associated with less access to cancer-related resources and worse quality of care for 5 prostate cancer quality measures.
RESULTSApproximately 25% of the 11,368 patients who were diagnosed with prostate cancer in 2008 lived in either a rural area or a large town. Rural patients tended to be white (62% urban vs 86% rural) and married (47% urban vs 63% rural), and they tended to have slightly higher incomes (all P<.01) but similar tumor grade (P=.23) and stage (P=.12) compared with urban patients. Rural patients were significantly less likely to be treated at facilities with comprehensive cancer resources, although they received a similar or better quality of care for 4 of the 5 prostate cancer quality measures. The time to prostate cancer treatment was similar (rural patients vs urban patients, 96.6 days vs 105.7 days).
CONCLUSIONSRural patients with prostate cancer had less access to comprehensive oncology resources, although they received a similar quality of care, compared with their urban counterparts in the Veterans Health Administration integrated delivery system. A better understanding of the degree to which facility factors contribute to the quality of cancer care may assist other organizations involved in rural health care delivery. Cancer 2013;119:3629-3635. (c) 2013 American Cancer Society.
C1 [Skolarus, Ted A.; Sales, Anne E.] Vet Affairs Ann Arbor Healthcare Syst, Hlth Serv Res & Dev Serv, Ctr Clin Management Res, Ann Arbor, MI USA.
[Skolarus, Ted A.] Univ Michigan, Dow Div Hlth Serv Res, Dept Urol, Ann Arbor, MI 48109 USA.
[Chan, Stephanie] Frederick S Pardee RAND Grad Sch, Santa Monica, CA USA.
[Shelton, Jeremy B.; Antonio, Anna Liza; Malin, Jennifer L.; Saigal, Christopher S.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Shelton, Jeremy B.; Saigal, Christopher S.] Univ Calif Los Angeles, Dept Urol, Los Angeles, CA USA.
[Sales, Anne E.] Univ Michigan, Sch Nursing, Ann Arbor, MI 48109 USA.
[Malin, Jennifer L.] Wellpoint Inc, Med Oncol, Indianapolis, IN USA.
RP Skolarus, TA (reprint author), Univ Michigan, Dept Urol, VA Ctr Clin Management Res, VA Ann Arbor Healthcare Syst, Ann Arbor, MI 48109 USA.
EM tskolar@med.umich.edu
OI Sales, Anne/0000-0001-9360-3334
FU Veterans Health Administration Office of Analytics and Business
Intelligence; VA HSR&D Career Development Award - 2 [CDA 12-171]
FX This work was supported by the Veterans Health Administration Office of
Analytics and Business Intelligence "Supportive Care, End of Life Care,
and Crosscutting Quality Indicators for Patients with Cancer Within VA"
Project. Dr. Skolarus is supported by a VA HSR&D Career Development
Award - 2 (CDA 12-171).
NR 33
TC 7
Z9 7
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD OCT 15
PY 2013
VL 119
IS 20
BP 3629
EP 3635
DI 10.1002/cncr.28275
PG 7
WC Oncology
SC Oncology
GA 230WJ
UT WOS:000325373700043
PM 23913676
ER
PT J
AU Wills, LP
Beeson, GC
Trager, RE
Lindsey, CC
Beeson, CC
Peterson, YK
Schnellmann, RG
AF Wills, Lauren P.
Beeson, Gyda C.
Trager, Richard E.
Lindsey, Christopher C.
Beeson, Craig C.
Peterson, Yuri K.
Schnellmann, Rick G.
TI High-throughput respirometric assay identifies predictive toxicophore of
mitochondrial injury
SO TOXICOLOGY AND APPLIED PHARMACOLOGY
LA English
DT Article
DE Mitochondria; Toxicophore; Renal proximal tubule cells; LOPAC;
ChemBridge; Seahorse Biosciences Extracellular Flux
ID OXYGEN-SENSITIVE PROBES; IN-VITRO; PERMEABILITY TRANSITION; TOXICITY;
CELLS; DRUGS; MECHANISMS; APOPTOSIS; CULTURE; TARGETS
AB Many environmental chemicals and drugs negatively affect human health through deleterious effects on mitochondrial function. Currently there is no chemical library of mitochondrial toxicants, and no reliable methods for predicting mitochondrial toxicity. We hypothesized that discrete toxicophores defined by distinct chemical entities can identify previously unidentified mitochondrial toxicants. We used a respirometric assay to screen 1760 compounds (5 mu M) from the LOPAC and ChemBridge DIVERSet libraries. Thirty-one of the assayed compounds decreased uncoupled respiration, a stress test for mitochondrial dysfunction, prior to a decrease in cell viability and reduced the oxygen consumption rate in isolated mitochondria. The mitochondrial toxicants were grouped by chemical similarity and two clusters containing four compounds each were identified. Cheminformatic analysis of one of the clusters identified previously uncharacterized mitochondrial toxicants from the ChemBridge DIVERSet This approach will enable the identification of mitochondrial toxicants and advance the prediction of mitochondrial toxicity for both drug discovery and risk assessment. (C) 2013 The Authors. Published by Elsevier Inc. All rights reserved.
C1 [Beeson, Gyda C.; Trager, Richard E.; Lindsey, Christopher C.; Peterson, Yuri K.; Schnellmann, Rick G.] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA.
[Schnellmann, Rick G.] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA.
[Wills, Lauren P.; Beeson, Craig C.] MitoHealth Inc, Charleston, SC 29403 USA.
RP Schnellmann, RG (reprint author), Med Univ S Carolina, Dept Pharmaceut & Biomed Sci, 280 Calhoun St,MSC140, Charleston, SC 29425 USA.
EM schnell@musc.edu
FU NCRR NIH HHS [S10 RR027122]; NIEHS NIH HHS [R44 ES019378, R43 ES019378];
NIGMS NIH HHS [R43 GM097770, R01 GM084147]
NR 44
TC 5
Z9 5
U1 1
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0041-008X
EI 1096-0333
J9 TOXICOL APPL PHARM
JI Toxicol. Appl. Pharmacol.
PD OCT 15
PY 2013
VL 272
IS 2
BP 490
EP 502
DI 10.1016/j.taap.2013.06.014
PG 13
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA 237XS
UT WOS:000325905500025
PM 23811330
ER
PT J
AU Jorgenson, TC
Zhong, WX
Oberley, TD
AF Jorgenson, Tonia C.
Zhong, Weixiong
Oberley, Terry D.
TI Redox Imbalance and Biochemical Changes in Cancer
SO CANCER RESEARCH
LA English
DT Article
ID MOLECULAR-MECHANISMS; S-GLUTATHIONYLATION; OXIDATIVE STRESS;
THIOREDOXIN; ACTIVATION; CELLS; NRF2; SUMOYLATION; METHYLATION; LEUKEMIA
AB For this article, we explore a hypothesis involving the possible role of reduction/oxidation (redox) state in cancer. We hypothesize that many modifications in cellular macromolecules, observed in cancer progression, may be caused by redox imbalance. Recent biochemical data suggest that human prostate cancer cell lines show a redox imbalance (oxidizing) compared with benign primary prostate epithelial cells; the degree of oxidation varied with aggressive behavior of each cell line. Our recent data suggest that human breast cancer tissues show a redox imbalance (reducing) compared with benign adjacent breast tissues. Accumulating data summarized in this article suggest that redox imbalance may regulate gene expression and alter protein stability by posttranslational modifications, in turn modulating existing cellular programs. Despite significant improvements in cancer therapeutics, resistance occurs, and redox imbalance may play a role in this process. Studies show that some cancer therapeutic agents increase generation of reactive oxygen/nitrogen species and antioxidant enzymes, which may alter total antioxidant capacity, cause cellular adaptation, and result in reduced effectiveness of treatment modalities. Approaches involving modulations of intra-and extracellular redox states, in combination with other therapies, may lead to new treatment options, especially for patients who are resistant to standard treatments. Cancer Res; 73(20); 6118-23. (C) 2013 AACR.
C1 [Jorgenson, Tonia C.; Zhong, Weixiong; Oberley, Terry D.] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Inst Med Res, Dept Pathol & Lab Med, Madison, WI 53705 USA.
[Zhong, Weixiong; Oberley, Terry D.] William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Med Serv, Madison, WI 53705 USA.
RP Jorgenson, TC (reprint author), Univ Wisconsin, Wisconsin Inst Med Res, 1111 Highland Ave, Madison, WI 53705 USA.
EM tjorgenson@wisc.edu
FU Department of Pathology and Laboratory Medicine, University of
Wisconsin; NCI UW Carbone Comprehensive Cancer Center (NIH) [P30
CA014520]; NIH [RO1CA139844, RO1CA139843, RO1CA073599]
FX This work was supported in part by funds from the Department of
Pathology and Laboratory Medicine, University of Wisconsin, NCI UW
Carbone Comprehensive Cancer Center (NIH grant P30 CA014520), NIH grants
RO1CA139844, RO1CA139843, RO1CA073599 (TDO-CoI), and resources and
facilities at the William S. Middleton Memorial Veterans Hospital
(Madison, WI). Tonia C. Jorgenson is supported in part by
PF-13-286-01-TBE from the American Cancer Society.
NR 30
TC 27
Z9 28
U1 0
U2 13
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD OCT 15
PY 2013
VL 73
IS 20
BP 6118
EP 6123
DI 10.1158/0008-5472.CAN-13-1117
PG 6
WC Oncology
SC Oncology
GA 236KV
UT WOS:000325796100004
PM 23878188
ER
PT J
AU Yarchoan, M
Louneva, N
Xie, SX
Swenson, FJ
Hu, W
Soares, H
Trojanowski, JQ
Lee, VMY
Kling, MA
Shaw, LM
Chen-Plotkin, A
Wolk, DA
Arnold, SE
AF Yarchoan, Mark
Louneva, Natalia
Xie, Sharon X.
Swenson, Frank J.
Hu, William
Soares, Holly
Trojanowski, John Q.
Lee, Virginia M. -Y.
Kling, Mitchel A.
Shaw, Leslie M.
Chen-Plotkin, Alice
Wolk, David A.
Arnold, Steven E.
TI Association of plasma C-reactive protein levels with the diagnosis of
Alzheimer's disease
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE Alzheimer disease; Mild cognitive impairment; C-reactive protein;
Inflammation; Biological markers; Apolipoprotein E
ID COGNITIVE FUNCTION; INFLAMMATION; RISK; DEMENTIA; MARKER; HEALTH; CRP
AB C-reactive protein (CRP) participates in the systemic response to inflammation. Previous studies report inconsistent findings regarding the relationship between plasma CRP and Alzheimer's disease (AD). We measured plasma CRP in 203 subjects with AD, 58 subjects with mild cognitive impairment (MCI) and 117 normal aging subjects and administered annual Mini-Mental State Examinations (MMSE) during a 3-year follow-up period to investigate CRP's relationship with diagnosis and progression of cognitive decline. Adjusted for age, sex, and education, subjects with AD had significantly lower levels of plasma CRP than subjects with MCI and normal aging. However, there was no significant association between plasma CRP at baseline and subsequent cognitive decline as assessed by longitudinal changes in MMSE score. Our results support previous reports of reduced levels of plasma CRP in AD and indicate its potential utility as a biomarker for the diagnosis of AD. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Yarchoan, Mark] Univ Penn, Dept Internal Med, Philadelphia, PA 19104 USA.
[Louneva, Natalia; Arnold, Steven E.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
[Xie, Sharon X.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
[Swenson, Frank J.] Pfizer Diagnost, PharmaTX Precis Med, Groton, CT USA.
[Hu, William] Emory Univ, Emory Alzheimers Dis Res Ctr, Atlanta, GA 30322 USA.
[Soares, Holly] Pfizer Global Res & Dev, Groton, CT USA.
[Trojanowski, John Q.; Lee, Virginia M. -Y.] Univ Penn, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA.
[Kling, Mitchel A.] Philadelphia VA Med Ctr, Behav Hlth Serv, Philadelphia, PA USA.
[Shaw, Leslie M.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA.
[Chen-Plotkin, Alice; Wolk, David A.; Arnold, Steven E.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA.
RP Arnold, SE (reprint author), 3615 Chestnut St, Philadelphia, PA 19104 USA.
EM steven.arnold@uphs.upenn.edu
OI Kling, Mitchel/0000-0002-2232-1409
FU National Institutes of Health [AG10124]; Penn-Pfizer Research Alliance
at the University of Pennsylvania; Marian S. Ware Alzheimer's Program;
Allen H. and Selma W. Berkman Charitable Trust
FX This study has been supported by the National Institutes of Health
(grant no. AG10124), the Penn-Pfizer Research Alliance at the University
of Pennsylvania, the Marian S. Ware Alzheimer's Program, and the Allen
H. and Selma W. Berkman Charitable Trust. We thank Xiaoyan Han, M.S.,
for her help with the statistical programming of the mixed-effects model
analysis.
NR 16
TC 12
Z9 12
U1 0
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 1878-5883
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD OCT 15
PY 2013
VL 333
IS 1-2
BP 9
EP 12
DI 10.1016/j.jns.2013.05.028
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 235SN
UT WOS:000325741100003
PM 23978419
ER
PT J
AU Yukl, SA
Shergill, AK
Ho, T
Killian, M
Girling, V
Epling, L
Li, PL
Wong, LK
Crouch, P
Deeks, SG
Havlir, DV
McQuaid, K
Sinclair, E
Wong, JK
AF Yukl, Steven A.
Shergill, Amandeep K.
Ho, Terence
Killian, Maudi
Girling, Valerie
Epling, Lorrie
Li, Peilin
Wong, Lisa K.
Crouch, Pierre
Deeks, Steven G.
Havlir, Diane V.
McQuaid, Kenneth
Sinclair, Elizabeth
Wong, Joseph K.
TI The Distribution of HIV DNA and RNA in Cell Subsets Differs in Gut and
Blood of HIV-Positive Patients on ART: Implications for Viral
Persistence
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV; HIV-1; ART; persistence; reservoir; CD4(+) T cell; gut; intestine;
ileum; rectum
ID ACTIVE ANTIRETROVIRAL THERAPY; CD4(+) T-CELLS; VIRUS TYPE-1 RNA;
LYMPHOID-TISSUE; IN-VIVO; PERIPHERAL-BLOOD; CENTRAL MEMORY; INFECTION;
PLASMA; RESERVOIR
AB Even with optimal antiretroviral therapy, human immunodeficiency virus (HIV) persists in plasma, blood cells, and tissues. To develop new therapies, it is essential to know what cell types harbor residual HIV. We measured levels of HIV DNA, RNA, and RNA/DNA ratios in sorted subsets of CD4(+) T cells (CCR7(+), transitional memory, and effector memory) and non-CD4(+) T leukocytes from blood, ileum, and rectum of 8 ART-suppressed HIV-positive subjects. Levels of HIV DNA/million cells in CCR7(+) and effector memory cells were higher in the ileum than blood. When normalized by cell frequencies, most HIV DNA and RNA in the blood were found in CCR7(+) cells, whereas in both gut sites, most HIV DNA and RNA were found in effector memory cells. HIV DNA and RNA were observed in non-CD4(+) T leukocytes at low levels, particularly in gut tissues. Compared to the blood, the ileum had higher levels of HIV DNA and RNA in both CD4(+) T cells and non-CD4(+) T leukocytes, whereas the rectum had higher HIV DNA levels in both cell types but lower RNA levels in CD4(+) T cells. Future studies should determine whether different mechanisms allow HIV to persist in these distinct reservoirs, and the degree to which different therapies can affect each reservoir.
C1 [Yukl, Steven A.; Shergill, Amandeep K.; Li, Peilin; Crouch, Pierre; McQuaid, Kenneth; Wong, Joseph K.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA 94121 USA.
[Yukl, Steven A.; Shergill, Amandeep K.; Ho, Terence; Killian, Maudi; Girling, Valerie; Epling, Lorrie; Li, Peilin; Crouch, Pierre; Deeks, Steven G.; Havlir, Diane V.; McQuaid, Kenneth; Sinclair, Elizabeth; Wong, Joseph K.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Ho, Terence; Killian, Maudi; Girling, Valerie; Epling, Lorrie; Deeks, Steven G.; Havlir, Diane V.; Sinclair, Elizabeth] San Francisco Gen Hosp, Dept Med, San Francisco, CA 94110 USA.
[Wong, Lisa K.] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA.
RP Yukl, SA (reprint author), San Francisco VA Med Ctr, 4150 Clement St,111W3, San Francisco, CA 94121 USA.
EM steven.yukl@ucsf.edu
FU US Department of Veterans Affairs [1 IK2 CX000520-01, I01 BX000192];
UCSF-Gladstone Center for AIDS Research (CFAR) [P30-AI027763]; National
Institute of Allergy and Infectious Diseases at the National Institutes
of Health [R56AI091573, K24 AI069994, U19AI096109]
FX This work was supported by the US Department of Veterans Affairs (1 IK2
CX000520-01 [to S. Y.], I01 BX000192 [to J. W.]); the UCSF-Gladstone
Center for AIDS Research (CFAR) (P30-AI027763 [to S. Y.]); and the
National Institute of Allergy and Infectious Diseases at the National
Institutes of Health (R56AI091573 [J. W., S. Y., A. S., D. H.], K24
AI069994 [to S. D.], U19AI096109 [to S. D., J. W.]).
NR 43
TC 42
Z9 42
U1 1
U2 15
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD OCT 15
PY 2013
VL 208
IS 8
BP 1212
EP 1220
DI 10.1093/infdis/jit308
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 223TJ
UT WOS:000324832800004
PM 23852128
ER
PT J
AU Caverly, TJ
Prochazka, AV
Stickrath, C
AF Caverly, Tanner J.
Prochazka, Allan V.
Stickrath, Chad
TI Do Physicians Have an Obligation to Disclose the Uncertainty About Harms
or Just the Harms? Reply
SO JAMA INTERNAL MEDICINE
LA English
DT Letter
ID COMPUTED-TOMOGRAPHY; RADIATION-EXPOSURE; CT SCANS; CHILDHOOD; RISK
C1 [Caverly, Tanner J.; Prochazka, Allan V.; Stickrath, Chad] Univ Colorado, Div Gen Internal Med, Dept Med, Aurora, CO 80042 USA.
[Caverly, Tanner J.; Prochazka, Allan V.; Stickrath, Chad] Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Caverly, TJ (reprint author), Univ Colorado, Univ Phys Inc, Div Gen Internal Med, Dept Med,Sch Med, 13199 E Montview Blvd,3rd Floor,Ste 300, Aurora, CO 80042 USA.
EM Tanner.Caverly@gmail.com
FU PHS HHS [T32HP1006]
NR 6
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD OCT 14
PY 2013
VL 173
IS 18
BP 1752
EP 1752
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 268TO
UT WOS:000328193600024
PM 24126773
ER
PT J
AU Singh, H
Sittig, DF
AF Singh, Hardeep
Sittig, Dean F.
TI Toward Electronic Medical Record Alerts That Consume Less Physician Time
Reply
SO JAMA INTERNAL MEDICINE
LA English
DT Letter
C1 [Singh, Hardeep] Baylor Coll Med, Dept Med, Houston VA Hlth Serv Res & Dev HSR&D, Ctr Excellence,Michael E DeBakey Vet Affairs Med, Houston, TX 77030 USA.
[Singh, Hardeep] Sect Hlth Serv Res, Houston, TX USA.
[Sittig, Dean F.] Univ Texas Houston, Sch Biomed Informat, Houston, TX USA.
[Sittig, Dean F.] Univ Texas Houston, Mem Hermann Ctr Healthcare Qual & Safety, Houston, TX USA.
RP Singh, H (reprint author), VA Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM hardeeps@bcm.edu
NR 6
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD OCT 14
PY 2013
VL 173
IS 18
BP 1756
EP 1756
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 268TO
UT WOS:000328193600031
PM 24126782
ER
PT J
AU Turner, EH
AF Turner, Erick H.
TI How to access and process FDA drug approval packages for use in research
SO BMJ-BRITISH MEDICAL JOURNAL
LA English
DT Article
ID CLINICAL-TRIALS; PUBLICATION; INFORMATION; DOCUMENTS; REVIEWS
C1 [Turner, Erick H.] Portland VA Med Ctr, Behav Hlth & Neurosci Div, Portland, OR USA.
[Turner, Erick H.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA.
[Turner, Erick H.] Oregon Hlth & Sci Univ, Dept Pharmacol, Portland, OR 97201 USA.
[Turner, Erick H.] Oregon Hlth & Sci Univ, Ctr Eth Hlth Care, Portland, OR 97201 USA.
RP Turner, EH (reprint author), Portland VA Med Ctr, Behav Hlth & Neurosci Div, Portland, OR USA.
EM turnere@ohsu.edu
RI Turner, Erick/A-4848-2008
OI Turner, Erick/0000-0002-3522-3357
NR 25
TC 15
Z9 15
U1 1
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1756-1833
J9 BMJ-BRIT MED J
JI BMJ-British Medical Journal
PD OCT 14
PY 2013
VL 347
AR f5992
DI 10.1136/bmj.f5992
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 238VR
UT WOS:000325980100001
PM 24126858
ER
PT J
AU Bekelman, JE
Epstein, AJ
Emanuel, EJ
AF Bekelman, Justin E.
Epstein, Andrew J.
Emanuel, Ezekiel J.
TI Single- vs Multiple-Fraction Radiotherapy for Bone Metastases From
Prostate Cancer
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter
C1 [Bekelman, Justin E.] Univ Penn, Perelman Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA.
[Epstein, Andrew J.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
[Emanuel, Ezekiel J.] Univ Penn, Perelman Sch Med, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA.
RP Bekelman, JE (reprint author), Univ Penn, Perelman Sch Med, 3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA.
EM bekelman@uphs.upenn.edu
FU NCI NIH HHS [K07 CA163616, K07-CA163616]
NR 6
TC 24
Z9 24
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD OCT 9
PY 2013
VL 310
IS 14
BP 1501
EP 1502
DI 10.1001/jama.2013.277081
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 230PK
UT WOS:000325354100027
PM 24104375
ER
PT J
AU Raitt, MH
AF Raitt, Merritt H.
TI Inappropriate Implantable Defibrillator Shocks
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Editorial Material
DE beta-blockers; carvedilol; defibrillator; heart failure; inappropriate
therapy
ID CARDIAC-RESYNCHRONIZATION THERAPY; HEART-FAILURE;
CARDIOVERTER-DEFIBRILLATORS; BETA-BLOCKERS; CARVEDILOL; METOPROLOL;
METAANALYSIS; PREVENTION; OUTCOMES; TRIAL
C1 [Raitt, Merritt H.] Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Div Cardiol, Portland, OR 97201 USA.
[Raitt, Merritt H.] Oregon Hlth & Sci Univ, Knight Cardiovasc Inst, Portland, OR 97201 USA.
RP Raitt, MH (reprint author), Portland VA Med Ctr, P-3 CARD,3710 SW US Vet Rd, Portland, OR 97239 USA.
EM merritt.raitt@va.gov
NR 14
TC 3
Z9 3
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD OCT 8
PY 2013
VL 62
IS 15
BP 1351
EP 1352
DI 10.1016/j.jacc.2013.05.055
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 225ZY
UT WOS:000325005000008
PM 23770170
ER
PT J
AU Zhang, JH
Palevsky, PM
Chertow, GM
Hartigan, J
O'Connor, TZ
Guarino, P
Zhou, BQ
AF Zhang, Jane H.
Palevsky, Paul M.
Chertow, Glenn M.
Hartigan, John
O'Connor, Theresa Z.
Guarino, Peter
Zhou, Bingqing
TI Piecewise Analysis of Patient Survival after Onset of AKI
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID ACUTE-RENAL-FAILURE; CRITICALLY-ILL PATIENTS; MORTALITY; EPIDEMIOLOGY;
INTENSITY; OUTCOMES; THERAPY; SUPPORT; TRIAL; POINT
AB Background and objectivesAKI affects approximately 2%-7% of hospitalized patients and >35% of critically ill patients. Survival after AKI may be described as having an acute phase (including an initial hyperacute component) followed by a convalescent phase, which may itself have early and late components.Design, setting, participants, & measurementsData from the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network (ATN) study was used to model mortality risk among patients with dialysis-requiring AKI. This study assumed that the mortality hazard can be described by a piecewise log-linear function with change points. Using an average likelihood method, the authors tested for the number of change points in a piecewise log-linear hazard model. The maximum likelihood approach to locate the change point(s) was then adopted, and associated parameters and standard errors were estimated.ResultsThere were 1124 ATN participants with follow-up to 1 year. The mortality hazard of AKI decreased over time with inflections in the rate of decrease at days 4, 42, and 148, with the sharpest change at day 42. The daily rate of decline in the log of the hazard for death was 0.220 over the first 4 days, 0.046 between day 4 and day 42, 0.017 between day 42 and day 148, and 0.003 between day 148 and day 365.ConclusionsThere appear to be two major phases of mortality risk after AKI: an early phase extending over the first 6 weeks and a late phase from 6 weeks to 1 year. Within the first 42 days, this can be further divided into hyperacute (days 1-4) and acute (days 4-42) phases. After 42 days, there appear to be early (days 42-148) and late (after day 148) convalescent phases. These findings may help to inform the design of AKI clinical trials and assist critical care physicians in prognostic stratification.
C1 [Zhang, Jane H.; O'Connor, Theresa Z.; Guarino, Peter; Zhou, Bingqing] Vet Affairs Connecticut Hlth Care Syst, Cooperat Studies Program Coordinating Ctr, West Haven, CT 06516 USA.
[Palevsky, Paul M.] Vet Affairs Pittsburgh Hlth Care Syst, Pittsburgh, PA USA.
[Palevsky, Paul M.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
[Chertow, Glenn M.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA.
[Hartigan, John] Yale Univ, Dept Stat, New Haven, CT USA.
[Zhou, Bingqing] Yale Univ, Sch Publ Hlth, Div Biostat, New Haven, CT USA.
RP Zhang, JH (reprint author), Vet Affairs Connecticut Hlth Care Syst, Cooperat Studies Program Coordinating Ctr, 950 Campbell Ave, West Haven, CT 06516 USA.
EM Jane.Zhang@va.gov
OI Palevsky, Paul/0000-0002-7334-5400
FU Department of Veterans Affairs Office of Research and Development;
National Institute of Diabetes and Digestive and Kidney Diseases
[Y1-DK-3508-01]
FX This study was supported by the Cooperative Studies Program of the
Department of Veterans Affairs Office of Research and Development and by
the National Institute of Diabetes and Digestive and Kidney Diseases
(interagency agreement Y1-DK-3508-01).
NR 19
TC 4
Z9 4
U1 0
U2 1
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
EI 1555-905X
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD OCT 7
PY 2013
VL 8
IS 10
BP 1679
EP 1684
DI 10.2215/CJN.07250712
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA 229MA
UT WOS:000325268200008
PM 23813558
ER
PT J
AU Lee, DY
Wauquier, F
Eid, AA
Roman, LJ
Ghosh-Choudhury, G
Khazim, K
Block, K
Gorin, Y
AF Lee, Doug-Yoon
Wauquier, Fabien
Eid, Assaad A.
Roman, Linda J.
Ghosh-Choudhury, Goutam
Khazim, Khaled
Block, Karen
Gorin, Yves
TI Nox4 NADPH Oxidase Mediates Peroxynitrite-dependent Uncoupling of
Endothelial Nitric-oxide Synthase and Fibronectin Expression in Response
to Angiotensin II ROLE OF MITOCHONDRIAL REACTIVE OXYGEN SPECIES
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE Angiotensin II; Extracellular Matrix Proteins; Kidney; Nitric-oxide
Synthase; Nox; Oxidative Stress
ID RAT MESANGIAL CELLS; EXPERIMENTAL DIABETIC-NEPHROPATHY; NAD(P)H OXIDASE;
MOLECULAR-MECHANISMS; GLOMERULAR INJURY; RECEPTOR BLOCKADE;
VASCULAR-DISEASE; REDOX CONTROL; UP-REGULATION; SUPEROXIDE
AB Activation of glomerular mesangial cells (MCs) by angiotensin II (Ang II) leads to extracellular matrix accumulation. Here, we demonstrate that, in MCs, Ang II induces endothelial nitric-oxide synthase (eNOS) uncoupling with enhanced generation of reactive oxygen species (ROS) and decreased production of NO. Ang II promotes a rapid increase in 3-nitrotyrosine formation, and uric acid attenuates Ang II-induced decrease in NO bioavailability, demonstrating that peroxynitrite mediates the effects of Ang II on eNOS dysfunction. Ang II rapidly up-regulates Nox4 protein. Inhibition of Nox4 abolishes the increase in ROS and peroxynitrite generation as well as eNOS uncoupling triggered by Ang II, indicating that Nox4 is upstream of eNOS. This pathway contributes to Ang II-mediated fibronectin accumulation in MCs. Ang II also elicits an increase in mitochondrial abundance of Nox4 protein, and the oxidase contributes to ROS production in mitochondria. Overexpression of mitochondrial manganese superoxide dismutase prevents the stimulatory effects of Ang II on mitochondrial ROS production, loss of NO availability, and MC fibronectin accumulation, whereas manganese superoxide dismutase depletion increases mitochondrial ROS, NO deficiency, and fibronectin synthesis basally and in cells exposed to Ang II. This work provides the first evidence that uncoupled eNOS is responsible for Ang II-induced MC fibronectin accumulation and identifies Nox4 and mitochondrial ROS as mediators of eNOS dysfunction. These data shed light on molecular processes underlying the oxidative signaling cascade engaged by Ang II and identify potential targets for intervention to prevent renal fibrosis.
C1 [Lee, Doug-Yoon; Wauquier, Fabien; Eid, Assaad A.; Ghosh-Choudhury, Goutam; Khazim, Khaled; Block, Karen; Gorin, Yves] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Roman, Linda J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA.
[Ghosh-Choudhury, Goutam] Vet Adm Res & Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA.
[Ghosh-Choudhury, Goutam; Block, Karen] South Texas Vet Hlth Care Syst, Audie Leon Murphy Mem Hosp Div, San Antonio, TX 78229 USA.
RP Gorin, Y (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Nephrol MC 7882, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM gorin@uthscsa.edu
FU National Institutes of Health [RO1 DK 079996, RO1 CA 131272, RO1 DK
50190]; Juvenile Diabetes Research Foundation Multiproject Grant;
Juvenile Diabetes Research Foundation Advanced Research Fellowship
Grant; Veterans Administration Merit Awards; Veterans Administration
Senior Research Career Scientist Award
FX This work was supported, in whole or in part, by National Institutes of
Health Grants RO1 DK 079996 (to Y. G.), RO1 CA 131272 (to K. B.), and
RO1 DK 50190 (to G. G. C.). This work was also supported in part by a
Juvenile Diabetes Research Foundation Multiproject Grant (to Y. G. and
K. B.), a Juvenile Diabetes Research Foundation Advanced Research
Fellowship Grant (to A. A. E.), and Veterans Administration Merit Awards
(to K. B. and G. G. C.).; Recipient of Veterans Administration Senior
Research Career Scientist Award.
NR 78
TC 46
Z9 47
U1 2
U2 14
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD OCT 4
PY 2013
VL 288
IS 40
BP 28668
EP 28686
DI 10.1074/jbc.M113.470971
PG 19
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 298BL
UT WOS:000330298800022
PM 23940049
ER
PT J
AU Sano, M
Egelko, S
Donohue, M
Paparello, S
Sun, CK
Aisen, P
Ferris, S
Kaye, J
Hayes, T
Mundt, J
AF Sano, Mary
Egelko, Susan
Donohue, Michael
Paparello, Silvia
Sun, Chung-Kai
Aisen, Paul
Ferris, Steven
Kaye, Jeffrey
Hayes, Tamara
Mundt, James
TI Satisfaction of elderly research participants with home-based clinical
trial participation
SO INTERNATIONAL PSYCHOGERIATRICS
LA English
DT Meeting Abstract
C1 [Sano, Mary; Egelko, Susan] Mt Sinai Sch Med, New York, NY USA.
[Sano, Mary; Egelko, Susan] James J Peters VAMC, New York, NY USA.
[Donohue, Michael; Paparello, Silvia; Sun, Chung-Kai; Aisen, Paul] Univ Calif San Diego, San Diego, CA 92103 USA.
[Ferris, Steven] NYU Langone Med Ctr ADC, New York, NY USA.
[Kaye, Jeffrey; Hayes, Tamara] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Mundt, James] Ctr Psychol Res Training & Consultat, Little Rock, AR USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1041-6102
EI 1741-203X
J9 INT PSYCHOGERIATR
JI Int. Psychogeriatr.
PD OCT
PY 2013
VL 25
SU 1
MA PS01-106
BP S109
EP S110
PG 2
WC Psychology, Clinical; Geriatrics & Gerontology; Gerontology; Psychiatry;
Psychology
SC Psychology; Geriatrics & Gerontology; Psychiatry
GA AJ5UB
UT WOS:000337753100247
ER
PT J
AU Havasi, V
Clines, GA
Stalvey, MS
AF Havasi, V
Clines, G. A.
Stalvey, M. S.
TI REDUCED BONE DENSITY IN G551D-CFTR MICE: A NOVEL MODEL TO STUDY EFFECTS
OF CFTR ON BONE METABOLISM
SO PEDIATRIC PULMONOLOGY
LA English
DT Meeting Abstract
C1 [Havasi, V; Clines, G. A.; Stalvey, M. S.] Univ Alabama Birmingham, Birmingham, AL USA.
[Clines, G. A.] Univ Alabama Birmingham, Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 8755-6863
EI 1099-0496
J9 PEDIATR PULM
JI Pediatr. Pulmonol.
PD OCT
PY 2013
VL 48
SU 36
BP 419
EP 420
PG 2
WC Pediatrics; Respiratory System
SC Pediatrics; Respiratory System
GA AF0FB
UT WOS:000334387200658
ER
PT J
AU Roetker, NS
Page, CD
Yonker, JA
Chang, V
Roan, CL
Herd, P
Hauser, TS
Hauser, RM
Atwood, CS
AF Roetker, Nicholas S.
Page, C. David
Yonker, James A.
Chang, Vicky
Roan, Carol L.
Herd, Pamela
Hauser, Taissa S.
Hauser, Robert M.
Atwood, Craig S.
TI Assessment of Genetic and Nongenetic Interactions for the Prediction of
Depressive Symptomatology: An Analysis of the Wisconsin Longitudinal
Study Using Machine Learning Algorithms
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID NATIONAL COMORBIDITY SURVEY; SEROTONIN TRANSPORTER GENE; GENOME-WIDE
ASSOCIATION; STRESSFUL LIFE EVENTS; HORMONE-RECEPTOR GENE; MAJOR
DEPRESSION; ADULT DEPRESSION; ENVIRONMENT INTERACTIONS; CHILDHOOD
MALTREATMENT; TREATMENT RESPONSE
AB Objectives. We examined depression within a multidimensional framework consisting of genetic, environmental, and sociobehavioral factors and, using machine learning algorithms, explored interactions among these factors that might better explain the etiology of depressive symptoms.
Methods. We measured current depressive symptoms using the Center for Epidemiologic Studies Depression Scale (n = 6378 participants in the Wisconsin Longitudinal Study). Genetic factors were 78 single nucleotide polymorphisms (SNPs); environmental factors-13 stressful life events (SLEs), plus a composite proportion of SLEs index; and sociobehavioral factors-18 personality, intelligence, and other health or behavioral measures. We performed traditional SNP associations via logistic regression likelihood ratio testing and explored interactions with support vector machines and Bayesian networks.
Results. After correction for multiple testing, we found no significant single genotypic associations with depressive symptoms. Machine learning algorithms showed no evidence of interactions. Naive Bayes produced the best models in both subsets and included only environmental and sociobehavioral factors.
Conclusions. We found no single or interactive associations with genetic factors and depressive symptoms. Various environmental and sociobehavioral factors were more predictive of depressive symptoms, yet their impacts were independent of one another. A genome-wide analysis of genetic alterations using machine learning methodologies will provide a framework for identifying genetic-environmental-sociobehavioral interactions in depressive symptoms.
C1 [Roetker, Nicholas S.; Yonker, James A.; Chang, Vicky; Roan, Carol L.; Herd, Pamela; Hauser, Taissa S.; Hauser, Robert M.] Univ Wisconsin Madison, Dept Sociol, Madison, WI 53715 USA.
[Herd, Pamela] Univ Wisconsin Madison, La Follete Sch Publ Affairs, Madison, WI USA.
[Page, C. David] Univ Wisconsin Madison, Dept Biostat & Med Informat, Madison, WI USA.
[Atwood, Craig S.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA.
[Atwood, Craig S.] Univ Wisconsin Madison Sch Med & Publ Hlth, Dept Med, Madison, WI 53705 USA.
RP Atwood, CS (reprint author), Univ Wisconsin Madison Sch Med & Publ Hlth, William S Middleton Mem Vet Hosp GRECC 11G, 2500 Overlook Terrace, Madison, WI 53705 USA.
EM csa@medicine.wisc.edu
RI Yonker, James/J-6561-2014
OI Yonker, James/0000-0002-9483-8511
FU National Institute on Aging [AG-9775, AG-21079, AG-033285]; Vilas Estate
Trust; National Science Foundation; Spencer Foundation; Graduate School
of the University of Wisconsin-Madison
FX This research used data from the Wisconsin Longitudinal Study (WLS) of
the University of Wisconsin-Madison. Since 1991, the WLS has been
supported principally by the National Institute on Aging (AG-9775,
AG-21079, and AG-033285), with additional support from the Vilas Estate
Trust, the National Science Foundation, the Spencer Foundation, and the
Graduate School of the University of Wisconsin-Madison. A public use
file of data from the Wisconsin Longitudinal Study is available from the
WLS, University of Wisconsin-Madison, 1180 Observatory Drive, Madison,
WI 53706, and at http://www.ssc.wisc.edu/wlsresearch/data. This material
is the result of work supported with resources at the William S.
Middleton Memorial Veterans Hospital, Madison, WI.
NR 82
TC 1
Z9 1
U1 2
U2 9
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD OCT
PY 2013
VL 103
SU 1
BP 136
EP 144
DI 10.2105/AJPH.2012.301141
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AA4NC
UT WOS:000331071600021
ER
PT J
AU Ioannou, GN
Scott, JD
Yang, Y
Green, P
Beste, LA
AF Ioannou, George N.
Scott, John D.
Yang, Yin
Green, Pamela
Beste, Lauren A.
TI Antiviral Treatment for Hepatitis C Virus in HIV/HCV Co-infected
Patients
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Ioannou, George N.; Yang, Yin; Green, Pamela; Beste, Lauren A.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
[Ioannou, George N.; Scott, John D.] Univ Washington, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 37
BP 225A
EP 225A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252201037
ER
PT J
AU Harwood, NM
Golden-Mason, L
Rosen, HR
Mengshol, JA
AF Harwood, Noah M.
Golden-Mason, Lucy
Rosen, Hugo R.
Mengshol, John A.
TI Macrophage Immunoregulatory Galectin-9 Production is increased by
Contact with Hepatitis C Virus-infected Hepatocytes and Differentiation
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Harwood, Noah M.; Golden-Mason, Lucy; Rosen, Hugo R.; Mengshol, John A.] Univ Colorado SOM, Denver VA Med Ctr, Denver, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 235
BP 325A
EP 325A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252201235
ER
PT J
AU Bril, F
Lomonaco, R
Orsak, B
Chang, Z
Ortiz-Lopez, C
Hecht, J
Tio, F
Cusi, K
AF Bril, Fernando
Lomonaco, Romina
Orsak, Beverly
Chang, Zhi
Ortiz-Lopez, Carolina
Hecht, Joan
Tio, Fermin
Cusi, Kenneth
TI Role of plasma FGF21 as a biomarker for nonalcoholic fatty liver disease
(NAFLD) and steatohepatitis (NASH)
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Bril, Fernando; Lomonaco, Romina; Cusi, Kenneth] Univ Florida, Gainesville, FL USA.
[Orsak, Beverly; Chang, Zhi; Ortiz-Lopez, Carolina; Hecht, Joan; Tio, Fermin; Cusi, Kenneth] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Hecht, Joan; Tio, Fermin] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA.
NR 0
TC 0
Z9 0
U1 3
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 585
BP 487A
EP 487A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252202189
ER
PT J
AU Bril, F
Lomonaco, R
Orsak, B
Hecht, J
Ortiz-Lopez, C
Hardies, J
Tio, F
Cusi, K
AF Bril, Fernando
Lomonaco, Romina
Orsak, Beverly
Hecht, Joan
Ortiz-Lopez, Carolina
Hardies, Jean
Tio, Fermin
Cusi, Kenneth
TI Predictors of response after extended pioglitazone treatment in patients
with prediabetes or T2DM and nonalcoholic steatohepatitis (NASH)
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Bril, Fernando; Lomonaco, Romina; Hardies, Jean; Cusi, Kenneth] Univ Florida, Gainesville, FL USA.
[Orsak, Beverly; Hecht, Joan; Ortiz-Lopez, Carolina; Tio, Fermin; Cusi, Kenneth] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Hecht, Joan; Tio, Fermin] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 639
BP 513A
EP 514A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252202243
ER
PT J
AU Bril, F
Lomonaco, R
Orsak, B
Subbarayan, S
Kadiyala, S
Ortiz-Lopez, C
Webb, A
Cusi, K
AF Bril, Fernando
Lomonaco, Romina
Orsak, Beverly
Subbarayan, Sreevidya
Kadiyala, Sushma
Ortiz-Lopez, Carolina
Webb, Amy
Cusi, Kenneth
TI Is there a link between hypothyroidism and nonalcoholic fatty liver
disease?
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Bril, Fernando; Lomonaco, Romina; Subbarayan, Sreevidya; Kadiyala, Sushma; Cusi, Kenneth] Univ Florida, Gainesville, FL USA.
[Orsak, Beverly; Ortiz-Lopez, Carolina; Webb, Amy; Cusi, Kenneth] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Webb, Amy] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 656
BP 521A
EP 522A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252202260
ER
PT J
AU Bril, F
Lomonaco, R
Orsak, B
Ortiz-Lopez, C
Biernacki, D
Klaczak, A
Chang, Z
Hardies, J
Cusi, K
AF Bril, Fernando
Lomonaco, Romina
Orsak, Beverly
Ortiz-Lopez, Carolina
Biernacki, Diane
Klaczak, Ashley
Chang, Zhi
Hardies, Jean
Cusi, Kenneth
TI Vitamin D deficiency and development of nonalcoholic fatty liver disease
(NAFLD) and nonalcoholic steatohepatitis (NASH)
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Bril, Fernando; Lomonaco, Romina; Biernacki, Diane; Klaczak, Ashley; Cusi, Kenneth] Univ Florida, Gainesville, FL USA.
[Orsak, Beverly; Ortiz-Lopez, Carolina; Chang, Zhi; Hardies, Jean; Cusi, Kenneth] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Biernacki, Diane] Malcom Randall Vet Adm Med Ctr, Gainesville, FL USA.
[Hardies, Jean] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA.
NR 0
TC 0
Z9 0
U1 2
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 657
BP 522A
EP 522A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252202261
ER
PT J
AU Chang, MF
Dominitz, JA
Ioannou, GN
Forsberg, CW
Boyko, EJ
Sporleder, JL
Smith, NL
AF Chang, Michael F.
Dominitz, Jason A.
Ioannou, George N.
Forsberg, Christopher W.
Boyko, Edward J.
Sporleder, Jennifer L.
Smith, Nicholas L.
TI Elevated prevalence of hepatitis B chronic infection and exposure in
users of United States Veterans Medical Centers
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Chang, Michael F.] OHSU PVAMC, Portland, OR USA.
[Chang, Michael F.] Portland VA Med Ctr, Northwest Hepatitis Resource Ctr C, Portland, OR USA.
[Dominitz, Jason A.; Ioannou, George N.] VA Puget Sound Hlth Care Syst, Dept Med, Div Gastroenterol, Seattle, WA USA.
[Dominitz, Jason A.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Sporleder, Jennifer L.] VA Puget Sound Hlth Care Syst, Northwest Hepatitis Resource Ctr C, Seattle, WA USA.
[Forsberg, Christopher W.; Sporleder, Jennifer L.; Smith, Nicholas L.] VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA.
[Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA.
[Boyko, Edward J.; Smith, Nicholas L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 876
BP 623A
EP 624A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252203044
ER
PT J
AU Basu, P
Shah, NJ
Rahman, MA
Siriki, R
Farhat, S
AF Basu, Patrick
Shah, Niraj J.
Rahman, Md A.
Siriki, Ravi
Farhat, Sakina
TI Restless Leg Syndrome (RLS) is associated with Hepatic Encephalopathy
(HE) in decompensated cirrhosis. A clinical pilot study
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Basu, Patrick; Farhat, Sakina] Columbia Univ, Sch Phys & Surg, Forest Hills, NY USA.
[Basu, Patrick; Rahman, Md A.; Siriki, Ravi] NSLIJHS Hofstra North Shore LIJ Sch Med, New York, NY USA.
[Shah, Niraj J.] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 1355
BP 867A
EP 867A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252204138
ER
PT J
AU Tartaglione, E
Derleth, M
Yu, L
Ioannou, GN
AF Tartaglione, Erica
Derleth, Mark
Yu, Lei
Ioannou, George N.
TI Can computerized brain training games be used to identify early
cognitive impairment in cirrhosis?
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Tartaglione, Erica; Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
[Derleth, Mark; Yu, Lei; Ioannou, George N.] Univ Washington, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 1391
BP 884A
EP 884A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252204174
ER
PT J
AU Berry, K
Ioannou, GN
AF Berry, Kristin
Ioannou, George N.
TI The association between transjugular intrahepatic portosystemic shunt
and survival
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Berry, Kristin; Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
[Ioannou, George N.] Univ Washington, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 1634
BP 996A
EP 996A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252204417
ER
PT J
AU Tarlow, B
Naugler, WE
Orloff, SL
Haft, A
Grompe, M
AF Tarlow, Branden
Naugler, Willscott E.
Orloff, Susan L.
Haft, Annelise
Grompe, Markus
TI Repopulation of mouse liver with human hepatocytes from core biopsies: a
new approach to modeling human liver diseases
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Tarlow, Branden; Naugler, Willscott E.; Haft, Annelise; Grompe, Markus] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Orloff, Susan L.] Portland VA Med Ctr, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 1664
BP 1010A
EP 1010A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252205014
ER
PT J
AU Basu, P
Shah, NJ
Siriki, R
Rahman, MA
Farhat, S
AF Basu, Patrick
Shah, Niraj J.
Siriki, Ravi
Rahman, Md A.
Farhat, Sakina
TI Romiplostim's Effect to Optimize SVR with Telaprevir, Ribavirin, And Peg
Interferon-alfa 2a in Thrombocytopenic Cirrhotics with Chronic Hepatitis
C. A Placebo Controlled Prospective Clinical Trial: RESTRAINT C Trial
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Basu, Patrick; Farhat, Sakina] Columbia Univ Sch Phys & Surg, New York, NY USA.
[Basu, Patrick; Siriki, Ravi; Rahman, Md A.] NSLIJHS Hofstra North Shore LIJ Sch Med, New York, NY USA.
[Shah, Niraj J.] Mt Sinai, Icahn Sch Med, James J Peters VA Med Ctr, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 1886
BP 1117A
EP 1117A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252205236
ER
PT J
AU Saxena, V
Yee, HS
Catalli, L
Wayne, EM
Chua, J
Monto, A
Terrault, N
AF Saxena, Varun
Yee, Helen S.
Catalli, Lisa
Wayne, Elizabeth M.
Chua, Joshua
Monto, Alexander
Terrault, Norah
TI Protease-Inhibitor (PI) Triple Therapy (TT) in Mildly Decompensated
Cirrhotics: Predictors of Treatment Discontinuation, Worsening
Decompensation and Sustained Virologic Response
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Saxena, Varun; Yee, Helen S.; Catalli, Lisa; Wayne, Elizabeth M.; Monto, Alexander; Terrault, Norah] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Yee, Helen S.; Chua, Joshua; Monto, Alexander] San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 1969
BP 1161A
EP 1161A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252205319
ER
PT J
AU Ojiro, K
Kikuchi, M
Park, JJ
Bunchorntavakul, C
Jones, LM
Valiga, ME
Kaplan, DE
Nunes, F
Reddy, R
Chang, KM
AF Ojiro, Keisuke
Kikuchi, Masahiro
Park, Jang-June
Bunchorntavakul, Chalermrat
Jones, Lisa M.
Valiga, Mary E.
Kaplan, David E.
Nunes, Frederick
Reddy, Rajender
Chang, Kyong-Mi
TI IL28B genotype defines differential immune costimulatory receptor
expression in acute hepatitis C
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Ojiro, Keisuke; Kikuchi, Masahiro; Park, Jang-June; Bunchorntavakul, Chalermrat; Jones, Lisa M.; Valiga, Mary E.; Kaplan, David E.; Nunes, Frederick; Reddy, Rajender; Chang, Kyong-Mi] Univ Penn, Philadelphia, PA 19104 USA.
[Ojiro, Keisuke; Kikuchi, Masahiro; Park, Jang-June; Valiga, Mary E.; Kaplan, David E.; Chang, Kyong-Mi] Philadelphia VA Med Ctr, Philadelphia, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 2024
BP 1187A
EP 1187A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252205374
ER
PT J
AU Beste, LA
Ioannou, GN
Yang, Y
Chang, MF
Ross, D
Dominitz, JA
AF Beste, Lauren A.
Ioannou, George N.
Yang, Yin
Chang, Michael F.
Ross, David
Dominitz, Jason A.
TI Improvement in use of hepatocellular carcinoma surveillance by a
primary-care oriented computerized clinical reminder
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Beste, Lauren A.] VA Puget Sound Hlth Care Syst, Primary Care, Seattle, WA USA.
[Beste, Lauren A.; Ioannou, George N.; Dominitz, Jason A.] Univ Washington, Seattle, WA 98195 USA.
[Ioannou, George N.; Dominitz, Jason A.] VA Puget Sound Hlth Care Syst, Gastroenterol, Seattle, WA USA.
[Chang, Michael F.] Portland VA Med Ctr, Hepatol, Portland, OR USA.
[Ross, David] VA Cent Off, HIV Hepatitis C & Publ Hlth Pathogens Program, Washington, DC USA.
[Chang, Michael F.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Yang, Yin] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 2037
BP 1193A
EP 1193A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252205387
ER
PT J
AU Beste, LA
Harp, BK
Blais, RK
Zickmund, S
AF Beste, Lauren A.
Harp, Bonnie K.
Blais, Rebecca K.
Zickmund, Susan
TI "They Gotta Want to Live More Than They Want to Die": Primary Care
Attitudes and Beliefs about Cirrhosis
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Beste, Lauren A.] VA Puget Sound Hlth Care Syst, Primary Care, Seattle, WA USA.
[Harp, Bonnie K.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA.
[Blais, Rebecca K.] VA Puget Sound Hlth Care Syst, Mental Hlth, Seattle, WA USA.
[Beste, Lauren A.] Univ Washington, Seattle, WA 98195 USA.
[Zickmund, Susan] VA Pittsburgh Hlth Care Syst, Hlth Serv Res & Dev, Pittsburgh, PA USA.
[Zickmund, Susan] Univ Pittsburgh, Dept Med & Clin & Translat Sci, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 2061
BP 1204A
EP 1205A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252206013
ER
PT J
AU Fox, RK
Marcus, S
Merchante, N
Kikuchi, L
Minguez, B
Vispo, E
Harris, M
Badshah, MB
Jain, MK
Page, EE
Kaplan, DE
Nelson, M
Barrero, P
Pineda, JA
Brau, N
AF Fox, Rena K.
Marcus, Sonja
Merchante, Nicolas
Kikuchi, Luciana
Minguez, Beatriz
Vispo, Eugenia
Harris, Marianne
Badshah, Maaz B.
Jain, Mamta K.
Page, Emma E.
Kaplan, David E.
Nelson, Mark
Barrero, Pablo
Pineda, Juan A.
Brau, Norbert
TI Impact of Screening on Staging and Survival of Hepatocellular Carcinoma
(HCC) in HIV/HCV-Coinfected Patients
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Fox, Rena K.] Univ Calif San Francicso, San Francisco, CA USA.
[Marcus, Sonja; Badshah, Maaz B.; Brau, Norbert] Bronx VA Med Ctr, Bronx, NY USA.
[Merchante, Nicolas; Pineda, Juan A.] Hosp Univ Valme, Seville, Spain.
[Kikuchi, Luciana] Univ Sao Paulo, Sao Paulo, Brazil.
[Minguez, Beatriz] Hosp Univ Vall dHebron, Barcelona, Spain.
[Vispo, Eugenia; Barrero, Pablo] Hosp Carlos III, Madrid, Spain.
[Harris, Marianne] St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada.
[Harris, Marianne] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
[Jain, Mamta K.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
[Page, Emma E.; Nelson, Mark] Chelsea & Westminster Hosp, London, England.
[Page, Emma E.; Nelson, Mark] Univ London Imperial Coll Sci Technol & Med, London, England.
[Kaplan, David E.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Kaplan, David E.] Univ Penn, Philadelphia, PA 19104 USA.
[Brau, Norbert] Mt Sinai Sch Med, New York, NY USA.
RI Minguez, Beatriz/N-4456-2014
OI Minguez, Beatriz/0000-0002-7276-9666
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 2125
BP 1236A
EP 1236A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252206077
ER
PT J
AU Marks, KM
Page, EE
Merchante, N
Kikuchi, LO
Minguez, B
Vispo, E
Harris, M
Badshah, MB
Jain, MK
Marcus, S
Kaplan, DE
Nelson, M
Barrero, P
Pineda, JA
Brau, N
AF Marks, Kristen M.
Page, Emma E.
Merchante, Nicolas
Kikuchi, Luciana O.
Minguez, Beatriz
Vispo, Eugenia
Harris, Marianne
Badshah, Maaz B.
Jain, Mamta K.
Marcus, Sonja
Kaplan, David E.
Nelson, Mark
Barrero, Pablo
Pineda, Juan A.
Brau, Norbert
TI Trends of Hepatocellular Carcinoma (HCC) in HIV-Infected Patients over
Time, 1995-2013
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Marks, Kristen M.] Weill Cornell Coll Med, New York, NY USA.
[Badshah, Maaz B.; Marcus, Sonja; Brau, Norbert] Bronx VA Med Ctr, Bronx, NY USA.
[Merchante, Nicolas; Pineda, Juan A.] Hosp Univ Valme, Seville, Spain.
[Harris, Marianne] St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada.
[Harris, Marianne] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
[Kikuchi, Luciana O.] Univ Sao Paulo, Sao Paulo, Brazil.
[Minguez, Beatriz] Hosp Univ Vall dHebron, Barcelona, Spain.
[Vispo, Eugenia; Barrero, Pablo] Hosp Carlos III, Madrid, Spain.
[Jain, Mamta K.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
[Nelson, Mark] Chelsea & Westminster Hosp, London, England.
[Nelson, Mark] Univ London Imperial Coll Sci Technol & Med, London, England.
[Kaplan, David E.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Kaplan, David E.] Univ Penn, Philadelphia, PA 19104 USA.
[Brau, Norbert] Mt Sinai Sch Med, New York, NY USA.
RI Minguez, Beatriz/N-4456-2014
OI Minguez, Beatriz/0000-0002-7276-9666
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 2151
BP 1249A
EP 1249A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252206103
ER
PT J
AU Ioannou, GN
Bryson, C
Weiss, NS
Boyko, EJ
AF Ioannou, George N.
Bryson, Christopher
Weiss, Noel S.
Boyko, Edward J.
TI Antiretroviral medications, lipodystrophy and cirrhosis in HIV-infected
patients
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Ioannou, George N.; Bryson, Christopher; Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
[Ioannou, George N.; Bryson, Christopher; Weiss, Noel S.; Boyko, Edward J.] Univ Washington, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 2216
BP 1279A
EP 1280A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252206168
ER
PT J
AU Yu, L
Morishima, C
Ioannou, GN
AF Yu, Lei
Morishima, Chihiro
Ioannou, George N.
TI Dietary cholesterol intake is associated with death and liver
transplantation in chronic hepatitis C virus infection: Analysis of
extended follow-up data from the HALT-C trial
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Yu, Lei; Morishima, Chihiro; Ioannou, George N.] Univ Washington, Seattle, WA 98195 USA.
[Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 2219
BP 1281A
EP 1281A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252206171
ER
PT J
AU Dieperink, E
Fuller, B
Ho, SB
Thuras, P
McMaken, K
Shira, K
Lenox, R
Wasil, MM
Isenhart, C
Morgan, TR
Hauser, P
AF Dieperink, Eric
Fuller, Bret
Ho, Samuel B.
Thuras, Paul
McMaken, Kelly
Shira, Kern
Lenox, Rebecca
Wasil, Michelene M.
Isenhart, Carl
Morgan, Timothy R.
Hauser, Peter
TI Association of self-reported change in alcohol use behavior with changes
in percent carbohydrate deficient transferring (%CDT), ethyl glucuronide
(EtG) and ethyl sulfate (EtS) levels in Veterans with Hepatitis C
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Ho, Samuel B.; Wasil, Michelene M.] VA San Diego Healthcare Syst, San Diego, CA USA.
[Fuller, Bret; Lenox, Rebecca] Portland VA Med Ctr, Portland, OR USA.
[Dieperink, Eric; Thuras, Paul; McMaken, Kelly; Isenhart, Carl] Minneapolis VA Med Ctr, Minneapolis, MN USA.
[Shira, Kern; Morgan, Timothy R.; Hauser, Peter] Long Beach VA Med Ctr, Long Beach, CA USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 2229
BP 1286A
EP 1286A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252206181
ER
PT J
AU Chapman, LW
Hsiao, JL
Sarantopoulos, P
Chiu, MW
AF Chapman, Lance W.
Hsiao, Jennifer L.
Sarantopoulos, Peter
Chiu, Melvin W.
TI Reddish-Brown Nodules and Papules in an Elderly Man Progressive nodular
histiocytosis
SO JAMA DERMATOLOGY
LA English
DT Editorial Material
C1 [Chapman, Lance W.; Hsiao, Jennifer L.; Chiu, Melvin W.] Univ Calif Los Angeles, David Geffen Sch Med, Div Dermatol, Los Angeles, CA 90095 USA.
[Sarantopoulos, Peter] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA.
[Chiu, Melvin W.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Dermatol, Los Angeles, CA USA.
RP Chiu, MW (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Dermatol, 200 UCLA Med Plaza,Ste 450, Los Angeles, CA 90095 USA.
EM mchiu@mednet.ucla.edu
NR 9
TC 0
Z9 2
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6068
EI 2168-6084
J9 JAMA DERMATOL
JI JAMA Dermatol.
PD OCT
PY 2013
VL 149
IS 10
BP 1229
EP 1230
DI 10.1001/jamadermatol.2013.4040
PG 2
WC Dermatology
SC Dermatology
GA AA3DT
UT WOS:000330973800025
PM 23945611
ER
PT J
AU Alishahi, Y
Kundrotas, L
AF Alishahi, Yasmin
Kundrotas, Leon
TI A Retrospective Review of the Clinical Impact of Hydrogen Breath Testing
for Small Bowel Bacterial Overgrowth in South Texas Veterans Health Care
System
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Alishahi, Yasmin] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Kundrotas, Leon] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 1643
BP S493
EP S493
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178101795
ER
PT J
AU Anderson, J
Goel, G
Cohen, H
Leung, F
AF Anderson, Joshua
Goel, Gati
Cohen, Hartley
Leung, Felix
TI Water Infusion Distension during Colonoscopy Is a Safe Alternative
Technique to Facilitate Polypectomy in a "Difficult Location"
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Anderson, Joshua; Goel, Gati; Cohen, Hartley; Leung, Felix] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 1484
BP S440
EP S440
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178101636
ER
PT J
AU Basu, P
Shah, N
Siriki, R
Rahaman, M
Farhat, S
AF Basu, Patrick
Shah, Niraj
Siriki, Ravi
Rahaman, Md
Farhat, S.
TI Romiplostim's Effect to Optimize SVR with Telaprevir, Ribavirin, and PEG
Interferon-alfa 2a in Thrombocytopenic Cirrhotics with Chronic Hepatitis
C: A Placebo-controlled Prospective Clinical Trial: RESTRAINT C Trial
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Basu, Patrick; Farhat, S.] Columbia Sch Physicians & Surg, New York, NY USA.
[Siriki, Ravi; Rahaman, Md] NSLIJHS Hofstra N Shore LIJ Sch Med, New York, NY USA.
[Shah, Niraj] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 506
BP S150
EP S150
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178100506
ER
PT J
AU Basu, P
Shah, N
Siriki, R
Rahaman, M
Farhat, S
AF Basu, Patrick
Shah, Niraj
Siriki, Ravi
Rahaman, Md
Farhat, S.
TI Telaprevir with Adjusted Dose of Ribavirin in Naive CHC-G1: Efficacy and
Treatment in CHC in Hemodialysis Population TARGET C Trial: A Placebo
Randomized Control Clinical Trial
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Basu, Patrick; Farhat, S.] Columbia Sch Phys & Surg, New York, NY USA.
[Siriki, Ravi; Rahaman, Md] NSLIJHS Hofstra N Shore LIJ Sch Med, New York, NY USA.
[Shah, Niraj] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 513
BP S152
EP S152
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178100513
ER
PT J
AU Basu, P
Shah, N
Siriki, R
Rahaman, M
Farhat, S
AF Basu, Patrick
Shah, Niraj
Siriki, Ravi
Rahaman, Md
Farhat, S.
TI Curcumin, Antioxidant, and Pioglitazone Therapy with Inclusion of
Vitamin E In Non-Alcoholic Fatty Liver Disease: A Randomized,
Open-label, Placebo-controlled Clinical Prospective Trial (CAPTIVE)
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Basu, Patrick; Farhat, S.] Columbia Sch Phys & Surg, New York, NY USA.
[Siriki, Ravi; Rahaman, Md] NSLIJHS Hofstra North Shore LIJ Sch Med, New York, NY USA.
[Shah, Niraj] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 505
BP S149
EP S150
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178100505
ER
PT J
AU Basu, P
Shah, N
Rahaman, M
Siriki, R
Farhat, S
AF Basu, Patrick
Shah, Niraj
Rahaman, Md
Siriki, Ravi
Farhat, S.
TI Prevalence of Small Bowel Bacterial Overgrowth (SIBO) in Decompensated
Cirrhosis with Portal Hypertension: A Clinical Pilot Study
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Basu, Patrick; Farhat, S.] Columbia Sch Phys & Surg, New York, NY USA.
[Rahaman, Md; Siriki, Ravi] NSLIJHS Hofstra North Shore LIJ Sch Med, New York, NY USA.
[Shah, Niraj] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 486
BP S144
EP S145
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178100486
ER
PT J
AU Basu, P
Shah, N
Farhat, S
Siriki, R
Rahaman, M
AF Basu, Patrick
Shah, Niraj
Farhat, S.
Siriki, Ravi
Rahaman, Md
TI Restless Leg Syndrome (RLS) is Associated with Hepatic Encephalopathy
(HE) in Decompensated Cirrhosis: A Clinical Pilot Study
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Basu, Patrick; Farhat, S.] Columbia Sch Phys & Surg, New York, NY USA.
[Siriki, Ravi; Rahaman, Md] NSLIJHS Hofstra North Shore LIJ Sch Med, New York, NY USA.
[Shah, Niraj] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 485
BP S144
EP S144
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178100485
ER
PT J
AU Basu, P
Shah, N
Siriki, R
Rahaman, M
Farhat, S
AF Basu, Patrick
Shah, Niraj
Siriki, Ravi
Rahaman, Md
Farhat, S.
TI Effect of N Acetylcysteine (NAC) in Hypoxia-Induced Liver Injury (HILI):
A Randomized Placebo Control Clinical Trial
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Basu, Patrick; Farhat, S.] Columbia Sch Phys & Surg, New York, NY USA.
[Siriki, Ravi; Rahaman, Md] NSLIJHS Hofstra North Shore LIJ Sch Med, New York, NY USA.
[Shah, Niraj] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 484
BP S144
EP S144
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178100484
ER
PT J
AU Basu, P
Shah, N
Rahaman, MD
Siriki, R
Farhat, S
AF Basu, Patrick
Shah, Niraj
Rahaman, M. D.
Siriki, Ravi
Farhat, S.
TI Rifabutin, Omeprazole, Alinia, and Doxycycline Therapy for Prior
Treatment Failure Helicobacter pylori Population: A Randomized,
Open-Label Clinical Pilot Study ROAD Trial
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Basu, Patrick; Farhat, S.] Columbia Sch Phys & Surg, New York, NY USA.
[Rahaman, M. D.; Siriki, Ravi] NSLIJHS Hofstra North Shore LIJ Sch Med, New York, NY USA.
[Shah, Niraj] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY USA.
NR 0
TC 1
Z9 1
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 157
BP S49
EP S49
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178100158
ER
PT J
AU Basu, P
Shah, N
Siriki, R
Rahaman, MD
Farhat, S
AF Basu, Patrick
Shah, Niraj
Siriki, Ravi
Rahaman, M. D.
Farhat, S.
TI Latent Eosinophilic Esophagitis (LEOE) Is a Unraveled Novel Clinical
Entity: A Randomized, Open Clinical Pilot Study
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Basu, Patrick; Farhat, S.] Columbia Sch Phys & Surg, New York, NY USA.
[Siriki, Ravi; Rahaman, M. D.] NSLIJHS Hofstra North Shore LIJ Sch Med, New York, NY USA.
[Shah, Niraj] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 68
BP S23
EP S24
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178100069
ER
PT J
AU Hotte, C
Vela, M
AF Hotte, Charles
Vela, Marcelo
TI Body Mass Index (BMI) and Percent Fat Are Not Associated with Increased
Reflux in a Veteran Hospital Review
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Hotte, Charles] Baylor Coll Med, Houston, TX 77030 USA.
[Vela, Marcelo] Michael E Debakey Vet Med Ctr, Houston, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 38
BP S14
EP S14
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178100039
ER
PT J
AU Kaung, A
Chak, E
Cohen, H
Ohning, G
Leung, F
AF Kaung, Aung
Chak, Eric
Cohen, Hartley
Ohning, Gordon
Leung, Felix
TI Water Exchange Colonoscopy without Air Insufflation May Facilitate
Terminal Ileum Intubation
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Kaung, Aung; Cohen, Hartley; Ohning, Gordon; Leung, Felix] W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA.
[Chak, Eric] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 1483
BP S439
EP S440
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178101635
ER
PT J
AU Kovacs, T
Jensen, D
Ohning, G
Ghassemi, K
Dulai, G
Machicado, G
Jutabha, R
AF Kovacs, Thomas
Jensen, Dennis
Ohning, Gordon
Ghassemi, Kevin
Dulai, Gareth
Machicado, Gustavo
Jutabha, Rome
TI A Prospective Study of Patients with Bleeding Mallory Weiss Tears: Does
Portal Hypertension Matter?
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Ghassemi, Kevin; Jutabha, Rome] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Dulai, Gareth] CURE DDRC GI Hemostasis Res Unit, Los Angeles, CA USA.
[Ohning, Gordon] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Kovacs, Thomas; Jensen, Dennis; Machicado, Gustavo] Univ Calif Los Angeles, Div Digest Dis, Los Angeles, CA USA.
[Kovacs, Thomas; Jensen, Dennis; Machicado, Gustavo] VA WLA Med Ctr, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 2029
BP S615
EP S615
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178102357
ER
PT J
AU McPhaul, C
Sonnenberg, A
Genta, R
AF McPhaul, Christopher
Sonnenberg, Amnon
Genta, Robert
TI Low Prevalence of Colon Polyps in Patients with Diarrhea and Microscopic
Colitis
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Genta, Robert] Miraca Life Sci Res Inst, GI Pathol, Irving, TX USA.
[McPhaul, Christopher] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
[Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR USA.
[Sonnenberg, Amnon] OHSU, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 558
BP S164
EP S164
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178100558
ER
PT J
AU Nguyen, K
Jacobs, J
Cao, WW
Chak, E
Cohen, H
Leung, F
AF Nguyen, Ken
Jacobs, Jonathan
Cao, Weiwei
Chak, Eric
Cohen, Hartley
Leung, Felix
TI Water Exchange Colonoscopy for Evaluation of Severe Ulcerative Colitis:
A Case Series
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Cohen, Hartley; Leung, Felix] VA Greater Los Angeles Healthcare Syst, Div Gastroenterol, Los Angeles, CA USA.
[Nguyen, Ken] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA.
[Jacobs, Jonathan; Cao, Weiwei; Chak, Eric] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 1405
BP S416
EP S417
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178101557
ER
PT J
AU Raza, MQ
Trang, T
Qureshi, W
AF Raza, Mohammad Qasim
Trang, Tony
Qureshi, Waqar
TI Colo-colonic Intussusception Presenting as Intermittent Testicular Pain
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Raza, Mohammad Qasim; Qureshi, Waqar] Baylor Coll Med, Houston, TX 77030 USA.
[Trang, Tony] VA Med Ctr, Houston, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 1324
BP S394
EP S394
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178101476
ER
PT J
AU Sonnenberg, A
Byrd-Clark, D
AF Sonnenberg, Amnon
Byrd-Clark, Danita
TI US Hospitalizations for Colorectal Cancer: 1970-2010
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Sonnenberg, Amnon] Portland VA Med Ctr, GI P3, Portland, OR USA.
[Byrd-Clark, Danita] Social & Sci Syst, Silver Spring, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 557
BP S164
EP S164
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178100557
ER
PT J
AU Sonnenberg, A
AF Sonnenberg, Amnon
TI Time Trends of US Hospitalization for Esophageal Disease
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 13
BP S5
EP S5
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178100014
ER
PT J
AU Taydas, E
Malik, M
Russell, S
Latt, N
Gurakar, A
AF Taydas, Eren
Malik, Mohammad
Russell, Stuart
Latt, Nyan
Gurakar, Ahmet
TI The Role of Coronary Artery Calcium Score and Age in Early
Identification of Occult Coronary Artery Disease among Patients
Undergoing Liver Transplant Work-up for End-stage Liver Disease
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Taydas, Eren] MedStar Franklin Sq Med Ctr, Baltimore, MD USA.
[Malik, Mohammad; Russell, Stuart; Gurakar, Ahmet] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA.
[Latt, Nyan] W Los Angeles Vet Affairs Med Ctr, Dept Gastroenterol & Hepatol, Los Angeles, CA 90073 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 500
BP S148
EP S148
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178100500
ER
PT J
AU Maust, DT
Oslin, DW
Thase, ME
AF Maust, Donovan T.
Oslin, David W.
Thase, Michael E.
TI Going Beyond Antidepressant Monotherapy for Incomplete Response in
Nonpsychotic Late-Life Depression: A Critical Review
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Review
DE Antidepressant; augmentation; depression; pharmacotherapy
ID TREATMENT-RESISTANT DEPRESSION; RECURRENT MAJOR DEPRESSION; LITHIUM
AUGMENTATION; GERIATRIC DEPRESSION; PRIMARY-CARE; REFRACTORY DEPRESSION;
UNIPOLAR DEPRESSION; ELDERLY-PATIENTS; CONTROLLED-TRIAL; OLDER PATIENTS
AB Many older adults with major depressive disorder (MDD) do not respond to antidepressant monotherapy. Although there are evidence-based treatment options to support treatment beyond monotherapy for adults, the evidence for such strategies, specifically in late-life MDD, is relatively scarce. This review examines the published data describing strategies for antidepressant augmentation or acceleration studied specifically in older adults, including lithium, stimulants, and second-generation antipsychotics. In addition, the authors suggest strategies for future research, such as study of specific agents, refining understanding of the impact of medical or cognitive comorbidity in late-life depression, and comparative effectiveness to examine methods already used in clinical practice.
C1 [Maust, Donovan T.; Oslin, David W.; Thase, Michael E.] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA.
[Oslin, David W.; Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Oslin, David W.; Thase, Michael E.] VISN 4 Mental Illness Res Educ & Clin Ctr MIREC, Philadelphia, PA USA.
[Thase, Michael E.] Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA USA.
RP Maust, DT (reprint author), Univ Penn, Sect Geriatr Psychiat, 3615 Chestnut St, Philadelphia, PA 19104 USA.
EM Donovan.Maust@uphs.upenn.edu
FU NIMH [R25-MH060490]
FX Dr. Maust is supported through the NIMH-funded Clinical Research
Scholars Program (R25-MH060490) of the Department of Psychiatry,
University of Pennsylvania, Perelman School of Medicine.
NR 58
TC 10
Z9 10
U1 3
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD OCT
PY 2013
VL 21
IS 10
BP 973
EP 986
DI 10.1016/j.jagp.2013.01.030
PG 14
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 298YZ
UT WOS:000330362300007
PM 23567381
ER
PT J
AU Sakurai, D
Zhao, J
Deng, Y
Kelly, JA
Brown, EE
Harley, JB
Bae, SC
Alarcon-Riqueime, ME
Edberg, JC
Kimberly, RP
Ramsey-Goldman, R
Petri, MA
Reveille, JD
Vila, LM
Alarcon, GS
Kaufman, KM
Vyse, TJ
Jacob, CO
Gaffney, PM
Sivils, KM
James, JA
Kamen, DL
Gilkeson, GS
Niewold, TB
Merrill, JT
Scofield, RH
Criswell, LA
Stevens, AM
Boackle, SA
Kim, JH
Choi, J
Pons-Estel, BA
Freedman, BI
Anaya, JM
Martin, J
Yu, CY
Chang, DM
Song, YW
Langefeld, CD
Chen, WL
Grossman, JM
Cantor, RM
Hahn, BH
Tsao, BP
AF Sakurai, Daisuke
Zhao, Jian
Deng, Yun
Kelly, Jennifer A.
Brown, Elizabeth E.
Harley, John B.
Bae, Sang-Cheol
Alarcon-Riqueime, Marta E.
Edberg, Jeffrey C.
Kimberly, Robert P.
Ramsey-Goldman, Rosalind
Petri, Michelle A.
Reveille, John D.
Vila, Luis M.
Alarcon, Graciela S.
Kaufman, Kenneth M.
Vyse, Timothy J.
Jacob, Chaim O.
Gaffney, Patrick M.
Sivils, Kathy Moser
James, Judith A.
Kamen, Diane L.
Gilkeson, Gary S.
Niewold, Timothy B.
Merrill, Joan T.
Scofield, R. Hal
Criswell, Lindsey A.
Stevens, Anne M.
Boackle, Susan A.
Kim, Jae-Hoon
Choi, Jiyoung
Pons-Estel, Bernardo A.
Freedman, Barry I.
Anaya, Juan-Manuel
Martin, Javier
Yu, C. Yung
Chang, Deh-Ming
Song, Yeong Wook
Langefeld, Carl D.
Chen, Weiling
Grossman, Jennifer M.
Cantor, Rita M.
Hahn, Bevra H.
Tsao, Betty P.
CA BIOLUPUS & GENLES networks
Argentine Collaborative Grp
TI Preferential Binding to Elk-1 by SLE-Associated IL10 Risk Allele
Upregulates IL10 Expression
SO PLOS GENETICS
LA English
DT Article
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; GENOME-WIDE ASSOCIATION;
INFLAMMATORY-BOWEL-DISEASE; HUMAN B-LYMPHOCYTES; CELL-DERIVED IL-10;
RHEUMATOID-ARTHRITIS; SUSCEPTIBILITY LOCI; AUTOIMMUNE-DISEASE;
INTERLEUKIN-10 PRODUCTION; 1ST-DEGREE RELATIVES
AB Immunoregulatory cytokine interleukin-10 (IL-10) is elevated in sera from patients with systemic lupus erythematosus (SLE) correlating with disease activity. The established association of IL10 with SLE and other autoimmune diseases led us to fine map causal variant(s) and to explore underlying mechanisms. We assessed 19 tag SNPs, covering the IL10 gene cluster including IL19, IL20 and IL24, for association with SLE in 15,533 case and control subjects from four ancestries. The previously reported IL10 variant, rs3024505 located at 1 kb downstream of IL10, exhibited the strongest association signal and was confirmed for association with SLE in European American (EA) (P = 2.7x10(-8), OR = 1.30), but not in non-EA ancestries. SNP imputation conducted in EA dataset identified three additional SLE-associated SNPs tagged by rs3024505 (rs3122605, rs3024493 and rs3024495 located at 9.2 kb upstream, intron 3 and 4 of IL10, respectively), and SLE-risk alleles of these SNPs were dose-dependently associated with elevated levels of IL10 mRNA in PBMCs and circulating IL-10 protein in SLE patients and controls. Using nuclear extracts of peripheral blood cells from SLE patients for electrophoretic mobility shift assays, we identified specific binding of transcription factor Elk-1 to oligodeoxynucleotides containing the risk (G) allele of rs3122605, suggesting rs3122605 as the most likely causal variant regulating IL10 expression. Elk-1 is known to be activated by phosphorylation and nuclear localization to induce transcription. Of interest, phosphorylated Elk-1 (p-Elk-1) detected only in nuclear extracts of SLE PBMCs appeared to increase with disease activity. Co-expression levels of p-Elk-1 and IL-10 were elevated in SLE T, B cells and monocytes, associated with increased disease activity in SLE B cells, and were best downregulated by ERK inhibitor. Taken together, our data suggest that preferential binding of activated Elk-1 to the IL10 rs3122605-G allele upregulates IL10 expression and confers increased risk for SLE in European Americans.
C1 [Sakurai, Daisuke; Zhao, Jian; Deng, Yun; Chen, Weiling; Grossman, Jennifer M.; Hahn, Bevra H.; Tsao, Betty P.] Univ Calif Los Angeles, David Geffen Sch Med, Div Rheumatol, Los Angeles, CA 90095 USA.
[Kelly, Jennifer A.; Alarcon-Riqueime, Marta E.; Gaffney, Patrick M.; Sivils, Kathy Moser; James, Judith A.; Scofield, R. Hal] Oklahoma Med Res Fdn, Arthritis & Clin Immunol Program, Oklahoma City, OK 73104 USA.
[Brown, Elizabeth E.; Edberg, Jeffrey C.; Kimberly, Robert P.; Alarcon, Graciela S.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
[Brown, Elizabeth E.] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USA.
[Harley, John B.; Kaufman, Kenneth M.] Cincinnati Childrens Hosp Med Ctr, Div Rheumatol, Cincinnati, OH 45229 USA.
[Harley, John B.; Kaufman, Kenneth M.] Cincinnati Childrens Hosp Med Ctr, Ctr Autoimmune Genom & Etiol, Cincinnati, OH 45229 USA.
[Harley, John B.; Kaufman, Kenneth M.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA.
[Bae, Sang-Cheol; Kim, Jae-Hoon; Choi, Jiyoung] Hanyang Univ, Hosp Rheumat Dis, Dept Rheumatol, Seoul 133791, South Korea.
[Alarcon-Riqueime, Marta E.] Univ Granada Junta Andalucia, Pfizer, GENYO, Ctr Genom & Invest Oncol, Granada, Spain.
[Ramsey-Goldman, Rosalind] Northwestern Univ, Feinberg Sch Med, Div Rheumatol, Chicago, IL 60611 USA.
[Petri, Michelle A.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
[Reveille, John D.] Univ Texas Houston, Hlth Sci Ctr, Dept Internal Med, Houston, TX 77225 USA.
[Vila, Luis M.] Univ Puerto Rico, Dept Med, San Juan, PR 00936 USA.
[Vyse, Timothy J.] Kings Coll London, Div Genet, London WC2R 2LS, England.
[Vyse, Timothy J.] Kings Coll London, Div Mol Med, London WC2R 2LS, England.
[Vyse, Timothy J.] Kings Coll London, Div Immunol, London WC2R 2LS, England.
[Jacob, Chaim O.] Univ So Calif, Keck Sch Med, Dept Med, Los Angeles, CA 90033 USA.
[James, Judith A.; Scofield, R. Hal] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA.
[Kamen, Diane L.; Gilkeson, Gary S.] Med Univ S Carolina, Dept Med, Div Rheumatol, Charleston, SC 29425 USA.
[Niewold, Timothy B.] Mayo Clin, Div Rheumatol, Rochester, MN USA.
[Niewold, Timothy B.] Mayo Clin, Dept Immunol, Rochester, MN USA.
[Merrill, Joan T.] Oklahoma Med Res Fdn, Clin Pharmacol Program, Oklahoma City, OK 73104 USA.
[Scofield, R. Hal] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA.
[Criswell, Lindsey A.] Univ Calif San Francisco, Rosalind Russell Med Res Ctr Arthritis, Dept Med, San Francisco, CA 94143 USA.
[Stevens, Anne M.] Univ Washington, Dept Pediat, Div Rheumatol, Seattle, WA 98195 USA.
[Stevens, Anne M.] Seattle Childrens Res Inst, Ctr Immun & Immunotherapies, Seattle, WA USA.
[Boackle, Susan A.] Univ Colorado, Sch Med, Div Rheumatol, Aurora, CO USA.
[Pons-Estel, Bernardo A.] Sanatorio Parque, Dept Med, Rosario, Argentina.
[Freedman, Barry I.] Wake Forest Sch Med, Dept Internal Med, Winston Salem, NC USA.
[Anaya, Juan-Manuel] Univ Rosario, Ctr Autoimmune Dis Res, Bogota, Colombia.
[Martin, Javier] CSIC, Inst Parasitol & Biomed Lopez Neyra, Granada, Spain.
[Yu, C. Yung] Nationwide Childrens Hosp, Ctr Mol & Human Genet, Res Inst, Columbus, OH USA.
[Yu, C. Yung] Ohio State Univ, Columbus, OH 43210 USA.
[Chang, Deh-Ming] Natl Def Med Ctr, Taipei, Taiwan.
[Song, Yeong Wook] Seoul Natl Univ, Div Rheumatol, Seoul, South Korea.
[Langefeld, Carl D.] Wake Forest Sch Med, Dept Biostat Sci, Winston Salem, NC USA.
[Cantor, Rita M.] Univ Calif Los Angeles, Dept Human Genet, Los Angeles, CA USA.
RP Sakurai, D (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Rheumatol, Los Angeles, CA 90095 USA.
EM btsao@mednet.ucla.edu
RI ; Martin, Javier/B-8141-2008; Yu, Chack-Yung/E-4360-2011; Anaya,
Juan-Manuel/J-1960-2016
OI Kimberly, Robert/0000-0002-5330-3086; Niewold,
Timothy/0000-0003-3532-6660; Anaya, Juan-Manuel/0000-0002-6444-1249;
Catoggio, Luis Jose/0000-0002-4047-4863; Universidad del Rosario,
Biblioteca/0000-0003-3491-9392; Silva, Berta/0000-0001-6579-5068
FU US National Institutes of Health [R01AR043814, P30AR48311, R01CA141700,
RC1AR058621, P01AI083194, P01AR049084, R01AR33062, K24AR002138,
P602AR30692, UL1RR025741, R01AR43727, P01AR052915, U01AI090909]; Lupus
Research Institute; Alliance for Lupus Research grants; U.S. Department
of Defense [PR094002]; US Department of Veterans Affairs; Arthritis
National Research Foundation; Charles Barkley Research Award; Ministry
for Health and Welfare, Republic of Korea [A120404]; Swedish Research
Council of Medicine; Arthritis Research UK; Arthritis Foundation;
National Center for Advancing Translational Sciences (NCATS)
[UL1RR025014-02, UL1TR000165, UL1RR025005]; National Center for Research
Resources (NCRR) component of the National Institutes of Health (NIH);
Kirkland Scholar Award; Federico Wilhelm Agricola Foundation; Wake
Forest University Health Sciences Center for Public Health Genomics;
MKE/KEIT [10035615]; UCLA Clinical and Translational Science Institute
(CTSI) [UL1RR033176, UL1TR000124]; US NIH [R01AR057172, R01AI063274,
RC2AR058959, R01AR043274, P30AR053483, P30GM103510, U19AI082714,
U01AI101934, P60AR049459, UL1RR029882, K08AI083790, L30AI071651,
UL1RR024999, P60AR053308, UL1TR000004, R01AR051545-01A2, R21AI070304,
1R01AR054459]
FX Support for this work was provided by the US National Institutes of
Health grants: R01AR043814 (BPT), P30AR48311 (EEB), R01CA141700 and
RC1AR058621 (MEAR), P01AI083194 (JBH KMS RPK LAC TJV MEAR COJ BPT PMG),
P01AR049084 (RPK JBH EEB JCE RRG LMV MAP), R01AR33062 (RPK),
K24AR002138, P602AR30692 and UL1RR025741 (RRG), R01AR43727 (MAP),
P01AR052915 and U01AI090909 (JDR), R01AR057172 (COJ), R01AI063274 and
RC2AR058959 (PMG), R01AR043274 (KMS), P30AR053483, P30GM103510,
U19AI082714 and U01AI101934 (JAJ), P60AR049459 and UL1RR029882 (GSG
DLK), K08AI083790, L30AI071651 and UL1RR024999 (TBN), P60AR053308 and
UL1TR000004 (LAC), R01AR051545-01A2 (AMS), R21AI070304 (SAB), and
1R01AR054459 (CYY). Additional support was provided by the Lupus
Research Institute grant (BPT); the Alliance for Lupus Research grants
(BPT YD KMS TBN LAC COJ); the U.S. Department of Defense PR094002 and
the US Department of Veterans Affairs Merit Award (JBH); the Arthritis
National Research Foundation Eng Tan Scholar Award (TBN JZ); Charles
Barkley Research Award (EEB); the Korea Healthcare Technology R&D
Project, Ministry for Health and Welfare, Republic of Korea (A120404;
SCB); funding from the Swedish Research Council of Medicine (MEAR); the
Arthritis Research UK (TJV); the Arthritis Foundation (AMS PMG);
Clinical and Translational Science Grant Number UL1RR025014-02 (AMS),
UL1TR000165 (JCE) and UL1RR025005 (MAP) from the National Center for
Advancing Translational Sciences (NCATS) and National Center for
Research Resources (NCRR) component of the National Institutes of Health
(NIH); Kirkland Scholar Award (LAC); the Federico Wilhelm Agricola
Foundation Research grant (BAPE); Wake Forest University Health Sciences
Center for Public Health Genomics (CDL); the Korean Research and
Development Program of MKE/KEIT (10035615; YWS); and UCLA Clinical and
Translational Science Institute (CTSI) grants: UL1RR033176 and
UL1TR000124. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
NR 89
TC 13
Z9 13
U1 322
U2 328
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD OCT
PY 2013
VL 9
IS 10
AR e1003870
DI 10.1371/journal.pgen.1003870
PG 12
WC Genetics & Heredity
SC Genetics & Heredity
GA 299AR
UT WOS:000330367200046
PM 24130510
ER
PT J
AU Hatano, H
Yukl, SA
Ferre, AL
Graf, EH
Somsouk, M
Sinclair, E
Abdel-Mohsen, M
Liegler, T
Harvill, K
Hoh, R
Palmer, S
Bacchetti, P
Hunt, PW
Martin, JN
McCune, JM
Tracy, RP
Busch, MP
O'Doherty, U
Shacklett, BL
Wong, JK
Deeks, SG
AF Hatano, Hiroyu
Yukl, Steven A.
Ferre, April L.
Graf, Erin H.
Somsouk, Ma
Sinclair, Elizabeth
Abdel-Mohsen, Mohamed
Liegler, Teri
Harvill, Kara
Hoh, Rebecca
Palmer, Sarah
Bacchetti, Peter
Hunt, Peter W.
Martin, Jeffrey N.
McCune, Joseph M.
Tracy, Russell P.
Busch, Michael P.
O'Doherty, Una
Shacklett, Barbara L.
Wong, Joseph K.
Deeks, Steven G.
TI Prospective Antiretroviral Treatment of Asymptomatic, HIV-1 Infected
Controllers
SO PLOS PATHOGENS
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELL-ACTIVATION;
POLYMERASE-CHAIN-REACTION; HIV-1 ELITE CONTROLLERS; BLOOD
MONONUCLEAR-CELLS; LOW-LEVEL VIREMIA; RALTEGRAVIR INTENSIFICATION;
IMMUNE ACTIVATION; RECTAL MUCOSA; TYPE-1 RNA
AB The study of HIV-infected "controllers'' who are able to maintain low levels of plasma HIV RNA in the absence of antiretroviral therapy (ART) may provide insights for HIV cure and vaccine strategies. Despite maintaining very low levels of plasma viremia, controllers have elevated immune activation and accelerated atherosclerosis. However, the degree to which low-level replication contributes to these phenomena is not known. Sixteen asymptomatic controllers were prospectively treated with ART for 24 weeks. Controllers had a statistically significant decrease in ultrasensitive plasma and rectal HIV RNA levels with ART. Markers of T cell activation/dysfunction in blood and gut mucosa also decreased substantially with ART. Similar reductions were observed in the subset of "elite'' controllers with pre-ART plasma HIV RNA levels below conventional assays (<40 copies/mL). These data confirm that HIV replication persists in controllers and contributes to a chronic inflammatory state. ART should be considered for these individuals (ClinicalTrials.gov NCT01025427).
C1 [Hatano, Hiroyu; Yukl, Steven A.; Somsouk, Ma; Sinclair, Elizabeth; Abdel-Mohsen, Mohamed; Liegler, Teri; Harvill, Kara; Hoh, Rebecca; Hunt, Peter W.; McCune, Joseph M.; Wong, Joseph K.; Deeks, Steven G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
[Yukl, Steven A.; Wong, Joseph K.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA.
[Ferre, April L.; Shacklett, Barbara L.] Univ Calif Davis, Sch Med, Dept Med Microbiol & Immunol, Davis, CA 95616 USA.
[Graf, Erin H.; O'Doherty, Una] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA.
[Palmer, Sarah] Karolinska Inst, Solna, Sweden.
[Palmer, Sarah] Swedish Inst Infect Dis Control, Solna, Sweden.
[Palmer, Sarah] Westmead Millennium Inst, Ctr Virus Res, Westmead, NSW, Australia.
[Palmer, Sarah] Univ Sydney, Westmead, NSW 2145, Australia.
[Bacchetti, Peter; Martin, Jeffrey N.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Tracy, Russell P.] Univ Vermont, Dept Pathol, Colchester, VT USA.
[Tracy, Russell P.] Univ Vermont, Dept Biochem, Colchester, VT USA.
[Busch, Michael P.] Blood Syst Res Inst, San Francisco, CA USA.
[Busch, Michael P.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA.
RP Hatano, H (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
EM hhatano@php.ucsf.edu
RI Shacklett, Barbara/A-7288-2009
OI Shacklett, Barbara/0000-0002-7067-732X
FU National Institute of Allergy and Infectious Diseases [R01 AI087145, K23
AI075985, K24 AI069994, R56 AI091573, R01 NS051132, R01 AI057020];
National Cancer Institute [K23 CA157929]; Delaney AIDS Research
Enterprise (DARE) [U19 AI0961090]; California HIV/AIDS Research Program
[ID08-SF-004]; American Foundation for AIDS Research [106710-40-RGRL,
107170-44-RGRL, 108073-50-RGRL]; UCSF/Gladstone Institute of Virology &
Immunology CFAR [P30 AI027763]; UCSF Clinical and Translational Research
Institute Clinical Research Center [UL1 RR024131]; Center for AIDS
Prevention Studies [P30 MH62246]; CFAR Network of Integrated Systems
[R24 AI067039]; U.S. Department of Veterans Affairs [1 IK2 CX000520-01,
5101BX001048]
FX This work was supported by grants from the National Institute of Allergy
and Infectious Diseases (R01 AI087145, K23 AI075985, K24 AI069994, R56
AI091573, R01 NS051132, R01 AI057020), the National Cancer Institute
(K23 CA157929), the Delaney AIDS Research Enterprise (DARE; U19
AI0961090), California HIV/AIDS Research Program (ID08-SF-004), the
American Foundation for AIDS Research (106710-40-RGRL, 107170-44-RGRL,
and 108073-50-RGRL), the UCSF/Gladstone Institute of Virology &
Immunology CFAR (P30 AI027763), the UCSF Clinical and Translational
Research Institute Clinical Research Center (UL1 RR024131), the Center
for AIDS Prevention Studies (P30 MH62246), the CFAR Network of
Integrated Systems (R24 AI067039), and the U.S. Department of Veterans
Affairs (1 IK2 CX000520-01, 5101BX001048). The funders had no role in
study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 67
TC 35
Z9 35
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD OCT
PY 2013
VL 9
IS 10
AR e1003691
DI 10.1371/journal.ppat.1003691
PG 13
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 299GJ
UT WOS:000330383800060
PM 24130489
ER
PT J
AU Feldt, B
Dion, GR
Weitzel, EK
McMains, KC
AF Feldt, Brent
Dion, Gregory R.
Weitzel, Erik K.
McMains, Kevin C.
TI Acute Sinusitis
SO SOUTHERN MEDICAL JOURNAL
LA English
DT Review
DE acute sinusitis; bacterial sinusitis; nasal airway obstruction; purulent
rhinorrhea; sinusitis
ID ACUTE BACTERIAL RHINOSINUSITIS; ANTIMICROBIAL THERAPY; CONTROLLED TRIAL;
DOUBLE-BLIND; ADULTS; METAANALYSIS; ANTIBIOTICS; AMOXICILLIN; DIAGNOSIS;
RHINITIS
AB Sinusitis is a common patient complaint that carries with it a large economic burden. It is one of the most common reasons patients visit their primary care physician. Acute bacterial rhinosinusitis (ABRS) can be distinguished from other forms of rhinosinusitis based on symptom duration of <4 weeks in a patient with purulent rhinorrhea associated with facial pain or pressure. Native upper aerodigestive tract bacteria are the most common etiologic agents. Treatment of ABRS is targeted primarily at symptom improvement. Amoxicillin can be used based on the clinical scenario and patient comorbidities. Computed tomographic scans are reserved for complicated presentations or when there is concern for intracranial extension or other complications. A systematic approach to ABRS will allow for improved patient quality of life and a decreased overall economic burden of this common entity.
C1 Wilford Hall Ambulatory Surg Ctr, San Antonio, TX USA.
Brooke Army Med Ctr, San Antonio Mil Med Ctr, Ft Sam Houston, TX 78234 USA.
Audie L Murphy Mem Vet Adm Med Ctr, South Texas Vet Hlth Care, San Antonio, TX 78284 USA.
RP Dion, GR (reprint author), ATTN MCHE SDT Oto, Dept Otolaryngol, 3551 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA.
EM greg.r.dion@us.army.mil
NR 32
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0038-4348
EI 1541-8243
J9 SOUTH MED J
JI South.Med.J.
PD OCT
PY 2013
VL 106
IS 10
BP 577
EP 581
DI 10.1097/SMJ.0000000000000002
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 298UK
UT WOS:000330349800007
PM 24096952
ER
PT J
AU Mrejen, S
Sarraf, D
Mukkamala, K
Freund, KB
AF Mrejen, Sarah
Sarraf, David
Mukkamala, Krishna
Freund, K. Bailey
TI MULTIMODAL IMAGING OF PIGMENT EPITHELIAL DETACHMENT A Guide to
Evaluation
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Review
DE retinal pigment epithelial detachment; age-related macular degeneration;
drusenoid pigment epithelial detachment; serous pigment epithelial
detachment; vascularized pigment epithelial detachment; retinal
angiomatous proliferation; polypoidal choroidal vasculopathy; multimodal
imaging; central serous chorioretinopathy
ID CENTRAL SEROUS CHORIORETINOPATHY; OPTICAL COHERENCE TOMOGRAPHY; RETINAL
ANGIOMATOUS PROLIFERATION; POLYPOIDAL CHOROIDAL VASCULOPATHY;
INDOCYANINE-GREEN VIDEOANGIOGRAPHY; COMBINED INTRAVITREAL RANIBIZUMAB;
SCANNING LASER OPHTHALMOSCOPE; GROWTH-FACTOR THERAPY; TERM-FOLLOW-UP;
MACULAR DEGENERATION
AB Purpose: To describe the spectrum of pigment epithelial detachments (PEDs) occurring mainly in age-related macular degeneration and central serous chorioretinopathy and also in other inflammatory, neoplastic and iatrogenic, retinal, and systemic disorders.
Methods: Pigment epithelial detachments are divided into drusenoid, serous, vascularized, or mixed categories.
Results: The clinical presentation, classification, and natural history of PEDs are reviewed as illustrated with multimodal imaging combining traditional and novel imaging techniques, including fluorescein angiography, indocyanine green angiography, fundus autofluorescence, and spectral domain optical coherence tomography. Most PEDs occur because of pathophysiologic mechanisms taking place below the retinal pigment epithelium that are difficult to identify with conventional imaging modalities. Enhanced depth imaging optical coherence tomography and indocyanine green angiography allow a better analysis of the subretinal pigment epithelium compartment.
Conclusion: The differentiation between various kinds of PEDs is essential because each PED type is a distinct entity that has a specific pathogenesis, natural history, prognosis, and optimal treatment strategy.
C1 [Mrejen, Sarah; Mukkamala, Krishna; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
[Mrejen, Sarah; Mukkamala, Krishna; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
[Sarraf, David] Univ Calif Los Angeles, Jules Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, Los Angeles, CA 90024 USA.
[Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA.
RP Freund, KB (reprint author), Vitreous Retina Macula Consultants New York, 460 Pk Ave,Fifth Floor, New York, NY 10022 USA.
EM kbfnyf@aol.com
FU Macula Foundation, Inc.
FX Supported in part by the Macula Foundation, Inc.
NR 151
TC 24
Z9 26
U1 0
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2013
VL 33
IS 9
BP 1735
EP 1762
PG 28
WC Ophthalmology
SC Ophthalmology
GA 297DL
UT WOS:000330235500002
PM 23873168
ER
PT J
AU Leonardis, RL
Duvvuri, U
Mehta, D
AF Leonardis, Rachel L.
Duvvuri, Umamaheswar
Mehta, Deepak
TI Transoral Robotic-Assisted Lingual Tonsillectomy in the Pediatric
Population
SO JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY
LA English
DT Article
ID OBSTRUCTIVE SLEEP-APNEA; SURGERY; HEAD; NECK; OTOLARYNGOLOGY; SAFETY
AB IMPORTANCE Since technologic advances allow the use of robotic assistance in various surgical interventions performed to treat pediatric otolaryngology patients, the feasibility and outcomes of potential procedures must be assessed.
OBJECTIVE To assess the feasibility and outcomes of robotic-assisted lingual tonsillectomy in the pediatric population.
DESIGN, SETTING, AND PARTICIPANTS Retrospective medical record review in a tertiary care children's hospital of 16 pediatric patients who underwent robotic-assisted lingual tonsillectomy from March 1, 2011, through December 31, 2012.
INTERVENTION All patients underwent robotic-assisted lingual tonsillectomy using the da Vinci Surgical System (Intuitive Surgical, Inc) at the Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center.
MAIN OUTCOMES AND MEASURES Demographic data, comorbidities, robot docking time, operative time, estimated blood loss, and postoperative course, including complications in the immediate and longer-term postoperative period, were collected and analyzed.
RESULTS All patients successfully underwent lingual tonsillectomy using the da Vinci Surgical System. Endotracheal intubation was performed in all patients and did not interfere with visualization of the oropharynx. Optimal retraction allowed visualization of pertinent structures and maximized transoral access. A significant learning curve from the first 5 surgical cases to subsequent cases with respect to robot docking time was observed (9 vs 3 minutes, respectively; P < .05). Operative time, estimated blood loss, and postoperative complication profiles are within the expected and acceptable limitations for performing lingual tonsillectomy in the pediatric population.
CONCLUSIONS AND RELEVANCE Technologic advances have allowed miniaturization of robotic instrumentation and have expanded the scope of surgical options for the pediatric airway. Robotic-assisted lingual tonsillectomy is well tolerated and can be performed in the pediatric population with excellent success. It should be considered a feasible option for implementation at an institution-based level.
C1 [Leonardis, Rachel L.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
[Duvvuri, Umamaheswar] Univ Pittsburgh, Vet Affairs Pittsburgh Hlth Syst, Med Ctr, Inst Eye & Ear,Dept Otolaryngol, Pittsburgh, PA 15213 USA.
[Mehta, Deepak] Univ Pittsburgh, Childrens Hosp Pittsburgh, Med Ctr, Dept Otolaryngol, Pittsburgh, PA 15213 USA.
RP Duvvuri, U (reprint author), Univ Pittsburgh, Vet Affairs Pittsburgh Hlth Syst, Med Ctr, Inst Eye & Ear,Dept Otolaryngol, 203 Lothrop St,Ste 300, Pittsburgh, PA 15213 USA.
EM duvvuriu@upmc.edu
NR 15
TC 8
Z9 8
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6181
EI 2168-619X
J9 JAMA OTOLARYNGOL
JI JAMA Otolaryngol-Head Neck Surg.
PD OCT
PY 2013
VL 139
IS 10
BP 1032
EP 1036
DI 10.1001/jamaoto.2013.4924
PG 5
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA 279DU
UT WOS:000328941400007
PM 24135744
ER
PT J
AU West, JS
Price, M
Gros, KS
Ruggiero, KJ
AF West, Jenny S.
Price, Matthew
Gros, Kirstin Stauffacher
Ruggiero, Kenneth J.
TI Community Support as a Moderator of Postdisaster Mental Health Symptoms
in Urban and Nonurban Communities
SO DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS
LA English
DT Article
DE community support; urban nonurban; PTSD; depression
ID SOCIAL SUPPORT; NATURAL DISASTER; HURRICANE IKE; PSYCHOLOGICAL DISTRESS;
VIOLENT CRIME; STRESS; INTERVENTION; PTSD; ADULTS; CONSERVATION
AB Objective We examined the association between disaster exposure, community support, and mental health outcomes in urban and nonurban participants of Galveston and Chambers counties after Hurricane Ike. The moderating effect of community support was evaluated as a protective factor relative to postdisaster mental health.
Methods A representative population-based sample of 157 urban and 714 nonurban adults were interviewed 12 to 17 months after the hurricane about their mental health functioning, disaster exposure, and perceptions of community support.
Results A series of multiple regressions demonstrated that disaster exposure was associated with mental health outcomes for both groups. The strength of the association varied across population samples.Community support moderated the association between interpersonal effects of the disaster and posttraumatic stress disorder (PTSD) and depression outcomes in nonurban participants and the association between property damage and PTSD in urban participants.
Conclusions Community support played a larger role in reducing PTSD and depression symptoms associated with the interpersonal effects of a disaster in the nonurban sample only. Communities may play a more beneficial role in the recovery process in nonurban areas that have elevated levels of injury or death attributed to a disaster.
C1 [West, Jenny S.; Price, Matthew; Gros, Kirstin Stauffacher; Ruggiero, Kenneth J.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Price, Matthew; Gros, Kirstin Stauffacher; Ruggiero, Kenneth J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
[West, Jenny S.] Univ Calif Irvine, Irvine, CA USA.
RP Ruggiero, KJ (reprint author), Med Univ S Carolina, Natl Crime Victims Ctr, 67 President St, Charleston, SC 29425 USA.
EM prima@musc.edu
FU National Institutes of Mental Health [R34MH77149]; [T32MH018869]
FX This study is supported by the National Institutes of Mental Health
Grant R34MH77149 (Dr Ruggiero). Dr. Price is supported by T32MH018869.
NR 34
TC 2
Z9 2
U1 1
U2 6
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1935-7893
EI 1938-744X
J9 DISASTER MED PUBLIC
JI Dis. Med. Public Health Prep.
PD OCT
PY 2013
VL 7
IS 5
BP 443
EP 451
DI 10.1017/dmp.2013.74
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 273PC
UT WOS:000328546700003
PM 24274123
ER
PT J
AU Yoo, JW
Kim, S
Seol, H
Kim, SJ
Yang, JM
Ryu, WS
Min, TJ
Choi, JB
Kwon, M
Nakagawa, S
AF Yoo, Ji Won
Kim, Sulgi
Seol, Haesun
Kim, Sun Jung
Yang, Janet Miyoung
Ryu, Woo Sang
Min, Too Jae
Choi, Jong Bum
Kwon, Minkyung
Nakagawa, Shunichi
TI Effects of an internal medicine floor interdisciplinary team on hospital
and clinical outcomes of seniors with acute medical illness
SO GERIATRICS & GERONTOLOGY INTERNATIONAL
LA English
DT Article
DE clinical education; geriatric assessment; hospital medicine;
interdisciplinary team; quality improvement
ID CONFUSION ASSESSMENT METHOD; LENGTH-OF-STAY; PROSPECTIVE-PAYMENT;
DELIRIUM; GERIATRICS; RELIABILITY; RESIDENTS; TRENDS; RISK; CARE
AB AimTo examine whether an internal medicine interdisciplinary floor team enhances the hospital and clinical outcomes for seniors with acute medical illness.
MethodsSeniors admitted to medical floor teaching services of a USA teaching hospital were recruited and allocated to the interdisciplinary (ITD; n=236) and usual care teams (n=248). Compared with the usual care team, the interdisciplinary team physicians carried out daily geriatric assessment and management, and led the interdisciplinary team meeting designed for improving interprofessional collaboration.
ResultsAfter controlling for patient and physician characteristics, the mean hospital length of stay in the ITD team (6.1 days; 95% CI 5.2-7.7 days) was 0.7 days shorter than that in the usual care team (6.8 days; 95% CI 5.7-8.3 days; P=0.008). There was no significant difference in delirium and 30-day hospital readmission between care groups.
ConclusionsNotwithstanding partly positive associations, the results from the present study suggest that interdisciplinary team-based care is, at best, associated with enhancing the clinical and hospital outcomes for seniors with acute medical illness. Geriatr Gerontol Int 2013; 13: 942-948.
C1 [Yoo, Ji Won] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA.
[Yoo, Ji Won] Univ Michigan, Sch Med, Inst Gerontol, Ann Arbor, MI 48109 USA.
[Yang, Janet Miyoung] St Joseph Mercy, Dept Internal Med, Ann Arbor, MI USA.
[Kim, Sulgi] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA.
[Seol, Haesun] VNA Hlth Ctr, Federally Qualified Hlth Ctr, Bensenville, IL USA.
[Nakagawa, Shunichi] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY USA.
[Nakagawa, Shunichi] James J Peters Vet Affairs Med Ctr, GRECC, Bronx, NY USA.
[Yoo, Ji Won] Korea Univ, Coll Med, Dept Internal Med, Seoul 136705, South Korea.
[Ryu, Woo Sang; Min, Too Jae] Korea Univ, Coll Med, Ctr Clin Educ, Seoul 136705, South Korea.
[Kim, Sun Jung] Yonsei Univ, Sch Publ Hlth, Seoul 120749, South Korea.
[Choi, Jong Bum; Kwon, Minkyung] Yonsei Univ, Coll Med, Ctr Clin Educ, Seoul, South Korea.
RP Yoo, JW (reprint author), Univ Michigan, Sch Med, Dept Internal Med, 300 North Ingalls Bldg,Room 932, Ann Arbor, MI 48109 USA.
EM yoojiw@trinity-health.org
RI Kwon, Minkyung/H-3787-2012
OI Kwon, Minkyung/0000-0003-2437-7606
FU Junior Researcher Seed Grant (American Geriatrics Society); Excellence
for Graduate Medical Education Grant (Ministry of Education, Science and
Technology, Republic of Korea)
FX This study was funded by a Junior Researcher Seed Grant (American
Geriatrics Society) and an Excellence for Graduate Medical Education
Grant (Ministry of Education, Science and Technology, Republic of
Korea).
NR 31
TC 2
Z9 2
U1 2
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1444-1586
EI 1447-0594
J9 GERIATR GERONTOL INT
JI Geriatr. Gerontol. Int.
PD OCT
PY 2013
VL 13
IS 4
BP 942
EP 948
DI 10.1111/ggi.12035
PG 7
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 271LE
UT WOS:000328392600016
PM 23441847
ER
PT J
AU Wamsley, MA
Julian, KA
O'Sullivan, P
McCance-Katz, EF
Batki, SL
Satre, DD
Satterfield, J
AF Wamsley, Maria A.
Julian, Katherine A.
O'Sullivan, Patricia
McCance-Katz, Elinore F.
Batki, Steven L.
Satre, Derek D.
Satterfield, Jason
TI Team-Based Learning Exercise Efficiently Teaches Brief Intervention
Skills to Medicine Residents
SO SUBSTANCE ABUSE
LA English
DT Article
DE Curriculum development and evaluation; graduate medical education;
substance use; team-based learning
ID PATIENTS ALCOHOL-USE; PRIMARY-CARE; SUBSTANCE-ABUSE; TREATMENT SBIRT;
DRUG-USE; IMPACT; CURRICULUM; EDUCATION; PERFORMANCE; SETTINGS
AB Background: Evaluations of substance use screening and brief intervention (SBI) curricula typically focus on learner attitudes and knowledge, although effects on clinical skills are of greater interest and utility. Moreover, these curricula often require large amounts of training time and teaching resources. This study examined whether a 3-hour SBI curriculum for internal medicine residents utilizing a team-based learning (TBL) format is effective for SBI skills as measured by a standardized patient (SP) assessment. Methods: A waitlist-controlled design was employed. Results: Twenty-four postgraduate year 2 (PGY-2) and PGY-3 residents participated in a SP assessment prior to the TBL session (waitlist control group) and 32 participated in a SP assessment after the TBL session (intervention group). The intervention residents demonstrated better brief intervention skills than waitlist control residents, but there were no differences between the groups in screening and assessment skills. Residents receiving the TBL curriculum prior to the SP assessment reported increased confidence in all SBI skills. Conclusion: Findings indicate that a brief educational intervention can improve brief intervention skills. However, more intensive education may be needed to improve substance use screening and assessment.
C1 [Wamsley, Maria A.; Julian, Katherine A.; O'Sullivan, Patricia; Satterfield, Jason] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA.
[McCance-Katz, Elinore F.; Batki, Steven L.; Satre, Derek D.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Batki, Steven L.] San Francisco Vet Adm Med Ctr, San Francisco, CA USA.
[Satre, Derek D.] Kaiser Permanente, Div Res, San Francisco, CA USA.
RP Wamsley, MA (reprint author), Univ Calif San Francisco, Div Gen Internal Med, 1545 Divisadero St,Room 322,Campus Box 0320, San Francisco, CA 94143 USA.
EM maria.wamsley@ucsf.edu
RI Herring, Anna/L-7859-2014
FU SAMHSA [U79T1020295]
FX This research was funded by SAMHSA grant U79T1020295 awarded to Dr.
Satterfield.
NR 41
TC 4
Z9 4
U1 1
U2 9
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 0889-7077
EI 1547-0164
J9 SUBST ABUS
JI Subst. Abus.
PD OCT 1
PY 2013
VL 34
IS 4
BP 344
EP 349
DI 10.1080/08897077.2013.787958
PG 6
WC Substance Abuse
SC Substance Abuse
GA 269LB
UT WOS:000328241700003
PM 24159904
ER
PT J
AU Engineer, DR
Burney, BO
Hayes, TG
Garcia, JM
AF Engineer, Diana R.
Burney, Basil O.
Hayes, Teresa G.
Garcia, Jose M.
TI Exposure to ACEI/ARB and beta-Blockers Is Associated with Improved
Survival and Decreased Tumor Progression and Hospitalizations in
Patients with Advanced Colon Cancer
SO TRANSLATIONAL ONCOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; HEART-FAILURE; CELLS; ANGIOGENESIS;
PROPRANOLOL; INHIBITION; EXPRESSION; RECEPTOR; MODEL; PROLIFERATION
AB BACKGROUND: Advanced colon cancer is associated with weight loss and decreased survival. Studies suggest that angiotensin and beta-adrenergic blockade decrease colon cancer progression and ameliorate weight loss. This study aims to determine whether exposure to beta-adrenoceptor blockers (BBs), angiotensin-converting enzyme inhibitors (ACEIs), or angiotensin receptor blockers (ARBs) is associated with decreased mortality, tumor progression, number of hospitalizations, or weight loss in colorectal cancer. METHODS: Retrospective chart review included patients with advanced colorectal cancer. Survival, stage, hospitalization, cancer progression, cancer treatment, and body weight history were collected. RESULTS: Two hundred sixty-two of 425 new stage III to IV colorectal cancer cases reviewed met the study criteria. Those exposed to ACEI/ARB, BB, or both were more likely to have diabetes, hypertension, and stage III colorectal cancer. Adjusting for age, presence of hypertension and diabetes, and stage, ACEI/ARB + BB exposure was associated with decreased mortality compared to unexposed individuals [hazard ratio (HR) = 0.5, confidence interval (CI) = 0.29-0.85; Cox regression, P =.01]. Fewer total and cancer-related hospitalizations and decreased cancer progression in the ACEI/ARB + BB group versus the unexposed group (HR = 0.59, CI = 0.36-0.99, P =.047) were seen. Exposure did not affect weight changes; furthermore, body weight changes from both prediagnosis and at diagnosis to 6, 12, 18, and 24 months postdiagnosis predicted survival. CONCLUSIONS: We have observed an association between exposure to a combination of ACEI/ ARB + BB and increased survival, decreased hospitalizations, and decreased tumor progression in advanced colorectal cancer. Future studies will be needed to replicate these results and generalize them to broader populations. Determination of causality will require a randomized controlled trial.
C1 [Engineer, Diana R.; Burney, Basil O.; Garcia, Jose M.] Michael E DeBakey VA Med Ctr, Div Diabet Endocrinol & Metab, Ctr Translat Res Inflammatory Dis, Houston, TX USA.
[Engineer, Diana R.; Garcia, Jose M.] Baylor Coll Med, Houston, TX 77030 USA.
[Engineer, Diana R.] St Lukes Episcopal Hosp, Houston, TX 77030 USA.
[Hayes, Teresa G.] Baylor Coll Med, Div Hematol & Oncol, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Garcia, Jose M.] Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA.
RP Garcia, JM (reprint author), Baylor Coll Med, Div Endocrinol Diabet & Metab, Michael E DeBakey Vet Affairs Med Ctr, Rm 210,Bldg 109,2002 Holcombe Blvd, Houston, TX 77030 USA.
EM jgarcia1@bcm.edu
FU Veterans Affairs Medical Center (Houston, TX); Department of Veterans
Affairs (MERIT awards) [BX000507, CX000174]; National Institutes of
Health [AG040583]
FX This material is based on the work supported by the Michael E. DeBakey
Veterans Affairs Medical Center (Houston, TX), Department of Veterans
Affairs (MERIT awards BX000507 and CX000174), and the National
Institutes of Health (AG040583) to J.M.G. The authors report no
conflicts of interest.
NR 32
TC 17
Z9 18
U1 0
U2 2
PU NEOPLASIA PRESS
PI ANN ARBOR
PA 1150 W MEDICAL CENTER DR, MSRB III, RM 9303, ANN ARBOR, MI 48109-0648
USA
SN 1944-7124
EI 1936-5233
J9 TRANSL ONCOL
JI Transl. Oncol.
PD OCT
PY 2013
VL 6
IS 5
BP 539
EP 545
DI 10.1593/tlo.13346
PG 7
WC Oncology
SC Oncology
GA 271AQ
UT WOS:000328362800005
PM 24151534
ER
PT J
AU Vashishta, R
Soler, ZM
Nguyen, SA
Schlosser, RJ
AF Vashishta, Rishi
Soler, Zachary M.
Nguyen, Shaun A.
Schlosser, Rodney J.
TI A systematic review and meta-analysis of asthma outcomes following
endoscopic sinus surgery for chronic rhinosinusitis
SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY
LA English
DT Article
DE asthma; chronic rhinosinusitis; endoscopic sinus surgery; ESS; FESS
ID ALLERGEN-INDUCED RHINITIS; ASPIRIN TRIAD PATIENTS; NASAL POLYPS;
INTRANASAL CORTICOSTEROIDS; BRONCHIAL RESPONSIVENESS; TISSUE
EOSINOPHILIA; SURGICAL-TREATMENT; MESSENGER-RNA; MILD ASTHMA;
PROVOCATION
AB BackgroundPatients suffering from both chronic rhinosinusitis (CRS) and asthma demonstrate improved asthma outcomes when upper airway inflammation is controlled with medications. It is unclear if similar benefits exist when the upper airway is treated surgically. This study presents a systematic review and meta-analysis to assess the effects of endoscopic sinus surgery (ESS) on asthma outcomes.
MethodsOvid MEDLINE and the Cochrane databases were searched to identify studies examining asthma outcomes in patients with CRS following ESS. Included studies involved a cohort of at least 5 patients and reported at least 1 postoperative asthma outcome.
ResultsTwenty-two studies involving a total of 891 patients were identified. Mean follow-up across all studies was 26.4 months. Patients reported improved overall asthma control in 76.1% (95% confidence interval [CI], 71.9% to 80.3%) of cases. The frequency of asthma attacks decreased in 84.8% (95% CI, 76.6% to 93.0%) of patients and the number of hospitalizations decreased in 64.4% (95% CI, 53.3% to 75.6%). Decreased use of oral corticosteroids was seen in 72.8% (95% CI, 67.5% to 78.1%) of patients; inhaled corticosteroid use decreased in 28.5% (95% CI, 22.6% to 34.5%) and bronchodilator use decreased in 36.3% (95% CI, 28.9% to 43.7%) of patients. Mean improvement in predicted forced expiratory volume at 1 second (FEV1) was 1.62%, but was not statistically significant (p = 0.877).
ConclusionESS in patients with concomitant bronchial asthma improves clinical asthma outcome measures, but not lung function testing. Difficulty conducting controlled clinical trials of ESS limits the strength of conclusions which can be reached.
C1 [Vashishta, Rishi; Soler, Zachary M.; Nguyen, Shaun A.; Schlosser, Rodney J.] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA.
[Schlosser, Rodney J.] Ralph H Johnson VA Med Ctr, Dept Surg Otolaryngol, Charleston, SC USA.
RP Schlosser, RJ (reprint author), Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, 135 Rutledge Ave,MSC 550, Charleston, SC 29425 USA.
EM schlossr@musc.edu
FU Merit Award from the Clinical Sciences Research and Development program
of the Department of Veterans Affairs at the Ralph H. Johnson VA Medical
Center, Charleston, SC
FX Funding sources for the study: Merit Award from the Clinical Sciences
Research and Development program of the Department of Veterans Affairs
at the Ralph H. Johnson VA Medical Center, Charleston, SC.
NR 42
TC 24
Z9 25
U1 0
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2042-6976
EI 2042-6984
J9 INT FORUM ALLERGY RH
JI Int. Forum Allergy Rhinol.
PD OCT
PY 2013
VL 3
IS 10
BP 788
EP 794
DI 10.1002/alr.21182
PG 7
WC Otorhinolaryngology
SC Otorhinolaryngology
GA 269EG
UT WOS:000328223500003
PM 23818462
ER
PT J
AU Maia, Q
Grandner, MA
Findley, J
Gurubhagavatula, I
AF Maia, Querino
Grandner, Michael A.
Findley, James
Gurubhagavatula, Indira
TI Short and long sleep duration and risk of drowsy driving and the role of
subjective sleep insufficiency
SO ACCIDENT ANALYSIS AND PREVENTION
LA English
DT Article
DE Sleep; Driving; Accidents; Sleep duration; Insufficient sleep;
Epidemiology
ID MOTOR-VEHICLE CRASH; METAANALYSIS; PERFORMANCE; DEPRIVATION; ADULTS;
STATES; APNEA
AB Experimental sleep restriction increases sleepiness and impairs driving performance. However, it is unclear whether short sleep duration in the general population is associated with drowsy driving. The goal of the present study was to evaluate whether individuals in the general population who obtained sleep of 6 h or less are more likely to report drowsy driving, and evaluate the role of perceived sleep sufficiency. Data exploring whether subgroups of short sleepers (those who report the most or least unmet sleep need) show different risk profiles for drowsy driving are limited. From the 2009 Behavioral Risk Factor Surveillance System (N = 31,522), we obtained the following self-reported data: (1) sleep duration (<= 5, 6, 7, 8, 9, or >= 10h/night); (2) number of days/week of perceived insufficient sleep; (3) among drivers, yes/no response to: "During the past 30 days, have you ever nodded off or fallen asleep, even just for a brief moment, while driving?" (4) demographics, physical/mental health. Using 7 h/night as reference, logistic regression analyses evaluated whether self-reported sleep duration was associated with drowsy driving. Overall, 3.6% reported drowsy driving. Self-identified short-sleepers reported drowsy driving more often, and long sleepers, less often. Among those who perceived sleep as always insufficient, drowsy driving was reported more often when sleep duration was <= 5 h, 6 h, or >= 10 h. Among those who perceived sleep as always sufficient, drowsy driving was reported more often among <= 5 h and 6 h sleepers. Overall, drowsy driving was common, particularly in self-identified short-sleepers as a whole, as well as subgroups based on sleep insufficiency. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Maia, Querino; Grandner, Michael A.; Findley, James; Gurubhagavatula, Indira] Univ Penn, Ctr Sleep & Circadian Neurobiol, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Grandner, Michael A.; Findley, James] Univ Penn, Dept Psychiat, Behav Sleep Med Program, Philadelphia, PA 19104 USA.
[Gurubhagavatula, Indira] Philadelphia VA Med Ctr, Pulm Crit Care Sleep Sect, Philadelphia, PA USA.
RP Grandner, MA (reprint author), Univ Penn, Ctr Sleep & Circadian Neurobiol, 3624 Market St,Suite 205, Philadelphia, PA 19104 USA.
EM grandner@upenn.edu
FU NCRR NIH HHS [UL1RR024134, UL1 RR024134]; NHLBI NIH HHS [K23 HL110216,
K23HL110216]; NIEHS NIH HHS [R21 ES022931, R21ES022931]; NIOSH CDC HHS
[R01 OH009149, R01OH009149]
NR 23
TC 16
Z9 16
U1 1
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0001-4575
EI 1879-2057
J9 ACCIDENT ANAL PREV
JI Accid. Anal. Prev.
PD OCT
PY 2013
VL 59
BP 618
EP 622
DI 10.1016/j.aap.2013.07.028
PG 5
WC Ergonomics; Public, Environmental & Occupational Health; Social
Sciences, Interdisciplinary; Transportation
SC Engineering; Public, Environmental & Occupational Health; Social
Sciences - Other Topics; Transportation
GA 261SX
UT WOS:000327686000071
PM 23973762
ER
PT J
AU Sano, M
Egelko, S
Donohue, M
Ferris, S
Kaye, J
Hayes, TL
Mundt, JC
Sun, CK
Paparello, S
Aisen, PS
AF Sano, Mary
Egelko, Susan
Donohue, Michael
Ferris, Steven
Kaye, Jeffrey
Hayes, Tamara L.
Mundt, James C.
Sun, Chung-Kai
Paparello, Silvia
Aisen, Paul S.
CA Alzheimer Disease Cooperative
TI Developing Dementia Prevention Trials Baseline Report of the Home-Based
Assessment Study
SO ALZHEIMER DISEASE & ASSOCIATED DISORDERS
LA English
DT Article
DE Alzheimer disease; clinical trials; in-home assessment; prevention
studies
ID INSTRUMENT PROJECT; CLINICAL-TRIALS
AB This report describes the baseline experience of the multicenter, Home-Based Assessment study, designed to develop methods for dementia prevention trials using novel technologies for test administration and data collection. Nondemented individuals of 75 years of age or more were recruited and evaluated in-person using established clinical trial outcomes of cognition and function, and randomized to one of 3 assessment methodologies: (1) mail-in questionnaire/live telephone interviews [mail-in/phone (MIP)]; (2) automated telephone with interactive voice recognition; and (3) internet-based computer Kiosk. Brief versions of cognitive and noncognitive outcomes were adapted to each methodology and administered at baseline and repeatedly over a 4-year period. Efficiency measures assessed the time from screening to baseline, and staff time required for each methodology. A total of 713 individuals signed consent and were screened; 640 met eligibility and were randomized to one of 3 assessment arms; and 581 completed baseline. Dropout, time from screening to baseline, and total staff time were highest among those assigned to internet-based computer Kiosk. However, efficiency measures were driven by nonrecurring start-up activities suggesting that differences may be mitigated over a long trial. Performance among Home-Based Assessment instruments collected through different technologies will be compared with established outcomes over this 4-year study.
C1 [Sano, Mary; Egelko, Susan] Mt Sinai Sch Med, New York, NY USA.
[Ferris, Steven] NYU, Langone Med Ctr, New York, NY USA.
[Sano, Mary; Egelko, Susan] James J Peters VA Med Ctr, Bronx, NY 10468 USA.
[Donohue, Michael; Sun, Chung-Kai; Paparello, Silvia; Aisen, Paul S.] Univ Calif San Diego, La Jolla, CA 92093 USA.
[Kaye, Jeffrey; Hayes, Tamara L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Kaye, Jeffrey] Portland VA Med Ctr, Portland, OR USA.
[Mundt, James C.] Ctr Psychol Consultat, Madison, WI USA.
[Mundt, James C.] Univ Arkansas Med Sci, Little Rock, AR 72205 USA.
RP Sano, M (reprint author), James J Peters VA Med Ctr, 130 Kingsbridge Rd,Code 151 Room 1F01, Bronx, NY 10468 USA.
EM mary.sano@mssm.edu
OI Ferris, Steven/0000-0001-8641-6223; Kaye, Jeffrey/0000-0002-9971-3478
FU NIA [U01AG10483, P50AG005138, P30AG008051, P30AG024978, P30AG08017];
Intel Corporation
FX Supported by the following NIA Grants: U01AG10483, P50AG005138,
P30AG008051, and P30AG024978. Development of the Kiosk and MedTracker
was supported in part by Grants from NIA (P30AG024978; P30AG08017) and
Intel Corporation.
NR 18
TC 7
Z9 7
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0893-0341
EI 1546-4156
J9 ALZ DIS ASSOC DIS
JI Alzheimer Dis. Assoc. Dis.
PD OCT-DEC
PY 2013
VL 27
IS 4
BP 356
EP 362
DI 10.1097/WAD.0b013e3182769c05
PG 7
WC Clinical Neurology; Pathology
SC Neurosciences & Neurology; Pathology
GA 262NR
UT WOS:000327742800010
PM 23151596
ER
PT J
AU White, S
Acierno, R
Ruggiero, KJ
Koenen, KC
Kilpatrick, DG
Galea, S
Gelernter, J
Williamson, V
McMichael, O
Vladimirov, VI
Amstadter, AB
AF White, Simone
Acierno, Ron
Ruggiero, Kenneth J.
Koenen, Karestan C.
Kilpatrick, Dean G.
Galea, Sandro
Gelernter, Joel
Williamson, Vernell
McMichael, Omari
Vladimirov, Vladimir I.
Amstadter, Ananda B.
TI Association of CRHR1 variants and posttraumatic stress symptoms in
hurricane exposed adults
SO JOURNAL OF ANXIETY DISORDERS
LA English
DT Article
DE Posttraumatic stress disorder; CRHR1; HPA axis; Disasters; Trauma
ID POPULATION GROUP ASSIGNMENT; DISORDER SYMPTOMS; COMBAT VETERANS;
TRAUMATIC EVENT; RECEPTOR GENE; GENOTYPE DATA; RISK; TWIN; DEPRESSION;
MARKERS
AB Posttraumatic stress disorder (PTSD) is a moderately heritable anxiety disorder that may develop after exposure to trauma. However, only few genetic variants that relate to PTSD have been studied. This study examined the relationship between 12 single nucleotide polymorphisms (SNPs) in the corticotropin-releasing hormone receptor 1 gene (CRHR1) and post-disaster PTSD symptoms and diagnosis in adults exposed to 2004 Florida hurricanes. CRHR1 regulates the hypothalamic-pituitary-adrenal (HPA) axis; dysregulation of the HPA axis is characteristic of stress phenotypes. Final analyses were conducted in the European-American (EA) subsample (n = 564) due to population stratification. After correction for multiple testing, rs12938031 and rs4792887 remained associated with post-hurricane PTSD symptoms. Additionally, rs12938031 was associated with post-hurricane diagnosis of PTSD. This study is the first to examine CRHR1 in relation to PTSD in adults, and provides evidence for the importance of CRHR1 variation in the etiology of PTSD. Although results are preliminary and require replication, they justify follow-up efforts to characterize how this gene relates to PTSD. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [White, Simone; Williamson, Vernell; McMichael, Omari; Vladimirov, Vladimir I.; Amstadter, Ananda B.] Virginia Commonwealth Univ, Virginia Inst Psychiat & Behav Genet, Richmond, VA 23298 USA.
[Acierno, Ron; Ruggiero, Kenneth J.; Kilpatrick, Dean G.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Acierno, Ron; Ruggiero, Kenneth J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
[Koenen, Karestan C.; Galea, Sandro] Columbia Univ, Dept Epidemiol, New York, NY USA.
[Gelernter, Joel] Yale Univ, Sch Med, Div Human Genet Psychiat, New Haven, CT USA.
RP Amstadter, AB (reprint author), Virginia Commonwealth Univ, Virginia Inst Psychiat & Behav Genet, 800 E Leigh St,Biotech 1,POB 980126, Richmond, VA 23298 USA.
EM slw257@cornell.edu; abamstadter@vcu.edu
FU NIAAA NIH HHS [R01 AA020179]; NIGMS NIH HHS [R25 GM089614]; NIMH NIH HHS
[R21 MH074469]; PHS HHS [NIGMS 089614, NIMH 05220]
NR 47
TC 15
Z9 16
U1 4
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0887-6185
EI 1873-7897
J9 J ANXIETY DISORD
JI J. Anxiety Disord.
PD OCT
PY 2013
VL 27
IS 7
BP 678
EP 683
DI 10.1016/j.janxdis.2013.08.003
PG 6
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 261ST
UT WOS:000327685600008
PM 24077033
ER
PT J
AU MacDonald, DE
Rapuano, BE
Vyas, P
Lane, JM
Meyers, K
Wright, T
AF MacDonald, Daniel E.
Rapuano, Bruce E.
Vyas, Parth
Lane, Joseph M.
Meyers, Kathleen
Wright, Timothy
TI Heat and Radiofrequency Plasma Glow Discharge Pretreatment of a Titanium
Alloy Promote Bone Formation and Osseointegration
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE DENTAL IMPLANT; FIBRONECTIN; OSTEOBLAST; CELL DIFFERENTIATION; BONE
MINERALIZATION; OSSEOINTEGRATION
ID OXIDE NET CHARGE; OSTEOBLAST ADHESION; DENTAL IMPLANTS; CELL-ADHESION;
SURFACE; FIBRONECTIN; TOPOGRAPHY; SITES; DIFFERENTIATION; INTEGRATION
AB Orthopedic and dental implants manifest increased failure rates when inserted into low density bone. We determined whether chemical pretreatments of a titanium alloy implant material stimulated new bone formation to increase osseointegration in vivo in trabecular bone using a rat model. Titanium alloy rods were untreated or pretreated with heat (600 degrees C) or radiofrequency plasma glow discharge (RFGD). The rods were then coated with the extracellular matrix protein fibronectin (1nM) or left uncoated and surgically implanted into the rat femoral medullary cavity. Animals were euthanized 3 or 6 weeks later, and femurs were removed for analysis. The number of trabeculae in contact with the implant surface, surface contact between trabeculae and the implant, and the length and area of bone attached to the implant were measured by histomorphometry. Implant shear strength was measured by a pull-out test. Both pretreatments and fibronectin enhanced the number of trabeculae bonding with the implant and trabeculae-to-implant surface contact, with greater effects of fibronectin observed with pretreated compared to untreated implants. RFGD pretreatment modestly increased implant shear strength, which was highly correlated (r(2)=0.87-0.99) with measures of trabecular bonding for untreated and RFGD-pretreated implants. In contrast, heat pretreatment increased shear strength 3-5-fold for both uncoated and fibronectin-coated implants at 3 and 6 weeks, suggesting a more rapid increase in implant-femur bonding compared to the other groups. In summary, our findings suggest that the heat and RFGD pretreatments can promote the osseointegration of a titanium alloy implant material. J. Cell. Biochem. 114: 2363-2374, 2013. (c) 2013 Wiley Periodicals, Inc.
C1 [MacDonald, Daniel E.; Rapuano, Bruce E.; Vyas, Parth; Lane, Joseph M.; Meyers, Kathleen; Wright, Timothy] Cornell Univ, Weill Med Coll, Hosp Special Surg, New York, NY 10021 USA.
[MacDonald, Daniel E.] James J Peters VA Med Ctr, Bronx, NY 10468 USA.
[MacDonald, Daniel E.] Columbia Univ, Langmuir Ctr Colloids & Interfaces, New York, NY 10027 USA.
RP MacDonald, DE (reprint author), Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA.
EM dem14@columbia.edu
FU National Center for Research Resources, NIH [C06-RR12538-01]
FX The sponsor did not have any role in the study design; the collection,
analysis and interpretation of data; the writing of the report; or the
decision to submit the article for publication. This material also
resulted from work supported with resources and the use of facilities at
the James J. Peters VA Medical Center, Bronx, New York. This
investigation was also conducted at the HSS research facility
constructed with support of Grant C06-RR12538-01 from the National
Center for Research Resources, NIH. We thank Dr. Hannes Schniepp for the
AFM surface analyses, Dr. Stephen Doty, and Tony Labissiere for
technical assistance with the SEM analyses, Dr. Adele Boskey and
Lyudmila Spevak for assistance with FTIR, and Kyle Hackshaw, Carrie
Guan, and Jenny Lee for help with preparation of the alloy implants.
NR 50
TC 4
Z9 4
U1 0
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
EI 1097-4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD OCT
PY 2013
VL 114
IS 10
BP 2363
EP 2374
DI 10.1002/jcb.24585
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 263NP
UT WOS:000327815600017
PM 23649564
ER
PT J
AU Garrido, MM
Idler, EL
Leventhal, H
Carr, D
AF Garrido, Melissa M.
Idler, Ellen L.
Leventhal, Howard
Carr, Deborah
TI Pathways From Religion to Advance Care Planning: Beliefs About Control
Over Length of Life and End-of-Life Values
SO GERONTOLOGIST
LA English
DT Article
DE Advance directive; living wills; durable power of attorney for
healthcare
ID TREATMENT PREFERENCES; DECISION-MAKING; RACIAL-DIFFERENCES;
CANCER-PATIENTS; DIRECTIVES; HEALTH; DEATH; PHYSICIANS; RESIDENTS;
ATTITUDES
AB Purpose of the Study: To evaluate the extent to which religious affiliation and self-identified religious importance affect advance care planning (ACP) via beliefs about control over life length and end-of-life values. Design and Methods: Three hundred and five adults aged 55 and older from diverse racial and socioeconomic groups seeking outpatient care in New Jersey were surveyed. Measures included discussion of end-of-life preferences; living will (LW) completion; durable power of attorney for healthcare (DPAHC) appointment; religious affiliation; importance of religion; and beliefs about who/what controls life length, end-of-life values, health status, and sociodemographics. Results: Of the sample, 68.9% had an informal discussion and 46.2% both discussed their preferences and did formal ACP (LW and/or DPAHC). Conservative Protestants and those placing great importance on religion/spirituality had a lower likelihood of ACP. These associations were largely accounted for by beliefs about God's controlling life length and values for using all available treatments. Implications: Beliefs and values about control account for relationships between religiosity and ACP. Beliefs and some values differ by religious affiliation. As such, congregations may be one nonclinical setting in which ACP discussions could be held, as individuals with similar attitudes toward the end of life could discuss their treatment preferences with those who share their views.
C1 [Garrido, Melissa M.] GRECC, James J Peters VA Med Ctr, Bronx, NY 10468 USA.
[Garrido, Melissa M.] Mt Sinai Sch Med, Brookdale Dept Geriatr & Palliat Med, New York, NY USA.
[Idler, Ellen L.] Emory Univ, Dept Sociol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
[Idler, Ellen L.] Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
[Leventhal, Howard] Rutgers State Univ, Dept Psychol, New Brunswick, NJ 08903 USA.
[Leventhal, Howard] Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, New Brunswick, NJ 08903 USA.
[Carr, Deborah] Rutgers State Univ, Dept Sociol, New Brunswick, NJ 08903 USA.
[Carr, Deborah] Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, New Brunswick, NJ 08903 USA.
RP Garrido, MM (reprint author), GRECC, James J Peters VA Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM melissa.garrido@mssm.edu
FU NIA NIH HHS [AG023958]; NIMH NIH HHS [T32 MH16242-29]
NR 38
TC 11
Z9 11
U1 4
U2 23
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
EI 1758-5341
J9 GERONTOLOGIST
JI Gerontologist
PD OCT
PY 2013
VL 53
IS 5
BP 801
EP 816
DI 10.1093/geront/gns128
PG 16
WC Gerontology
SC Geriatrics & Gerontology
GA 258DL
UT WOS:000327439300010
PM 23161430
ER
PT J
AU Bradley, KA
Chavez, LJ
Lapham, GT
Williams, EC
Achtmeyer, CE
Rubinsky, AD
Hawkins, EJ
Saitz, R
Kivlahan, DR
AF Bradley, Katharine A.
Chavez, Laura J.
Lapham, Gwendolyn T.
Williams, Emily C.
Achtmeyer, Carol E.
Rubinsky, Anna D.
Hawkins, Eric J.
Saitz, Richard
Kivlahan, Daniel R.
TI When Quality Indicators Undermine Quality: Bias in a Quality Indicator
of Follow-Up for Alcohol Misuse
SO PSYCHIATRIC SERVICES
LA English
DT Article
ID SERVICES-TASK-FORCE; PRIMARY-CARE; HEALTH-CARE; PREVENTIVE-SERVICES;
MENTAL-HEALTH; PERFORMANCE-MEASURES; MEANINGFUL USE; INTERVENTIONS;
ACCOUNTABILITY; IMPROVEMENT
AB Objective: Valid quality indicators are needed to monitor and encourage identification and management of mental health and substance use conditions (behavioral conditions). Because behavioral conditions are frequently underidentified, quality indicators often evaluate the proportion of patients who screen positive for a condition who also have appropriate follow-up care documented. However, these "positive-screen-based" quality indicators of follow-up for behavioral conditions could be biased by differences in the denominator due to differential screening quality ("denominator bias") and could reward identification of fewer patients with the behavioral conditions of interest. This study evaluated denominator bias in the performance of Veterans Health Administration (VHA) networks on a quality indicator of follow-up for alcohol misuse that used the number of patients with positive alcohol screens as the denominator. Methods: Two quality indicators of follow-up for alcohol misuse-a positive-screen-based quality indicator and a population-based quality indicator-were compared among 21 VHA networks by review of 219,119 medical records. Results: Results for the two quality indicators were inconsistent. For example, two networks performed similarly on the quality indicators (64.7% and 65.4% follow-up) even though one network identified and documented follow-up for almost twice as many patients (5,411 and 2,899 per 100,000 eligible, respectively). Networks that performed better on the positive-screen-based quality indicator identified fewer patients with alcohol misuse than networks that performed better on the population-based quality indicator (mean 4.1% versus 7.4%, respectively). Conclusions: A positive-screen-based quality indicator of follow-up for alcohol misuse preferentially rewarded networks that identified fewer patients with alcohol misuse.
C1 [Bradley, Katharine A.; Lapham, Gwendolyn T.] Grp Hlth Res Inst, Seattle, WA 98101 USA.
[Chavez, Laura J.; Williams, Emily C.; Achtmeyer, Carol E.; Rubinsky, Anna D.; Kivlahan, Daniel R.] Vet Affairs VA Hlth Serv Res & Dev, Northwest Ctr Excellence, Seattle, WA USA.
[Chavez, Laura J.; Williams, Emily C.] Univ Washington, Dept Hlth Serv, Sch Publ Hlth, Seattle, WA 98195 USA.
[Hawkins, Eric J.] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA.
[Saitz, Richard] Boston Univ, Dept Gen Internal Med, Boston, MA 02215 USA.
RP Bradley, KA (reprint author), Grp Hlth Res Inst, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA.
EM bradley.k@ghc.org
FU Substance Use Disorders Quality Enhancement Research Initiative from VA
Health Services Research and Development [SUB98-000]; National Institute
on Alcohol Abuse and Alcoholism [NIAAA R21 AA020894-01A1]; Group Health
Research Institute
FX This study was supported by the Substance Use Disorders Quality
Enhancement Research Initiative SUB98-000 from VA Health Services
Research and Development, by grant NIAAA R21 AA020894-01A1 from the
National Institute on Alcohol Abuse and Alcoholism, and by the Group
Health Research Institute. Funders had no role in the conduct or
reporting of research. Data were provided via a data use agreement with
the VA OABI (formerly the VA Office of Quality and Performance), which
had no role in design or analyses but reviewed the manuscript before
submission to ensure accurate use and reporting of data.
NR 51
TC 12
Z9 12
U1 3
U2 6
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
EI 1557-9700
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD OCT
PY 2013
VL 64
IS 10
BP 1018
EP 1025
DI 10.1176/appi.ps.201200449
PG 8
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 255ZH
UT WOS:000327278200022
PM 23852137
ER
PT J
AU Robinson, TN
Wu, DS
Pointer, L
Dunn, CL
Cleveland, JC
Moss, M
AF Robinson, Thomas N.
Wu, Daniel S.
Pointer, Lauren
Dunn, Christina L.
Cleveland, Joseph C., Jr.
Moss, Marc
TI Simple frailty score predicts postoperative complications across
surgical specialties
SO AMERICAN JOURNAL OF SURGERY
LA English
DT Article
DE Geriatric surgery; Preoperative risk assessment; Surgical morbidity
ID OLDER-ADULTS; NONCARDIAC SURGERY; ELDERLY-PATIENTS; CO-MORBIDITY; CARE;
MORTALITY; RISK; POPULATION; VALIDATION; SEVERITY
AB BACKGROUND: Our purpose was to determine the relationship between preoperative frailty and the occurrence of postoperative complications after colorectal and cardiac operations.
METHODS: Patients 65 years or older undergoing elective colorectal or cardiac surgery were enrolled. Seven baseline frailty traits were measured preoperatively: Katz score less than or equal to 5, Timed Up and Go test greater than or equal to 15 seconds, Charlson Index greater than or equal to 3, anemia less than 35%, Mini-Cog score less than or equal to 3, albumin less than 3.4 g/dL, and 1 or more falls within 6 months. Patients were categorized by the number of positive traits as follows: non-frail: 0 to 1 traits, prefrail: 2 to 3 traits, and frail: 4 or more traits.
RESULTS: Two hundred one subjects (age 74 +/- 6 years) were studied. Preoperative frailty was associated with increased postoperative complications after colorectal (nonfrail: 21%, prefrail: 40%, frail: 58%; P = .016) and cardiac operations (nonfrail: 17%, prefrail: 28%, frail: 56%; P < .001). This finding in both groups was independent of advancing age. Frail individuals in both groups had longer hospital stays and higher 30-day readmission rates. Receiver operating characteristic curves examining frailty's ability to forecast complications were colorectal (.702, P = .004) and cardiac (. 711, P < .001).
CONCLUSIONS: A simple preoperative frailty score defines older adults at higher risk for postoperative complications across surgical specialties. Published by Elsevier Inc.
C1 [Robinson, Thomas N.; Wu, Daniel S.; Dunn, Christina L.; Cleveland, Joseph C., Jr.] Univ Colorado Denver Sch Med, Dept Surg, Aurora, CO 80045 USA.
[Moss, Marc] Univ Colorado Denver Sch Med, Dept Med, Aurora, CO 80045 USA.
[Robinson, Thomas N.; Wu, Daniel S.; Cleveland, Joseph C., Jr.] Denver Vet Affairs Med Ctr, Dept Surg, Denver, CO USA.
[Pointer, Lauren] Denver Vet Affairs Med Ctr, Dept Biostat, Denver, CO USA.
RP Robinson, TN (reprint author), Univ Colorado Denver Sch Med, Dept Surg, 12631 East 17th Ave,MS C313, Aurora, CO 80045 USA.
EM thomas.robinson@ucdenver.edu
FU Paul B. Beeson Award [NIA K23AG034632]; Dennis W. Jahnigen Award;
American Geriatrics Society; National Institutes of Health
[K24-HL-089223]
FX Supported by the Paul B. Beeson Award (NIA K23AG034632 [TNR]), Dennis W.
Jahnigen Award, American Geriatrics Society (TNR) and National
Institutes of Health (K24-HL-089223 [MM]).
NR 26
TC 76
Z9 76
U1 1
U2 12
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9610
EI 1879-1883
J9 AM J SURG
JI Am. J. Surg.
PD OCT
PY 2013
VL 206
IS 4
BP 544
EP 550
DI 10.1016/j.amjsurg.2013.03.012
PG 7
WC Surgery
SC Surgery
GA 246BF
UT WOS:000326510500016
PM 23880071
ER
PT J
AU An, HM
Tan, YL
Shi, J
Wang, ZR
Li, J
Wang, YC
Kosten, TR
Zhou, DF
Yang, FD
Zhang, XY
AF An, Hui-Mei
Tan, Yun-Long
Shi, Jing
Wang, Zhi-Ren
Li, Jia
Wang, Yue-Chan
Kosten, Thomas R.
Zhou, Dong Feng
Yang, Fu-De
Zhang, Xiang-Yang
TI Extract of Ginkgo biloba is equivalent to vitamin E in attenuating and
preventing vacuous chewing movements in a rat model of tardive
dyskinesia
SO BEHAVIOURAL PHARMACOLOGY
LA English
DT Article
DE animal model; antioxidant; extract of Ginkgo biloba; free radical; rat;
tardive dyskinesia; vacuous chewing movements; vitamin E
ID INDUCED OROFACIAL DYSKINESIA; PLACEBO-CONTROLLED TRIAL; LONG-TERM
TREATMENT; DOUBLE-BLIND; JAW MOVEMENTS; POSSIBLE INVOLVEMENT;
ANIMAL-MODELS; SUPEROXIDE-DISMUTASE; PARKINSONIAN TREMOR; OXIDATIVE
STRESS
AB Free radical-mediated abnormalities may contribute toward the pathogenesis of tardive dyskinesia (TD). Many studies have reported the protective antioxidant and free radical-scavenging activities of extract of Ginkgo biloba (EGb761) against free radical-induced cell damage and dysfunction. This study aimed to compare the efficacy of EGb761 with that of vitamin E for the prevention and treatment of TD in a rat model. We carried out two studies. First, rats were injected with haloperidol (2 mg/kg intraperitoneally) daily for 5 weeks. EGb761 (50mg/kg/day) or vitamin E (20mg/kg/day) were then administered for another 5 weeks, and their effects on vacuous chewing movements (VCMs) were compared. Second, we compared 10 weeks of haloperidol alone with 10 weeks of haloperidol plus EGb761 or vitamin E. The administration of haloperidol led to a progressive increase in VCMs, which peaked at week 5. In study one, EGb761 and vitamin E, administered by an oral gavage for 5 weeks during withdrawal from chronic haloperidol treatment, decreased VCMs significantly, showing 83.8 and 91.0% reduction, respectively, compared with the haloperidol-alone group. In study two, the concomitant administration of EGb761 and vitamin E led to significantly fewer VCMs, by 64.4 and 73.9%, respectively, compared with the haloperidol-alone group. There was no significant difference in either study between EGb761 and vitamin E treatment. EGb761 shows promise for the prevention and treatment of TD in a rat model with a magnitude that was similar to that of vitamin E. (C) 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins.
C1 [An, Hui-Mei; Tan, Yun-Long; Shi, Jing; Wang, Zhi-Ren; Li, Jia; Wang, Yue-Chan; Yang, Fu-De; Zhang, Xiang-Yang] Peking Univ, Beijing Huilongguan Hosp, Psychiat Res Ctr, Beijing 100871, Peoples R China.
[Zhou, Dong Feng] Peking Univ, Inst Mental Hlth, Beijing 100871, Peoples R China.
[Kosten, Thomas R.; Zhang, Xiang-Yang] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
[Kosten, Thomas R.; Zhang, Xiang-Yang] Michael E DeBakey VA Med Ctr, Houston, TX USA.
RP Zhang, XY (reprint author), VA Med Ctr, Res Bldg 109,Room 130,2002 Holcombe Blvd, Houston, TX 77030 USA.
EM xyzhang@bcm.edu
FU National Natural Science Foundation of China [30770782, 81071086];
Stanley Medical Research Institute [03T-459, 05T-726]; United States
National Institute of Health [K05-DA0454, P50-DA18827, U01-MH79639]
FX This work was supported by grants from the National Natural Science
Foundation of China (30770782, 81071086), the Stanley Medical Research
Institute (03T-459 and 05T-726), and the United States National
Institute of Health K05-DA0454, P50-DA18827 and U01-MH79639.
NR 71
TC 3
Z9 3
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0955-8810
EI 1473-5849
J9 BEHAV PHARMACOL
JI Behav. Pharmacol.
PD OCT
PY 2013
VL 24
IS 7
BP 610
EP 616
DI 10.1097/FBP.0b013e3283656d87
PG 7
WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy
SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy
GA 251YP
UT WOS:000326971200008
PM 23994817
ER
PT J
AU Johnson, GJ
Leis, LA
Slater, BCS
Bach, RR
AF Johnson, Gerhard J.
Leis, Linda A.
Slater, Billie C. S.
Bach, Ronald R.
TI Elevated platelet count, C-reactive protein and thromboxane
analog-induced platelet aggregation in patients with Gulf War veterans'
illnesses: evidence of a chronic inflammatory state?
SO BLOOD COAGULATION & FIBRINOLYSIS
LA English
DT Article
DE C-reactive protein; Gulf War illness; platelet aggregation; platelet
secretion; thromboxane A(2)
ID CHRONIC-FATIGUE-SYNDROME; THROMBOCYTOSIS; DYSFUNCTION; ACTIVATION; LINK
AB A previous study of Gulf War veteran's illnesses (GWVI) observed evidence of platelet activation in a majority of patients with GWVI. To further characterize platelet function, we studied 43 patients (40 men) with GWVI (GWVI+) and 21 veterans who served concurrently in the Gulf War but who lacked criteria for GWVI (GWVI-). All participants were free of infection and known inflammatory diseases. Studies performed included platelet count, immature platelet fraction (IPF), plasma thrombopoietin (TPO), C-reactive protein (CRP), platelet aggregation and ATP secretion in response to six agonists, and spontaneous aggregation. Platelet counts and CRP were significantly elevated in GWVI+ compared to GWVI- patients without elevation in IPF or TPO. Platelet aggregation did not differ between GWVI+ and GWVI- patients except for spontaneous aggregation that was significantly greater in GWVI+ patients. Platelet ATP secretion was similar in the two groups, except the response to 50mol/l thrombin receptor agonist peptide 6 (TRAP 6) was significantly greater in GWVI+ patients. When platelet aggregation was analyzed in relation to CRP, the response to 0.5mol/l U46619 was significantly greater in patients whose CRP was at least 2g/ml. Therefore, GWVI+ patients had elevated platelet counts, spontaneous aggregation, TRAP 6-induced secretion, and CRP, but no impairment of platelet function. The increased platelet counts and U46619-induced aggregation appear to be consequences of an underlying inflammatory state in GWVI. (C) 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins.
C1 [Johnson, Gerhard J.; Leis, Linda A.; Slater, Billie C. S.; Bach, Ronald R.] VA Healthcare Syst, Minneapolis, MN 55417 USA.
[Johnson, Gerhard J.; Leis, Linda A.; Slater, Billie C. S.; Bach, Ronald R.] Univ Minnesota, Minneapolis, MN USA.
[Leis, Linda A.; Slater, Billie C. S.; Bach, Ronald R.] Univ Minnesota, US Dept Vet Affairs, Res Serv, Minneapolis, MN USA.
[Johnson, Gerhard J.] Univ Minnesota, Dept Med, Div Hematol Oncol & Transplant, Minneapolis, MN 55455 USA.
RP Johnson, GJ (reprint author), VA Healthcare Syst, Hematol Oncol 111E,1 Vet Dr, Minneapolis, MN 55417 USA.
EM johns337@umn.edu
FU Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development; US Department of Defense, Gulf War Illness
Research Programs
FX Source of support for the work: This material is based upon work
supported by the Department of Veterans Affairs, Veterans Health
Administration, Office of Research and Development, and by the US
Department of Defense, Gulf War Illness Research Programs.
NR 25
TC 5
Z9 5
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0957-5235
EI 1473-5733
J9 BLOOD COAGUL FIBRIN
JI Blood Coagul. Fibrinolysis
PD OCT
PY 2013
VL 24
IS 7
BP 736
EP 741
DI 10.1097/MBC.0b013e328362627f
PG 6
WC Hematology
SC Hematology
GA 247EM
UT WOS:000326598300011
PM 23751609
ER
PT J
AU Singh, H
AF Singh, Hardeep
TI Diagnostic errors: moving beyond 'no respect' and getting ready for
prime time
SO BMJ QUALITY & SAFETY
LA English
DT Editorial Material
DE Accreditation; Adverse events; epidemiology and detection; Ambulatory
care
ID PRIMARY-CARE; INFORMATION-TECHNOLOGY; MISSED OPPORTUNITIES; MALPRACTICE
CLAIMS; CANCER DIAGNOSIS; PATIENT-SAFETY; SETTINGS; MEDICINE; AUTOPSY;
RECORDS
C1 [Singh, Hardeep] Baylor Coll Med, Houston VA HSR&D Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, VA Med Ctr, Houston, TX 77030 USA.
[Singh, Hardeep] Baylor Coll Med, VA Med Ctr, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA.
RP Singh, H (reprint author), Baylor Coll Med, Houston VA HSR&D Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, VA Med Ctr, 152 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM hardeeps@bcm.edu
FU AHRQ HHS [R13 HS019252, R13 HS19252-01, R18HS017820, R18 HS017820]; NCI
NIH HHS [K23CA125585, K23 CA125585]
NR 39
TC 9
Z9 9
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-5415
EI 2044-5423
J9 BMJ QUAL SAF
JI BMJ Qual. Saf.
PD OCT
PY 2013
VL 22
IS 10
BP 789
EP 792
DI 10.1136/bmjqs-2013-002387
PG 4
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 247XU
UT WOS:000326659100001
PM 24048615
ER
PT J
AU Daniel, S
Soleymani, T
Garvey, WT
AF Daniel, Sunil
Soleymani, Taraneh
Garvey, W. Timothy
TI A complications-based clinical staging of obesity to guide treatment
modality and intensity
SO CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY
LA English
DT Review
DE cardiometabolic disease; complications; obesity; treatment algorithm;
weight loss
ID BODY-MASS INDEX; OBSTRUCTIVE SLEEP-APNEA; QUALITY-OF-LIFE;
POLYCYSTIC-OVARY-SYNDROME; FATTY LIVER-DISEASE; BINGE-EATING DISORDER;
CONTROLLED-RELEASE PHENTERMINE/TOPIRAMATE; GASTROESOPHAGEAL-REFLUX
DISEASE; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL
AB Purpose of reviewThe current medical model for obesity management is BMI-centric because BMI is the predominant measure used to gauge disease severity, as well as indications for various treatment modalities. Recent advancements in therapy and understanding of the relationship between BMI and obesity-related complications call for a re-examination of this approach.Recent findingsAdvancements in treatment, including the recent approval of two new weight loss medications in the USA, have enabled development of new medical models for management of obesity. On the basis of accumulating data demonstrating the benefits of weight loss regarding multiple obesity-related complications (e.g., diabetes prevention, type 2 diabetes mellitus, cardiovascular disease risk, nonalcoholic steatohepatitis, sleep apnea), a complications-centric model is proposed that employs weight loss as a tool to treat and prevent obesity comorbidities. This model assures that the aggressiveness of therapy is commensurate with disease severity, and that therapy is directed at those obese patients who will benefit most from weight loss therapy. The treatment algorithm is comprehensive in addressing complications and quantitative when possible in the staging of risk or disease severity.SummaryA complications-centric approach to obesity management identifies patients who will benefit most from weight loss, and optimizes patient outcomes, benefit/risk ratio, and the cost-effectiveness of interventions.
C1 [Daniel, Sunil] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA.
Birmingham VA Med Ctr, Birmingham, MA USA.
RP Daniel, S (reprint author), Univ Alabama Birmingham, Dept Nutr Sci, Webb 232,1720 2nd Ave South, Birmingham, AL 35294 USA.
EM sunild@uab.edu
FU Department of Veterans Affairs; National Institutes of Health
[DK-038765, DK-083562]; UAB Diabetes Research Center [P60-DK079626];
Merck; Amylin; Weight Watchers
FX This work was supported by the Merit Review program of the Department of
Veterans Affairs, the National Institutes of Health (DK-038765 and
DK-083562), and the UAB Diabetes Research Center (P60-DK079626).; W.T.G.
is a speaker for Merck, Amylin, and Liposcience. He is on the advisory
boards of Daiichi-Sankyo, Vivus, Alkermes, Eisai, Liposcience, Tethys
Bioscience, and Janssen. He receives research support from Merck,
Amylin, and Weight Watchers. S. D. is a speaker for Vivus. T. S. is a
speaker for Vivus.
NR 130
TC 11
Z9 11
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1752-296X
EI 1752-2978
J9 CURR OPIN ENDOCRINOL
JI Curr. Opin. Endocrinol. Diabetes Obes.
PD OCT
PY 2013
VL 20
IS 5
BP 377
EP 388
DI 10.1097/01.med.0000433067.01671.f5
PG 12
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 247BG
UT WOS:000326587900003
PM 23974764
ER
PT J
AU Frankel, HL
Kaplan, LJ
AF Frankel, Heidi L.
Kaplan, Lewis J.
TI In brief
SO CURRENT PROBLEMS IN SURGERY
LA English
DT Editorial Material
C1 [Frankel, Heidi L.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
[Kaplan, Lewis J.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Kaplan, Lewis J.] Yale Univ, Sch Med, Sect Trauma Surg Crit Care & Surg Emergencies, New Haven, CT USA.
RP Frankel, HL (reprint author), Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0011-3840
EI 1535-6337
J9 CURR PROB SURG
JI Curr. Probl. Surg.
PD OCT
PY 2013
VL 50
IS 10
BP 414
EP 417
DI 10.1067/j.cpsurg.2013.07.002
PG 4
WC Surgery
SC Surgery
GA 245QQ
UT WOS:000326479300002
ER
PT J
AU Tinti, MS
Gracias, VH
Kaplan, LJ
AF Tinti, Meridith S.
Gracias, Vincente H.
Kaplan, Lewis J.
TI Adjuncts to ventilation part II: Monitoring, fluid management, bundles,
and positioning
SO CURRENT PROBLEMS IN SURGERY
LA English
DT Review
ID RESPIRATORY-DISTRESS-SYNDROME; RANDOMIZED CONTROLLED-TRIAL; CENTRAL
VENOUS CATHETER; ACUTE LUNG INJURY; COMPARTMENT SYNDROME;
PULMONARY-ARTERY; FAILURE; PNEUMONIA; THERAPY
C1 [Tinti, Meridith S.] UMDNJ Robert Wood Johnson Med Sch, New Brunswick, NJ USA.
[Tinti, Meridith S.; Gracias, Vincente H.] Univ Penn, Med Ctr, Philadelphia, PA 19104 USA.
[Gracias, Vincente H.] UMDNJ Robert Wood Johnson Med Sch, Div Trauma & Acute Care Surg, New Brunswick, NJ USA.
[Gracias, Vincente H.] Univ Illinois, Chicago, IL 60680 USA.
[Gracias, Vincente H.] Univ Penn, Surg ICU, Philadelphia, PA 19104 USA.
[Kaplan, Lewis J.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Kaplan, Lewis J.] Yale Univ, Sch Med, Sect Trauma Surg Crit Care & Surg Emergencies, New Haven, CT USA.
RP Tinti, MS (reprint author), UMDNJ Robert Wood Johnson Med Sch, New Brunswick, NJ USA.
NR 22
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0011-3840
EI 1535-6337
J9 CURR PROB SURG
JI Curr. Probl. Surg.
PD OCT
PY 2013
VL 50
IS 10
BP 433
EP 437
DI 10.1067/j.cpsurg.2013.08.006
PG 5
WC Surgery
SC Surgery
GA 245QQ
UT WOS:000326479300004
PM 24156840
ER
PT J
AU Maung, AA
Kaplan, LJ
AF Maung, Adrian A.
Kaplan, Lewis J.
TI Waveform analysis during mechanical ventilation
SO CURRENT PROBLEMS IN SURGERY
LA English
DT Review
ID RECRUITMENT; PRESSURE
C1 [Maung, Adrian A.; Kaplan, Lewis J.] Yale Univ, Sch Med, Sect Trauma Surg Crit Care & Surg Emergencies, New Haven, CT 06520 USA.
[Maung, Adrian A.] Univ Maryland, R Adams Cowley Shock Trauma Ctr, College Pk, MD 20742 USA.
[Kaplan, Lewis J.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
RP Maung, AA (reprint author), Yale Univ, Sch Med, Sect Trauma Surg Crit Care & Surg Emergencies, New Haven, CT 06520 USA.
NR 10
TC 0
Z9 0
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0011-3840
EI 1535-6337
J9 CURR PROB SURG
JI Curr. Probl. Surg.
PD OCT
PY 2013
VL 50
IS 10
BP 438
EP 446
DI 10.1067/j.cpsurg.2013.08.007
PG 9
WC Surgery
SC Surgery
GA 245QQ
UT WOS:000326479300005
PM 24156841
ER
PT J
AU Jung, HS
Kaplan, LJ
Park, PK
AF Jung, Hee Soo
Kaplan, Lewis J.
Park, Pauline K.
TI Reviewing the studies of the National Heart, Lung, and Blood Institute
Acute Respiratory Distress Syndrome Network: Outcomes and clinical
findings
SO CURRENT PROBLEMS IN SURGERY
LA English
DT Review
ID GAMMA-LINOLENIC ACID; MECHANICALLY VENTILATED PATIENTS; RANDOMIZED
CONTROLLED-TRIAL; ACUTE MYOCARDIAL-INFARCTION; PULMONARY-ARTERY
CATHETERS; CRITICALLY-ILL PATIENTS; EICOSAPENTAENOIC ACID;
CALORIC-INTAKE; SURGICAL PATIENTS; AIRWAY PRESSURE
C1 [Jung, Hee Soo] Univ Wisconsin Madison, Madison, WI USA.
[Kaplan, Lewis J.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Kaplan, Lewis J.] Yale Univ, Sch Med, Sect Trauma Surg Crit Care & Surg Emergencies, New Haven, CT USA.
[Park, Pauline K.] Univ Michigan, Dept Surg, Sect Gen Surg, Ann Arbor, MI 48109 USA.
RP Jung, HS (reprint author), Univ Wisconsin Madison, Madison, WI USA.
NR 56
TC 0
Z9 0
U1 1
U2 4
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0011-3840
EI 1535-6337
J9 CURR PROB SURG
JI Curr. Probl. Surg.
PD OCT
PY 2013
VL 50
IS 10
BP 451
EP 462
DI 10.1067/j.cpsurg.2013.08.009
PG 12
WC Surgery
SC Surgery
GA 245QQ
UT WOS:000326479300007
PM 24156843
ER
PT J
AU Kaplan, LJ
Toevs, CC
AF Kaplan, Lewis J.
Toevs, Christine C.
TI Weaning from mechanical ventilation
SO CURRENT PROBLEMS IN SURGERY
LA English
DT Review
ID SPONTANEOUS-BREATHING TRIAL; EXTUBATION FAILURE; INDEX; METAANALYSIS;
LIBERATION; SEDATION; PROTOCOL; PREDICT; TRAUMA
C1 [Kaplan, Lewis J.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Kaplan, Lewis J.] Yale Univ, Sch Med, Sect Trauma Surg Crit Care & Surg Emergencies, New Haven, CT USA.
[Toevs, Christine C.] E Carolina Univ, Sch Med, Greenville, NC 27858 USA.
RP Kaplan, LJ (reprint author), Philadelphia VA Med Ctr, Philadelphia, PA USA.
NR 22
TC 0
Z9 0
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0011-3840
EI 1535-6337
J9 CURR PROB SURG
JI Curr. Probl. Surg.
PD OCT
PY 2013
VL 50
IS 10
BP 489
EP 494
DI 10.1067/j.cpsurg.2013.08.014
PG 6
WC Surgery
SC Surgery
GA 245QQ
UT WOS:000326479300012
PM 24156848
ER
PT J
AU Loftis, JM
Hauser, P
AF Loftis, Jennifer M.
Hauser, Peter
TI Pain and Opioid Use in Chronic Liver Disease: Optimal Treatment Must
Address the Mental Health Care Needs of the Patient
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Editorial Material
ID SUBSTANCE USE DISORDERS; CHRONIC HEPATITIS-C; PSYCHIATRIC-DISORDERS;
DEPRESSED-PATIENTS; VETERANS; INFECTION
C1 [Loftis, Jennifer M.] Portland VA Med Ctr, Res & Dev Serv, Portland, OR 97239 USA.
[Loftis, Jennifer M.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97239 USA.
[Hauser, Peter] VISN 22 Network Off, Long Beach, CA 90802 USA.
RP Hauser, P (reprint author), VISN 22 Network Off, 300 Oceangate,Suite 700, Long Beach, CA 90802 USA.
EM Peter.Hauser2@va.gov
FU BLRD VA [I01 BX002061]; NIDA NIH HHS [P50 DA018165]
NR 21
TC 1
Z9 1
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
EI 1573-2568
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD OCT
PY 2013
VL 58
IS 10
BP 2753
EP 2755
DI 10.1007/s10620-013-2809-4
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 223BO
UT WOS:000324778900044
PM 23959213
ER
PT J
AU Sonnenberg, A
Genta, RM
AF Sonnenberg, Amnon
Genta, Robert M.
TI Lymphocytic and Collagenous Colitis: Epidemiologic Differences and
Similarities
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Article
DE Adenomatous polyps; Collagenous colitis; Geographic distribution;
Epidemiology; Lymphocytic colitis; Microscopic colitis
ID MICROSCOPIC COLITIS; DISORDERS; DISEASE
AB Background It is unknown whether the subtypes of microscopic colitis (MC) represent distinct nosologic entities or related presentations of the same disease. Our aim was to search for epidemiologic differences among its various histopathologic subtypes.
Methods In a computerized database of 789,568 colon pathology reports, we compared the characteristics of 8,745 MC patients with those of the remaining population.
Results MC was diagnosed as three distinct histopathologic subtypes: lymphocytic colitis (LC) in 51 %, collagenous colitis (CC) in 43 %, and incomplete colitis (IC) in 6 % of patients. Only 0.65 % was simultaneously diagnosed with more than one subtype of MC. The prevalence of all three subtypes showed an age-dependent rise, with the average age (SD) being 63.3 (14.3) years in LC, 66.4 (12.1) years in CC, and 67.3 (12.7) years in IC (p < 0.0001). There was a striking female predominance in all three subtypes, the female fraction being 72 % in LC, 82 % in CC, and 79 % in IC (p < 0.0001). All three subtypes showed similar geographic distributions among different US states. They were similarly associated with diarrhea and weight loss, the odds ratios for all MC being 45.92 (43.35-48.63) and 5.12 (4.68-5.60), respectively, compared to control patients without MC. All three subtypes also harbored significantly less colonic adenomas, the overall odds ratio being 0.11 (0.10-0.12).
Conclusion MC comes in three distinct histopathologic entities, which show striking similarities of their general epidemiologic features. The slight differences in their demographic characteristics could point at varying sets of environmental influences that affect the occurrence of subtypes.
C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Dept Gastroenterol, Portland, OR 97239 USA.
[Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Genta, Robert M.] Miraca Life Sci, Irving, TX USA.
[Genta, Robert M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
[Genta, Robert M.] Dallas VA Med Ctr, Dallas, TX USA.
RP Sonnenberg, A (reprint author), Portland VA Med Ctr, Dept Gastroenterol, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM sonnenbe@ohsu.edu
FU Takeda Pharmaceuticals
FX Amnon Sonnenberg was supported by a grant from Takeda Pharmaceuticals.
No funding was obtained for this study.
NR 14
TC 11
Z9 11
U1 1
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
EI 1573-2568
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD OCT
PY 2013
VL 58
IS 10
BP 2970
EP 2975
DI 10.1007/s10620-013-2718-6
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 223BO
UT WOS:000324778900010
PM 23709158
ER
PT J
AU Barnett, CM
Corless, CL
Heinrich, MC
AF Barnett, Christine M.
Corless, Christopher L.
Heinrich, Michael C.
TI Gastrointestinal Stromal Tumors Molecular Markers and Genetic Subtypes
SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
LA English
DT Article
DE GIST; KIT; PDGFRA; RTK-wild-type; SDH
ID SUCCINATE-DEHYDROGENASE SUBUNIT; RECEPTOR TYROSINE KINASE; OF-FUNCTION
MUTATIONS; C-KIT; PDGFRA MUTATIONS; SDHA MUTATIONS; INTERSTITIAL-CELLS;
CARNEY-STRATAKIS; STRUCTURAL BASIS; BRAF MUTATIONS
AB Mutation-activated signaling from the KIT and PDGFRA kinases has been successfully targeted in gastrointestinal stromal tumors (GISTs), with subtle differences between the mutations serving to refine prognosis and more precisely tailor therapy. There is a growing understanding of the molecular drivers of GISTs lacking mutations in KIT or PDGFRA, so called wild-type GISTs, further aiding in management decisions. This article provides an overview of all the known molecular subtypes of GIST and provides information about clinical correlates, treatment, and prognosis depending on the subtype.
C1 [Barnett, Christine M.] Oregon Hlth & Sci Univ, OHSU Knight Canc Inst, Div Hematol Oncol, Portland VA Med Ctr, Portland, OR 97239 USA.
[Corless, Christopher L.] Oregon Hlth & Sci Univ, OHSU Knight Canc Inst, Dept Pathol, Portland, OR 97239 USA.
[Heinrich, Michael C.] Oregon Hlth & Sci Univ, OHSU Knight Canc Inst, Div Hematol Oncol, Portland VA Med Ctr,Dept Med, Portland, OR 97239 USA.
[Heinrich, Michael C.] Oregon Hlth & Sci Univ, OHSU Knight Canc Inst, Div Hematol Oncol, Dept Cell & Dev Biol,Portland VA Med Ctr, Portland, OR 97239 USA.
RP Heinrich, MC (reprint author), Oregon Hlth & Sci Univ, OHSU Knight Canc Inst, Div Hematol Oncol, Dept Cell & Dev Biol,Portland VA Med Ctr, R&D-19 3710,US Vet Hosp Rd, Portland, OR 97239 USA.
EM heinrich@ohsu.edu
FU Novartis; Pfizer; Bayer; Ariad; MolecularMD; AROG; Imclone
FX None (C.M. Barnett); honoraria from Novartis; consulting fees from
Novartis and Pfizer; research support from Novartis, Pfizer, and Bayer
(C.L. Corless); honoraria from Onyx; consulting fees from Novartis,
Pfizer, Ariad, MolecularMD; research support from Novartis, Pfizer,
AROG, Ariad, Imclone; equity interest: MolecularMD (M.C. Heinrich).
NR 78
TC 14
Z9 14
U1 1
U2 8
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8588
EI 1558-1977
J9 HEMATOL ONCOL CLIN N
JI Hematol. Oncol. Clin. North Am.
PD OCT
PY 2013
VL 27
IS 5
BP 871
EP 888
DI 10.1016/j.hoc.2013.07.003
PG 18
WC Oncology; Hematology
SC Oncology; Hematology
GA 244CL
UT WOS:000326364600002
PM 24093165
ER
PT J
AU Harb, GC
Phelps, AJ
Forbes, D
Ross, RJ
Gehrman, PR
Cook, JM
AF Harb, Gerlinde C.
Phelps, Andrea J.
Forbes, David
Ross, Richard J.
Gehrman, Philip R.
Cook, Joan M.
TI A Critical Review of the Evidence Base of Imagery Rehearsal for
Posttraumatic Nightmares: Pointing the Way for Future Research
SO JOURNAL OF TRAUMATIC STRESS
LA English
DT Article
ID COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CONTROLLED-TRIALS; SEXUAL
ASSAULT SURVIVORS; STRESS-DISORDER; CONSORT STATEMENT; CLINICAL-TRIALS;
PTSD; VETERANS; INSOMNIA; QUALITY
AB In this article, the authors provide information on key characteristics of imagery rehearsal treatment protocols and examine the quality of reporting of randomized controlled and uncontrolled trials of imagery rehearsal for treating posttraumatic nightmares. Using a reliable and valid scale, two independent psychologists rated 16 trials. Most reports provided insufficient information on a range of variables including the definition of treatment delivery (e.g., therapist supervision, treatment fidelity), description of the participant sample, data analysis (e.g., determination of sample size), and treatment assignment (e.g., randomization procedures). Low methodological quality and poor reporting can lead to inflation of estimates of treatment effects and inadequately substantiated conclusions, such as inflated effect sizes in meta-analytic studies. Numerous imagery rehearsal protocols exist, but in some cases are given different names and tested in pilot studies, slowing progression in the field. Randomized controlled trials of imagery rehearsal with credible comparison conditions, examination of predictors of dropout and outcome, as well as dismantling studies of imagery rehearsal treatment components are needed.
C1 [Harb, Gerlinde C.; Ross, Richard J.; Gehrman, Philip R.] Philadelphia VA Med Ctr, Behav Hlth Serv, Philadelphia, PA USA.
[Phelps, Andrea J.; Forbes, David] Univ Melbourne, Australian Ctr Posttraumat Mental Hlth, Dept Psychiat, Melbourne, Vic, Australia.
[Ross, Richard J.; Gehrman, Philip R.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Cook, Joan M.] Yale Univ, Sch Med, Dept Psychiat, West Haven, CT 06516 USA.
[Cook, Joan M.] Natl Ctr PTSD, West Haven, CT USA.
RP Cook, JM (reprint author), Yale Univ, Sch Med, Dept Psychiat, NEPEC 182,950 Campbell Ave, West Haven, CT 06516 USA.
EM Joan.Cook@yale.edu
NR 46
TC 7
Z9 7
U1 3
U2 20
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0894-9867
EI 1573-6598
J9 J TRAUMA STRESS
JI J. Trauma Stress
PD OCT
PY 2013
VL 26
IS 5
BP 570
EP 579
DI 10.1002/jts.21854
PG 10
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 242ZF
UT WOS:000326284900008
PM 24114887
ER
PT J
AU Tucker, RP
Judah, MR
O'Keefe, VM
Mills, AC
Lechner, WV
Davidson, CL
Grant, DM
Wingate, LR
AF Tucker, Raymond P.
Judah, Matt R.
O'Keefe, Victoria M.
Mills, Adam C.
Lechner, William V.
Davidson, Collin L.
Grant, DeMond M.
Wingate, LaRicka R.
TI Humor styles impact the relationship between symptoms of social anxiety
and depression
SO PERSONALITY AND INDIVIDUAL DIFFERENCES
LA English
DT Article
DE Humor styles; Humor; Social anxiety; Depression; Dysphoria
ID SUICIDAL IDEATION; PHOBIA; RISK; DISORDER; ADULTS; COMORBIDITY;
LONELINESS; VALIDATION; PREDICTORS; MODEL
AB Recent research suggests that examining humor styles may contribute to our understanding of clinical problems, such as risk and resiliency. The goal of the current study was to examine whether humor styles moderate the association between social anxiety and depressive symptoms in an unselected sample. Three-hundred and six participants (66% female) at a large Southern US university completed self-report measures of humor styles and symptoms of social anxiety and depression. Regression analyses suggested that affiliative and self-defeating humor styles individually moderated the relationship between social anxiety and depressive symptoms. Clinical implications regarding the monitoring of humor use as a means of understanding the maintenance of depressive symptoms among socially anxious individuals are discussed. (C) 2013 Published by Elsevier Ltd.
C1 [Tucker, Raymond P.; Judah, Matt R.; O'Keefe, Victoria M.; Mills, Adam C.; Lechner, William V.; Grant, DeMond M.; Wingate, LaRicka R.] Oklahoma State Univ, Stillwater, OK 74078 USA.
[Davidson, Collin L.] Denver VA Med Ctr, VA VISN MIRECC 19, Denver, CO USA.
RP Wingate, LR (reprint author), Oklahoma State Univ, Dept Psychol, 116 North Murray Hall, Stillwater, OK 74078 USA.
EM laricka.wingate@okstate.edu
OI Grant, DeMond/0000-0002-5231-6563
NR 35
TC 3
Z9 4
U1 1
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0191-8869
J9 PERS INDIV DIFFER
JI Pers. Individ. Differ.
PD OCT
PY 2013
VL 55
IS 7
BP 823
EP 827
DI 10.1016/j.paid.2013.07.008
PG 5
WC Psychology, Social
SC Psychology
GA 214SL
UT WOS:000324156000018
ER
PT J
AU Fernandez, JF
Restrepo, MI
AF Fernandez, Juan Felipe
Restrepo, Marcos I.
TI Too Passive to Prevent Ventilator-Associated Pneumonia
SO RESPIRATORY CARE
LA English
DT Editorial Material
ID SUBGLOTTIC SECRETION DRAINAGE; CARE SAFETY NETWORK; ENDOTRACHEAL-TUBES;
METAANALYSIS; CUFF
C1 [Fernandez, Juan Felipe; Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm Dis & Crit Care, San Antonio, TX 78229 USA.
[Restrepo, Marcos I.] South Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA.
[Restrepo, Marcos I.] Evidence Based Res Disseminat & Implementat Ctr, San Antonio, TX USA.
RP Restrepo, MI (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Pulm Dis & Crit Care, 7400 Merton Minter St,MC 111E, San Antonio, TX 78229 USA.
EM Restrepom@uthscsa.edu
RI Restrepo, Marcos/H-4442-2014
FU NHLBI NIH HHS [K23 HL096054]
NR 13
TC 0
Z9 0
U1 0
U2 0
PU DAEDALUS ENTERPRISES INC
PI IRVING
PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA
SN 0020-1324
EI 1943-3654
J9 RESP CARE
JI Respir. Care
PD OCT
PY 2013
VL 58
IS 10
BP 1704
EP 1706
DI 10.4187/respcare.02803
PG 3
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 245RH
UT WOS:000326481000017
PM 24064628
ER
PT J
AU Flynn, JM
O'Leary, MN
Zambataro, CA
Academia, EC
Presley, MP
Garrett, BJ
Zykovich, A
Mooney, SD
Strong, R
Rosen, CJ
Kapahi, P
Nelson, MD
Kennedy, BK
Melov, S
AF Flynn, James M.
O'Leary, Monique N.
Zambataro, Christopher A.
Academia, Emmeline C.
Presley, Michael P.
Garrett, Brittany J.
Zykovich, Artem
Mooney, Sean D.
Strong, Randy
Rosen, Clifford J.
Kapahi, Pankaj
Nelson, Michael D.
Kennedy, Brian K.
Melov, Simon
TI Late-life rapamycin treatment reverses age-related heart dysfunction
SO AGING CELL
LA English
DT Article
DE RNA-seq; rapamycin; aging; strain echocardiography; RAD; hypertrophy;
mTOR
ID CARDIAC-HYPERTROPHY; PRESSURE-OVERLOAD; MAMMALIAN TARGET; MTOR
INHIBITION; SPAN; BETA; RAD; DIFFERENTIATION; PERFORMANCE; MODULATION
AB Summary
Rapamycin has been shown to extend lifespan in numerous model organisms including mice, with the most dramatic longevity effects reported in females. However, little is known about the functional ramifications of this longevity-enhancing paradigm in mammalian tissues. We treated 24-month-old female C57BL/6J mice with rapamycin for 3 months and determined health outcomes via a variety of noninvasive measures of cardiovascular, skeletal, and metabolic health for individual mice. We determined that while rapamycin has mild transient metabolic effects, there are significant benefits to late-life cardiovascular function with a reversal or attenuation of age-related changes in the heart. RNA-seq analysis of cardiac tissue after treatment indicated inflammatory, metabolic, and antihypertrophic expression changes in cardiac tissue as potential mechanisms mediating the functional improvement. Rapamycin treatment also resulted in beneficial behavioral, skeletal, and motor changes in these mice compared with those fed a control diet. From these findings, we propose that late-life rapamycin therapy not only extends the lifespan of mammals, but also confers functional benefits to a number of tissues and mechanistically implicates an improvement in contractile function and antihypertrophic signaling in the aged heart with a reduction in age-related inflammation.
C1 [Flynn, James M.; O'Leary, Monique N.; Zambataro, Christopher A.; Academia, Emmeline C.; Presley, Michael P.; Garrett, Brittany J.; Zykovich, Artem; Mooney, Sean D.; Kapahi, Pankaj; Kennedy, Brian K.; Melov, Simon] Buck Inst Res Aging, Novato, CA 94945 USA.
[Strong, Randy] UTHSC, South Texas Vet Hlth Care Syst, Dept Pharmacol, San Antonio, TX 78229 USA.
[Strong, Randy] UTHSC, South Texas Vet Hlth Care Syst, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
[Rosen, Clifford J.] Maine Med Ctr, Res Inst, Ctr Clin & Translat Res, Scarborough, ME 04074 USA.
[Nelson, Michael D.] Cedars Sinai Med Ctr, Inst Heart, Los Angeles, CA 90048 USA.
RP Melov, S (reprint author), Buck Inst Res Aging, 8001 Redwood Blvd, Novato, CA 94945 USA.
EM smelov@buckinstitute.org
FU Larry L. Hillblom Foundation [2007 2/F]; Ellison Medical Foundation;
Glenn Foundation for Medical Research; Investigator Initiated Studies
Program [39326, 50196]; [PO1 AG025901]; [RO1 AG033373];
[1U01-AG022307]; [T32AG000266]
FX Funding support for this research was generously provided by the
following grants; PO1 AG025901(SM), RO1 AG033373 (BKK), 1U01-AG022307
(RS), T32AG000266 (Buck Institute), and partial support from the Larry
L. Hillblom Foundation Network grant (2007 2/F), the Ellison Medical
Foundation (BKK), and the Glenn Foundation for Medical Research (SM and
JF). This research was also supported in part by grants from Merck to SM
(Investigator Initiated Studies Program, # 39326, and #50196).
NR 45
TC 76
Z9 78
U1 0
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1474-9718
EI 1474-9726
J9 AGING CELL
JI Aging Cell
PD OCT
PY 2013
VL 12
IS 5
BP 851
EP 862
DI 10.1111/acel.12109
PG 12
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA 217RA
UT WOS:000324376300013
PM 23734717
ER
PT J
AU Adrianto, I
Dozmorov, MG
Wiley, GB
Ice, JA
Li, H
Kelly, JA
Rasmussen, A
Stone, DU
Anaya, JM
Segal, BM
Rhodus, NL
Radfar, L
Harley, JB
James, JA
Montgomery, CG
Scofield, RH
Gaffney, PM
Wren, JD
Sivils, KL
Lessard, CJ
AF Adrianto, Indra
Dozmorov, Mikhail G.
Wiley, Graham B.
Ice, John A.
Li, He
Kelly, Jennifer A.
Rasmussen, Astrid
Stone, Donald U.
Anaya, Juan-Manuel
Segal, Barbara M.
Rhodus, Nelson L.
Radfar, Lida
Harley, John B.
James, Judith A.
Montgomery, Courtney G.
Scofield, R. Hal
Gaffney, Patrick M.
Wren, Jonathan D.
Sivils, Kathy L.
Lessard, Christopher J.
TI RNA-Sequencing Identifies Novel Differentially Expressed Coding and
Non-Coding Transcripts In Sjogren's Syndrome
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Adrianto, Indra; Dozmorov, Mikhail G.; Wiley, Graham B.; Ice, John A.; Kelly, Jennifer A.; Rasmussen, Astrid; Montgomery, Courtney G.; Gaffney, Patrick M.; Wren, Jonathan D.; Sivils, Kathy L.; Lessard, Christopher J.] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA.
[Li, He; Stone, Donald U.; Radfar, Lida; James, Judith A.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA.
[Anaya, Juan-Manuel] Univ Rosario, Sch Med & Hlth Sci, Bogota, Colombia.
[Segal, Barbara M.] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA.
[Rhodus, Nelson L.] Univ Minnesota, Minneapolis, MN USA.
[Harley, John B.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA.
[James, Judith A.] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA.
[Scofield, R. Hal] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA.
RI Anaya, Juan-Manuel/J-1960-2016
OI Anaya, Juan-Manuel/0000-0002-6444-1249
NR 0
TC 1
Z9 1
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 1489
BP S632
EP S633
PG 2
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359203467
ER
PT J
AU Anyanwu, CO
Fiorentino, D
Chung, L
Wang, YL
Propert, KJ
Werth, VP
AF Anyanwu, Cynthia O.
Fiorentino, David
Chung, Lorinda
Wang, Yanli
Propert, Kathleen J.
Werth, Victoria P.
TI Validation Of The Cutaneous Dermatomyositis Disease Area and Severity
Index: Characterizing Severity and Assessing Responsiveness To Clinical
Change
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Anyanwu, Cynthia O.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Fiorentino, David] Stanford Univ, Sch Med, Redwood City, CA USA.
[Chung, Lorinda] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA.
[Wang, Yanli; Propert, Kathleen J.] Univ Penn, Philadelphia, PA 19104 USA.
[Werth, Victoria P.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 1935
BP S824
EP S824
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359204393
ER
PT J
AU Aquino-Beaton, C
Persselin, JE
Weinreb, A
Fang, MA
Singh, JA
Duffy, E
Elashoff, D
Khanna, P
Khanna, D
AF Aquino-Beaton, Cleopatra
Persselin, Jay E.
Weinreb, Ari
Fang, Meika A.
Singh, Jasvinder A.
Duffy, Erin
Elashoff, David
Khanna, Puja
Khanna, Dinesh
TI Impact Of Educational Attainment On Health-Related Quality Of Life and
Healthcare Utilization Among Veterans With Gout
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Aquino-Beaton, Cleopatra; Persselin, Jay E.; Weinreb, Ari; Fang, Meika A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Singh, Jasvinder A.] Univ Alabama, Tuscaloosa, AL USA.
[Duffy, Erin] Univ Calif Los Angeles, Los Angeles, CA USA.
[Elashoff, David] Univ Calif Los Angeles, Dept Med Stat Core, Los Angeles, CA USA.
[Khanna, Puja] Ann Arbor VA, Ann Arbor, MI USA.
[Khanna, Dinesh] Univ Michigan, Med Ctr, Ann Arbor, MI USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 1984
BP S846
EP S846
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359204442
ER
PT J
AU Barker, AM
Battistone, MJ
Beck, JP
Butler, J
Grotzke, M
Huhtala, TA
Cannella, AC
Daikh, DI
Fang, MA
Lazzari, AA
Roldan, P
Von Feldt, JM
Cannon, GW
AF Barker, Andrea M.
Battistone, Michael J.
Beck, J. Peter
Butler, Jorie
Grotzke, Marissa
Huhtala, Timothy A.
Cannella, Amy C.
Daikh, David I.
Fang, Meika A.
Lazzari, Antonio A.
Roldan, Pedro
Von Feldt, Joan Marie
Cannon, Grant W.
TI Objective Assessment Of Musculoskeletal Physical Examination Skills
During Continuing Education Programs For Primary Care Providers Adds
Significant Information Not Obtained Through Self-Assessment
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Barker, Andrea M.; Battistone, Michael J.; Beck, J. Peter; Butler, Jorie; Grotzke, Marissa; Huhtala, Timothy A.; Cannon, Grant W.] Salt Lake City VA, Salt Lake City, UT USA.
[Barker, Andrea M.; Battistone, Michael J.; Beck, J. Peter; Grotzke, Marissa; Huhtala, Timothy A.; Cannon, Grant W.] Univ Utah, Salt Lake City, UT USA.
[Cannella, Amy C.] Omaha Vet Affairs Hosp, Omaha, NE USA.
[Cannella, Amy C.] Univ Nebraska Med Ctr, Omaha, NE USA.
[Daikh, David I.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Fang, Meika A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Lazzari, Antonio A.] Boston VA Med Ctr, Boston, MA USA.
[Roldan, Pedro] Leesburg VA CBOC, Leesburg, FL USA.
[Von Feldt, Joan Marie] Univ Penn Philadelphia VAMC, Philadelphia, PA USA.
RI Beck, James Peter/F-9407-2015
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 2817
BP S1206
EP S1207
PG 2
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359206246
ER
PT J
AU Battistone, MJ
Barker, AM
Beck, JP
Grotzke, M
Huhtala, TA
Butler, J
Cannella, AC
Daikh, DI
Fang, MA
Lazzari, AA
Roldan, P
Von Feldt, JM
Cannon, GW
AF Battistone, Michael J.
Barker, Andrea M.
Beck, J. Peter
Grotzke, Marissa
Huhtala, Timothy A.
Butler, Jorie
Cannella, Amy C.
Daikh, David I.
Fang, Meika A.
Lazzari, Antonio A.
Roldan, Pedro
Von Feldt, Joan Marie
Cannon, Grant W.
TI Retrospective Self-Assessment Of Pre-Course Competency: A Useful Tool
For Musculoskeletal Curriculum Assessment In a Multi-Center,
Interprofessional Cohort.
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Battistone, Michael J.; Barker, Andrea M.; Beck, J. Peter; Grotzke, Marissa; Huhtala, Timothy A.; Butler, Jorie; Cannon, Grant W.] Salt Lake City VA, Salt Lake City, UT USA.
[Battistone, Michael J.; Barker, Andrea M.; Beck, J. Peter; Grotzke, Marissa; Huhtala, Timothy A.; Cannon, Grant W.] Univ Utah, Salt Lake City, UT USA.
[Cannella, Amy C.] Omaha Vet Affairs Hosp, Omaha, NE USA.
[Cannella, Amy C.] Univ Nebraska, Med Ctr, Omaha, NE USA.
[Daikh, David I.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Fang, Meika A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Lazzari, Antonio A.] Boston VA Med Ctr, Boston, MA USA.
[Roldan, Pedro] Leesburg VA CBOC, Leesburg, FL USA.
[Von Feldt, Joan Marie] Univ Penn, Philadelphia, PA 19104 USA.
[Von Feldt, Joan Marie] Philadelphia VAMC, Philadelphia, PA USA.
RI Beck, James Peter/F-9407-2015
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 972
BP S415
EP S415
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359202476
ER
PT J
AU Bharat, A
Singh, JA
Khanna, P
Aquino-Beaton, C
Persselin, JE
Duffy, E
Elashoff, D
Khanna, D
AF Bharat, Aseem
Singh, Jasvinder A.
Khanna, Puja
Aquino-Beaton, Cleopatra
Persselin, Jay E.
Duffy, Erin
Elashoff, David
Khanna, Dinesh
TI Racial/Ethnicity Differences In Health-Related Quality Of Life (HRQOL),
Functional Ability and Health Care Utilization In Gout Patients
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Bharat, Aseem] Univ Alabama Birmingham, Birmingham, AL USA.
[Singh, Jasvinder A.] Univ Alabama, Tuscaloosa, AL USA.
[Khanna, Puja] Univ Michigan, Med Ctr, Ann Arbor, MI USA.
[Aquino-Beaton, Cleopatra; Persselin, Jay E.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Duffy, Erin] Univ Calif Los Angeles, Los Angeles, CA USA.
[Elashoff, David] Univ Calif Los Angeles, Dept Med, Stat Core, Los Angeles, CA 90024 USA.
[Khanna, Dinesh] Univ Michigan, Ann Arbor, MI 48109 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 1996
BP S851
EP S852
PG 2
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359204454
ER
PT J
AU Cannon, GW
DuVall, SL
Hayden, CL
Caplan, L
Curtis, JR
Michaud, K
Mikuls, TR
Reimold, AM
Collier, DH
Joseph, G
Harrison, DJ
Sauer, BC
AF Cannon, Grant W.
DuVall, Scott L.
Hayden, Candace L.
Caplan, Liron
Curtis, Jeffrey R.
Michaud, Kaleb
Mikuls, Ted R.
Reimold, Andreas M.
Collier, David H.
Joseph, George
Harrison, David J.
Sauer, Brian C.
TI US Veterans With Rheumatoid Arthritis Who Switch Among Tumor Necrosis
Factor Blocking Agents Have No Additional Clinical Benefit With The
Change In Therapy and Incur Higher Costs
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Cannon, Grant W.] Salt Lake City VA, Salt Lake City, UT USA.
[Cannon, Grant W.] Univ Utah, Salt Lake City, UT USA.
[DuVall, Scott L.; Hayden, Candace L.] VA Salt Lake City Hlth Care Syst, Salt Lake City, UT USA.
[DuVall, Scott L.; Hayden, Candace L.] Univ Utah, Sch Med, Salt Lake City, UT USA.
[Caplan, Liron] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Curtis, Jeffrey R.] Univ Alabama Birmingham, Birmingham, AL USA.
[Michaud, Kaleb] Natl Data Bank Rheumat Dis, Omaha, NE USA.
[Michaud, Kaleb; Mikuls, Ted R.] Univ Nebraska Med Ctr, Omaha, NE USA.
[Mikuls, Ted R.] Omaha VA, Omaha, NE USA.
[Reimold, Andreas M.] Dallas VA, Dallas, TX USA.
[Reimold, Andreas M.] Univ Texas Southwestern, Dallas, TX USA.
[Collier, David H.; Joseph, George; Harrison, David J.] Amgen Inc, Thousand Oaks, CA 91320 USA.
[Sauer, Brian C.] George E Wahlen Vet Affairs Med Ctr, Salt Lake City, UT USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 427
BP S184
EP S185
PG 2
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359201426
ER
PT J
AU Daikh, DI
Battistone, MJ
Barker, AM
Avins, AL
Grotzke, M
Fang, MA
Lazzari, AA
Cannella, AC
Roldan, P
Von Feldt, JM
Cannon, GW
AF Daikh, David I.
Battistone, Michael J.
Barker, Andrea M.
Avins, Andy L.
Grotzke, Marissa
Fang, Meika A.
Lazzari, Antonio A.
Cannella, Amy C.
Roldan, Pedro
Von Feldt, Joan Marie
Cannon, Grant W.
TI Inter-Professional Training Programs For Primary Care Providers Can
Successfully Educate Practitioners With Dramatically Different
Educational and Training Background Through a Common Mini-Residency
Training Program.
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Daikh, David I.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Daikh, David I.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Battistone, Michael J.; Barker, Andrea M.; Grotzke, Marissa; Cannon, Grant W.] Salt Lake City VA, Salt Lake City, UT USA.
[Battistone, Michael J.; Barker, Andrea M.; Grotzke, Marissa; Cannon, Grant W.] Univ Utah, Salt Lake City, UT USA.
[Avins, Andy L.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Fang, Meika A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Lazzari, Antonio A.] Boston VA Med Ctr, Boston, MA USA.
[Cannella, Amy C.] Omaha Vet Affairs Hosp, Omaha, NE USA.
[Cannella, Amy C.] Univ Nebraska, Med Ctr, Omaha, NE USA.
[Roldan, Pedro] Leesburg VA CBOC, Leesburg, FL USA.
[Von Feldt, Joan Marie] Univ Penn, Philadelphia, PA 19104 USA.
[Von Feldt, Joan Marie] Philadelphia VAMC, Philadelphia, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 978
BP S417
EP S418
PG 2
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359202482
ER
PT J
AU Davis, LA
Luong, P
Bobba, S
Dischinger, H
Quinzanos, I
Caplan, L
AF Davis, Lisa A.
Phat Luong
Bobba, Sushmitha
Dischinger, Hannah
Quinzanos, Itziar
Caplan, Liron
TI Acceptability Of Various Technology-Based Communication Modalities In a
Rheumatology Clinic
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Davis, Lisa A.] Denver Hlth & Hosp Author, Denver, CO USA.
[Phat Luong; Bobba, Sushmitha; Dischinger, Hannah; Caplan, Liron] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Quinzanos, Itziar] Univ Colorado, Sch Med, Aurora, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 1907
BP S812
EP S813
PG 2
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359204366
ER
PT J
AU Ding, YN
Hsu, HC
Li, J
Yang, PA
Wu, Q
Zajac, AJ
Mountz, JD
AF Ding, Yanna
Hsu, Hui-Chen
Li, Jun
Yang, PingAr
Wu, Qi
Zajac, Allan J.
Mountz, John D.
TI IL-21 Inhibited Follicular Regulatory T Cells To Promote Autoreactive
Germinal Center Development In Autoimmune BXD2 Mice
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Ding, Yanna; Li, Jun; Yang, PingAr; Wu, Qi; Zajac, Allan J.; Mountz, John D.] Univ Alabama Birmingham, Birmingham, AL USA.
[Hsu, Hui-Chen] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 2713
BP S1159
EP S1159
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359206143
ER
PT J
AU Hill, E
Higgs, JB
Sky, K
Sit, M
Collamer, AN
AF Hill, Erica
Higgs, Jay B.
Sky, Karen
Sit, Michelle
Collamer, Angelique N.
TI Does Starting Allopurinol Prolong Acute Treated Gout?
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Hill, Erica; Higgs, Jay B.] San Antonio Mil Med Ctr, Ft Sam Houston, TX USA.
[Sky, Karen] Alaska VA Healthcare Syst, US Dept Vet Affairs, Anchorage, AK USA.
[Sit, Michelle] David Grant Med Ctr, Travis AFB, CA USA.
[Collamer, Angelique N.] Langley AFB Hosp, Langley AFB, VA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 1722
BP S730
EP S730
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359204182
ER
PT J
AU Hirsh, JM
Davis, LA
Quinzanos, I
Keniston, A
Caplan, L
AF Hirsh, Joel M.
Davis, Lisa A.
Quinzanos, Itziar
Keniston, Angela
Caplan, Liron
TI Health Literacy Predicts Discrepancies Between Traditional Written
Rheumatoid Arthritis Patient Assessments and Verbally-Administered
Assessments
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Hirsh, Joel M.; Keniston, Angela] Denver Hlth, Denver, CO USA.
[Hirsh, Joel M.; Keniston, Angela] Hosp Author, Denver, CO USA.
[Davis, Lisa A.; Quinzanos, Itziar] Univ Colorado, Sch Med, Aurora, CO USA.
[Caplan, Liron] Denver Vet Affairs Med Ctr, Denver, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 1031
BP S439
EP S440
PG 2
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359203017
ER
PT J
AU Khanna, P
Aquino-Beaton, C
Singh, JA
Duffy, E
Elashoff, D
Khanna, D
AF Khanna, Puja
Aquino-Beaton, Cleopatra
Singh, Jasvinder A.
Duffy, Erin
Elashoff, David
Khanna, Dinesh
TI Predictors Of Outcomes In Tophaceous Gout-Results From a Prospective
Cohort At The Veterans Affairs
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Khanna, Puja] Ann Arbor VA, Ann Arbor, MI USA.
[Aquino-Beaton, Cleopatra] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Singh, Jasvinder A.] Univ Alabama, Tuscaloosa, AL USA.
[Duffy, Erin] Univ Calif Los Angeles, Los Angeles, CA USA.
[Elashoff, David] Univ Calif Los Angeles, Dept Med, Stat Core, Los Angeles, CA 90024 USA.
[Khanna, Dinesh] Univ Michigan, Med Ctr, Div Rheumatol, Ann Arbor, MI USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 2005
BP S856
EP S856
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359204463
ER
PT J
AU Khanna, P
Aquino-Beaton, C
Singh, JA
Duffy, E
Elashoff, D
Khanna, D
AF Khanna, Puja
Aquino-Beaton, Cleopatra
Singh, Jasvinder A.
Duffy, Erin
Elashoff, David
Khanna, Dinesh
TI Performance Of Gout Impact Scale Of The Gout Assessment Questionnaire In
a Longitudinal Observational Study Of Patients With Gout
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Khanna, Puja] Univ Michigan, Med Ctr, Ann Arbor, MI USA.
[Aquino-Beaton, Cleopatra] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Singh, Jasvinder A.] Univ Alabama, Tuscaloosa, AL USA.
[Duffy, Erin] Univ Calif Los Angeles, Los Angeles, CA USA.
[Elashoff, David] Univ Calif Los Angeles, Dept Med, Stat Core, Los Angeles, CA 90024 USA.
[Khanna, Dinesh] Univ Michigan, Div Rheumatol, Ann Arbor, MI 48109 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 1994
BP S850
EP S851
PG 2
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359204452
ER
PT J
AU Koristka, S
Cartellieri, M
Arndt, C
Feldmann, A
Michalk, I
Bippes, CC
Berndt, N
Hermsdorf, A
Stamova, S
Kurien, BT
Scofield, RH
Farris, AD
James, JA
Bartsch, H
Bachmann, M
AF Koristka, Stefanie
Cartellieri, Marc
Arndt, Claudia
Feldmann, Anja
Michalk, Irene
Bippes, Claudia C.
Berndt, Nicole
Hermsdorf, Anne
Stamova, Slava
Kurien, Biji T.
Scofield, Robert Hal
Farris, A. Darise
James, Judith A.
Bartsch, Holger
Bachmann, Michael
TI Bispecific Antibodies For Redirection Of Human Regulatory T Cells To
Surface-Inducible Autoantigen La/SS-B
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Koristka, Stefanie; Cartellieri, Marc; Arndt, Claudia; Feldmann, Anja; Michalk, Irene; Bippes, Claudia C.; Berndt, Nicole; Hermsdorf, Anne; Stamova, Slava; Bartsch, Holger; Bachmann, Michael] Carl Gustav Carus TU Dresden, Dresden, Germany.
[Kurien, Biji T.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA.
[Scofield, Robert Hal] Oklahoma Med Res Fdn, Arthrit & Clin Immunol Program, Oklahoma City, OK 73104 USA.
[Scofield, Robert Hal] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA.
[Scofield, Robert Hal] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA.
[Farris, A. Darise] Oklahoma Med Res Foun, Oklahoma City, OK USA.
[James, Judith A.] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA.
RI Bachmann, Michael/E-8850-2010; Feldmann, Anja/D-7843-2014
OI Bachmann, Michael/0000-0002-8029-5755; Feldmann,
Anja/0000-0001-5099-2448
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 1641
BP S696
EP S696
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359204105
ER
PT J
AU Li, H
Hsu, HC
Wu, Q
Li, J
Yang, PA
Fu, YX
Mountz, JD
AF Li, Hao
Hsu, Hui-Chen
Wu, Qi
Li, Jun
Yang, PingAr
Fu, Yang-Xin
Mountz, John D.
TI Follicular Entry Of Lymphotoxin-Expressing B Cells Via Type I Interferon
Disrupts Marginal Zone Barrier Integrity and Exacerbates Systemic
Autoimmunity
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Li, Hao; Wu, Qi; Li, Jun; Yang, PingAr; Mountz, John D.] Univ Alabama Birmingham, Birmingham, AL USA.
[Hsu, Hui-Chen] Birmingham VA Med Ctr, Birmingham, AL USA.
[Fu, Yang-Xin] Univ Chicago, Chicago, IL 60637 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 37
BP S15
EP S16
PG 2
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359201037
ER
PT J
AU Li, J
Hsu, HC
Yang, PA
Wu, Q
Luo, B
Rowse, AL
Spalding, DM
Mobley, JA
Bridges, SL
Mountz, JD
AF Li, Jun
Hsu, Hui-Chen
Yang, PingAr
Wu, Qi
Luo, Bao
Rowse, Amber L.
Spalding, David M.
Mobley, James A.
Bridges, S. Louis, Jr.
Mountz, John D.
TI Reshaping Inflammatory Macrophage Development and Functions by a
Monosaccharide Analogue In Rheumatoid Arthritis
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Li, Jun; Yang, PingAr; Wu, Qi; Luo, Bao; Rowse, Amber L.; Spalding, David M.; Mobley, James A.; Bridges, S. Louis, Jr.; Mountz, John D.] Univ Alabama Birmingham, Birmingham, AL USA.
[Hsu, Hui-Chen] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 2745
BP S1171
EP S1172
PG 2
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359206174
ER
PT J
AU Liu, ML
Bashir, M
Sharma, M
Xu, HH
Williams, K
Anyanwu, CO
Okawa, J
Werth, VP
AF Liu, Ming-Lin
Bashir, Muhammad
Sharma, Meena
Xu, Honghui
Williams, Kevin
Anyanwu, Cynthia O.
Okawa, Joyce
Werth, Victoria P.
TI Novel Proinflammatory Microvesicles That Carry LL-37 In Patients With
Cutaneous Lupus
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Liu, Ming-Lin; Sharma, Meena] Univ Penn, Philadelphia, PA 19104 USA.
[Bashir, Muhammad; Xu, Honghui; Okawa, Joyce] Philadelphia VA Hosp, Philadelphia, PA USA.
[Williams, Kevin] Temple Univ, Sch Med, Philadelphia, PA 19122 USA.
[Anyanwu, Cynthia O.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Werth, Victoria P.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 1860
BP S793
EP S793
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359204319
ER
PT J
AU Michalk, I
Berndt, N
Bippes, CC
Bartsch, H
Koristka, S
Arndt, C
Feldmann, A
Kurien, BT
Scofield, RH
Farris, AD
James, JA
Cartellieri, M
Bachmann, M
AF Michalk, Irene
Berndt, Nicole
Bippes, Claudia C.
Bartsch, Holger
Koristka, Stefanie
Arndt, Claudia
Feldmann, Anja
Kurien, Biji T.
Scofield, Robert Hal
Farris, A. Darise
James, Judith A.
Cartellieri, Marc
Bachmann, Michael
TI Redox Dependent Conformational Changes Of The Autoantigen La Are
Responsible For Its Shuttling, Translocation and a Pathophysiological
Role Of Anti-La Autoantibodies
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Michalk, Irene; Berndt, Nicole; Bippes, Claudia C.; Bartsch, Holger; Koristka, Stefanie; Arndt, Claudia; Feldmann, Anja; Cartellieri, Marc; Bachmann, Michael] Carl Gustav Carus TU Dresden, Dresden, Germany.
[Kurien, Biji T.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA.
[Scofield, Robert Hal] Oklahoma Med Res Fdn, Arthrit & Clin Immunol Program, Oklahoma City, OK 73104 USA.
[Scofield, Robert Hal] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA.
[Scofield, Robert Hal] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA.
[Farris, A. Darise] Oklahoma Med Res Foun, Oklahoma City, OK USA.
[James, Judith A.] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA.
RI Bachmann, Michael/E-8850-2010; Feldmann, Anja/D-7843-2014
OI Bachmann, Michael/0000-0002-8029-5755; Feldmann,
Anja/0000-0001-5099-2448
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 923
BP S396
EP S396
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359202428
ER
PT J
AU Ruth, NM
Kral, MC
Nowling, TK
Slan, S
Passo, MH
Gilkeson, GS
AF Ruth, Natasha M.
Kral, Mary C.
Nowling, Tamara K.
Slan, Stephanie
Passo, Murray H.
Gilkeson, Gary S.
TI The Usefulness Of Traditional Neurocognitive Testing and
N-Methyl-D-Aspartate Receptor Antibodies In Pediatric Lupus Patients
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Ruth, Natasha M.; Kral, Mary C.; Nowling, Tamara K.; Slan, Stephanie; Passo, Murray H.; Gilkeson, Gary S.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Nowling, Tamara K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 1261
BP S533
EP S533
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359203244
ER
PT J
AU Sato, S
Williams, S
Karam, E
Zhang, X
AF Sato, Shuzo
Williams, Sarah
Karam, Eva
Zhang, Xian
TI Fli-1 Regulates Immune Cell Infiltration Through Affecting Local
Chemokine Expression and IL-6 Expression In The Kidney Of Lupus Prone
Mice
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Sato, Shuzo; Karam, Eva; Zhang, Xian] Med Univ S Carolina, Charleston, SC 29425 USA.
[Williams, Sarah; Zhang, Xian] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 558
BP S242
EP S242
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359202070
ER
PT J
AU Schmajuk, G
Yazdany, J
Miao, YH
Daikh, DI
Steinman, M
AF Schmajuk, Gabriela
Yazdany, Jinoos
Miao, Yinghui
Daikh, David I.
Steinman, Michael
TI Folic Acid Prescription Among Older Adult Methotrexate Initiators Is
Poor
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Schmajuk, Gabriela] UCSF San Francisco VA Med Ctr, San Francisco, CA USA.
[Yazdany, Jinoos; Daikh, David I.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Miao, Yinghui; Steinman, Michael] San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 1711
BP S725
EP S725
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359204171
ER
PT J
AU Singh, JA
Bharat, A
Khanna, P
Aquino-Beaton, C
Persselin, JE
Duffy, E
Elashoff, D
Khanna, D
AF Singh, Jasvinder A.
Bharat, Aseem
Khanna, Puja
Aquino-Beaton, Cleopatra
Persselin, Jay E.
Duffy, Erin
Elashoff, David
Khanna, Dinesh
TI Health Care Utilization In Gout Patients: A Prospective Multicenter
Cohort Study
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Singh, Jasvinder A.] Univ Alabama, Tuscaloosa, AL USA.
[Bharat, Aseem] Univ Alabama Birmingham, Birmingham, AL USA.
[Khanna, Puja] Univ Michigan, Med Ctr, Ann Arbor, MI USA.
[Aquino-Beaton, Cleopatra; Persselin, Jay E.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Duffy, Erin] Univ Calif Los Angeles, Los Angeles, CA USA.
[Elashoff, David] Univ Calif Los Angeles, Dept Med, Stat Core, Los Angeles, CA 90024 USA.
[Khanna, Dinesh] Univ Michigan, Ann Arbor, MI 48109 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 1997
BP S852
EP S853
PG 2
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359204455
ER
PT J
AU Vina, ER
Utset, TO
Hannon, MJ
Roberts, N
Masi, CM
Kwoh, CK
AF Vina, Ernest R.
Utset, Tammy O.
Hannon, Michael J.
Roberts, Nicole
Masi, Christopher M.
Kwoh, C. Kent
TI Racial Differences In Systemic Lupus Erythematosus Patients' Treatment
Preferences: A Two-Site Study
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Vina, Ernest R.; Kwoh, C. Kent] Univ Pittsburgh, Pittsburgh, PA USA.
[Vina, Ernest R.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Utset, Tammy O.] Univ Chicago, Dept Med, Chicago, IL 60637 USA.
[Hannon, Michael J.; Roberts, Nicole] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
[Masi, Christopher M.] NorthShore Univ Hlth Syst, Evanston, IL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 1069
BP S456
EP S457
PG 2
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359203055
ER
PT J
AU Werth, VP
Khamashta, MA
Illei, GG
Yoo, S
Wang, LW
Greth, W
AF Werth, Victoria P.
Khamashta, Munther A.
Illei, Gabor G.
Yoo, Stephen
Wang, Liangwei
Greth, Warren
TI Smoking Is Associated With More Severe Skin Disease In Subjects With
Moderate To Severe Systemic Lupus Erythematosus (SLE)
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Werth, Victoria P.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Khamashta, Munther A.] Kings Coll London, Sch Med, Rayne Inst, Lupus Res Unit, London, England.
[Illei, Gabor G.; Yoo, Stephen; Wang, Liangwei; Greth, Warren] MedImmune LLC, Gaithersburg, MD USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 2512
BP S1072
EP S1073
PG 2
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359205457
ER
PT J
AU Werth, VP
Fiorentino, D
Cohen, SB
Fivenson, D
Hansen, C
Zoog, S
Arnold, G
Wang, C
Boedigheimer, M
Welcher, A
Chung, J
Sullivan, B
Martin, DA
AF Werth, Victoria P.
Fiorentino, David
Cohen, Stanley B.
Fivenson, David
Hansen, Chris
Zoog, Steve
Arnold, Greg
Wang, Christine
Boedigheimer, Michael
Welcher, Andrew
Chung, James
Sullivan, Barbara
Martin, David A.
TI A Phase I Single-Dose Crossover Study To Evaluate The Safety,
Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy
Of AMG 811 (anti-IFN-gamma) In Subjects With Discoid Lupus Erythematosus
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Werth, Victoria P.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Fiorentino, David] Stanford Univ, Sch Med, Redwood City, CA USA.
[Cohen, Stanley B.] Metroplex Clin Res Ctr, Dallas, TX USA.
[Fivenson, David] Dermatology PLLC, MD, Ann Arbor, MI USA.
[Hansen, Chris] Univ Utah, Sch Med, Salt Lake City, UT USA.
[Zoog, Steve; Arnold, Greg; Wang, Christine; Boedigheimer, Michael; Welcher, Andrew; Chung, James; Sullivan, Barbara] Amgen Inc, Thousand Oaks, CA USA.
[Martin, David A.] Amgen Inc, Seattle, WA USA.
NR 0
TC 4
Z9 4
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 1608
BP S682
EP S683
PG 2
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359204072
ER
PT J
AU Young, K
Benissan-Messan, D
Duryee, MJ
Anderson, D
Caplan, L
Davis, LA
Sayles, H
Hunter, CD
Klassen, LW
O'Dell, JR
Mikuls, TR
Thiele, GM
AF Young, Kathleen
Benissan-Messan, Dathe
Duryee, Michael J.
Anderson, Daniel
Caplan, Liron
Davis, Lisa A.
Sayles, Harlan
Hunter, Carlos D.
Klassen, Lynell W.
O'Dell, James R.
Mikuls, Ted R.
Thiele, Geoffrey M.
TI Antibody To Malondialdehyde-Acetaldehyde Adducts (MAA) Is a Biomarker Of
Inflammation and Is Correlated With The Disease Activity In Rheumatoid
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Young, Kathleen; Benissan-Messan, Dathe; Duryee, Michael J.; Anderson, Daniel; Sayles, Harlan; Hunter, Carlos D.; Klassen, Lynell W.; O'Dell, James R.; Mikuls, Ted R.; Thiele, Geoffrey M.] Univ Nebraska Med Ctr, Omaha, NE USA.
[Caplan, Liron] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Davis, Lisa A.] Denver Hlth & Hosp Author, Denver, CO USA.
[Klassen, Lynell W.; Thiele, Geoffrey M.] Omaha VA Med Ctr, Omaha, NE USA.
[Mikuls, Ted R.] Omaha VA, Omaha, NE USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 2262
BP S962
EP S962
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359205209
ER
PT J
AU Zhao, J
Giles, BM
Taylor, RL
Yette, GA
Lough, KM
Abraham, LJ
Wu, H
Gaffney, PM
Kelly, JA
Kaufman, KM
Harley, JB
Langefeld, CD
Brown, EE
Edberg, JC
Kimberly, RP
Ulgiati, D
Tsao, BP
Boackle, SA
AF Zhao, Jian
Giles, Brendan M.
Taylor, Rhonda L.
Yette, Gabriel A.
Lough, Kara M.
Abraham, Lawrence J.
Wu, Hui
Gaffney, Patrick M.
Kelly, Jennifer A.
Kaufman, Kenneth M.
Harley, John B.
Langefeld, Carl D.
Brown, Elizabeth E.
Edberg, Jeffrey C.
Kimberly, Robert P.
Ulgiati, Daniela
Tsao, Betty P.
Boackle, Susan A.
TI An Intronic CR2 Polymorphism Associated With Systemic Lupus
Erythematosus Alters CTCF Binding and CR1 Expression
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Zhao, Jian; Wu, Hui; Tsao, Betty P.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Giles, Brendan M.; Yette, Gabriel A.; Lough, Kara M.; Boackle, Susan A.] Univ Colorado, Sch Med, Aurora, CO USA.
[Taylor, Rhonda L.; Abraham, Lawrence J.; Ulgiati, Daniela] Univ Western Australia, Perth, WA 6009, Australia.
[Gaffney, Patrick M.; Kelly, Jennifer A.] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA.
[Kaufman, Kenneth M.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA.
[Kaufman, Kenneth M.] Univ Cincinnati, Cincinnati, OH USA.
[Harley, John B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA.
[Langefeld, Carl D.] Wake Forest Sch Med, Winston Salem, NC USA.
[Brown, Elizabeth E.; Kimberly, Robert P.] Univ Alabama Birmingham, Birmingham, AL USA.
[Edberg, Jeffrey C.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 2703
BP S1155
EP S1155
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359206133
ER
PT J
AU Rahman, M
Baimbridge, C
Davis, BR
Barzilay, JI
Basile, JN
Henriquez, MA
Huml, A
Kopyt, N
Louis, GT
Pressel, SL
Rosendorr, C
Sastrasinh, S
Stanford, C
AF Rahman, Mahboob
Baimbridge, Charles
Davis, Barry R.
Barzilay, Joshua I.
Basile, Jan N.
Henriquez, Mario A.
Huml, Anne
Kopyt, Nelson
Louis, Gail T.
Pressel, Sara L.
Rosendorr, Clive
Sastrasinh, Sithiporn
Stanford, Carol
CA ALLHAT Collaborative Res Grp
TI Pravastatin and cardiovascular outcomes stratified by baseline eGFR in
the lipid-lowering component of ALLHAT
SO CLINICAL NEPHROLOGY
LA English
DT Article
DE hyperlipidemia; kidney disease; cardiovascular outcomes; chronic renal
failure
ID CHRONIC KIDNEY-DISEASE; CHRONIC RENAL-INSUFFICIENCY;
GLOMERULAR-FILTRATION-RATE; ATTACK TRIAL ALLHAT; USUAL CARE; EVENTS;
HEART; ATORVASTATIN; HEMODIALYSIS; CHOLESTEROL
AB Background/Aims: The role of statins in preventing cardiovascular outcomes in patients with chronic kidney disease (CKD) is unclear. This paper compares cardiovascular outcomes with pravastatin vs. usual care, stratified by baseline estimated glomerular filtration rate (eGFR). Methods: Post-hoc analyses of a prospective randomized open-label clinical trial; 10,151 participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (lipid-lowering component) were randomized to pravastatin 40 mg/day or usual care. Mean follow-up was 4.8 years. Results: Through Year 6, total cholesterol declined in pravastatin (-20.7%) and usual-care groups (-11.2%). Use of statin therapy in the pravastatin group was 89.8% (Year 2) and 87.0% (Year 6). Usual-care group statin use increased from 8.2% (Year 2) to 23.5% (Year 6). By primary intention-to-treat analyses, no significant differences were seen between groups for coronary heart disease (CHD), total mortality or combined cardiovascular disease; findings were consistent across eGFR strata. In exploratory "as-treated" analyses (patients actually using pravastatin vs. not using), pravastatin therapy was associated with lower mortality (HR = 0.76 (0.68 - 0.85), p < 0.001) and lower CHID (HR = 0.84 (0.73 - 0.97), p = 0.01), but not combined cardiovascular disease (HR = 0.95 (0.88 - 1.04), p = 0.30). Total cholesterol reduction of 10 mg/dL from baseline to Year 2 was associated with 5% lower CHD risk. Conclusions: In hypertensive patients with moderate dyslipidemia, pravastatin was not superior to usual care in preventing total mortality or CHD independent of baseline eGFR level. However, exploratory "as-treated" analyses suggest improved mortality and CHD risk in participants using pravastatin, and decreased CHD events associated with achieved reduction in total cholesterol. Potential benefit from statin therapy may depend on degree of reduction achieved in total and LDL-cholesterol and adherence to therapy.
C1 [Rahman, Mahboob; Huml, Anne] Case Western Reserve Univ, Univ Hosp Case Med Ctr, Louis Stokes Cleveland Vet Affairs Med Ctr, Cleveland, OH 44106 USA.
[Baimbridge, Charles; Davis, Barry R.; Pressel, Sara L.] Univ Texas Houston, Sch Publ Hlth, Houston, TX 77030 USA.
[Barzilay, Joshua I.] Kaiser Permanente Georgia, Tucker, GA USA.
[Basile, Jan N.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
[Henriquez, Mario A.] Bronx Nephrol Hypertens, Bronx, NY USA.
[Kopyt, Nelson] Lehigh Valley Hosp, Allentown, PA USA.
[Louis, Gail T.] Tulane Univ, Sch Publ Hlth & Trop Med, New Orleans, LA 70118 USA.
[Rosendorr, Clive] Mt Sinai Sch Med, New York, NY USA.
[Rosendorr, Clive] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
[Sastrasinh, Sithiporn] Vet Affairs New Jersey Hlth Care Syst, E Orange, NJ USA.
[Stanford, Carol] Univ Missouri, Sch Med, Kansas City, MO 64108 USA.
RP Pressel, SL (reprint author), Univ Texas Houston, Sch Publ Hlth, Coordinating Ctr Clin Trials, 1200 Herman Pressler St,Suite W908, Houston, TX 77030 USA.
EM Sara.L.Pressel@uth.tmc.edu
FU National Heart, Lung, and Blood Institute [NO1-HC-35130]; Pfizer
FX This study was supported by contract NO1-HC-35130 with the National
Heart, Lung, and Blood Institute. The ALLHAT investigators acknowledge
contributions of study medications supplied by Pfizer (amlodipine and
doxazosin), AstraZeneca (atenolol and lisinopril) and Bristol-Myers
Squibb (pravastatin), and financial support provided by Pfizer.
NR 23
TC 2
Z9 2
U1 0
U2 4
PU DUSTRI-VERLAG DR KARL FEISTLE
PI DEISENHOFEN-MUENCHEN
PA BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY
SN 0301-0430
J9 CLIN NEPHROL
JI Clin. Nephrol.
PD OCT
PY 2013
VL 80
IS 4
BP 235
EP 248
DI 10.5414/CN107922
PG 14
WC Urology & Nephrology
SC Urology & Nephrology
GA 241YS
UT WOS:000326205200001
PM 23816477
ER
PT J
AU Metra, M
Ponikowski, P
Cotter, G
Davison, BA
Felker, GM
Filippatos, G
Greenberg, BH
Hua, TA
Severin, T
Unemori, E
Voors, AA
Teerlink, JR
AF Metra, Marco
Ponikowski, Piotr
Cotter, Gad
Davison, Beth A.
Felker, G. Michael
Filippatos, Gerasimos
Greenberg, Barry H.
Hua, Tsushung A.
Severin, Thomas
Unemori, Elaine
Voors, Adriaan A.
Teerlink, John R.
TI Effects of serelaxin in subgroups of patients with acute heart failure:
results from RELAX-AHF
SO EUROPEAN HEART JOURNAL
LA English
DT Article
DE Acute heart failure; Serelaxin; Mortality; Subgroups
ID NATRIURETIC PEPTIDE; CLINICAL-TRIALS; OUTCOMES; HOSPITALIZATION;
ANTAGONIST; PROGRAM; STATE
AB Aim Patients hospitalized for acute heart failure (AHF) differ with respect of many clinical characteristics which may influence their prognosis and response to treatment. We have assessed possible differences in the effects of serelaxin on dyspnoea relief, 60 Day outcomes and 180 Day mortality across patient subgroups in the RELAX-AHF trial.
Methods and results Subgroups were based on pre-specified covariates (age, sex, race, geographic region, estimated glomerular filtration rate, time from presentation to randomization, baseline systolic blood pressure, history of diabetes, atrial fibrillation, ischaemic heart disease, cardiac devices, i.v. nitrates at randomization). Other covariates which may modify the efficacy of AHF treatment were also analysed. Subgroup analyses did not show any difference in the effects of serelaxin vs. placebo on dyspnoea relief or on the incidence of cardiovascular death or rehospitalizations for heart failure or renal failure at 60 days. Nominally significant interactions between some patient subgroups and the effects of serelaxin on 180 days cardiovascular and all-cause mortality were noted but should be interpreted cautiously due to the number of comparisons and the low incidence of deaths in the subgroups at lower risk.
Conclusion The effects of serelaxin vs. placebo appeared to be similar across subgroups of patients in RELAX-AHF.
C1 [Metra, Marco] Univ Brescia, Dept Med & Surg Specialties, Brescia, Italy.
[Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Wroclaw, Poland.
[Cotter, Gad; Davison, Beth A.] Momentum Res Inc, Durham, NC USA.
[Felker, G. Michael] Duke Univ, Sch Med, Duke Heart Ctr, Durham, NC USA.
[Filippatos, Gerasimos] Athens Univ Hosp, Athens, Greece.
[Greenberg, Barry H.] Univ Calif San Diego, San Diego, CA 92103 USA.
[Hua, Tsushung A.] Novartis Pharmaceut, E Hanover, NJ USA.
[Severin, Thomas] Novartis Pharma AG, Basel, Switzerland.
[Unemori, Elaine] Corthera Inc, San Carlos, CA USA.
[Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands.
[Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Metra, M (reprint author), Spedali Civil Brescia, Piazza Spedali Civili 1, I-25123 Brescia, Italy.
EM metramarco@libero.it
RI Lainscak, Mitja/F-3237-2015; Ponikowski, Piotr/O-6454-2015
OI Ponikowski, Piotr/0000-0002-3391-7064; Metra, Marco/0000-0001-6691-8568;
Davison, Beth/0000-0003-2374-6449
FU Corthera, Inc.; Novartis Pharma AG, Basel, Switzerland
FX The RELAX-AHF trial was supported by Corthera, Inc., a member of the
Novartis group of companies. Graham Allcock of CircleScience provided
editorial assistance, which was funded by Novartis Pharma AG, Basel,
Switzerland.
NR 29
TC 29
Z9 31
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
EI 1522-9645
J9 EUR HEART J
JI Eur. Heart J.
PD OCT
PY 2013
VL 34
IS 40
BP 3128
EP 3136
DI 10.1093/eurheartj/eht371
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 243BX
UT WOS:000326292600012
PM 23999454
ER
PT J
AU Gensheimer, MF
Hummel-Kramer, SM
Cain, D
Quang, TS
AF Gensheimer, M. F.
Hummel-Kramer, S. M.
Cain, D.
Quang, T. S.
TI Simple Rule for Prediction of Parotid Gland Sparing Early in the
Radiation Treatment Planning Process
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Meeting Abstract
CT 55th Annual Meeting of the American-Society-for-Radiation-Oncology
(ASTRO)
CY SEP 22-25, 2013
CL Atlanta, GA
SP Amer Soc Radiat Oncol
C1 [Gensheimer, M. F.] Univ Washington, Med Ctr, Seattle, WA 98195 USA.
[Hummel-Kramer, S. M.; Cain, D.; Quang, T. S.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
EI 1879-355X
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD OCT 1
PY 2013
VL 87
IS 2
SU S
BP S588
EP S588
PG 1
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 219JY
UT WOS:000324503602211
ER
PT J
AU Quang, TS
AF Quang, T. S.
TI Privilege and Immunity - An Underutilized Tool in the Quality
Improvement Program
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Meeting Abstract
CT 55th Annual Meeting of the American-Society-for-Radiation-Oncology
(ASTRO)
CY SEP 22-25, 2013
CL Atlanta, GA
SP Amer Soc Radiat Oncol
C1 [Quang, T. S.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Quang, T. S.] Univ Washington, Med Ctr, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
EI 1879-355X
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD OCT 1
PY 2013
VL 87
IS 2
SU S
BP S578
EP S578
PG 1
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 219JY
UT WOS:000324503602185
ER
PT J
AU Chattergoon, NN
Louey, S
Stork, PJ
Giraud, GD
Thornburg, KL
AF Chattergoon, N. N.
Louey, S.
Stork, P. J.
Giraud, G. D.
Thornburg, K. L.
TI SURPRISING SIGNAL TRANSDUCTION CHANGES IN MATURING FETAL OVINE
CARDIOMYOCYTES
SO PEDIATRIC RESEARCH
LA English
DT Meeting Abstract
C1 [Chattergoon, N. N.; Louey, S.; Stork, P. J.; Giraud, G. D.; Thornburg, K. L.] Oregon Hlth & Sci Univ, Heart Res Ctr, Portland, OR 97201 USA.
[Louey, S.; Giraud, G. D.; Thornburg, K. L.] Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97201 USA.
[Chattergoon, N. N.; Louey, S.; Giraud, G. D.; Thornburg, K. L.] Oregon Hlth & Sci Univ, Knight Cardiovasc Inst, Portland, OR 97201 USA.
[Stork, P. J.] Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97201 USA.
[Giraud, G. D.] Portland VA Med Ctr, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0031-3998
EI 1530-0447
J9 PEDIATR RES
JI Pediatr. Res.
PD OCT
PY 2013
VL 74
IS 4
BP 480
EP 480
PG 1
WC Pediatrics
SC Pediatrics
GA 239XT
UT WOS:000326060000024
ER
PT J
AU Shapiro, S
Traiger, G
Hill, W
Zhang, LX
Doran, AK
AF Shapiro, Shelley
Traiger, Glenna
Hill, Wendy
Zhang, Lixia
Doran, Aimee K.
TI Safety, Tolerability, and Efficacy of Overnight Switching From
Sildenafil to Tadalafil in Patients With Pulmonary Arterial Hypertension
SO CARDIOVASCULAR THERAPEUTICS
LA English
DT Article
DE Tadalafil; Retrospective; Transition; Sildenafil; Pulmonary arterial
hypertension; Phosphodiesterase type 5 inhibitor
ID THERAPY; PHARMACOKINETICS
AB SummaryAims
Tadalafil, a once-daily phosphodiesterase type 5 inhibitor (PDE-5I), offers clinicians an alternative to sildenafil, a 3-times-daily (t.i.d.) PDE-5I for treatment of pulmonary arterial hypertension (PAH). However, there are limited data describing the risks and benefits or recommended methodology of switching patients from sildenafil to tadalafil. Methods
Chart reviews were conducted on all World Health Organization group 1 patients on sildenafil for >= 3 months who transitioned to tadalafil with documented clinic visits and 6-min walk tests on both drugs. Most patients were transitioned by discontinuing sildenafil after the evening dose and initiating tadalafil 40 mg/day the next day. Data collected included demographics, PAH etiology, diagnostic hemodynamics, 6-min walk distance (6MWD), PDE-5I side effects, and concomitant medications. Data on B-type natriuretic peptide (BNP) levels were available for most patients also receiving endothelin receptor antagonists (ERAs). Results
Medical records from 98 patients were evaluated. Most patients (92%) were on sildenafil for > 1 year, and 78% were receiving sildenafil 80-100 mg t.i.d. Ninety-seven percent of patients (95/98) were successfully transitioned and maintained on 40 mg/day. With a mean duration on tadalafil therapy of 243 +/- 127 days at the time of analysis, 6MWD was unchanged. Patient-reported adverse events included headache (4%) and heartburn (2%). There was minimal change in BNP levels in the subset of patients receiving an ERA concomitantly. Conclusions
Transition from sildenafil to tadalafil 40 mg/day appears feasible without clinical deterioration or intolerable side effects. This study provides guidance to physicians considering transition from sildenafil to tadalafil for selecting patients.
C1 [Shapiro, Shelley; Hill, Wendy] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA 90073 USA.
[Shapiro, Shelley; Traiger, Glenna; Hill, Wendy] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Zhang, Lixia; Doran, Aimee K.] United Therapeut Corp, Res Triangle Pk, NC USA.
RP Shapiro, S (reprint author), Greater Los Angeles VA Healthcare Syst, Cardiol Sect 111E, 11301 Wilshire Blvd Bldg 500, Los Angeles, CA 90073 USA.
EM Shelley.Shapiro@va.gov
FU United Therapeutics
FX The site's principal investigators prepared the manuscript without
compensation. Assistance with medical writing and editing was provided
under the direction of the authors by Larry Nelson and Chris Lawrence,
MedThink SciCom, with support from United Therapeutics. Funding was
received from United Therapeutics to help supply staff for data
collection, for statistician, and for poster and manuscript preparation.
The principal investigator received funding from United Therapeutics for
other pulmonary hypertension-related studies.
NR 16
TC 4
Z9 4
U1 1
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-5914
EI 1755-5922
J9 CARDIOVASC THER
JI Cardiovasc. Ther.
PD OCT
PY 2013
VL 31
IS 5
BP 274
EP 279
DI 10.1111/1755-5922.12038
PG 6
WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy
SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy
GA 216RY
UT WOS:000324302900007
PM 23841794
ER
PT J
AU Uraizee, I
Cheng, S
Hung, CL
Verma, A
Thomas, JD
Zile, MR
Aurigemma, GP
Solomon, SD
AF Uraizee, Imran
Cheng, Susan
Hung, Chung-Lieh
Verma, Anil
Thomas, James D.
Zile, Michael R.
Aurigemma, Gerard P.
Solomon, Scott D.
TI Relation of N-Terminal Pro-B-Type Natriuretic Peptide With Diastolic
Function in Hypertensive Heart Disease
SO AMERICAN JOURNAL OF HYPERTENSION
LA English
DT Article
DE blood pressure; diastolic function; hypertension; imaging; natriuretic
peptides; speckle-tracking echocardiography; strain
ID VENTRICULAR SYSTOLIC DYSFUNCTION; BLOOD-PRESSURE; CYCLIC-GMP; FAILURE;
AGE; ECHOCARDIOGRAPHY; HYPERTROPHY; ASSOCIATION; RECEPTOR;
RECOMMENDATIONS
AB BACKGROUND
Elevated natriuretic peptide levels in asymptomatic individuals without heart failure are associated with increased risk of adverse cardiovascular outcomes and may reflect subclinical cardiac dysfunction.
METHODS
In a sample of 313 asymptomatic individuals (51% women, mean age 61 years) with hypertension and diastolic dysfunction, we examined the association of plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) with both conventional and advanced echocardiographic measures of systolic and diastolic function, including myocardial strain, using speckle-tracking-based analyses.
RESULTS
In univariate analyses, higher NT-proBNP was associated with greater left ventricular mass index (P = 0.003), left atrial volume index (P = 0.007), lateral E' velocity (P < 0.0001), E/E' ratio (P < 0.0001), peak global longitudinal systolic strain (P = 0.015), systolic strain rate (P = 0.021), and early diastolic strain rate (P < 0.0001). In multivariable analyses, NT-proBNP remained associated with measures of diastolic dysfunction, including lateral E' velocity (P = 0.013) and the E/E' ratio (P = 0.008). However, early diastolic strain rate was the echocardiographic parameter most strongly associated with NT-proBNP (P = 0.003).
CONCLUSIONS
In the setting of asymptomatic hypertensive heart disease and preserved ejection fraction, elevation in natriuretic peptide levels is predominantly associated with subclinical diastolic dysfunction.
C1 [Uraizee, Imran; Cheng, Susan; Solomon, Scott D.] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA.
[Hung, Chung-Lieh] Mackay Mem Hosp, Taipei, Taiwan.
[Verma, Anil] Ochsner Clin Fdn, Dept Cardiol, New Orleans, LA USA.
[Thomas, James D.] Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA.
[Zile, Michael R.] Ralph H Johnson Dept VA Med Ctr, Charleston, SC USA.
[Zile, Michael R.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Aurigemma, Gerard P.] Univ Massachusetts, Sch Med, Dept Med, Div Cardiovasc Med, Worcester, MA USA.
RP Solomon, SD (reprint author), Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.
EM ssolomon@rics.bwh.harvard.edu
FU Novartis Pharmaceuticals
FX The original clinical trial was funded by Novartis Pharmaceuticals.
NR 40
TC 4
Z9 6
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0895-7061
EI 1941-7225
J9 AM J HYPERTENS
JI Am. J. Hypertens.
PD OCT
PY 2013
VL 26
IS 10
BP 1234
EP 1241
DI 10.1093/ajh/hpt098
PG 8
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 239TF
UT WOS:000326047700014
PM 23792241
ER
PT J
AU Wang, ZJ
Subramanya, AR
Satlin, LM
Pastor-Soler, NM
Carattino, MD
Kleyman, TR
AF Wang, Zhijian
Subramanya, Arohan R.
Satlin, Lisa M.
Pastor-Soler, Nuria M.
Carattino, Marcelo D.
Kleyman, Thomas R.
TI Regulation of large-conductance Ca2+-activated K+ channels by WNK4
kinase
SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
LA English
DT Article
DE BK channel; familial hyperkalemic hypertension; Maxi-K; With-no-lysine
kinase 4; WNK4
ID CORTICAL COLLECTING DUCT; POTASSIUM CHANNELS; APICAL MEMBRANE;
CONNECTING TUBULE; INTERCALATED CELLS; SURFACE EXPRESSION;
BARTTERS-SYNDROME; DISTAL NEPHRON; ALPHA-SUBUNIT; ROMK
AB Large-conductance, Ca2+-activated K+ channels, commonly referred to as BK channels, have a major role in flow-induced K+ secretion in the distal nephron. With-no-lysine kinase 4 (WNK4) is a serine-threonine kinase expressed in the distal nephron that inhibits ROMK activity and renal K+ secretion. WNK4 mutations have been described in individuals with familial hyperkalemic hypertension (FHHt), a Mendelian disorder characterized by low-renin hypertension and hyperkalemia. As BK channels also have an important role in renal K+ secretion, we examined whether they are regulated by WNK4 in a manner similar to ROMK. BK channel activity was inhibited in a rabbit intercalated cell line transfected with WNK4 or a WNK4 mutant found in individuals with FHHt. Coexpression of an epitope-tagged BK alpha-subunit with WNK4 or the WNK4 mutant in HEK293 cells reduced BK alpha-subunit plasma membrane and whole cell expression. A region within WNK4 encompassing the autoinhibitory domain and a coiled coil domain was required for WNK4 to inhibit BK alpha-subunit expression. The relative fraction of BK alpha-subunit that was ubiquitinated was significantly increased in cells expressing WNK4, compared with controls. Our results suggest that WNK4 inhibits BK channel activity, in part, by increasing channel degradation through an ubiquitin-dependent pathway. Based on these results, we propose that WNK4 provides a cellular mechanism for the coordinated regulation of two key secretory K+ channels in the distal nephron, ROMK and BK.
C1 [Wang, Zhijian; Subramanya, Arohan R.; Pastor-Soler, Nuria M.; Carattino, Marcelo D.; Kleyman, Thomas R.] Univ Pittsburgh, Dept Med, Renal Electrolyte Div, Pittsburgh, PA USA.
[Subramanya, Arohan R.; Pastor-Soler, Nuria M.; Carattino, Marcelo D.; Kleyman, Thomas R.] Univ Pittsburgh, Dept Cell Biol, Pittsburgh, PA USA.
[Satlin, Lisa M.] Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY USA.
[Subramanya, Arohan R.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Carattino, MD (reprint author), Dept Med, Renal Electrolyte Div, S828 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.
EM mdc4@pitt.edu
FU National Institutes of Health [R01 DK-038470, R01 DK-084184, R37
DK-051391, T32 DK-061296, P30 DK0-79307]
FX This work was supported by grants from the National Institutes of
Health, including R01 DK-038470, R01 DK-084184, R37 DK-051391, T32
DK-061296, and P30 DK0-79307 (Pittsburgh Center for Kidney Research,
Univ. of Pittsburgh).
NR 48
TC 12
Z9 12
U1 0
U2 1
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6143
EI 1522-1563
J9 AM J PHYSIOL-CELL PH
JI Am. J. Physiol.-Cell Physiol.
PD OCT
PY 2013
VL 305
IS 8
BP C846
EP C853
DI 10.1152/ajpcell.00133.2013
PG 8
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA 237KV
UT WOS:000325869700006
PM 23885063
ER
PT J
AU Hunnibell, LS
Slatore, CG
Ballard, EA
AF Hunnibell, Laura S.
Slatore, Christopher G.
Ballard, Ellen A.
TI Foundations for Lung Nodule Management for Nurse Navigators
SO CLINICAL JOURNAL OF ONCOLOGY NURSING
LA English
DT Article
ID PRACTICAL ALGORITHMIC APPROACH; SMALL PULMONARY NODULES;
FLEISCHNER-SOCIETY; CANCER; CT; DIAGNOSIS; GUIDELINES; STATEMENT;
DESIGN; SCANS
AB Lung cancer remains the most deadly cancer, with more than half of patients dying within one year of diagnosis. However, mortality rates improve with early detection. Until recently, attempts at improving early detection of lung cancer have not been shown to be beneficial, but when results from the National Lung Screening Trial showed a survivor benefit for high-risk patients who had a computed tomography scan, interest grew rapidly in creating guidelines and programs that restructure lung nodule management and screening. Oncology nurse navigators will play a crucial role in the development and administration of tracking methods, data analysis, and program development that will contribute to the multidisciplinary team in screening, tracking, and diagnosing early-stage lung cancer.
C1 [Hunnibell, Laura S.] Dayton VA Med Ctr, Dayton, OH USA.
[Slatore, Christopher G.] Portland VA Med Ctr, Portland, OR USA.
[Slatore, Christopher G.] Portland VA Med Ctr, Sect Pulm & Crit Care Med, Portland, OR USA.
[Slatore, Christopher G.] Oregon Hlth & Sci Univ, Dept Med, Div Pulm & Crit Care Med, Portland, OR 97201 USA.
[Ballard, Ellen A.] VA Loma Linda Healthcare Syst, Ctr Canc, Loma Linda, CA USA.
RP Hunnibell, LS (reprint author), Dayton VA Med Ctr, Dayton, OH USA.
EM laura@hunnibell.net
OI Slatore, Christopher/0000-0003-0958-8122
NR 34
TC 8
Z9 8
U1 0
U2 0
PU ONCOLOGY NURSING SOC
PI PITTSBURGH
PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA
SN 1092-1095
EI 1538-067X
J9 CLIN J ONCOL NURS
JI Clin. J. Oncol. Nurs.
PD OCT
PY 2013
VL 17
IS 5
BP 525
EP 531
DI 10.1188/13.CJON.525-531
PG 7
WC Oncology; Nursing
SC Oncology; Nursing
GA 237ZE
UT WOS:000325909400010
PM 24080051
ER
PT J
AU Burke, RE
Ryan, P
AF Burke, Robert E.
Ryan, Patrick
TI Postdischarge Clinics: Hospitalist Attitudes and Experiences
SO JOURNAL OF HOSPITAL MEDICINE
LA English
DT Article
ID FOLLOW-UP; CARE; DISCHARGE; TRANSITIONS; CONTINUITY; PHYSICIANS
AB Novel methods for improving transitions of care are needed. Hospitalist-run postdischarge clinics (PDCs) may improve access to postdischarge care, but require practice change from providers. We conducted a Web-based cross-sectional survey of hospitalists at 37 academic medical centers across the United States and a large private employer of hospitalists to assess the attitudes of hospitalists toward postdischarge care and PDCs. Two hundred twenty-eight of 814 hospitalists responded to the survey (28%). Responding hospitalists commonly (55%) experienced difficulty arranging outpatient follow-up, and felt that lack of access was responsible for most patient problems after discharge (61%). Despite this, 62% felt hospitalists should not provide postdischarge care in a clinic, and 77% felt they would require extra compensation for work in a PDC. However, 74% thought such a clinic would decrease emergency department visits. Practicing in a PDC was associated with a trend toward positive attitudes about providing postdischarge care (P = 0.054). Responding hospitalists expressed difficulty arranging appropriate postdischarge care, confidence that PDCs would reduce postdischarge utilization, and reservations about working in a PDC, perhaps because of practical or financial concerns. These results are important given the current emphasis on reducing hospital readmissions. Further work evaluating the experience of hospitalists in PDCs is needed. Journal of Hospital Medicine 2013;8:578-581. (c) 2013 Society of Hospital Medicine
C1 [Burke, Robert E.] Eastern Colorado Hlth Care Syst, Dept Vet Affairs Med Ctr, Hosp Med Sect, Denver, CO USA.
[Burke, Robert E.; Ryan, Patrick] Univ Colorado, Sch Med, Dept Med, Div Gen Internal Med, Denver, CO USA.
RP Burke, RE (reprint author), Denver VA Med Ctr, Mailstop 111,1055 Clermont St, Denver, CO 80220 USA.
EM Robert.Burke5@va.gov
FU Colorado Research Enhancement Award Program
FX Dr. Burke had full access to all of the data in the study and takes
responsibility for the integrity of the data and the accuracy of the
data analysis. The views expressed in this article are those of the
authors and do not necessarily represent the views of the Department of
Veterans Affairs. Dr. Burke was supported by grant funding from the
Colorado Research Enhancement Award Program to Improve Care Coordination
for Veterans. Dr. Ryan has no conflicts of interest to disclose.
NR 14
TC 4
Z9 4
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1553-5592
EI 1553-5606
J9 J HOSP MED
JI J. Hosp. Med.
PD OCT
PY 2013
VL 8
IS 10
BP 578
EP 581
DI 10.1002/jhm.2085
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA 230NF
UT WOS:000325347000007
PM 24101543
ER
PT J
AU Ersek, M
Carpenter, JG
AF Ersek, Mary
Carpenter, Joan G.
TI Geriatric Palliative Care in Long-Term Care Settings with a Focus on
Nursing Homes
SO JOURNAL OF PALLIATIVE MEDICINE
LA English
DT Article
ID OF-LIFE CARE; RANDOMIZED CONTROLLED-TRIAL; SUSTAINING TREATMENT PROGRAM;
QUALITY-IMPROVEMENT PROJECT; PAIN MANAGEMENT-PRACTICES; ADVANCED
DEMENTIA; HOSPICE ENROLLMENT; PHYSICIAN ORDERS; REDUCE HOSPITALIZATIONS;
IMPLEMENTATION SCIENCE
AB Almost 1.7 million older Americans live in nursing homes, representing a large proportion of the frailest, most vulnerable elders needing long-term care. In the future, increasing numbers of older adults are expected to spend time and to die in nursing homes. Thus, understanding and addressing the palliative care needs of this population are critical. The goals of this paper are to describe briefly the current state of knowledge about palliative care needs, processes, and outcomes for nursing home residents; identify gaps in this knowledge; and propose priorities for future research in this area.
C1 [Ersek, Mary] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
[Ersek, Mary] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA.
[Carpenter, Joan G.] Univ Utah, Coll Nursing, Hartford Ctr Geriatr Nursing Excellence, Salt Lake City, UT 84112 USA.
[Carpenter, Joan G.] Coastal Hosp & Palliat Care, Salisbury, MD USA.
RP Ersek, M (reprint author), Philadelphia Vet Affairs Med Ctr, 3900 Woodland Ave Annex, Philadelphia, PA 19104 USA.
EM ersekm@nursing.upenn.edu
FU John A. Hartford Foundation's National Hartford Centers of
Gerontological Nursing Excellence Award Program
FX Ms. Carpenter is a 2011-2013 Patricia G. Archbold Scholar supported by
the John A. Hartford Foundation's National Hartford Centers of
Gerontological Nursing Excellence Award Program.
NR 110
TC 7
Z9 7
U1 5
U2 22
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-6218
EI 1557-7740
J9 J PALLIAT MED
JI J. Palliat. Med.
PD OCT 1
PY 2013
VL 16
IS 10
BP 1180
EP 1187
DI 10.1089/jpm.2013.9474
PG 8
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 229LI
UT WOS:000325265800009
PM 23984636
ER
PT J
AU Greenawalt, DS
Copeland, LA
MacCarthy, AA
Sun, FFF
Zeber, JE
AF Greenawalt, David Sloan
Copeland, Laurel Anne
MacCarthy, Andrea A.
Sun, Fangfang F.
Zeber, John Edward
TI Posttraumatic stress disorder and odds of major invasive procedures
among US Veterans Affairs patients
SO JOURNAL OF PSYCHOSOMATIC RESEARCH
LA English
DT Article
DE Posttraumatic stress disorder; Depression; Veterans; Invasive
procedures; Surgery
ID CORONARY-HEART-DISEASE; ADMINISTRATIVE DATA; HEALTH-CARE;
MENTAL-DISORDERS; MEDICAL-CARE; DISPARITIES; DEPRESSION; MORTALITY;
PTSD; ASSOCIATION
AB Objectives: Although individuals with posttraumatic stress disorder (PTSD) are at heightened risk for several serious health conditions, research has not examined how having PTSD impacts receipt of invasive procedures that may alleviate these problems. We examined whether PTSD, after controlling for major depression, was associated with odds of receiving common types of major invasive procedures, and whether race, ethnicity, and gender was associated with odds of procedures.
Methods: Veterans Health Administration patients with PTSD and/or depression were age-matched with patients without these disorders. The odds of invasive hip/knee, digestive system, coronary artery bypass graft/percutaneous coronary intervention (CABG/PCI), and vascular procedures during FY2006-2009 were modeled for the full sample of 501,489 patients and for at-risk subsamples with medical conditions alleviated by the procedures examined.
Results: Adjusting for demographic covariates and medical comorbidity, PTSD without depression was associated with decreased odds of all types of procedures (odds ratios [OR] range 0.74-0.82), as was depression without PTSD (OR range 0.59-0.77). In analyses of at-risk patients, those with PTSD only were less likely to undergo hip/knee (OR = 0.78) and vascular procedures (OR = 0.73) but not CABG/PCI. African-Americans and women at-risk patients were less likely to undergo hip/knee, vascular, and CABG/PCI procedures (OR range 031-0.82).
Conclusion: With the exception of CABG/PCI among at-risk patients, Veterans with PTSD and/or depression were less likely to undergo all types of procedures examined. Future studies should examine the reasons for this disparity and whether it is associated with subsequent adverse outcomes. Published by Elsevier Inc.
C1 [Greenawalt, David Sloan] VISN 17 Ctr Excellence Res Returning War Vet, Waco, TX 76711 USA.
[Copeland, Laurel Anne; Sun, Fangfang F.; Zeber, John Edward] Cent Texas Vet Hlth Care Syst, Ctr Appl Hlth Res, Dept Vet Affairs, Temple, TX 76504 USA.
[Copeland, Laurel Anne; Sun, Fangfang F.; Zeber, John Edward] Scott & White Healthcare, Ctr Appl Hlth Res, Temple, TX 76502 USA.
[MacCarthy, Andrea A.] South Texas Vet Hlth Care Syst, Ctr Improving Vet Hlth Res, San Antonio, TX 78229 USA.
RP Greenawalt, DS (reprint author), Albany Stratton VA Med Ctr, 113 Holland Ave 151, Albany, NY 12208 USA.
EM mycapemaypoint@yahoo.com
OI Copeland, Laurel/0000-0002-9478-0209
FU Veterans Health Administration, Health Services Research and Development
[IIR-09-335]; Department of Veterans Affairs Office of Academic
Affiliations Advanced Fellowship Program in Mental Illness Research and
Treatment VISN 17 Center of Excellence for Research on Returning War
Veterans; Central Texas Veterans Health Care System (CTVHCS); Center for
Applied Health Research; CTVHCS; Scott & White Healthcare, Temple, TX
FX This study was funded by a grant from the Veterans Health
Administration, Health Services Research and Development #IIR-09-335
(PI: Laurel A. Copeland). Preparation of this manuscript was supported
by the Department of Veterans Affairs Office of Academic Affiliations
Advanced Fellowship Program in Mental Illness Research and Treatment
VISN 17 Center of Excellence for Research on Returning War Veterans,
Central Texas Veterans Health Care System (CTVHCS), and the Center for
Applied Health Research, a research center jointly sponsored by CTVHCS
and Scott & White Healthcare, Temple, TX.
NR 57
TC 2
Z9 3
U1 2
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3999
EI 1879-1360
J9 J PSYCHOSOM RES
JI J. Psychosomat. Res.
PD OCT
PY 2013
VL 75
IS 4
BP 386
EP 393
DI 10.1016/j.jpsychores.2013.08.012
PG 8
WC Psychiatry
SC Psychiatry
GA 236ZQ
UT WOS:000325838400016
PM 24119948
ER
PT J
AU Ellis, C
Knapp, RG
Gilbert, GE
Egede, LE
AF Ellis, Charles
Knapp, Rebecca G.
Gilbert, Gregory E.
Egede, Leonard E.
TI Factors Associated with Delays in Seeking Treatment for Stroke Care in
Veterans
SO JOURNAL OF STROKE & CEREBROVASCULAR DISEASES
LA English
DT Article
DE Stroke; delays seeking treatment; veterans
ID SEVERITY; LITERACY; HEALTH; DISPARITIES
AB Background: Our objective was to examine the association between delay in seeking treatment (DST) for stroke care and demographic and clinical characteristics variables in a sample of veterans. Methods: We used survey data from 100 veterans with a diagnosis of stroke who were receiving poststroke care at a Veterans Affairs (VA) Medical Center in the southeastern United States to evaluate the relationship between DST and key sample demographic and clinical characteristics. We used backward stepwise logistic regression models to assess the independent association between DSTand demographic and clinical variables. Results: We found that stroke survivors reporting DST were more likely to be black (56.4% versus 32.8%; P = .02) and younger at the time of stroke onset (58.1 years versus 63.7 years; P = .02). In backward stepwise logistic regression models, being black was an independent predictor of DST (odds ratio [OR] 2.76; 95% confidence interval [CI], 1.04-7.30; P = .04) in this veteran population. Conclusions: Race appears to be a key factor associated with an increased likelihood of delays in seeking urgent stroke care in veterans. Future studies need to further examine the complex sociodemographic profile of patients who are most likely to delay seeking care for stroke and to develop interventions to reduce the impact of DST.
C1 [Ellis, Charles; Knapp, Rebecca G.; Gilbert, Gregory E.; Egede, Leonard E.] Ralph H Johnson VA Med Ctr, VA Ctr Dis Prevent & Hlth Intervent Diverse Popul, Charleston, SC USA.
[Ellis, Charles] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA.
[Knapp, Rebecca G.] Med Univ S Carolina, Dept Med, Div Biostat & Epidemiol, Charleston, SC 29425 USA.
[Egede, Leonard E.] Med Univ S Carolina, Dept Med, Ctr Hlth Dispar Res, Charleston, SC 29425 USA.
RP Ellis, C (reprint author), Med Univ S Carolina, Dept Hlth Sci & Res, 77 President St,MSC 700, Charleston, SC 29425 USA.
EM ellisc@musc.edu
RI Gilbert, Gregory/C-7735-2016
OI Gilbert, Gregory/0000-0003-0879-5496
FU Veterans Health Administration Health Services Research and Development
program (CDA) [07-012-3]
FX Dr Ellis was supported by a career development award (CDA# 07-012-3)
from the Veterans Health Administration Health Services Research and
Development program for this project.
NR 18
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1052-3057
EI 1532-8511
J9 J STROKE CEREBROVASC
JI J. Stroke Cerebrovasc. Dis.
PD OCT
PY 2013
VL 22
IS 7
BP E136
EP E141
DI 10.1016/j.jstrokecerebrovasdis.2012.09.017
PG 6
WC Neurosciences; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 237MK
UT WOS:000325874200021
PM 23219014
ER
PT J
AU Fordham, MT
Mulligan, JK
Casey, SE
Mulligan, RM
Wang, EW
Sansoni, ER
Schlosser, RJ
AF Fordham, M. Taylor
Mulligan, Jennifer K.
Casey, Sarah E.
Mulligan, Ryan M.
Wang, Eric W.
Sansoni, E. Ritter
Schlosser, Rodney J.
TI Reactive Oxygen Species in Chronic Rhinosinusitis and Secondhand Smoke
Exposure
SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY
LA English
DT Article
DE chronic rhinosinusitis; reactive oxygen species; secondhand smoke; nasal
polyps
ID OXIDATIVE STRESS; ANTIOXIDANT BALANCE; CHRONIC SINUSITIS; DISEASES;
OXIDANT; EPITHELIUM; RADICALS; EXPLANTS; ASTHMA; COPD
AB Objective
Reactive oxygen species (ROS) can potentiate cellular injury and inflammation. This study aimed to (1) assess the presence of reactive oxygen species in the sinus tissue of patients with chronic rhinosinusitis (CRS) and (2) assess the impact of secondhand smoke (SHS) exposure on reactive oxygen species (ROS) production.
Study Design
Retrospective cohort study.
Setting
Academic medical center.
Subjects and Methods
Sinus tissue samples from patients undergoing sinus surgery were analyzed using diaminobenzidine (DAB) staining to assess for ROS. Stained specimens were photographed at random by a blinded photographer and then quantified by 3 blinded graders. The patient's SHS exposure was determined by hair nicotine levels.
Results were compared between non-smoke exposed cohorts and those exposed to secondhand smoke and by diagnosis.
Results
Sixty-nine adults undergoing sinus surgery were included in the study. For the non-SHS-exposed cohorts, chronic rhinosinusitis with nasal polyps (CRSwNP) had the highest number of DAB+ cells/high-powered field (hpf) followed by chronic rhinosinusitis without nasal polyps (CRSsNP) and controls. When comparing the control patients to their SHS-exposed counterparts, SHS exposure yielded statistically significantly higher levels of DAB-positive cells/hpf. SHS exposure did not affect DAB staining in CRSsNP or CRSwNP patients.
Conclusion
ROS are differentially expressed in various subtypes of CRS. SHS exposure increases ROS in sinus tissue of control patients, but the clinical significance of this is unclear.
C1 [Fordham, M. Taylor; Mulligan, Jennifer K.] Med Univ S Carolina, Dept Otolaryngol, Charleston, SC 29425 USA.
[Mulligan, Jennifer K.] Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC USA.
[Mulligan, Jennifer K.; Wang, Eric W.] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA.
[Casey, Sarah E.; Mulligan, Ryan M.; Wang, Eric W.; Sansoni, E. Ritter; Schlosser, Rodney J.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Schlosser, Rodney J.] Ralph H Johnson VA Med Ctr, Dept Surg, Charleston, SC USA.
RP Fordham, MT (reprint author), Med Univ S Carolina, Dept Otolaryngol, MSC 550,135 Rutledge Ave, Charleston, SC 29425 USA.
EM fordham@musc.edu
OI Wang, Eric/0000-0002-1180-5854
FU AAO CORE Resident Research Grant; Flight Attendant Medical Research
Institute; VA Merit Grant
FX AAO CORE Resident Research Grant, Flight Attendant Medical Research
Institute, VA Merit Grant.
NR 27
TC 2
Z9 2
U1 0
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0194-5998
EI 1097-6817
J9 OTOLARYNG HEAD NECK
JI Otolaryngol. Head Neck Surg.
PD OCT
PY 2013
VL 149
IS 4
BP 633
EP 638
DI 10.1177/0194599813496377
PG 6
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA 218ZR
UT WOS:000324472800018
PM 23838308
ER
PT J
AU Harmon, T
Worrall, TJ
AF Harmon, Timothy
Worrall, Thomas J.
TI Retrospective case-control study comparing twice daily insulin glargine
and insulin detemir in veteran patients with type 2 diabetes
SO PHARMACOTHERAPY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-College-of-Clinical-Pharmacy (ACCP)
CY OCT 13-16, 2013
CL Albuquerque, NM
SP Amer Coll Clin Pharm
C1 [Harmon, Timothy] Ralph H Johnson VAMC, Charleston, SC USA.
[Worrall, Thomas J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0277-0008
EI 1875-9114
J9 PHARMACOTHERAPY
JI Pharmacotherapy
PD OCT
PY 2013
VL 33
IS 10
MA 10
BP E184
EP E184
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 230RM
UT WOS:000325360100038
ER
PT J
AU Higginson, A
Pfeifer, M
Roberti, A
Yi, S
McGregor, JC
Manning, J
Hinton, K
Singh, H
AF Higginson, Amy
Pfeifer, Michelle
Roberti, Angie
Yi, Stellar
McGregor, Jessina C.
Manning, Jane
Hinton, Kristina
Singh, Harleen
TI Conversion of Veterans Affairs Patients to Combivent Respimat: A patient
follow-up to evaluate adherence, appropriate use, and symptom control.
SO PHARMACOTHERAPY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-College-of-Clinical-Pharmacy (ACCP)
CY OCT 13-16, 2013
CL Albuquerque, NM
SP Amer Coll Clin Pharm
C1 [Higginson, Amy; Pfeifer, Michelle; Roberti, Angie; Yi, Stellar; Singh, Harleen] Oregon Hlth & Sci Univ, Oregon State Univ, Coll Pharm, Portland, OR USA.
[Manning, Jane] Portland VA Med Ctr, Portland, OR USA.
[Hinton, Kristina] Portland VA Med Ctr, Vancouver, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0277-0008
EI 1875-9114
J9 PHARMACOTHERAPY
JI Pharmacotherapy
PD OCT
PY 2013
VL 33
IS 10
MA 375
BP E294
EP E294
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 230RM
UT WOS:000325360100403
ER
PT J
AU Ranganath, VK
Maranian, P
Elashoff, DA
Woodworth, T
Khanna, D
Hahn, T
Sarkisian, C
Kremer, JM
Furst, DE
Paulus, HE
AF Ranganath, Veena K.
Maranian, Paul
Elashoff, David A.
Woodworth, Thasia
Khanna, Dinesh
Hahn, Theodore
Sarkisian, Catherine
Kremer, Joel M.
Furst, Daniel E.
Paulus, Harold E.
TI Comorbidities are associated with poorer outcomes in community patients
with rheumatoid arthritis
SO RHEUMATOLOGY
LA English
DT Article
DE comorbidities; rheumatoid arthritis; age; remission
ID LESS AGGRESSIVE TREATMENT; MINIMAL DISEASE-ACTIVITY; PHYSICAL FUNCTION;
CORRONA REGISTRY; ELDERLY-PATIENTS; UNITED-STATES; REMISSION;
ETANERCEPT; AGE; POPULATION
AB Objective. To evaluate the impact of comorbidities on achieving remission by examining changes in the clinical disease activity index (CDAI) in RA patients in the community-based Consortium of Rheumatology Researchers of North America (CORRONA) registry.
Methods. A subcohort of 1548 RA subjects with varying disease duration met the following inclusion criteria: started a DMARD/biologic agent, continued therapy 53 months, CDAI 52.8 at study entry and followed longitudinally from baseline to follow-up (mean time 7.46 months). Patients reported comorbidities according to a standardized list of 33 conditions. Entry characteristics were compared across age categories using one-way analysis of variance. Linear and logistic regression models were constructed to assess characteristics [e. g. age, disease duration, number of previous DMARDs/biologics, baseline modified health assessment questionnaire (MHAQ), baseline CDAI and number of comorbidities] associated with primary outcomes: change in CDAI (baseline to follow-up) and CDAI remission (yes/no).
Results. Although disease activity measures at entry were similar across age categories, older patients had more comorbidities, less improvement in CDAI/MHAQ and were less likely to attain remission at follow-up. However, after adjusting covariates an increasing number of patient-reported comorbidities and higher baseline CDAI (but not age) were consistently and independently associated with a lower likelihood of clinical improvement or remission (P<0.001).
Conclusion. In this observational cohort of community RA patients an increasing number of patients reported comorbidities, independently correlated with less CDAI improvement over time. These results reaffirm that comorbidities may be an important factor in consideration of treat-to-target recommendations and aid in understanding achievable RA therapeutic goals.
C1 [Ranganath, Veena K.; Maranian, Paul; Woodworth, Thasia; Furst, Daniel E.; Paulus, Harold E.] Univ Calif Los Angeles, Dept Med, Div Rheumatol, Los Angeles, CA 90095 USA.
[Elashoff, David A.] Univ Calif Los Angeles, Dept Med & Biostat, Los Angeles, CA 90095 USA.
[Khanna, Dinesh] Univ Michigan, Div Rheumatol, Ann Arbor, MI 48109 USA.
[Hahn, Theodore; Sarkisian, Catherine] Vet Adm Greater Los Angeles Healthcare Syst, Ctr Geriatr Res Educ & Clin, Dept Med, Los Angeles, CA USA.
[Kremer, Joel M.] Albany Med Coll, Ctr Rheumatol, Albany, NY 12208 USA.
RP Ranganath, VK (reprint author), Univ Calif Los Angeles, 1000 Veteran Ave,Rehab Bldg 32-59, Los Angeles, CA 90095 USA.
EM vranganath@mednet.ucla.edu
FU ACR/REF/ASP Junior Career Development Award in Geriatric Medicine;
National Institute of Arthritis and Musculoskeletal and Skin Diseases,
part of the National Institutes of Health [NIAMS K23 AR057818-02];
Scleroderma Foundation; National Institutes of Health Award [NIAMS K23
AR053858-04]; Abbvie; Actelion; Amgen; BMS; Gilead; GSK; NIH; Novartis;
Pfizer; Roche/Genentech; UCB; Biogen Idec; Janssen; Genetech
FX The authors thank Janet Elashoff, PhD, for her editorial comments and
insightful discussions. The ACR/REF/ASP Junior Career Development Award
in Geriatric Medicine was awarded to V. K. R. The National Institute of
Arthritis and Musculoskeletal and Skin Diseases, part of the National
Institutes of Health, under award number NIAMS K23 AR057818-02 helped to
support V. K. R. The content is solely the responsibility of the authors
and does not necessarily represent the official views of the National
Institutes of Health. The New Investigator Award from the Scleroderma
Foundation and the National Institutes of Health Award (NIAMS K23
AR053858-04) helped to support D.K.'s time.; Disclosure statement: D. E.
F is a consultant for and received honoraria and research
grants/research support from Abbvie, Actelion, Amgen, BMS, Gilead, GSK,
NIH, Novartis, Pfizer, Roche/Genentech, UCB, Biogen Idec and Janssen.
J.M.K. is a consultant for Abbvie, Amgen, BMS, Genetech, Pfizer, UCB and
Vertex and has received grants from Abbvie, Amgen, BMS, Genetech and
Pfizer. All other authors have declared no conflicts of interest.
NR 47
TC 20
Z9 21
U1 1
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1462-0324
EI 1462-0332
J9 RHEUMATOLOGY
JI RHEUMATOLOGY
PD OCT
PY 2013
VL 52
IS 10
BP 1809
EP 1817
DI 10.1093/rheumatology/ket224
PG 9
WC Rheumatology
SC Rheumatology
GA 239CA
UT WOS:000325997900013
PM 23813577
ER
PT J
AU Smith, MW
Bentley, MA
Fernandez, AR
Gibson, G
Schweikhart, SB
Woods, DD
AF Smith, Michael W.
Bentley, Melissa A.
Fernandez, Antonio R.
Gibson, Gregory
Schweikhart, Sharon B.
Woods, David D.
TI Performance of Experienced Versus Less Experienced Paramedics in
Managing Challenging Scenarios: A Cognitive Task Analysis Study
SO ANNALS OF EMERGENCY MEDICINE
LA English
DT Article
ID HEALTH-CARE; EXPERTISE; SCENE; WORK
AB Study objective: Out-of-hospital care is becoming more complex, thus placing greater reliance on the cognitive abilities of paramedics to manage difficult situations. In adapting to the challenges in their work, paramedics develop expertise. We study the cognitive strategies used by expert paramedics to contribute to understanding how paramedics and the EMS system can adapt to new challenges.
Methods: We conducted a "staged-world" cognitive task analysis to explore paramedics' handling of cognitive challenges related to sense-making and to resource and task management. A mixed-fidelity simulation was used to present paramedics with 2 challenging scenarios: a pulmonary embolism initially presenting as a myocardial infarction and a 2-person shooting with limited resources available.
Results: Participants were 10 paramedics, 6 more experienced and 4 less experienced. Analysis involved comparing the performance of the 2 groups to identify strategies associated with expertise. The more experienced paramedics made more assessments, explored a wider variety of presumptive diagnoses, and identified the pulmonary embolism earlier. They switched attention between the 2 shooting victims more, used their emergency medical technician basic level partners more, and provided more advanced level care for both patients. Their patients arrived at the emergency department more prepared for specialized emergency care.
Conclusion: Our findings correspond to general cognitive attributes of expertise: greater cue gathering and inferential reasoning, and more functional and strategic thinking. These results suggest potential areas and methods to facilitate development of expertise, as well as ways to better support use of expertise. Future studies should expand on these findings through larger sample sizes and more complex scenarios.
C1 [Smith, Michael W.; Woods, David D.] Ohio State Univ, Cognit Syst Engn Lab, Inst Ergon, Columbus, OH 43210 USA.
[Schweikhart, Sharon B.] Ohio State Univ, Div Hlth Serv Management & Policy, Columbus, OH 43210 USA.
[Smith, Michael W.] Baylor Coll Med, Houston VA HSR&D Ctr Excellence, Houston, TX 77030 USA.
[Smith, Michael W.] Baylor Coll Med, Ctr Inquiry Improve Outpatient Safety Effect Elec, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Smith, Michael W.] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA.
[Bentley, Melissa A.] Natl Registry Emergency Med Tech, Columbus, OH USA.
[Fernandez, Antonio R.] Univ N Carolina, Dept Emergency Med, Chapel Hill, NC USA.
[Gibson, Gregory] Kent State Univ, Dept Sociol, Kent, OH 44242 USA.
RP Smith, MW (reprint author), Ohio State Univ, Cognit Syst Engn Lab, Inst Ergon, Columbus, OH 43210 USA.
EM ms6@bcm.edu
FU National Registry of Emergency Medical Technicians; Google Research
Award; Department of Integrated Systems Engineering, College of
Engineering, Ohio State University
FX By Annals policy, all authors are required to disclose any and all
commercial, financial, and other relationships in any way related to the
subject of this article as per ICMJE conflict of interest guidelines
(see www.icmje.org). The authors have stated that no such relationships
exist. This research was supported by the National Registry of Emergency
Medical Technicians, a Google Research Award, and the Department of
Integrated Systems Engineering, College of Engineering, Ohio State
University.
NR 52
TC 5
Z9 5
U1 1
U2 13
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-0644
J9 ANN EMERG MED
JI Ann. Emerg. Med.
PD OCT
PY 2013
VL 62
IS 4
BP 367
EP 379
DI 10.1016/j.annemergmed.2013.04.026
PG 13
WC Emergency Medicine
SC Emergency Medicine
GA 229ZZ
UT WOS:000325307700016
PM 23787209
ER
PT J
AU Ganesh, S
Guernon, A
Chalcraft, L
Harton, B
Smith, B
Pape, TLB
AF Ganesh, Shanti
Guernon, Ann
Chalcraft, Laura
Harton, Brett
Smith, Bridget
Pape, Theresa Louise-Bender
TI Medical Comorbidities in Disorders of Consciousness Patients and Their
Association With Functional Outcomes
SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION
LA English
DT Article
DE Brain injuries; Comorbidity; Consciousness disorders; Rehabilitation
ID TRAUMATIC BRAIN-INJURY; VEGETATIVE STATE; HEAD-INJURY; FOLLOW-UP;
RECOVERY; UNCONSCIOUSNESS; HYDROCEPHALUS; DYSAUTONOMIA; OVERACTIVITY;
PREDICTION
AB Objective: To identify, for patients in states of seriously impaired consciousness, comorbid conditions present during inpatient rehabilitation and their association with function at 1 year.
Design: Abstracted data from a prospective cross-sectional observational study with data collection occurring January 1996 through December 2007.
Setting: Four inpatient rehabilitation facilities in metropolitan areas.
Participants: The study sample of 68 participants is abstracted from a database of 157 patients remaining in states of seriously impaired consciousness for at least 28 days.
Interventions: Not applicable.
Main Outcome Measure: One-year cognitive, motor, and total FIM score.
Results: The most common medical complications during inpatient rehabilitation for the study sample are active seizures (46%), spasticity (57%), urinary tract infections (47%), and hydrocephalus with and without shunt (38%). Presence of >= 3 medical complications during inpatient rehabilitation, controlling for injury severity, is significantly (P<.05) associated with poorer total FIM and FIM motor scores 1 year after injury. The presence of hydrocephalus with and without shunt (r=-.20, -.21, -.18; P <=.15), active seizures (r=-.31, -.22, -.42), spasticity (r=-.38, -.28, -.40), and urinary tract infections (r=-.25, -.24, -.26) were significantly (P<.10) associated with total FIM, FIM cognitive, and FIM motor scores, respectively.
Conclusions: Reported findings indicate that persons in states of seriously impaired consciousness with higher numbers of medical complications during inpatient rehabilitation are more likely to have lower functional levels 1-year postinjury. The findings indicate that persons with >= 3 medical complications during inpatient rehabilitation are at a higher risk for poorer functional outcomes at 1 year. It is, therefore, prudent to evaluate these patients for indications of these complications during inpatient rehabilitation. (c) 2013 by the American Congress of Rehabilitation Medicine
C1 [Ganesh, Shanti; Harton, Brett; Smith, Bridget; Pape, Theresa Louise-Bender] US Dept Vet Affairs, Dept Vet Affairs, Res Serv, Edward Hines Jr Vet Affairs Hosp, Hines, IL 60141 USA.
[Ganesh, Shanti; Harton, Brett; Smith, Bridget; Pape, Theresa Louise-Bender] US Dept Vet Affairs, Ctr Management Complex Chron Care, Ctr Excellence, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA.
[Ganesh, Shanti; Chalcraft, Laura] US Dept Vet Affairs, Phys Med & Rehabil Serv, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA.
[Guernon, Ann] Marianjoy Rehabil Hosp, Wheaton, IL USA.
[Smith, Bridget] Loyola Univ Chicago, Program Hlth Serv Res, Stritch Sch Med, Maywood, IL USA.
[Pape, Theresa Louise-Bender] Northwestern Univ, Dept Phys Med & Rehabil, Feinberg Sch Med, Chicago, IL 60611 USA.
RP Pape, TLB (reprint author), Hines VA Hosp, Ctr Management Complex Chron Care, 5000 S 5th Ave 151H,Bldg 1B260, Hines, IL 60141 USA.
EM Theresa.Pape@va.gov
OI Pape, Theresa/0000-0001-7738-5963
FU United States Department of Veterans Affairs, Office of Research and
Development, Health Services Research and Development Merit [CCN 07-133]
FX Supported by the United States Department of Veterans Affairs, Office of
Research and Development, Health Services Research and Development Merit
(grant no. CCN 07-133).
NR 33
TC 9
Z9 10
U1 0
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0003-9993
EI 1532-821X
J9 ARCH PHYS MED REHAB
JI Arch. Phys. Med. Rehabil.
PD OCT
PY 2013
VL 94
IS 10
BP 1899
EP 1907
DI 10.1016/j.apmr.2012.12.026
PG 9
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 231TU
UT WOS:000325442100008
PM 23735521
ER
PT J
AU Wecht, JM
Rosado-Rivera, D
Weir, JP
Ivan, A
Yen, C
Bauman, WA
AF Wecht, Jill M.
Rosado-Rivera, Dwindally
Weir, Joseph P.
Ivan, Adrian
Yen, Christina
Bauman, William A.
TI Hemodynamic Effects of L-Threo-3,4-Dihydroxyphenylserine (Droxidopa) in
Hypotensive Individuals With Spinal Cord Injury
SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION
LA English
DT Article
DE Blood pressure; Droxidopa; Hypotension; Orthostatic hypotension;
Paraplegia; Rehabilitation; Tetraplegia
ID NEUROGENIC ORTHOSTATIC HYPOTENSION; LOW BLOOD-PRESSURE;
L-DIHYDROXYPHENYLSERINE DROXIDOPA; L-THREO-DOPS; COGNITIVE PERFORMANCE;
AUTONOMIC FAILURE; TETRAPLEGIC MAN; PREVALENCE; MANAGEMENT; MIDODRINE
AB Objectives: To determine the effect of an escalating dose of droxidopa (100, 200, and 400mg) compared with placebo on seated blood pressure (BP) in hypotensive individuals with spinal cord injury (SCI). Secondarily, we aimed to determine the effect of droxidopa on (1) supine BP and heart rate, (2) the change in BP and heart rate when these individuals were transferred from the supine to the seated position, and (3) adverse event (AE) reporting.
Design: Open-label dose titration trial.
Setting: A Veterans Administration Medical Center.
Participants: Participants with SCI (C3-T12) (N=10) were studied during 4 laboratory visits. Subjects visited the laboratory for about 5 hours on each visit, which incorporated a 30-minute seated baseline, a 30- to 60-minute supine, and a 4-hour seated postdrug observation.
Interventions: Placebo on visit 1, droxidopa 100mg on visit 2, droxidopa 200mg on visit 3, and droxidopa 400mg on visit 4.
Main Outcome Measures: BP and heart rate changes from baseline to the postdrug period, orthostatic heart rate and BP responses, and subjective AE reporting.
Results: Seated BP was significantly elevated with 400mg droxidopa compared with placebo and 100mg droxidopa for 3 hours and was elevated for 2 hours compared with 200mg droxidopa. Increase in supine BP was not worsened following droxidopa, and the expected fall in BP when transferred to the seated position was prevented with droxidopa 200 and 400mg. There were no significant differences in the heart rate response or AE reporting among the study visits.
Conclusions: Our preliminary findings suggest that droxidopa, at the doses tested, does not cause excessive increases in supine BP and the 400-mg dose appears to be effective at increasing seated BP for up to 3 hours in persons with SCI. (c) 2013 by the American Congress of Rehabilitation Medicine
C1 [Wecht, Jill M.; Rosado-Rivera, Dwindally; Ivan, Adrian; Yen, Christina; Bauman, William A.] James J Peters VA Med Ctr, Ctr Excellence, Bronx, NY 10468 USA.
[Wecht, Jill M.; Bauman, William A.] James J Peters VA Med Ctr, Med Serv, Bronx, NY 10468 USA.
[Wecht, Jill M.; Bauman, William A.] Mt Sinai Sch Med, Dept Med, New York, NY USA.
[Wecht, Jill M.; Bauman, William A.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA.
[Weir, Joseph P.] Univ Kansas, Dept Hlth Sport & Exercise Sci, Lawrence, KS 66045 USA.
RP Wecht, JM (reprint author), James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Rm 7A-13,130 West Kingsbridge Rd, Bronx, NY 10468 USA.
EM JM.Wecht@va.gov
FU Veterans Affairs Rehabilitation Research and Development Service
[B2648C]
FX Supported by the Veterans Affairs Rehabilitation Research and
Development Service (grant no. B2648C).
NR 33
TC 3
Z9 3
U1 2
U2 8
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0003-9993
EI 1532-821X
J9 ARCH PHYS MED REHAB
JI Arch. Phys. Med. Rehabil.
PD OCT
PY 2013
VL 94
IS 10
BP 2006
EP 2012
DI 10.1016/j.apmr.2013.03.028
PG 7
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 231TU
UT WOS:000325442100020
PM 23602882
ER
PT J
AU Trowbridge, RL
Dhaliwal, G
Cosby, KS
AF Trowbridge, Robert L.
Dhaliwal, Gurpreet
Cosby, Karen S.
TI Educational agenda for diagnostic error reduction
SO BMJ QUALITY & SAFETY
LA English
DT Review
DE Diagnostic errors; Medical education; Cognitive biases
ID COGNITIVE FORCING STRATEGIES; CLINICAL DECISION-MAKING; PATIENT SAFETY;
MORTALITY CONFERENCES; MEDICAL ERRORS; MORBIDITY; INTERVENTIONS;
PERCEPTIONS; PERFORMANCE; IMPROVEMENT
AB Diagnostic errors are a major patient safety concern. Although the majority of diagnostic errors are partially attributable to cognitive mistakes, the most effective means of improving clinician cognition in order to achieve gains in diagnostic reliability are unclear. We propose a tripartite educational agenda for improving diagnostic performance among students, residents and practising physicians. This agenda includes strengthening the metacognitive abilities of clinicians, fostering intuitive reasoning and increasing awareness of the role of systems in the diagnostic process. The evidence supporting initiatives in each of these realms is reviewed and a course of future implementation and study is proposed. The barriers to designing and implementing this agenda are substantial and include limited evidence supporting these initiatives and the challenges of changing the practice patterns of practising physicians. Implementation will need to be accompanied by rigorous evaluation.
C1 [Trowbridge, Robert L.] Maine Med Ctr, Dept Med, Portland, ME 04012 USA.
[Trowbridge, Robert L.] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA.
[Dhaliwal, Gurpreet] San Francisco Vet Adm Med Ctr, Med Serv, San Francisco, CA USA.
[Dhaliwal, Gurpreet] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA USA.
[Cosby, Karen S.] Cook Cty Med Ctr, Dept Emergency Med, Chicago, IL USA.
[Cosby, Karen S.] Rush Med Coll, Dept Emergency Med, Chicago, IL 60612 USA.
RP Trowbridge, RL (reprint author), Maine Med Ctr, Dept Med, 22 Bramhall St, Portland, ME 04012 USA.
EM trowbr@mmc.org
NR 57
TC 1
Z9 1
U1 2
U2 13
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-5415
EI 2044-5423
J9 BMJ QUAL SAF
JI BMJ Qual. Saf.
PD OCT
PY 2013
VL 22
SU 2
BP ii28
EP ii32
DI 10.1136/bmjqs-2012-001622
PG 5
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 222NC
UT WOS:000324736900005
PM 23764435
ER
PT J
AU Dawson, DW
Hertzer, K
Moro, A
Donald, G
Chang, HH
Go, VL
Pandol, SJ
Lugea, A
Gukovskaya, AS
Li, G
Hines, OJ
Rozengurt, E
Eibl, G
AF Dawson, David W.
Hertzer, Kathleen
Moro, Aune
Donald, Graham
Chang, Hui-Hua
Go, Vay Liang
Pandol, Steven J.
Lugea, Aurelia
Gukovskaya, Anna S.
Li, Gang
Hines, Oscar J.
Rozengurt, Enrique
Eibl, Guido
TI High-Fat, High-Calorie Diet Promotes Early Pancreatic Neoplasia in the
Conditional Kras(G12D) Mouse Model
SO CANCER PREVENTION RESEARCH
LA English
DT Article
ID BODY-MASS INDEX; INTRAEPITHELIAL NEOPLASIA; DUCTAL ADENOCARCINOMA;
RISK-FACTORS; CANCER; MICE; CARCINOGENESIS; INFLAMMATION; ENHANCEMENT;
PROGRESSION
AB There is epidemiologic evidence that obesity increases the risk of cancers. Several underlying mechanisms, including inflammation and insulin resistance, are proposed. However, the driving mechanisms in pancreatic cancer are poorly understood. The goal of the present study was to develop a model of diet- induced obesity and pancreatic cancer development in a state-of-the-art mouse model, which resembles important clinical features of human obesity, for example, weight gain and metabolic disturbances. Offspring of Pdx-1-Cre and LSL-KrasG12D mice were allocated to either a high-fat, highcalorie diet (HFCD; similar to 4,535 kcal/kg; 40% of calories from fats) or control diet (similar to 3,725 kcal/kg; 12% of calories from fats) for 3 months. Compared with control animals, mice fed with the HFCD significantly gained more weight and developed hyperinsulinemia, hyperglycemia, hyperleptinemia, and elevated levels of insulin- like growth factor I (IGF-I). The pancreas of HFCD-fed animals showed robust signs of inflammation with increased numbers of infiltrating inflammatory cells (macrophages and T cells), elevated levels of several cytokines and chemokines, increased stromal fibrosis, and more advanced PanIN lesions. Our results show that a diet high in fats and calories leads to obesity and metabolic disturbances similar to humans and accelerates early pancreatic neoplasia in the conditional KrasG12D mouse model. This model and findings will provide the basis for more robust studies attempting to unravel the mechanisms underlying the cancer-promoting properties of obesity, as well as to evaluate dietary- and chemopreventive strategies targeting obesity-associated pancreatic cancer development. (C)2013 AACR.
C1 [Dawson, David W.] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Ctr Excellence Pancreat Dis, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA.
[Hertzer, Kathleen; Moro, Aune; Donald, Graham; Chang, Hui-Hua; Hines, Oscar J.; Eibl, Guido] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Ctr Excellence Pancreat Dis, Dept Surg, Los Angeles, CA 90095 USA.
[Go, Vay Liang; Pandol, Steven J.; Lugea, Aurelia; Gukovskaya, Anna S.; Rozengurt, Enrique] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Ctr Excellence Pancreat Dis, Dept Med, Los Angeles, CA 90095 USA.
[Li, Gang] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA.
[Dawson, David W.; Li, Gang; Hines, Oscar J.; Rozengurt, Enrique; Eibl, Guido] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA.
[Pandol, Steven J.; Lugea, Aurelia; Gukovskaya, Anna S.] Vet Affairs Greater Los Angeles Hlth Care Syst, Dept Med, Los Angeles, CA USA.
[Pandol, Steven J.] Cedars Sinai Med Ctr, Dept Internal Med, Los Angeles, CA 90048 USA.
RP Eibl, G (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, 10833 LeConte Ave,72-236 CHS, Los Angeles, CA 90095 USA.
EM Geibl@mednet.ucla.edu
RI Dawson, David/I-5917-2014
FU NIH [P01 CA163200, P01 AT003960, R01 CA122042, P30DK41301]; Department
of Veterans Affairs; Hirshberg Foundation for Pancreatic Cancer Research
FX This work was supported by NIH ( P01 CA163200, P01 AT003960, R01
CA122042, P30DK41301), Department of Veterans Affairs, and Hirshberg
Foundation for Pancreatic Cancer Research.
NR 40
TC 30
Z9 30
U1 0
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1940-6207
EI 1940-6215
J9 CANCER PREV RES
JI Cancer Prev. Res.
PD OCT
PY 2013
VL 6
IS 10
BP 1064
EP 1073
DI 10.1158/1940-6207.CAPR-13-0065
PG 10
WC Oncology
SC Oncology
GA 229NE
UT WOS:000325272400008
PM 23943783
ER
PT J
AU Rubinsky, AD
Bishop, MJ
Maynard, C
Henderson, WG
Hawn, MT
Harris, AHS
Beste, LA
Tonnesen, H
Bradley, KA
AF Rubinsky, Anna D.
Bishop, Michael J.
Maynard, Charles
Henderson, William G.
Hawn, Mary T.
Harris, Alex H. S.
Beste, Lauren A.
Tonnesen, Hanne
Bradley, Katharine A.
TI Postoperative risks associated with alcohol screening depend on
documented drinking at the time of surgery
SO DRUG AND ALCOHOL DEPENDENCE
LA English
DT Article
DE Alcohol; Drinking; AUDIT-C; Postoperative complications; Postoperative
health care utilization
ID DISORDERS IDENTIFICATION TEST; QUALITY IMPROVEMENT PROGRAM; MAJOR
NONCARDIAC SURGERY; ELECTIVE SURGERY; AUDIT-C; VETERANS; CONSUMPTION;
MORTALITY; PATIENT; CARE
AB Background: Both AUDIT-C alcohol screening scores up to a year before surgery and clinical documentation of drinking over 2 drinks per day immediately prior to surgery ("documented drinking >2 d/d") are associated with increased postoperative complications and health care utilization. The purpose of this study was to evaluate whether documented drinking >2 d/d contributed additional information about postoperative risk beyond past-year AUDIT-C screening results.
Method: Male Veterans Affairs (VA) patients who had a non-emergent, non-cardiac, major surgery assessed by the VA's Surgical Quality Improvement Program 10/2003-9/2006 and completed the AUDIT-C by mailed survey in the prior year were eligible for this study. Linear or logistic regression models compared 30-day postoperative complication(s), return to operating room (OR), hospital length of stay (LOS), and intensive care unit (ICU) days across eight groups defined by past-year AUDIT-C score and clinically documented drinking >2 d/d, with AUDIT-C scores 1-4 and no documented drinking >2 d/d as the referent, after adjusting for important covariates.
Results: Overall 8811 patients met inclusion criteria. Among patients with documented drinking >2 d/d immediately prior to surgery, postoperative risk varied widely depending on past-year AUDIT-C score; scores >= 5 were associated with increased risk of complication(s), and scores >= 9 with increased hospital LOS and ICU days. Among patients without documentation of drinking >2 d/d, increasing AUDIT-C scores were not associated with these outcomes.
Conclusions: Clinical documentation of drinking >2 d/d immediately prior to surgery contributed additional information about postoperative risk beyond past-year AUDIT-C score. However, among patients with documented drinking >2 d/d, postoperative risk varied widely depending on the AUDIT-C score. Published by Elsevier Ireland Ltd.
C1 [Rubinsky, Anna D.; Maynard, Charles; Beste, Lauren A.; Bradley, Katharine A.] Dept Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Henderson, William G.] Dept Vet Affairs Eastern Colorado Healthcare Syst, Denver, CO USA.
[Harris, Alex H. S.] Dept Vet Affairs Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk, CA 94025 USA.
[Hawn, Mary T.] Birmingham Vet Affairs Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL USA.
[Beste, Lauren A.; Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA 98195 USA.
[Rubinsky, Anna D.; Maynard, Charles; Bradley, Katharine A.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Bishop, Michael J.] Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA.
[Henderson, William G.] Univ Colorado, Hlth Outcomes Program, Aurora, CO 80045 USA.
[Hawn, Mary T.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35233 USA.
[Tonnesen, Hanne] Bispebjerg Hosp, World Hlth Org Collaborating Ctr Evidence Based H, DK-2400 Copenhagen, Denmark.
[Bradley, Katharine A.] Grp Hlth Res Inst, Seattle, WA USA.
RP Rubinsky, AD (reprint author), 1660 South Columbian Way S-152, Seattle, WA 98108 USA.
EM Anna.Rubinsky@va.gov
RI Maynard, Charles/N-3906-2015
OI Maynard, Charles/0000-0002-1644-7814
FU Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development and Health Services Research and Development
[IAC 06-021]; Agency for Healthcare Research and Quality (AHRQ) National
Research Services Award (NRSA) at the University of Washington [T32
HS013853]
FX The research reported here was supported by the Department of Veterans
Affairs, Veterans Health Administration, Office of Research and
Development and Health Services Research and Development (IAC 06-021).
Dr. Rubinsky was also supported by an Agency for Healthcare Research and
Quality (AHRQ) National Research Services Award (NRSA) at the University
of Washington (T32 HS013853). The Department of Veterans Affairs and
AHRQ had no further role in study design; in the analysis or
interpretation of data; in the writing of this report; or in the
decision to submit the paper for publication. The views expressed in
this article are those of the authors and do not necessarily reflect the
position or policy of the Department of Veterans Affairs, AHRQ the
United States Government, or any of the authors' institutions.
NR 36
TC 4
Z9 4
U1 1
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0376-8716
EI 1879-0046
J9 DRUG ALCOHOL DEPEN
JI Drug Alcohol Depend.
PD OCT 1
PY 2013
VL 132
IS 3
BP 521
EP 527
DI 10.1016/j.drugalcdep.2013.03.022
PG 7
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA 232RC
UT WOS:000325510700018
PM 23683792
ER
PT J
AU Winston, FK
McDonald, CC
McGehee, DV
AF Winston, Flaura K.
McDonald, Catherine C.
McGehee, Daniel V.
TI Are We Doing Enough to Prevent the Perfect Storm? Novice Drivers, ADHD,
and Distracted Driving
SO JAMA PEDIATRICS
LA English
DT Editorial Material
ID PROGRAM; TEENS
C1 [Winston, Flaura K.; McDonald, Catherine C.] Childrens Hosp Philadelphia, Ctr Injury Res & Prevent, Philadelphia, PA 19104 USA.
[Winston, Flaura K.] Univ Penn, Sch Med, Perelman Sch Med, Div Gen Pediat, Philadelphia, PA 19104 USA.
[Winston, Flaura K.] Univ Penn, Sch Med, Perelman Sch Med, Leonard David Inst Hlth Econ, Philadelphia, PA 19104 USA.
[McDonald, Catherine C.] Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Ctr Global Womens Hlth, Philadelphia, PA 19104 USA.
[McGehee, Daniel V.] Univ Iowa, Human Factors & Vehicle Safety Res Div, Publ Policy Ctr, Injury Prevent Res Ctr, Iowa City, IA USA.
RP Winston, FK (reprint author), Childrens Hosp Philadelphia, Ctr Injury Res & Prevent, 3535 Market St,11th Fl, Philadelphia, PA 19104 USA.
EM flaura@mail.med.upenn.edu
FU NINR NIH HHS [K99 NR013548]
NR 15
TC 2
Z9 2
U1 2
U2 16
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6203
EI 2168-6211
J9 JAMA PEDIATR
JI JAMA Pediatr.
PD OCT
PY 2013
VL 167
IS 10
BP 892
EP 894
DI 10.1001/jamapediatrics.2013.2315
PG 3
WC Pediatrics
SC Pediatrics
GA 232GQ
UT WOS:000325480900005
PM 23939682
ER
PT J
AU Chase, MH
AF Chase, Michael H.
TI A unified survival theory of the functioning of the hypocretinergic
system
SO JOURNAL OF APPLIED PHYSIOLOGY
LA English
DT Review
DE hypocretin; orexin; behaviors; survival
ID CORTICOTROPIN-RELEASING-FACTOR; COERULEUS-NORADRENERGIC SYSTEM;
HYPOTHALAMIC DEFENSIVE SYSTEM; SLEEP BEHAVIOR DISORDER; VENTRAL
TEGMENTAL AREA; OREXIN KNOCKOUT MICE; BROWN ADIPOSE-TISSUE;
HYPOCRETIN/OREXIN NEURONS; ENERGY HOMEOSTASIS; SPINAL-CORD
AB This article advances the theory that the hypocretinergic (orexinergic) system initiates, coordinates, and maintains survival behaviors and survival-related processes (i.e., the Unified Survival Theory of the Functioning of the Hypocretinergic System or "Unified Hypocretinergic Survival Theory"). A priori presumptive support for the Unified Hypocretinergic Survival Theory emanates from the fact that neurons that contain hypocretin are located in the key executive central nervous system (CNS) site, the lateral hypothalamus, that for decades has been well-documented to govern core survival behaviors such as fight, flight, and food consumption. In addition, the hypocretinergic system exhibits the requisite morphological and electrophysiological capabilities to control survival behaviors and related processes. Complementary behavioral data demonstrate that all facets of "survival" are coordinated by the hypocretinergic system and that hypocretinergic directives are not promulgated except during survival behaviors. Importantly, it has been shown that survival behaviors are selectively impacted when the hypocretinergic system is impaired or rendered nonfunctional, whereas other behaviors are relatively unaffected. The Unified Hypocretinergic Survival Theory resolves the disparate, perplexing, and often paradoxical-appearing results of previous studies; it also provides a foundation for future hypothesis-driven basic science and clinical explorations of the hypocretinergic system.
C1 [Chase, Michael H.] Univ Calif Los Angeles, Sch Med, Vet Affairs Greater Los Angeles Healthcare Syst, WebSci Int, Los Angeles, CA 90024 USA.
RP Chase, MH (reprint author), Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, WebSci Int, 1251 Westwood Blvd, Los Angeles, CA 90024 USA.
EM mchase@websciences.org
NR 197
TC 10
Z9 10
U1 1
U2 7
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 8750-7587
EI 1522-1601
J9 J APPL PHYSIOL
JI J. Appl. Physiol.
PD OCT
PY 2013
VL 115
IS 7
BP 954
EP 971
DI 10.1152/japplphysiol.00700.2012
PG 18
WC Physiology; Sport Sciences
SC Physiology; Sport Sciences
GA 231YX
UT WOS:000325455400002
PM 23640599
ER
PT J
AU Hanson, LC
Ersek, M
Lin, FC
Carey, TS
AF Hanson, Laura C.
Ersek, Mary
Lin, Feng Chang
Carey, Timothy S.
TI Outcomes of Feeding Problems in Advanced Dementia in a Nursing Home
Population
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE dementia; nutrition; nursing home
ID IMPROVING DECISION-MAKING; RESIDENTS; SURVIVAL; TRIAL
AB ObjectivesTo describe quality of care for feeding problems in advanced dementia and probability and predictors of weight loss and mortality.
DesignProspective cohort.
SettingTwenty-four nursing homes (NHs).
ParticipantsNursing home residents with advanced dementia and feeding problems and family surrogates (N=256).
MeasurementsFamily reported on quality of feeding care at enrollment and 3months. Chart reviews at enrollment and 3, 6, and 9months provided data on feeding problems, treatments, weight loss of more than 5% in 30days or more than 10% in 6months, and mortality. Organizational variables were obtained from administrator surveys and publically reported data.
ResultsResidents with advanced dementia and feeding problems had an average age of 85; 80% had chewing and swallowing problems, 11% weight loss, and 48% poor intake. Family reported feeding assistance of moderate quality; 23% felt the resident received less assistance than needed. Mortality risk was significant; 8% died within 3months, 17% within 6months, and 27% within 9months. Residents with advanced dementia who had stable weight over 3months had a 5.4% rate of significant weight loss and a 2.1% risk of death over the next 3months. Residents with advanced dementia and weight loss over 3months had a 38.9% chance of stabilizing weight over the next 3months but also had a 19.2% chance of dying. Weight loss was the only independent predictor of death.
ConclusionWeight loss is a predictor of death in advanced dementia. Treatments can often stabilize weight, but weight loss should be used to trigger discussion of goals of care and treatment options.
C1 [Hanson, Laura C.] Univ N Carolina, Div Geriatr Med, Chapel Hill, NC 27599 USA.
[Hanson, Laura C.] Univ N Carolina, Ctr Aging & Hlth, Chapel Hill, NC 27599 USA.
[Hanson, Laura C.; Carey, Timothy S.] Univ N Carolina, Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC 27599 USA.
[Ersek, Mary] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
[Ersek, Mary] Philadelphia Vet Affairs Med Ctr, Natl PROMISE Ctr, Philadelphia, PA USA.
[Ersek, Mary] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA.
[Lin, Feng Chang] Univ N Carolina, Sch Publ Hlth, Dept Biostat, Chapel Hill, NC 27599 USA.
[Carey, Timothy S.] Univ N Carolina, Div Gen Internal Med & Clin Epidemiol, Chapel Hill, NC 27599 USA.
RP Hanson, LC (reprint author), Univ N Carolina, Div Geriatr Med, CB 7550, Chapel Hill, NC 27599 USA.
EM lhanson@med.unc.edu
FU National Institutes of Health National Institute for Nursing Research
[R01 NR009826]
FX Funding was received from National Institutes of Health National
Institute for Nursing Research Grant R01 NR009826: Laura C. Hanson, Mary
Ersek, Feng Chang Lin, Timothy S. Carey.
NR 18
TC 15
Z9 15
U1 3
U2 18
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD OCT
PY 2013
VL 61
IS 10
BP 1692
EP 1697
DI 10.1111/jgs.12448
PG 6
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 233FG
UT WOS:000325551500007
PM 24083403
ER
PT J
AU Huang, DL
Chan, KCG
Young, BA
AF Huang, Deborah L.
Chan, Kwun Chuen Gary
Young, Bessie A.
TI Poor Oral Health and Quality of Life in Older U.S. Adults with Diabetes
Mellitus
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE health-related quality of life; oral health; diabetes mellitus
ID UNITED-STATES; CARE VISITS; COMMUNITY; DISEASE
AB ObjectiveTo determine the association between health-related quality of life (HRQOL) and oral health in older U.S. adults with diabetes mellitus (DM).
DesignCross-sectional.
SettingData from the U.S. Behavioral Risk Factor Surveillance System 2006, 2008, and 2010.
ParticipantsNationally representative sample of 70,363 adults aged 65 and older with DM.
ResultsOlder adults with DM were more likely to report permanent tooth loss due to caries or periodontal disease than those without (82.3% vs 74.3%, P<.001) and less likely to receive dental care in the past year (59.0% vs 70.9%, P<.001). Loss of permanent teeth from caries or periodontal disease was associated with 1.25 times greater odds of worse self-rated general health (95% confidence interval (CI)=1.13-1.37). Lack of dental care in the preceding 12months was associated with 1.34 times greater odds of worse self-rated general health (95% CI=1.25-1.44) than receiving dental care in the preceding 12months. Poor dentition and longer time since last dental visit were associated with more physically unhealthy days.
ConclusionsPoor dentition and lack of dental care were associated with worse HRQOL in older adults with DM. Further research is needed to determine whether better oral health improves HRQOL in this population.
C1 [Huang, Deborah L.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA.
[Huang, Deborah L.] Univ Washington, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA.
[Chan, Kwun Chuen Gary] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Young, Bessie A.] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence Hosp & Special, Epidemiol Res & Informat Ctr, Seattle, WA USA.
[Young, Bessie A.] Univ Washington, Div Nephrol, Seattle, WA 98195 USA.
[Young, Bessie A.] Univ Washington, Kidney Res Inst, Seattle, WA 98195 USA.
RP Huang, DL (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr S GRECC 182, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM huangdx@u.washington.edu
FU Veterans Affairs (VA) Puget Sound Health Care System in Seattle,
Washington; VA Advanced Fellowship in Geriatrics; VA, from the VA Puget
Sound Health Care System, Seattle, Washington; National Institutes of
Health, National Institute of Diabetes and Digestive and Kidney Diseases
[R01DK079745-01]
FX This material is the result of work supported by resources from the
Veterans Affairs (VA) Puget Sound Health Care System in Seattle,
Washington. Dr. Huang receives salary support from a VA Advanced
Fellowship in Geriatrics. Dr. Young receives support from the VA, from
the VA Puget Sound Health Care System, Seattle, Washington, and National
Institutes of Health, National Institute of Diabetes and Digestive and
Kidney Diseases Grant R01DK079745-01.
NR 28
TC 4
Z9 5
U1 4
U2 17
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD OCT
PY 2013
VL 61
IS 10
BP 1782
EP 1788
DI 10.1111/jgs.12452
PG 7
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 233FG
UT WOS:000325551500020
PM 24001058
ER
PT J
AU Estrella, MM
Wyatt, CM
Pearce, CL
Li, M
Shlipak, MG
Aouizerat, BE
Gustafson, D
Cohen, MH
Gange, SJ
Kao, WHL
Parekh, RS
AF Estrella, Michelle M.
Wyatt, Christina M.
Pearce, C. Leigh
Li, Man
Shlipak, Michael G.
Aouizerat, Bradley E.
Gustafson, Deborah
Cohen, Mardge H.
Gange, Stephen J.
Kao, W. H. Linda
Parekh, Rulan S.
TI Host APOL1 genotype is independently associated with proteinuria in HIV
infection
SO KIDNEY INTERNATIONAL
LA English
DT Article
DE genetic renal disease; HIV; kidney disease; proteinuria
ID STAGE RENAL-DISEASE; FOCAL SEGMENTAL GLOMERULOSCLEROSIS; GENOME-WIDE
ASSOCIATION; WOMENS INTERAGENCY HIV; KIDNEY-DISEASE; AFRICAN-AMERICANS;
ALLOGRAFT SURVIVAL; RISK; VARIANTS; GENE
AB Proteinuria is associated with adverse clinical outcomes in HIV infection. Here we evaluated whether APOL1 risk alleles, previously associated with advanced kidney disease, are independently associated with proteinuria in HIV infection in a cross-sectional study of HIV-infected women in the Women's Interagency HIV Study. We estimated the percent difference in urine protein excretion and odds of proteinuria (>= 200 mg/g) associated with two versus one or no APOL1 risk allele using linear and logistic regression, respectively. Of 1285 women successfully genotyped, 379 carried one and 80 carried two risk alleles. Proteinuria was present in 124 women, 78 of whom had proteinuria confirmed on a second sample. In women without prior AIDS, two risk alleles were independently associated with a 69% higher urine protein excretion (95% confidence interval (Cl): 36, 108) and five-fold higher odds of proteinuria (95% CI: 2.45, 10.37) as compared with one or no risk allele. No association was found in women with prior AIDS. Analyses in which women with impaired kidney function were excluded and proteinuria was confirmed by a second urine sample yielded similar estimates. Thus, APOL1 risk alleles are associated with significant proteinuria in HIV-infected persons without prior clinical AIDS, independent of clinical factors traditionally associated with proteinuria. Trials are needed to determine whether APOL1 genotyping identifies individuals who could benefit from earlier intervention to prevent overt renal disease.
C1 [Estrella, Michelle M.; Kao, W. H. Linda; Parekh, Rulan S.] Johns Hopkins Univ, Sch Med, Dept Med, Div Nephrol, Baltimore, MD 21205 USA.
[Wyatt, Christina M.] Mt Sinai Sch Med, Dept Med, New York, NY USA.
[Pearce, C. Leigh] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA.
[Li, Man; Gange, Stephen J.; Kao, W. H. Linda; Parekh, Rulan S.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco Vet Affairs Med Ctr, San Francisco, CA USA.
[Aouizerat, Bradley E.] Univ Calif San Francisco, Dept Physiol Nursing, Inst Human Genet, San Francisco, CA USA.
[Gustafson, Deborah] Suny Downstate Med Ctr, Dept Neurol, Brooklyn, NY 11203 USA.
[Gustafson, Deborah] Univ Gothenburg, Sahlgrenska Acad, Neuropsychiat Epidemiol Unit, Sect Psychiat & Neurochem, Gothenburgh, Sweden.
[Cohen, Mardge H.] Rush Univ, Med Ctr, Cook Cty Hlth & Hosp Syst, Dept Med, Chicago, IL 60612 USA.
[Parekh, Rulan S.] Univ Toronto, Hosp Sick Children, Univ Hlth Network, Toronto, ON M5G 1X8, Canada.
RP Estrella, MM (reprint author), Johns Hopkins Univ, Sch Med, Dept Med, Div Nephrol, 1830 E Monument St,Suite 416, Baltimore, MD 21205 USA.
EM mestrel1@jhmi.edu
OI Gange, Stephen/0000-0001-7842-512X
FU National Institute of Diabetes and Digestive and Kidney Diseases [1
K23DK08131]; National Kidney Foundation of Maryland; National Institute
of Allergy and Infectious Diseases [UO1-AI-35004, UO1-AI-31834,
UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, UO1-AI-42590]; Eunice Kennedy
Shriver National Institute of Child Health and Human Development
[UO1-HD-32632]; National Cancer Institute; National Institute on Drug
Abuse; National Institute on Deafness and Other Communication Disorders;
National Center for Research Resources (UCSF-CTSI) [UL1 RR024131]
FX This work was supported by the National Institute of Diabetes and
Digestive and Kidney Diseases (1 K23DK08131 to MME) and through a
Mini-Grant provided by the National Kidney Foundation of Maryland (to
MME). Data in this manuscript were collected by the Women's Interagency
HIV Study (WIHS) Collaborative Study Group with centers (Principal
Investigators) at New York City/Bronx Consortium (Kathryn Anastos);
Brooklyn, NY (Howard Minkoff); Washington DC, Metropolitan Consortium
(Mary Young); The Connie Wofsy Study Consortium of Northern California
(Ruth Greenblatt); Los Angeles County/Southern California Consortium
(Alexandra Levine); Chicago Consortium (Mardge Cohen); and Data
Coordinating Center (Stephen Gange). The WINS is funded by the National
Institute of Allergy and Infectious Diseases (UO1-AI-35004,
UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, and
UO1-AI-42590) and by the Eunice Kennedy Shriver National Institute of
Child Health and Human Development (UO1-HD-32632). The study is cofunded
by the National Cancer Institute, the National Institute on Drug Abuse,
and the National Institute on Deafness and Other Communication
Disorders. Funding is also provided by the National Center for Research
Resources (UCSF-CTSI Grant number UL1 RR024131). The contents of this
publication are solely the responsibility of the authors and do not
necessarily represent the official views of the National Institutes of
Health.
NR 39
TC 12
Z9 12
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0085-2538
EI 1523-1755
J9 KIDNEY INT
JI Kidney Int.
PD OCT
PY 2013
VL 84
IS 4
BP 834
EP 840
DI 10.1038/ki.2013.203
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA 229BX
UT WOS:000325237900026
PM 23715117
ER
PT J
AU Bergstrom, AR
Nur, F
Davis, DL
AF Bergstrom, A. Renee
Nur, Filsan
Davis, Denise Lynne
TI Consider the Personhood of Women Who Experienced Genital Cutting
SO MAYO CLINIC PROCEEDINGS
LA English
DT Letter
ID FEMALE CIRCUMCISION; CARE
C1 [Bergstrom, A. Renee; Nur, Filsan] Mayo Clin, Rochester, MN USA.
[Davis, Denise Lynne] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA.
RP Bergstrom, AR (reprint author), Mayo Clin, Rochester, MN USA.
NR 5
TC 1
Z9 1
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0025-6196
EI 1942-5546
J9 MAYO CLIN PROC
JI Mayo Clin. Proc.
PD OCT
PY 2013
VL 88
IS 10
BP 1180
EP 1180
DI 10.1016/j.mayocp.2013.08.004
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 232DR
UT WOS:000325470800024
PM 24079688
ER
PT J
AU Steinman, MA
Dimaano, L
Peterson, CA
Heidenreich, PA
Knight, SJ
Fung, KZ
Kaboli, PJ
AF Steinman, Michael A.
Dimaano, Liezel
Peterson, Carolyn A.
Heidenreich, Paul A.
Knight, Sara J.
Fung, Kathy Z.
Kaboli, Peter J.
TI Reasons for Not Prescribing Guideline-recommended Medications to Adults
With Heart Failure
SO MEDICAL CARE
LA English
DT Article
DE guideline adherence; heart failure; drug prescribing; performance
measurement
ID ELECTRONIC HEALTH RECORDS; CORONARY-ARTERY-DISEASE; QUALITY MEASURES;
PRIMARY-CARE; PERFORMANCE; PAY; EXCEPTIONS; MANAGEMENT; VETERANS;
BARRIERS
AB Background:Little is known about how often contextual factors such as patient preferences and competing priorities impact prescribing of guideline-recommended medications, or about the extent to which these factors are documented in medical records and available to performance measurement systems.Methods:Mixed-methods study of 295 veterans aged 50 years and older in 4 VA health care systems who had systolic heart failure and were not prescribed a -blocker and/or an angiotensin converting enzyme inhibitor or angiotensin-receptor blocker. Reasons for nontreatment were identified from clinic notes and from interviews with 62 primary care clinicians caring for these patients. These reasons were classified using a published taxonomy.Results:Among 295 patients not receiving guideline-recommended drugs for heart failure, chart review identified biomedical reasons for nonprescribing in 42%-58% of patients and contextual reasons in 11%-17%. Clinician interviews identified twice as many reasons for nonprescribing as chart review (mean 1.6 vs. 0.8 reasons per patient, P<0.001). In these interviews, biomedical reasons for nonprescribing were cited in 50%-70% of patients, and contextual reasons in 64%-70%. The most common contextual reasons were comanagement with other clinicians (32%-35% of patients), patient preferences and nonadherence (15%-24%), and clinician belief that the medication is not indicated in the patient (12%-20%).Conclusions:Contextual reasons for not prescribing angiotensin converting enzyme inhibitor / angiotensin-receptor blockers and -blockers are present in two thirds of patients with heart failure who did not receive these medications, yet are poorly documented in medical records. The structure of medical records should be improved to facilitate documentation of contextual reasons for not providing guideline-recommended care.
C1 [Steinman, Michael A.; Peterson, Carolyn A.; Fung, Kathy Z.] San Francisco VA Med Ctr, Hlth Serv Res & Dev Res Enhancement Award Program, San Francisco, CA 94121 USA.
[Steinman, Michael A.; Dimaano, Liezel; Peterson, Carolyn A.; Fung, Kathy Z.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA.
[Peterson, Carolyn A.] Univ Oregon, Dept Psychol, Eugene, OR 97403 USA.
[Heidenreich, Paul A.] Stanford Univ, Dept Med, Palo Alto VA Hlth Care Syst, Stanford, CA 94305 USA.
[Knight, Sara J.] Univ Calif San Francisco, Vet Affairs Off Res & Dev, San Francisco, CA 94143 USA.
[Knight, Sara J.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Knight, Sara J.] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA.
[Kaboli, Peter J.] Iowa City VA Healthcare Syst, CADRE Ctr, Iowa City, IA USA.
[Kaboli, Peter J.] Univ Iowa, Dept Internal Med, Carver Coll Med, Iowa City, IA 52242 USA.
RP Steinman, MA (reprint author), San Francisco VA Med Ctr, Hlth Serv Res & Dev Res Enhancement Award Program, POB 181G,4150 Clement St, San Francisco, CA 94121 USA.
EM mike.steinman@ucsf.edu
FU Department of Veterans Affairs, Veterans Health Administration, Health
Services Research and Development Service [IIR 06-080-02, CHF
QUERI-04-326]; National Institute on Aging; American Federation for
Aging Research [1K23-AG030999]
FX Supported by the Department of Veterans Affairs, Veterans Health
Administration, Health Services Research and Development Service (IIR
06-080-02 and CHF QUERI-04-326), and by the National Institute on Aging
and the American Federation for Aging Research (1K23-AG030999). The
funders had no role in study design, data collection, analysis,
interpretation, or the decision to publish this manuscript.
NR 28
TC 14
Z9 15
U1 1
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
EI 1537-1948
J9 MED CARE
JI Med. Care
PD OCT
PY 2013
VL 51
IS 10
BP 901
EP 907
PG 7
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 222SI
UT WOS:000324751000008
PM 23969589
ER
PT J
AU Lapham, GT
Rubinsky, AD
Heagerty, PJ
Williams, EC
Hawkins, EJ
Maynard, C
Kivlahan, DR
Bradley, KA
AF Lapham, Gwen T.
Rubinsky, Anna D.
Heagerty, Patrick J.
Williams, Emily C.
Hawkins, Eric J.
Maynard, Charles
Kivlahan, Daniel R.
Bradley, Katharine A.
TI Annual Rescreening for Alcohol Misuse Diminishing Returns for Some
Patient Subgroups
SO MEDICAL CARE
LA English
DT Article
DE alcoholism and addictive behaviors; screening; public health
ID RANDOMIZED CONTROLLED-TRIAL; IDENTIFICATION TEST AUDIT;
SERVICES-TASK-FORCE; PRIMARY-CARE; VETERANS-AFFAIRS; HEALTH-CARE;
PREVENTIVE-SERVICES; HAZARDOUS DRINKING; SCREENING SCORES; USE DISORDER
AB Background:Routine alcohol screening is widely recommended, and Medicare now reimburses for annual alcohol screening. Although up to 18% of patients will screen positive for alcohol misuse, the value of annual rescreening for patients who repeatedly screen negative is unknown.Objective:To evaluate the probability of converting to a positive alcohol screen at annual rescreening among VA outpatients who previously screened negative 2-4 times.Research Design:Retrospective cohort study.Subjects:A total of 179,035 VA outpatients (10,588 women) who previously screened negative on 2 and up to 4 consecutive annual alcohol screens and were rescreened the next year.Measures:AUDIT-C alcohol screening scores (range, 0-12) were obtained from electronic medical record data. The probability of converting to a positive screen (scores: men 4; women, 3) at rescreening after 2-4 prior negative screens was evaluated overall and across subgroups based on age, sex, and prior negative screen scores (scores: men, 0-3; women, 0-2).Results:The overall probability of converting to a positive subsequent screen decreased modestly from 3.5% to 1.9% as the number of prior consecutive negative screens increased from 2 to 4, yet varied widely across subgroups based on age, sex, and prior negative screen scores (0.6%-38.7%).Conclusions:The likelihood of converting to a positive screen at annual rescreening is strongly influenced by age, sex, and scaled screening scores on prior negative alcohol screens. Algorithms for the frequency of repeat alcohol screening for patients who repeatedly screen negative should be based on these factors. These results may have implications for other routine behavioral health screenings.
C1 [Lapham, Gwen T.; Rubinsky, Anna D.; Williams, Emily C.; Hawkins, Eric J.; Maynard, Charles; Kivlahan, Daniel R.; Bradley, Katharine A.] Northwest Ctr Excellence, Hlth Serv Res & Dev HSR&D, Seattle, WA USA.
[Lapham, Gwen T.; Rubinsky, Anna D.; Heagerty, Patrick J.; Williams, Emily C.; Maynard, Charles; Bradley, Katharine A.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Lapham, Gwen T.; Bradley, Katharine A.] Grp Hlth Res Inst, Seattle, WA USA.
[Heagerty, Patrick J.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Hawkins, Eric J.; Kivlahan, Daniel R.; Bradley, Katharine A.] CESATE, Seattle, WA USA.
[Hawkins, Eric J.; Kivlahan, Daniel R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA USA.
RP Lapham, GT (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA.
EM gwendolyn.lapham@va.gov
RI Maynard, Charles/N-3906-2015
OI Maynard, Charles/0000-0002-1644-7814
FU VA HSR&D Substance Use Disorders Quality Enhancement Research Initiative
(QUERI) [RRP 11-021]
FX Supported by VA HSR&D Substance Use Disorders Quality Enhancement
Research Initiative (QUERI) RRP 11-021.
NR 50
TC 5
Z9 5
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
EI 1537-1948
J9 MED CARE
JI Med. Care
PD OCT
PY 2013
VL 51
IS 10
BP 914
EP 921
PG 8
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 222SI
UT WOS:000324751000010
PM 23969582
ER
PT J
AU Charalambous, CC
Bonilha, HS
Kautz, SA
Gregory, CM
Bowden, MG
AF Charalambous, Charalambos C.
Bonilha, Heather Shaw
Kautz, Steven A.
Gregory, Chris M.
Bowden, Mark G.
TI Rehabilitating Walking Speed Poststroke With Treadmill-Based
Interventions: A Systematic Review of Randomized Controlled Trials
SO NEUROREHABILITATION AND NEURAL REPAIR
LA English
DT Article
DE cerebrovascular accident; walking; activity-based interventions;
rehabilitation
ID BODY-WEIGHT SUPPORT; SPINAL-CORD-INJURY; OVERGROUND WALKING; IMPROVES
WALKING; STROKE REHABILITATION; ASSISTED WALKING; EXERCISE; OUTCOMES;
AMBULATION; SURVIVORS
AB Background. In the past several years, several randomized controlled trials (RCTs) have been reported regarding the efficacy of treadmill-based walking-specific rehabilitation programs, either individually (TT) or combined with body weight support (BWSTT), over control group therapies poststroke. No clear consensus exists as to whether treadmill-based interventions are superior in rehabilitating walking speed (WS) poststroke. Objective. To review published RCTs examining TT and BWSTT poststroke and describe the effects on improving and retaining WS. Methods. A systematic literature search in computerized databases was conducted to identify RCTs whose methodological quality was assessed with PEDro. Pre- and post-WS, change in WS, functional outcomes, and follow-up speed were extracted and calculated from each study. Additionally, statistical results of each study were examined, and the intragroup and intergroup effect sizes (ESintra and ESinter, respectively) were calculated. Results. All studies (8 TT; 7 BWSTT) met the inclusion criteria, and their methodological quality was generally good, with a mean PEDro score 6.9/10. Of the 15 studies, 8 studies (4 TT; 4 BWSTT) reported intragroup significant increases of WS, whereas only 4 (4 TT) found superiority of treadmill interventions. Nine studies demonstrated large ESintra (4 TT; 5 BWSTT), yet only 3 showed large ESinter (1 TT; 2 BWSTT). Four studies (2 TT and 2 BWSTT) reported retention of gains in WS, regardless of intervention. Conclusions. Treadmill-based interventions poststroke may increase and retain WS, but their universal superiority to other control group therapies has failed to be established.
C1 [Charalambous, Charalambos C.; Bonilha, Heather Shaw; Kautz, Steven A.; Gregory, Chris M.; Bowden, Mark G.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Kautz, Steven A.; Gregory, Chris M.; Bowden, Mark G.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Bowden, MG (reprint author), 77 President St,MSC 700, Charleston, SC 29425 USA.
EM bowdenm@musc.edu
OI Kautz, Steven/0000-0003-3151-8235
FU NIH [KL2 RR029880, KL2 TR000060]; VA RRD [A6776S, B7177M]
FX The author(s) disclosed receipt of the following financial support for
the research, authorship, and/or publication of this article: This
material is the result of work supported with resources and the use of
facilities at the Ralph H. Johnson VA Medical Center in Charleston, SC.
This work was supported by NIH Grant Numbers KL2 RR029880 and KL2
TR000060 (HSB), VA RR&D A6776S (SAK), and VA RR&D B7177M (MGB).
NR 31
TC 2
Z9 2
U1 0
U2 11
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1545-9683
EI 1552-6844
J9 NEUROREHAB NEURAL RE
JI Neurorehabil. Neural Repair
PD OCT
PY 2013
VL 27
IS 8
BP 709
EP 721
DI 10.1177/1545968313491005
PG 13
WC Clinical Neurology; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA 220NQ
UT WOS:000324591700005
PM 23764885
ER
PT J
AU Dobscha, SK
AF Dobscha, Steven K.
TI Prescription Opioids and Benzodiazepines: Moving Beyond "Just Say No"
SO PAIN MEDICINE
LA English
DT Editorial Material
ID PERSISTENT PAIN; THERAPY
C1 Portland VA Med Ctr, Ctr Improve Vet Involvement Care CIVIC, Portland, OR USA.
RP Dobscha, SK (reprint author), Portland VA Med Ctr, Ctr Improve Vet Involvement Care CIVIC, Portland, OR USA.
NR 16
TC 1
Z9 1
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1526-2375
EI 1526-4637
J9 PAIN MED
JI Pain Med.
PD OCT
PY 2013
VL 14
IS 10
BP 1447
EP 1449
DI 10.1111/pme.12237
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 235BX
UT WOS:000325691000003
PM 24588852
ER
PT J
AU Stephens, C
Sackett, N
Pierce, R
Schopfer, D
Schmajuk, G
Moy, N
Bachhuber, M
Wallhagen, MI
Lee, SJ
AF Stephens, Caroline
Sackett, Nathan
Pierce, Read
Schopfer, David
Schmajuk, Gabriela
Moy, Nicholas
Bachhuber, Melissa
Wallhagen, Margaret I.
Lee, Sei J.
TI Transitional Care Challenges of Rehospitalized Veterans: Listening to
Patients and Providers
SO POPULATION HEALTH MANAGEMENT
LA English
DT Article
ID HEALTH-CARE; HOSPITAL DISCHARGE; HOMELESS PERSONS; CONTROLLED-TRIAL;
PROGRAM; ELDERS
AB Readmissions to the hospital are common and costly, often resulting from poor care coordination. Despite increased attention given to improving the quality and safety of care transitions, little is known about patient and provider perspectives of the transitional care needs of rehospitalized Veterans. As part of a larger quality improvement initiative to reduce hospital readmissions, the authors conducted semi-structured interviews with 25 patients and 14 of their interdisciplinary health care providers to better understand their perspectives of the transitional care needs and challenges faced by rehospitalized Veterans. Patients identified 3 common themes that led to rehospitalization: (1) knowledge gaps and deferred power; (2) difficulties navigating the health care system; and (3) complex psychiatric and social needs. Providers identified different themes that led to rehospitalization: (1) substance abuse and mental illness; (2) lack of social or financial support and homelessness; (3) premature discharge and poor communication; and (4) nonadherence with follow-up. Results underscore that rehospitalized Veterans have a complex overlapping profile of real and perceived physical, mental, and social needs. A paradigm of disempowerment and deferred responsibility appears to exist between patients and providers that contributes to ineffective care transitions, resulting in readmissions. These results highlight the cultural constraints on systems of care and suggest that process improvements should focus on increasing the sense of partnership between patients and providers, while simultaneously creating a culture of empowerment, ownership, and engagement, to achieve success in reducing hospital readmissions. (Population Health Management 2013;16:326-331)
C1 [Stephens, Caroline; Sackett, Nathan; Moy, Nicholas; Lee, Sei J.] San Francisco VA Med Ctr, Div Geriatr Palliat & Extended Care, San Francisco, CA 94121 USA.
[Pierce, Read; Bachhuber, Melissa] San Francisco VA Med Ctr, Dept Hosp Med, San Francisco, CA 94121 USA.
[Schopfer, David] San Francisco VA Med Ctr, Dept Cardiol, San Francisco, CA 94121 USA.
[Schmajuk, Gabriela] San Francisco VA Med Ctr, Dept Rheumatol, San Francisco, CA 94121 USA.
[Stephens, Caroline; Schopfer, David; Schmajuk, Gabriela; Moy, Nicholas; Wallhagen, Margaret I.; Lee, Sei J.] San Francisco VA Med Ctr, Dept VA Qual Scholar, San Francisco, CA 94121 USA.
[Stephens, Caroline] Univ Calif San Francisco, San Francisco Sch Nursing, Dept Community Hlth Syst & Social & Behav Sci, San Francisco, CA 94143 USA.
[Wallhagen, Margaret I.] Univ Calif San Francisco, San Francisco Sch Nursing, Dept Physiol Nursing, San Francisco, CA 94143 USA.
[Stephens, Caroline] John A Hartford Fdn, San Francisco, CA USA.
[Sackett, Nathan] Univ Calif Berkeley, Berkeley, CA 94720 USA.
[Sackett, Nathan] Univ Calif San Francisco, Joint Med Program, San Francisco, CA 94143 USA.
[Pierce, Read; Bachhuber, Melissa] Univ Calif San Francisco, Div Hosp Med, San Francisco, CA 94143 USA.
[Schmajuk, Gabriela] Univ Calif San Francisco, Div Rheumatol, San Francisco, CA 94143 USA.
[Lee, Sei J.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA.
RP Stephens, C (reprint author), San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA.
EM caroline.stephens@ucsf.edu
FU Gordon & Betty Moore Foundation; California Health Care Foundation
FX The authors received the following financial support for the research,
authorship, and/or publication of this article: The Gordon & Betty Moore
Foundation and the California Health Care Foundation provided funding
for this project; the VA Quality Scholars program provided postdoctoral
training support for Drs. Stephens, Schopfer, Schmajuk, and Moy; the
John A. Hartford Foundation/Atlantic Philanthropies Claire M. Fagin
Fellows program provided postdoctoral training support for Dr Stephens.
NR 32
TC 4
Z9 5
U1 1
U2 7
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1942-7891
EI 1942-7905
J9 POPUL HEALTH MANAG
JI Popul. Health Manag.
PD OCT 1
PY 2013
VL 16
IS 5
BP 326
EP 331
DI 10.1089/pop.2012.0104
PG 6
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 216SU
UT WOS:000324305200008
PM 23560514
ER
PT J
AU Babson, KA
Heinz, AJ
Bonn-Miller, MO
AF Babson, Kimberly A.
Heinz, Adrienne J.
Bonn-Miller, Marcel O.
TI HIV Medication Adherence and HIV Symptom Severity: The Roles of Sleep
Quality and Memory
SO AIDS PATIENT CARE AND STDS
LA English
DT Article
ID ACTIVE ANTIRETROVIRAL THERAPY; AFRICAN-AMERICAN; UNITED-STATES;
SUBSTANCE USE; OF-LIFE; INFECTION; WOMEN; DEPRESSION; MORTALITY; ADULTS
AB The purpose of the current study was to examine the extent to which self-reported sleep quality, a clinically malleable factor, is associated with both HIV medication adherence and self-reported HIV symptom severity. In addition, we sought to examine whether sleep quality may explain the association between HIV medication adherence and symptom severity, as well as the role of self-reported memory functioning in terms of the above relations. This study took place from April 2010 to March 2012. Participants were 129 HIV-positive individuals who completed an ART pill count and series of structured clinical interviews and self-report questionnaires on sleep, memory, and HIV symptom severity. A series of regressions were conducted to test study hypotheses. After accounting for covariates (i.e., problematic alcohol, nicotine, and cannabis use, and mood disorder diagnosis), results indicated that self-reported sleep quality was associated with HIV medication adherence and self-reported HIV symptom severity, and that sleep quality partially mediated the relation between medication adherence and self-reported HIV symptom severity. In addition, memory functioning moderated the relation between self-reported sleep quality and HIV symptom severity, such that the interaction of poor sleep quality and relatively good memory functioning was associated with heightened self-reported HIV symptom severity. This study highlights the importance of assessing sleep and memory among HIV-infected individuals as they may represent treatment targets for those experiencing poor medication adherence or particularly severe HIV symptoms. Such information could lead to the inclusion of adjunct brief interventions to target sleep and memory functioning in order to reduce symptom severity among HIV-positive individuals with poor medication adherence.
C1 [Babson, Kimberly A.; Heinz, Adrienne J.; Bonn-Miller, Marcel O.] VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, Menlo Pk, CA 94025 USA.
[Bonn-Miller, Marcel O.] VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, Menlo Pk, CA 94025 USA.
[Babson, Kimberly A.; Heinz, Adrienne J.] Stanford Sch Med, Dept Psychiat & Behav Sci, Stanford, CA USA.
[Bonn-Miller, Marcel O.] Philadelphia VA Med Ctr, Ctr Excellence Subst Abuse Treatment & Educ, Philadelphia, PA USA.
[Bonn-Miller, Marcel O.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA.
RP Babson, KA (reprint author), VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, 795 Willow Rd,152-MPD, Menlo Pk, CA 94025 USA.
EM Kimberly.Babson@va.gov
FU California HIV/AIDS Research Program IDEA Award [163836]; VA Clinical
Science Research and Development (CSR&D) Career Development Award-2;
Health Services Research and Development Service funds
FX This work was supported, in part, by the following: A California
HIV/AIDS Research Program IDEA Award (163836; Bonn-Miller), a VA
Clinical Science Research and Development (CSR&D) Career Development
Award-2 (Bonn-Miller), and Health Services Research and Development
Service funds provided to Drs. Babson and Heinz. The expressed views do
not necessarily represent those of the Department of Veterans Affairs.
NR 58
TC 9
Z9 10
U1 1
U2 13
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1087-2914
J9 AIDS PATIENT CARE ST
JI Aids Patient Care STDS
PD OCT 1
PY 2013
VL 27
IS 10
BP 544
EP 552
DI 10.1089/apc.2013.0221
PG 9
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 229ME
UT WOS:000325268600003
PM 24032625
ER
PT J
AU Tellalian, D
Maznavi, K
Bredeek, UF
Hardy, WD
AF Tellalian, David
Maznavi, Khalid
Bredeek, U. Fritz
Hardy, W. David
TI Pre-Exposure Prophylaxis (PrEP) for HIV Infection: Results of a Survey
of HIV Healthcare Providers Evaluating Their Knowledge, Attitudes, and
Prescribing Practices
SO AIDS PATIENT CARE AND STDS
LA English
DT Article
ID POSTEXPOSURE PROPHYLAXIS; INTERIM GUIDANCE; PREVENTION; MEN;
IMPLEMENTATION; POPULATION; PERCEPTION; WOMEN; SEX; US
AB Antiretroviral medications can be taken by HIV-negative persons to prevent HIV infection, also known as pre-exposure prophylaxis (PrEP). PrEP was first shown to be effective during the iPrEX study. We conducted a survey involving HIV healthcare providers to document their attitudes and prescribing practices about PrEP in response to this study. An online survey was completed by 189 members and credentialees of the American Academy of HIV Medicine between April 2011 and September 2011. Ninety percent of respondents were familiar with the results of the iPrEx study, and most (78%) were familiar with CDC's interim guidance regarding the use of PrEP in MSM. Only 19% of respondents had prescribed PrEP. The majority of PrEP prescribers were compliant with CDC interim guidance; however, only 61% screened for hepatitis B. Of PrEP prescribers, 78% prescribed to MSM, 31% to MSW, and 28% to WSM. Greatest concerns about prescribing PrEP included development of antiretroviral resistance (32%), potential increase in high-risk behavior, (22%) and poor medication adherence (21%). Fifty-eight percent stated that HIV serodiscordance within a relationship most influenced their decision to prescribe PrEP to the HIV-seronegative partner. This study demonstrates that, despite awareness of the efficacy of PrEP, its use is limited. Survey participants used PrEP most commonly in MSM; however, a significant percentage also prescribed PrEP to women. The best candidate for PrEP is felt to be individuals in an HIV-serodiscordant relationship. Limitations to our study included a low response rate, changes in the evidence base, and the novelty of PrEP.
C1 [Tellalian, David; Hardy, W. David] Cedars Sinai Med Ctr, Dept Internal Med, Div Infect Dis, Los Angeles, CA 90048 USA.
[Maznavi, Khalid] Torrance Mem Med Ctr, Torrance, CA USA.
[Bredeek, U. Fritz] Metropolis Med, San Francisco, CA USA.
[Hardy, W. David] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Tellalian, D (reprint author), VA Greater Los Angeles, Infect Dis Sect IIIF, 11301 Wilshire Blvd,Bldg 500,Ste 4669, Los Angeles, CA 90073 USA.
EM dmtellalian@yahoo.com
NR 22
TC 44
Z9 44
U1 4
U2 15
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1087-2914
J9 AIDS PATIENT CARE ST
JI Aids Patient Care STDS
PD OCT 1
PY 2013
VL 27
IS 10
BP 553
EP 559
DI 10.1089/apc.2013.0173
PG 7
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 229ME
UT WOS:000325268600004
PM 24053478
ER
PT J
AU Froehlich, JC
Hausauer, BJ
Rasmussen, DD
AF Froehlich, Janice C.
Hausauer, Brett J.
Rasmussen, Dennis D.
TI Combining Naltrexone and Prazosin in a Single Oral Medication Decreases
Alcohol Drinking More Effectively Than Does Either Drug Alone
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
DE Alcoholism Treatment; Genetic Selection; Naltrexone; Prazosin
ID DEPENDENCE-INDUCED INCREASES; RANDOMIZED CONTROLLED-TRIAL; PREFERRING P
RATS; RECEPTOR ANTAGONIST; USE DISORDERS; ETHANOL; PREFERENCE; PLACEBO;
MODEL; BLOCKADE
AB BackgroundNaltrexone (NTX) is underutilized in clinical treatment settings because its efficacy is modest, and it is not effective for all alcoholics and, when it is effective, a significant number of alcoholics fail to maintain initial treatment gains and subsequently relapse to heavy drinking. This has slowed acceptance of NTX by the treatment community, and there is a clear need for additional treatments for alcoholism and alcohol use disorders. Given that NTX and prazosin can each reduce alcohol drinking in rats selectively bred for alcohol preference and high voluntary alcohol drinking (alcohol-preferring P rats), we tested whether a combination of NTX+prazosin is more effective in decreasing alcohol drinking than is either drug alone.
MethodsP rats were given access to a 15% (v/v) alcohol solution for 2hours daily. Rats were fed NTX and prazosin, alone or in combination, prior to onset of the daily 2-hour alcohol access period for 4weeks and the effect of drug treatment on alcohol and water intake was assessed.
ResultsDuring the first week of treatment, neither a low dose of NTX, nor prazosin, was effective in decreasing alcohol intake when each drug was administered alone, but combining the 2 drugs in a single medication significantly reduced alcohol intake. The combination was as effective as was a higher dose of NTX. Using a low dose of NTX in combination with prazosin may reduce the potential for undesirable side effects early in treatment which, in turn, may improve patient compliance and result in a more successful outcome when NTX is used for treating alcoholism and alcohol use disorders.
ConclusionsCombining low-dose NTX and prazosin in a single medication may be more useful than is either drug alone for treating both inpatient and outpatient alcoholics and heavy drinkers early in the treatment process.
C1 [Froehlich, Janice C.; Hausauer, Brett J.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA.
[Rasmussen, Dennis D.] VA Puget Sound Hlth Care Syst, VISN Mental Illness Res Educ & Clin Ctr 20, Seattle, WA USA.
Univ Washington, Seattle, WA 98195 USA.
RP Froehlich, JC (reprint author), Indiana Univ Sch Med, 975 West Walnut St IB 448, Indianapolis, IN 46202 USA.
EM jcfroehl@iupui.edu
FU NIH [AA018604, AA07611, AA13881]
FX We thank Dr. Ting-Kai Li and the Indiana Alcohol Research Center for
supplying the selectively bred rats used in this study. This study was
supported by NIH grants AA018604 (JCF and DDR), AA07611 (JCF), and
AA13881 (DDR). The content is solely the responsibility of the authors
and does not necessarily represent the official views of the National
Institute on Alcohol Abuse and Alcoholism or the National Institutes of
Health.
NR 55
TC 14
Z9 14
U1 1
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD OCT
PY 2013
VL 37
IS 10
BP 1763
EP 1770
DI 10.1111/acer.12148
PG 8
WC Substance Abuse
SC Substance Abuse
GA 229KR
UT WOS:000325263500017
PM 23875623
ER
PT J
AU Durazzo, TC
Pennington, DL
Schmidt, TP
Mon, A
Abe, C
Meyerhoff, DJ
AF Durazzo, Timothy C.
Pennington, David L.
Schmidt, Thomas P.
Mon, Anderson
Abe, Christoph
Meyerhoff, Dieter J.
TI Neurocognition in 1-Month-Abstinent Treatment-Seeking Alcohol-Dependent
Individuals: Interactive Effects of Age and Chronic Cigarette Smoking
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
DE Alcohol Use Disorders; Cigarette Smoking; Neurocognition; Alcohol
Dependence; Age
ID NATIONAL EPIDEMIOLOGIC SURVEY; DSM-IV ALCOHOL; PROCESSING SPEED;
COGNITIVE IMPAIRMENT; ABSTINENT ALCOHOLICS; FEMALE ALCOHOLICS;
UNITED-STATES; USE DISORDERS; CONSUMPTION; DEFICITS
AB BackgroundIncreasing age and chronic cigarette smoking are independently associated with adverse effects on multiple aspects of neurocognition in those seeking treatment for alcohol use disorders. However, the potential interactive effects of age and cigarette smoking on neurocognition in early abstinent alcohol-dependent individuals (ALC) have not investigated.
MethodsCross-sectional performances of never-smoking healthy comparison participants (nvsCOM; n=39) and 1-month-abstinent, treatment-seeking, never-smoking (nvsALC; n=30), former-smoking (fsALC; n=21), and actively smoking (asALC; n=68) ALC were compared on a comprehensive neurocognitive battery. Domains of functioning evaluated were cognitive efficiency, executive functions, fine motor skills, general intelligence, learning and memory, processing speed, visuospatial functions and working memory. Participants were between 26 and 71years of age at the time of assessment.
ResultsasALC showed steeper age-related effects than nvsCOM on the domains of visuospatial learning, auditory-verbal memory, cognitive efficiency, executive functions, processing speed, and fine motor skills. In pairwise comparisons, fsALC and asALC performed more poorly than both nvsCOM and nvsALC on multiple domains; nvsCOM and nvsALC showed no significant differences. Domain scores for the ALC groups generally fell in the low-to-high-average range of functioning. A clinically significant level of impairment was apparent in only 25% of ALC participants on visuospatial learning, visuospatial memory, and fine motor skills domains. Measures of alcohol use or consumption were not significantly related to neurocognition in the ALC cohorts.
ConclusionsThe age-related findings suggest that the combination of active chronic smoking and alcohol dependence in this 1-month-abstinent ALC cohort was associated with greater than normal age-related effects in multiple domains. In general, a low level of clinically significant impairment was observed in the alcohol-dependent participants. The findings from this study, in conjunction with previous research, strongly support smoking cessation interventions for those seeking treatment for alcohol and substance use disorders.
C1 [Durazzo, Timothy C.; Pennington, David L.; Schmidt, Thomas P.; Mon, Anderson; Abe, Christoph; Meyerhoff, Dieter J.] San Francisco VA Med Ctr, CIND, San Francisco, CA 94121 USA.
[Durazzo, Timothy C.; Pennington, David L.; Abe, Christoph; Meyerhoff, Dieter J.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA.
RP Durazzo, TC (reprint author), San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis 114 M, 4150 Clement St, San Francisco, CA 94121 USA.
EM timothy.durazzo@ucsf.edu
OI Abe, Christoph/0000-0002-1680-8480
FU National Institutes of Health [NIH DA24136, NIH AA10788]
FX We thank Mary Rebecca Young, Kathleen Altieri, Ricky Chen, and Drs.
Peter Banys and Ellen Herbst of the Veterans Administration Substance
Abuse Day Hospital, and Dr. David Pating, Karen Moise, and their
colleagues at CDRP for their valuable assistance in recruiting
participants. We also wish to extend our gratitude to the study
participants, who made this research possible. This work was supported
by the National Institutes of Health (NIH DA24136 to TCD and NIH AA10788
to DJM) and by the use of resources and facilities at the San Francisco
Veterans Administration Medical Center.
NR 51
TC 8
Z9 8
U1 1
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD OCT
PY 2013
VL 37
IS 10
BP 1794
EP 1803
DI 10.1111/acer.12140
PG 10
WC Substance Abuse
SC Substance Abuse
GA 229KR
UT WOS:000325263500021
PM 23682867
ER
PT J
AU Qaseem, A
Holty, JEC
Owens, DK
Dallas, P
Starkey, M
Shekelle, P
AF Qaseem, Amir
Holty, Jon-Erik C.
Owens, Douglas K.
Dallas, Paul
Starkey, Melissa
Shekelle, Paul
CA Amer Coll Phys
TI Management of Obstructive Sleep Apnea in Adults: A Clinical Practice
Guideline From the American College of Physicians
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID POSITIVE AIRWAY PRESSURE; RANDOMIZED CONTROLLED-TRIAL;
PLACEBO-CONTROLLED TRIAL; QUALITY-OF-LIFE; CONTROLLED CROSSOVER TRIAL;
TEMPERATURE-CONTROLLED-RADIOFREQUENCY; MANDIBULAR REPOSITIONING SPLINT;
CORONARY-ARTERY-DISEASE; CHRONIC HEART-FAILURE; 7-YEAR FOLLOW-UP
AB Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the management of obstructive sleep apnea (OSA) in adults.
Methods: This guideline is based on published literature from 1966 to September 2010 that was identified by using MEDLINE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews. A supplemental MEDLINE search identified additional articles through October 2012. Searches were limited to English-language publications. The clinical outcomes evaluated for this guideline included cardiovascular disease (such as heart failure, hypertension, stroke, and myocardial infarction), type 2 diabetes, death, sleep study measures (such as the Apnea-Hypopnea Index), measures of cardiovascular status (such as blood pressure), measures of diabetes status (such as hemoglobin A(1c) levels), and quality of life. This guideline grades the evidence and recommendations using ACP's clinical practice guidelines grading system.
Recommendation 1: ACP recommends that all overweight and obese patients diagnosed with OSA should be encouraged to lose weight. (Grade: strong recommendation; low-quality evidence)
Recommendation 2: ACP recommends continuous positive airway pressure treatment as initial therapy for patients diagnosed with OSA. (Grade: strong recommendation; moderate-quality evidence)
Recommendation 3: ACP recommends mandibular advancement devices as an alternative therapy to continuous positive airway pressure treatment for patients diagnosed with OSA who prefer mandibular advancement devices or for those with adverse effects associated with continuous positive airway pressure treatment. (Grade: weak recommendation; low-quality evidence)
C1 [Qaseem, Amir] Amer Coll Physicians, Philadelphia, PA 19106 USA.
Stanford Univ, Stanford, CA 94305 USA.
Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA.
Virginia Tech Univ, Caril Sch Med, Roanoke, VA USA.
W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA.
RP Qaseem, A (reprint author), Amer Coll Physicians, 190 N Independence Mall West, Philadelphia, PA 19106 USA.
EM aqaseem@acponline.org
FU ACP operating budget
FX Financial support for the development of this guideline comes
exclusively from the ACP operating budget.
NR 163
TC 52
Z9 56
U1 0
U2 18
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD OCT 1
PY 2013
VL 159
IS 7
BP 471
EP U94
DI 10.7326/00030003-4819-159-7-201310010-00704
PG 18
WC Medicine, General & Internal
SC General & Internal Medicine
GA 234FQ
UT WOS:000325628000005
PM 24061345
ER
PT J
AU Maciejewski, ML
Hanlon, JT
AF Maciejewski, Matthew L.
Hanlon, Joseph T.
TI Underreporting Potentially Inappropriate Prescribing for Older
Outpatients: Does It Matter?
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Editorial Material
ID BEERS CRITERIA; MEDICATION USE; ADULTS; PEOPLE
C1 [Maciejewski, Matthew L.] Duke Univ, Med Ctr, Ctr Hlth Serv Res Primary Care, Durham Vet Affairs Med Ctr, Durham, NC USA.
[Maciejewski, Matthew L.] Duke Univ, Med Ctr, Sch Med, Durham, NC 27710 USA.
[Hanlon, Joseph T.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
[Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot & Geriatr Res, Educ & Clin Ctr, Pittsburgh, PA USA.
RP Maciejewski, ML (reprint author), Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, 508 Fulton St,Mailstop 152, Durham, NC 27705 USA.
FU NIA NIH HHS [K07 AG033174]
NR 10
TC 0
Z9 0
U1 0
U2 2
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD OCT 1
PY 2013
VL 159
IS 7
BP 496
EP U113
DI 10.7326/00030003-4819-159-7-201310010-00012
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 234FQ
UT WOS:000325628000010
PM 24081290
ER
PT J
AU Chen, JQ
Bao, Y
Lee, J
Murray, JL
Litton, JK
Xiao, L
Zhou, R
Wu, Y
Shen, XY
Zhang, H
Sahin, AA
Katz, RL
Bondy, ML
Berinstein, NL
Hortobagyi, GN
Radvanyi, LG
AF Chen, J. Q.
Bao, Y.
Lee, J.
Murray, J. L.
Litton, J. K.
Xiao, L.
Zhou, R.
Wu, Y.
Shen, X. Y.
Zhang, H.
Sahin, A. A.
Katz, R. L.
Bondy, M. L.
Berinstein, N. L.
Hortobagyi, G. N.
Radvanyi, L. G.
TI Prognostic value of the trichorhinophalangeal syndrome-1 (TRPS-1), a
GATA family transcription factor, in early-stage breast cancer
SO ANNALS OF ONCOLOGY
LA English
DT Article
DE breast cancer; immunohistochemistry; prognostic marker; TRPS-1
ID TO-MESENCHYMAL TRANSITION; ESTROGEN-RECEPTOR; FINGER PROTEIN;
MAMMARY-GLAND; CLAUDIN-LOW; E-CADHERIN; EXPRESSION; GENE; SUBTYPES;
APOPTOSIS
AB TRPS-1 is a new GATA transcription factor that is differentially expressed in breast cancer (BC) where it been found recently to regulate epithelial-to-mesenchymal transition (EMT).
We carried out a quantitative immunohistochemistry (qIHC) analysis of TRPS-1 expression in 341 primary-stage I-III BC samples in relation to patient clinical characteristics as well as its prognostic value, especially in an estrogen receptor-positive (ER+) subgroup.
Higher TRPS-1 expression was significantly associated with a number of clinical and pathological characteristics as well as with improved overall survival (OS) and disease-free survival (DFS). Among stage I/II ER+ BC patients who received endocrine therapy alone, those with high TRPS-1 expression had significantly longer OS and DFS. There was also a strong association between TRPS-1 levels and the EMT marker E-cadherin in the ER+ invasive ductal carcinoma cases. Analysis of gene expression data on a panel of BC lines found that TRPS-1 expression was low or absent in BC lines having enriched mesenchymal features.
Our data indicated that TRPS-1 is an independent prognostic marker in early-stage BC and a new EMT marker that can distinguish patients with ER+ BC who will respond longer to adjuvant endocrine therapy.
C1 [Chen, J. Q.; Bao, Y.; Murray, J. L.; Litton, J. K.; Hortobagyi, G. N.; Radvanyi, L. G.] UT MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX USA.
[Chen, J. Q.; Bao, Y.; Radvanyi, L. G.] UT MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX USA.
[Lee, J.] UT MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX USA.
[Xiao, L.; Wu, Y.; Zhang, H.; Sahin, A. A.; Katz, R. L.] UT MD Anderson Canc Ctr, Dept Pathol, Houston, TX USA.
[Xiao, L.] Shanghai Huadong Hosp, Dept Pathol, Shanghai, Peoples R China.
[Zhou, R.; Bondy, M. L.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA.
[Shen, X. Y.] Baylor Coll Med, Vet Adm Hosp, Dept Pathol, Houston, TX 77030 USA.
[Berinstein, N. L.] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada.
RP Radvanyi, LG (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Dept Melanoma Med Oncol, Box 904,1515 Holcombe Blvd, Houston, TX 77030 USA.
EM lradvanyi@mdanderson.org
FU Sanofi Pasteur Canada; Susan G. Komen for the Cure [KG080061]; National
Institutes of Health (NIH) [1 P50 CA 116199-01, CA 16672]
FX This work was supported in part by a research grant from Sanofi Pasteur
Canada (LR), by Susan G. Komen for the Cure grant KG080061 (LR), and by
the National Institutes of Health (NIH) grant 1 P50 CA 116199-01 (Breast
Cancer SPORE grant), and NIH grant CA 16672 (Cancer Center Support
Grant).
NR 52
TC 4
Z9 4
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
J9 ANN ONCOL
JI Ann. Oncol.
PD OCT
PY 2013
VL 24
IS 10
BP 2534
EP 2542
DI 10.1093/annonc/mdt190
PG 9
WC Oncology
SC Oncology
GA 227ZI
UT WOS:000325153800012
PM 23729783
ER
PT J
AU Li, J
Yang, PA
Wu, Q
Li, H
Ding, YN
Hsu, HC
Spalding, DM
Mountz, JD
AF Li, Jun
Yang, PingAr
Wu, Qi
Li, Hao
Ding, Yanna
Hsu, Hui-Chen
Spalding, David M.
Mountz, John D.
TI Death Receptor 5-Targeted Depletion of Interleukin-23-Producing
Macrophages, Th17, and Th1/17 Associated With Defective Tyrosine
Phosphatase in Mice and Patients With Rheumatoid Arthritis
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article
ID COLONY-STIMULATING FACTOR; MOTH-EATEN MICE; COLLAGEN-INDUCED ARTHRITIS;
DR5 MONOCLONAL-ANTIBODY; CYTOKINE GM-CSF; T-CELLS; SYNOVIAL FIBROBLASTS;
EFFECTOR PHASE; T(H)17 CELLS; MUTANT MICE
AB ObjectiveBidirectional interactions between granulocyte-macrophage colony-stimulating factor-positive (GM-CSF+) T cells and interferon regulatory factor 5-positive (IRF-5+) macrophages play a major role in autoimmunity. In the absence of SH2 domain-containing phosphatase 1 (SHP-1), GM-CSF-stimulated cells are resistant to death receptor (DR)-mediated apoptosis. The objective of this study was to determine whether TRA-8, an anti-DR5 agonistic antibody, can eliminate inflammatory macrophages and CD4 T cells in the SHP-1-deficient condition.
MethodsUbiquitous Cre (Ubc.Cre) human/mouse-chimeric DR5-transgenic mice were crossed with viable SHP-1-defective motheaten (me(v)/me(v)) mice. TRA-8 was administered weekly for up to 4 weeks. The clinical scores, histopathologic severity, and macrophage and CD4 T cell phenotypes were evaluated. The role of TRA-8 in depleting inflammatory macrophages and CD4 T cells was also evaluated, using synovial fluid obtained from patients with rheumatoid arthritis (RA).
ResultsThe levels of inflammatory macrophages (interleukin-23-positive [IL-23+] IRF-5+) and CD4 T cells (IL-17+ GM-CSF+) were elevated in me(v)/me(v) mice. In DR5-transgenic me(v)/me(v) mice, DR5 expression was up-regulated in these 2 cell populations. TRA-8 treatment depleted these cell populations and resulted in a significant reduction in inflammation and in the titers of autoantibodies. In synovial cells from patients with RA, the expression of IRF5 and DR5 was negatively correlated with the expression of PTPN6. TRA-8, but not TRAIL, suppressed RA inflammatory macrophages and Th17 cells under conditions in which the expression of SHP-1 is low.
ConclusionIn contrast to TRAIL, which lacks the capability to counteract the survival signal in the absence of SHP-1, TRA-8 eliminated both IRF-5+ IL-23+ M1 macrophages and pathogenic GM-CSF+ IL-17+ CD4 T cells in a SHP-1-independent manner. The results of the current study suggest that TRA-8 can deplete inflammatory cell populations that result from a hyperactive GM-CSF/IRF-5 axis.
C1 [Li, Jun; Yang, PingAr; Wu, Qi; Li, Hao; Ding, Yanna; Hsu, Hui-Chen; Spalding, David M.; Mountz, John D.] Univ Alabama Birmingham, Birmingham, AL 35294 USA.
[Wu, Qi; Mountz, John D.] Birmingham VA Med Ctr, Birmingham, AL USA.
RP Mountz, JD (reprint author), Univ Alabama Birmingham, SHEL 307,1825 Univ Blvd, Birmingham, AL 35294 USA.
EM jdmountz@uab.edu
RI Li, Hao/N-7406-2015
OI Li, Hao/0000-0002-2171-8826
FU Arthritis Foundation; Lupus Research Institute; NIH [1R01-AI-083705,
1R01-AI-071110, P30-AR-48311, P30-AR-46031]; Rheumatology Research
Foundation grant; Daiichi Sankyo Company, Ltd.; Department of Veterans
Affairs [1I01BX000600-01]; University of Alabama at Birmingham Center
for Metabolic Bone Disease-Histomorphometry and Molecular Analysis Core
Laboratory
FX Supported by the Arthritis Foundation (grant to Dr. Li), the Lupus
Research Institute (grant to Dr. Hsu), the NIH (grants 1R01-AI-083705 to
Dr. Hsu and 1R01-AI-071110 to Dr. Mountz), a Rheumatology Research
Foundation grant to Dr. Mountz, Daiichi Sankyo Company, Ltd. (grant to
Dr. Mountz), and the Department of Veterans Affairs (Merit Review grant
1I01BX000600-01 to Dr. Mountz). Portions of the study were performed at
the University of Alabama at Birmingham Rheumatic Diseases Core Center
(Analytical Genomics and Transgenics Core, Comprehensive Flow Cytometry
Core, and Analytic Imaging and Immunoreagents Core), supported by NIH
grant P30-AR-48311, and the University of Alabama at Birmingham Center
for Metabolic Bone Disease-Histomorphometry and Molecular Analysis Core
Laboratory, supported by NIH grant P30-AR-46031.
NR 43
TC 6
Z9 6
U1 1
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
IS 10
BP 2594
EP 2605
DI 10.1002/art.38057
PG 12
WC Rheumatology
SC Rheumatology
GA 227TE
UT WOS:000325136600013
PM 23818173
ER
PT J
AU Anyanwu, CO
Ang, CC
Werth, VP
AF Anyanwu, Cynthia O.
Ang, Chia Chun
Werth, Victoria P.
TI Clinical Image: Oral mucosal involvement in bullous lupus
SO ARTHRITIS AND RHEUMATISM
LA English
DT Editorial Material
ID ERYTHEMATOSUS; RITUXIMAB
C1 [Anyanwu, Cynthia O.] Univ Penn, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
RP Anyanwu, CO (reprint author), Univ Penn, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
FU NIAMS NIH HHS [K24 AR002207]
NR 3
TC 2
Z9 4
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
IS 10
BP 2622
EP 2622
DI 10.1002/art.38051
PG 1
WC Rheumatology
SC Rheumatology
GA 227TE
UT WOS:000325136600016
PM 23780804
ER
PT J
AU Wang, JH
New, JS
Xie, ST
Yang, PA
Wu, Q
Li, J
Luo, B
Ding, YN
Druey, KM
Hsu, HC
Mountz, JD
AF Wang, John H.
New, James S.
Xie, Shutao
Yang, PingAr
Wu, Qi
Li, Jun
Luo, Bao
Ding, Yanna
Druey, Kirk M.
Hsu, Hui-Chen
Mountz, John D.
TI Extension of the Germinal Center Stage of B Cell Development Promotes
Autoantibodies in BXD2 Mice
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; CYCLIC CITRULLINATED PEPTIDE; INDUCED
CYTIDINE DEAMINASE; FOLLICULAR DENDRITIC CELLS; ANTIBODY CLASS SWITCH;
RHEUMATOID-ARTHRITIS; PATHOGENIC AUTOANTIBODIES; PLASMA-CELLS; HAPTEN
NP; T-CELLS
AB ObjectiveRegulator of G protein signaling (RGS) proteins inhibit chemokine signaling by desensitizing G protein-coupled receptor signals. This study was undertaken to determine the mechanisms by which RGS13 promotes the generation of pathogenic autoantibodies in germinal centers (GCs), using BXD2-Rgs13(-/-) mice.
MethodsConfocal and light microscopy imaging techniques were used to determine the location of cells that express RGS13 and activation-induced cytidine deaminase (AID) in the mouse spleen, and the number of plasmablasts. The levels of GC and plasma cell program transcripts in GC B cells were determined by real-time quantitative polymerase chain reaction (qPCR). Differential interleukin-17 (IL-17)-mediated expression of RGS13 in GC versus non-GC B cells was analyzed using A20 and 70Z/3 B cells.
ResultsIn the spleens of BXD2 mice, RGS13 was mainly expressed by GC B cells and was stimulated by IL-17 but not IL-21. IL-17 up-regulated RGS13 in A20 GC cells but not 70Z/3 non-GC B cells. BXD2- Rgs13(-/-) mice exhibited smaller GCs and lower AID levels, suggesting lower somatic hypermutation and affinity maturation. However, GC B cells from BXD2- Rgs13(-/-) mice showed increased levels of IgM(bright) plasmablasts, up-regulation of the genes encoding plasma program, including interferon regulatory factor 4, B lymphocyte-induced maturation protein 1, and X-box binding protein 1 and the p-CREB target genes Fosb and Obf1, and down-regulation of the GC program genes Aid, Pax5, and Bach2 compared to BXD2 mice. BXD2-Rgs13(-/-) mice had lower titers of IgG autoantibodies and IgG deposits in the glomeruli, suggesting reduced autoantibody pathogenicity.
ConclusionRGS13 deficiency is associated with a reduction in GC program genes and the exit of fewer pathogenic IgM plasmablasts in BXD2 mice. Our findings indicate that prolonged GC program, mediated by up-regulation of RGS13, enhances AID expression and enables the generation of pathogenic autoantibodies in autoreactive GCs.
C1 [Wang, John H.; New, James S.; Xie, Shutao; Yang, PingAr; Wu, Qi; Li, Jun; Luo, Bao; Ding, Yanna; Hsu, Hui-Chen; Mountz, John D.] Univ Alabama Birmingham, Birmingham, AL 35294 USA.
[Druey, Kirk M.] NIAID, NIH, Bethesda, MD 20892 USA.
[Mountz, John D.] Birmingham VA Med Ctr, Birmingham, AL USA.
RP Mountz, JD (reprint author), Univ Alabama Birmingham, SHEL 307,1825 Univ Blvd, Birmingham, AL 35294 USA.
EM jdmountz@uab.edu
FU NIH (National Institute of Allergy and Infectious Diseases)
[1-AI-071110, ARRA 3R01-AI-71110-02S1, 1R01-AI-083705]; NIH (National
Institute of Arthritis and Musculoskeletal and Skin Diseases)
[P30-AR-048311, P30-AI-027767]; NIH (National Institute of Allergy and
Infectious Diseases Intramural Research Program); Department of Veterans
Affairs [1I01BX000600-01]; Rheumatology Research Foundation; Alliance
for Lupus Research; Arthritis Foundation; Lupus Research Institute; NIH
[P30-AR-048311, P30-A-I027767]
FX Supported by the NIH (National Institute of Allergy and Infectious
Diseases grants 1-AI-071110, ARRA 3R01-AI-71110-02S1, and
1R01-AI-083705, National Institute of Arthritis and Musculoskeletal and
Skin Diseases grants P30-AR-048311 and P30-AI-027767, and the National
Institute of Allergy and Infectious Diseases Intramural Research
Program), the Department of Veterans Affairs (Merit Review grant
1I01BX000600-01), the Rheumatology Research Foundation (Within Our Reach
grant), the Alliance for Lupus Research, the Arthritis Foundation, and
the Lupus Research Institute. Flow cytometry and confocal imaging data
acquisition were performed at the University of Alabama at Birmingham
Comprehensive Flow Cytometry Core (supported by NIH grants P30-AR-048311
and P30-A-I027767) and Analytic Imaging and Immunoreagents Core
(supported by NIH grant P30-AR-048311).
NR 48
TC 9
Z9 9
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
IS 10
BP 2703
EP 2712
DI 10.1002/art.38059
PG 10
WC Rheumatology
SC Rheumatology
GA 227TE
UT WOS:000325136600026
PM 23818250
ER
PT J
AU Boekholdt, SM
Arsenault, BJ
Hovingh, GK
Mora, S
Pedersen, TR
LaRosa, JC
Welch, KMA
Amarenco, P
DeMicco, DA
Tonkin, AM
Sullivan, DR
Kirby, A
Colhoun, HM
Hitman, GA
Betteridge, DJ
Durrington, PN
Clearfield, MB
Downs, JR
Gotto, AM
Ridker, PM
Kastelein, JJP
AF Boekholdt, S. Matthijs
Arsenault, Benoit J.
Hovingh, G. Kees
Mora, Samia
Pedersen, Terje R.
LaRosa, John C.
Welch, K. M. A.
Amarenco, Pierre
DeMicco, David A.
Tonkin, Andrew M.
Sullivan, David R.
Kirby, Adrienne
Colhoun, Helen M.
Hitman, Graham A.
Betteridge, D. John
Durrington, Paul N.
Clearfield, Michael B.
Downs, John R.
Gotto, Antonio M., Jr.
Ridker, Paul M.
Kastelein, John J. P.
TI Levels and Changes of HDL Cholesterol and Apolipoprotein A-I in Relation
to Risk of Cardiovascular Events Among Statin-Treated Patients A
Meta-Analysis
SO CIRCULATION
LA English
DT Article
DE apolipoproteins; cardiovascular diseases; high-density lipoprotein
cholesterol; meta-analysis
ID DENSITY-LIPOPROTEIN CHOLESTEROL; RANDOMIZED CONTROLLED-TRIAL;
CORONARY-HEART-DISEASE; HIGH-DOSE ATORVASTATIN; PRIMARY PREVENTION; LDL
CHOLESTEROL; THERAPY; ATHEROSCLEROSIS; ASSOCIATION; SIMVASTATIN
AB Background It is unclear whether levels of high-density lipoprotein cholesterol (HDL-C) or apolipoprotein A-I (apoA-I) remain inversely associated with cardiovascular risk among patients who achieve very low levels of low-density lipoprotein cholesterol on statin therapy. It is also unknown whether a rise in HDL-C or apoA-I after initiation of statin therapy is associated with a reduced cardiovascular risk.
Methods and Results We performed a meta-analysis of 8 statin trials in which lipids and apolipoproteins were determined in all study participants at baseline and at 1-year follow-up. Individual patient data were obtained for 38153 trial participants allocated to statin therapy, of whom 5387 suffered a major cardiovascular event. HDL-C levels were associated with a reduced risk of major cardiovascular events (adjusted hazard ratio [HR], 0.83; 95% confidence interval [CI], 0.81-0.86 per 1 standard deviation increment), as were apoA-I levels (HR, 0.79; 95% CI, 0.72-0.82). This association was also observed among patients achieving on-statin low-density lipoprotein cholesterol levels <50 mg/dL. An increase of HDL-C was not associated with reduced cardiovascular risk (HR, 0.98; 95% CI, 0.94-1.01 per 1 standard deviation increment), whereas a rise in apoA-I was (HR, 0.93; 95% CI, 0.90-0.97).
Conclusions Among patients treated with statin therapy, HDL-C and apoA-I levels were strongly associated with a reduced cardiovascular risk, even among those achieving very low low-density lipoprotein cholesterol. An apoA-I increase was associated with a reduced risk of major cardiovascular events, whereas for HDL-C this was not the case. These findings suggest that therapies that increase apoA-I concentration require further exploration with regard to cardiovascular risk reduction.
C1 [Arsenault, Benoit J.; Hovingh, G. Kees; Kastelein, John J. P.] Univ Amsterdam, Acad Med Ctr, Dept Cardiol, NL-1105 AZ Amsterdam, Netherlands.
[Arsenault, Benoit J.; Hovingh, G. Kees; Kastelein, John J. P.] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands.
[Mora, Samia; Ridker, Paul M.] Brigham & Womens Hosp, Ctr Cardiovasc Dis Prevent, Boston, MA 02115 USA.
[Pedersen, Terje R.] Oslo Univ Hosp, Ctr Prevent Med, Ulleval, Norway.
[Pedersen, Terje R.] Univ Oslo, N-0316 Oslo, Norway.
[LaRosa, John C.] SUNY Hlth Sci Ctr, Brooklyn, NY USA.
[Welch, K. M. A.] Rosalind Franklin Univ Med & Sci, N Chicago, IL USA.
[Amarenco, Pierre] Hop Xavier Bichat, Dept Neurol, Paris, France.
[Amarenco, Pierre] Hop Xavier Bichat, Stroke Ctr, Paris, France.
[DeMicco, David A.] Global Pharmaceut Pfizer, New York, NY USA.
[Tonkin, Andrew M.] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia.
[Sullivan, David R.] Univ Sydney, Royal Prince Alfred Hosp, Dept Biochem, Sydney, NSW 2006, Australia.
[Sullivan, David R.] Univ Sydney, Royal Prince Alfred Hosp, Lipid Clin, Sydney, NSW 2006, Australia.
[Kirby, Adrienne] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW 2006, Australia.
[Colhoun, Helen M.] Univ Dundee, Med Res Inst, Dundee, Scotland.
[Hitman, Graham A.] Queen Mary Univ London, Barts & London Sch Med & Dent, Ctr Diabet, London, England.
[Betteridge, D. John] Royal Free & Univ Coll Med Sch, Dept Med, London WC1E 6BT, England.
[Durrington, Paul N.] Univ Manchester, Sch Biomed, Manchester, Lancs, England.
[Clearfield, Michael B.] Touro Univ, Mare Isl, CA USA.
[Downs, John R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Downs, John R.] South Texas Vet Hlth Care Syst, VERDICT, San Antonio, TX USA.
[Gotto, Antonio M., Jr.] Weill Cornell Med Coll, New York, NY USA.
RP Kastelein, JJP (reprint author), Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
EM j.j.kastelein@amc.uva.nl
RI Boekholdt, Matthijs/G-7562-2014
OI Colhoun, Helen/0000-0002-8345-3288
FU Veni grant from the Netherlands Organisation for Scientific Research
(NWO) [91612122)]; National Heart, Lung, and Blood Institute
[R01HL117861]
FX This study was not supported by any funding. The contributing trials
were funded by their respective sponsors. Dr Hovingh is funded by a Veni
grant (project number 91612122) from the Netherlands Organisation for
Scientific Research (NWO). Dr Mora is funded by a National Heart, Lung,
and Blood Institute grant (number R01HL117861). The sponsors of the
contributing trials provided the requested data. They did not play any
role in the statistical analysis, interpretation of the data, or the
decision to submit the manuscript. The views expressed in this article
are those of the authors and do not necessarily reflect the position or
policy of the Department of Veterans Affairs or the United States
government.
NR 31
TC 62
Z9 65
U1 4
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD OCT 1
PY 2013
VL 128
IS 14
BP 1504
EP 1512
DI 10.1161/CIRCULATIONAHA.113.002670
PG 9
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 228WB
UT WOS:000325221500011
PM 23965489
ER
PT J
AU Borrero, S
Farkas, A
Dehlendorf, C
Rocca, CH
AF Borrero, Sonya
Farkas, Amy
Dehlendorf, Christine
Rocca, Corinne H.
TI Racial and ethnic differences in men's knowledge and attitudes about
contraception
SO CONTRACEPTION
LA English
DT Article
DE Race; Disparities; Men; Contraception; Attitudes; Knowledge
ID DECISION-MAKING; UNITED-STATES; UNINTENDED PREGNANCY; YOUNG-ADULTS;
DISPARITIES; WOMEN
AB Background: Little is known about racial/ethnic differences in men's contraceptive knowledge and attitudes.
Study Design: We used multivariable logistic regression to examine racial/ethnic differences in contraceptive knowledge and attitudes among 903 men aged 18-29 in the 2009 National Survey of Reproductive and Contraceptive Knowledge.
Results: Black and Hispanic men were less likely than Whites to have heard of most contraceptive methods, including female and male sterilization, and also had lower knowledge about hormonal and long-acting reversible methods. They were less likely to know that pills are ineffective when 2-3 pills are missed [Blacks: adjusted odds ratio (aOR)=0.42; Hispanics: aOR=0.53] and that fertility was not delayed after stopping the pill (Blacks: aOR=0.52; Hispanics: aOR=0.27). Hispanics were less likely to know that nulliparous women can use the intrauterine device (aOR=0.47). Condom knowledge was similar by race/ethnicity, but Blacks were less likely to view condoms as a hassle than Whites (aOR=0.46).
Conclusions: Efforts to educate men, especially men of color, about contraceptive methods are needed. Published by Elsevier Inc.
C1 [Borrero, Sonya] Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA 15213 USA.
[Borrero, Sonya] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Farkas, Amy] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15213 USA.
[Dehlendorf, Christine] Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA.
[Dehlendorf, Christine; Rocca, Corinne H.] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, Bixby Ctr Global Reprod Hlth, San Francisco, CA 94143 USA.
RP Borrero, S (reprint author), Univ Pittsburgh, Ctr Res Hlth Care, 230 McKee Pl,Suite 600, Pittsburgh, PA 15213 USA.
EM borrerosp@upmc.edu
FU Eunice Kennedy Shriver National Institute of Child Health & Human
Development [1R21HD068736-01A1, K23HD067197]; National Campaign to
Prevent Teenage and Unplanned Pregnancy [1R21HD068736-01A1, K23HD067197]
FX This work was supported by grant numbers 1R21HD068736-01A1 and
K23HD067197 from the Eunice Kennedy Shriver National Institute of Child
Health & Human Development and the National Campaign to Prevent Teenage
and Unplanned Pregnancy. The content is solely the responsibility of the
authors and does not necessarily represent the official views of the
Eunice Kennedy Shriver National Institute of Child Health & Human
Development or the National Institutes of Health.
NR 32
TC 7
Z9 7
U1 4
U2 21
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0010-7824
J9 CONTRACEPTION
JI Contraception
PD OCT
PY 2013
VL 88
IS 4
BP 532
EP 538
DI 10.1016/j.contraception.2013.04.002
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 225PN
UT WOS:000324974900011
PM 23697702
ER
PT J
AU Bramoweth, AD
Germain, A
AF Bramoweth, Adam D.
Germain, Anne
TI Deployment-Related Insomnia in Military Personnel and Veterans
SO CURRENT PSYCHIATRY REPORTS
LA English
DT Article
DE Insomnia; Comorbid insomnia; Military personnel; Veterans; PTSD;
Depression; Anxiety; Traumatic brain injury; Suicide; Psychotherapy;
Pharmacotherapy; Sleep disorders; Psychiatry
ID TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; BRIEF BEHAVIORAL
TREATMENT; ADVERSE CHILDHOOD EXPERIENCES; SLEEP DISTURBANCES; COMBAT
VETERANS; CHRONIC NIGHTMARES; SERVICE MEMBERS; DEPRESSION; IRAQ
AB Insomnia is a prevalent disorder that greatly impacts military personnel, especially those deployed in support of combat efforts. Deployment-related stressors like combat exposure, mild traumatic brain injury (mTBI) irregular sleep-wake schedules, and adjustment to the return home all contribute to insomnia. However, insomnia can also exacerbate the deployment experience and is a risk factor for traumatic stress reactions such as PTSD, depression, and suicide. Military personnel with mTBI are significantly impacted by insomnia; the majority experience sleep disruption and this can impede recovery and rehabilitation. As more service members return home from deployment, treatment is vital to reduce the impact of insomnia. Preliminary outcome data, showing positive results for reduction of sleep disruption, has been found with treatments such as combined cognitive behavioral treatment of insomnia (CBTI) and imagery rehearsal therapy (IRT), preference-based interventions, as well as efforts to broadly disseminate CBTI. The recent literature on the impact and treatment of deployment-related insomnia is reviewed.
C1 [Bramoweth, Adam D.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Pittsburgh, PA 15206 USA.
[Bramoweth, Adam D.; Germain, Anne] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA.
[Germain, Anne] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA.
RP Germain, A (reprint author), Univ Pittsburgh, Sch Med, Dept Psychiat, 3811 OHara St,Sterling Plaza 239, Pittsburgh, PA 15213 USA.
EM adam.bramoweth@va.gov; germax@upmc.edu
OI Bramoweth, Adam/0000-0002-3535-0292
FU VISN 4 Mental Illness Research, Education and Clinical Center (MIRECC),
VA Pittsburgh Healthcare System; Congressionally Directed Medical
Research Program [PT073961 W81XWH-08-1-0637,
PR054093-W81XWH-07-PTSD-IIRA]; National Institute of Mental Health
[MH080696]
FX Dr. Bramoweth's work is supported by resources and funding from the VISN
4 Mental Illness Research, Education and Clinical Center (MIRECC,
Director: D. Oslin; Pittsburgh Site Director: G. Haas), VA Pittsburgh
Healthcare System. Dr. Germain's work is supported by the
Congressionally Directed Medical Research Program (PT073961
W81XWH-08-1-0637; PR054093-W81XWH-07-PTSD-IIRA) and the National
Institute of Mental Health (MH080696). The contents do not represent the
views of the Department of Veterans Affairs, Department of Defense, or
the United States Government.
NR 65
TC 14
Z9 15
U1 1
U2 18
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523-3812
J9 CURR PSYCHIAT REP
JI Curr. Psychiatry Rep.
PD OCT
PY 2013
VL 15
IS 10
AR 401
DI 10.1007/s11920-013-0401-4
PG 8
WC Psychiatry
SC Psychiatry
GA 224JI
UT WOS:000324880100003
PM 24005883
ER
PT J
AU Lu, H
Zhang, W
Graham, DY
AF Lu, Hong
Zhang, Wei
Graham, David Y.
TI Bismuth-containing quadruple therapy for Helicobacter pylori: lessons
from China
SO EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
LA English
DT Review
DE Helicobacter pylori; quadruple therapy; review; treatment; treatment
success
ID TRIPLE THERAPY; ANTIBIOTIC-RESISTANCE; DUODENAL-ULCER; PEPTIC-ULCER;
OPEN-LABEL; CURE RATE; IN-VITRO; ERADICATION; EFFICACY; INFECTION
AB Antimicrobial resistance has continued to undermine many popular anti-Helicobacter pylori therapies. Antibiotic resistance to commonly used anti-H. pylori drugs in China has increased markedly, making China an ideal site to identify regimens that remain effective despite widespread antimicrobial resistance. Bismuth is one of the few antimicrobials to which resistance does not develop. Factors contributing to H. pylori treatment success include host factors (e.g. genetic differences in the metabolism of the drugs used), bacterial factors (e.g. susceptibility), and details of the regimen (e.g. doses, dosing interval, dosing in relation to meals, formulation, etc.). We reviewed the recent experience in China with bismuth-containing quadruple therapies. The experience consists of 16 studies with 25 arms involving 1971 patients to identify successful regimens (defined as reliably obtaining 90% or greater eradication per protocol) deserving further study. Despite high rates of resistance to commonly used antimicrobials, several regimens could achieve high success. These were characteristically 14-day regimens containing a proton pump inhibitor and either tetracycline and metronidazole or furazolidone and amoxicillin. We propose approaches for further development including for optimization and simplification related to convenience and side effects (e.g. twice rather than three or four times daily or administration at the noon and evening meal instead of at breakfast and evening) while maintaining effectiveness of at least 90%. Studies in China identified regimens that were highly effective despite the high prevalence of resistance to metronidazole, fluoroquinolones, and macrolides. Multicenter randomized studies will be required to confirm which is the best.
C1 [Lu, Hong; Zhang, Wei] Shanghai Jiao Tong Univ, Key Lab Gastroenterol & Hepatol, Shanghai Inst Digest Dis, Sch Med,GI Div,Ren Ji Hosp,Minist Hlth, Shanghai 200030, Peoples R China.
[Graham, David Y.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA.
RP Graham, DY (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Med, RM 3A-322 111D,2002 Holcombe Blvd, Houston, TX 77030 USA.
EM dgraham@bcm.tmc.edu
FU Key Laboratory of Gastroenterology & Hepatology, Ministry of Health
(Renji Hospital, Shanghai Jiao-Tong University School of Medicine);
National Natural Science Foundation of China [81170355, 81200287];
Office of Research and Development Medical Research Service Department
of Veterans Affairs, Public Health Service Grant [DK56338, DK067366,
CA116845]
FX This study was supported by the grant for Key Laboratory of
Gastroenterology & Hepatology, Ministry of Health (Renji Hospital,
Shanghai Jiao-Tong University School of Medicine), and the National
Natural Science Foundation of China (81170355, 81200287). Dr Graham is
supported in part by the Office of Research and Development Medical
Research Service Department of Veterans Affairs, Public Health Service
Grant DK56338, which funds the Texas Medical Center Digestive Diseases
Center, DK067366 and CA116845.
NR 58
TC 21
Z9 24
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0954-691X
J9 EUR J GASTROEN HEPAT
JI Eur. J. Gastroenterol. Hepatol.
PD OCT
PY 2013
VL 25
IS 10
BP 1134
EP 1140
DI 10.1097/MEG.0b013e3283633b57
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 219SX
UT WOS:000324530800002
PM 23778309
ER
PT J
AU Win, AZ
Aparici, CM
AF Win, Aung Zaw
Aparici, Carina Mari
TI Real-time FDG PET/CT-guided bone biopsy in a patient with two primary
malignancies
SO EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
LA English
DT Editorial Material
C1 [Win, Aung Zaw] San Francisco VA Med Ctr, Nucl Med Sect, Dept Radiol, San Francisco, CA 94121 USA.
[Aparici, Carina Mari] Univ Calif San Francisco, Dept Radiol, Nucl Med Sect, San Francisco, CA 94143 USA.
RP Win, AZ (reprint author), San Francisco VA Med Ctr, Nucl Med Sect, Dept Radiol, 4150 Clement St, San Francisco, CA 94121 USA.
EM aungzwin@gmail.com
NR 4
TC 3
Z9 3
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1619-7070
J9 EUR J NUCL MED MOL I
JI Eur. J. Nucl. Med. Mol. Imaging
PD OCT
PY 2013
VL 40
IS 11
BP 1787
EP 1788
DI 10.1007/s00259-013-2492-x
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 227QO
UT WOS:000325128800017
PM 23828652
ER
PT J
AU LaVela, SL
Gering, J
Schectman, G
Locatelli, SM
Weaver, FM
Davies, M
AF LaVela, Sherri L.
Gering, Jeffrey
Schectman, Gordon
Locatelli, Sara M.
Weaver, Frances M.
Davies, Michael
TI Improving the quality of telephone-delivered health care: a national
quality improvement transformation initiative
SO FAMILY PRACTICE
LA English
DT Article
DE Health communication; health care delivery; primary health care; patient
preference; patient-centred care; quality improvement
ID PATIENT SATISFACTION; CONSULTATION; INFORMATION; CALLERS; VETERAN;
ADVICE; ACCESS
AB Many Veterans Affairs (VA) primary care (PC) patients prefer telephone-delivered care to other health care delivery modalities.
To evaluate PC patients telephone experiences and outcomes before and after a national telephone transformation quality improvement (QI) collaborative.
Cross-sectional surveys were conducted pre- and post-collaborative. We used bivariate analyses to assess differences in pre/post outcomes and multivariate regression to identify variables associated with patients perceptions of poor quality care.
Patients from 13 VA facilities participated (n 730; pre-intervention 314, post-intervention 416); most of them were males (90%) with a mean age of 62 years. After the collaborative (versus pre-collaborative), few experienced transfers (52% versus 62%, P 0.0006) and most reported timely call answer (88% versus 80%, P 0.003). Improvements in staff understanding why patients were calling and providing needed medical information were also found. There were measurable improvements in patient satisfaction (87% versus 82% very/mostly satisfied, P 0.04) and perceived quality of telephone care (85% versus 78% excellent/good quality, P 0.01) post- collaborative. The proportion of veterans who reported delayed care due to telephone access issues decreased from 41% to 15% after the collaborative, P < 0.0001. Perceptions of poor quality care were higher when calls were for urgent care needs did not result in receipt of needed information and included a transfer or untimely answer.
The QI collaborative led to improvements in timeliness of answering calls, patient satisfaction and perceptions of high-quality telephone care and fewer reports of health care delays. Barriers to optimal telephone care quality include untimely answer, transfers, non-receipt of needed information and urgent care needs.
C1 [LaVela, Sherri L.; Locatelli, Sara M.; Weaver, Frances M.] US Dept Vet Affairs, Ctr Management Complex Chron Care, Edward Hines Jr VA Hosp, Hines, IL 60141 USA.
[LaVela, Sherri L.] Northwestern Univ, Feinberg Sch Med, Inst Publ Hlth & Med, Ctr Healthcare Studies, Chicago, IL 60611 USA.
[Gering, Jeffrey] Chillicothe Vet Affairs Med Ctr, Chillicothe, OH USA.
[Gering, Jeffrey] Ohio Univ, Chillicothe, OH USA.
[Schectman, Gordon] Vet Affairs Cent Off, Off Patient Care Serv, Washington Dc, CO USA.
[Schectman, Gordon] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA.
[Weaver, Frances M.] Loyola Univ, Stritch Sch Med, Program Hlth Serv Res, Maywood, IL 60153 USA.
[Davies, Michael] Vet Affairs Cent Off, Off Syst Redesign, Washington Dc, CO USA.
RP LaVela, SL (reprint author), US Dept Vet Affairs, Ctr Management Complex Chron Care, 5000 S 5th Ave,151H, Hines, IL 60141 USA.
EM Sherri.LaVela@va.gov
FU Office of Systems Redesign of the Department of Veterans Affairs
FX The authors wish to thank the PC patients who participated in this
study. This material is based upon work supported by the Office of
Systems Redesign of the Department of Veterans Affairs. This paper
reflects only the authors' opinions and does not necessarily reflect the
official position of the Department of Veterans Affairs. A portion of
these findings were presented as a poster at the VA HSR&D 2012 annual
meeting.
NR 24
TC 2
Z9 2
U1 2
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0263-2136
J9 FAM PRACT
JI Fam. Pr.
PD OCT
PY 2013
VL 30
IS 5
BP 533
EP 540
DI 10.1093/fampra/cmt020
PG 8
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA 228KF
UT WOS:000325184200009
PM 23689516
ER
PT J
AU Mayer, CL
Huber, BR
Peskind, E
AF Mayer, Cynthia L.
Huber, Bertrand R.
Peskind, Elaine
TI Traumatic Brain Injury, Neuroinflammation, and Post-Traumatic Headaches
SO HEADACHE
LA English
DT Review
DE traumatic brain injury; inflammation; glia; microglia; astrocytes;
satellite cells; blood brain barrier; cytokines; post-traumatic
headaches; inflammatory mediators
ID CENTRAL-NERVOUS-SYSTEM; SATELLITE GLIAL-CELLS; CORTICAL SPREADING
DEPRESSION; DIFFUSE AXONAL INJURY; TUMOR-NECROSIS-FACTOR; CHRONIC PAIN;
HEAD-INJURY; INFLAMMATORY RESPONSE; NEUROPATHIC PAIN; CERVICOGENIC
HEADACHE
AB Concussions following head and/or neck injury are common, and although most people with mild injuries recover uneventfully, a subset of individuals develop persistent post-concussive symptoms that often include headaches. Post-traumatic headaches vary in presentation and may progress to become chronic and in some cases debilitating. Little is known about the pathogenesis of post-traumatic headaches, although shared pathophysiology with that of the brain injury is suspected. Following primary injury to brain tissues, inflammation rapidly ensues; while this inflammatory response initially provides a defensive/reparative function, it can persist beyond its beneficial effect, potentially leading to secondary injuries because of alterations in neuronal excitability, axonal integrity, central processing, and other changes. These changes may account for the neurological symptoms often observed after traumatic brain injury, including headaches. This review considers selected aspects of the inflammatory response following traumatic brain injury, with an emphasis on the role of glial cells as mediators of maladaptive post-traumatic inflammation.
C1 [Mayer, Cynthia L.; Huber, Bertrand R.; Peskind, Elaine] VA Puget Sound Hlth Care Syst, VA Northwest Network Mental Illness Res Educ & Cl, Seattle, WA 98108 USA.
[Mayer, Cynthia L.; Peskind, Elaine] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
RP Mayer, CL (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,S116 MIRECC, Seattle, WA 98108 USA.
EM cmayer@u.washington.edu
FU NIA NIH HHS [P50 AG005136]
NR 143
TC 27
Z9 28
U1 0
U2 37
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0017-8748
EI 1526-4610
J9 HEADACHE
JI Headache
PD OCT
PY 2013
VL 53
IS 9
BP 1523
EP 1530
DI 10.1111/head.12173
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA 228AH
UT WOS:000325156600020
PM 24090534
ER
PT J
AU Chapman, LW
Hsiao, JL
Lewis, M
Chiu, MW
Shellow, WVR
AF Chapman, Lance W.
Hsiao, Jennifer L.
Lewis, Michael
Chiu, Melvin W.
Shellow, William V. R.
TI Progressive violaceous nodules and plaques in an elderly man
SO INTERNATIONAL JOURNAL OF DERMATOLOGY
LA English
DT Article
C1 [Chapman, Lance W.; Hsiao, Jennifer L.; Chiu, Melvin W.] Univ Calif Los Angeles, David Geffen Sch Med, Div Dermatol, Los Angeles, CA 90095 USA.
[Lewis, Michael] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Pathol, Los Angeles, CA USA.
[Lewis, Michael] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Lab Med, Los Angeles, CA USA.
[Chiu, Melvin W.; Shellow, William V. R.] Vet Affairs West Los Angeles Healthcare Ctr, Dept Dermatol, Los Angeles, CA USA.
RP Chiu, MW (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Dermatol, Dept Med, 200 Med Plaza,Suite 450, Los Angeles, CA 90095 USA.
EM mchiu@mednet.ucla.edu
NR 7
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0011-9059
J9 INT J DERMATOL
JI Int. J. Dermatol.
PD OCT
PY 2013
VL 52
IS 10
BP 1165
EP 1167
DI 10.1111/ijd.12141
PG 3
WC Dermatology
SC Dermatology
GA 227EA
UT WOS:000325090800001
PM 23834652
ER
PT J
AU Dubsky, M
Jirkovska, A
Bem, R
Fejfarova, V
Skibova, J
Schaper, NC
Lipsky, BA
AF Dubsky, Michal
Jirkovska, Alexandra
Bem, Robert
Fejfarova, Vladimira
Skibova, Jelena
Schaper, Nicolaas C.
Lipsky, Benjamin A.
TI Risk factors for recurrence of diabetic foot ulcers: prospective
follow-up analysis in the Eurodiale subgroup
SO INTERNATIONAL WOUND JOURNAL
LA English
DT Article
DE Diabetic foot ulcer; Risk factors for reulceration; Ulcer recurrence
ID PERIPHERAL ARTERIAL-DISEASE; COHORT; INFECTION; PEOPLE; CARE;
POPULATION; ULCERATION; AMPUTATION; CONSENSUS; ISCHEMIA
AB Few studies have examined factors associated with diabetic foot ulcer (DFU) recurrence. Using data from patients enrolled in the prospective Eurodiale DFU study, we investigated the frequency of and risk factors for DFU recurrence after healing during a 3-year follow-up period. At our site, 93 Eurodiale-enrolled patients had a healed DFU. Among these, 14 were not alive; of the remaining 79 patients we enrolled 73 in this study. On entry to the Eurodiale study, we assessed demographic factors (age, sex and distance from hospital); diabetes-related factors [duration, and glycated haemoglobin (HbA1c) levels]; comorbidities (obesity, renal failure, smoking and alcohol abuse) and DFU-related factors [peripheral arterial disease, ulcer infection, C-reactive protein (CRP) and; foot deformities]. During the 3-year follow-up period, a DFU had recurred in 42 patients (575%). By stepwise logistic regression of findings at initial DFU presentation, the significant independent predictors for recurrence were plantar ulcer location [odds ratio (OR) 862, 95% confidence interval (CI) 22-332]; presence of osteomyelitis (OR 517, 95% CI 14-187); HbA1c > 75% ([DCCT], OR 407, 95% CI 11-156) and CRP > 5 mg/l (OR 427, 95% CI 12-157). In these patients with a healed DFU, the majority had a recurrence of DFU during a 3-year follow-up period, despite intensive foot care. The findings at diagnosis of the initial DFU were independent risk factors associated with ulcer recurrence (plantar location, bone infection, poor diabetes control and elevated CRP) and define those at high risk for recurrence, but may be amenable to targeted interventions.
C1 [Dubsky, Michal; Jirkovska, Alexandra; Bem, Robert; Fejfarova, Vladimira; Skibova, Jelena] Inst Clin & Expt Med, Ctr Diabet, Prague 14021 4, Czech Republic.
[Schaper, Nicolaas C.] Univ Hosp Maastricht, Dept Internal Med, Maastricht, Netherlands.
[Lipsky, Benjamin A.] Univ Washington, Dept Med, Gen Med Serv, VA Puget Sound Hlth Care Syst, Seattle, WA USA.
RP Dubsky, M (reprint author), Inst Clin & Expt Med, Ctr Diabet, Videnska 1958-9, Prague 14021 4, Czech Republic.
EM michal.dubsky@gmail.com
RI Schaper, Nicolaas/E-7112-2014
OI Lipsky, Benjamin A./0000-0001-9886-5114
FU [MZO 00023001]
FX We thank the members of Eurodiale group for realisation of first step of
the study: L. Prompers, M. Huijberts, J. Apelqvist, E. Jude, A.
Piaggesi, K. Bakker, M. Edmonds, P. Holstein, D. Mauricio, G. Ragnarson
Tennvall, H. Reike, M. Spraul, L. Uccioli, V. Urbancic, K. Van Acker, J.
van Baal and F. van Merode. This research was supported by grant MZO
00023001. The authors do not have any competing interests.
NR 33
TC 25
Z9 31
U1 0
U2 19
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1742-4801
J9 INT WOUND J
JI Int. Wound J.
PD OCT
PY 2013
VL 10
IS 5
BP 555
EP 561
DI 10.1111/j.1742-481X.2012.01022.x
PG 7
WC Dermatology; Surgery
SC Dermatology; Surgery
GA 227DW
UT WOS:000325090300013
PM 22712631
ER
PT J
AU Erickson, MA
Banks, WA
AF Erickson, Michelle A.
Banks, William A.
TI Blood-brain barrier dysfunction as a cause and consequence of
Alzheimer's disease
SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
LA English
DT Review
DE Alzheimer's disease; blood-brain barrier; cerebrospinal fluid; diabetes;
inflammation; neurovascular unit
ID AMYLOID-BETA-PROTEIN; CEREBROSPINAL-FLUID BARRIER; RECEPTOR-RELATED
PROTEIN-1; ENDOTHELIAL GROWTH-FACTOR; CENTRAL-NERVOUS-SYSTEM; MILD
COGNITIVE IMPAIRMENT; INDUCED DIABETIC MICE; WHITE-MATTER LESIONS;
SMOOTH-MUSCLE-CELLS; P-GLYCOPROTEIN
AB The blood-brain barrier (BBB) plays critical roles in the maintenance of central nervous system (CNS) homeostasis. Dysfunction of the BBB occurs in a number of CNS diseases, including Alzheimer's disease (AD). A prevailing hypothesis in the AD field is the amyloid cascade hypothesis that states that amyloid-beta (A beta) deposition in the CNS initiates a cascade of molecular events that cause neurodegeneration, leading to AD onset and progression. In this review, the participation of the BBB in the amyloid cascade and in other mechanisms of AD neurodegeneration will be discussed. We will specifically focus on three aspects of BBB dysfunction: disruption, perturbation of transporters, and secretion of neurotoxic substances by the BBB. We will also discuss the interaction of the BBB with components of the neurovascular unit in relation to AD and the potential contribution of AD risk factors to aspects of BBB dysfunction. From the results discussed herein, we conclude that BBB dysfunction contributes to AD through a number of mechanisms that could be initiated in the presence or absence of A beta pathology.
C1 [Erickson, Michelle A.; Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA.
[Erickson, Michelle A.; Banks, William A.] Univ Washington, Sch Med, Dept Internal Med, Div Gerontol & Geriatr Med, Seattle, WA 98108 USA.
[Erickson, Michelle A.] Univ Penn, Sch Dent Med, Dept Pathol, Seattle, WA USA.
RP Banks, WA (reprint author), Univ Washington, Sch Med, Dept Internal Med, Div Gerontol & Geriatr Med, Bldg 1,Room 810A,1660 Columbian Way, Seattle, WA 98108 USA.
EM wabanks1@uw.edu
FU NIEHS NIH HHS [T32 ES019851]
NR 237
TC 108
Z9 113
U1 5
U2 55
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0271-678X
EI 1559-7016
J9 J CEREBR BLOOD F MET
JI J. Cereb. Blood Flow Metab.
PD OCT
PY 2013
VL 33
IS 10
BP 1500
EP 1513
DI 10.1038/jcbfm.2013.135
PG 14
WC Endocrinology & Metabolism; Hematology; Neurosciences
SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology
GA 228PV
UT WOS:000325199600004
PM 23921899
ER
PT J
AU Lin, AL
Pulliam, DA
Deepa, SS
Halloran, JJ
Hussong, SA
Burbank, RR
Bresnen, A
Liu, YH
Podlutskaya, N
Soundararajan, A
Muir, E
Duong, TQ
Bokov, AF
Viscomi, C
Zeviani, M
Richardson, AG
Van Remmen, H
Fox, PT
Galvan, V
AF Lin, Ai-Ling
Pulliam, Daniel A.
Deepa, Sathyaseelan S.
Halloran, Jonathan J.
Hussong, Stacy A.
Burbank, Raquel R.
Bresnen, Andrew
Liu, Yuhong
Podlutskaya, Natalia
Soundararajan, Anuradha
Muir, Eric
Duong, Timothy Q.
Bokov, Alex F.
Viscomi, Carlo
Zeviani, Massimo
Richardson, Arlan G.
Van Remmen, Holly
Fox, Peter T.
Galvan, Veronica
TI Decreased in vitro mitochondrial function is associated with enhanced
brain metabolism, blood flow, and memory in Surf1-deficient mice
SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
LA English
DT Article
DE glucose metabolism; memory; mitochondrial complex IV; mitochondrial
dysfunction; Surf1
ID ELEGANS LIFE-SPAN; CAENORHABDITIS-ELEGANS; OXIDATIVE STRESS; BINDING
PROTEIN; FACTOR 1-ALPHA; RESPIRATION; SENSITIVITY; ANESTHESIA;
INCREASES; LONGEVITY
AB Recent studies have challenged the prevailing view that reduced mitochondrial function and increased oxidative stress are correlated with reduced longevity. Mice carrying a homozygous knockout (KO) of the Surf1 gene showed a significant decrease in mitochondrial electron transport chain Complex IV activity, yet displayed increased lifespan and reduced brain damage after excitotoxic insults. In the present study, we examined brain metabolism, brain hemodynamics, and memory of Surf1 KO mice using in vitro measures of mitochondrial function, in vivo neuroimaging, and behavioral testing. We show that decreased respiration and increased generation of hydrogen peroxide in isolated Surf1 KO brain mitochondria are associated with increased brain glucose metabolism, cerebral blood flow, and lactate levels, and with enhanced memory in Surf1 KO mice. These metabolic and functional changes in Surf1 KO brains were accompanied by higher levels of hypoxia-inducible factor 1 alpha, and by increases in the activated form of cyclic AMP response element-binding factor, which is integral to memory formation. These findings suggest that Surf1 deficiency-induced metabolic alterations may have positive effects on brain function. Exploring the relationship between mitochondrial activity, oxidative stress, and brain function will enhance our understanding of cognitive aging and of age-related neurologic disorders.
C1 [Lin, Ai-Ling; Bresnen, Andrew; Soundararajan, Anuradha; Muir, Eric; Duong, Timothy Q.; Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA.
[Lin, Ai-Ling; Pulliam, Daniel A.; Deepa, Sathyaseelan S.; Halloran, Jonathan J.; Hussong, Stacy A.; Burbank, Raquel R.; Liu, Yuhong; Podlutskaya, Natalia; Bokov, Alex F.; Richardson, Arlan G.; Van Remmen, Holly; Galvan, Veronica] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA.
[Lin, Ai-Ling; Pulliam, Daniel A.; Deepa, Sathyaseelan S.; Liu, Yuhong; Podlutskaya, Natalia; Bokov, Alex F.; Richardson, Arlan G.; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78245 USA.
[Halloran, Jonathan J.; Hussong, Stacy A.; Burbank, Raquel R.; Podlutskaya, Natalia; Duong, Timothy Q.; Fox, Peter T.; Galvan, Veronica] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78245 USA.
[Viscomi, Carlo; Zeviani, Massimo] Ist Neurol C Besta, Mol Neurogenet Unit, Milan, Italy.
[Richardson, Arlan G.; Van Remmen, Holly] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA.
[Richardson, Arlan G.; Van Remmen, Holly] South Texas Vet Hlth Care Syst, Res Serv, San Antonio, TX USA.
RP Galvan, V (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, 15355 Lambda Dr, San Antonio, TX 78245 USA.
EM lina3@uthscsa.edu; galvanv@uthscsa.edu
RI Duong, Timothy/B-8525-2008; Zeviani, Massimo/K-2891-2014; Fox,
Peter/B-4725-2010; Viscomi, Carlo/R-1940-2016
OI Fox, Peter/0000-0002-0465-2028;
FU Ellison Medical Foundation; William and Ella Owens Medical Research
Foundation; CTSA/KL2 [UL1TR000149]; NIA [K01AG040164, T32AG21890]
FX This work was supported by an Ellison Medical Foundation Senior Scholar
Award in Aging and a New Scholar Award in Aging to HVR and VG,
respectively, a William and Ella Owens Medical Research Foundation Grant
to VG, and by CTSA/KL2 (UL1TR000149) and an NIA grant K01AG040164 to
ALL. SAH is supported by NIA Training Grant T32AG21890.
NR 33
TC 13
Z9 13
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0271-678X
J9 J CEREBR BLOOD F MET
JI J. Cereb. Blood Flow Metab.
PD OCT
PY 2013
VL 33
IS 10
BP 1605
EP 1611
DI 10.1038/jcbfm.2013.116
PG 7
WC Endocrinology & Metabolism; Hematology; Neurosciences
SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology
GA 228PV
UT WOS:000325199600015
PM 23838831
ER
PT J
AU Goetz, MB
Hoang, T
Knapp, H
Burgess, J
Fletcher, MD
Gifford, AL
Asch, SM
AF Goetz, Matthew Bidwell
Tuyen Hoang
Knapp, Herschel
Burgess, Jane
Fletcher, Michael D.
Gifford, Allen L.
Asch, Steven M.
CA QUERI-HIV-Hepatitis Program
TI Central Implementation Strategies Outperform Local Ones in Improving HIV
Testing in Veterans Healthcare Administration Facilities
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE HIV/AIDS; implementation research; quality improvement; diagnosis
ID UNITED-STATES; PRACTICE GUIDELINES; COST-EFFECTIVENESS; FEEDBACK; AUDIT;
ADOLESCENTS; REMINDERS; SETTINGS; ADULTS; TRIAL
AB Pilot data suggest that a multifaceted approach may increase HIV testing rates, but the scalability of this approach and the level of support needed for successful implementation remain unknown.
To evaluate the effectiveness of a scaled-up multi-component intervention in increasing the rate of risk-based and routine HIV diagnostic testing in primary care clinics and the impact of differing levels of program support.
Three arm, quasi-experimental implementation research study.
Veterans Health Administration (VHA) facilities.
Persons receiving primary care between June 2009 and September 2011
A multimodal program, including a real-time electronic clinical reminder to facilitate HIV testing, provider feedback reports and provider education, was implemented in Central and Local Arm Sites; sites in the Central Arm also received ongoing programmatic support. Control Arm sites had no intervention
Frequency of performing HIV testing during the 6 months before and after implementation of a risk-based clinical reminder (phase I) or routine clinical reminder (phase II).
The adjusted rate of risk-based testing increased by 0.4 %, 5.6 % and 10.1 % in the Control, Local and Central Arms, respectively (all comparisons, p < 0.01). During phase II, the adjusted rate of routine testing increased by 1.1 %, 6.3 % and 9.2 % in the Control, Local and Central Arms, respectively (all comparisons, p < 0.01). At study end, 70-80 % of patients had been offered an HIV test.
Use of clinical reminders, provider feedback, education and social marketing significantly increased the frequency at which HIV testing is offered and performed in VHA facilities. These findings support a multimodal approach toward achieving the goal of having every American know their HIV status as a matter of routine clinical practice.
C1 [Goetz, Matthew Bidwell] VA Greater Los Angeles Healthcare Syst, Infect Dis Sect 111F, Los Angeles, CA 90073 USA.
[Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Tuyen Hoang; Knapp, Herschel; Burgess, Jane; Fletcher, Michael D.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Gifford, Allen L.] Edith Nourse Rogers Mem Vet Hosp, VA Bedford Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA.
[Gifford, Allen L.] Boston Univ, Sch Publ Hlth, Boston, MA USA.
[Gifford, Allen L.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Asch, Steven M.] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA.
[Asch, Steven M.] Stanford Univ, Sch Med, Div Gen Med Disciplines, Palo Alto, CA 94304 USA.
RP Goetz, MB (reprint author), VA Greater Los Angeles Healthcare Syst, Infect Dis Sect 111F, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM mgoetz@ucla.edu
OI Goetz, Matthew/0000-0003-4542-992X
FU Health Services Research & Development Service [SDP 08-002]
FX We acknowledge and are grateful for the invaluable support for this
project that was provided by Ana Goffin, Barbara Kertz, Thomas Giordano,
MD, and Scott Sherman, MD, MPH, as well as the providers and leadership
in the many VHA medical facilities that participated in this study. This
project was supported by a research grant to Drs. Goetz and Asch by the
Health Services Research & Development Service (SDP 08-002).
NR 37
TC 14
Z9 14
U1 2
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD OCT
PY 2013
VL 28
IS 10
BP 1311
EP 1317
DI 10.1007/s11606-013-2420-6
PG 7
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 226DP
UT WOS:000325015000015
PM 23605307
ER
PT J
AU Steinhilber, S
Rodriguez, JM
Estrada, CA
Kraemer, RR
AF Steinhilber, Starr
Rodriguez, J. Martin
Estrada, Carlos A.
Kraemer, Ryan R.
TI A 76-Year-Old Woman with Diaphoresis and Anxiety
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Editorial Material
ID METACOGNITION; PERCEPTIONS; PERSPECTIVE; STRATEGIES; EXPERTISE; MODEL
C1 [Steinhilber, Starr; Kraemer, Ryan R.] Univ Alabama Birmingham, Tinsley Harrison Internal Med Residency Program, Birmingham, AL 35294 USA.
[Rodriguez, J. Martin; Estrada, Carlos A.; Kraemer, Ryan R.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
[Estrada, Carlos A.; Kraemer, Ryan R.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Estrada, Carlos A.] Vet Affairs Qual Scholars Program, Birmingham, AL USA.
RP Kraemer, RR (reprint author), Univ Alabama Birmingham, Dept Med, 720 Fac Off Tower 510 20th St, Birmingham, AL 35294 USA.
EM rkraemer@uab.edu
NR 23
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD OCT
PY 2013
VL 28
IS 10
BP 1376
EP 1380
DI 10.1007/s11606-013-2500-7
PG 5
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 226DP
UT WOS:000325015000026
PM 23729373
ER
PT J
AU Denby, K
Nelson, G
Estrada, CA
AF Denby, Kara
Nelson, George
Estrada, Carlos A.
TI Bedside Hand Grip Assessment with the Sphygmomanometer
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Editorial Material
DE physical examination; hand Strength; muscle strength dynamometer
C1 [Denby, Kara; Nelson, George; Estrada, Carlos A.] Univ Alabama Birmingham, Birmingham, AL 35294 USA.
[Nelson, George] Univ Alabama Birmingham, Tinsley Harrison Internal Med Residency Program, Birmingham, AL 35294 USA.
[Estrada, Carlos A.] Birmingham Vet Affairs Med Ctr, Vet Affairs Qual Scholars Program, Birmingham, AL USA.
[Estrada, Carlos A.] Univ Alabama Birmingham, Div Gen Internal Med, Birmingham, AL 35294 USA.
RP Estrada, CA (reprint author), Univ Alabama Birmingham, Div Gen Internal Med, 732 Fac Off Tower,510 20th St South, Birmingham, AL 35294 USA.
EM cestrada@uab.edu
NR 2
TC 1
Z9 1
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD OCT
PY 2013
VL 28
IS 10
BP 1381
EP 1381
DI 10.1007/s11606-013-2426-0
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 226DP
UT WOS:000325015000027
PM 23568188
ER
PT J
AU Sakamoto, M
Woods, SP
Kolessar, M
Kriz, D
Anderson, JR
Olavarria, H
Sasaki, AW
Chang, M
Flora, KD
Loftis, JM
Huckans, M
AF Sakamoto, Maiko
Woods, Steven Paul
Kolessar, Michael
Kriz, Daniel
Anderson, J. Renee
Olavarria, Hannah
Sasaki, Anna W.
Chang, Michael
Flora, Kenneth D.
Loftis, Jennifer M.
Huckans, Marilyn
TI Protective effects of higher cognitive reserve for neuropsychological
and daily functioning among individuals infected with hepatitis C
SO JOURNAL OF NEUROVIROLOGY
LA English
DT Article
DE Hepatitis C; Cognitive reserve; Neuropsychological assessment; Daily
functioning
ID INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW;
MAGNETIC-RESONANCE-SPECTROSCOPY; CENTRAL-NERVOUS-SYSTEM;
VIRUS-INFECTION; ALZHEIMERS-DISEASE; DSM-IV; HIV; IMPAIRMENT; RISK;
METHAMPHETAMINE
AB Higher levels of cognitive reserve (CR) can be protective against the neuropsychological manifestation of neural injury across a variety of clinical disorders. However, the role of CR in the expression of neurocognitive deficits among persons infected with the hepatitis C virus (HCV) is not well understood. Thirty-nine HCV-infected participants were classified as having either high (n = 19) or low (n = 20) CR based on educational attainment, oral word reading, and IQ scores. A sample of 40 demographically comparable healthy adults (HA) was also included. All participants completed the Neuropsychological Assessment Battery, Delis-Kaplan Executive Function System, and Behavioral Rating Inventory of Executive Function, Adult Version (BRIEF-A). Linear regression analyses, controlling for gender, depression, and lifetime substance use disorders, found significant effects of HCV/CR group on verbal fluency, executive functions, and daily functioning T scores, but not in learning or the BRIEF-A. Pairwise comparisons revealed that the HCV group with low CR performed significantly below the HCV high CR and HA cohorts, who did not differ from one another. Findings indicate that higher levels of CR may be a protective factor in the neurocognitive and real-world manifestation of neural injury commonly associated with HCV infection.
C1 [Sakamoto, Maiko; Woods, Steven Paul] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.
[Kolessar, Michael; Kriz, Daniel; Anderson, J. Renee] Univ Pacific, Sch Profess Psychol, Hillsboro, OR 97123 USA.
[Kriz, Daniel] Oregon Hlth & Sci Univ, Inst Dev & Disabil, Portland, OR 97239 USA.
[Olavarria, Hannah; Loftis, Jennifer M.; Huckans, Marilyn] Portland VA Med Ctr, Res & Dev Serv, Portland, OR 97239 USA.
[Sasaki, Anna W.; Chang, Michael] Portland VA Med Ctr, Gastroenterol Serv, Portland, OR 97239 USA.
[Chang, Michael] Oregon Hlth & Sci Univ, Dept Internal Med, Portland, OR 97239 USA.
[Flora, Kenneth D.] Oregon Clin, Portland Gastroenterol Div, Clackamas, OR 97015 USA.
[Loftis, Jennifer M.; Huckans, Marilyn] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97239 USA.
[Huckans, Marilyn] Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, Portland, OR 97239 USA.
[Huckans, Marilyn] Portland VA Med Ctr, Portland, OR 97239 USA.
RP Huckans, M (reprint author), Portland VA Med Ctr, Mailstop P3MHN,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM marilyn.huckans@va.gov
FU Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development, Clinical Sciences Research and Development
[R25-MH081482]
FX This study was supported in part by R25-MH081482 to MS as well as by
career development awards to MH and JML from the Department of Veterans
Affairs, Veterans Health Administration, Office of Research and
Development, Clinical Sciences Research and Development. This material
is the result of work supported with resources and the use of facilities
at the Portland Veterans Affairs Medical Center, Portland, OR. The
authors thank the study participants and staff at each of the
recruitment sites, especially Betsy Zucker and Janice Voukidis. The
authors also acknowledge Peter Hauser, William Hoffman, Diane Howieson,
Daniel Storzbach, and Alexander Stevens for study design consultation.
NR 55
TC 6
Z9 6
U1 4
U2 14
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1355-0284
J9 J NEUROVIROL
JI J. Neurovirol.
PD OCT
PY 2013
VL 19
IS 5
BP 442
EP 451
DI 10.1007/s13365-013-0196-4
PG 10
WC Neurosciences; Virology
SC Neurosciences & Neurology; Virology
GA 228YM
UT WOS:000325228100005
PM 24018902
ER
PT J
AU Chemerinski, E
Triebwasser, J
Roussos, P
Siever, LJ
AF Chemerinski, Eran
Triebwasser, Joseph
Roussos, Panos
Siever, Larry J.
TI SCHIZOTYPAL PERSONALITY DISORDER
SO JOURNAL OF PERSONALITY DISORDERS
LA English
DT Article
ID EVENT-RELATED POTENTIALS; CARD SORTING TEST; SCHIZOPHRENIA SPECTRUM
DISORDERS; OBSESSIVE-COMPULSIVE DISORDER; AUDITORY WORKING-MEMORY;
PURSUIT EYE-MOVEMENTS; FRONTAL-LOBE FUNCTION; DSM-III; PREPULSE
INHIBITION; ROSCOMMON FAMILY
AB Early phenomenological descriptions of schizophrenia have acknowledged the existence of milder schizophrenia spectrum disorders characterized by the presence of attenuated symptoms typically present in chronic schizophrenia. The investigation of the schizophrenia spectrum disorders offers an opportunity to elucidate the pathophysiological mechanisms giving rise to schizophrenia. Differences and similarities between subjects with schizotypal personality disorder (SPD), the prototypical schizophrenia personality disorder, and chronic schizophrenia have been investigated with genetic, neurochemical, imaging, and pharmacological techniques. Patients with SPD and the more severely ill patients with chronic schizophrenia share cognitive, social, and attentional deficits hypothesized to result from common neurodevelopmentally based cortical temporal and prefrontal pathology. However, these deficits are milder in SPD patients due to their capacity to recruit other related brain regions to compensate for dysfunctional areas. Individuals with SPD are also less vulnerable to psychosis due to the presence of protective factors mitigating subcortical DA hyperactivity. Given the documented close relationship to other schizophrenic disorders, SPD will be included in the psychosis section of DSM-5 as a schizophrenia spectrum disorder as well as in the personality disorder section.
C1 [Chemerinski, Eran; Triebwasser, Joseph; Roussos, Panos; Siever, Larry J.] James J Peters VA Med Ctr, New York, NY USA.
RP Siever, LJ (reprint author), Bronx VA Med Ctr OOMH, 130 West Kingsbridge Rd, Bronx, NY 10468 USA.
EM larry.siever@mssm.edu
RI Roussos, Panos/J-7090-2013
OI Roussos, Panos/0000-0002-4640-6239
NR 227
TC 4
Z9 4
U1 4
U2 16
PU GUILFORD PUBLICATIONS INC
PI NEW YORK
PA 72 SPRING STREET, NEW YORK, NY 10012 USA
SN 0885-579X
J9 J PERS DISORD
JI J. Pers. Disord.
PD OCT
PY 2013
VL 27
IS 5
BP 652
EP 679
PG 28
WC Psychiatry
SC Psychiatry
GA 226NU
UT WOS:000325043900011
PM 22928856
ER
PT J
AU Merkow, RP
Bentrem, DJ
Cohen, ME
Paruch, JL
Weber, SM
Ko, CY
Bilimoria, KY
AF Merkow, Ryan P.
Bentrem, David J.
Cohen, Mark E.
Paruch, Jennifer L.
Weber, Sharon M.
Ko, Clifford Y.
Bilimoria, Karl Y.
TI Effect of Cancer Surgery Complexity on Short-Term Outcomes, Risk
Predictions, and Hospital Comparisons
SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
LA English
DT Article; Proceedings Paper
CT 8th Annual Academic Surgical Congress
CY FEB 05-07, 2013
CL New Orleans, LA
SP Assoc Acad Surg, Soc Univ Surg
ID QUALITY IMPROVEMENT PROGRAM; PATIENT SAFETY; MODELS; ADJUSTMENT;
VARIABLES; CARE
AB BACKGROUND: Concern exists that oncologic surgical complexity is not adequately captured by the primary procedure code alone. Our objectives were to characterize the association between secondary procedures and 30-day outcomes, evaluate the effect of surgical complexity on risk predictions, and assess the influence of surgical complexity on hospital-quality comparisons.
STUDY DESIGN: Patients who underwent colon, rectal, or pancreatic resection for cancer (2007-2011) were identified from theAmerican College of Surgeons NSQIP. Complexity was assessed by creating categorical complexity variables using secondary procedure codes and using total work relative value units. Regression methods were used to evaluate surgical complexity and hospital-quality comparisons.
RESULTS: Patients had at least one secondary procedure documented in 48.0% of colon, 55.5% of rectal, and 63.1% of pancreatic cases. Surgical complexity variables were associated with worse outcomes across nearly all complications assessed. For example, serious morbidity was increased after an index colon resection with a synchronous liver resection (odds ratio = 1.39; 95% CI, 1.10-1.76) and a pancreatic resection with vascular reconstruction (odds ratio = 1.21; 95% CI, 1.01-1.45). Based on discrimination improvement indices and the likelihood ratio test, model-based predictions were enhanced with the addition of secondary surgical complexity variables, as well as total work relative value units, for nearly all procedures and outcomes assessed. Models that included total work relative value units had similar or marginally better discrimination compared with models with secondary procedure categories. Hospital performance did not change substantially after complexity adjustment.
CONCLUSIONS: Surgical complexity adjustment is feasible and improves risk estimation of 30-day postoperative outcomes for colon, rectal, and pancreatic resections for cancer. Oncology-specific risk-adjustment models should include complexity adjustment using secondary procedure codes. (C) 2013 by the American College of Surgeons
C1 [Merkow, Ryan P.; Cohen, Mark E.; Paruch, Jennifer L.; Bilimoria, Karl Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA.
[Merkow, Ryan P.; Bentrem, David J.; Bilimoria, Karl Y.] Northwestern Univ, Dept Surg, Surg Outcomes & Qual Improvement Ctr, Feinberg Sch Med, Evanston, IL 60208 USA.
[Merkow, Ryan P.; Bentrem, David J.; Bilimoria, Karl Y.] Northwestern Univ, Northwestern Inst Comparat Effectiveness Res Onco, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA.
[Merkow, Ryan P.; Paruch, Jennifer L.] Univ Chicago, Dept Surg, Pritzker Sch Med, Chicago, IL 60637 USA.
[Bentrem, David J.] Jesse Brown VA Med Ctr, Dept Surg, Chicago, IL USA.
[Weber, Sharon M.] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, Madison, WI USA.
[Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA.
[Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Merkow, RP (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair St,22nd Fl, Chicago, IL 60611 USA.
EM RMerkow@facs.org
NR 23
TC 19
Z9 19
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1072-7515
J9 J AM COLL SURGEONS
JI J. Am. Coll. Surg.
PD OCT
PY 2013
VL 217
IS 4
BP 685
EP 693
DI 10.1016/j.jamcollsurg.2013.05.015
PG 9
WC Surgery
SC Surgery
GA 227YR
UT WOS:000325152100017
PM 23830986
ER
PT J
AU Ramanan, B
Gupta, PK
Sundaram, A
Gupta, H
Johanning, JM
Lynch, TG
MacTaggart, JN
Pipinos, II
AF Ramanan, Bala
Gupta, Prateek K.
Sundaram, Abhishek
Gupta, Himani
Johanning, Jason M.
Lynch, Thomas G.
MacTaggart, Jason N.
Pipinos, Iraklis I.
TI Development of a risk index for prediction of mortality after open
aortic aneurysm repair
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Article
ID SURGICAL CARE; ADJUSTMENT; SURGERY; QUALITY; SCORE
AB Objective: Open infrarenal abdominal aortic aneurysm (oAAA) repair is associated with significant morbidity and mortality. Although there has been a shift toward endovascular repair, many patients continue to undergo an open repair due to anatomic considerations. Tools currently existing for estimation of periprocedural risk in patients undergoing open aortic surgery have certain limitations. The objective of this study was to develop a risk index to estimate the risk of 30-day perioperative mortality after elective oAAA repair.
Methods: Patients who underwent elective oAAA repair (n = 2845) were identified from the American College of Surgeons' 2007 to 2009 National Surgical Quality Improvement Program (NSQIP), a prospective database maintained at >250 centers. Univariable and multivariable analyses were performed to evaluate risk factors associated with 30-day mortality after oAAA repair and a risk index was developed.
Results: The 30-day mortality after oAAA repair was 3.3%. Multivariable analysis identified six preoperative predictors of mortality, and a risk index was created by assigning weighted points to each predictor using the beta-coefficients from the regression analysis. The predictors included dyspnea (at rest: 8 points; on moderate exertion: 2 points; none: 0 points), history of peripheral arterial disease requiring revascularization or amputation (3 points), age >65 years (3 points), preoperative creatinine >1.5 mg/dL (2 points), female gender (2 points), and platelets <150,000/mm(3) or >350,000/mm3 (2 points). Patients were classified as low (<7%), intermediate (7%-15%), and high (>15%) risk for 30-day mortality based on a total point score of <8, 8 to 11, and >11, respectively. There were 2508 patients (88.2%) patients in the low-risk category, 278 (9.8%) in the intermediate-risk category, and 59 (2.1%) in the high-risk category.
Conclusions: This risk index has excellent predictive ability for mortality after oAAA repair and awaits validation in subsequent studies. It is anticipated to aid patients and surgeons in informed patient consent, preoperative risk assessment, and optimization.
C1 [Ramanan, Bala; Sundaram, Abhishek] Creighton Univ, Dept Surg, Omaha, NE 68178 USA.
[Gupta, Prateek K.] Univ Wisconsin Hosp & Clin, Dept Surg, Madison, WI 53792 USA.
[Gupta, Himani] William S Middleton Mem Vet Adm Med Ctr, Dept Med, Madison, WI USA.
[Johanning, Jason M.; MacTaggart, Jason N.; Pipinos, Iraklis I.] Univ Nebraska Med Ctr, Dept Surg, Omaha, NE 68198 USA.
[Johanning, Jason M.; MacTaggart, Jason N.; Pipinos, Iraklis I.] VA Nebraska & Western Iowa Hlth Care Syst, Omaha, NE USA.
[Lynch, Thomas G.] Vet Hlth Adm, Washington, DC USA.
RP Pipinos, II (reprint author), Univ Nebraska Med Ctr, Dept Surg, Div Gen Surg, 985182 Nebraska Med Ctr, Omaha, NE 68198 USA.
EM ipipinos@unmc.edu
FU National Institutes of Health [R01-AG-034995]; American Vascular
Association; Charles and Mary Heider Fund for Excellence in Vascular
Surgery
FX This study was partly supported National Institutes of Health Grant
R01-AG-034995, the William J. von Liebig Award by the American Vascular
Association, and the Charles and Mary Heider Fund for Excellence in
Vascular Surgery.
NR 15
TC 14
Z9 14
U1 1
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD OCT
PY 2013
VL 58
IS 4
BP 871
EP 878
DI 10.1016/j.jvs.2013.03.024
PG 8
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 227RS
UT WOS:000325132100002
PM 23676190
ER
PT J
AU Sobel, M
Moreno, KI
Yagi, M
Kohler, TR
Tang, GL
Clowes, AW
Zhou, XHA
Eugenio, E
AF Sobel, Michael
Moreno, Katherine I.
Yagi, Mayumi
Kohler, Ted R.
Tang, Gale L.
Clowes, Alexander W.
Zhou, Xiao-Hua A.
Eugenio, Evercita
TI Low levels of a natural IgM antibody are associated with vein graft
stenosis and failure
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Article
ID OXIDATION-SPECIFIC EPITOPES; REDUCES ATHEROSCLEROSIS; PROTECTIVE
FACTORS; IMMUNE-MODULATION; PHOSPHORYLCHOLINE; BYPASS; SURVEILLANCE;
INFLAMMATION; IDENTIFICATION; MULTICENTER
AB Background: All humans have natural, protective antibodies directed against phosphorylcholine (PC) epitopes, a common inflammatory danger signal appearing at sites of cell injury, oxidative stress, and on bacterial capsules. In large human cohorts, low levels of anti-PC IgM were associated with a significantly increased risk of stroke or myocardial infarction. However, it is not known if these antibodies protect against the premature closure of arterial reconstructions.
Methods: A prospective, observational study of patients undergoing elective, infrainguinal, autogenous vein bypasses for atherosclerotic occlusive disease of the legs was conducted. Clinical data were recorded prospectively, and preoperative levels of anti-PC IgM measured with the CVDefine kit from Athera Biotechnologies (Solna, Sweden). The principal clinical end point was the loss of primary patency (loss of graft flow, or any intervention for stenosis). Patients were followed regularly by duplex ultrasound at 1, 3, 6, 12, 18 months, and yearly thereafter.
Results: Fifty-six patients were studied, for an average of 1.3 years. Indications for surgery were claudication (33.9%), ischemic rest pain (17.9%), and ischemia with ulceration or gangrene (48.2%). Seventeen (30.4%) patients experienced loss of primary patency (10 graft occlusions, seven surgical or endovascular revisions of graft stenoses). Kaplan-Meier survival analysis showed that the quartile of patients with the lowest anti-PC IgM levels had significantly worse primary graft patency (log-rank test, P = .0085). Uni- and multivariate Cox proportional hazards analysis revealed that the preoperative anti-PC IgM level was an important predictor of graft failure. Patients with IgM values in the lowest quartile had a 3.6-fold increased risk of graft failure (95% confidence interval: 1.1-12.1), even after accounting for other significant clinical or technical factors such as indication for surgery, site of distal anastomosis, or vein graft diameter.
Conclusions: A naturally occurring IgM antibody directed against the proinflammatory epitope PC may be protective against vein graft stenosis and failure, through anti-inflammatory mechanisms. Measurement of this antibody may be a useful prognostic indicator, although larger studies of more diverse populations will be needed to confirm these results. The biological actions of anti-PC IgM suggest it may be useful in developing immunotherapies to improve bypass longevity.
C1 [Sobel, Michael; Moreno, Katherine I.; Yagi, Mayumi; Kohler, Ted R.; Tang, Gale L.; Clowes, Alexander W.] VA Puget Sound Hlth Care Syst, Div Vasc Surg, Seattle, WA USA.
[Sobel, Michael; Moreno, Katherine I.; Yagi, Mayumi; Kohler, Ted R.; Tang, Gale L.; Clowes, Alexander W.] Univ Washington, Seattle, WA 98195 USA.
[Zhou, Xiao-Hua A.; Eugenio, Evercita] VA Puget Sound Hlth Care Syst, Northwest Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA.
[Zhou, Xiao-Hua A.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
RP Sobel, M (reprint author), VA Puget Sound Hlth Care Syst S112, Div Vasc Surg, 1660 Columbian Way S, Seattle, WA 98108 USA.
EM sobelm@uw.edu
FU Department of Veterans Affairs, Veterans Health Administration, Merit
Review Agency; Research Career Scientist Award [RCS 05-196]; National
Institutes of Health [T32 HL007828, R01HL030946]
FX This work was supported by grants from the Department of Veterans
Affairs, Veterans Health Administration, Merit Review Agency (M.S.) and
Research Career Scientist Award (RCS 05-196 - X.H.Z.); and National
Institutes of Health T32 HL007828 and R01HL030946 (A.C., M.S.). The
content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institutes of
Health.
NR 40
TC 4
Z9 4
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD OCT
PY 2013
VL 58
IS 4
BP 997
EP +
DI 10.1016/j.jvs.2013.04.042
PG 11
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 227RS
UT WOS:000325132100020
PM 23856610
ER
PT J
AU Gray, KM
Saladin, ME
Baker, NL
McClure, EA
Hartwell, KJ
Carpenter, MJ
AF Gray, Kevin M.
Saladin, Michael E.
Baker, Nathaniel L.
McClure, Erin A.
Hartwell, Karen J.
Carpenter, Matthew J.
TI Varenicline Versus Nicotine Patch for Smoking Cessation in Women:
Efficacy Findings from a 4-Week Double-blind Trial
SO JOURNAL OF WOMENS HEALTH
LA English
DT Meeting Abstract
C1 [Gray, Kevin M.; Saladin, Michael E.; Baker, Nathaniel L.; McClure, Erin A.; Hartwell, Karen J.; Carpenter, Matthew J.] Med Univ S Carolina, Charleston, SC USA.
[Hartwell, Karen J.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-9996
J9 J WOMENS HEALTH
JI J. Womens Health
PD OCT 1
PY 2013
VL 22
IS 10
BP 904
EP 904
PG 1
WC Public, Environmental & Occupational Health; Medicine, General &
Internal; Obstetrics & Gynecology; Women's Studies
SC Public, Environmental & Occupational Health; General & Internal
Medicine; Obstetrics & Gynecology; Women's Studies
GA 227TD
UT WOS:000325136500099
ER
PT J
AU Wei, CC
Adappa, ND
Cohen, NA
AF Wei, Calvin C.
Adappa, Nithin D.
Cohen, Noam A.
TI Use of Topical Nasal Therapies in the Management of Chronic
Rhinosinusitis
SO LARYNGOSCOPE
LA English
DT Review
DE Chronic rhinosinusitis; antifungals; antibiotics; antimicrobials; nasal
irrigations; topical therapy
ID ENDOSCOPIC SINUS SURGERY; RANDOMIZED CONTROLLED-TRIAL; FLUTICASONE
PROPIONATE; DOUBLE-BLIND; MOMETASONE FUROATE; AMPHOTERICIN-B; INTRANASAL
BUDESONIDE; STAPHYLOCOCCUS-AUREUS; ANTIFUNGAL TREATMENT; SINONASAL
SYMPTOMS
AB Objectives/HypothesisTo determine whether the use of topical nasal therapies with saline alone and in combination with antibiotics, antifungals, or corticosteroids is effective in the treatment of patients with chronic rhinosinusitis (CRS).
Data SourcesA systematic literature search was performed utilizing the MEDLINE database (1966 to May 2012), EMBASE database (1980 to May 2012), and the Cochrane Central Register of Controlled Trials.
Review MethodsElectronic databases were searched by three otolaryngologists. Studies on five major categories of topical nasal therapies searched included saline (hypotonic, isotonic and hypertonic); topical antibiotics, topical steroids, and topical antifungals were obtained. Randomized controlled trials and meta-analyses of randomized controlled trials were included.
ResultsSixteen randomized controlled trials were identified examining topical saline (hypertonic or isotonic) in CRS patients. Two randomized controlled trials were found studying the effect of topical antibiotics in patients with CRS. Four randomized controlled trials were identified studying topical antifungal treatment for CRS. Twenty-five randomized controlled trials were found studying topical steroids in CRS patients.
ConclusionA high aggregate quality of evidence supports the effectiveness of saline irrigations in treating CRS. There is insufficient evidence to support a clear benefit of topical antibiotics in patients with chronic rhinosinusitis. Topical antifungal therapies have not been shown to be significantly different in efficacy than saline controls on CRS outcomes. Topical steroids are beneficial in the treatment of CRS with nasal polyps, but have not been shown to be effective in CRS without nasal polyps. Laryngoscope, 123:2347-2359, 2013
C1 [Wei, Calvin C.] St Lukes Roosevelt Hosp, Dept Otolaryngol Head & Neck Surg, New York, NY 10025 USA.
[Adappa, Nithin D.; Cohen, Noam A.] Univ Penn, Sch Med, Hosp Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA.
[Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Cohen, NA (reprint author), Univ Penn, Sch Med, Hosp Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Ravdin 5th Floor,3400 Spruce St, Philadelphia, PA 19104 USA.
EM Noam.Cohen@uphs.upenn.edu
OI Cohen, Noam/0000-0002-9462-3932
NR 72
TC 22
Z9 22
U1 1
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0023-852X
J9 LARYNGOSCOPE
JI Laryngoscope
PD OCT
PY 2013
VL 123
IS 10
BP 2347
EP 2359
DI 10.1002/lary.24066
PG 13
WC Medicine, Research & Experimental; Otorhinolaryngology
SC Research & Experimental Medicine; Otorhinolaryngology
GA 227EC
UT WOS:000325091100006
PM 23553558
ER
PT J
AU Pandey, GS
Yanover, C
Miller-Jenkins, LM
Garfield, S
Cole, SA
Curran, JE
Moses, EK
Rydz, N
Simhadri, V
Kimchi-Sarfaty, C
Lillicrap, D
Viel, KR
Przytycka, TM
Pierce, GF
Howard, TE
Sauna, ZE
AF Pandey, Gouri Shankar
Yanover, Chen
Miller-Jenkins, Lisa M.
Garfield, Susan
Cole, Shelley A.
Curran, Joanne E.
Moses, Eric K.
Rydz, Natalia
Simhadri, Vijaya
Kimchi-Sarfaty, Chava
Lillicrap, David
Viel, Kevin R.
Przytycka, Teresa M.
Pierce, Glenn F.
Howard, Tom E.
Sauna, Zuben E.
CA PATH Personalized Alternative
TI Endogenous factor VIII synthesis from the intron 22-inverted F8 locus
may modulate the immunogenicity of replacement therapy for hemophilia A
SO NATURE MEDICINE
LA English
DT Article
ID COAGULATION-FACTOR VIII; MONOCLONAL-ANTIBODIES; HUMAN-LIVER; INHIBITOR;
ANTIGEN; HISTORY; GENE
AB Neutralizing antibodies (inhibitors) to replacement factor VIII (FVIII, either plasma derived or recombinant) impair the effective management of hemophilia A1. Individuals with hemophilia A due to major deletions of the FVIII gene (F8) lack antigenically cross-reactive material in their plasma ("CRM-negative"), and the prevalence of inhibitors in these individuals may be as high as 90%. Conversely, individuals with hemophilia A caused by F8 missense mutations are CRM-positive, and their overall prevalence of inhibitors is < 10% (ref. 2). Individuals with the F8 intron 22 inversion (found in similar to 50% of individuals with severe hemophilia A) have been grouped with the former on the basis of their genetic defect and CRM-negative status. However, only similar to 20% of these individuals develop inhibitors3. Here we demonstrate that the levels of F8 mRNA and intracellular FVIII protein in B lymphoblastoid cells and liver biopsies from individuals with the intron 22 inversion are comparable to those in healthy controls. These results support the hypothesis that most individuals with the intron 22 inversion are tolerized to FVIII and thus do not develop inhibitors. Furthermore, we developed a new pharmacogenetic algorithm that permits the stratification of inhibitor risk for individuals and subpopulations by predicting the immunogenicity of replacement FVIII using, as input, the number of putative T cell epitopes in the infused protein and the competence of major histocompatibility complex class II molecules to present such epitopes. This algorithm showed statistically significant accuracy in predicting the presence of inhibitors in 25 unrelated individuals with the intron 22 inversion.
C1 [Pandey, Gouri Shankar; Simhadri, Vijaya; Kimchi-Sarfaty, Chava; Sauna, Zuben E.] US FDA, Ctr Biol Evaluat & Res, Div Hematol, Lab Hemostasis, Bethesda, MD 20892 USA.
[Yanover, Chen] Fred Hutchinson Canc Res Ctr, Program Computat Biol, Seattle, WA 98104 USA.
[Miller-Jenkins, Lisa M.] NCI, Lab Cell Biol, Expt Carcinogenesis Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA.
[Garfield, Susan] NCI, Expt Carcinogenesis Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Cole, Shelley A.; Curran, Joanne E.; Moses, Eric K.] Texas Biomed Res Inst, Dept Genet, San Antonio, TX USA.
[Rydz, Natalia; Lillicrap, David] Queens Univ, Dept Pathol & Mol Med, Kingston, ON, Canada.
[Viel, Kevin R.] Histonis, Atlanta, GA USA.
[Przytycka, Teresa M.] Natl Ctr Biotechnol Informat, Natl Lib Med, NIH, Bethesda, MD USA.
[Pierce, Glenn F.] Biogen Idec Hemophilia, Waltham, MA USA.
[Howard, Tom E.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA.
[Howard, Tom E.] Univ So Calif, Keck Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90033 USA.
[Howard, Tom E.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA.
RP Sauna, ZE (reprint author), US FDA, Ctr Biol Evaluat & Res, Div Hematol, Lab Hemostasis, Bethesda, MD 20892 USA.
EM tom.howard@va.gov; zuben.sauna@fda.hhs.gov
RI Yanover, Chen/A-3754-2012
OI Yanover, Chen/0000-0003-3663-4286
FU US National Institute of Allergy and Infectious Diseases Committee on
Human Research [10-01178]; modernization of science program of the
Center for Biologics Evaluation and Research, US Food and Drug
Administration; National Heart, Lung and Blood Institute, National
Institutes of Health [1RC2-HL101851, HL-71130, HL-72533)]; Bayer
Healthcare Corporation; Bayer Hemophilia Awards Program; Baxter
Healthcare Corporation; Clinical Translational Science Institute at the
University of Southern California; Intramural Program of the US National
Library of Medicine, NIH
FX We would like to thank P. Matzinger, B. Golding, J. Lozier, D. Levin, M.
Carcao, V. Blanchette, G. Rivard and V. La Terza for helpful comments
and J. Sauna for help with the graphics. We thank S. V. Ambudkar (US
National Cancer Institute) for the use of facilities, M. J. Lenardo and
K. Shafer-Weaver (US National Institute of Allergy and Infectious
Diseases) for the gift of the purified C2 domain of FVIII and P. Stock
(University of California, San Francisco) for liver tissue samples.
These samples were obtained under the University of California
University-Wide AIDS Research Program (TP-99-SF-001) Committee on Human
Research (H802423454) and the Solid Organ Transplantation in HIV:
Multi-Site Study (AI052748) funded by the US National Institute of
Allergy and Infectious Diseases Committee on Human Research (10-01178).
Research conducted in the laboratory of Z. E. S. is funded by the
modernization of science program of the Center for Biologics Evaluation
and Research, US Food and Drug Administration. Research conducted in the
laboratory of T. E. H. is funded by grants from the National Heart, Lung
and Blood Institute, National Institutes of Health (1RC2-HL101851,
HL-71130 and HL-72533), the Bayer Healthcare Corporation, Bayer
Hemophilia Awards Program, Baxter Healthcare Corporation and the
Clinical Translational Science Institute at the University of Southern
California. The work of T. M. P. is fully supported by the Intramural
Program of the US National Library of Medicine, NIH.
NR 22
TC 27
Z9 27
U1 1
U2 18
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
J9 NAT MED
JI Nat. Med.
PD OCT
PY 2013
VL 19
IS 10
BP 1318
EP +
DI 10.1038/nm.3270
PG 10
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
Medicine
GA 232YW
UT WOS:000325531700032
PM 24037092
ER
PT J
AU Flickinger, TE
Rose, G
Wilson, IB
Wolfe, H
Saha, S
Korthuis, PT
Massa, M
Berry, S
Laws, MB
Sharp, V
Moore, RD
Beach, MC
AF Flickinger, Tabor E.
Rose, Gary
Wilson, Ira B.
Wolfe, Hannah
Saha, Somnath
Korthuis, Philip Todd
Massa, Michele
Berry, Stephen
Laws, Michael Barton
Sharp, Victoria
Moore, Richard D.
Beach, Mary Catherine
TI Motivational interviewing by HIV care providers is associated with
patient intentions to reduce unsafe sexual behavior
SO PATIENT EDUCATION AND COUNSELING
LA English
DT Article
DE Motivational interviewing; Physicians; HIV/AIDS; Sexual risk reduction;
Counseling
ID SAFER SEX; INFECTED PATIENTS; CLIENT LANGUAGE; SUBSTANCE USE; USE
OUTCOMES; COMMUNICATION; INTERVENTION; PREVENTION; CLINICIAN; DRINKING
AB Objective: Motivational interviewing (MI) can promote behavior change, but HIV care providers rarely have training in MI. Little is known about the use of MI-consistent behavior among untrained providers. This study examines the prevalence of such behaviors and their association with patient intentions to reduce high-risk sexual behavior.
Methods: Audio-recorded visits between HIV-infected patients and their healthcare providers were searched for counseling dialog regarding sexual behavior. The association of providers' MI-consistence with patients' statements about behavior change was assessed.
Results: Of 417 total encounters, 27 met inclusion criteria. The odds of patient commitment to change were higher when providers used more reflections (p = 0.017), used more MI consistent utterances (p = 0.044), demonstrated more empathy (p = 0.049), and spent more time discussing sexual behavior (p = 0.023). Patients gave more statements in favor of change (change talk) when providers used more reflections (p < 0.001) and more empathy (p < 0.001), even after adjusting for length of relevant dialog.
Conclusion: Untrained HIV providers do not consistently use MI techniques when counseling patients about sexual risk reduction. However, when they do, their patients are more likely to express intentions to reduce sexual risk behavior.
Practice implications: MI holds promise as one strategy to reduce transmission of HIV and other sexually transmitted infections. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 [Flickinger, Tabor E.; Massa, Michele; Berry, Stephen; Moore, Richard D.; Beach, Mary Catherine] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21287 USA.
[Rose, Gary] Massachusetts Sch Profess Psychol, Boston, MA USA.
[Wilson, Ira B.; Laws, Michael Barton] Brown Univ, Dept Med, Providence, RI 02912 USA.
[Wolfe, Hannah; Sharp, Victoria] Dept Med, New York, NY USA.
[Saha, Somnath; Korthuis, Philip Todd] Oregon Hlth & Sci Univ, Dept Med, Portland, OR USA.
[Saha, Somnath] Portland VA Med Ctr, Dept Med, Portland, OR USA.
RP Flickinger, TE (reprint author), Johns Hopkins Univ, Sch Med, 2024 East Monument St,Suite 2-600, Baltimore, MD 21287 USA.
EM tflicki1@jhmi.edu
RI Wilson, Ira/F-9190-2016
OI Wilson, Ira/0000-0002-0246-738X
FU Health Resources Service Administration; National Institutes of Health
[5 T32 HL007180-35]; National Institute of Allergy and Infectious
Disease [K23 A1084854]; National Institute of Drug Abuse [K23 DA019809];
Department of Veterans Affairs; Agency for Healthcare Research and
Quality [K08 HS013903-05, AHRQ 290-01-0012]; NIMH [2K24MH092242]; Robert
Wood Johnson Generalist Physician Faculty Scholars Awards
FX This research was supported by a contract from the Health Resources
Service Administration and the Agency for Healthcare Research and
Quality (AHRQ 290-01-0012). In addition, Dr. Flickinger was supported by
the National Institutes of Health (5 T32 HL007180-35), Dr. Berry was
supported by the National Institute of Allergy and Infectious Disease
(K23 A1084854), Dr. Korthuis was supported by the National Institute of
Drug Abuse (K23 DA019809), Dr. Saha was supported by the Department of
Veterans Affairs, Dr. Beach was supported by the Agency for Healthcare
Research and Quality (K08 HS013903-05) and both Drs. Beach and Saha were
supported by Robert Wood Johnson Generalist Physician Faculty Scholars
Awards. Dr. Wilson was supported by a K24 from NIMH (2K24MH092242). None
of the funders had a role in the design and conduct of this analysis,
nor was it subject to their final approval. None of the authors have any
relevant financial conflicts of interest.
NR 51
TC 5
Z9 5
U1 0
U2 9
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0738-3991
J9 PATIENT EDUC COUNS
JI Patient Educ. Couns.
PD OCT
PY 2013
VL 93
IS 1
BP 122
EP 129
DI 10.1016/j.pec.2013.04.001
PG 8
WC Public, Environmental & Occupational Health; Social Sciences,
Interdisciplinary
SC Public, Environmental & Occupational Health; Social Sciences - Other
Topics
GA 226TE
UT WOS:000325058100017
PM 23647982
ER
PT J
AU Mautner, DB
Pang, HC
Brenner, JC
Shea, JA
Gross, KS
Frasso, R
Cannuscio, CC
AF Mautner, Dawn B.
Pang, Hauchie
Brenner, Jeffrey C.
Shea, Judy A.
Gross, Kennen S.
Frasso, Rosemary
Cannuscio, Carolyn C.
TI Generating Hypotheses About Care Needs of High Utilizers: Lessons from
Patient Interviews
SO POPULATION HEALTH MANAGEMENT
LA English
DT Article
ID ADVERSE CHILDHOOD EXPERIENCES; EMERGENCY-DEPARTMENT; HOUSEHOLD
DYSFUNCTION; FREQUENT USERS; HEALTH-CARE; CASE-MANAGEMENT; SERVICE USE;
RISK; CONTINUITY; ADULTS
AB Informed by a largely secondary and quantitative literature, efforts to improve care and outcomes for complex patients with high levels of emergency and hospital-based health care utilization have offered mixed results. This qualitative study identifies psychosocial factors and life experiences described by these patients that may be important to their care needs. Semi-structured interviews were conducted with 19 patients of the Camden Coalition of Healthcare Providers' Care Management Team. Investigators coded transcripts using a priori and inductively-derived codes, then identified 3 key themes: (1) Early-life instability and traumas, including parental loss, unstable or violent relationships, and transiency, informed many participants' health and health care experiences; (2) Many high utilizers described a history of difficult interactions with health care providers during adulthood; (3) Over half of the participants described the importance to their well-being of positive and caring relationships with primary health care providers and the outreach team. Additionally, the transient and vulnerable nature of this complex population posed challenges to follow-up, both for research and care delivery. These themes illuminate potentially important hypotheses to be explored in more generalizable samples using robust and longitudinal methods. Future work should explore the prevalence and impact of adverse childhood experiences among high utilizers, and the different types of relationships they have with providers. Investigators should test new modes of care delivery that attend to patients' trauma histories. This qualitative study was well suited to provide insight into the life stories of these complex, vulnerable patients, informing research questions for further investigation. (Population Health Management 2013;16:S-26-S-33)
C1 [Mautner, Dawn B.] Thomas Jefferson Univ, Dept Family & Community Med, Philadelphia, PA 19107 USA.
[Mautner, Dawn B.] Thomas Jefferson Univ, Robert Wood Johnson Fdn, Clin Scholars Program, Philadelphia, PA 19107 USA.
[Pang, Hauchie; Frasso, Rosemary] Univ Penn, Sch Social Policy & Practice, Ctr Publ Hlth Initiat, Philadelphia, PA 19104 USA.
[Brenner, Jeffrey C.; Gross, Kennen S.] Camden Coalit Healthcare Providers, Camden, NJ USA.
[Brenner, Jeffrey C.; Gross, Kennen S.] Rowan Univ, Cooper Med Sch, Dept Family Med, Camden, NJ USA.
[Shea, Judy A.; Cannuscio, Carolyn C.] Philadelphia VA, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
[Shea, Judy A.] Univ Penn, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA.
[Cannuscio, Carolyn C.] Univ Penn, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA.
[Cannuscio, Carolyn C.] Univ Penn, Perelman Sch Med, Mixed Methods Res Lab, Philadelphia, PA 19104 USA.
RP Mautner, DB (reprint author), Thomas Jefferson Univ, Dept Family & Community Med, 1015 Walnut St,401 Curtis, Philadelphia, PA 19107 USA.
EM dawn.mautner@jefferson.edu
FU Robert Wood Johnson Health and Society Scholars Program Fund at the
University of Pennsylvania
FX The authors appreciate the sponsorship of the Robert Wood Johnson Health
and Society Scholars Program Fund at the University of Pennsylvania. We
wish to acknowledge the support of Katrina Armstrong, MD, MSCE and
Glenda Wrenn, MD, MA throughout the process of developing this project.
Finally, we wish to thank the Robert Wood Johnson Foundation Clinical
Scholars Program at the University of Pennsylvania for the postdoctoral
training support of Dr. Mautner, during which this work was completed.
Parts of this work have been presented at the Robert Wood Johnson
Clinical Scholars' National Meeting in November 2011.
NR 45
TC 12
Z9 12
U1 7
U2 26
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1942-7891
EI 1942-7905
J9 POPUL HEALTH MANAG
JI Popul. Health Manag.
PD OCT 1
PY 2013
VL 16
SU 1
BP S26
EP S33
DI 10.1089/pop.2013.0033
PG 8
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 224MT
UT WOS:000324891700007
PM 24070247
ER
PT J
AU Morland, LA
Raab, M
Mackintosh, MA
Rosen, CS
Dismuke, CE
Greene, CJ
Frueh, BC
AF Morland, Leslie A.
Raab, Michelle
Mackintosh, Margaret-Anne
Rosen, Craig S.
Dismuke, Clara E.
Greene, Carolyn J.
Frueh, B. Christopher
TI Telemedicine: A Cost-Reducing Means of Delivering Psychotherapy to Rural
Combat Veterans with PTSD
SO TELEMEDICINE AND E-HEALTH
LA English
DT Article
DE medicine; military medicine; telehealth; telepsychiatry
ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH-SERVICES; PRIMARY-CARE
CLINICS; VIETNAM VETERANS; NONINFERIORITY TRIAL; TELEHEALTH;
TELEPSYCHIATRY; ANGER; OUTCOMES; THERAPY
AB Background:Although effective psychotherapies for posttraumatic stress disorder (PTSD) exist, high percentages of Veterans in need of services are unable to access them. One particular challenge to providing cost-effective psychological treatments to Veterans with PTSD involves the difficulty and high cost of delivering in-person, specialized psychotherapy to Veterans residing in geographically remote locations. The delivery of these services via clinical videoteleconferencing (CVT) has been presented as a potential solution to this access to care problem.Materials and Methods:This study is a retrospective cost analysis of a randomized controlled trial investigating telemedicine service delivery of an anger management therapy for Veterans with PTSD. The parent trial found that the CVT condition provided clinical results that were comparable to the in-person condition. Several cost outcomes were calculated in order to investigate the clinical and cost outcomes associated with the CVT delivery modality relative to in-person delivery.Results:The CVT condition was significantly associated with lower total costs compared with the in-person delivery condition. The delivery of mental health services via CVT enables Veterans who would not normally receive these services access to empirically based treatments. Additional studies addressing long-term healthcare system costs, indirect cost factors at the patient and societal levels, and the use of CVT in other geographic regions of the United States are needed.Conclusions:The results of this study provide evidence that CVT is a cost-reducing mode of service delivery to Veterans with PTSD relative to in-person delivery.
C1 [Morland, Leslie A.; Raab, Michelle; Mackintosh, Margaret-Anne; Greene, Carolyn J.] Dept Vet Affairs Pacific Isl Healthcare Syst, Pacific Isl Div, Natl Ctr PTSD, Honolulu, HI 96819 USA.
[Raab, Michelle; Mackintosh, Margaret-Anne] Pacific Hlth Res & Educ Inst, Honolulu, HI USA.
[Rosen, Craig S.] Dept Vet Affairs Palo Alto Healthcare Syst, Disseminat & Training Div, Natl Ctr PTSD, Palo Alto, CA USA.
[Rosen, Craig S.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA.
[Dismuke, Clara E.] Ralph H Johnson VAMC, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Dept Vet Affairs, Charleston, SC USA.
[Dismuke, Clara E.] Med Univ S Carolina, Dept Med, Ctr Hlth Dispar Res, Charleston, SC 29425 USA.
[Greene, Carolyn J.] Dept Vet Affairs Palo Alto Healthcare Syst, Ctr Hlth Care Evaluat, Palo Alto, CA USA.
[Frueh, B. Christopher] Menninger Clin, Houston, TX USA.
[Frueh, B. Christopher] Univ Hawaii, Hilo, HI 96720 USA.
RP Morland, LA (reprint author), Dept Vet Affairs Pacific Isl Healthcare Syst, Pacific Isl Div, Natl Ctr PTSD, 3375 Koapaka St,Suite I-560, Honolulu, HI 96819 USA.
EM Leslie.Morland@va.gov
OI Mackintosh, Margaret-Anne/0000-0002-2725-3177
FU Veterans Affairs Health Services and Development [TEL 03-080-3]; Office
of Research and Development, Medical Research Service, Department of
Veterans Affairs
FX This work was partially supported by grant TEL 03-080-3 from the
Veterans Affairs Health Services and Development. This work was also
supported by the Office of Research and Development, Medical Research
Service, Department of Veterans Affairs. L. A. M., Principal
Investigator of this study, had full access to all of the data in the
study and takes responsibility for the integrity of the data and the
accuracy of the data analysis.
NR 53
TC 16
Z9 16
U1 2
U2 22
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1530-5627
J9 TELEMED E-HEALTH
JI Telemed. e-Health
PD OCT 1
PY 2013
VL 19
IS 10
BP 754
EP 759
DI 10.1089/tmj.2012.0298
PG 6
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 227RU
UT WOS:000325132300005
PM 23931729
ER
PT J
AU Banerjee, A
Wang, JM
Bodhankar, S
Vandenbark, AA
Murphy, SJ
Offner, H
AF Banerjee, Anirban
Wang, Jianming
Bodhankar, Sheetal
Vandenbark, Arthur A.
Murphy, Stephanie J.
Offner, Halina
TI Phenotypic Changes in Immune Cell Subsets Reflect Increased Infarct
Volume in Male vs. Female Mice
SO TRANSLATIONAL STROKE RESEARCH
LA English
DT Article
DE Experimental stroke; Gender bias; Immune markers; Activated Tcells;
Suppressor Tcells; Ischemia
ID REGULATORY T-CELLS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FOCAL
CEREBRAL-ISCHEMIA; EXPERIMENTAL STROKE; SEX-DIFFERENCES; ALPHA-4
INTEGRIN; MULTIPLE-SCLEROSIS; INFLAMMATORY CELLS; NADPH OXIDASE;
BRAIN-INJURY
AB Inflammatory responses in the brain after cerebral ischemia have been studied extensively in male mice, but not female mice, thus potentially giving a less-than-accurate view of gender associated pathological processes. In humans, cerebral infarcts are typically smaller in premenopausal females than in age-matched males. In the current study, we confirmed smaller infarcts in female vs. male mice after middle cerebral artery occlusion and 96 h of reperfusion. Moreover, we explored immunological alterations related to this difference and found that the percentage of CD4(+) T lymphocytes was significantly higher in spleens in males than females, with increased expression of the activation markers, CD69 and CD44. In contrast, the percentage of CD8(+) T lymphocytes was significantly higher in spleens of females than males, leading to the identification of a small but distinct population of IL-10-secreting CD8(+)CD122(+) suppressor T cells that were also increased in females. Finally, we observed that males have a greater percentage of activated macrophages/microglia in the brain than females, as well as increased expression of the VLA-4 adhesion molecule in both brain and spleen. This new information suggesting gender-dependent immunological mechanisms in stroke implies that effective treatments for human stroke may also be gender specific.
C1 [Banerjee, Anirban; Bodhankar, Sheetal; Vandenbark, Arthur A.; Offner, Halina] Portland VA Med Ctr, Portland, OR USA.
[Banerjee, Anirban; Bodhankar, Sheetal; Vandenbark, Arthur A.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA.
[Wang, Jianming; Murphy, Stephanie J.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA.
[Vandenbark, Arthur A.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA.
RP Offner, H (reprint author), Portland VA Med Ctr, R&D 31,3710 SW US Vet Hosp Rd, Portland, OR USA.
EM offnerva@ohsu.edu
FU NIH [NS076013]; Department of Veterans Affairs, Veterans Health
Administration, Office of Research and Development, Biomedical
Laboratory Research and Development
FX The authors wish to thank Dr. Gil Benedek for the helpful discussions
and Melissa Barber for the assistance in submitting the manuscript. This
work was supported by NIH grant no. NS076013. This material is based
upon work supported in part by the Department of Veterans Affairs,
Veterans Health Administration, Office of Research and Development,
Biomedical Laboratory Research and Development. The contents do not
represent the views of the Department of Veterans Affairs or the United
States Government.
NR 46
TC 21
Z9 21
U1 2
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1868-4483
J9 TRANSL STROKE RES
JI Transl. Stroke Res.
PD OCT
PY 2013
VL 4
IS 5
BP 554
EP 563
DI 10.1007/s12975-013-0268-z
PG 10
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 227IN
UT WOS:000325106200010
PM 24187596
ER
PT J
AU Small, AC
Tsao, CK
Moshier, EL
Gartrell, BA
Wisnivesky, JP
Godbold, J
Sonpavde, G
Palese, MA
Hall, SJ
Oh, WK
Galsky, MD
AF Small, Alexander C.
Tsao, Che-Kai
Moshier, Erin L.
Gartrell, Benjamin A.
Wisnivesky, Juan P.
Godbold, James
Sonpavde, Guru
Palese, Michael A.
Hall, Simon J.
Oh, William K.
Galsky, Matthew D.
TI Trends and variations in utilization of nephron-sparing procedures for
stage I kidney cancer in the United States
SO WORLD JOURNAL OF UROLOGY
LA English
DT Article
DE Renal surgery; Nephrectomy; Nephron-sparing surgery; Kidney cancer
ID RENAL-CELL CARCINOMA; RADICAL NEPHRECTOMY; DATA-BASE; TUMORS; OUTCOMES;
SURVIVAL; MORTALITY; SURGERY; IMPACT; MASSES
AB The incidental detection of early-stage kidney tumors is increasing in the United States. Nephron-sparing approaches (NS) to managing these tumors are equivalent to radical nephrectomy (RN) in oncologic outcomes and have a decreased impact on renal function. Our objective was to evaluate trends in the use of NS over the past decade and the socioeconomic factors associated with its use.
The National Cancer Database was queried to identify patients with stage I kidney cancer between 2000 and 2008. Patients were classified by the type of surgery as NS (local destruction and local excision) or RN. Patients were further categorized by age, race, insurance status, and income. Log-binomial regression was used to estimate prevalence ratios (PR) for the proportion of NS to RN according to demographic and socioeconomic characteristics.
From 2000 to 2008, there were 142,194 cases of kidney cancer reported to the NCDB. In these cases, 43,034 (30.3 %) patients had NS, and 86,431 (60.78 %) patients had RN. The prevalence of NS increased 10 % per year (PR = 1.10, p < 0.0001)-from 20.0 % in 2000 to 45.1 % in 2008. Older age, lower income, Black race, Hispanic ethnicity, and lack of health insurance were associated with a decreased prevalence of NS.
NS as a treatment for stage I kidney cancer has increased steadily since 2000. Age, racial, and socioeconomic differences may exist in the utilization of NS. Additional analyses, with patient level data, are required to address the independent significance of these variables in an effort to develop strategies to mitigate these potential disparities.
C1 [Small, Alexander C.; Tsao, Che-Kai; Moshier, Erin L.; Gartrell, Benjamin A.; Godbold, James; Oh, William K.; Galsky, Matthew D.] Mt Sinai Sch Med, Tisch Canc Inst, Div Hematol & Med Oncol, New York, NY 10029 USA.
[Wisnivesky, Juan P.] Mt Sinai Sch Med, Div Gen Internal Med, New York, NY 10029 USA.
[Wisnivesky, Juan P.] Mt Sinai Sch Med, Div Pulm & Crit Care Med, New York, NY 10029 USA.
[Sonpavde, Guru] Texas Oncol, Houston, TX USA.
[Sonpavde, Guru] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Sect Med Oncol, Houston, TX 77030 USA.
[Palese, Michael A.; Hall, Simon J.] Mt Sinai Sch Med, Dept Urol, New York, NY 10029 USA.
RP Galsky, MD (reprint author), Mt Sinai Sch Med, Tisch Canc Inst, Div Hematol & Med Oncol, 1 Gustave L Levy Pl, New York, NY 10029 USA.
EM matthew.galsky@mssm.edu
FU Doris Duke Charitable Foundation
FX Source of Funding: Doris Duke Charitable Foundation.
NR 29
TC 6
Z9 6
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-4983
J9 WORLD J UROL
JI World J. Urol.
PD OCT
PY 2013
VL 31
IS 5
BP 1211
EP 1217
DI 10.1007/s00345-012-0873-6
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA 226HJ
UT WOS:000325025500030
PM 22622394
ER
PT J
AU Gerson, LB
Vela, MF
Katz, PO
AF Gerson, Lauren B.
Vela, Marcelo F.
Katz, Philip O.
TI Stretta For Refractory GERD: Now More Than Ever Response
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Letter
ID GASTROESOPHAGEAL-REFLUX DISEASE; RADIOFREQUENCY ENERGY; SHAM; SYMPTOMS;
TRIAL
C1 [Gerson, Lauren B.] Stanford Univ, Div Gastroenterol & Hepatol, Redwood City, CA 94063 USA.
[Vela, Marcelo F.] Baylor Coll Med, Houston, TX 77030 USA.
[Vela, Marcelo F.] ME DeBakey VA Med Ctr, Houston, TX USA.
[Katz, Philip O.] Albert Einstein Med Ctr, Dept Gastroenterol, Philadelphia, PA 19141 USA.
RP Gerson, LB (reprint author), Stanford Univ, Div Gastroenterol & Hepatol, 450 Broadway St,Pavil C,Mail Code 5241, Redwood City, CA 94063 USA.
EM lgersonmd@yahoo.com
NR 9
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
IS 10
BP 1656
EP 1657
DI 10.1038/ajg.2013.283
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 229OI
UT WOS:000325276100018
PM 24091510
ER
PT J
AU Vela, MF
Gerson, LB
Katz, PO
AF Vela, Marcelo F.
Gerson, Lauren B.
Katz, Philip O.
TI Non-Erosive Reflux Disease is More Complex Than Negative Endoscopy Only
Response
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Letter
ID GASTROESOPHAGEAL-REFLUX; FUNDOPLICATION; INDEX
C1 [Vela, Marcelo F.] Baylor Coll Med, Div Gastroenterol & Hepatol, Houston, TX 77030 USA.
[Vela, Marcelo F.] ME DeBakey VA Med Ctr, Houston, TX USA.
[Gerson, Lauren B.] Stanford Univ, Div Gastroenterol & Hepatol, Stanford, CA 94305 USA.
[Katz, Philip O.] Albert Einstein Med Ctr, Dept Gastroenterol, Philadelphia, PA 19141 USA.
RP Vela, MF (reprint author), Baylor Coll Med, Div Gastroenterol, 1 Baylor Plaza,BCM 901, Houston, TX 77030 USA.
EM mvela@bcm.edu
NR 11
TC 1
Z9 1
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
IS 10
BP 1658
EP 1659
DI 10.1038/ajg.2013.284
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 229OI
UT WOS:000325276100020
PM 24091512
ER
PT J
AU Carter, CE
Katz, R
Kramer, H
de Boer, IH
Kestenbaum, BR
Peralta, CA
Siscovick, D
Sarnak, MJ
Levey, AS
Inker, LAS
Allison, MA
Criqui, MH
Shlipak, MG
Ix, JH
AF Carter, Caitlin E.
Katz, Ronit
Kramer, Holly
de Boer, Ian H.
Kestenbaum, Bryan R.
Peralta, Carmen A.
Siscovick, David
Sarnak, Mark J.
Levey, Andrew S.
Inker, Lesley A. S.
Allison, Matthew A.
Criqui, Michael H.
Shlipak, Michael G.
Ix, Joachim H.
TI Influence of Urine Creatinine Concentrations on the Relation of
Albumin-Creatinine Ratio With Cardiovascular Disease Events: The
Multi-Ethnic Study of Atherosclerosis (MESA)
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Article
DE Urine creatinine concentration; cardiovascular disease events
ID GLOMERULAR-FILTRATION-RATE; NONDIABETIC INDIVIDUALS; SERUM CREATININE;
BLOOD-PRESSURE; EXCRETION RATE; COOKED MEAT; RISK; MORTALITY; HEART;
METAANALYSIS
AB Background: Higher urine albumin-creatinine ratio (ACR) is associated with cardiovascular disease (CVD) events, an association that is stronger than that between spot urine albumin on its own and CVD. Urine creatinine excretion is correlated with muscle mass, and low muscle mass also is associated with CVD. Whether low urine creatinine concentration in the denominator of theACRcontributes to the association of ACR with CVD is uncertain.
Study Design: Prospective cohort study.
Setting & Participants: 6,770 community-living individuals without CVD.
Predictors: Spot urine albumin concentration, the reciprocal of the urine creatinine concentration (1/UCr), and ACR.
Outcome: Incident CVD events.
Results: During a mean of 7.1 years of follow-up, 281 CVD events occurred. Geometric mean values for spot urine creatinine concentration, urine albumin concentration, and ACR were 95 +/- 2 (SD) mg/dL, 0.7 +/- 3.7 mg/dL, and 7.0 +/- 3.1 mg/g. Urine creatinine concentration was lower in older, female, and low-weight individuals. Adjusted HRs per 2-fold higher increment in each urinary measure with CVD events were similar (1/UCr: 1.07 [95% CI, 0.94-1.22]; urine albumin concentration: 1.08 [95% CI, 1.01-1.14]; and ACR: 1.11 [95% CI, 1.04-1.18]). ACR >= 10 mg/g was associated more strongly with CVD events in individuals with low weight (HR for lowest vs highest tertile: 4.34 vs 1.97; P for interaction = 0.006). Low weight also modified the association of urine albumin concentration with CVD (P for interaction = 0.06), but 1/UCr did not (P for interaction = 0.9).
Limitations: We lacked 24-hour urine data.
Conclusions: Although ACR is associated more strongly with CVD events in persons with low body weight, this association is not driven by differences in spot urine creatinine concentration. Overall, the associations of ACR with CVD events appear to be driven primarily by urine albumin concentration and less by urine creatinine concentration. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is aUS Government Work. There are no restrictions on its use.
C1 [Carter, Caitlin E.; Ix, Joachim H.] Univ Calif San Diego, Dept Med, Div Nephrol & Hypertens, San Diego, CA 92161 USA.
[Katz, Ronit] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Kramer, Holly] Loyola Med Ctr, Dept Med, Div Nephrol & Hypertens, Maywood, IL USA.
[de Boer, Ian H.; Kestenbaum, Bryan R.] Univ Washington, Div Nephrol, Seattle, WA 98195 USA.
[de Boer, Ian H.; Kestenbaum, Bryan R.] Univ Washington, Dept Med, Kidney Res Inst, Seattle, WA USA.
[Peralta, Carmen A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Siscovick, David] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA.
[Siscovick, David] Univ Washington, Dept Epidemiol, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA.
[Sarnak, Mark J.; Levey, Andrew S.; Inker, Lesley A. S.] Tufts Med Ctr, Dept Med, Boston, MA USA.
[Allison, Matthew A.; Criqui, Michael H.; Ix, Joachim H.] Univ Calif San Diego, Dept Family & Prevent Med, Div Prevent Med, San Diego, CA 92161 USA.
[Shlipak, Michael G.] San Francisco VA Med Ctr, Div Gen Internal Med, San Francisco, CA USA.
[Ix, Joachim H.] Vet Affairs San Diego Healthcare Syst, Nephrol Sect, San Diego, CA 92161 USA.
RP Ix, JH (reprint author), Univ Calif San Diego, Dept Med, Div Nephrol & Hypertens, 3350 La Jolla Village Dr,Mail Code 111-H, San Diego, CA 92161 USA.
EM joeix@ucsd.edu
OI Kramer, Holly/0000-0002-6374-837X; Allison, Matthew/0000-0003-0777-8272
FU National Heart, Lung and Blood Institute [R01-HL-096851, T32 HL007261,
R21HL091217, N01-HC-95159, N01-HC-95166, N01-HC-95169, R01-HL-071739,
R01-HL-072403]
FX Supported by the National Heart, Lung and Blood Institute (grants
R01-HL-096851, T32 HL007261, and R21HL091217 and contracts N01-HC-95159,
N01-HC-95166, N01-HC-95169, R01-HL-071739, and R01-HL-072403).
NR 25
TC 4
Z9 4
U1 0
U2 4
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD OCT
PY 2013
VL 62
IS 4
BP 722
EP 729
DI 10.1053/j.ajkd.2013.05.010
PG 8
WC Urology & Nephrology
SC Urology & Nephrology
GA 224CB
UT WOS:000324858000013
PM 23830183
ER
PT J
AU Shariff, N
Desai, RV
Patel, K
Ahmed, MI
Fonarow, GC
Rich, MW
Aban, IB
Banach, M
Love, TE
White, M
Aronow, WS
Epstein, AE
Ahmed, A
AF Shariff, Nasir
Desai, Ravi V.
Patel, Kanan
Ahmed, Mustafa I.
Fonarow, Gregg C.
Rich, Michael W.
Aban, Inmaculada B.
Banach, Maciej
Love, Thomas E.
White, Michel
Aronow, Wilbert S.
Epstein, Andrew E.
Ahmed, Ali
TI Rate-control versus Rhythm-control Strategies and Outcomes in
Septuagenarians with Atrial Fibrillation
SO AMERICAN JOURNAL OF MEDICINE
LA English
DT Article
DE Atrial fibrillation; Hospitalization; Mortality; Propensity score; Older
adults; Rate control; Rhythm control
ID RENIN-ANGIOTENSIN INHIBITION; SYSTOLIC HEART-FAILURE; CHRONIC
KIDNEY-DISEASE; MANAGEMENT AFFIRM; PROPENSITY SCORE; RANDOMIZED-TRIAL;
COSTS; RISK
AB BACKGROUND: The prevalence of atrial fibrillation substantially increases after 70 years of age. However, the effect of rate-control versus rhythm-control strategies on outcomes in these patients remains unclear.
METHODS: In the randomized Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial, 4060 patients (mean age 70 years, range 49-80 years) with paroxysmal and persistent atrial fibrillation were randomized to rate-control versus rhythm-control strategies. Of these, 2248 were 70-80 years, of whom 1118 were in the rate-control group. Propensity scores for rate-control strategy were estimated for each of the 2248 patients and were used to assemble a cohort of 937 pairs of patients receiving rate-control versus rhythm-control strategies, balanced on 45 baseline characteristics.
RESULTS: Matched patients had a mean age of 75 years; 45% were women, 7% were nonwhite, and 47% had prior hospitalizations due to arrhythmias. During 3.4 years of mean follow-up, all-cause mortality occurred in 18% and 23% of matched patients in the rate-control and rhythm-control groups, respectively (hazard ratio [HR] associated with rate control, 0.77; 95% confidence interval [CI], 0.63-0.94; P = .010). HRs (95% CIs) for cardiovascular and noncardiovascular mortality associated with rate control were 0.88 (0.65-1.18) and 0.62 (0.46-0.84), respectively. All-cause hospitalization occurred in 61% and 68% of rate-control and rhythm-control patients, respectively (HR 0.76; 95% CI, 0.68-0.86). HRs (95% CIs) for cardiovascular and noncardiovascular hospitalization were 0.66 (0.56-0.77) and 1.07 (0.91-1.27), respectively.
CONCLUSION: In septuagenarian patients with atrial fibrillation, compared with rhythm-control, a rate-control strategy was associated with significantly lower mortality and hospitalization. (c) 2013 Elsevier Inc. All rights reserved.
C1 [Shariff, Nasir] Univ Pittsburgh, Pittsburgh, PA USA.
[Desai, Ravi V.] Lehigh Valley Hosp, Allentown, PA USA.
[Patel, Kanan; Ahmed, Mustafa I.; Aban, Inmaculada B.; Ahmed, Ali] Univ Alabama Birmingham, Birmingham, AL 35294 USA.
[Fonarow, Gregg C.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Rich, Michael W.] Washington Univ, St Louis, MO USA.
[Banach, Maciej] Med Univ Lodz, Lodz, Poland.
[Love, Thomas E.] Case Western Reserve Univ, Cleveland, OH 44106 USA.
[White, Michel] Montreal Heart Inst, Quebec City, PQ, Canada.
[Aronow, Wilbert S.] New York Med Coll, Valhalla, NY 10595 USA.
[Epstein, Andrew E.] Vet Affairs Med Ctr, Philadelphia, PA USA.
[Epstein, Andrew E.] Univ Penn, Philadelphia, PA 19104 USA.
[Ahmed, Ali] Vet Affairs Med Ctr, Birmingham, AL USA.
RP Ahmed, A (reprint author), Univ Alabama Birmingham, 1720 2nd Ave South,CH-19,Suite 219, Birmingham, AL 35294 USA.
EM aahmed@uab.edu
RI Banach, Maciej/A-1271-2009
OI Banach, Maciej/0000-0001-6690-6874
FU National Institutes of Health from the National Heart, Lung, and Blood
Institute [R01-HL085561, R01-HL085561-S, R01-HL097047]
FX AA was, in part, supported by the National Institutes of Health through
grants (R01-HL085561, R01-HL085561-S, and R01-HL097047) from the
National Heart, Lung, and Blood Institute and a generous gift from Ms.
Jean B. Morris of Birmingham, Alabama.
NR 31
TC 10
Z9 12
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9343
EI 1555-7162
J9 AM J MED
JI Am. J. Med.
PD OCT
PY 2013
VL 126
IS 10
BP 887
EP 893
DI 10.1016/j.amjmed.2013.04.021
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 218YV
UT WOS:000324469800024
PM 24054956
ER
PT J
AU Jin, JF
Zhang, XM
Lu, ZY
Perry, DM
Li, YC
Russo, SB
Cowart, LA
Hannun, YA
Huang, Y
AF Jin, Junfei
Zhang, Xiaoming
Lu, Zhongyang
Perry, David M.
Li, Yanchun
Russo, Sarah Brice
Cowart, L. Ashley
Hannun, Yusuf A.
Huang, Yan
TI Acid sphingomyelinase plays a key role in palmitic acid-amplified
inflammatory signaling triggered by lipopolysaccharide at low
concentrations in macrophages
SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
LA English
DT Article
DE fatty acid; sphingomyelinase; lipopolysaccharide; toll-like receptor;
inflammation
ID FATTY-ACIDS; INSULIN-RESISTANCE; HUMAN MONOCYTES; SPHINGOLIPID
BIOSYNTHESIS; CERAMIDE SYNTHESIS; INTERLEUKIN-6; MECHANISMS; EXPRESSION;
ENDOTOXIN; IL-6
AB Periodontal disease is more prevalent and severe in patients with diabetes than in nondiabetic patients. In addition to diabetes, a large number of studies have demonstrated an association between obesity and chronic periodontal disease. However, the underlying mechanisms have not been well understood. Since plasma free fatty acids (FAs) are elevated in obese patients and saturated FAs such as palmitic acid (PA) have been shown to increase host inflammatory response, we sought to find out how PA interacts with lipopolysaccharide (LPS), an important pathological factor involved in periodontal disease, to enhance inflammation. We found that whereas low concentration of LPS (1 ng/ml) stimulated interleukin (IL)-6 expression in RAW 264.7 macrophages, PA further augmented it fourfold. Besides IL-6, PA amplified the stimulatory effect of LPS on a large amount of Toll-like receptor (TLR) 4-mediated expression of proinflammatory signaling molecules such as IL-1 receptor-associated kinase-like 2 and proinflammatory molecules, including monocyte chemotactic protein-1 and colony-stimulating factor. We also observed that PA augmented TLR4 but not TLR2 signal, and the augmentation was mediated by nuclear factor-kappa B (NF-kappa B) pathways. To further elucidate the regulatory mechanism whereby PA amplifies LPS signal, our studies showed that PA and LPS synergistically increased hydrolysis of sphingomyelin by stimulating acid sphingomyelinase (ASMase) activity, which contributed to a marked increase in ceramide production and IL-6 upregulation. Taken together, this study has demonstrated that PA markedly augments TLR4-mediated proinflammatory signaling triggered by low concentration of LPS in macrophages, and ASMase plays a key role in the augmentation.
C1 [Lu, Zhongyang; Cowart, L. Ashley; Huang, Yan] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29403 USA.
[Jin, Junfei; Zhang, Xiaoming; Li, Yanchun; Huang, Yan] Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA.
[Perry, David M.; Russo, Sarah Brice; Cowart, L. Ashley] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
[Hannun, Yusuf A.] SUNY Stony Brook, Stony Brook Canc Ctr, Stony Brook, NY 11794 USA.
RP Huang, Y (reprint author), Ralph H Johnson Vet Affairs Med Ctr, 114 Doughty St, Charleston, SC 29403 USA.
EM huangyan@musc.edu
FU Biomedical Laboratory Research and Development Program of the Department
of Veterans Affairs; National Institutes of Health [DE-016353,
CA-97132]; Lipidomics Shared Resource, Hollings Cancer Center, Medical
University of South Carolina [P30 CA138313]; Lipidomics Core in the SC
Lipidomics and Pathobiology COBRE [P20 RR017677]; National Center for
Research Resources; Office of the Director of the National Institutes of
Health [C06 RR-018823]
FX This work was supported by the Biomedical Laboratory Research and
Development Program of the Department of Veterans Affairs and National
Institutes of Health Grant DE-016353 (to Y. Huang) and Grant CA-97132
(to Y. A. Hannun). The work on sphingolipid analysis was supported in
part by the Lipidomics Shared Resource, Hollings Cancer Center, Medical
University of South Carolina (P30 CA138313), the Lipidomics Core in the
SC Lipidomics and Pathobiology COBRE (P20 RR017677), and the National
Center for Research Resources and the Office of the Director of the
National Institutes of Health through Grant No. C06 RR-018823.
NR 54
TC 17
Z9 17
U1 2
U2 10
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0193-1849
J9 AM J PHYSIOL-ENDOC M
JI Am. J. Physiol.-Endocrinol. Metab.
PD OCT
PY 2013
VL 305
IS 7
BP E853
EP E867
DI 10.1152/ajpendo.00251.2013
PG 15
WC Endocrinology & Metabolism; Physiology
SC Endocrinology & Metabolism; Physiology
GA 230MO
UT WOS:000325344800010
PM 23921144
ER
PT J
AU Gabler, NB
Ratcliffe, SJ
Wagner, J
Asch, DA
Rubenfeld, GD
Angus, DC
Halpern, SD
AF Gabler, Nicole B.
Ratcliffe, Sarah J.
Wagner, Jason
Asch, David A.
Rubenfeld, Gordon D.
Angus, Derek C.
Halpern, Scott D.
TI Mortality among Patients Admitted to Strained Intensive Care Units
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article
DE critical care; resource allocation; intensive care unit; physician
staffing; regionalization
ID CRITICALLY-ILL PATIENTS; OUTCOMES; STATES; WORKLOAD; REGIONALIZATION;
POPULATION; ALLOCATION; OCCUPANCY; SHORTAGE; CRISIS
AB Rationale: The aging population may strain intensive care unit (ICU) capacity and adversely affect patient outcomes. Existing fluctuations in demand for ICU care offer an opportunity to explore such relationships.
Objectives: To determine whether transient increases in ICU strain influence patient mortality, and to identify characteristics of ICUs that are resilient to surges in capacity strain.
Methods: Retrospective cohort study of 264,401 patients admitted to 155 U. S. ICUs from 2001 to 2008. We used logistic regression to examine relationships of measures of ICU strain (census, average acuity, and proportion of new admissions) near the time of ICU admission with mortality.
Measurements and Main Results: A total of 36,465 (14%) patients died in the hospital. ICU census on the day of a patient's admission was associated with increased mortality (odds ratio [OR], 1.02 per standardized unit increase; 95% confidence interval [CI]: 1.00, 1.03). This effect was greater among ICUs employing closed (OR, 1.07; 95% CI: 1.02, 1.12) versus open (OR, 1.01; 95% CI: 0.99, 1.03) physician staffing models (interaction P value = 0.02). The relationship between census and mortality was stronger when the census was composed of higher acuity patients (interaction P value < 0.01). Averaging strain over the first 3 days of patients' ICU stays yielded similar results except that the proportion of new admissions was now also associated with mortality (OR, 1.04 for each 10% increase; 95% CI: 1.02, 1.06).
Conclusions: Several sources of ICU strain are associated with small but potentially important increases in patient mortality, particularly in ICUs employing closed staffing models. Although closed ICUs may promote favorable outcomes under static conditions, they are susceptible to being overwhelmed by patient influxes.
C1 [Gabler, Nicole B.; Ratcliffe, Sarah J.; Halpern, Scott D.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
[Gabler, Nicole B.; Wagner, Jason; Angus, Derek C.; Halpern, Scott D.] Univ Penn, Fostering Improvement End of Life Decis Sci FIELD, Philadelphia, PA 19104 USA.
[Wagner, Jason; Halpern, Scott D.] Univ Penn, Dept Med, Div Pulm Allergy & Crit Care Med, Philadelphia, PA 19104 USA.
[Asch, David A.; Halpern, Scott D.] Univ Penn, Ctr Innovat, Philadelphia, PA 19104 USA.
[Asch, David A.; Halpern, Scott D.] Univ Penn, Ctr Hlth Incent & Behav Econ, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
[Asch, David A.; Halpern, Scott D.] Univ Penn, Perelman Sch Med, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA.
[Asch, David A.] VA Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
[Rubenfeld, Gordon D.] Sunnybrook Hlth Sci Ctr, Program Trauma Crit Care & Emergency Med, Toronto, ON M4N 3M5, Canada.
[Angus, Derek C.] Univ Pittsburgh, Sch Med, Dept Crit Care, Pittsburgh, PA USA.
RP Halpern, SD (reprint author), Univ Penn, Perelman Sch Med, 719 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM shalpern@exchange.upenn.edu
OI Asch, David/0000-0002-7970-286X; Ratcliffe, Sarah/0000-0002-6644-8284
FU Agency for Healthcare Research and Quality [K08HS018406]; Society of
Critical Care Medicine Vision Grant
FX Supported by K08HS018406 from the Agency for Healthcare Research and
Quality and a Society of Critical Care Medicine Vision Grant (S.D.H.).
NR 37
TC 27
Z9 28
U1 0
U2 8
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD OCT 1
PY 2013
VL 188
IS 7
BP 800
EP 806
DI 10.1164/rccm.201304-0622OC
PG 7
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 230OG
UT WOS:000325350600010
PM 23992449
ER
PT J
AU Puterman, E
Epel, ES
Lin, J
Blackburn, EH
Gross, JJ
Whooley, MA
Cohen, BE
AF Puterman, Eli
Epel, Elissa S.
Lin, Jue
Blackburn, Elizabeth H.
Gross, James J.
Whooley, Mary A.
Cohen, Beth E.
TI Multisystem resiliency moderates the major depression-Telomere length
association: Findings from the Heart and Soul Study
SO BRAIN BEHAVIOR AND IMMUNITY
LA English
DT Article
DE Major depressive disorder; Telomeres; Cell aging; Resiliency; Social
connections; Emotion regulation; Physical activity
ID ALL-CAUSE MORTALITY; PHYSICAL-ACTIVITY; SOCIAL SUPPORT; EMOTION
REGULATION; OLDER-ADULTS; CARDIOVASCULAR MORTALITY; DISPOSITIONAL
OPTIMISM; INDIVIDUAL-DIFFERENCES; POSTMENOPAUSAL WOMEN; OXIDATIVE STRESS
AB Major depressive disorder (MDD) has been associated with reduced leukocyte telomere length (LTL). It is not known, however, whether psychosocial and behavioral protective factors moderate this association. In the current study, we examine whether multisystem resiliency - defined by healthy emotion regulation, strong social connections, and health behaviors (sleep and exercise) - predicts LTL and mitigates previously demonstrated associations between depression diagnosis and LTL. LTL was measured, using a quantitative PCR assay, in 954 patients with stable cardiovascular disease in the Heart and Soul Study. In a fully adjusted model, high multisystem resiliency predicted longer LTL (b = 80.00, SE = 27.17, p = .003), whereas each individual factor did not. Multisystem resiliency significantly moderated the MDD-LTL association (p = .02). Specifically, MDD was significantly related to LTL at 1 SD below the mean of multisystem resiliency (b = -142.86, SE = 56.46, p = .01), but not at I SD above the mean (b = 49.07, SE = 74.51, p = .51). This study suggests that MDD associations with biological outcomes should be examined within a psychosocial-behavioral context, because this context shapes the nature of the direct relationship. Further research should explore the cognitive, neural, and other physiological pathways through which multisystem resiliency may confer biological benefit. (c) 2013 Elsevier Inc. All rights reserved.
C1 [Puterman, Eli; Epel, Elissa S.; Lin, Jue; Blackburn, Elizabeth H.; Whooley, Mary A.; Cohen, Beth E.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Gross, James J.] Stanford Univ, Stanford, CA 94305 USA.
[Whooley, Mary A.; Cohen, Beth E.] San Francisco Vet Adm Med Ctr, San Francisco, CA 94143 USA.
RP Puterman, E (reprint author), Univ Calif San Francisco, 3333 Calif St Suite 465, San Francisco, CA 94143 USA.
EM eli.puterman@ucsf.edu
OI Puterman, Eli/0000-0002-5898-2348
FU NIH/NHLBI Grant [K99HL109247, K23 HL 094765-01]; Robert Wood Johnson
Foundation; Irene Perstein Foundation; Department of Veterans Affairs,
Washington, DC; National Heart Lung and Blood Institute, Bethesda, MD
[R01 HL079235]; American Federation for Aging Research (Paul Beeson
Scholars Program), New York, NY; Robert Wood Johnson Foundation (Faculty
Scholars Program), Princeton, NJ; Ischemia Research and Education
Foundation, South San Francisco, CA; Nancy Kirwan Heart Research Fund,
San Francisco, CA
FX We thank the study participants for their support and generous
contribution of time. This research was supported in part by NIH/NHLBI
Grant K99HL109247 and the Robert Wood Johnson Foundation to Dr. Puterman
and NIH/NHLBI Grant K23 HL 094765-01 and a Grant from the Irene Perstein
Foundation to Dr. Cohen. The Heart and Soul Study was funded by the
Department of Veterans Affairs, Washington, DC, the National Heart Lung
and Blood Institute (R01 HL079235), Bethesda, MD, the American
Federation for Aging Research (Paul Beeson Scholars Program), New York,
NY, the Robert Wood Johnson Foundation (Faculty Scholars Program),
Princeton, NJ, the Ischemia Research and Education Foundation, South San
Francisco, CA, and the Nancy Kirwan Heart Research Fund, San Francisco,
CA. This material is the result of work supported with resources and the
use of facilities at the Veterans Affairs Medical Center, San Francisco,
CA. The funding organizations had no role in the design or conduct of
the study; data collection, management, analysis or interpretation of
the data; or preparation, review or approval of the manuscript.
NR 110
TC 18
Z9 19
U1 3
U2 33
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0889-1591
J9 BRAIN BEHAV IMMUN
JI Brain Behav. Immun.
PD OCT
PY 2013
VL 33
BP 65
EP 73
DI 10.1016/j.bbi.2013.05.008
PG 9
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA 223EU
UT WOS:000324788300010
PM 23727245
ER
PT J
AU Abraham, NS
Richardson, P
Castillo, D
Kane, SV
AF Abraham, Neena S.
Richardson, Peter
Castillo, Diana
Kane, Sunanda V.
TI Dual Therapy With Infliximab and Immunomodulator Reduces One-Year Rates
of Hospitalization and Surgery Among Veterans With Inflammatory Bowel
Disease
SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Article
DE Remicade; Imuran; Anti-Tumor Necrosis Factor (TNF)-alpha; Patient
Management; Therapeutic Strategy
ID QUALITY-OF-LIFE; CROHNS-DISEASE; MAINTENANCE THERAPY;
ULCERATIVE-COLITIS; COMBINATION THERAPY; CERTOLIZUMAB PEGOL; PROPENSITY
SCORE; CHARM TRIAL; ADALIMUMAB; REMISSION
AB BACKGROUND & AIMS: Effectiveness of early treatment with biologics and immunomodulator therapy on healthcare utilization remains poorly defined. We assessed rates of hospitalization and surgery within 1 year after initiation of infliximab and/or immunomodulator therapy in a United States cohort of patients with inflammatory bowel disease.
METHODS: We conducted a retrospective, observational cohort study of veterans with Crohn's disease or ulcerative colitis by using administrative data from 176 Department of Veteran Affairs facilities (October 1, 2001 through September 30, 2009). Inpatient, outpatient, and death records were linked longitudinally with prescription fill data. Each person-day of follow-up was assessed for treatment with infliximab, immunomodulators, both (dual therapy), or neither. We calculated drug exposure time and used Poisson and logistic regression analyses to assess outcomes.
RESULTS: The cohort of 20,474 patients included 8042 patients with Crohn's disease and 12,432 with ulcerative colitis (93.9% male; 72.5% white; mean age, 60.9 +/- 14.5 years) prescribed infliximab (0.17%), immunomodulator (1.3%), or dual therapy (1.5%). Adjusted models revealed 50% relative reductions in hospitalization among patients who received 9.2 months of immunomodulator monotherapy, 8 months of infliximab, or 7.7 months of dual therapy. A 50% relative reduction in surgery was observed among patients receiving 7 months of infliximab or 5 months of dual therapy. Analysis of dose-response data revealed 73.1% and 92% reductions in risk of hospitalization and surgery, respectively, after 9 months of dual therapy.
CONCLUSIONS: On the basis of a retrospective cohort study, dual therapy with infliximab and an immunomodulator for <8 months is associated with significant reductions in hospitalization and surgery within 1 year of the start of therapy. These findings indicate that patients with IBD are more likely to benefit if dual therapy is initiated earlier in their first year of therapy.
C1 [Abraham, Neena S.] Baylor Coll Med, Div Gastroenterol & Hepatol, Sect Digest Dis, Houston, TX 77030 USA.
[Abraham, Neena S.; Richardson, Peter; Castillo, Diana] Baylor Coll Med, Houston VA Hlth Serv Res & Dev Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Kane, Sunanda V.] Mayo Clin, Div Gastroenterol & Hepatol, Coll Med, Scottsdale, AZ 85259 USA.
RP Abraham, NS (reprint author), Mayo Clin, Div Gastroenterol, 13400 East Shea Blvd, Scottsdale, AZ 85259 USA.
EM abraham.neena@mayo.edu
FU Janssen Biotech, Inc.
FX Supported by an investigator-initiated grant from Janssen Biotech, Inc.
NR 42
TC 9
Z9 9
U1 1
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1542-3565
J9 CLIN GASTROENTEROL H
JI Clin. Gastroenterol. Hepatol.
PD OCT
PY 2013
VL 11
IS 10
BP 1281
EP 1287
DI 10.1016/j.cgh.2013.06.004
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 223QU
UT WOS:000324823200016
PM 23792295
ER
PT J
AU Raab, PA
Mackintosh, MA
Gros, DF
Morland, LA
AF Raab, Phillip A.
Mackintosh, Margaret-Anne
Gros, Daniel F.
Morland, Leslie A.
TI Influence of Depression on State and Trait Anger in Veterans with
Posttraumatic Stress Disorder (vol 37, pg 673, 2013)
SO COGNITIVE THERAPY AND RESEARCH
LA English
DT Correction
C1 [Raab, Phillip A.; Mackintosh, Margaret-Anne; Morland, Leslie A.] Natl Ctr Posttraumat Stress Disorder, Dept Vet Affairs Pacific Isl Healthcare Syst, Pacific Isl Div, Honolulu, HI 96819 USA.
[Raab, Phillip A.; Mackintosh, Margaret-Anne; Morland, Leslie A.] Pacific Hlth Res & Educ Inst, Honolulu, HI USA.
[Gros, Daniel F.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
[Gros, Daniel F.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Morland, Leslie A.] Univ Hawaii Manoa, John A Burns Sch Med, Honolulu, HI 96822 USA.
RP Raab, PA (reprint author), Natl Ctr Posttraumat Stress Disorder, Dept Vet Affairs Pacific Isl Healthcare Syst, Pacific Isl Div, 3375 Koapaka,Suite 1-560, Honolulu, HI 96819 USA.
EM drewraab@gmail.com
NR 1
TC 0
Z9 0
U1 1
U2 4
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0147-5916
J9 COGNITIVE THER RES
JI Cogn. Ther. Res.
PD OCT
PY 2013
VL 37
IS 5
BP 1089
EP 1090
DI 10.1007/s10608-013-9534-3
PG 2
WC Psychology, Clinical
SC Psychology
GA 223PD
UT WOS:000324817600021
ER
PT J
AU Cohen, R
Caravatto, PP
Petry, T
Cummings, D
AF Cohen, Ricardo
Caravatto, Pedro Paulo
Petry, Tarissa
Cummings, David
TI Role of Metabolic Surgery in Less Obese or Non-Obese Subjects with Type
2 Diabetes: Influence Over Cardiovascular Events
SO CURRENT ATHEROSCLEROSIS REPORTS
LA English
DT Article
DE Type 2 diabetes mellitus; Metabolic surgery; Bariatric surgery; Obesity;
Gastrointestinal surgery
ID GASTRIC BYPASS-SURGERY; BODY-MASS INDEX; LIFE-STYLE INTERVENTION;
BARIATRIC SURGERY; WEIGHT-LOSS; MULTIFACTORIAL INTERVENTION; SLEEVE
GASTRECTOMY; MEDICAL THERAPY; PREVALENCE; MORTALITY
AB Bariatric surgery was initially developed as a tool for weight reduction only, but it is gaining increasing popularity because of its remarkable effect on glucose metabolism in morbidly obese and less obese patients. Recent publications have shown the good results of metabolic surgery, creating a new field of clinical research that is currently overflowing in the medical community with outstanding high-quality data. In morbidly obese population, there is compelling data on long term cardiovascular risk reduction and mortality, coming from longitudinal prospective studies and systematic reviews. Numbers range from 33 to 92 % of decrease in fatal and nonfatal cardiovascular events. In low body mass index (BMI) diabetics, there is an increasing number of reported good outcomes after metabolic surgery with the aim to treat type 2 diabetes (T2DM). There is scarce information on cardiovascular outcomes in non-morbidly obese subjects, but the extraordinary glucose, lipid and blood pressure control in the published series are suggesting good long-term effects on cardiovascular risk profile and mortality. The papers review was comprehensive, including the available randomized controlled trials, long-term prospective series and systematic reviews.
C1 [Cohen, Ricardo; Caravatto, Pedro Paulo; Petry, Tarissa] Oswaldo Cruz Hosp, Ctr Excellence Metab & Bariatr Surg, Sao Paulo, Brazil.
[Cummings, David] Univ Washington, Sch Med, Diabet & Obes Ctr Excellence, Seattle, WA USA.
[Cummings, David] Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
RP Cohen, R (reprint author), Oswaldo Cruz Hosp, Ctr Excellence Metab & Bariatr Surg, Sao Paulo, Brazil.
EM ricardo.cohen@haoc.com.br
NR 54
TC 4
Z9 4
U1 0
U2 9
PU CURRENT MEDICINE GROUP
PI PHILADELPHIA
PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA
SN 1523-3804
J9 CURR ATHEROSCLER REP
JI Curr. Atheroscleros. Rep.
PD OCT
PY 2013
VL 15
IS 10
AR 355
DI 10.1007/s11883-013-0355-3
PG 6
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 221EF
UT WOS:000324639800001
PM 23955664
ER
PT J
AU Kwee, TC
Cheng, G
Lam, MGEH
Basu, S
Alavi, A
AF Kwee, Thomas C.
Cheng, Gang
Lam, Marnix G. E. H.
Basu, Sandip
Alavi, Abass
TI SUVmax of 2.5 should not be embraced as a magic threshold for separating
benign from malignant lesions
SO EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
LA English
DT Editorial Material
ID DUAL TIME-POINT; PARTIAL VOLUME CORRECTION; STANDARDIZED UPTAKE VALUE;
FDG-PET; INDETERMINATE BIOPSY; METABOLIC BIOPSY; NODULES; TOOL
C1 [Kwee, Thomas C.; Lam, Marnix G. E. H.] Univ Med Ctr Utrecht, Dept Radiol & Nucl Med, Utrecht, Netherlands.
[Cheng, Gang] Philadelphia VA Med Ctr, Dept Radiol, Philadelphia, PA USA.
[Cheng, Gang; Alavi, Abass] Hosp Univ Penn, Dept Radiol, Div Nucl Med, Philadelphia, PA 19104 USA.
[Basu, Sandip] Tata Mem Ctr Annexe, Bhabha Atom Res Ctr, Radiat Med Ctr, Bombay, Maharashtra, India.
RP Alavi, A (reprint author), Hosp Univ Penn, Dept Radiol, Div Nucl Med, 3400 Spruce St,110 Donner Bldg, Philadelphia, PA 19104 USA.
EM abass.alavi@uphs.upenn.edu
NR 17
TC 11
Z9 11
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1619-7070
J9 EUR J NUCL MED MOL I
JI Eur. J. Nucl. Med. Mol. Imaging
PD OCT
PY 2013
VL 40
IS 10
BP 1475
EP 1477
DI 10.1007/s00259-013-2484-x
PG 3
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 221GE
UT WOS:000324645100001
PM 23801170
ER
PT J
AU Cooper, JN
Fried, L
Tepper, P
Barinas-Mitchell, E
Conroy, MB
Evans, RW
Brooks, MM
Woodard, GA
Sutton-Tyrrell, K
AF Cooper, Jennifer N.
Fried, Linda
Tepper, Ping
Barinas-Mitchell, Emma
Conroy, Molly B.
Evans, Rhobert W.
Brooks, Maria Mori
Woodard, Genevieve A.
Sutton-Tyrrell, Kim
TI Changes in serum aldosterone are associated with changes in
obesity-related factors in normotensive overweight and obese young
adults
SO HYPERTENSION RESEARCH
LA English
DT Article
DE adipokines; adipose tissue; aldosterone; metabolic syndrome; obesity
ID RENIN-ANGIOTENSIN SYSTEM; BLOOD-PRESSURE; WEIGHT-LOSS;
PLASMA-ALDOSTERONE; METABOLIC SYNDROME; ADIPOSE-TISSUE;
INSULIN-RESISTANCE; MINERALOCORTICOID RECEPTOR; SCIENTIFIC STATEMENT;
NERVOUS-SYSTEM
AB Recent data suggest excess circulating aldosterone promotes cardiometabolic decline. Weight loss may lower aldosterone levels, but little longitudinal data is available in normotensive adults. We aimed to determine whether, independent of changes in sodium excretion, reductions in serum aldosterone are associated with favorable changes in obesity-related factors in normotensive overweight/obese young adults. We studied 285 overweight/obese young adult participants (body mass index >= 25 and<40 kg m(-2), age 20-45 years) in a clinical trial examining the effects of a 1-year diet and physical activity intervention with or without sodium restriction on vascular health. Body weight, serum aldosterone, 24-h sodium and potassium excretion and obesity-related factors were measured at baseline, 6, 12 and 24 months. Weight loss was significant at 6 (7%), 12 (6%) and 24 months (4%; all P<0.0001). Decreases in aldosterone were associated with decreases in C-reactive protein, leptin, insulin, homeostasis assessment of insulin resistance, heart rate, tonic cardiac sympathovagal balance and increases in adiponectin (all P<0.05) in models adjusting for baseline age, sex, race, intervention arm, time since baseline, and sodium and potassium excretion. Weight loss and reductions in thigh intermuscular fat (intermuscular adipose tissue area; IMAT) were associated with decreases in aldosterone in the subgroup (n = 98) with metabolic syndrome (MetS) at baseline (MetS x weight loss, P = 0.04; MetS x change in IMAT, P 0.04). Favorable changes in obesity-related factors are associated with reductions in aldosterone in young adults with no risk factors besides excess weight, an important finding, given aldosterone's emergence as an important cardiometabolic risk factor.
C1 [Cooper, Jennifer N.; Fried, Linda; Tepper, Ping; Barinas-Mitchell, Emma; Conroy, Molly B.; Evans, Rhobert W.; Brooks, Maria Mori; Woodard, Genevieve A.; Sutton-Tyrrell, Kim] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15261 USA.
[Cooper, Jennifer N.; Brooks, Maria Mori] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA.
[Fried, Linda] VA Pittsburgh Healthcare Syst, Univ Dr Div, Pittsburgh, PA USA.
[Conroy, Molly B.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA 15261 USA.
RP Cooper, JN (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Epidemiol Data Ctr, 130 DeSoto St, Pittsburgh, PA 15261 USA.
EM jennifer.njoroge@gmail.com
OI Brooks, Maria/0000-0002-2030-7873; Barinas-Mitchell,
Emma/0000-0002-7280-7781
FU National Heart, Lung, and Blood Institute of the National Institutes of
Health [R01 HL077525, F31 HL106986]
FX This work was supported by Grants R01 HL077525 and F31 HL106986 from the
National Heart, Lung, and Blood Institute of the National Institutes of
Health. We thank Beth Hauth for expert laboratory analyses. We greatly
appreciate the efforts of the SAVE trial volunteers and the study and
clinic coordinators (Laura Kinzel and Eileen Cole).
NR 42
TC 9
Z9 9
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0916-9636
J9 HYPERTENS RES
JI Hypertens. Res.
PD OCT
PY 2013
VL 36
IS 10
BP 895
EP 901
DI 10.1038/hr.2013.45
PG 7
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 230GR
UT WOS:000325325600013
PM 23657296
ER
PT J
AU Richter, HE
Morgan, SL
Gleason, JL
Szychowski, JM
Goode, PS
Burgio, KL
AF Richter, Holly E.
Morgan, Sarah L.
Gleason, Jonathan L.
Szychowski, Jeff M.
Goode, Patricia S.
Burgio, Kathryn L.
TI Pelvic floor symptoms and bone mineral density in women undergoing
osteoporosis evaluation
SO INTERNATIONAL UROGYNECOLOGY JOURNAL
LA English
DT Article
DE Pelvic floor disorders; Bone mineral density; Pathophysiology
ID STRESS URINARY-INCONTINENCE; FECAL INCONTINENCE; ORGAN PROLAPSE; OLDER
WOMEN; QUESTIONNAIRES; PREVALENCE; DISORDERS; ADULTS; TRENDS; ICIQ
AB Our aim was to characterize pelvic floor symptoms in postmenopausal women who had undergone osteoporosis evaluation and examine their association with bone mineral density (BMD).
Pelvic floor symptom questionnaires were mailed to 4,026 women. Multivariate logistic regression models controlling for age, race, body mass index (BMI), and chronic obstructive pulmonary disease (COPD) were performed comparing symptoms in women with osteoporosis (T score a parts per thousand currency sign -2.5) and osteopenia (T score > -2.5 to < -1) at any site to women with normal BMD (T score: a parts per thousand yen -1, referent).
There were 1,774/4,026 (44 %) questionnaires returned; 1,655 were included in the analysis (362 osteoporosis, 870 osteopenia, 423 normal BMD). Overall prevalence of any urinary incontinence (UI) was 1,226/1,640 (75 %), with UI a parts per thousand yen2-3 times/week in 699/1,197 (58 %), fecal incontinence over the past month in 247/1,549 (16 %), and prolapse in 162/1,582 (10 %). Multivariate analyses revealed that women with osteopenia had increased risk of incontinence of solid stool [adjusted odds ratio (aOR) 1.7, 95 % confidence interval (CI) 1.1-2.4). Risk of UI a parts per thousand yen2-3 times/week was not increased in women with osteoporosis (aOR 0.9, CI 0.6-1.3) and was lower in women with osteopenia (aOR 0.7, CI 0.5-0.9). In women with osteoporosis, the odds of moderate- to large-volume urine loss versus small/none was higher for those in the lower T-score quartile (lower BMD; aOR 1.43, CI 1.1-1.9).
In women undergoing osteoporosis evaluation, those with osteopenia were at increased risk of fecal incontinence but not UI compared with normal women. Osteoporotic women with the lowest T scores had higher risk of moderate- to large-volume UI. It is unclear whether there is a pathophysiologic link between BMD loss and development of pelvic floor symptoms.
C1 [Richter, Holly E.; Morgan, Sarah L.; Gleason, Jonathan L.; Szychowski, Jeff M.; Goode, Patricia S.; Burgio, Kathryn L.] Univ Alabama Birmingham, Birmingham, AL 35233 USA.
[Goode, Patricia S.; Burgio, Kathryn L.] Birmingham VA Med Ctr, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Birmingham, AL USA.
RP Richter, HE (reprint author), Univ Alabama Birmingham, 1700 6th Av South,Suite 10382, Birmingham, AL 35233 USA.
EM hrichter@uabmc.edu
FU HER-Astellas Consultant, Pelvalon [COI]; SLM-ISCD Board [COI]; JLG;
PSG-Pfizer [COI]; KLB-Pfizer Consultant [COI]; University of Alabama at
Birmingham, Protective Life Clinical Initiatives (PLCI) Award Program;
National Institutes of Diabetes and Digestive and Kidney Diseases
[2K24-DK068389]
FX HER-Astellas Consultant, Pelvalon research funding, no COI; SLM-ISCD
Board and Amgen Consultant, no COI; JLG-no disclosures or COI; JMS-no
disclosures or COI; PSG-Pfizer research funding, no COI; KLB-Pfizer
Consultant, no COI. Funding sources wer the University of Alabama at
Birmingham, Protective Life Clinical Initiatives (PLCI) Award Program;
partially supported by the National Institutes of Diabetes and Digestive
and Kidney Diseases, 2K24-DK068389 to HER
NR 27
TC 4
Z9 4
U1 0
U2 1
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937-3462
J9 INT UROGYNECOL J
JI Int. Urogynecol. J.
PD OCT
PY 2013
VL 24
IS 10
BP 1663
EP 1669
DI 10.1007/s00192-013-2056-4
PG 7
WC Obstetrics & Gynecology; Urology & Nephrology
SC Obstetrics & Gynecology; Urology & Nephrology
GA 221HD
UT WOS:000324647700011
PM 23389642
ER
PT J
AU Steidtmann, D
Manber, R
Blasey, C
Markowitz, JC
Klein, DN
Rothbaum, BO
Thase, ME
Kocsis, JH
Arnow, BA
AF Steidtmann, Dana
Manber, Rachel
Blasey, Christine
Markowitz, John C.
Klein, Daniel N.
Rothbaum, Barbara O.
Thase, Michael E.
Kocsis, James H.
Arnow, Bruce A.
TI Detecting Critical Decision Points in Psychotherapy and Psychotherapy
plus Medication for Chronic Depression
SO JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY
LA English
DT Article
DE chronic depression; psychotherapy for depression; psychotherapy
nonremission; adaptive designs; receiver operating curve
ID STAR-ASTERISK-D; SEQUENCED TREATMENT ALTERNATIVES; ADAPTIVE TREATMENT
STRATEGY; PSYCHOMETRIC PROPERTIES; ALGORITHM PROJECT; TREATMENT FAILURE;
FEEDBACK; ANTIDEPRESSANTS; DISORDER; OUTCOMES
AB Objective: We sought to quantify clinical decision points for identifying depression treatment nonremitters prior to end-of-treatment. Method: Data came from the psychotherapy arms of a randomized clinical trial for chronic depression. Participants (n = 352; 65.6% female; 92.3% White; mean age = 44.3 years) received 12 weeks of cognitive behavioral analysis system of psychotherapy (CBASP) or CBASP plus an antidepressant medication. In half of the sample, receiver operating curve analyses were used to identify efficient percentage of symptom reduction cut points on the Inventory of Depressive Symptoms-Self-Report (IDS-SR) for predicting end-of-treatment nonremission based on the Hamilton Rating Scale for Depression (HRSD). Sensitivity, specificity, predictive values, and Cohen's kappa for identified cut points were calculated using the remaining half of the sample. Results: Percentage of IDS-SR symptom reduction at Weeks 6 and 8 predicted end-of-treatment HRSD remission status in both the combined treatment (Week 6 cut point = 50.0%, Cohen's kappa = .42; Week 8 cut point = 54.3%, Cohen's kappa = .45) and psychotherapy only (Week 6 cut point = 60.7%, Cohen's kappa = .41; Week 8 cut point = 48.7%, Cohen's kappa = .49). Status at Week 8 was more reliable for identifying nonremitters in psychotherapy-only treatment. Conclusions: Those with chronic depression who will not remit in structured, time-limited psychotherapy for depression, either with therapy alone or in combination with antidepressant medication, are identifiable prior to end of treatment. Findings provide an operationalized strategy for designing adaptive psychotherapy interventions.
C1 [Steidtmann, Dana; Manber, Rachel; Blasey, Christine; Arnow, Bruce A.] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA.
[Markowitz, John C.] Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY USA.
[Markowitz, John C.] New York State Psychiat Inst & Hosp, New York, NY 10032 USA.
[Klein, Daniel N.] SUNY Stony Brook, Dept Psychol, Stony Brook, NY USA.
[Rothbaum, Barbara O.] Emory Univ, Sch Med, Dept Psychiat, Atlanta, GA 30322 USA.
[Thase, Michael E.] Univ Penn, Dept Psychiat, Sch Med, Philadelphia, PA 19104 USA.
[Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Kocsis, James H.] Weill Cornell Med Coll, Dept Psychiat, New York, NY USA.
RP Steidtmann, D (reprint author), Stanford Univ, Dept Psychiat & Behav Sci, 401 Quarry Rd, Stanford, CA 94305 USA.
EM dsteidt@stanford.edu
FU NIMH NIH HHS [T32 MH019938]
NR 44
TC 9
Z9 9
U1 1
U2 12
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0022-006X
EI 1939-2117
J9 J CONSULT CLIN PSYCH
JI J. Consult. Clin. Psychol.
PD OCT
PY 2013
VL 81
IS 5
BP 783
EP 792
DI 10.1037/a0033250
PG 10
WC Psychology, Clinical
SC Psychology
GA 223CE
UT WOS:000324780500004
PM 23750462
ER
PT J
AU Karlin, BE
Trockel, M
Taylor, CB
Gimeno, J
Manber, R
AF Karlin, Bradley E.
Trockel, Mickey
Taylor, C. Barr
Gimeno, Julia
Manber, Rachel
TI National Dissemination of Cognitive Behavioral Therapy for Insomnia in
Veterans: Therapist- and Patient-Level Outcomes
SO JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY
LA English
DT Article
DE cognitive-behavioral therapy; insomnia; dissemination; training; US
Department of Veterans Affairs
ID RANDOMIZED CONTROLLED-TRIAL; PSYCHOLOGICAL TREATMENTS; PERSISTENT
INSOMNIA; METAANALYSIS; SLEEP; PHARMACOTHERAPY; DEPRESSION; EFFICACY;
DISORDER
AB Objective: To evaluate the effects of national training in and implementation of Cognitive Behavioral Therapy for Insomnia (CBT-I) in the U.S. Department of Veterans Affairs (VA) health care system on clinicians' competency and patients' insomnia severity, symptoms of depression, and quality of life. Method: A prospective cohort of 102 VA clinicians (including mental health staff in various mental health and primary care settings) participated in the VA CBT-I Training Program during 2011 and 2012. Patients included 182 veterans treated by clinicians enrolled in the training. Clinicians were rated on taped therapy sessions, using a standardized competency rating form. Patients' symptoms were assessed using the Insomnia Severity Index (ISI) and standardized measures of depression and quality of life. Results: Of 102 clinicians attending workshop training, 94 (92%) met all training requirements, including minimum competency score criteria. Of 182 patients, 122 (67%) completed treatment. The mixed effects model revealed significant reductions in average patient ISI score (from 19.9 to 10.2, standard error = 3.0). Patients also improved on measures of depression and quality of life. Conclusion: National training in and implementation of CBT-I resulted in a significant increase in therapist competency to deliver CBT-I for almost all clinicians and in a large reduction in insomnia severity and improvement in depression and quality of life among veterans. Observed effect sizes are comparable to results of randomized clinical trials. These results suggest CBT-I can be feasibly and effectively disseminated to routine clinical settings, with very favorable patient outcomes.
C1 [Karlin, Bradley E.] US Dept Vet Affairs, Cent Off, Mental Hlth Serv, Washington, DC 20420 USA.
[Karlin, Bradley E.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD 21218 USA.
[Trockel, Mickey; Taylor, C. Barr; Gimeno, Julia; Manber, Rachel] Stanford Univ, Med Ctr, Dept Psychiat, Stanford, CA 94305 USA.
[Trockel, Mickey; Taylor, C. Barr; Gimeno, Julia; Manber, Rachel] Vet Affairs Palo Alto Hlth Care Syst, Sierra Pacific Mental Illness Res Educ & Clin Ctr, Dept Psychiat, Palo Alto, CA USA.
RP Karlin, BE (reprint author), US Dept Vet Affairs, Cent Off, Mental Hlth Serv 10P4M, 810 Vermont Ave NW, Washington, DC 20420 USA.
EM Bradley.Karlin2@va.gov
NR 21
TC 30
Z9 30
U1 0
U2 20
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0022-006X
J9 J CONSULT CLIN PSYCH
JI J. Consult. Clin. Psychol.
PD OCT
PY 2013
VL 81
IS 5
BP 912
EP 917
DI 10.1037/a0032554
PG 6
WC Psychology, Clinical
SC Psychology
GA 223CE
UT WOS:000324780500017
PM 23586730
ER
PT J
AU Lina, TT
Pinchuk, IV
House, J
Yamaoka, Y
Graham, DY
Beswick, EJ
Reyes, VE
AF Lina, Taslima T.
Pinchuk, Irina V.
House, Jennifer
Yamaoka, Yoshio
Graham, David Y.
Beswick, Ellen J.
Reyes, Victor E.
TI CagA-Dependent Downregulation of B7-H2 Expression on Gastric Mucosa and
Inhibition of Th17 Responses during Helicobacter pylori Infection
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID INDUCIBLE COSTIMULATOR LIGAND; T-CELL RESPONSE; EPITHELIAL-CELLS;
POTENTIAL ROLE; IV SECRETION; MICE; PATHOGENESIS; ACTIVATION; PROTEIN;
INTERLEUKIN-8
AB Gastric epithelial cells (GECs) are the primary target for Helicobacter pylori infection and may act as APCs regulating local T cell responses. We previously reported that H. pylori infection of GECs induces the expression of the T cell coinhibitory molecule B7-H1 on GECs. This process contributes to the hyporesponsiveness of CD4(+) effector T cells and accumulation of regulatory T cells. In the present study, we investigated the impact of H. pylori cytotoxin-associated gene A (CagA) on the modulation of the expression of the T cell costimulator B7-H2 by GECs. B7-H2 is involved in promoting Th17 type responses. H. pylori infection downregulates B7-H2 expression by GECs in a CagA-dependent manner. IFN-gamma, which is increased in the H. pylori-infected gastric mucosa, synergizes with H. pylori in downregulating B7-H2 expression by GECs. CagA-mediated modulation of B7-H2 on GECs involves p70 S6 kinase phosphorylation. The CagA-dependent B7-H2 downregulation in GECs correlates with a decrease in Th17 type responses in vitro and in vivo. Furthermore, CagA-dependent modulation of Th17 responses was inversely correlated with the H. pylori colonization levels in vivo. Our data suggest that CagA contributes to the ability of H. pylori to evade Th17-mediated clearance by modulating expression of B7-H2 and, thus, to the establishment of the H. pylori chronic infection.
C1 [Lina, Taslima T.; Pinchuk, Irina V.; Reyes, Victor E.] Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA.
[Pinchuk, Irina V.] Univ Texas Med Branch, Dept Internal Med, Galveston, TX 77555 USA.
[House, Jennifer; Reyes, Victor E.] Univ Texas Med Branch, Dept Pediat, Galveston, TX 77555 USA.
[Yamaoka, Yoshio; Graham, David Y.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA.
[Beswick, Ellen J.] Univ New Mexico, Hlth Sci Ctr, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA.
RP Reyes, VE (reprint author), Univ Texas Med Branch, Childrens Hosp, Dept Pediat, 301 Univ Blvd, Galveston, TX 77555 USA.
EM vreyes@utmb.edu
RI Pinchuk, Irina/A-7227-2008
OI Pinchuk, Irina/0000-0003-1505-5779
FU National Institutes of Health [AI68712, DK090090-01, CA127022,
1U54RR02614, 8UL1TR000041]; American Gastroenterological Association;
University of Texas Medical Branch; University of Texas Medical Branch
Sealy Center for Vaccine Development; American Cancer Society
[RSG-10-159-01-LIB]; University of New Mexico Clinical and Translational
Science Center
FX This work was supported by National Institutes of Health Grants AI68712,
DK090090-01, and CA127022; the American Gastroenterological Association
Research Scholar Award; National Institutes of Health Grant 1U54RR02614;
the University of Texas Medical Branch Clinical and Translational
Sciences Award; a University of Texas Medical Branch Sealy Center for
Vaccine Development predoctoral fellowship (to T.T.L.); American Cancer
Society Grant RSG-10-159-01-LIB; National Institutes of Health Grant
8UL1TR000041; and by the University of New Mexico Clinical and
Translational Science Center.
NR 60
TC 10
Z9 11
U1 0
U2 3
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD OCT 1
PY 2013
VL 191
IS 7
BP 3838
EP 3846
DI 10.4049/jimmunol.1300524
PG 9
WC Immunology
SC Immunology
GA 221CH
UT WOS:000324634500039
PM 23997227
ER
PT J
AU Lafosse, JM
Mitchell, SM
Corboy, JR
Filley, CM
AF Lafosse, Jose M.
Mitchell, Sandra M.
Corboy, John R.
Filley, Christopher M.
TI The Nature of Verbal Memory Impairment in Multiple Sclerosis: A
List-Learning and Meta-analytic Study
SO JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY
LA English
DT Article
DE Multiple sclerosis; Memory; Learning; White matter disease;
Neuropsychological tests; Meta analysis
ID COGNITIVE IMPAIRMENT; WHITE-MATTER; NEUROPSYCHOLOGICAL IMPAIRMENT;
WORKING-MEMORY; MS; PERFORMANCE; DEFICITS; ATROPHY; RECALL; SPEED
AB The primary purpose of this study was to test the hypothesis that multiple sclerosis (MS) patients have impaired acquisition rather than a retrieval deficit. Verbal memory impairment in MS was examined in 53 relapsing-remitting MS patients and 31 healthy controls (HC), and in a meta-analysis of studies that examined memory functioning in MS with list-learning tasks. The MS group demonstrated significantly lower acquisition and delayed recall performance than the HC group, and the meta-analysis revealed that the largest effect sizes were obtained for acquisition measures relative to delayed recall and recognition. Our data argue against a retrieval deficit as the sole explanation for verbal memory impairment in MS, and make a consistent case for the position that deficient acquisition contributes to the memory dysfunction of MS patients. Deficient acquisition may result from demyelination in relevant white matter tracts that reduces encoding efficiency as a result of impaired speed of information processing.
C1 [Lafosse, Jose M.] Regis Univ, Dept Psychol & Neurosci, Denver, CO 80221 USA.
[Mitchell, Sandra M.] New Mexico Vet Affairs Healthcare Syst, Albuquerque, NM USA.
[Corboy, John R.; Filley, Christopher M.] Univ Colorado, Sch Med, Dept Neurol, Denver, CO USA.
[Corboy, John R.; Filley, Christopher M.] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Filley, Christopher M.] Univ Colorado, Sch Med, Dept Psychiat, Denver, CO 80262 USA.
RP Lafosse, JM (reprint author), Regis Univ, Dept Psychol & Neurosci, 3333 Regis Blvd,D-12, Denver, CO 80221 USA.
EM jlafosse@regis.edu
FU Regis University
FX None of the authors have any conflict of interest to report. This
research received no specific grant from any funding agency, commercial
or not-for-profit sectors, but was supported by a sabbatical leave to
Dr. Lafosse from Regis University. We thank Nancy L. Leech, Ph.D. for
her assistance with meta-analytic techniques, Ted Krmpotich for his
assistance with data collection, and the Regis University students
enrolled in Neuropsychology during spring 2013 for their helpful reviews
of the manuscript.
NR 100
TC 5
Z9 5
U1 0
U2 7
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1355-6177
J9 J INT NEUROPSYCH SOC
JI J. Int. Neuropsychol. Soc.
PD OCT
PY 2013
VL 19
IS 9
BP 995
EP 1008
DI 10.1017/S1355617713000957
PG 14
WC Clinical Neurology; Neurosciences; Psychiatry; Psychology
SC Neurosciences & Neurology; Psychiatry; Psychology
GA 223RY
UT WOS:000324827700006
PM 24059259
ER
PT J
AU Karlin, JD
Koontz, BF
Freedland, SJ
Moul, JW
Grob, BM
Wan, W
Hagan, MP
Anscher, MS
Moghanaki, D
AF Karlin, Jeremy D.
Koontz, Bridget F.
Freedland, Stephen J.
Moul, Judd W.
Grob, Baruch M.
Wan, Wen
Hagan, Michael P.
Anscher, Mitchell S.
Moghanaki, Drew
TI Identifying Appropriate Patients for Early Salvage Radiotherapy after
Prostatectomy
SO JOURNAL OF UROLOGY
LA English
DT Article
DE prostate; prostatic neoplasms; prostate-specific antigen; salvage
therapy; radiotherapy
ID RADICAL PROSTATECTOMY; RADIATION-THERAPY; BIOCHEMICAL RECURRENCE;
POSTOPERATIVE RADIOTHERAPY; ADJUVANT RADIOTHERAPY; TREATMENT FAILURE;
CANCER; RISK; TRIAL; CONSENSUS
AB Purpose: It remains unclear whether relapsed prostate specific antigen at postprostatectomy salvage radiotherapy impacts outcomes as long it is 1.0 ng/ml or less.
Materials and Methods: We performed a retrospective cohort study of 197 patients treated with salvage radiotherapy in the setting of detectable relapsed prostate specific antigen 1.0 ng/ml or less. Patients were excluded from analysis if they had lymph node involvement or received androgen deprivation therapy. Freedom from prostate specific antigen progression after salvage radiotherapy was analyzed by a Cox regression model.
Results: Median relapsed prostate specific antigen was 0.33 ng/ml (range 0.07 to 1.0). There was 86% freedom from prostate specific antigen progression at a median followup of 52 months. Relapsed prostate specific antigen (HR 1.9, p = 0.004), Gleason score 8-10 (HR 5.2, p <0.001) and negative margin status (HR 2.0, p = 0.02) were independently associated with an increased risk of prostate specific antigen progression after salvage radiotherapy. We identified interaction between relapsed prostate specific antigen and Gleason score (p = 0.04) but not margin status. A significant association was noted between higher relapsed prostate specific antigen and prostate specific antigen progression after salvage radiotherapy in patients with Gleason score 8-10 but not 7 or less. In patients with Gleason score 8-10 the rate of freedom from prostate specific antigen progression at 53 months was 77% vs 26% when salvage radiotherapy was initiated at a relapsed prostate specific antigen of 0.33 or less vs 0.34 to 1.0 ng/ml (log rank p = 0.003).
Conclusions: Different relapsed prostate specific antigen thresholds for unsuccessful salvage radiotherapy may exist based on Gleason score. These data suggest that patients with Gleason score 8-10 should be offered salvage radiotherapy at the earliest detectable relapsed prostate specific antigen, even 0.33 ng/ml or less. Those with Gleason score 7 or less may have the opportunity to be followed with serial prostate specific antigen measurements to improve risk stratification, and delay and/or avoid the potential toxicity of salvage radiotherapy.
C1 [Karlin, Jeremy D.; Hagan, Michael P.; Anscher, Mitchell S.; Moghanaki, Drew] Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA 23284 USA.
[Wan, Wen] Virginia Commonwealth Univ, Dept Biostat, Richmond, VA USA.
[Grob, Baruch M.] Hunter Holmes McGuire Vet Affairs Med Ctr, Urol Serv, Richmond, VA USA.
[Hagan, Michael P.; Moghanaki, Drew] Hunter Holmes McGuire Vet Affairs Med Ctr, Radiat Oncol Serv, Richmond, VA USA.
[Hagan, Michael P.] US Dept Vet Affairs, Natl Radiat Oncol Program, Richmond, VA USA.
[Koontz, Bridget F.] Duke Univ Med Ctr, Dept Radiat Oncol, Durham, NC USA.
[Freedland, Stephen J.; Moul, Judd W.] Duke Univ Med Ctr, Div Urol Surg, Durham, NC USA.
[Freedland, Stephen J.; Moul, Judd W.] Duke Univ Med Ctr, Duke Canc Inst, Durham, NC USA.
[Freedland, Stephen J.] Durham Vet Affairs Med Ctr, Urol Serv, Durham, NC USA.
[Freedland, Stephen J.] Duke Univ Sch Med, Dept Pathol, Durham, NC USA.
RP Moghanaki, D (reprint author), Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA 23284 USA.
OI Anscher, Mitchell/0000-0003-4480-111X
NR 22
TC 6
Z9 6
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5347
J9 J UROLOGY
JI J. Urol.
PD OCT
PY 2013
VL 190
IS 4
BP 1410
EP 1415
DI 10.1016/j.juro.2013.04.078
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA 227EH
UT WOS:000325091700103
PM 23648223
ER
PT J
AU Dubin, RF
Teerlink, JR
Schiller, NB
Alokozai, D
Peralta, CA
Johansen, KL
AF Dubin, Ruth F.
Teerlink, John R.
Schiller, Nelson B.
Alokozai, Dean
Peralta, Carmen A.
Johansen, Kirsten L.
TI Association of segmental wall motion abnormalities occurring during
hemodialysis with post-dialysis fatigue
SO NEPHROLOGY DIALYSIS TRANSPLANTATION
LA English
DT Article
DE end-stage renal disease; hemodialysis; post-dialysis fatigue
ID DIALYSIS; DYSFUNCTION; DEPRESSION; MORTALITY; OUTCOMES; IMPACT
AB Post-dialysis fatigue (PDF) is a common, debilitating symptom that remains poorly understood. Cardiac wall motion abnormalities (WMAs) may worsen during dialysis, but it is unknown whether WMA are associated with PDF.
Forty patients were recruited from University of California San Francisco-affiliated dialysis units between January 2010 and February 2011. Participants underwent echocardiograms before and during the last hour of 79 dialysis sessions. Myocardial segments were graded 14 by a blinded reviewer, with four representing the worst WMA, and the segmental scores were summed for each echocardiogram. Patients completed questionnaires about their symptoms. Severe PDF (defined as lasting 2 h after dialysis) was analysed using a generalized linear model with candidate predictors including anemia, intradialytic hemodynamics and cardiac function.
Forty-four percent of patients with worsened WMA (n9) had severe PDF, compared with 13 of patients with improved or unchanged WMA (P 0.04). A one-point increase in the WMA score during dialysis was associated with a 10 higher RR of severe PDF [RR: 1.1, 95 CI (1.1, 1.2), P 0.001]. After multivariable adjustment, every point increase in the WMA score was associated with a 2-fold higher risk of severe PDF [RR: 1.9, 95 CI (1.4, 2.6), P 0.001]. History of depression was associated with severe PDF after adjustment for demographics and comorbidities [RR: 3.4, 95 CI (1.3, 9), P 0.01], but anemia, hemodynamics and other parameters of cardiac function were not.
Although cross-sectional, these results suggest that some patients may experience severe PDF as a symptom of cardiac ischemia occurring during dialysis.
C1 [Dubin, Ruth F.; Peralta, Carmen A.; Johansen, Kirsten L.] Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Med Nephrol, San Francisco, CA 94143 USA.
[Teerlink, John R.; Schiller, Nelson B.] Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Med Cardiol, San Francisco, CA 94143 USA.
[Alokozai, Dean] Cardiocore, San Francisco, CA USA.
RP Dubin, RF (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Med Nephrol, San Francisco, CA 94143 USA.
EM ruth.dubin@ucsf.edu
FU University of California San Francisco Academic Senate, San Francisco,
CA, USA; Research Evaluation and Allocation Committee in the University
of California San Francisco, School of Medicine Dean's Office, San
Francisco, CA, USA; National Institute of Diabetes and Digestive and
Kidney Diseases [1K24-DK085153-02, 1K23-DK092354-01A1]; UCSF Clinical
and Translational Science Institute [UL1 TR000004]
FX Funding for this project came from the following sources. (i) Individual
Investigator Grant, University of California San Francisco Academic
Senate, San Francisco, CA, USA. (ii) Grant Huntington Fund provided by
the Research Evaluation and Allocation Committee in the University of
California San Francisco, School of Medicine Dean's Office, San
Francisco, CA, USA. (iii) National Institute of Diabetes and Digestive
and Kidney Diseases, 1K24-DK085153-02. (iv) National Institute of
Diabetes and Digestive and Kidney Diseases, 1K23-DK092354-01A1. (v) UCSF
Clinical and Translational Science Institute grant number UL1 TR000004.
NR 18
TC 8
Z9 8
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0931-0509
J9 NEPHROL DIAL TRANSPL
JI Nephrol. Dial. Transplant.
PD OCT
PY 2013
VL 28
IS 10
BP 2580
EP 2585
DI 10.1093/ndt/gft097
PG 6
WC Transplantation; Urology & Nephrology
SC Transplantation; Urology & Nephrology
GA 228JU
UT WOS:000325183100024
PM 23743019
ER
PT J
AU Schafer, AL
Burghardt, AJ
Sellmeyer, DE
Palermo, L
Shoback, DM
Majumdar, S
Black, DM
AF Schafer, A. L.
Burghardt, A. J.
Sellmeyer, D. E.
Palermo, L.
Shoback, D. M.
Majumdar, S.
Black, D. M.
TI Postmenopausal women treated with combination parathyroid hormone (1-84)
and ibandronate demonstrate different microstructural changes at the
radius vs. tibia: the PTH and Ibandronate Combination Study (PICS)
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Bisphosphonate; Bone microstructure; Cortical; High-resolution
peripheral quantitative computed tomography; Parathyroid hormone;
Trabecular
ID BONE-MINERAL DENSITY; QUANTITATIVE COMPUTED-TOMOGRAPHY; VERTEBRAL
FRACTURE RISK; FINITE-ELEMENT-ANALYSIS; IN-VIVO ASSESSMENT; DISTAL
RADIUS; CORTICAL BONE; HR-PQCT; INTRACORTICAL POROSITY; RANDOMIZED-TRIAL
AB In postmenopausal women receiving combination parathyroid hormone (PTH) (1-84) therapy and ibandronate, we evaluated bone microarchitecture and biomechanics using high-resolution peripheral quantitative computed tomography (HR-pQCT). Cortical and trabecular changes were different at the nonweight-bearing radius vs. the weight-bearing tibia, with more favorable overall changes at the tibia.
Introduction PTH therapy and bisphosphonates decrease fracture risk in postmenopausal osteoporosis, but their effects on bone microstructure and strength have not been fully characterized, particularly during combination therapy. PTH increases trabecular bone mineral density (BMD) substantially but may decrease cortical BMD, possibly by stimulating intracortical remodeling. We evaluated bone microarchitecture and biomechanics with HR-pQCT at the radius (a nonweight-bearing site) and tibia (weight bearing) in women receiving combination PTH(1-84) and ibandronate.
Methods Postmenopausal women with low bonemass (n=43) were treated with 6 months of PTH(1-84) (100 mu g/day), either as one 6- or two 3-month courses, in combination with ibandronate (150 mg/month) over 2 years. HR-pQCT was performed before and after therapy.
Results Because changes in HR-pQCT parameters did not differ between treatment arms, groups were pooled into one cohort for analysis. Trabecular BMD increased at both radius and tibia (p<0.01 for each). Cortical thickness and BMD decreased at the radius (p<0.01), consistent with changes in dual-energy X-ray absorptiometry, while these parameters did not change at the tibia (p=0.02 for difference between radius and tibia). In contrast, cortical porosity increased at the tibia (p<0.01) but not radius. Stiffness and failure load decreased at the radius (p<0.0001) but did not change at the tibia.
Conclusions Cortical and trabecular changes in response to the PTH/ibandronate treatment combinations utilized in this study were different at the nonweight-bearing radius vs. the weight-bearing tibia, with more favorable overall changes at the tibia. Our findings support the possibility that weight bearing may optimize the effects of osteoporosis therapy.
C1 [Schafer, A. L.; Shoback, D. M.] San Francisco VA Med Ctr, Endocrine Res Unit, San Francisco, CA 94121 USA.
[Schafer, A. L.; Shoback, D. M.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Burghardt, A. J.; Majumdar, S.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA.
[Sellmeyer, D. E.] Johns Hopkins Univ, Dept Med, Baltimore, MD USA.
[Palermo, L.; Black, D. M.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
RP Schafer, AL (reprint author), San Francisco VA Med Ctr, Endocrine Res Unit, 4150 Clement St,111N, San Francisco, CA 94121 USA.
EM anne.schafer@ucsf.edu
FU Genentech, Inc.; NPS Pharmaceuticals [PTH[1-84]]; Genentech; Bayer;
Department of Veterans Affairs through an Advanced Fellowship in Women's
Health; Career Development Award [5 IK2 CX000549-02]; Research
Enhancement Award Program; National Institute of Arthritis and
Musculoskeletal and Skin Diseases (NIAMS) [R01-AR055588, R01-AR060700];
NIAMS; National Institute on Aging; National Institute of Biomedical
Imaging and Bioengineering [R01-AG017762]
FX The PICS trial was supported by an investigator-initiated grant (to DMB)
from Genentech, Inc., a member of the Roche group. The sponsor was
involved in study design but not in the collection, analysis, or
interpretation of data, nor in the writing of the article. Study drugs
were supplied by NPS Pharmaceuticals (PTH[1-84]), Genentech
(ibandronate), and Bayer (calcium citrate+D3). Reagents for
bone turnover marker assays were provided by Roche Diagnostics. The
authors have full control of all data. Additional support was provided
by the Department of Veterans Affairs through an Advanced Fellowship in
Women's Health (to ALS), a Career Development Award under contract 5 IK2
CX000549-02 (to ALS), and the Research Enhancement Award Program (to
DMS); by the National Institute of Arthritis and Musculoskeletal and
Skin Diseases (NIAMS) under contracts R01-AR055588 (to DMS) and
R01-AR060700 (to AJB); and by NIAMS, the National Institute on Aging,
and the National Institute of Biomedical Imaging and Bioengineering
under contract R01-AG017762 (to SM). The authors thank Jean Hietpas,
Lucy Wu, and Laurel Denton for their roles in study direction and data
coordination; Rayshawnda Davis, Natasha Rathbun, Andrea Hacker, and
Makani da Silva for study coordination and DXA scan acquisition; Melissa
Guan, Thelma Munoz, and S. Paran Yap for their roles in HR-pQCT
coordination, image acquisition, and analysis; and Richard Eastell, MD,
and Fatma Gossiel for analysis of bone turnover markers.
NR 48
TC 12
Z9 12
U1 0
U2 9
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937-941X
EI 1433-2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD OCT
PY 2013
VL 24
IS 10
BP 2591
EP 2601
DI 10.1007/s00198-013-2349-y
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 219UN
UT WOS:000324536200006
PM 23589163
ER
PT J
AU Chahine, LM
Daley, J
Horn, S
Duda, JE
Colcher, A
Hurtig, H
Cantor, C
Dahodwala, N
AF Chahine, Lama M.
Daley, Joseph
Horn, Stacy
Duda, John E.
Colcher, Amy
Hurtig, Howard
Cantor, Charles
Dahodwala, Nabila
TI Association between dopaminergic medications and nocturnal sleep in
early-stage Parkinson's disease
SO PARKINSONISM & RELATED DISORDERS
LA English
DT Article
ID REM-SLEEP; BEHAVIOR DISORDER; L-DOPA; PRAMIPEXOLE; SYMPTOMS; RECEPTOR;
RAT; MICROSTRUCTURE; WAKEFULNESS; LEVODOPA
AB Background: Poor nocturnal sleep is common in Parkinson's disease (PD) and negatively impacts quality of life. There is little data on how dopaminergic drugs influence nocturnal sleep in PD, particularly in relation to medication timing. We examined the association between dopaminergic medications and subjective and objective nocturnal sleep in PD.
Methods: Individuals with PD were recruited from the outpatient clinic. Demographics and disease information were collected. Patients underwent one-night polysomnography and responded to SCOPA-SLEEP, a self-administered questionnaire which includes a section on nighttime sleep and an overall measure of sleep quality; higher scores indicate worse sleep. Medication intake, including medication timing in relation to bedtime, was obtained and converted to levodopa equivalents.
Results: 41 Males and 21 females, median age 63.9 years, participated. Median disease duration was 5 years. After adjusting for age, sex, disease severity, and disease duration, greater total levodopa equivalent intake within 4 h of sleep was associated with higher total SCOPA-nighttime score (p = 0.009) and greater wake time after sleep onset (p = 0.049). Greater dopaminergic medication intake prior to sleep was also associated with less rapid eye movement (REM) sleep as a percent of total sleep time (p = 0.004).
Conclusions: Higher amounts of dopaminergic medications taken prior to sleep were associated with poor sleep quality and less REM sleep. Although poor nocturnal sleep in PD is likely multi-factorial in etiology, our findings suggest that timing and dose of medications prior to sleep need to be considered in its management. (c) 2013 Elsevier Ltd. All rights reserved.
C1 [Chahine, Lama M.; Horn, Stacy; Duda, John E.; Colcher, Amy; Hurtig, Howard; Cantor, Charles; Dahodwala, Nabila] Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19107 USA.
[Chahine, Lama M.; Cantor, Charles] Univ Penn, Perelman Sch Med, Div Sleep Med, Philadelphia, PA 19107 USA.
[Daley, Joseph] Univ Alabama Birmingham, Sch Med, Birmingham VA Med Ctr, Birmingham, AL 35233 USA.
[Daley, Joseph] Univ Alabama Birmingham, Sch Med, Dept Neurol, Birmingham, AL 35233 USA.
[Duda, John E.] Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA 19104 USA.
RP Chahine, LM (reprint author), Univ Penn, Perelman Sch Med, Dept Neurol, 330 S 9th St, Philadelphia, PA 19107 USA.
EM lamachahine@hotmail.com
NR 38
TC 13
Z9 14
U1 0
U2 12
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1353-8020
J9 PARKINSONISM RELAT D
JI Parkinsonism Relat. Disord.
PD OCT
PY 2013
VL 19
IS 10
BP 859
EP 863
DI 10.1016/j.parkreldis.2013.05.009
PG 5
WC Clinical Neurology
SC Neurosciences & Neurology
GA 223EZ
UT WOS:000324788800002
PM 23751512
ER
PT J
AU Johnson, TJ
Weaver, MD
Borrero, S
Davis, EM
Myaskovsky, L
Zuckerbraun, NS
Kraemer, KL
AF Johnson, Tiffani J.
Weaver, Matthew D.
Borrero, Sonya
Davis, Esa M.
Myaskovsky, Larissa
Zuckerbraun, Noel S.
Kraemer, Kevin L.
TI Association of Race and Ethnicity With Management of Abdominal Pain in
the Emergency Department
SO PEDIATRICS
LA English
DT Article
DE abdominal pain; disparities; emergency department; racial difference
ID ANALGESIC TREATMENT; TRAUMA PATIENTS; CLINICAL-TRIAL; PUBLIC-HEALTH;
CHEST-PAIN; DISPARITIES; CHILDREN; RACE/ETHNICITY; CARE; QUALITY
AB OBJECTIVE: To determine if race/ethnicity-based differences exist in the management of pediatric abdominal pain in emergency departments (EDs).
METHODS: Secondary analysis of data from the 2006-2009 National Hospital Ambulatory Medical Care Survey regarding 2298 visits by patients <= 21 years old who presented to EDs with abdominal pain. Main outcomes were documentation of pain score and receipt of any analgesics, analgesics for severe pain (defined as >= 7 on a 10-point scale), and narcotic analgesics. Secondary outcomes included diagnostic tests obtained, length of stay (LOS), 72-hour return visits, and admission.
RESULTS: Of patient visits, 70.1% were female, 52.6% were from non-Hispanic white, 23.5% were from non-Hispanic black, 20.6% were from Hispanic, and 3.3% were from "other" racial/ethnic groups; patients' mean age was 14.5 years. Multivariate logistic regression models adjusting for confounders revealed that non-Hispanic black patients were less likely to receive any analgesic (odds ratio [OR]: 0.61; 95% confidence interval [CI]: 0.43-0.87) or a narcotic analgesic (OR: 0.38; 95% CI: 0.18-0.81) than non-Hispanic white patients (referent group). This finding was also true for non-Hispanic black and "other" race/ethnicity patients with severe pain (ORs [95% CI]: 0.43 [0.22-0.87] and 0.02 [0.00-0.19], respectively). Non-Hispanic black and Hispanic patients were more likely to have a prolonged LOS than non-Hispanic white patients (ORs [95% CI]: 1.68 [1.13-2.51] and 1.64 [1.09-2.47], respectively). No significant race/ethnicity-based disparities were identified in documentation of pain score, use of diagnostic procedures, 72-hour return visits, or hospital admissions.
CONCLUSIONS: Race/ethnicity-based disparities exist in ED analgesic use and LOS for pediatric abdominal pain. Recognizing these disparities may help investigators eliminate inequalities in care.
C1 [Johnson, Tiffani J.] Childrens Hosp Philadelphia, Div Pediat Emergency Med, Philadelphia, PA 19104 USA.
[Johnson, Tiffani J.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA.
[Weaver, Matthew D.; Kraemer, Kevin L.] Univ Pittsburgh, Sch Med, Dept Emergency Med, Pittsburgh, PA USA.
[Borrero, Sonya; Davis, Esa M.; Myaskovsky, Larissa; Kraemer, Kevin L.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA.
[Zuckerbraun, Noel S.] Univ Pittsburgh, Sch Med, Dept Pediat, Div Pediat Emergency Med, Pittsburgh, PA 15261 USA.
[Borrero, Sonya; Myaskovsky, Larissa] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
RP Johnson, TJ (reprint author), Childrens Hosp Philadelphia, Div Pediat Emergency Med, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.
EM johnsont6@email.chop.edu
FU Agency for Healthcare Research and Quality [T32HS017587]
FX Supported by grant T32HS017587 from the Agency for Healthcare Research
and Quality to Drs Johnson and Kraemer.
NR 38
TC 21
Z9 22
U1 2
U2 9
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
J9 PEDIATRICS
JI Pediatrics
PD OCT
PY 2013
VL 132
IS 4
BP E851
EP E858
DI 10.1542/peds.2012-3127
PG 8
WC Pediatrics
SC Pediatrics
GA 227FI
UT WOS:000325095400006
PM 24062370
ER
PT J
AU Lomond, KV
Henry, SM
Jacobs, JV
Hitt, JR
Horak, FB
Cohen, RG
Schwartz, D
Dumas, JA
Naylor, MR
Watts, R
DeSarno, MJ
AF Lomond, Karen V.
Henry, Sharon M.
Jacobs, Jesse V.
Hitt, Juvena R.
Horak, Fay B.
Cohen, Rajal G.
Schwartz, Daniel
Dumas, Julie A.
Naylor, Magdalena R.
Watts, Richard
DeSarno, Michael J.
TI Protocol to assess the neurophysiology associated with multi-segmental
postural coordination
SO PHYSIOLOGICAL MEASUREMENT
LA English
DT Article
DE postural coordination; MRI; EMG; cerebral cortex; multi-segmental
ID LOW-BACK-PAIN; LIMB MOVEMENT; ADJUSTMENTS; SIGNALS; PEOPLE; CORTEX
AB Anticipatory postural adjustments (APAs) stabilize potential disturbances to posture caused by movement. Impaired APAs are common with disease and injury. Brain functions associated with generating APAs remain uncertain due to a lack of paired tasks that require similar limb motion from similar postural orientations, but differ in eliciting an APA while also being compatible with brain imaging techniques (e. g., functional magnetic resonance imaging; fMRI). This study developed fMRI-compatible tasks differentiated by the presence or absence of APAs during leg movement. Eighteen healthy subjects performed two leg movement tasks, supported leg raise (SLR) and unsupported leg raise (ULR), to elicit isolated limb motion (no APA) versus multi-segmental coordination patterns (including APA), respectively. Ground reaction forces under the feet and electromyographic activation amplitudes were assessed to determine the coordination strategy elicited for each task. Results demonstrated that the ULR task elicited a multi-segmental coordination that was either minimized or absent in the SLR task, indicating that it would serve as an adequate control task for fMRI protocols. A pilot study with a single subject performing each task in an MRI scanner demonstrated minimal head movement in both tasks and brain activation patterns consistent with an isolated limb movement for the SLR task versus multi-segmental postural coordination for the ULR task.
C1 [Lomond, Karen V.] Cent Michigan Univ, Sch Hlth Sci, Mt Pleasant, MI 48859 USA.
[Lomond, Karen V.; Henry, Sharon M.; Jacobs, Jesse V.; Hitt, Juvena R.] Univ Vermont, Dept Rehabil & Movement Sci, Burlington, VT USA.
[Horak, Fay B.; Cohen, Rajal G.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA.
[Cohen, Rajal G.] Univ Idaho, Dept Psychol & Commun Studies, Moswow, ID 83843 USA.
[Schwartz, Daniel] Portland VA Med Ctr, Methamphetamine Abuse Res Ctr, Portland, OR USA.
[Schwartz, Daniel] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA.
[Schwartz, Daniel] Portland VA Med Ctr, Res Serv, Portland, OR USA.
[Dumas, Julie A.; Naylor, Magdalena R.] Univ Vermont, Dept Psychiat, Burlington, VT 05405 USA.
[Watts, Richard] Univ Vermont, MRI Ctr Bioimaging, Dept Radiol, Burlington, VT 05405 USA.
[DeSarno, Michael J.] Univ Vermont, Dept Med Biostat, Burlington, VT 05405 USA.
RP Lomond, KV (reprint author), Cent Michigan Univ, Sch Hlth Sci, Mt Pleasant, MI 48859 USA.
EM lomon2k@cmich.edu
FU National Institutes of Health [NIH2R01HD040909-06A2]
FX The authors wish to thank our research subjects for their participation
as well as Rebecca Ouelette-Morton and Kristen Zielinski for their
assistance in data collection. The study was supported by the National
Institutes of Health NIH2R01HD040909-06A2 (Principal Investigator: Henry
SM).
NR 21
TC 2
Z9 2
U1 0
U2 3
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0967-3334
J9 PHYSIOL MEAS
JI Physiol. Meas.
PD OCT
PY 2013
VL 34
IS 10
BP N97
EP N105
DI 10.1088/0967-3334/34/10/N97
PG 9
WC Biophysics; Engineering, Biomedical; Physiology
SC Biophysics; Engineering; Physiology
GA 224GN
UT WOS:000324871100002
PM 24065623
ER
PT J
AU Zhang, XY
Yao, JK
AF Zhang, Xiang Yang
Yao, Jeffrey K.
TI Oxidative stress and therapeutic implications in psychiatric disorders
SO PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
LA English
DT Editorial Material
DE Antioxidant defense system; Antioxidant therapy; Bipolar disorders;
Major depression; Schizophrenia; Tardive dyskinesia
ID TARDIVE-DYSKINESIA; BIPOLAR DISORDER; N-ACETYLCYSTEINE; SCHIZOPHRENIA;
INVOLVEMENT; DEPRESSION; RELEVANCE; EPISODES
AB Increasing evidence indicates that disturbances of antioxidant defense system and presence of oxidative stress can play a part in a wide range of neuropsychiatric disorders, including schizophrenia, bipolar disorder, and major depression, as well as antipsychotic-induced tardive dyskinesia (TD). Moreover, researchers have embarked on using antioxidant treatment as adjunct therapy for psychiatry disorders. Evidence from clinical, pre-clinical and epidemiological studies suggests that a benefit of using antioxidant compounds should be considered as an adjunctive therapy in these patients. These are some of the main perspectives that are reviewed by four articles in this special section. Overall, there has been growing recognition of the importance of oxidative stress in the pathophysiology of psychiatric disorders and the development of TD. The collection of articles in this special section will contribute to providing more efficacious treatments arising from a better appreciation of the roles of oxidative stress in these psychiatric disorders. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Zhang, Xiang Yang] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
[Zhang, Xiang Yang] Michael E DeBakey VA Med Ctr, Houston, TX USA.
[Zhang, Xiang Yang] Peking Univ, Beijing Hui Long Guan Hosp, Psychiat Res Ctr, Beijing, Peoples R China.
[Yao, Jeffrey K.] VA Pittsburgh Healthcare Syst, Med Res Serv, Pittsburgh, PA USA.
[Yao, Jeffrey K.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA.
[Yao, Jeffrey K.] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA.
RP Zhang, XY (reprint author), Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
EM xyzhang@bcm.edu
NR 29
TC 25
Z9 26
U1 3
U2 19
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0278-5846
J9 PROG NEURO-PSYCHOPH
JI Prog. Neuro-Psychopharmacol. Biol. Psychiatry
PD OCT 1
PY 2013
VL 46
BP 197
EP 199
DI 10.1016/j.pnpbp.2013.03.003
PG 3
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 219CA
UT WOS:000324480900029
PM 23523744
ER
PT J
AU Wu, JQ
Kosten, TR
Zhang, XY
AF Wu, Jing Qin
Kosten, Thomas R.
Zhang, Xiang Yang
TI Free radicals, antioxidant defense systems, and schizophrenia
SO PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE Antioxidant defense systems; Free radicals; Neuroleptics; Oxidative
stress; Schizophrenia; Tardive dyskinesia
ID ABNORMAL INVOLUNTARY MOVEMENTS; VITAMIN-E TREATMENT; MEMBRANE-LIPID
PEROXIDATION; GENE ALA-9VAL POLYMORPHISM; CT-SCAN ABNORMALITIES;
NITRIC-OXIDE SYNTHASE; TARDIVE-DYSKINESIA; SUPEROXIDE-DISMUTASE;
OXIDATIVE STRESS; GLUTATHIONE-PEROXIDASE
AB The etiopathogenic mechanisms of schizophrenia are to date unknown, although several hypotheses have been suggested. Accumulating evidence suggests that excessive free radical production or oxidative stress may be involved in the pathophysiology of schizophrenia as evidenced by increased production of reactive oxygen or decreased antioxidant protection in schizophrenic patients. This review aims to summarize the basic molecular mechanisms of free radical metabolism, the impaired antioxidant defense system and membrane pathology in schizophrenia, their interrelationships with the characteristic clinical symptoms and the implications for antipsychotic treatments. In schizophrenia, there is accumulating evidence of altered antioxidant enzyme activities and increased levels of lipid peroxidation, as well as altered levels of plasma antioxidants. Moreover, free radical-mediated abnormalities may contribute to specific aspects of schizophrenic symptomatology and complications of its treatment with antipsychotic drugs, as well as the development of tardive dyskinesia (TD). Finally, the potential therapeutic strategies implicated by the accumulating data on oxidative stress mechanisms for the treatment of schizophrenia are discussed. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Wu, Jing Qin] Univ Newcastle, Fac Hlth, Sch Biomed Sci & Pharm, Callaghan, NSW 2308, Australia.
[Wu, Jing Qin] Schizophrenia Res Inst, Sydney, NSW, Australia.
[Wu, Jing Qin; Kosten, Thomas R.; Zhang, Xiang Yang] Peking Univ, Beijing Hui Long Guan Hosp, Psychiat Res Ctr, Beijing 100096, Peoples R China.
[Kosten, Thomas R.; Zhang, Xiang Yang] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX USA.
[Kosten, Thomas R.; Zhang, Xiang Yang] Michael E DeBakey VA Med Ctr, Houston, TX USA.
RP Zhang, XY (reprint author), VA Med Ctr, Res Bldg 109,Room 130,2002 Holcombe Blvd, Houston, TX 77030 USA.
EM xyzhang@bcm.edu
FU Stanley Medical Research Institute [03T-459, 05T-726]; Department of
Veterans Affairs, VISN 16, Mental Illness Research, Education and
Clinical Center (MIRECC); United States National Institute of Health
[K05-DA0454, P50-DA18827, U01-MH79639]; NHMRC
FX This work was funded by the grant from the Stanley Medical Research
Institute (03T-459 and 05T-726), and the Department of Veterans Affairs,
VISN 16, Mental Illness Research, Education and Clinical Center
(MIRECC), United States National Institute of Health K05-DA0454,
P50-DA18827 and U01-MH79639. JQW received an NHMRC postdoctoral training
fellowship. These sources had no further role in study design, data
collection and analysis, decision to publish, or preparation of the
article.
NR 100
TC 54
Z9 57
U1 9
U2 41
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0278-5846
J9 PROG NEURO-PSYCHOPH
JI Prog. Neuro-Psychopharmacol. Biol. Psychiatry
PD OCT 1
PY 2013
VL 46
BP 200
EP 206
DI 10.1016/j.pnpbp.2013.02.015
PG 7
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 219CA
UT WOS:000324480900030
PM 23470289
ER
PT J
AU Baker, DA
Eudaly, J
Smith, CD
Obeid, LM
Gilkeson, GS
AF Baker, DeAnna A.
Eudaly, Jackie
Smith, Charles D.
Obeid, Lina M.
Gilkeson, Gary S.
TI Impact of sphingosine kinase 2 deficiency on the development of
TNF-alpha-induced inflammatory arthritis
SO RHEUMATOLOGY INTERNATIONAL
LA English
DT Article
DE Sphingosine kinase 2; Inflammatory arthritis; Sphingolipids; TNF
ID FUNCTIONAL-CHARACTERIZATION; MOLECULAR-CLONING; DISTINCT ROLES;
SPHINGOSINE-1-PHOSPHATE; COLITIS; FTY720; TRAFFICKING; SUPPRESSION;
MODULATION; ACTIVATION
AB Sphingolipids are components of the plasma membrane whose metabolic manipulation is of interest as a potential therapeutic approach in a number of diseases. Sphingosine kinase 1 (SphK1), the major kinase that phosphorylates sphingosine to sphingosine-1-phosphate (S1P), was previously shown by our group and others to modulate inflammation in murine models of inflammatory arthritis, inflammatory bowel disease and asthma. Sphingosine kinase 2's (SphK2) impact on inflammation is less well known, as variable results were reported depending on the disease model. A specific SphK2 inhibitor inhibited inflammatory arthritis in one model, while siRNA knockdown of SphK2 worsened arthritis in another. We previously demonstrated that SphK1 deficient mice are protected against development of hTNF-alpha-induced arthritis. To investigate the role of SphK2 in TNF-alpha-induced arthritis, we developed SphK2 deficient hTNF-alpha overexpressing mice and separately treated hTNF-alpha mice with ABC294640, a SphK2-specific inhibitor. Our data show that genetic inhibition of SphK2 did not significantly impact the severity or progression of inflammatory arthritis, while pharmacologic inhibition of SphK2 led to significantly more severe arthritis. Compared to vehicle-treated mice, ABC294640 treated mice also had less S1P in whole blood and inflamed joint tissue, although the differences were not significant. ABC294640 treatment did not affect SphK1 activity in the inflamed joint while little SphK2 activity was detected in the joint. We conclude that the differences in the inflammatory phenotype in genetic inhibition versus pharmacologic inhibition of SphK2 can be attributed to the amount of ABC294640 used in the experiments versus the impact of acute inhibition of SphK2 with ABC294640 versus genetically induced life-long SphK2 deficiency. Thus, inhibition of SphK2 appears to be proinflammatory in contrast to the clear anti-inflammatory effects of blocking SphK1. Therapies directed at this sphingosine kinase pathways will need to be specific in their targeting of sphingosine kinases.
C1 [Baker, DeAnna A.] Dept Microbiol, Charleston, SC 29425 USA.
[Baker, DeAnna A.] Dept Immunol, Charleston, SC 29425 USA.
[Eudaly, Jackie; Gilkeson, Gary S.] Med Univ S Carolina, Div Rheumatol, Charleston, SC 29425 USA.
[Smith, Charles D.] South Carolina Coll Pharm Pharmaceut & Biomed Sci, Charleston, SC 29425 USA.
[Obeid, Lina M.; Gilkeson, Gary S.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
[Obeid, Lina M.] Dept Biochem, Charleston, SC 29425 USA.
[Obeid, Lina M.] Dept Mol Biol, Charleston, SC 29425 USA.
[Obeid, Lina M.; Gilkeson, Gary S.] Ralph H Johnson VA Med Ctr, Med Res Serv, Charleston, SC USA.
[Gilkeson, Gary S.] Med Univ S Carolina, Dept Med, Div Rheumatol, Charleston, SC 29425 USA.
RP Gilkeson, GS (reprint author), Med Univ S Carolina, Dept Med, Div Rheumatol, 114 Doughty St,STB 425, Charleston, SC 29425 USA.
EM gilkeson@musc.edu
OI obeid, lina/0000-0002-0734-0847
FU NIAMS NIH HHS [T32 AR050958]
NR 22
TC 9
Z9 9
U1 0
U2 5
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0172-8172
J9 RHEUMATOL INT
JI Rheumatol. Int.
PD OCT
PY 2013
VL 33
IS 10
BP 2677
EP 2681
DI 10.1007/s00296-012-2493-2
PG 5
WC Rheumatology
SC Rheumatology
GA 223RC
UT WOS:000324824500033
PM 23011090
ER
PT J
AU Phillips, J
Cardile, AP
Patterson, TF
Lewis, JS
AF Phillips, Jason
Cardile, Anthony P.
Patterson, Thomas F.
Lewis, James S., II
TI Daptomycin-induced acute eosinophilic pneumonia: Analysis of the current
data and illustrative case reports
SO SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Daptomycin; acute eosinophilic pneumonia
ID OF-THE-LITERATURE; PULMONARY SURFACTANT; IMPACT
AB Acute eosinophilic pneumonia (AEP) is a rare but important complication of daptomycin therapy. We describe 2 cases of daptomycin-associated AEP, compile available data from another 22 published cases, and propose a revised set of diagnostic criteria.
C1 [Phillips, Jason; Patterson, Thomas F.; Lewis, James S., II] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Cardile, Anthony P.] Brooke Army Med Ctr, Infect Dis Serv, Ft Sam Houston, TX 78234 USA.
[Patterson, Thomas F.] South Texas Vet Hlth Care Syst, Med Serv, San Antonio, TX USA.
RP Cardile, AP (reprint author), Brooke Army Med Ctr, Infect Dis Serv MCHE MDI, 3851 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA.
EM anthony.cardile@us.army.mil
NR 18
TC 10
Z9 10
U1 0
U2 7
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0036-5548
J9 SCAND J INFECT DIS
JI Scand. J. Infect. Dis.
PD OCT
PY 2013
VL 45
IS 10
BP 804
EP 808
DI 10.3109/00365548.2013.805427
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA 220JN
UT WOS:000324579200013
PM 23826793
ER
PT J
AU Bhatt, SP
Dransfield, MT
AF Bhatt, Surya P.
Dransfield, Mark T.
TI Chronic obstructive pulmonary disease and cardiovascular disease
SO TRANSLATIONAL RESEARCH
LA English
DT Review
ID CORONARY-HEART-DISEASE; PARTICULATE AIR-POLLUTION; VENTRICULAR DIASTOLIC
DYSFUNCTION; 3RD NATIONAL-HEALTH; ANGIOTENSIN-CONVERTING ENZYME;
INCREASED ARTERIAL STIFFNESS; NUTRITION EXAMINATION SURVEY; ACUTE
MYOCARDIAL-INFARCTION; INTIMA-MEDIA THICKNESS; IMPAIRED LUNG-FUNCTION
AB Chronic obstructive pulmonary disease (COPD) is an inflammatory disease of the lung associated with progressive airflow limitation and punctuated by episodes of acute exacerbation. There is growing recognition that the inflammatory state associated with COPD is not confined to the lungs but also involves the systemic circulation and can impact nonpulmonary organs. Epidemiologic and mechanistic studies indicate that COPD is associated with a high frequency of coronary artery disease, congestive heart failure and cardiac arrhythmias, independent of shared risk factors. Possible pathways include complex interrelationships between chronic low-grade systemic inflammation and oxidative stress as well as shared risk factors such as age, cigarette smoking, and environmental pollutants. In this review, we provide an overview of the epidemiologic data linking COPD with cardiovascular disease, comment on the interrelationships among COPD, inflammation, and cardiovascular disease, and highlight diagnostic and therapeutic challenges.
C1 [Dransfield, Mark T.] Univ Alabama Birmingham, UAB Lung Hlth Ctr, Birmingham, AL 35209 USA.
Birmingham VA Med Ctr, Birmingham, AL USA.
RP Dransfield, MT (reprint author), Univ Alabama Birmingham, UAB Lung Hlth Ctr, Birmingham, AL 35209 USA.
EM mdrans99@uab.edu
FU National Institutes of Health; Aeris; Astra Zeneca; Boehringer
Ingelheim; Boston Scientific; Centocor; Forest; GlaxoSmithKline; Ikaria;
Medimmune; Otsuka; Pfizer
FX M. T. Dransfield has served as a consultant to Boehringer Ingelheim,
GlaxoSmithKline, and Ikaria, and his institution has received research
support from the National Institutes of Health, Aeris, Astra Zeneca,
Boehringer Ingelheim, Boston Scientific, Centocor, Forest,
GlaxoSmithKline, Ikaria, Medimmune, Otsuka, and Pfizer. S. P. Bhatt has
no conflicts of interest to declare pertinent to the content of this
article. Both authors have read the journal's policy on disclosure of
potential conflicts of interest.
NR 198
TC 48
Z9 52
U1 2
U2 22
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1931-5244
J9 TRANSL RES
JI Transl. Res.
PD OCT
PY 2013
VL 162
IS 4
BP 237
EP 251
DI 10.1016/j.trsl.2013.05.001
PG 15
WC Medical Laboratory Technology; Medicine, General & Internal; Medicine,
Research & Experimental
SC Medical Laboratory Technology; General & Internal Medicine; Research &
Experimental Medicine
GA 226RZ
UT WOS:000325055000004
PM 23727296
ER
PT J
AU Sillivan, SE
Whittard, JD
Jacobs, MM
Ren, YH
Mazloom, AR
Caputi, FF
Horvath, M
Keller, E
Ma'ayan, A
Pan, YX
Chiang, LW
Hurd, YL
AF Sillivan, Stephanie E.
Whittard, John D.
Jacobs, Michelle M.
Ren, Yanhua
Mazloom, Amin R.
Caputi, Francesca F.
Horvath, Monika
Keller, Eva
Ma'ayan, Avi
Pan, Ying-Xian
Chiang, Lillian W.
Hurd, Yasmin L.
TI ELK1 Transcription Factor Linked to Dysregulated Striatal Mu Opioid
Receptor Signaling Network and OPRM1 Polymorphism in Human Heroin
Abusers
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE Addiction; MAPK; opioid; rat; self-administration; transcriptome
ID IN-VIVO; NUCLEAR TRANSLOCATION; BEHAVIORAL-RESPONSES; REWARDING
PROPERTIES; SYNAPTIC PLASTICITY; OPIATE ADDICTION; GENE-EXPRESSION;
CALCIUM CURRENT; MICE LACKING; PHOSPHORYLATION
AB Background: Abuse of heroin and prescription opiate medications has grown to disturbing levels. Opioids mediate their effects through mu opioid receptors (MOR), but minimal information exists regarding MOR-related striatal signaling relevant to the human condition. The striatum is a structure central to reward and habitual behavior and neurobiological changes in this region are thought to underlie the pathophysiology of addiction disorders.
Methods: We examined molecular mechanisms related to MOR in postmortem human brain striatal specimens from a homogenous European Caucasian population of heroin abusers and control subjects and in an animal model of heroin self-administration. Expression of ets-like kinase 1 (ELK1) was examined in relation to polymorphism of the MOR gene OPRM1 and drug history.
Results: A characteristic feature of heroin abusers was decreased expression of MOR and extracellular regulated kinase signaling networks, concomitant with dysregulation of the downstream transcription factor ELK1. Striatal ELK1 in heroin abusers associated with the polymorphism rs2075572 in OPRM1 in a genotype dose-dependent manner and correlated with documented history of heroin use, an effect reproduced in an animal model that emphasizes a direct relationship between repeated heroin exposure and ELK1 dysregulation. A central role of ELK1 was evidenced by an unbiased whole transcriptome microarray that revealed similar to 20% of downregulated genes in human heroin abusers are ELK1 targets. Using chromatin immune precipitation, we confirmed decreased ELK1 promoter occupancy of the target gene Use1.
Conclusions: ELK1 is a potential key transcriptional regulatory factor in striatal disturbances associated with heroin abuse and relevant to genetic mutation of OPRM1.
C1 [Sillivan, Stephanie E.; Whittard, John D.; Jacobs, Michelle M.; Ren, Yanhua; Caputi, Francesca F.; Hurd, Yasmin L.] Ichan Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.
[Sillivan, Stephanie E.; Whittard, John D.; Jacobs, Michelle M.; Ren, Yanhua; Caputi, Francesca F.; Hurd, Yasmin L.] Ichan Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA.
[Sillivan, Stephanie E.; Jacobs, Michelle M.; Ren, Yanhua; Mazloom, Amin R.; Caputi, Francesca F.; Ma'ayan, Avi; Hurd, Yasmin L.] Ichan Sch Med Mt Sinai, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA.
[Hurd, Yasmin L.] James J Peters VA Med Ctr, Bronx, NY USA.
[Horvath, Monika] Uppsala Univ, Dept Forens Med, Uppsala, Sweden.
[Horvath, Monika; Keller, Eva] Semmelweis Univ, Dept Forens Med, H-1085 Budapest, Hungary.
[Pan, Ying-Xian] Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA.
[Pan, Ying-Xian] Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Chem Program Y XP, New York, NY 10021 USA.
[Chiang, Lillian W.] Purdue Pharma LP, Cranbury, NJ USA.
RP Hurd, YL (reprint author), Ichan Sch Med Mt Sinai, Dept Psychiat, 1 Gustave L Levy Pl,Box 1065, New York, NY 10029 USA.
EM yasmin.hurd@mssm.edu
FU National Institute on Drug Abuse [DA015446, DA013997, T32DA007135,
ETT/098/2009]; Department of Veterans Affairs, Veterans Health
Administration, Office of Research and Development
FX This work was funded by grants from the National Institute on Drug Abuse
DA015446 (YLH), DA013997 (Y-XP), and T32DA007135 (MMJ), as well as Grant
ETT/098/2009 (EK). The study was also supported in part by the
Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development.
NR 80
TC 8
Z9 8
U1 2
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD OCT 1
PY 2013
VL 74
IS 7
BP 511
EP 519
DI 10.1016/j.biopsych.2013.04.012
PG 9
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 216UJ
UT WOS:000324310000008
PM 23702428
ER
PT J
AU Peterson, YK
Cameron, RB
Wills, LP
Trager, RE
Lindsey, CC
Beeson, CC
Schnellmann, RG
AF Peterson, Yuri K.
Cameron, Robert B.
Wills, Lauren P.
Trager, Richard E.
Lindsey, Chris C.
Beeson, Craig C.
Schnellmann, Rick G.
TI beta(2)-Adrenoceptor agonists in the regulation of mitochondrial
biogenesis
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Adrenoceptor; Biogenesis; Mitochondria; Pharmacophore; Chemical
similarity; Clustering; Renal
ID NEURAL STEM-CELLS; FUNCTIONAL SELECTIVITY; RECEPTOR LIGANDS; CAMP;
BETA(2); CULTURE; GLUCONEOGENESIS; AVAILABILITY; ADRENOCEPTOR;
METABOLISM
AB The stimulation of mitochondrial biogenesis (MB) via cell surface G-protein coupled receptors is a promising strategy for cell repair and regeneration. Here we report the specificity and chemical rationale of a panel of beta(2)-adrenoceptor agonists with regards to MB. Using primary cultures of renal cells, a diverse panel of beta(2)-adrenoceptor agonists elicited three distinct phenotypes: full MB, partial MB, and non-MB. Full MB compounds had efficacy in the low nanomolar range and represent two chemical scaffolds containing three distinct chemical clusters. Interestingly, the MB phenotype did not correlate with reported receptor affinity or chemical similarity. Chemical clusters were then subjected to pharmacophore modeling creating two models with unique and distinct features, consisting of five conserved amongst full MB compounds were identified. The two discrete pharmacophore models were coalesced into a consensus pharmacophore with four unique features elucidating the spatial and chemical characteristics required to stimulate MB. (C) 2013 The Authors. Published by Elsevier Ltd. All rights reserved.
C1 [Peterson, Yuri K.; Cameron, Robert B.; Wills, Lauren P.; Trager, Richard E.; Lindsey, Chris C.; Beeson, Craig C.; Schnellmann, Rick G.] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA.
[Schnellmann, Rick G.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA.
RP Schnellmann, RG (reprint author), Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, 280 Calhoun St, Charleston, SC 29425 USA.
EM schnell@musc.edu
FU National Institutes of Health [T32 CA119945-04, F32 ES020103-01,
ES012878, DK071997, GM084147]; Biomedical LaboratoryResearch and
Development Program of the Department of Veterans Affairs [1BX000851];
[T32 GM08716]
FX R.B.C. is funded by T32 GM08716. L.P.W. is funded by the National
Institutes of Health grant T32 CA119945-04 and F32 ES020103-01. R.G.S.
is funded by the National Institutes of Health grants ES012878, DK071997
and GM084147, and the Biomedical LaboratoryResearch and Development
Program of the Department of Veterans Affairs [1BX000851]. The authors
also thank Kathryn Appleton and Louis Luttrell for thoughtful
discussions and Gyda Beeson for technical assistance.
NR 39
TC 8
Z9 8
U1 0
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD OCT 1
PY 2013
VL 23
IS 19
BP 5376
EP 5381
DI 10.1016/j.bmcl.2013.07.052
PG 6
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 216RX
UT WOS:000324302800023
PM 23954364
ER
PT J
AU Varghese, FP
Cummings, DL
AF Varghese, Femina P.
Cummings, Devon L.
TI Introduction: Why Apply Vocational Psychology to Criminal Justice
Populations?
SO COUNSELING PSYCHOLOGIST
LA English
DT Editorial Material
DE vocational; career; work; social justice; offender; criminal
ID PRISONER REENTRY; CORRECTIONAL PSYCHOLOGISTS; CAREER-DEVELOPMENT;
CLINICAL-PRACTICE; PUBLIC-POLICY; WORK; OFFENDERS; EMPLOYMENT; CRIME;
EXPECTANCIES
AB The criminal justice population has experienced exponential growth in recent decades. Yet, counseling and vocational psychology has not kept pace in addressing the vocational needs of this population. A recent literature search in counseling and vocational journals found that in the last quarter century, only 14 articles have been published that focus on this topic. Among these, even fewer are focused on developing effective vocational interventions for this population. The articles in this major contribution endeavor to begin filling this gap by (a) demonstrating the need and applicability for applying counseling and vocational psychology in developing vocational interventions for the criminal justice population, (b) providing an example and initial empirical findings of a vocational intervention used with this population, and (c) informing readers of best practices in interdisciplinary research for theoretical integration to work with this population.
C1 [Varghese, Femina P.] Univ Cent Arkansas, Counseling Psychol Program, Conway, AR 72035 USA.
[Cummings, Devon L.] Univ Cent Arkansas, Conway, AR 72035 USA.
VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Varghese, FP (reprint author), Univ Cent Arkansas, Dept Psychol & Counseling, 201 Donaghey Ave, Conway, AR 72035 USA.
EM fvarghese@uca.edu
NR 106
TC 2
Z9 2
U1 9
U2 35
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0011-0000
J9 COUNS PSYCHOL
JI Couns. Psychol.
PD OCT
PY 2013
VL 41
IS 7
BP 961
EP 989
DI 10.1177/0011000012459363
PG 29
WC Psychology, Applied
SC Psychology
GA 211HD
UT WOS:000323896200002
ER
PT J
AU Berg, AT
Caplan, R
Baca, CB
Vickrey, BG
AF Berg, Anne T.
Caplan, Rochelle
Baca, Christine B.
Vickrey, Barbara G.
TI Early-onset epilepsy, cognition, and behaviour: continuity and challenge
Reply
SO DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY
LA English
DT Letter
ID MRI
AB Please also see the reply to this letter by .
C1 [Berg, Anne T.] Ann & Robert H Lurie Childrens Hosp Chicago, Epilepsy Ctr, Chicago, IL USA.
[Berg, Anne T.] Northwest Mem Feinberg Sch Med, Dept Pediat, Chicago, IL USA.
[Caplan, Rochelle] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA.
[Baca, Christine B.; Vickrey, Barbara G.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA.
[Baca, Christine B.; Vickrey, Barbara G.] VA Greater Los Angeles Hlth Care Syst, Dept Neurol, Los Angeles, CA USA.
RP Berg, AT (reprint author), Ann & Robert H Lurie Childrens Hosp Chicago, Epilepsy Ctr, Chicago, IL USA.
EM atberg@luriechildrens.org
FU NINDS NIH HHS [R37 NS031146, R01 NS031146]
NR 5
TC 0
Z9 0
U1 1
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0012-1622
J9 DEV MED CHILD NEUROL
JI Dev. Med. Child Neurol.
PD OCT
PY 2013
VL 55
IS 10
BP 964
EP 965
DI 10.1111/dmcn.12203
PG 2
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 213OK
UT WOS:000324067100017
PM 23889464
ER
PT J
AU Zhang, XY
Al Jurdi, RK
Zoghbi, AW
Chen, DC
Xiu, MH
Tan, YL
Yang, FD
Kosten, TR
AF Zhang, Xiang Yang
Al Jurdi, Rayan K.
Zoghbi, Anthony William
Chen, Da Chun
Xiu, Mei Hong
Tan, Yun Long
Yang, Fu De
Kosten, Thomas R.
TI Prevalence, demographic and clinical correlates of suicide attempts in
Chinese medicated chronic inpatients with schizophrenia
SO JOURNAL OF PSYCHIATRIC RESEARCH
LA English
DT Article
DE Schizophrenia; Suicide; Risk factors; Smoking; China
ID RANDOMIZED CONTROLLED-TRIAL; NEGATIVE SYNDROME SCALE; 1ST EPISODE
PSYCHOSIS; QUALITY-OF-LIFE; CIGARETTE-SMOKING; RISK-FACTORS; 1ST-EPISODE
PSYCHOSIS; REVISED NOMENCLATURE; PSYCHIATRIC-PATIENTS; SPECTRUM
DISORDERS
AB The high prevalence of suicide in schizophrenia may be related to its demographic and clinical characteristics. Because suicide prevalence and its associations with clinical variables are less well characterized in Chinese than European patients with schizophrenia, we assessed the suicide attempts in 520 Chinese inpatients with schizophrenia. The suicide attempt data were collected from medical case notes and interviews with the patients and their family members. Patients were rated on the Positive and Negative Syndrome Scale (PANSS), the Simpson and Angus Extrapyramidal Symptom Rating Scale (SAES), and the Abnormal Involuntary Movement Scale (AIMS). Smoking severity was evaluated using clinician-administered questionnaires and the Fagerstrom Test for Nicotine Dependence (FTND). We found a suicide attempt rate of 9.2% in these schizophrenic inpatients. The attempters were single, had a significantly younger age but more hospitalizations, had higher depressive symptoms, and began smoking at an earlier age, smoked more cigarettes each day and had higher FTND total scores than patients without suicide attempts. The logistic regression analysis also indicated that suicide attempts were associated with the number of hospitalizations, depressive symptoms and FTND total scores. These results suggest that Chinese inpatients with schizophrenia attempt suicide more often than the general population. Further, some demographic and clinical variables are risk factors for suicide attempts in schizophrenia. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Zhang, Xiang Yang; Al Jurdi, Rayan K.; Zoghbi, Anthony William; Kosten, Thomas R.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
[Zhang, Xiang Yang; Al Jurdi, Rayan K.; Zoghbi, Anthony William; Kosten, Thomas R.] Michael E DeBakey VA Med Ctr, Houston, TX USA.
[Zhang, Xiang Yang; Chen, Da Chun; Xiu, Mei Hong; Tan, Yun Long; Yang, Fu De; Kosten, Thomas R.] Peking Univ, Beijing HuiLongGuan Hosp, Beijing 100871, Peoples R China.
RP Zhang, XY (reprint author), VA Med Ctr, Res Bldg 109,Room 130,2002 Holcombe Blvd, Houston, TX 77030 USA.
EM xyzhang@bcm.edu; kosten@bcm.edu
FU Stanley Medical Research Institute [03T-459, 05T-726]; Department of
Veterans Affairs, VISN 16, Mental Illness Research, Education and
Clinical Center (MIRECC), United States National Institute of Health
[K05-DA0454, P50-DA18827, U01-MH79639]
FX This study was supported by the Stanley Medical Research Institute
(03T-459 and 05T-726), and the Department of Veterans Affairs, VISN 16,
Mental Illness Research, Education and Clinical Center (MIRECC), United
States National Institute of Health K05-DA0454, P50-DA18827 and
U01-MH79639. These sources had no further role in study design; in the
collection, analysis and interpretation of data; in the writing of the
report; and in the decision to submit the paper for publication.
NR 54
TC 6
Z9 7
U1 2
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3956
J9 J PSYCHIATR RES
JI J. Psychiatr. Res.
PD OCT
PY 2013
VL 47
IS 10
BP 1370
EP 1375
DI 10.1016/j.jpsychires.2013.05.024
PG 6
WC Psychiatry
SC Psychiatry
GA 212TC
UT WOS:000324004700013
PM 23791457
ER
PT J
AU Corcorran, MA
Olson, JM
Hecht, C
Knezevich, S
Vary, JC
AF Corcorran, Maria A.
Olson, Jonathan M.
Hecht, Corinne
Knezevich, Stevan
Vary, Jay C.
TI Eruptive squamous cell carcinoma in a patient receiving abatacept for
rheumatoid arthritis
SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
LA English
DT Letter
C1 [Corcorran, Maria A.] Univ Washington, Sch Med, Seattle, WA 98195 USA.
[Olson, Jonathan M.; Hecht, Corinne; Vary, Jay C.] Univ Washington, Dept Med, Div Dermatol, Seattle, WA 98195 USA.
[Knezevich, Stevan] Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
[Olson, Jonathan M.; Hecht, Corinne; Knezevich, Stevan; Vary, Jay C.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
RP Vary, JC (reprint author), Univ Washington, Sch Med, Div Dermatol, Dept Med, 1959 NE Pacific St,Rm BB 1353,Box 356524, Seattle, WA 98195 USA.
EM jvary@uw.edu
NR 5
TC 1
Z9 1
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0190-9622
J9 J AM ACAD DERMATOL
JI J. Am. Acad. Dermatol.
PD OCT
PY 2013
VL 69
IS 4
BP E178
EP E179
DI 10.1016/j.jaad.2013.04.018
PG 3
WC Dermatology
SC Dermatology
GA 215VM
UT WOS:000324238900009
PM 24034388
ER
PT J
AU Jin, J
Limburg, S
Joshi, SK
Landman, R
Park, M
Zhang, Q
Kim, HT
Kuo, AC
AF Jin, Jenny
Limburg, Sonja
Joshi, Sunil K.
Landman, Rebeccah
Park, Michelle
Zhang, Qia
Kim, Hubert T.
Kuo, Alfred C.
TI Peripheral Nerve Repair in Rats Using Composite Hydrogel-Filled Aligned
Nanofiber Conduits with Incorporated Nerve Growth Factor
SO TISSUE ENGINEERING PART A
LA English
DT Article
ID INTRATHECAL DELIVERY-SYSTEM; HYALURONIC-ACID; SCIATIC-NERVE;
CONTROLLED-RELEASE; NEURON OUTGROWTH; COLLAGEN MATRIX; AXONAL GROWTH;
FIBER GROWTH; SPINAL-CORD; REGENERATION
AB Repair of peripheral nerve defects with current synthetic, tubular nerve conduits generally shows inferior recovery when compared with using nerve autografts, the current gold standard. We tested the ability of composite collagen and hyaluronan hydrogels, with and without the nerve growth factor (NGF), to stimulate neurite extension on a promising aligned, nanofiber poly-L-lactide-co-caprolactone (PLCL) scaffold. In vitro, the hydrogels significantly increased neurite extension from dorsal root ganglia explants. Consistent with these results, the addition of hydrogels as luminal fillers within aligned, nanofiber tubular PLCL conduits led to improved sensory function compared to autograft repair in a critical-size defect in the sciatic nerve in a rat model. Sensory recovery was assessed 3 and 12 weeks after repair using a withdrawal assay from thermal stimulation. The addition of hydrogel did not enhance recovery of motor function in the rat model. The NGF led to dose-dependent improvements in neurite out-growth in vitro, but did not have a significant effect in vivo. In summary, composite collagen/hyaluronan hydrogels enhanced sensory neurite outgrowth in vitro and sensory recovery in vivo. The use of such hydrogels as luminal fillers for tubular nerve conduits may therefore be useful in assisting restoration of protective sensation following peripheral nerve injury.
C1 [Jin, Jenny; Limburg, Sonja; Joshi, Sunil K.; Landman, Rebeccah; Park, Michelle; Zhang, Qia; Kim, Hubert T.; Kuo, Alfred C.] Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA USA.
[Jin, Jenny; Limburg, Sonja; Joshi, Sunil K.; Landman, Rebeccah; Park, Michelle; Zhang, Qia; Kim, Hubert T.; Kuo, Alfred C.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Kuo, AC (reprint author), San Francisco VA Med Ctr, 4150 Clement St Box 112, San Francisco, CA 94121 USA.
EM KuoAC@orthosurg.ucsf.edu
FU Department of Defense [W81XWH-05-2-0094]
FX We thank Professor Song Li and Shyam Patel for informative discussions,
Bora Shin and Judy Shigenaga for technical assistance, and Eva Grotkopp
for statistical assistance. This work was supported by the Department of
Defense Grant (W81XWH-05-2-0094), which was administered by the Northern
California Institute for Research and Education, and with resources of
the Veterans Affairs Medical Center, San Francisco, California.
NR 53
TC 8
Z9 10
U1 3
U2 91
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937-3341
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD OCT 1
PY 2013
VL 19
IS 19-20
BP 2138
EP 2146
DI 10.1089/ten.tea.2012.0575
PG 9
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
Biology
SC Cell Biology; Biotechnology & Applied Microbiology
GA 211TI
UT WOS:000323933400006
PM 23659607
ER
PT J
AU Horning, SM
Wilkins, SS
Dhanani, S
Henriques, D
AF Horning, Sheena M.
Wilkins, Stacy S.
Dhanani, Shawkat
Henriques, Donna
TI A Case of Elder Abuse and Undue Influence: Assessment and Treatment From
a Geriatric Interdisciplinary Team
SO CLINICAL CASE STUDIES
LA English
DT Article
DE elder abuse; undue influence; dementia; decision-making capacity
ID UNITED-STATES; MISTREATMENT; PREVALENCE
AB Elder abuse is a pervasive problem that can have lasting emotional and physical consequences, increasing its victims' risk of mortality. Healthcare providers are frequently involved in the detection and intervention of elder abuse. Because of the complexity of these cases, applying treatment interventions within an interdisciplinary care team has been recommended to ensure older adults' safety and welfare. Psychologists in particular are frequently relied upon in these situations because of their expertise in cognitive, psychiatric, and capacity assessment, as well as their ability to intervene in a variety of difficult situations. The following is a report examining the case of Mr. B, who was a victim of elder abuse involving financial exploitation and undue influence. Assessment and treatment interventions were used within the context of an interdisciplinary care team, using a bio-psychosocial approach. A decision-tree model describing the steps to take in assessing and treating financial elder abuse is proposed.
C1 [Horning, Sheena M.; Wilkins, Stacy S.; Dhanani, Shawkat; Henriques, Donna] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90025 USA.
[Wilkins, Stacy S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Dhanani, Shawkat] Univ Calif Los Angeles, Los Angeles, CA USA.
RP Horning, SM (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Psychol, 11301 Wilshire Blvd, Los Angeles, CA 90025 USA.
EM Sheena.Horning@va.gov
OI Horning, Sheena/0000-0002-9704-0070
NR 23
TC 1
Z9 1
U1 1
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-6501
EI 1552-3802
J9 CLIN CASE STUD
JI Clin. Case Stud.
PD OCT
PY 2013
VL 12
IS 5
BP 373
EP 387
DI 10.1177/1534650113496143
PG 15
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA AW9OT
UT WOS:000346587700004
ER
PT J
AU Rinker, JR
Cossey, TC
Cutter, GR
Culpepper, WJ
AF Rinker, John R., II
Cossey, Tiffany C.
Cutter, Gary R.
Culpepper, William J.
TI A retrospective review of lithium usage in veterans with multiple
sclerosis
SO MULTIPLE SCLEROSIS AND RELATED DISORDERS
LA English
DT Review
DE Multiple sclersosi; Lithium; Veteran; Retrospective study; Drug
toxicity; Drug tolerance
AB Objective: Lithium (Li) reduces disease activity in animal models of multiple sclerosis (MS), but has not been previously studied in human MS. While developing a clinical trial to test the effects of Li in MS, we performed a retrospective chart review to determine the safety and tolerability of Li among US veterans with MS.
Methods: We identified all veterans with MS prescribed Li from 1998 to 2009 using the Department of Veterans Affairs Pharmacy Benefits Management. Charts were reviewed for Li-related adverse events and effects on the MS disease course.
Results: Among 21,847 veterans with MS, 101 met inclusion criteria and took Li >6 months. Eighteen percent of subjects experienced a Li-associated adverse event. Later age of MS onset was associated with increased risk of Li-related adverse events (p=0.004). Associations between Li use and MS disease activity were mixed: Li was not associated with increased risk of enhancing MRI lesions (p=0.655), but annualized relapse rates were higher on Li (0.34 vs. 0.20, p=0.044). In contrast, change in Expanded Disability Status Scale scores was greater in the off-Li period than the on-Li period (0.8 vs. 0.3, p=0.003).
Conclusion: Adverse events occur in a minority of Li-treated MS patients. A consistent effect of Li on MS disease activity was not apparent. These findings indicate a clinical trial will be needed to ascertain Lis effects on the MS disease course. Published by Elsevier B.V.
C1 [Rinker, John R., II; Cossey, Tiffany C.] Birmingham VA Med Ctr, Birmingham, AL 35233 USA.
[Rinker, John R., II] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA.
[Cossey, Tiffany C.] Univ Alabama Birmingham, Dept Internal Med, Birmingham, AL 35294 USA.
[Cutter, Gary R.] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA.
[Culpepper, William J.] Baltimore VA Med Ctr, VA Multiple Sclerosis Ctr Excellence East, Baltimore, MD 20201 USA.
RP Rinker, JR (reprint author), Univ Alabama Birmingham, SC 440,1720 7th Ave South, Birmingham, AL 35233 USA.
EM rinkerj@uab.edu
FU Department of Veterans Affairs Career Development Award (CDA2); VA MS
Center of Excellence East
FX Dr. John Rinker is supported by a Department of Veterans Affairs Career
Development Award (CDA2).; Dr. Joel Culpepper is supported by the VA MS
Center of Excellence East. He reports no conflicts in regards to this
work.
NR 25
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2211-0348
EI 2211-0356
J9 MULT SCLER RELAT DIS
JI Mult. Scler. Relat. Disord.
PD OCT
PY 2013
VL 2
IS 4
BP 327
EP 333
DI 10.1016/j.msard.2013.03.004
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA V37LE
UT WOS:000209276500007
PM 25877842
ER
PT J
AU Zhao, S
Cao, L
Freeman, JW
AF Zhao, S.
Cao, L.
Freeman, J. W.
TI Knockdown of RON receptor kinase delays but does not prevent tumor
progression while enhancing HGF/MET signaling in pancreatic cancer cell
lines
SO ONCOGENESIS
LA English
DT Article
DE RON; MET; pancreatic cancer; cancer therapy
AB In this study, the role of RON (receptor originated from nantes) in tumor progression was further investigated in context with MET expression and activity. RON and MET expressions were not detected in an immortalized normal human pancreas cell line (HPNE), but were co-expressed in five of seven pancreatic ductal adenocarcinoma (PDAC) cell lines (PANC-1, BxPC-3, Capan-2, CFPAC-1 and AsPC-1). RON expression was knocked down by an shRNA approach in two PDAC cell lines (BxPC-3 and CFPAC-1) that co-express MET. Knockdown of RON significantly inhibited cell growth, clonogenicity and macrophage stimulating protein (MSP), RON ligand induced invasion by in vitro assays and significantly inhibited tumor growth (P<0.001) and metastasis (P<0.009) in an orthotopic pancreatic cancer mouse model at week 7. However, by week 9, the mice implanted with RON knockdown cells had developed similar size primary tumors and metastases compared with that seen in the control group at week 7. Western blotting and immunohistochemistry analyses showed that MET remains highly expressed in cells and tumor tissues where RON was knocked down. Moreover, knockdown of RON did not prevent hepatocyte growth factor (HGF) stimulated invasion in in vitro Matrigel assays. Treating cells with MSP induced the transphosphorylation of MET, suggesting that signaling may be modulated by relative levels of RON and MET receptors and their corresponding ligands. To this point, HGF treatment of RON knockdown cells caused an increase in intensity and duration of MET signaling, suggesting that MET signaling may compensate for loss of RON signaling. Treatment of cells with an MET inhibitor, PHA-665752, had minimal effects on inhibiting cell growth but significantly inhibited cell invasion induce by ligands for either MET or RON. These results suggest that HGF/MET signaling may have a more important role in tumor cell invasion and metastasis rather than in tumor cell proliferation. This study indicates that specific inhibition of RON delays but does not prevent progression of PDAC. Moreover, specific signaling may be modulated by the interaction of RON and MET receptors. This dynamic interaction of RON and MET in pancreatic cancer cells suggests that dual targeting of both RON and MET will be preferable to inhibition of either target alone.
C1 [Zhao, S.; Cao, L.; Freeman, J. W.] Univ Texas Hlth Sci Ctr San Antonio, Div Med Oncol, Dept Med, San Antonio, TX 78229 USA.
[Freeman, J. W.] Canc Therapy & Res Ctr S Texas, Expt & Dev Therapeut Program, San Antonio, TX 78229 USA.
[Freeman, J. W.] Audie L Murphy Mem Vet Adm Med Ctr, Res & Dev, San Antonio, TX USA.
RP Freeman, JW (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Med Oncol, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM freemanjw@uthscsa.edu
FU VA merit award; Cancer Center Grant [NIH-RO1CA069122, NIH-P30CA054174]
FX We thank Jenny Wang (University of Nebraska Medical Center, Omaha, NE)
for the pSuper-shRNA-RON and Ricardo Aguiar (University of Texas Health
Science Center, San Antonio, TX) for the PMMP-luciferase plasmids. We
thank the University of Texas Health Science Center Animal Care and Use
Committee and the Optical Imaging Facility Core of University of Texas
Health Science Center (San Antonio, TX) for housing the mice and
facility the animal images; and we thank the Histology and Pathology
Laboratory (University of Texas Health Science Center, San Antonio, TX)
for the histopathology and immunohistochemistry analysis. Grants to JWF,
VA merit award, and NIH-RO1CA069122, Cancer Center Grant to CTRC,
NIH-P30CA054174, supported this work.
NR 50
TC 7
Z9 7
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 2157-9024
J9 ONCOGENESIS
JI Oncogenesis
PD OCT
PY 2013
VL 2
AR UNSP e76
DI 10.1038/oncsis.2013.36
PG 10
WC Oncology
SC Oncology
GA V36OI
UT WOS:000209220600002
PM 24100611
ER
PT J
AU Clark-Cutaia, MN
Ren, DX
Hoffman, LA
Snetselaar, L
Sevick, MA
AF Clark-Cutaia, Maya N.
Ren, Dianxu
Hoffman, Leslie A.
Snetselaar, Linda
Sevick, Mary Ann
TI Psychometric Validation of the Self-Efficacy for Restricting Dietary
Salt in Hemodialysis Scale
SO TOPICS IN CLINICAL NUTRITION
LA English
DT Article
DE consistency; construct validity; convergent validity; dietary sodium
intake; fluid restriction; hemodialysis; psychometrics
AB The development and progression of left ventricular hypertrophy is a consequence of multiple comorbid conditions associated with end-stage renal disease and large variations in interdialytic weight gains. The literature suggests that dietary sodium restriction alone significantly reduces interdialytic weight gains. A total of 124 hemodialysis participants in an ongoing randomized control trial participated in the validation in which psychometric properties of a self-efficacy survey were a secondary analysis. We evaluated the internal consistency, construct validity, and convergent validity of the instrument. The overall Cronbach alpha was 0.93. Three factors extracted explain 67.8% of the variance of the white and African American participants. The Self-Efficacy Survey has adequate internal consistency and construct and convergent validity. Future research is needed to evaluate the stability and discriminant validity of the instrument.
C1 [Clark-Cutaia, Maya N.] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA.
[Ren, Dianxu] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA.
[Hoffman, Leslie A.] Univ Pittsburgh, Nursing Clin & Translat Sci, Pittsburgh, PA USA.
[Snetselaar, Linda] Univ Iowa, Dept Epidemiol, Preventat Nutr Educ, Iowa City, IA USA.
[Sevick, Mary Ann] US Dept Vet Affairs, VA Pittsburgh Healthcare Syst, Washington, DC USA.
[Sevick, Mary Ann] Univ Pittsburgh, Ctr Res Hlth Care, Publ Hlth Clin & Translat Sci, Pittsburgh, PA USA.
RP Clark-Cutaia, MN (reprint author), Univ Penn, Sch Nursing, Claire M Fagin Hall,418 Curie Blvd, Philadelphia, PA 19104 USA.
EM Mayan@nursing.upenn.edu
FU [NIH-R01-NR010135]; [NIH-K24-NR012226]; [1F31NR013410]
FX This study was supported through grants from NIH-R01-NR010135,
NIH-K24-NR012226 received by Mary Ann Sevick, and 1F31NR013410 received
by Maya N. Clark, PhD, ACNP-BC, RN. The authors have disclosed that they
have no significant relationships with, or financial interest in, any
commercial companies pertaining to this article .
NR 38
TC 2
Z9 2
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0883-5691
EI 1550-5146
J9 TOP CLIN NUTR
JI Top. Clin. Nutr.
PD OCT-DEC
PY 2013
VL 28
IS 4
BP 384
EP 391
DI 10.1097/01.TIN.0000437407.76867.65
PG 8
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA V41NM
UT WOS:000209552900008
PM 26213444
ER
PT J
AU Karlamangla, AS
Mori, T
Merkin, SS
Seeman, TE
Greendale, GA
Binkley, N
Crandall, CJ
AF Karlamangla, Arun S.
Mori, Takahiro
Merkin, Sharon S.
Seeman, Teresa E.
Greendale, Gail A.
Binkley, Neil
Crandall, Carolyn J.
TI Childhood socioeconomic status and adult femoral neck bone strength:
Findings from the Mid life in the United States Study
SO BONE
LA English
DT Article
DE Bone strength; Femoral neck; Childhood socioeconomic advantage; Health
behaviors
ID HIP FRACTURE RISK; PHYSICAL-ACTIVITY QUESTIONNAIRE; CORONARY
HEART-DISEASE; MINERAL DENSITY; POSTMENOPAUSAL WOMEN; SOCIAL-CLASS;
RANCHO-BERNARDO; ALLOSTATIC LOAD; WHITE WOMEN; ELDERLY-MEN
AB Purpose: Bone acquisition in childhood impacts adult bone mass, and can be influenced by childhood socioeconomic conditions. Socioeconomic status is also associated with body weight which affects the load that bone is exposed to in a fall. We hypothesized that socioeconomic advantage in childhood is associated with greater bone strength relative to load in adulthood.
Methods: Hip dual x-ray absorptiometry scans from 722 participants in the Midlife in the United States Study were used to measure femoral neck size and bone mineral density, and combined with body weight and height to create composite indices of femoral neck strength relative to load in different failure modes: compression, bending, and impact. A childhood socioeconomic advantage score was created for the same participants from parental education, self-rated financial status relative to others, and not being on welfare. Multiple linear regression was used to determine the association of childhood socioeconomic advantage with femoral neck composite strength indices, stratified by gender and race (white/non-white), and adjusted for study site, age, menopause status in women; education, and current financial advantage.
Results: Childhood socioeconomic advantage was independently associated with higher indices of all three composite strength indices in white men (adjusted standardized effect sizes, 0.19 to 0.27, all p values < 0.01), but not in the other three race/gender groups. Additional adjustment for adult obesity, physical activity in different life stages, smoking, and heavy drinking over the life-course significantly attenuated the associations in white men.
Conclusions: Socioeconomic disadvantage in childhood is associated with lower hip strength relative to load in white men, and these influences are dampened by healthy lifestyle choices. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Karlamangla, Arun S.; Merkin, Sharon S.; Seeman, Teresa E.; Greendale, Gail A.] Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr, Dept Med, Los Angeles, CA 90095 USA.
[Mori, Takahiro] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA 90073 USA.
[Binkley, Neil] Univ Wisconsin, Madison Osteoporosis Clin Ctr & Res Prog, Sch Med & Publ Hlth, Madison, WI 53706 USA.
[Crandall, Carolyn J.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA.
RP Karlamangla, AS (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr, Dept Med, 10945 Le Conte Ave,Suite 2339, Los Angeles, CA 90095 USA.
EM akarlamangla@mednet.ucla.edu
FU National Institutes of Health [1R01AG033067, R01-AG-032271,
P01-AG-020166]; UCLA GCRC [M01-RR000865]
FX This research was supported by the National Institutes of Health grant
numbers 1R01AG033067, R01-AG-032271, and P01-AG-020166. The UCLA GCRC
helped support this study (UCLA GCRC grant # M01-RR000865).
NR 86
TC 4
Z9 4
U1 1
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 8756-3282
J9 BONE
JI Bone
PD OCT
PY 2013
VL 56
IS 2
BP 320
EP 326
DI 10.1016/j.bone.2013.06.021
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 210VX
UT WOS:000323864000014
PM 23810840
ER
PT J
AU Gorin, Y
Block, K
AF Gorin, Yves
Block, Karen
TI Nox as a target for diabetic complications
SO CLINICAL SCIENCE
LA English
DT Review
DE diabetes; diabetic complications; hyperglycaemia; oxidative stress; Nox;
reactive oxygen species; small-molecule inhibitor
ID SMOOTH-MUSCLE-CELLS; ENDOTHELIAL GROWTH-FACTOR; GLYCATION END-PRODUCTS;
RENIN-ANGIOTENSIN SYSTEM; NITRIC-OXIDE SYNTHASE; PROTEIN-KINASE-C;
TUBULAR EPITHELIAL-CELLS; INDUCED OXIDATIVE STRESS; ALPHA-LIPOIC ACID;
DINUCLEOTIDE PHOSPHATE OXIDASE
AB Oxidative stress has been linked to the pathogenesis of the major complications of diabetes in the kidney, the heart, the eye or the vasculature. NADPH oxidases of the Nox family are a major source of ROS (reactive oxygen species) and are critical mediators of redox signalling in cells from different organs afflicted by the diabetic milieu. In the present review, we provide an overview of the current knowledge related to the understanding of the role of Nox in the processes that control cell injury induced by hyperglycaemia and other predominant factors enhanced in diabetes, including the renin angiotensin system, TGF-beta (transforming growth factor-beta) and AGEs (advanced glycation end-products). These observations support a critical role for Nox homologues in diabetic complications and indicate that NADPH oxidases are an important therapeutic target. Therefore the design and development of small-molecule inhibitors that selectively block Nox oxidases appears to be a reasonable approach to prevent or retard the complications of diabetes in target organs. The bioefficacy of these agents in experimental animal models is also discussed in the present review.
C1 [Gorin, Yves; Block, Karen] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Block, Karen] South Texas Vet Hlth Care Syst, Audie L Murphy Mem Hosp Div, San Antonio, TX 78229 USA.
RP Gorin, Y (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
EM gorin@uthscsa.edu
OI Gorin, Yves/0000-0003-4048-6925
FU Juvenile Diabetes Research Foundation; National Institutes of Health
[RO1 DK 079996, RO1 CA 131272]; Veterans Administration
FX Our own work was supported by the Juvenile Diabetes Research Foundation
[Multiproject grants (to Y.G and K.B.)], the National Institutes of
Health [grant number RO1 DK 079996 (to Y.G.), RO1 CA 131272 (to K.B)]
and the Veterans Administration (to K.B.).
NR 310
TC 49
Z9 52
U1 1
U2 50
PU PORTLAND PRESS LTD
PI LONDON
PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND
SN 0143-5221
J9 CLIN SCI
JI Clin. Sci.
PD OCT
PY 2013
VL 125
IS 7-8
BP 361
EP 382
DI 10.1042/CS20130065
PG 22
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 210RQ
UT WOS:000323852600006
PM 23767990
ER
PT J
AU Weintraub, D
Duda, JE
Carlson, K
Luo, P
Sagher, O
Stern, M
Follett, KA
Reda, D
Weaver, FM
AF Weintraub, Daniel
Duda, John E.
Carlson, Kimberly
Luo, Ping
Sagher, Oren
Stern, Matthew
Follett, Kenneth A.
Reda, Domenic
Weaver, Frances M.
CA CSP 468 Study Grp
TI Suicide ideation and behaviours after STN and GPi DBS surgery for
Parkinson's disease: results from a randomised, controlled trial
SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
LA English
DT Article
DE PARKINSON'S DISEASE; BEHAVIOURAL DISORDER; SURGERY
ID DEEP-BRAIN-STIMULATION; SUBTHALAMIC NUCLEUS STIMULATION; HEALTH SURVEY
SF-36; MOVEMENT-DISORDERS; MEDICAL THERAPY; DEPRESSION; OUTCOMES; MOOD;
RISK
AB Background
The risk of suicide behaviours post-deep brain stimulation (DBS) surgery in Parkinson's disease (PD) remains controversial. We assessed if suicide ideation and behaviours are more common in PD patients (1) randomised to DBS surgery versus best medical therapy (BMT); and (2) randomised to subthalamic nucleus (STN) versus globus pallidus interna (GPi) DBS surgery.
Methods
In Phase 1 of the Veterans Affairs CSP 468 study, 255 PD patients were randomised to DBS surgery (n=121) or 6months of BMT (n=134). For Phase 2, a total of 299 patients were randomised to STN (n=147) or GPi (n=152) DBS surgery. Patients were assessed serially with the Unified Parkinson's Disease Rating Scale Part I depression item, which queries for suicide ideation; additionally, both suicide behaviour adverse event data and proxy symptoms of increased suicide risk from the Parkinson's Disease Questionnaire (PDQ-39) and the Short Form Health Survey (SF-36) were collected.
Results
In Phase 1, no suicide behaviours were reported, and new-onset suicide ideation was rare (1.9% for DBS vs 0.9% for BMT; Fisher's exact p=0.61). Proxy symptoms of relevance to suicide ideation were similar in the two groups. Rates of suicide ideation at 6months were similar for patients randomised to STN versus GPi DBS (1.5% vs 0.7%; Fisher's exact p=0.61), but several proxy symptoms were worse in the STN group.
Conclusions
Results from the randomised, controlled phase of a DBS surgery study in PD patients do not support a direct association between DBS surgery and an increased risk for suicide ideation and behaviours.
C1 [Weintraub, Daniel; Duda, John E.; Stern, Matthew] Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr PADRECC, Philadelphia, PA USA.
[Weintraub, Daniel] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA.
[Weintraub, Daniel; Duda, John E.; Stern, Matthew] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Carlson, Kimberly; Luo, Ping; Reda, Domenic] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Dept Vet Affairs Cooperat Studies, Program Coordinating Ctr, Hines, IL 60141 USA.
[Sagher, Oren] Univ Michigan, Sch Med, Dept Neurosurg, Ann Arbor, MI USA.
[Follett, Kenneth A.] Univ Nebraska, Med Ctr, Omaha VA Med Ctr, Omaha, NE USA.
[Follett, Kenneth A.] Univ Nebraska, Med Ctr, Div Neurosurg, Omaha, NE USA.
[Weaver, Frances M.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hlth Serv Res Ctr, Hines, IL 60141 USA.
[Weaver, Frances M.] Loyola Univ, Stritch Sch Med, Dept Med, Chicago, IL 60611 USA.
RP Weintraub, D (reprint author), Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia VA Med Ctr, 3615 Chestnut St 330, Philadelphia, PA 19104 USA.
EM daniel.weintraub@uphs.upenn.edu
FU Cooperative Studies Programme of the Department of Veterans Affairs
Office of Research and Development; National Institute of Neurological
Disorders and Stroke; Medtronic Neuromodulation [NCT00056563, NCT
01076452.]
FX The Cooperative Studies Programme of the Department of Veterans Affairs
Office of Research and Development, the National Institute of
Neurological Disorders and Stroke, and Medtronic Neuromodulation
provided financial support for this study NCT00056563 and NCT 01076452.
NR 30
TC 30
Z9 30
U1 0
U2 18
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-3050
J9 J NEUROL NEUROSUR PS
JI J. Neurol. Neurosurg. Psychiatry
PD OCT
PY 2013
VL 84
IS 10
BP 1113
EP 1118
DI 10.1136/jnnp-2012-304396
PG 6
WC Clinical Neurology; Psychiatry; Surgery
SC Neurosciences & Neurology; Psychiatry; Surgery
GA 209SH
UT WOS:000323779800013
PM 23667214
ER
PT J
AU Kim, JY
Kim, N
Zheng, Z
Lee, JE
Yenari, MA
AF Kim, Jong Youl
Kim, Nuri
Zheng, Zhen
Lee, Jong Eun
Yenari, Midori A.
TI The 70 kDa heat shock protein protects against experimental traumatic
brain injury
SO NEUROBIOLOGY OF DISEASE
LA English
DT Article
DE Brain injury; Heat shock protein; Cerebral hemorrhage
ID OXYGEN-GLUCOSE DEPRIVATION; MATRIX METALLOPROTEINASES; EXPERIMENTAL
STROKE; CEREBRAL-ISCHEMIA; INFLAMMATORY RESPONSE; BARRIER DISRUPTION;
STRESS-RESPONSE; OVEREXPRESSION; BLOOD; MATRIX-METALLOPROTEINASE-9
AB Traumatic brain injury (TBI) causes disruption of the blood brain barrier (BBB) leading to hemorrhage which can complicate an already catastrophic illness. Matrix metalloproteinases (MMPs) involved in the breakdown of the extracellular matrix may lead to brain hemorrhage. We explore the contribution of the 70 kDa heat shock protein (Hsp70) to outcome and brain hemorrhage in a model of TBI. Male, wildtype (Wt), Hsp70 knockout (Ko) and transgenic (Tg) mice were subjected to TBI using controlled cortical impact (CCI). Motor function, brain hemorrhage and lesion size were assessed at 3, 7 and 14 days. Brains were evaluated for the effects of Hsp70 on MMPs.
In Hsp70 Tg mice, CCI led to smaller brain lesions, decreased hemorrhage and reduced expression and activation of MMPs compared to Wt. CCI also significantly decreased right-biased swings and corner turns in the Hsp70 Tg mice. Conversely, Hsp70 Ko mice had significantly increased lesion size, worsened brain hemorrhage and increased expression and activation of MMPs with worsened behavioral outcomes compared to Wt. Hsp70 is protective in experimental TBI. To our knowledge, this is the direct demonstration of brain protection by Hsp70 in a TBI model. Our data demonstrate a new mechanism linking TBI-induced hemorrhage and neuronal injury to the suppression of MMPs by Hsp70, and support the development of Hsp70 enhancing strategies for the treatment of TBI. Published by Elsevier Inc.
C1 [Kim, Jong Youl; Kim, Nuri; Zheng, Zhen; Yenari, Midori A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA.
[Kim, Jong Youl; Kim, Nuri; Zheng, Zhen; Yenari, Midori A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Lee, Jong Eun] Yonsei Univ, Coll Med, Dept Anat, Seoul, South Korea.
[Lee, Jong Eun] Yonsei Univ, Coll Med, BK Project Med Sci 21, Seoul, South Korea.
RP Yenari, MA (reprint author), VAMC 4150 Clement St, San Francisco, CA 94121 USA.
EM yenari@alum.mit.edu
OI Lee, Jong Eun/0000-0001-6203-7413
FU National Institutes of Health [NS40516]; Veteran's Merit Award; American
Heart Association Western States Affiliate Postdoctoral Fellowship
[13POST14810019]; NRF of KOREA; Ministry of Education, Science and
Technology [2012-0005827]
FX This work was supported by grants from the National Institutes of Health
(NS40516) and the Veteran's Merit Award to MY, an American Heart
Association Western States Affiliate Postdoctoral Fellowship
(13POST14810019) to JYK and Basic Science Research Program through the
NRF of KOREA funded by the Ministry of Education, Science and Technology
(2012-0005827) to JEL. Grants to MY and JYK were administered by the
Northern California Institute for Research and Education, and supported
by resources of the Veterans Affairs Medical Center, San Francisco,
California. The authors wish to thank Dr. Linda Noble-Haeusslein for
helpful discussion and advice.
NR 56
TC 18
Z9 19
U1 0
U2 16
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0969-9961
J9 NEUROBIOL DIS
JI Neurobiol. Dis.
PD OCT
PY 2013
VL 58
BP 289
EP 295
DI 10.1016/j.nbd.2013.06.012
PG 7
WC Neurosciences
SC Neurosciences & Neurology
GA 207GC
UT WOS:000323585900033
PM 23816752
ER
PT J
AU Mallampalli, RK
Kaercher, L
Snavely, C
Pulijala, R
Chen, BB
Coon, T
Zhao, J
Agassandian, M
AF Mallampalli, Rama K.
Kaercher, Leah
Snavely, Courtney
Pulijala, Roopa
Chen, Bill B.
Coon, Tiffany
Zhao, Jing
Agassandian, Marianna
TI Fbxl12 triggers G1 arrest by mediating degradation of calmodulin kinase
I
SO CELLULAR SIGNALLING
LA English
DT Article
DE F-box protein; CaMKI; Calcium signaling; Proteasome degradation;
p27(kip1); cdk4/cyclin D1; PKB/AKT
ID CELL-CYCLE ARREST; ACTIVATED PROTEIN-KINASE; NUCLEAR EXPORT SIGNAL;
SMOOTH-MUSCLE-CELLS; GROWTH-FACTOR-BETA; DEPENDENT PHOSPHORYLATION;
P27(KIP1) PHOSPHORYLATION; SUBCELLULAR-LOCALIZATION; CYTOPLASMIC
LOCALIZATION; P27 STABILIZATION
AB Cell cycle progression through its regulatory control by changes in intracellular Ca2+ levels at the Gl/S transition mediates cellular proliferation and viability. Ca2+/CaM-dependent kinase 1 (CaMKI) appears critical in regulating the assembly of the cyclin D1 /cdk4 complex essential for G1 progression, but how this occurs is unknown. Cyclin D1/cdk4 assembly in the early G1 phase is also regulated via binding to p27. Here, we show that a ubiquitin E3 ligase component, F-box protein Fbxl12, mediates CaMKI degradation via a proteasome-directed pathway leading to disruption of cyclin D1/cdk4 complex assembly and resultant G1 arrest in lung epithelia. We also demonstrate that i) CaMKI phosphorylates p27 at Thr(157) and Thr(198) in human cells and at Thr(170) and Thr(197) in mouse cells to modulate its subcellular localization; ii) Fbxl12-induced CaMKI degradation attenuates p27 phosphorylation at these sites in early G1 and iii) activation of CaMIG during G1 transition followed by p27 phosphorylation appears to be upstream to other p27 phosphorylation events, an effect abrogated by Fbxl12 overexpression. Lastly, known inducers of G1 arrest significantly increase Fbxl12 levels in cells. Thus, Fbxl12 may be a previously uncharacterized, functional growth inhibitor regulating cell cycle progression that might be used for mechanism-based therapy. (C) 2013 The Authors. Published by Elsevier Inc. All rights reserved.
C1 [Mallampalli, Rama K.; Kaercher, Leah; Snavely, Courtney; Pulijala, Roopa; Chen, Bill B.; Coon, Tiffany; Zhao, Jing; Agassandian, Marianna] Univ Pittsburgh, Acute Lung Injury Ctr Excellence, Dept Med, Pittsburgh, PA 15213 USA.
[Mallampalli, Rama K.] Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA.
[Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15213 USA.
RP Agassandian, M (reprint author), Univ Pittsburgh, BST 1,W1200-5B,200 Lothrop St, Pittsburgh, PA 15213 USA.
EM agassandianm@upmc.edu
FU US Department of Veterans Affairs; National Institutes of Health
[HL096376, HL097376, HL098174, HL116472]; American Heart Association
(AHA) [12SDG9050005]
FX We greatly appreciate Cheryl Lyn Walker, Director of Institute of
Biosciences & Technology Center for Translational Cancer Research of
University of Texas's kind gifts of p27WT, p27T170A, p27T197A and
p27T170A/197A plasmids. This material is based upon work supported, in
part, by the US Department of Veterans Affairs, Veterans Health
Administration, Office of Research and Development, Biomedical
Laboratory Research and Development. This work was supported by a Merit
Review Award from the US Department of Veterans Affairs and the National
Institutes of Health R01 grants HL096376, HL097376 and HL098174 (to
R.K.M.), and HL116472 (to B.B.C.) and from the American Heart
Association (AHA) awards 12SDG9050005 (J.Z.). The contents presented do
not represent the views of the Department of Veterans Affairs or the
United States Government.
NR 74
TC 5
Z9 9
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0898-6568
J9 CELL SIGNAL
JI Cell. Signal.
PD OCT
PY 2013
VL 25
IS 10
BP 2047
EP 2059
DI 10.1016/j.cellsig.2013.05.012
PG 13
WC Cell Biology
SC Cell Biology
GA 198SX
UT WOS:000322943700012
PM 23707388
ER
PT J
AU Dodson, M
Darley-Usmar, V
Zhang, JH
AF Dodson, Matthew
Darley-Usmar, Victor
Zhang, Jianhua
TI Cellular metabolic and autophagic pathways: Traffic control by redox
signaling
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Review
DE Autophagy; Mitophagy; Oxidative stress; Redox signaling; Cellular
bioenergetics; Mitochondria; Glucose; Glycolysis; Glutathione; Aging;
Cardiovascular disease; Neurodegeneration; Diabetes; Free radicals
ID MITOCHONDRIA-TARGETED ANTIOXIDANT; ENDOPLASMIC-RETICULUM STRESS;
ELECTRON-TRANSPORT-CHAIN; NEGATIVELY REGULATES AUTOPHAGY;
CHAPERONE-MEDIATED AUTOPHAGY; LIPID-PEROXIDATION PRODUCTS;
PENTOSE-PHOSPHATE PATHWAY; EMBRYONIC STEM-CELLS; OXIDATIVE STRESS;
ENDOTHELIAL-CELLS
AB It has been established that the key metabolic pathways of glycolysis and oxidative phosphorylation are intimately related to redox biology through control of cell signaling. Under physiological conditions glucose metabolism is linked to control of the NADH/NAD redox couple, as well as providing the major reductant, NADPH, for thiol-dependent antioxidant defenses. Retrograde signaling from the mitochondrion to the nucleus or cytosol controls cell growth and differentiation. Under pathological conditions mitochondria are targets for reactive oxygen and nitrogen species and are critical in controlling apoptotic cell death. At the interface of these metabolic pathways, the autophagy-lysosomal pathway functions to maintain mitochondrial quality and generally serves an important cytoprotective function. In this review we will discuss the autophagic response to reactive oxygen and nitrogen species that are generated from perturbations of cellular glucose metabolism and bioenergetic function. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Dodson, Matthew; Darley-Usmar, Victor; Zhang, Jianhua] Ctr Free Rad Biol, Birmingham, AL 35294 USA.
[Dodson, Matthew; Darley-Usmar, Victor; Zhang, Jianhua] Univ Alabama Birmingham, Birmingham, AL 35294 USA.
[Dodson, Matthew; Darley-Usmar, Victor; Zhang, Jianhua] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
[Zhang, Jianhua] Birmingham VA Med Ctr, Dept Vet Affairs, Birmingham, AL 35233 USA.
RP Zhang, JH (reprint author), Univ Alabama Birmingham, Dept Pathol, 901 19th St South,BMR2 534, Birmingham, AL 35294 USA.
EM zhanja@uab.edu
OI Zhang, Jianhua/0000-0002-2128-9574
FU VA merit award; NIH [ES10167, AA13395, DK 75865]; [NIHR01-NS064090]
FX The authors acknowledge funding from the following sources: Dr. Jianhua
Zhang was supported by NIHR01-NS064090 and a VA merit award. Dr. Victor
Darley-Usmar was supported by NIH Grants ES10167, AA13395, and DK 75865.
NR 209
TC 101
Z9 111
U1 13
U2 151
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0891-5849
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD OCT
PY 2013
VL 63
SI SI
BP 207
EP 221
DI 10.1016/j.freeradbiomed.2013.05.014
PG 15
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 200TV
UT WOS:000323094700019
PM 23702245
ER
PT J
AU Sun, XB
Cao, ZB
Yeh, CK
Sun, YY
AF Sun, Xinbo
Cao, Zhengbing
Yeh, Chih-Ko
Sun, Yuyu
TI Antifungal activity, biofilm-controlling effect, and biocompatibility of
poly(N-vinyl-2-pyrrolidinone)-grafted denture materials
SO COLLOIDS AND SURFACES B-BIOINTERFACES
LA English
DT Article
DE Drug delivery; Denture; Biofilm; Poly(N-vinyl-2-pyrrolidinone);
Biocompatibility
ID PLASMA SURFACE MODIFICATION; DRUG-DELIVERY SYSTEMS; CANDIDA-ALBICANS;
BIOMEDICAL APPLICATIONS; ANTIBACTERIAL ACTIVITY; TISSUE CONDITIONERS;
MICROBIAL BIOFILMS; DENTAL COMPOSITES; SILVER-ZEOLITE; IN-VITRO
AB Colonization and biofilm-formation of Candida species on denture surfaces cause Candida-associated denture stomatitis (CADS), a common, recurring disease affecting up to 67% of denture wearers. We developed poly(N-vinyl-2-pyrrolidinone)-grafted denture materials that can be repeatedly recharged with various antifungal drugs to achieve long-term antifungal and biofilm-controlling effects. The monomer, N-vinyl-2-pyrrolidinone (NVP), was grafted onto poly(methyl methacrylate) denture resins through plasma-initiated grafting polymerization. The physical properties and biocompatibility of the resulting resins were not negatively affected by the presence of up to 7.92% of grafted poly (N-vinyl-2-pyrrolidinone) (PNVP). Miconazole and chlorhexidine digluconate (CD) were used as model antifungal drugs. PNVP grafting significantly increased the drug absorption capability of the resulting denture materials. Further, the new materials showed sustained drug release and provided anti fungal effects for weeks (in the case of CD) to months (in the case of miconazole). The drug-depleted resins could be recharged with the same or a different class of antifungal drug to further extend antifungal duration. If needed, drugs on the PNVP-grafted denture materials could be "washed out" (quenched) by treating with PNVP aqueous solutions to stop drug release. These results point to great potentials of the new materials in controlling biofilm-formation in a wide range of device-related applications. (c) 2013 Elsevier B.V. All rights reserved.
C1 [Sun, Xinbo; Cao, Zhengbing] Medetech Dev Corp, Lynnwood, WA 98087 USA.
[Yeh, Chih-Ko] Univ Texas Hlth Sci Ctr San Antonio, Dept Dent Diagnost Sci, San Antonio, TX 78229 USA.
[Yeh, Chih-Ko] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Audie L Murphy Div, San Antonio, TX 78229 USA.
[Sun, Yuyu] Univ Massachusetts Lowell, Dept Chem, Lowell, MA 01854 USA.
RP Sun, YY (reprint author), Univ Massachusetts Lowell, Dept Chem, Lowell, MA 01854 USA.
EM yuyu_sun@uml.edu
FU NIDCR, NIH [R01 DE021084]; VA Merit Review [1101BX001103]
FX This study was supported by NIDCR, NIH (R01 DE021084) and VA Merit
Review (1101BX001103).
NR 70
TC 8
Z9 8
U1 1
U2 73
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927-7765
J9 COLLOID SURFACE B
JI Colloid Surf. B-Biointerfaces
PD OCT 1
PY 2013
VL 110
BP 96
EP 104
DI 10.1016/j.colsurfb.2013.04.043
PG 9
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
SC Biophysics; Chemistry; Materials Science
GA 185BM
UT WOS:000321940200014
PM 23708753
ER
PT J
AU Wang, LY
Murphy, RR
Hanscom, B
Li, G
Millard, SP
Petrie, EC
Galasko, DR
Sikkema, C
Raskind, MA
Wilkinson, CW
Peskind, ER
AF Wang, Lucy Y.
Murphy, Richard R.
Hanscom, Brett
Li, Ge
Millard, Steven P.
Petrie, Eric C.
Galasko, Douglas R.
Sikkema, Carl
Raskind, Murray A.
Wilkinson, Charles W.
Peskind, Elaine R.
TI Cerebrospinal fluid norepinephrine and cognition in subjects across the
adult age span
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE Noradrenergic system; Norepinephrine; Cognition; Aging
ID ALZHEIMERS-DISEASE; PLASMA NOREPINEPHRINE; NORADRENERGIC MODULATION;
PREFRONTAL CORTEX; LOCUS-COERULEUS; WORKING-MEMORY; STRESS; CORTISOL;
KINETICS; ENHANCEMENT
AB Adequate central nervous system noradrenergic activity enhances cognition, but excessive noradrenergic activity may have adverse effects on cognition. Previous studies have also demonstrated that noradrenergic activity is higher in older than younger adults. We aimed to determine relationships between cerebrospinal fluid (CSF) norepinephrine (NE) concentration and cognitive performance by using data from a CSF bank that includes samples from 258 cognitively normal participants aged 21-100 years. After adjusting for age, gender, education, and ethnicity, higher CSF NE levels (units of 100 pg/mL) are associated with poorer performance on tests of attention, processing speed, and executive function (Trail Making A: regression coefficient 1.5, standard error [SE] 0.77, p = 0.046; Trail Making B: regression coefficient 5.0, SE 2.2, p = 0.024; Stroop Word-Color Interference task: regression coefficient 6.1, SE 2.0, p = 0.003). Findings are consistent with the earlier literature relating excess noradrenergic activity with cognitive impairment. Published by Elsevier Inc.
C1 [Wang, Lucy Y.; Murphy, Richard R.; Li, Ge; Millard, Steven P.; Petrie, Eric C.; Raskind, Murray A.; Peskind, Elaine R.] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res & Educ Clin Ctr, Seattle, WA USA.
[Wang, Lucy Y.; Li, Ge; Petrie, Eric C.; Raskind, Murray A.; Wilkinson, Charles W.; Peskind, Elaine R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Murphy, Richard R.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA.
[Hanscom, Brett] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Galasko, Douglas R.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.
[Sikkema, Carl; Wilkinson, Charles W.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA.
RP Wang, LY (reprint author), VA Puget Sound Healthcare Syst, Mental Illness Res & Educ Clin Ctr, 1660 South Columbian Way,S-116 MIRECC, Seattle, WA 98115 USA.
EM wanglucy@u.washington.edu
FU VA Puget Sound Mental Illness Research, Education and Clinical Center
(MIRECC); VA Puget Sound Geriatric Research, Education, and Clinical
Center; VA Special Fellowship in Advanced Psychiatry (MIRECC);
University of Washington's ADRC Pilot Study Award; NIH/NIA [P50AG005136]
FX This study was supported by the VA Puget Sound Mental Illness Research,
Education and Clinical Center (MIRECC), the VA Puget Sound Geriatric
Research, Education, and Clinical Center, the VA Special Fellowship in
Advanced Psychiatry (MIRECC), the University of Washington's ADRC Pilot
Study Award, and NIH/NIA grant P50AG005136.
NR 48
TC 3
Z9 3
U1 0
U2 26
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4580
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD OCT
PY 2013
VL 34
IS 10
BP 2287
EP 2292
DI 10.1016/j.neurobiolaging.2013.04.007
PG 6
WC Geriatrics & Gerontology; Neurosciences
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 187JM
UT WOS:000322113800006
PM 23639207
ER
PT J
AU Weisbart, RH
Chan, G
Li, E
Farmani, N
Heinze, E
Rubell, A
Nishimura, RN
Colburn, K
AF Weisbart, Richard H.
Chan, Grace
Li, Erica
Farmani, Niloofar
Heinze, Emil
Rubell, Antonia
Nishimura, Robert N.
Colburn, Keith
TI BRAF splice variants in rheumatoid arthritis synovial fibroblasts
activate MAPK through CRAF
SO MOLECULAR IMMUNOLOGY
LA English
DT Article
DE Rheumatoid arthritis; Oncogene; MAPK cascade
ID TYPE-1 MATRIX-METALLOPROTEINASE; MUTATIONS; CELLS; AUTOANTIBODIES;
INFLAMMATION; INHIBITORS; CARTILAGE; CANCER
AB Rheumatoid arthritis (RA) is a destructive polyarthritis in which synovial-like fibroblasts (SFs) invade and erode cartilage by expressing membrane-anchored type 1 matrix metalloproteinase (MT1-MMP). The mitogen activated protein kinase (MAPK) pathway is activated in RA SFs, but the mechanism of activation is unknown. Here we identify aberrant BRAF splice variants with deletions in both the kinase domain and RAS-binding domain (RBD) in SFs from the majority of RA patients and show that these BRAF splice variants constitutively activate MAPK through CRAF, increase expression of MT1-MMP, and enhance fibroblast invasion of collagen. Published by Elsevier Ltd.
C1 [Weisbart, Richard H.; Chan, Grace; Li, Erica; Rubell, Antonia] Vet Affairs Greater Los Angeles Health Care Syst, Sepulveda, CA 91343 USA.
[Farmani, Niloofar; Heinze, Emil] Olive View UCLA Med Ctr, Dept Med, Sylmar, CA 91342 USA.
[Nishimura, Robert N.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA.
[Colburn, Keith] Vet Affairs Med Ctr, Loma Linda, CA 92357 USA.
[Colburn, Keith] Loma Linda Univ, Loma Linda, CA 92350 USA.
RP Weisbart, RH (reprint author), Vet Affairs Greater Los Angeles Health Care Syst, Dept Res, 16111 Plummer St 111S, Sepulveda, CA USA.
EM rweisbar@ucla.edu
FU Veterans Affairs
FX This work was sponsored by a grant from the Veterans Affairs.
NR 30
TC 2
Z9 5
U1 1
U2 51
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0161-5890
J9 MOL IMMUNOL
JI Mol. Immunol.
PD OCT
PY 2013
VL 55
IS 3-4
BP 247
EP 252
DI 10.1016/j.molimm.2013.02.001
PG 6
WC Biochemistry & Molecular Biology; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA 152OE
UT WOS:000319540200008
PM 23517740
ER
PT J
AU Milanak, ME
Gros, DF
Magruder, KM
Brawman-Mintzer, O
Frueh, BC
AF Milanak, Melissa E.
Gros, Daniel F.
Magruder, Kathryn M.
Brawman-Mintzer, Olga
Frueh, B. Christopher
TI Prevalence and features of generalized anxiety disorder in Department of
Veteran Affairs primary care settings
SO PSYCHIATRY RESEARCH
LA English
DT Article
DE Posttraumatic stress disorder; Veterans; Comorbidity; Healthcare
utilization
ID POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CONTROLLED-TRIAL; VA
PRIMARY-CARE; PSYCHOMETRIC PROPERTIES; MENTAL-HEALTH; MAJOR DEPRESSION;
US VETERANS; DSM-IV; COMORBIDITY; CLINICS
AB Generalized anxiety disorder (GAD) is a highly prevalent distressing condition for individuals in both community and community primary care settings. However, despite the high prevalence of GAD identified in epidemiological studies, little is known about GAD and its related symptoms and impairments in veteran populations. The present study investigated the prevalence, comorbidity, physical and mental health impairment, and healthcare utilization of veteran participants with GAD, as well as comparing symptoms of GAD and posttraumatic stress disorder (PTSD). Veterans (N=884) participated in a cross-sectional investigation in primary care clinics in four Veteran Affairs Medical Centers (VAMCs) and completed diagnostic interviews and self-report questionnaires; a chart review was conducted to assess their VAMC healthcare utilization. A large number of participants (12%) met diagnostic criteria for GAD, reporting significantly worse emotional health, pain, and general health, in addition to increased mental healthcare utilization and antidepressant medications. In addition, GAD was found in 40% of participants with PTSD, resulting in more severe symptoms and impairment than in patients with GAD alone. These findings provide evidence of high prevalence and severe impairment associated with GAD in veterans and highlight the need for improved recognition, assessment, and treatments for GAD. (c) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 [Milanak, Melissa E.; Gros, Daniel F.; Magruder, Kathryn M.; Brawman-Mintzer, Olga] Med Univ S Carolina, Charleston, SC 29403 USA.
[Gros, Daniel F.; Magruder, Kathryn M.; Brawman-Mintzer, Olga] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
[Frueh, B. Christopher] Univ Hawaii, Dept Psychol, Hilo, HI 96720 USA.
[Frueh, B. Christopher] Menninger Clin, Houston, TX USA.
RP Milanak, ME (reprint author), Med Univ S Carolina, Natl Crime Victims Ctr, 67 President St, Charleston, SC 29403 USA.
EM milanak@musc.edu
FU Veterans Affairs Health Services Research and Development [VCR-99-010-2]
FX This work was partially supported by a grant from Veterans Affairs
Health Services Research and Development (VCR-99-010-2).
NR 36
TC 11
Z9 11
U1 3
U2 9
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0165-1781
J9 PSYCHIAT RES
JI Psychiatry Res.
PD SEP 30
PY 2013
VL 209
IS 2
BP 173
EP 179
DI 10.1016/j.psychres.2013.03.031
PG 7
WC Psychiatry
SC Psychiatry
GA 223GA
UT WOS:000324791500008
PM 23659756
ER
PT J
AU Chao, L
Weiner, M
Neylan, T
AF Chao, Linda
Weiner, Michael
Neylan, Thomas
TI Regional cerebral volumes in veterans with current versus remitted
posttraumatic stress disorder
SO PSYCHIATRY RESEARCH-NEUROIMAGING
LA English
DT Article
DE Posttraumatic stress disorder; Magnetic resonance imaging; Hippocampus;
Anterior cingulate; Insula
ID SURFACE-BASED ANALYSIS; HIPPOCAMPAL VOLUME; GRAY-MATTER; AMYGDALA
VOLUME; BRAIN VOLUME; GULF-WAR; CHILDHOOD MALTREATMENT;
ANOREXIA-NERVOSA; DENTATE GYRUS; SEXUAL-ABUSE
AB We previously reported that hippocampal volume was associated with current, but not lifetime posttraumatic stress disorder (PTSD) symptom severity. In the present study, we test the hypothesis that like the hippocampus, the volumes of other brain regions previously implicated in PTSD, are also negatively related to current, but not lifetime PTSD symptom severity. One hundred ninety-one veterans underwent structural magnetic resonance imaging (MRI) on a 4 T scanner. Seventy-five veterans were trauma unexposed, 43 were trauma exposed without PTSD, 39 were trauma exposed with current PTSD, and 34 were trauma exposed veterans with remitted PTSD. Hippocampal, amygdala, rostral and caudal anterior cingulate, insula, and corpus callosum volumes, quantified with Freesurfer version 4.5, were analyzed by group using multivariate analysis of covariance. Veterans with PTSD had smaller hippocampal, caudal anterior cingulate, insula, and corpus callosum volumes than the unexposed controls (p <= 0.009); smaller hippocampal, caudal anterior cingulate, insula (p <= 0.009) and marginally smaller corpus callosum (p=0.06) than veterans with remitted PTSD; and smaller hippocampal and caudal anterior cingulate volumes than veterans without PTSD (p <= 0.04). In contrast, there was no significant volume differences between veterans with remitted PTSD compared to those without PTSD or unexposed controls. The finding that current but not lifetime PTSD accounts for the volumes of multiple brain regions suggests that either smaller brain volume is a vulnerability factor that impedes recovery from PTSD or that recovery from PTSD is accompanied by a wide-spread restoration of brain tissue. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 [Chao, Linda; Weiner, Michael] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94121 USA.
[Chao, Linda; Weiner, Michael] Univ Calif San Francisco, Dept Biomed Imaging, San Francisco, CA 94121 USA.
[Chao, Linda; Weiner, Michael; Neylan, Thomas] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA.
[Chao, Linda; Weiner, Michael] Ctr Imaging Neurodegenerat Dis, San Francisco, CA USA.
[Neylan, Thomas] Dept Vet Affairs Med Ctr, Mental Hlth Serv, San Francisco, CA USA.
RP Chao, L (reprint author), Univ Calif San Francisco, San Francisco VAMC, Dept Radiol, 4150 Clement St,114M, San Francisco, CA 94121 USA.
EM linda.chao@ucsf.edu
FU Mental Illness Research and Education Clinical Center of the US Veterans
Health Administration, Office of Research and Development, Department of
Defense [W81XWH-05-2-0094]; Mental Illness Research and Education
Clinical Center of Department of Veterans Affairs VA GWI [B3776]
FX This study was supported in part by grants from the Mental Illness
Research and Education Clinical Center of the US Veterans Health
Administration, Office of Research and Development, Department of
Defense (No. W81XWH-05-2-0094), and Department of Veterans Affairs VA
GWI (No. B3776). Resources and the use of facilities were provided by
the Veterans Administration Medical Center, San Francisco, California.
NR 96
TC 19
Z9 21
U1 1
U2 16
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0925-4927
J9 PSYCHIAT RES-NEUROIM
JI Psychiatry Res. Neuroimaging
PD SEP 30
PY 2013
VL 213
IS 3
BP 193
EP 201
DI 10.1016/j.pscychresns.2013.03.002
PG 9
WC Clinical Neurology; Neuroimaging; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 211TV
UT WOS:000323934800003
PM 23816189
ER
PT J
AU Rao, MN
Blackwell, T
Redline, S
Punjabi, NM
Barrett-Connor, E
Neylan, TC
Stone, KL
AF Rao, Madhu N.
Blackwell, Terri
Redline, Susan
Punjabi, Naresh M.
Barrett-Connor, Elizabeth
Neylan, Thomas C.
Stone, Katie L.
CA Osteoporotic Fractures Men MrOS St
TI Association between Sleep Duration and 24-Hour Urine Free Cortisol in
the MrOS Sleep Study
SO PLOS ONE
LA English
DT Article
ID SELF-REPORTED SLEEP; OSTEOPOROTIC FRACTURES; DEPRIVATION; ACTIGRAPHY;
FREQUENCY; RELEASE; ADULTS; MEN
AB Context: Short sleep duration is associated with adverse health outcomes, but the mechanisms involved are unknown. It has been postulated that short sleep duration may elevate cortisol levels, but studies have had conflicting results. It is unclear whether these differing findings may be due to methodological issues, such as assessment of sleep duration. Specifically, objective versus subjective methods of measuring habitual sleep duration may account for the conflicting results found in epidemiological studies.
Objective: Our goal was to determine whether habitual sleep duration, measured objectively (by actigraphy) and subjectively (by self-report), was associated with 24-hour urine free cortisol (UFC), a measure of integrated cortisol secretion. Our secondary goal was to determine whether slow wave sleep (SWS, determined by polysomnography) was associated with 24-hour UFC.
Design/Setting: Cross sectional study of community dwelling older men.
Patients/Participants: 325 men (mean age = 76.6 years, SD = 5.5) from the Portland site of the MrOS Sleep Study, who underwent 24-hour urine collection, polysomnography, actigraphy and sleep questionnaire.
Primary Outcome: 24-hour UFC.
Results: In this study of community dwelling older men, self-reported sleep duration was inversely related to 24-hour UFC levels. Participants reporting <5 hours of habitual sleep had an adjusted mean 24-hour UFC of 29.8 ug, compared to 28.0 ug in participants reporting >5 to <8 hours of sleep 25.5 ug in those reporting >8 hours of habitual sleep. However, sleep duration determined by actigraphy was not associated with 24-hour UFC in either univariable or multivariable regression models. SWS was not associated with 24-hour UFC.
Conclusion: Objectively measured (i.e., actigraphic) sleep duration is not associated with 24-hour UFC in these community dwelling older men. This finding, together with prior studies, suggests that elevated levels of integrated cortisol secretion is not the mechanisms by which short sleep duration leads to adverse health outcomes.
C1 [Rao, Madhu N.] Univ Calif San Francisco, Div Endocrinol, San Francisco, CA 94143 USA.
[Blackwell, Terri; Stone, Katie L.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA.
[Redline, Susan] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Redline, Susan] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
[Punjabi, Naresh M.] Johns Hopkins Univ, Div Pulm & Crit Care Med, Baltimore, MD USA.
[Barrett-Connor, Elizabeth] Univ Calif San Diego, Dept Epidemiol, La Jolla, CA 92093 USA.
[Neylan, Thomas C.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Neylan, Thomas C.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
RP Rao, MN (reprint author), Univ Calif San Francisco, Div Endocrinol, San Francisco, CA 94143 USA.
EM Madhu.Rao@ucsf.edu
FU National Institutes of Health; National Institute of Arthritis and
Musculoskeletal and Skin Diseases (NIAMS); National Institute on Aging
(NIA); National Cancer Institute (NCI); National Center for Research
Resources (NCRR); NIH Roadmap for Medical Research [U01 AR45580, U01
AR45614, U01 AR45632, U01 AR45647, U01 AR45654, U01 AR45583, U01
AG18197, U01-AG027810, UL1 RR024140]; National Heart, Lung, and Blood
Institute (NHLBI) [R01 HL071194, R01 HL070848, R01 HL070847, R01
HL070842, R01 HL070841, R01 HL070837, R01 HL070838, R01 HL070839]; NIH
Heart, Lung and Blood Institute [K23HL096832]
FX The Osteoporotic Fractures in Men (MrOS) Study is supported by National
Institutes of Health funding. The following institutes provide support:
the National Institute of Arthritis and Musculoskeletal and Skin
Diseases (NIAMS), the National Institute on Aging (NIA), the National
Cancer Institute (NCI), the National Center for Research Resources
(NCRR) and NIH Roadmap for Medical Research under the following grant
numbers: U01 AR45580, U01 AR45614, U01 AR45632, U01 AR45647, U01
AR45654, U01 AR45583, U01 AG18197, U01-AG027810, and UL1 RR024140. The
National Heart, Lung, and Blood Institute (NHLBI) provides funding for
the MrOS Sleep ancillary study "Outcomes of Sleep Disorders in Older
Men" under the following grant numbers: R01 HL071194, R01 HL070848, R01
HL070847, R01 HL070842, R01 HL070841, R01 HL070837, R01 HL070838, and
R01 HL070839. Dr. Rao received funding from the NIH Heart, Lung and
Blood Institute (K23HL096832), which also paid for measurement of
24-hour urine free cortisol. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the
manuscript.
NR 36
TC 5
Z9 5
U1 1
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 27
PY 2013
VL 8
IS 9
AR e75205
DI 10.1371/journal.pone.0075205
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 228WY
UT WOS:000325223900037
PM 24228086
ER
PT J
AU Le, DE
Pascotto, M
Leong-Poi, H
Sari, I
Micari, A
Kaul, S
AF Le, D. Elizabeth
Pascotto, Marco
Leong-Poi, Howard
Sari, Ibrahim
Micari, Antonio
Kaul, Sanjiv
TI Anti-inflammatory and pro-angiogenic effects of beta blockers in a
canine model of chronic ischemic cardiomyopathy: comparison between
carvedilol and metoprolol
SO BASIC RESEARCH IN CARDIOLOGY
LA English
DT Article
DE Ischemic cardiomyopathy; Beta blockers; Regional flow; Regional
function; Cytokines; Angiogenesis
ID CHRONIC HEART-FAILURE; LEFT-VENTRICULAR DYSFUNCTION; ACUTE
MYOCARDIAL-INFARCTION; HIBERNATING MYOCARDIUM; ADRENERGIC-BLOCKADE;
LIPID-PEROXIDATION; OXIDATIVE STRESS; BLOOD-FLOW; INTERLEUKIN-1-BETA;
EXERCISE
AB There is controversy regarding the superiority of carvedilol (C) over metoprolol (M) in congestive heart failure. We hypothesized that C is superior to M in chronic ischemic cardiomyopathy because of its better anti-inflammatory and pro-angiogenic effects. In order to test our hypothesis we used a chronic canine model of multivessel ischemic cardiomyopathy where myocardial microcatheters were placed from which interstitial fluid was collected over time to measure leukocyte count and cytokine levels. After development of left ventricular dysfunction, the animals were randomized into four groups: sham (n = 7), placebo (n = 8), M (n = 11), and C (n = 10), and followed for 3 months after treatment initiation. Tissue was examined for immunohistochemistry, oxidative stress, and capillary density. At 3 months both rest and stress wall thickening were better in C compared to the other groups. At the end of 3 months of treatment end-systolic wall stress also decreased the most in C. Similarly resting myocardial blood flow (MBF) improved the most in C as did the stress endocardial/epicardial MBF. Myocardial interstitial fluid showed greater attenuation of leukocytosis with C compared to M, which was associated with less fibrosis and oxidative stress. C also had higher IL-10 level and capillary density. In conclusion, in a chronic canine model of multivessel ischemic cardiomyopathy we found 3 months of C treatment resulted in better resting global and regional function as well as better regional function at stress compared to M. These changes were associated with higher myocardial levels of the anti-inflammatory cytokine IL-10 and less myocardial oxidative stress, leukocytosis, and fibrosis. Capillary density and MBF were almost normalized. Thus in the doses used in this study, C appears to be superior to M in a chronic canine model of ischemic cardiomyopathy from beneficial effects on inflammation and angiogenesis. Further studies are required for comparing additional doses of these drugs.
C1 [Le, D. Elizabeth] Portland VA Med Ctr, Portland, OR USA.
[Le, D. Elizabeth] Knight Cardiovasc Inst, Portland, OR USA.
[Le, D. Elizabeth; Kaul, Sanjiv] OHSU, Knight Cardiovasc Inst, Portland, OR 97239 USA.
[Pascotto, Marco] Buon Consiglio Fatebenefratelli Hosp, I-80123 Naples, Italy.
[Leong-Poi, Howard] Heart & Stroke Fdn Canada, Ottawa, ON, Canada.
[Leong-Poi, Howard] Canadian Inst Hlth Res, Ottawa, ON, Canada.
[Sari, Ibrahim] Turkish Cardiac Soc, Istanbul, Turkey.
[Micari, Antonio] Aventis Fdn, Italian Soc Cardiol, Milan, Italy.
RP Kaul, S (reprint author), OHSU, Knight Cardiovasc Inst, UHN62,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM kauls@ohsu.edu
FU National Institutes of Health [K-08-HL0742901, R01-HL660346]
FX Supported in part by grants from the National Institutes of Health
(K-08-HL0742901, D. Elizabeth Le and R01-HL660346, Sanjiv Kaul). The
radiolabeled microspheres were provided by Dupont Pharmaceuticals, North
Billerica, MA, and the ultrasound equipment was supplied by Philips
Ultrasound, Andover, MA.
NR 42
TC 14
Z9 16
U1 0
U2 9
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0300-8428
J9 BASIC RES CARDIOL
JI Basic Res. Cardiol.
PD SEP 27
PY 2013
VL 108
IS 6
AR 384
DI 10.1007/s00395-013-0384-7
PG 13
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 226IL
UT WOS:000325028700001
PM 24072434
ER
PT J
AU Bowling, CB
Sharma, P
Fox, CS
O'Hare, AM
Muntner, P
AF Bowling, C. Barrett
Sharma, Pradeep
Fox, Caroline S.
O'Hare, Ann M.
Muntner, Paul
TI Prevalence of Reduced Estimated Glomerular Filtration Rate Among the
Oldest Old From 1988-1994 Through 2005-2010
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter
ID CHRONIC KIDNEY-DISEASE; AGE
C1 [Bowling, C. Barrett] Vet Affairs Med Ctr, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Atlanta, GA 30033 USA.
[Sharma, Pradeep; Muntner, Paul] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL USA.
[Fox, Caroline S.] NHLBI, Ctr Populat Studies, Bethesda, MD 20892 USA.
[O'Hare, Ann M.] VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA.
RP Bowling, CB (reprint author), Atlanta Vet Affairs Med Ctr, 1670 Clairmont Rd 11B, Decatur, GA 30033 USA.
EM cbbowli@emory.edu
FU CSRD VA [IK2 CX000856]; NHLBI NIH HHS [Y1-HC-8039]; NIA NIH HHS [R03
AG042336, R03AG042336-01]
NR 6
TC 14
Z9 14
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD SEP 25
PY 2013
VL 310
IS 12
BP 1284
EP 1286
DI 10.1001/jama.2013.252441
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 222SO
UT WOS:000324751800026
PM 24065016
ER
PT J
AU Berg, AT
Baca, CB
Loddenkemper, T
Vickrey, BG
Dlugos, D
AF Berg, Anne T.
Baca, Christine B.
Loddenkemper, Tobias
Vickrey, Barbara G.
Dlugos, Dennis
TI Priorities in pediatric epilepsy research Improving children's futures
today
SO NEUROLOGY
LA English
DT Review
ID QUALITY STANDARDS SUBCOMMITTEE; INFANTILE SPASMS; INTRACTABLE EPILEPSY;
AMERICAN-ACADEMY; UNITED-STATES; PRACTICE PARAMETER; NEUROLOGY SOCIETY;
ONSET EPILEPSY; TEMPORAL-LOBE; CARE
AB The Priorities in Pediatric Epilepsy Research workshop was held in the spirit of patient-centered and patient-driven mandates for developing best practices in care, particularly for epilepsy beginning under age 3 years. The workshop brought together parents, representatives of voluntary advocacy organizations, physicians, allied health professionals, researchers, and administrators to identify priority areas for pediatric epilepsy care and research including implementation and testing of interventions designed to improve care processes and outcomes. Priorities highlighted were 1) patient outcomes, especially seizure control but also behavioral, academic, and social functioning; 2) early and accurate diagnosis and optimal treatment; 3) role and involvement of parents (communication and shared decision-making); and 4) integration of school and community organizations with epilepsy care delivery. Key factors influencing pediatric epilepsy care included the child's impairments and seizure presentation, parents, providers, the health care system, and community systems. Care was represented as a sequential process from initial onset of seizures to referral for comprehensive evaluation when needed. We considered an alternative model in which comprehensive care would be utilized from onset, proactively, rather than reactively after pharmacoresistance became obvious. Barriers, including limited levels of evidence about many aspects of diagnosis and management, access to care-particularly epilepsy specialty and behavioral health care-and implementation, were identified. Progress hinges on coordinated research efforts that systematically address gaps in knowledge and overcoming barriers to access and implementation. The stakes are considerable, and the potential benefits for reduced burden of refractory epilepsy and lifelong disabilities may be enormous.
C1 [Berg, Anne T.] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA.
[Baca, Christine B.; Vickrey, Barbara G.] Epilepsy Ctr, Chicago, IL USA.
[Baca, Christine B.; Vickrey, Barbara G.] Northwestern Mem Feinberg Sch Med, Dept Pediat, Chicago, IL USA.
[Baca, Christine B.; Vickrey, Barbara G.] Calif State Univ Los Angeles, Dept Neurol, Los Angeles, CA 90032 USA.
[Loddenkemper, Tobias] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA.
[Loddenkemper, Tobias] Div Epilepsy & Clin Neurophysiol, Los Angeles, CA USA.
[Dlugos, Dennis] Harvard Univ, Sch Med, Dept Neurol, Boston Childrens Hosp, Boston, MA 02115 USA.
[Dlugos, Dennis] Univ Penn, Pediat Reg Epilepsy Program, Philadelphia, PA 19104 USA.
[Dlugos, Dennis] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA.
[Dlugos, Dennis] Univ Penn, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA.
RP Berg, AT (reprint author), Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA.
EM atberg@luriechildrens.org
FU Citizens United for Research on Epilepsy (CURE)
FX Citizens United for Research on Epilepsy (CURE) provided funding for
travel and accommodations for many of the speakers and participants and
made possible the meeting summarized in this report. Additional support
for the meeting was provided by the Foundation of Ann & Robert H. Lurie
Children's Hospital of Chicago.
NR 59
TC 14
Z9 14
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD SEP 24
PY 2013
VL 81
IS 13
BP 1166
EP 1175
PG 10
WC Clinical Neurology
SC Neurosciences & Neurology
GA AA0EL
UT WOS:000330768000017
PM 23966254
ER
PT J
AU Singh, JA
Lewallen, DG
AF Singh, Jasvinder A.
Lewallen, David G.
TI Patients with osteoarthritis and avascular necrosis have better
functional outcomes and those with avascular necrosis worse pain
outcomes compared to rheumatoid arthritis after primary hip
arthroplasty: a cohort study
SO BMC MEDICINE
LA English
DT Article
DE Total hip replacement; Diagnosis; Osteoarthritis; Rheumatoid arthritis;
Avascular necrosis; Pain; Function; Arthroplasty; Joint replacement;
Patient-reported outcomes; Risk factors
ID TOTAL JOINT ARTHROPLASTY; QUALITY-OF-LIFE; KNEE REPLACEMENT SURGERY;
FOLLOW-UP; PREDICTORS; RESPONSIVENESS; QUESTIONNAIRE; RESPONSES; RATES;
SCORE
AB Background: This study was conducted to assess whether patient-reported outcomes (PROs) differ by the underlying diagnosis (rheumatoid arthritis (RA)/inflammatory arthritis, osteoarthritis (OA), avascular necrosis of bone (AVN), other) in patients undergoing primary total hip arthroplasty (THA).
Methods: We used prospectively collected data to assess the association of diagnosis with index hip function and pain. Moderate-severe activity limitation and moderate-severe pain were assessed at two-and five-year follow-up after primary THA using multivariable-adjusted logistic regression analyses. Odds ratios (OR) and 95% confidence intervals (CI) were calculated.
Results: There were 5,707 primary THAs at two-years and 3,289 at five-years, 51% were women and the mean age was 65 years. The underlying diagnosis was RA in 3%, OA in 87%, AVN in 7% and other in 3%. In multivariable-adjusted analyses, compared to RA, diagnoses of OA and AVN were significantly associated with lower odds of moderate-severe activities of daily living limitations with an OR (95% CI) of 0.5 (0.3 to 0.8) (P = 0.01) and 0.4 (0.2 to 0.8) (P = 0.01), respectively, at two-years, but not at five-years, 0.7 (0.4 to 1.4) (P = 0.36) and 0.9 (0.4 to 1.8) (P = 0.78), respectively. At two-years, neither OA nor AVN were significantly associated with higher odds of moderate-severe pain (1.6 (0.6 to 4.5) (P = 0.40) and 2.8 (0.9 to 8.5) (P = 0 0.06)), respectively. At five-years, AVN was associated with higher odds of moderate-severe pain with OR 4.1 (1.2 to 14.1) (P = 0.02), but not OA, 2.1 (0.7 to 6.5) (P = 0.22).
Conclusions: We found that patients with OA and AVN had better functional outcomes and those with AVN worse pain outcomes after primary THA, compared to patients with RA/inflammatory arthritis. Insights into mediators of these relationships are needed to better understand these associations.
C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA.
[Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL USA.
[Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL USA.
[Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.; Lewallen, David G.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA.
[Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham, AL 35294 USA.
RP Singh, JA (reprint author), Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA.
EM Jasvinder.md@gmail.com
OI singh, jasvinder/0000-0003-3485-0006
FU Mayo Clinic Orthopedic Surgery research funds; National Institutes of
Health (NIH) Clinical Translational Science Award [1 KL2 RR024151-01];
Agency for Health Quality and Research Center for Education and Research
on Therapeutics (CERTs); National Institute of Arthritis,
Musculoskeletal and Skin Diseases (NIAMS); National Institute of Aging
(NIA); National Cancer Institute (NCI)
FX This study was supported by research funds from the Mayo Clinic
Orthopedic Surgery research funds, National Institutes of Health (NIH)
Clinical Translational Science Award 1 KL2 RR024151-01 (Mayo Clinic
Center for Clinical and Translational Research) and the resources and
use of facilities at the Birmingham VA Medical Center, Alabama, USA. JAS
is also supported by grants from the Agency for Health Quality and
Research Center for Education and Research on Therapeutics (CERTs),
National Institute of Arthritis, Musculoskeletal and Skin Diseases
(NIAMS), National Institute of Aging (NIA) and National Cancer Institute
(NCI). The funding agencies played no role in the design, collection,
analysis, and interpretation of data; in the writing of the manuscript;
or in the decision to submit the manuscript for publication. This study
was presented as an oral abstract presentation at the 2012 American
College of Rheumatology Annual meeting in Washington, DC in November
2012.
NR 38
TC 6
Z9 6
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1741-7015
J9 BMC MED
JI BMC Med.
PD SEP 24
PY 2013
VL 11
AR 210
DI 10.1186/1741-7015-11-210
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA 241PO
UT WOS:000326179600001
PM 24063410
ER
PT J
AU Caverly, TJ
Prochazka, AV
AF Caverly, Tanner J.
Prochazka, Allan V.
TI General Health Checks in Adults Reply
SO JAMA INTERNAL MEDICINE
LA English
DT Letter
C1 [Caverly, Tanner J.] Univ Colorado, Sch Med, Div Gen Internal Med, Aurora, CO USA.
[Prochazka, Allan V.] Denver VA Med Ctr, Denver, CO 80200 USA.
RP Prochazka, AV (reprint author), Denver VA Med Ctr, 1055 Clermont, Denver, CO 80200 USA.
EM Allan.Prochazka@va.gov
NR 1
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD SEP 23
PY 2013
VL 173
IS 17
BP 1658
EP 1658
DI 10.1001/jamainternmed.2013.8194
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 228SU
UT WOS:000325210600028
PM 24061395
ER
PT J
AU Kayani, WT
Bandeali, SJ
Lee, VV
Elayda, M
Khan, A
Nambi, V
Jneid, H
Alam, M
Wilson, JM
Huang, HD
Birnbaum, Y
Ballantyne, CM
Virani, SS
AF Kayani, Waleed T.
Bandeali, Salman J.
Lee, Vei-Vei
Elayda, MacArthur
Khan, Anam
Nambi, Vijay
Jneid, Hani
Alam, Mahboob
Wilson, James M.
Huang, Henry D.
Birnbaum, Yochai
Ballantyne, Christie M.
Virani, Salim S.
TI Association between statins and infections after coronary artery bypass
grafting
SO INTERNATIONAL JOURNAL OF CARDIOLOGY
LA English
DT Article
DE Statins; Infection; Coronary artery bypass grafting
ID COMMUNITY-ACQUIRED PNEUMONIA; SURGICAL SITE INFECTIONS; PREOPERATIVE
STATIN; CARDIAC-SURGERY; MORTALITY; RISK; THERAPY; INHIBITORS; OUTCOMES;
DISEASE
AB Background: We determined whether pre-operative statin therapy is associated with a decrease in the incidence of infections after coronary artery bypass grafting (CABG).
Methods: A retrospective cohort study of 6253 patients undergoing isolated CABG, from the Texas Heart Institute Database from January 1, 2000 to December 31, 2010 (3869 receiving statins and 2384 not receiving statins) was conducted. Primary outcome was the development of any postoperative infection (composite of deep-sternal wound infection, leg harvest-site infection, pneumonia, or sepsis) after CABG. Secondary outcome was the association between pre-operative statin use and individual incidence of each aforementioned infection. Logistic regression analyses were performed.
Results: Incidence of any postoperative infection in patients who received statins pre-operatively was 6.5% compared to 8.3% in patients who did not receive statins. Pre-operative statin therapy was associated with a significant reduction in the primary outcome (odds ratio (OR) 0.74, 95% confidence interval (CI) 0.60-0.90) in adjusted models. Among individual secondary outcomes, pre-operative statin therapy was associated with a reduced incidence of sternal wound infections (2.5% vs. 3.2%, OR 0.6, 95% CI 0.5-0.8) and leg harvest site infections (0.6% vs. 1.3%, OR 0.46, 95% CI 0.2-0.8). Pre-operative statin therapy was not associated with a reduced incidence of pneumonia or sepsis.
Conclusion: Pre-operative statin use is associated with a decrease in overall incidence of post-operative infections after CABG. We propose immunomodulatory effects of statins leading to a dampening of inflammatory cascade as the cause of our findings. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Kayani, Waleed T.; Bandeali, Salman J.; Nambi, Vijay; Jneid, Hani; Birnbaum, Yochai; Ballantyne, Christie M.; Virani, Salim S.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
[Virani, Salim S.] Hlth Serv Res & Dev Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, Hlth Policy & Qual Program, Houston, TX USA.
[Lee, Vei-Vei; Elayda, MacArthur] St Lukes Episcopal Hosp, Texas Heart Inst, Dept Epidemiol & Biostat, Houston, TX USA.
[Nambi, Vijay; Ballantyne, Christie M.; Virani, Salim S.] Baylor Coll Med, Sect Cardiovasc Res, Houston, TX 77030 USA.
[Nambi, Vijay; Ballantyne, Christie M.; Virani, Salim S.] Methodist DeBakey Heart & Vasc Ctr, Ctr Cardiovasc Dis Prevent, Houston, TX USA.
[Virani, Salim S.] Michael E DeBakey VA Med Ctr, Cardiol Sect, Houston, TX USA.
[Alam, Mahboob] Memphis Vet Affairs Med Ctr, Cardiol Sect, Memphis, TN USA.
[Wilson, James M.] St Lukes Episcopal Hosp, Texas Heart Inst, Dept Cardiol, Houston, TX USA.
[Nambi, Vijay; Jneid, Hani; Huang, Henry D.; Birnbaum, Yochai; Ballantyne, Christie M.; Virani, Salim S.] Baylor Coll Med, Dept Med, Cardiol Sect, Houston, TX 77030 USA.
[Khan, Anam] Aga Khan Univ, Karachi, Pakistan.
RP Kayani, WT (reprint author), Baylor Coll Med, Dept Med, 1 Baylor Plaza, Houston, TX 77030 USA.
EM kayani@bcm.edu
OI Virani, Salim/0000-0001-9541-6954
FU Department of Veterans Affairs Health Services Research and Development
Service (HSR&D) Career Development Award [CDA-09-028]; Abbott;
AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Genentech; Kowa;
Merck; Novartis; Roche; Sanofi-Synthelabo; Takeda; NIH; ADA; AHA;
Anthera Pharmaceuticals Research collaboration GE; Medipattern; Tomtec
FX Vijay Nambi: disclosures-National monitor, study sponsored by Anthera
Pharmaceuticals Research collaboration GE, Medipattern, Tomtec.;
Christie M Ballantyne: grant/research support (all paid to institution,
not individual): Abbott, AstraZeneca, Bristol-Myers Squibb,
GlaxoSmithKline, Genentech, Kowa, Merck, Novartis, Roche,
Sanofi-Synthelabo, Takeda, NIH, ADA, AHA.; Salim S. Virani: Dr. Virani
is supported by a Department of Veterans Affairs Health Services
Research and Development Service (HSR&D) Career Development Award (grant
number: CDA-09-028).
NR 37
TC 11
Z9 13
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0167-5273
EI 1874-1754
J9 INT J CARDIOL
JI Int. J. Cardiol.
PD SEP 20
PY 2013
VL 168
IS 1
BP 117
EP 120
DI 10.1016/j.ijcard.2012.09.060
PG 4
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 231IL
UT WOS:000325409800032
PM 23046597
ER
PT J
AU Wiechers, IR
Perin, NC
Cook-Deegan, R
AF Wiechers, Ilse R.
Perin, Noah C.
Cook-Deegan, Robert
TI The emergence of commercial genomics: analysis of the rise of a
biotechnology subsector during the Human Genome Project, 1990 to 2004
SO GENOME MEDICINE
LA English
DT Article
AB Background: Development of the commercial genomics sector within the biotechnology industry relied heavily on the scientific commons, public funding, and technology transfer between academic and industrial research. This study tracks financial and intellectual property data on genomics firms from 1990 through 2004, thus following these firms as they emerged in the era of the Human Genome Project and through the 2000 to 2001 market bubble.
Methods: A database was created based on an early survey of genomics firms, which was expanded using three web-based biotechnology services, scientific journals, and biotechnology trade and technical publications. Financial data for publicly traded firms was collected through the use of four databases specializing in firm financials. Patent searches were conducted using firm names in the US Patent and Trademark Office website search engine and the DNA Patent Database.
Results: A biotechnology subsector of genomics firms emerged in parallel to the publicly funded Human Genome Project. Trends among top firms show that hiring, capital improvement, and research and development expenditures continued to grow after a 2000 to 2001 bubble. The majority of firms are small businesses with great diversity in type of research and development, products, and services provided. Over half the public firms holding patents have the majority of their intellectual property portfolio in DNA-based patents.
Conclusions: These data allow estimates of investment, research and development expenditures, and jobs that paralleled the rise of genomics as a sector within biotechnology between 1990 and 2004.
C1 [Wiechers, Ilse R.; Perin, Noah C.; Cook-Deegan, Robert] Duke Univ, Inst Genome Sci & Policy, Ctr Publ Genom, Durham, NC 27708 USA.
[Cook-Deegan, Robert] Duke Univ, Sanford Sch Publ Policy, Durham, NC 27708 USA.
[Wiechers, Ilse R.] Yale Univ, Sch Med, Johnson Fdn Clin Scholars Program, New Haven, CT 06520 USA.
[Wiechers, Ilse R.] US Dept Vet Affairs, New Haven, CT 06520 USA.
RP Wiechers, IR (reprint author), Duke Univ, Inst Genome Sci & Policy, Ctr Publ Genom, Box 90141, Durham, NC 27708 USA.
EM ilse.wiechers@yale.edu
OI Cook-Deegan, Robert/0000-0002-8251-4237
FU Ewing Marion Kauffman Foundation; US Department of Energy [P50
HG003391]; Duke Endowment; National Human Genome Research Institute
FX This work was supported in part by grants from the Ewing Marion Kauffman
Foundation, the National Human Genome Research Institute and US
Department of Energy (P50 HG003391) and the Duke Endowment. The views do
not necessarily represent those of the funders. The authors would like
to thank the following students and research assistants at the Center
for Genome Ethics, Law & Policy whose countless hours of data gathering
and entry were invaluable: Phebe Ko, Suparna Salil, Whitney Laemmli, Joe
Fore, Alessandra Colaianni, Daidree Tofano, Molly Nicholson, Stacy
Lavin, Britt Russert, Marjorie Gurganus, Anupama Kotha, and Cindy Wang.
NR 19
TC 1
Z9 1
U1 2
U2 20
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1756-994X
J9 GENOME MED
JI Genome Med.
PD SEP 20
PY 2013
VL 5
AR 83
DI 10.1186/gm487
PG 9
WC Genetics & Heredity
SC Genetics & Heredity
GA 230GD
UT WOS:000325324000001
PM 24050173
ER
PT J
AU Leentjens, AFG
Moonen, AJH
Dujardin, K
Marsh, L
Martinez-Martin, P
Richard, IH
Starkstein, SE
Kohler, S
AF Leentjens, Albert F. G.
Moonen, Anja J. H.
Dujardin, Kathy
Marsh, Laura
Martinez-Martin, Pablo
Richard, Irene H.
Starkstein, Sergio E.
Kohler, Sebastian
TI Modeling depression in Parkinson disease Disease-specific and
nonspecific risk factors
SO NEUROLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; RATING-SCALES; ANXIETY; RECOMMENDATIONS; PREVALENCE;
VALIDATION; DEMENTIA; MARKERS; MINI
AB Objective: To construct a model for depression in Parkinson disease (PD) and to study the relative contribution of PD-specific and nonspecific risk factors to this model.
Methods: Structural equation modeling of direct and indirect associations of risk factors with the latent depression outcome using a cross-sectional dataset of 342 patients with PD.
Results: A model with acceptable fit was generated that explained 41% of the variance in depression. In the final model, 3 PD-specific variables (increased disease duration, more severe motor symptoms, the use of levodopa) and 6 nonspecific variables (female sex, history of anxiety and/or depression, family history of depression, worse functioning on activities of daily living, and worse cognitive status) were maintained and significantly associated with depression. Nonspecific risk factors had a 3-times-higher influence in the model than PD-specific risk factors.
Conclusion: In this cross-sectional study, we showed that nonspecific factors may be more prominent markers of depression than PD-specific factors. Accordingly, research on depression in PD should focus not only on factors associated with or specific for PD, but should also examine a wider scope of factors including general risk factors for depression, not specific for PD.
C1 [Leentjens, Albert F. G.; Moonen, Anja J. H.] Maastricht Univ, Med Ctr, Dept Psychiat, Maastricht, Netherlands.
[Leentjens, Albert F. G.; Moonen, Anja J. H.; Kohler, Sebastian] Maastricht Univ, Sch Mental Hlth & Neurosci, Maastricht, Netherlands.
[Dujardin, Kathy] Univ Lille, Med Ctr, Neurol & Movement Disorders Unit, Lille, France.
[Marsh, Laura] Michael E DeBakey Vet Adm Med Ctr, Houston, TX USA.
[Marsh, Laura] Baylor Coll Med, Dept Psychiat, Houston, TX 77030 USA.
[Marsh, Laura] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA.
[Martinez-Martin, Pablo] Carlos III Inst Hlth, Alzheimer Ctr Reina Sofia Fdn, Alzheimer Dis Res Unit, Madrid, Spain.
[Martinez-Martin, Pablo] Carlos III Inst Hlth, Alzheimer Ctr Reina Sofia Fdn, CIBERNED, Madrid, Spain.
[Richard, Irene H.] Univ Rochester, Sch Med & Dent, Dept Neurol, Rochester, NY 14642 USA.
[Richard, Irene H.] Univ Rochester, Sch Med & Dent, Dept Psychiat, Rochester, NY 14642 USA.
[Starkstein, Sergio E.] Univ Western Australia, Sch Psychiat, Fremantle, WA, Australia.
[Starkstein, Sergio E.] Fremantle Hosp, Fremantle, WA, Australia.
RP Leentjens, AFG (reprint author), Maastricht Univ, Med Ctr, Dept Psychiat, Maastricht, Netherlands.
EM a.leentjens@maastrichtuniversity.nl
FU Michael J. Fox Foundation for Parkinson's Research
FX This study did not receive any funding. The study on which database this
analysis was performed received funding from the Michael J. Fox
Foundation for Parkinson's Research.
NR 32
TC 12
Z9 13
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD SEP 17
PY 2013
VL 81
IS 12
BP 1036
EP 1043
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA AA0EK
UT WOS:000330767900007
PM 23946309
ER
PT J
AU Neve, KA
Ford, CP
Buck, DC
Grandy, DK
Neve, RL
Phillips, TJ
AF Neve, K. A.
Ford, C. P.
Buck, D. C.
Grandy, D. K.
Neve, R. L.
Phillips, T. J.
TI NORMALIZING DOPAMINE D2 RECEPTOR-MEDIATED RESPONSES IN D2 NULL MUTANT
MICE BY VIRUS-MEDIATED RECEPTOR RESTORATION: COMPARING D2(L) AND D2(S)
SO NEUROSCIENCE
LA English
DT Article
DE dopamine D2 receptor; methamphetamine; D2 receptor null mutant mouse;
potassium channel
ID DEFICIENT MICE; AUTORECEPTOR FUNCTION; D2-DOPAMINE RECEPTOR; IN-VIVO;
ISOFORMS; NEURONS; EXPRESSION; METHAMPHETAMINE; STIMULATION; FORMS
AB D2 receptor null mutant (Drd2(-/-)) mice have altered responses to the rewarding and locomotor effects of psychostimulant drugs, which is evidence of a necessary role for D2 receptors in these behaviors. Furthermore, work with mice that constitutively express only the D2 receptor short form (D2(S)), as a result of genetic deletion of the long form (D2(L)), provides the basis for a current model in which D2(L) is thought to be the postsynaptic D2 receptor on medium spiny neurons in the basal forebrain, and D2(S) the autoreceptor that regulates the activity of dopamine neurons and dopamine synthesis and release. Because constitutive genetic deletion of the D2 or D2(L) receptor may cause compensatory changes that influence functional outcomes, our approach is to identify aspects of the abnormal phenotype of a Drd2(-/-) mouse that can be normalized by virus-mediated D2 receptor expression. Drd2(-/-) mice are deficient in basal and methamphetamine-induced locomotor activation and lack D2 receptor agonist-induced activation of G protein-regulated inward rectifying potassium channels (GIRKs) in dopaminergic neurons. Here we show that virus-mediated expression of D2(L) in the nucleus accumbens significantly restored methamphetamine-induced locomotor activation, but not basal locomotor activity, compared to mice receiving the control virus. It also restored the effect of methamphetamine to decrease time spent in the center of the activity chamber in female but not male Drd2(-/-) mice. Furthermore, the effect of expression of D2(S) was indistinguishable from D2(L). Similarly, virus-mediated expression of either D2(S) or D2(L) in substantia nigra neurons restored D2 agonist-induced activation of GIRKs. In this acute expression system, the alternatively spliced forms of the D2 receptor appear to be equally capable of acting as postsynaptic receptors and autoreceptors. Published by Elsevier Ltd. on behalf of IBRO.
C1 [Neve, K. A.; Buck, D. C.; Phillips, T. J.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Res Serv, Portland, OR 97239 USA.
[Neve, K. A.; Buck, D. C.; Phillips, T. J.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA.
[Neve, K. A.; Buck, D. C.; Phillips, T. J.] Oregon Hlth & Sci Univ, Methamphetamine Abuse Res Ctr, Portland, OR 97239 USA.
[Ford, C. P.] Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97239 USA.
[Grandy, D. K.] Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97239 USA.
[Neve, R. L.] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA.
RP Neve, KA (reprint author), VA Med Ctr, Res Serv R&D 30, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM nevek@ohsu.edu; cpf21@case.edu; buckd@ohsu.edu; grandyd@ohsu.edu;
rneve@MIT.EDU; phillipt@ohsu.edu
FU NIH [MH045372, DA018165, DA026416]; VA Merit Review program; Career
Scientist program
FX This work was support by NIH Grants MH045372, DA018165, and DA026416,
and the VA Merit Review and Career Scientist programs.
NR 33
TC 7
Z9 7
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4522
EI 1873-7544
J9 NEUROSCIENCE
JI Neuroscience
PD SEP 17
PY 2013
VL 248
BP 479
EP 487
DI 10.1016/j.neuroscience.2013.06.035
PG 9
WC Neurosciences
SC Neurosciences & Neurology
GA 299UV
UT WOS:000330422100044
PM 23811070
ER
PT J
AU Humphrey, LL
Deffebach, M
Pappas, M
Baumann, C
Artis, K
Mitchell, JP
Zakher, B
Fu, RW
Slatore, CG
AF Humphrey, Linda L.
Deffebach, Mark
Pappas, Miranda
Baumann, Christina
Artis, Kathryn
Mitchell, Jennifer Priest
Zakher, Bernadette
Fu, Rongwei
Slatore, Christopher G.
TI Screening for Lung Cancer With Low-Dose Computed Tomography: A
Systematic Review to Update the U. S. Preventive Services Task Force
Recommendation
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Review
ID 2-YEAR FOLLOW-UP; SMOKING-CESSATION; SPIRAL CT; RANDOMIZED FEASIBILITY;
CUMULATIVE INCIDENCE; CHEST RADIOGRAPH; FORMER SMOKERS; ITALUNG TRIAL;
DANTE TRIAL; RISK
AB Background: Lung cancer is the leading cause of cancer-related death in the United States. Because early-stage lung cancer is associated with lower mortality than late-stage disease, early detection and treatment may be beneficial.
Purpose: To update the 2004 review of screening for lung cancer for the U.S. Preventive Services Task Force, focusing on screening with low-dose computed tomography (LDCT).
Data Sources: MEDLINE (2000 to 31 May 2013), the Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews (through the fourth quarter of 2012), Scopus, and reference lists.
Study Selection: English-language randomized, controlled trials or cohort studies that evaluated LDCT screening for lung cancer.
Data Extraction: One reviewer extracted study data about participants, design, analysis, follow-up, and results, and a second reviewer checked extractions. Two reviewers rated study quality using established criteria.
Data Synthesis: Four trials reported results of LDCT screening among patients with smoking exposure. One large good-quality trial reported that screening was associated with significant reductions in lung cancer (20%) and all-cause (6.7%) mortality. Three small European trials showed no benefit of screening. Harms included radiation exposure, overdiagnosis, and a high rate of falsepositive findings that typically were resolved with further imaging. Smoking cessation was not affected. Incidental findings were common.
Limitations: Three trials were underpowered and of insufficient duration to evaluate screening effectiveness. Overdiagnosis, an important harm of screening, is of uncertain magnitude. No studies reported results in women or minority populations.
Conclusion: Strong evidence shows that LDCT screening can reduce lung cancer and all-cause mortality. The harms associated with screening must be balanced with the benefits.
C1 Oregon Hlth & Sci Univ, Pacific Northwest Evidence Based Practice Ctr, Portland, OR 97239 USA.
Portland VA Med Ctr, Portland, OR USA.
RP Humphrey, LL (reprint author), Oregon Hlth & Sci Univ, Mailcode BICC, Pacific Northwest Evidence Based Practice Ctr, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM linda.humphrey@va.gov
OI Slatore, Christopher/0000-0003-0958-8122
FU AHRQ [HHSA-290-2007-10057-IEPC3]; Portland Veterans Affairs Medical
Center; Veterans Affairs Health Services Research and Development Career
Development Award
FX By AHRQ under contract HHSA-290-2007-10057-IEPC3, task order 13, and the
Portland Veterans Affairs Medical Center. Drs. Humphrey, Deffebach, and
Slatore are supported by resources from the Portland Veterans Affairs
Medical Center. Dr. Slatore is sponsored by a Veterans Affairs Health
Services Research and Development Career Development Award.
NR 100
TC 161
Z9 167
U1 2
U2 22
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD SEP 17
PY 2013
VL 159
IS 6
BP 411
EP +
DI 10.7326/0003-4819-159-6-201309170-00690
PG 18
WC Medicine, General & Internal
SC General & Internal Medicine
GA 234EY
UT WOS:000325625900017
PM 23897166
ER
PT J
AU Vengust, M
Staempfli, H
Viel, L
Swenson, ER
Heigenhauser, G
AF Vengust, Modest
Staempfli, Henry
Viel, Laurent
Swenson, Erik R.
Heigenhauser, George
TI Acetazolamide attenuates transvascular fluid flux in equine lungs during
intense exercise
SO JOURNAL OF PHYSIOLOGY-LONDON
LA English
DT Article
ID CARBONIC-ANHYDRASE INHIBITION; PULMONARY VASCULAR-RESISTANCE; HUMAN
ERYTHROCYTE-MEMBRANE; RED-CELL MEMBRANE; ACID-BASE CONTROL; MAXIMAL
EXERCISE; HEAVY EXERCISE; GAS-EXCHANGE; WATER PERMEABILITY;
CAPILLARY-PRESSURE
AB During intense exercise in horses the transvascular fluid flux in the pulmonary circulation (J(v-a)) represents 4% of cardiac output . This fluid flux has been attributed to an increase in pulmonary transmural hydrostatic forces, increases in perfused microvascular surface area, and reversible alterations in capillary permeability under conditions of high flow and pressure. Erythrocyte fluid efflux, however, accounts for a significant fraction of J(v-a). In the lung the Jacobs-Stewart cycle occurs with diffusion of CO2 into alveolar space with possible accompanying chloride (Cl-) and water movement from the erythrocyte directly into the pulmonary interstitium. We hypothesised that inhibition of carbonic anhydrase in erythrocytes inhibits the Jacobs-Stewart cycle and attenuates J(v-a). Five horses were exercised on a treadmill until fatigue without (control) and with acetazolamide treatment (30 mg kg(-1) 30 min before exercise). Erythrocyte fluid efflux, plasma fluid flux across the lung and J(v-a) were calculated using haemoglobin, haematocrit, plasma protein and Q. Fluid fluxes were used to calculate erythrocyte, plasma and whole blood Cl- fluxes across the lung. Cardiac output was not different between control and acetazolamide treatment. During exercise erythrocyte fluid efflux and J(v-a) increased in control (9.3 +/- 3.3 and 11.0 +/- 4.4 l min(-1), respectively) and was higher than after acetazolamide treatment (3.8 +/- 1.6 and 1.2 +/- 1.2 l min(-1), respectively) (P < 0.05). Plasma fluid flux did not change from rest in control and decreased after acetazolamide treatment (-4.5 +/- 1.5 l min(-1)) (P < 0.05). Erythrocyte Cl- flux increased during exercise in control and after acetazolamide treatment (P < 0.05). During exercise plasma Cl- flux across the lung did not change in control; however, it increased with acetazolamide treatment (P= 0.0001). During exercise whole blood Cl- flux increased across the lung in control (P < 0.05) but not after acetazolamide treatment. The results indicate that J(v-a) in the lung is dependent on the Jacobs-Stewart cycle and mostly independent of transmural hydrostatic forces. It also appears that J(v-a) is mediated by Cl- and water egress from erythrocytes directly into the interstitium without transit through plasma.
C1 [Vengust, Modest] Univ Ljubljana, Fac Vet, SI-1115 Ljubljana, Slovenia.
[Vengust, Modest; Viel, Laurent] Univ Guelph, Firestone Equine Resp Res Lab, Guelph, ON N1G 2W1, Canada.
[Staempfli, Henry; Viel, Laurent] Univ Guelph, Dept Clin Studies, Guelph, ON N1G 2W1, Canada.
[Swenson, Erik R.] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Heigenhauser, George] McMaster Univ, Dept Med, Med Ctr, Hamilton, ON L8N 3Z5, Canada.
RP Vengust, M (reprint author), Univ Ljubljana, Fac Vet, POB 3425, SI-1115 Ljubljana, Slovenia.
EM modest.vengust@vf.uni-lj.si
FU Ontario Ministry of Agriculture and Food - Equine Program; Department of
Clinical Studies at the University of Guelph; Canadian Institutes of
Health Research; Slovenian Research Agency [P4-0053]
FX This study was supported by the Ontario Ministry of Agriculture and Food
- Equine Program, Department of Clinical Studies at the University of
Guelph, Canadian Institutes of Health Research and the Slovenian
Research Agency grant P4-0053.
NR 62
TC 1
Z9 1
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3751
EI 1469-7793
J9 J PHYSIOL-LONDON
JI J. Physiol.-London
PD SEP 15
PY 2013
VL 591
IS 18
BP 4499
EP 4513
DI 10.1113/jphysiol.2013.257956
PG 15
WC Neurosciences; Physiology
SC Neurosciences & Neurology; Physiology
GA 219AU
UT WOS:000324476900020
PM 23818694
ER
PT J
AU Schoneburg, B
Mancini, M
Horak, F
Nutt, JG
AF Schoneburg, Bernadette
Mancini, Martina
Horak, Fay
Nutt, John G.
TI Framework for Understanding Balance Dysfunction in Parkinson's Disease
SO MOVEMENT DISORDERS
LA English
DT Review
DE balance; gait; posture; Parkinson's disease
ID DEEP BRAIN-STIMULATION; ANTICIPATORY POSTURAL ADJUSTMENTS; SUBTHALAMIC
NUCLEUS; STEP INITIATION; DUAL TASKING; GAIT VARIABILITY; STOOPED
POSTURE; OLDER-ADULTS; SWAY; LEVODOPA
AB People with Parkinson's disease (PD) suffer from progressive impairment in their mobility. Locomotor and balance dysfunction that impairs mobility in PD is an important cause of physical and psychosocial disability. The recognition and evaluation of balance dysfunction by the clinician are an essential component of managing PD. In this review, we describe a framework for understanding balance dysfunction in PD to help clinicians recognize patients who are at risk for falling and impaired mobility. (c) 2013 International Parkinson and Movement Disorder Society
C1 [Schoneburg, Bernadette; Mancini, Martina; Horak, Fay; Nutt, John G.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA.
[Schoneburg, Bernadette; Nutt, John G.] Portland VA Med Ctr, Portland, OR USA.
RP Nutt, JG (reprint author), Parkinson Ctr Oregon, 3181 SW Sam Jackson Pk Rd W OP32, Portland, OR 97239 USA.
EM nuttj@ohsu.edu
FU PADRECC fellowship; National Institute of Aging; National Parkinson
Foundation; National Institute of Neurological Disorders and Stroke;
Ceregene
FX This study has support from a PADRECC fellowship, the National Institute
of Aging, the National Parkinson Foundation, the National Institute of
Neurological Disorders and Stroke, and Ceregene.
NR 96
TC 36
Z9 36
U1 6
U2 35
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-3185
EI 1531-8257
J9 MOVEMENT DISORD
JI Mov. Disord.
PD SEP 15
PY 2013
VL 28
IS 11
SI SI
BP 1474
EP 1482
DI 10.1002/mds.25613
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA 238VI
UT WOS:000325979100002
PM 23925954
ER
PT J
AU Luo, JH
Rossouw, J
Tong, E
Giovino, GA
Lee, CC
Chen, C
Ockene, JK
Qi, LH
Margolis, KL
AF Luo, Juhua
Rossouw, Jacques
Tong, Elisa
Giovino, Gary A.
Lee, Cathy C.
Chen, Chu
Ockene, Judith K.
Qi, Lihong
Margolis, Karen L.
TI Smoking and Diabetes: Does the Increased Risk Ever Go Away?
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE risk factors; smoking; smoking cessation; type 2 diabetes
ID BASE-LINE CHARACTERISTICS; MIDDLE-AGED MEN; CIGARETTE-SMOKING;
UNITED-STATES; WEIGHT-GAIN; INSULIN-RESISTANCE; CESSATION; MELLITUS;
PARTICIPANTS; HAZARDS
AB Recent studies reported that smoking cessation leads to higher short-term risk of type 2 diabetes than continuing to smoke. However, the duration of increased diabetes risk following smoking cessation needs further investigation. We followed 135,906 postmenopausal women aged 50-79 years enrolled in the Women's Health Initiative between September 1, 1993, and December 31, 1998, over an average of 11 years to examine the association between smoking cessation and risk of diabetes using Cox proportional hazard multivariable-adjusted regression models. Compared with that for never smokers, the risk for diabetes was significantly elevated in current smokers (hazard ratio = 1.28, 95% confidence interval: 1.20, 1.36) but was even higher in women who quit smoking during the first 3 years of follow-up (hazard ratio = 1.43, 95% confidence interval: 1.26, 1.63). Among former smokers, the risk of diabetes decreased significantly as the time since quitting increased and was equal to that of never smokers following a cessation period of 10 years. In new quitters with low cumulative exposure (<20 pack-years), diabetes risk was not elevated following smoking cessation. In conclusion, the risk of diabetes in former smokers returns to that in never smokers 10 years after quitting, and even more quickly in lighter smokers.
C1 [Luo, Juhua] W Virginia Univ, Dept Community Med, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA.
[Rossouw, Jacques] NHLBI, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA.
[Tong, Elisa] Univ Calif Davis, Med Ctr, Div Gen Internal Med, Sacramento, CA 95817 USA.
[Giovino, Gary A.] SUNY Buffalo, Dept Community Hlth & Hlth Behav, Sch Publ Hlth & Hlth Profess, Buffalo, NY 14260 USA.
[Lee, Cathy C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Internal Med, Div Geriatr, Los Angeles, CA 90095 USA.
[Lee, Cathy C.] Vet Affairs Greater Los Angeles Healthcare Syst, Ctr Geriatr Res Educ & Clin, Los Angeles, CA USA.
[Chen, Chu] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA.
[Ockene, Judith K.] Univ Massachusetts, Sch Med, Dept Med, Div Prevent & Behav Med, Worcester, MA USA.
[Qi, Lihong] Univ Calif Davis, Div Biostat, Dept Publ Hlth Sci, Sch Med, Davis, CA 95616 USA.
[Margolis, Karen L.] HealthPartners Res Fdn, Minneapolis, MN USA.
RP Luo, JH (reprint author), Indiana Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, 1025 East 7th St, Bloomington, IN 47405 USA.
EM juhluo@indiana.edu
FU National Heart, Lung, and Blood Institute, National Institutes of
Health, US Department of Health and Human Services [N01WH22110, 24152,
32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122,
42107-26, 42129-32, 44221]; [HHSN268201100003C]
FX The Women's Health Initiative program is funded by the National Heart,
Lung, and Blood Institute, National Institutes of Health, US Department
of Health and Human Services, through contracts N01WH22110, 24152,
32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122,
42107-26, 42129-32, and 44221, and by HHSN268201100003C.
NR 41
TC 12
Z9 12
U1 2
U2 9
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD SEP 15
PY 2013
VL 178
IS 6
BP 937
EP 945
DI 10.1093/aje/kwt071
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 227YC
UT WOS:000325150600016
PM 23817918
ER
PT J
AU Bratcher, PE
Gaggar, A
AF Bratcher, Preston E.
Gaggar, Amit
TI Characterization and Prevention of the Adsorption of Surfactant Protein
D to Polypropylene
SO PLOS ONE
LA English
DT Article
ID LUNG
AB Surfactant Protein D (SP-D) is a multifunctional protein present in the lung and in respiratory secretions. In the process of developing new experimental approaches to examine SP-D function, we observed that SP-D adsorbs to polypropylene tubes to a great extent, thereby depleting SP-D from the solution. Although it is well known that proteins adsorb nonspecifically to plastic, this effect is usually diminished by treatments to make the plastic "low-retention" or "low-binding". However, these treatments actually increased the binding of SP-D to the plastic. In addition, this adsorption affected the results of several assays, including proteolytic cleavage assays. In order to block SP-D from adsorbing to polypropylene and the effects caused by this adsorption, we coated the tubes with bovine serum albumin (BSA), as is commonly performed for ELISAs. This coating greatly diminished the amount of SP-D sticking to the plastic, providing an inexpensive and effective method for preventing adsorption and the artifacts resulting from this adsorption.
C1 [Bratcher, Preston E.; Gaggar, Amit] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
[Gaggar, Amit] Univ Alabama Birmingham, Gregory Fleming James Cyst Fibrosis Res Ctr, Birmingham, AL 35294 USA.
[Gaggar, Amit] Univ Alabama Birmingham, Lung Hlth Ctr, Birmingham, AL 35294 USA.
[Gaggar, Amit] Med Serv, US Dept Vet Affairs, Med Ctr, Birmingham, AL USA.
RP Bratcher, PE (reprint author), Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
EM bratcher@uab.edu
FU National Institutes of Health [HL102371, 5T32HL105346-02]; Cystic
Fibrosis Foundation [GAGGAR07]
FX This work is supported by the National Institutes of Health (HL102371 to
AG, 5T32HL105346-02 to PEB) and the Cystic Fibrosis Foundation (GAGGAR07
to AG). The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
NR 11
TC 5
Z9 5
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 11
PY 2013
VL 8
IS 9
AR e73467
DI 10.1371/journal.pone.0073467
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 248VW
UT WOS:000326734500034
PM 24039953
ER
PT J
AU Venkatasubbarao, K
Peterson, L
Zhao, SJ
Hill, P
Cao, L
Zhou, Q
Nawrocki, ST
Freeman, JW
AF Venkatasubbarao, Kolaparthi
Peterson, Lindsay
Zhao, Shujie
Hill, Ping
Cao, Lin
Zhou, Qing
Nawrocki, Steffan T.
Freeman, James W.
TI Inhibiting signal transducer and activator of transcription-3 increases
response to gemcitabine and delays progression of pancreatic cancer
SO MOLECULAR CANCER
LA English
DT Article
DE Pancreatic cancer; STAT3; EGFR inhibitor; Cancer therapy
ID GROWTH-FACTOR RECEPTOR; CELL-LINE; STAT3; CARCINOMA; APOPTOSIS;
SURVIVAL; THERAPY; PATHWAY; ADENOCARCINOMA; CHEMOTHERAPY
AB Background: Among the solid tumors, human pancreatic ductal adenocarcinoma (PDAC) has the worst prognosis. Gemcitabine is the standard first line of therapy for pancreatic cancer but has limited efficacy due to inherent or rapid development of resistance and combining EGFR inhibitors with this regimen results in only a modest clinical benefit. The goal of this study was to identify molecular targets that are activated during gemcitabine therapy alone or in combination with an EGFR inhibitor.
Methods: PDAC cell lines were used to determine molecular changes and rates of growth after treatment with gemcitabine or an EGFR inhibitor, AG1478, by Western blot analysis and MTT assays respectively. Flow cytometric analysis was performed to study the cell cycle progression and rate of apoptosis after gemcitabine treatment. ShRNA was used to knockdown STAT3. An in vivo orthotopic animal model was used to evaluate STAT3 as a target. Immunohistochemical analysis was performed to analyze Ki67 and STAT3 expression in tumors.
Results: Treatment with gemcitabine increased the levels of EGFR(Tyr1068) and ERK phosphorylation in the PDAC cell lines tested. The constitutive STAT3(Tyr705) phosphorylation observed in PDAC cell lines was not altered by treatment with gemcitabine. Treatment of cells with gemcitabine or AG1478 resulted in differential rate of growth inhibition. AG1478 efficiently blocked the phosphorylation of EGFR(Tyr1068) and inhibited the phosphorylation of down-stream effectors AKT and ERKs, while STAT3(Tyr705) phosphorylation remained unchanged. Combining these two agents neither induced synergistic growth suppression nor inhibited STAT3(Tyr705) phosphorylation, thus prompting further studies to assess whether targeting STAT3 improves the response to gemcitabine or AG1478. Indeed, knockdown of STAT3 increased sensitivity to gemcitabine by inducing pro-apoptotic signals and by increasing G1 cell cycle arrest. However, knockdown of STAT3 did not enhance the growth inhibitory potential of AG1478. In vivo orthotopic animal model results show that knockdown of STAT3 caused a significant reduction in tumor burden and delayed tumor progression with increased response to gemcitabine associated with a decrease in the Ki-67 positive cells.
Conclusions: This study suggests that STAT3 should be considered an important molecular target for therapy of PDAC for enhancing the response to gemcitabine.
C1 [Venkatasubbarao, Kolaparthi; Peterson, Lindsay; Zhao, Shujie; Hill, Ping; Cao, Lin; Zhou, Qing; Nawrocki, Steffan T.; Freeman, James W.] Univ Texas San Antonio, Hlth Sci Ctr, Div Hematol & Oncol, Dept Med, San Antonio, TX 78229 USA.
[Venkatasubbarao, Kolaparthi; Peterson, Lindsay; Zhao, Shujie; Hill, Ping; Cao, Lin; Zhou, Qing; Nawrocki, Steffan T.; Freeman, James W.] Canc Therapy & Res Ctr S Texas, Expt & Dev Therapeut Program, San Antonio, TX 78229 USA.
[Freeman, James W.] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78229 USA.
RP Freeman, JW (reprint author), Univ Texas San Antonio, Hlth Sci Ctr, Div Hematol & Oncol, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM FREEMANJW@UTHSCSA.EDU
FU NIH/NCI [RO1 CA69122]; VA-Merit Award; Cancer Center Grant NIH/NCI
[P30CA054174]
FX This study was supported by NIH/NCI grant RO1 CA69122 and VA-Merit Award
to JWF and Cancer Center Grant NIH/NCI P30CA054174 in support of the
UTHSCSA Core Flow Cytometry Facility. The authors would like to thank
Dr. Subrata Haldar and Ms. Susan Beardales, Division of Scientific
Writing, CTRC, UTHSCSA for helpful suggestions during the preparation of
this manuscript.
NR 34
TC 12
Z9 13
U1 0
U2 13
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD SEP 11
PY 2013
VL 12
AR 104
DI 10.1186/1476-4598-12-104
PG 12
WC Biochemistry & Molecular Biology; Oncology
SC Biochemistry & Molecular Biology; Oncology
GA 220BE
UT WOS:000324554900001
PM 24025152
ER
PT J
AU Eckhouse, SR
Logdon, CB
Oelsen, JM
Patel, RK
Rice, AD
Stroud, RE
Wince, WB
Mukherjee, R
Spinale, FG
Ikonomidis, JS
Jones, JA
AF Eckhouse, Shaina R.
Logdon, Christina B.
Oelsen, J. Marshall
Patel, Risha K.
Rice, Allison D.
Stroud, Robert E.
Wince, W. Benjamin
Mukherjee, Rupak
Spinale, Francis G.
Ikonomidis, John S.
Jones, Jeffrey A.
TI Reproducible Porcine Model of Thoracic Aortic Aneurysm
SO CIRCULATION
LA English
DT Article; Proceedings Paper
CT Scientific Sessions of the American-Heart-Association (AHA)
CY NOV 03-07, 2012
CL Los Angeles, CA
SP Amer Heart Assoc
DE animal models; aortic diseases; aneurysm; cardiovascular disease;
remodeling
ID MATRIX METALLOPROTEINASES; MURINE MODEL; TISSUE INHIBITORS;
ABDOMINAL-AORTA; VALVES; EXPRESSION; DISSECTIONS; INDUCTION; INFUSION;
DISEASE
AB Background-Thoracic aortic aneurysms (TAAs) develop secondary to abnormal aortic extracellular matrix remodeling, resulting in a weakened and dilated aortic wall that progressed to rupture if left unattended. Currently, no diagnostic/prognostic tests are available for the detection of TAA disease. This is largely driven by the lack of a large animal model, which would permit longitudinal/mechanistic studies. Accordingly, the objective of the present study was to establish a reproducible porcine model of aortic dilatation, which recapitulates the structural and biochemical changes observed during human TAA development.
Methods and Results-Descending TAAs were induced in Yorkshire pigs (20-25 kg; n=7) through intra-adventitial injections of collagenase (5 mL, 0.35 mg/mL) and periadventitial application of crystalline CaCl2 (0.5 g). Three weeks after TAA induction, aortas were harvested and tissue was collected for biochemical and histological measurements. A subset of animals underwent MRI preoperatively and at terminal surgery. Results were compared with sham-operated controls (n=6). Three weeks after TAA induction, aortic luminal area increased by 38 +/- 13% (P=0.018 versus control). Aortic structural changes included elastic lamellar degradation and decreased collagen content. The protein abundance of matrix metalloproteinases 3, 8, 9, and 12 increased in TAA tissue homogenates, whereas tissue inhibitors of metalloproteinases 1 and 4 decreased.
Conclusions-These data demonstrate aortic dilatation, aortic medial degeneration, and alterations in matrix metalloproteinase/tissue inhibitors of metalloproteinase abundance, consistent with TAA formation. This study establishes for the first time a large animal model of TAA that recapitulates the hallmarks of human disease and provides a reproducible test bed for examining diagnostic, prognostic, and therapeutic strategies.
C1 [Eckhouse, Shaina R.; Logdon, Christina B.; Oelsen, J. Marshall; Patel, Risha K.; Rice, Allison D.; Stroud, Robert E.; Mukherjee, Rupak; Ikonomidis, John S.; Jones, Jeffrey A.] Med Univ S Carolina, Div Cardiothorac Surg, Dept Surg, Charleston, SC 29425 USA.
[Wince, W. Benjamin] Med Univ S Carolina, Dept Med, Div Cardiol, Charleston, SC 29425 USA.
[Jones, Jeffrey A.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC USA.
[Spinale, Francis G.] Univ S Carolina, Sch Med, Dept Cell Biol & Anat, Columbia, SC USA.
[Spinale, Francis G.] Wm Jennings Bryan Dorn Vet Affairs Med Ctr, Columbia, SC USA.
RP Jones, JA (reprint author), Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Strom Thurmond Res Bldg,114 Doughty St,Suite 326C, Charleston, SC 29425 USA.
EM jonesja@musc.edu
FU NHLBI NIH HHS [T32 HL007260]
NR 39
TC 4
Z9 4
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD SEP 10
PY 2013
VL 128
IS 11
SU 1
BP S186
EP S193
DI 10.1161/CIRCULATIONAHA.112.000363
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 301MD
UT WOS:000330535500023
PM 24030405
ER
PT J
AU Richard, EM
Thiyagarajan, T
Bunni, MA
Basher, F
Roddy, PO
Siskind, LJ
Nietert, PJ
Nowling, TK
AF Richard, Erin Morris
Thiyagarajan, Thirumagal
Bunni, Marlene A.
Basher, Fahmin
Roddy, Patrick O.
Siskind, Leah J.
Nietert, Paul J.
Nowling, Tamara K.
TI Reducing FLI1 Levels in the MRL/lpr Lupus Mouse Model Impacts T Cell
Function by Modulating Glycosphingolipid Metabolism
SO PLOS ONE
LA English
DT Article
ID TRANSCRIPTION FACTOR; CYTOKINE PRODUCTION; RENAL-DISEASE; ETS FAMILY;
DECREASED EXPRESSION; ANTIGEN RECEPTOR; MURINE LUPUS; MICE;
ERYTHEMATOSUS; LYMPHOCYTES
AB Systemic Lupus erythematosus (SLE) is an autoimmune disease caused, in part, by abnormalities in cells of the immune system including B and T cells. Genetically reducing globally the expression of the ETS transcription factor FLI1 by 50% in two lupus mouse models significantly improves disease measures and survival through an unknown mechanism. In this study we analyze the effects of reducing FLI1 in the MRL/lpr lupus prone model on T cell function. We demonstrate that adoptive transfer of MRL/lpr Fli1(+/+) or Fli1(+/-) T cells and B cells into Rag1-deficient mice results in significantly decreased serum immunoglobulin levels in animals receiving Fli1(+/-) lupus T cells compared to animals receiving Fli1(+/+) lupus T cells regardless of the genotype of co-transferred lupus B cells. Ex vivo analyses of MRL/lpr T cells demonstrated that Fli1(+/-) T cells produce significantly less IL-4 during early and late disease and exhibited significantly decreased TCR-specific activation during early disease compared to Fli1(+/+) T cells. Moreover, the Fli1(+/-) T cells expressed significantly less neuraminidase 1 (Neu1) message and decreased NEU activity during early disease and significantly decreased levels of glycosphingolipids during late disease compared to Fli1(+/+) T cells. FLI1 dose-dependently activated the Neu1 promoter in mouse and human T cell lines. Together, our results suggest reducing FLI1 in lupus decreases the pathogenicity of T cells by decreasing TCR-specific activation and IL-4 production in part through the modulation of glycosphingolipid metabolism. Reducing the expression of FLI1 or targeting the glycosphingolipid metabolic pathway in lupus may serve as a therapeutic approach to treating lupus.
C1 [Richard, Erin Morris; Thiyagarajan, Thirumagal; Basher, Fahmin; Nowling, Tamara K.] Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, Charleston, SC 29425 USA.
[Bunni, Marlene A.] Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA.
[Nietert, Paul J.] Med Univ S Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA.
[Roddy, Patrick O.; Siskind, Leah J.] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA.
[Siskind, Leah J.; Nowling, Tamara K.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29425 USA.
RP Nowling, TK (reprint author), Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, Charleston, SC 29425 USA.
EM nowling@musc.edu
FU Veteran's Administration [BX000115]; National Institutes of Health [NCRR
P20 RR17677 COBRE, NIDDK R01 DK093462, NCRR UL1TR000062, NIAMS 1P60
AR062755-01]; Cancer Center Support Grant [P30 CA138313]
FX These studies were supported by funding from the Veteran's
Administration (Merit Review Grant BX000115 to TKN) and in part by
National Institutes of Health (NCRR P20 RR17677 COBRE in Lipidomics and
Pathobiology pilot project and NIDDK R01 DK093462 to LJS) and Lipidomics
Shared Resource of the Hollings Cancer Center at the Medical University
of South Carolina supported by a Cancer Center Support Grant (P30
CA138313). Support for PJN was provided by the National Institutes of
Health (NCRR UL1TR000062 and NIAMS 1P60 AR062755-01). The contents of
this publication do not represent the views of the Department of
Veterans Affairs or the United States Government. The funders had no
role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.
NR 46
TC 9
Z9 10
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 10
PY 2013
VL 8
IS 9
AR e75175
DI 10.1371/journal.pone.0075175
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 259PK
UT WOS:000327538600131
PM 24040398
ER
PT J
AU Hatano, H
Somsouk, M
Sinclair, E
Harvill, K
Gilman, L
Cohen, M
Hoh, R
Hunt, PW
Martin, JN
Wong, JK
Deeks, SG
Yukl, SA
AF Hatano, Hiroyu
Somsouk, Ma
Sinclair, Elizabeth
Harvill, Kara
Gilman, Lee
Cohen, Michelle
Hoh, Rebecca
Hunt, Peter W.
Martin, Jeffrey N.
Wong, Joseph K.
Deeks, Steven G.
Yukl, Steven A.
TI Comparison of HIV DNA and RNA in gut-associated lymphoid tissue of
HIV-infected controllers and noncontrollers
SO AIDS
LA English
DT Article
DE controllers; gut-associated lymphoid tissue; HIV; viral reservoir
ID HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELL RESPONSES; SUPPRESSIVE
ANTIRETROVIRAL THERAPY; LOW-LEVEL VIREMIA; ELITE CONTROLLERS; TYPE-1
RNA; REPLICATION; PLASMA; INDIVIDUALS; ACTIVATION
AB Objectives:HIV-infected controllers have provided novel insights into mechanisms of viral control. We investigated the degree to which HIV DNA and RNA are present in gut-associated lymphoid tissue (GALT) of controllers.
Design:Cross-sectional cohort study.
Methods:Colorectal biopsy pieces were obtained from five untreated noncontrollers, five ART-suppressed patients, and nine untreated controllers.
Results:Rectal HIV DNA was lower in controllers (median 496copies/10(6) CD4(+) T cells) than in untreated noncontrollers (117483copies/10(6) CD4(+) T cells, P=0.001) and ART-suppressed patients (6116copies/10(6) CD4(+) T cells, P=0.004). Similarly, rectal HIV RNA was lower in controllers (19copies/10(6) CD4(+) T cells) than in noncontrollers (15210copies/10(6) CD4(+) T cells, P=0.001) and ART-suppressed patients (1625copies/10(6) CD4(+) T cells, P=0.0599). Rectal HIV RNA/DNA ratios were not statistically different between the three groups.
Conclusion:Despite being able to maintain very low plasma HIV RNA levels in the absence of antiretroviral therapy (ART), HIV-infected controllers have readily measurable levels of HIV DNA and RNA in GALT. As expected, controllers had lower rectal HIV DNA and RNA compared with untreated noncontrollers and ART-suppressed individuals. Compared with the mechanisms of natural' viral control of controllers, long-term ART does not reduce the total HIV reservoir to the level of controllers.
C1 [Hatano, Hiroyu; Somsouk, Ma; Sinclair, Elizabeth; Harvill, Kara; Gilman, Lee; Cohen, Michelle; Hoh, Rebecca; Hunt, Peter W.; Wong, Joseph K.; Deeks, Steven G.; Yukl, Steven A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Martin, Jeffrey N.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA USA.
[Wong, Joseph K.; Yukl, Steven A.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Hatano, H (reprint author), San Francisco Gen Hosp, Bldg 80,Ward 84,995 Potrero Ave, San Francisco, CA 94110 USA.
EM hhatano@php.ucsf.edu
FU National Institute of Allergy and Infectious Diseases [R01 AI087145, K23
AI075985, K24 AI069994, R56 AI091573, R01 NS051132]; National Cancer
Institute [K23 CA157929]; Delaney AIDS Research Enterprise (DARE) [U19
AI0961090]; California HIV/AIDS Research Program [ID08-SF-004]; American
Foundation for AIDS Research [106710-40-RGRL]; UCSF/Gladstone Institute
of Virology & Immunology CFAR [P30 AI027763]; UCSF Clinical and
Translational Research Institute Clinical Research Center [UL1
RR024131]; Center for AIDS Prevention Studies [P30 MH62246]; CFAR
Network of Integrated Systems [R24 AI067039]; U.S. Department of
Veterans Affairs [1 IK2 CX000520-01, 5101BX001048]
FX This work was supported by grants from the National Institute of Allergy
and Infectious Diseases (R01 AI087145, K23 AI075985, K24 AI069994, R56
AI091573, R01 NS051132), the National Cancer Institute (K23 CA157929),
the Delaney AIDS Research Enterprise (DARE; U19 AI0961090), California
HIV/AIDS Research Program (grant number ID08-SF-004), American
Foundation for AIDS Research (106710-40-RGRL), the UCSF/Gladstone
Institute of Virology & Immunology CFAR (P30 AI027763), the UCSF
Clinical and Translational Research Institute Clinical Research Center
(UL1 RR024131), the Center for AIDS Prevention Studies (P30 MH62246),
the CFAR Network of Integrated Systems (R24 AI067039), and the U.S.
Department of Veterans Affairs (1 IK2 CX000520-01, 5101BX001048). The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the article.
NR 30
TC 10
Z9 10
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD SEP 10
PY 2013
VL 27
IS 14
BP 2255
EP 2260
DI 10.1097/QAD.0b013e328362692f
PG 6
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 248LZ
UT WOS:000326702700012
PM 24157906
ER
PT J
AU Driver, TH
Scherzer, R
Peralta, CA
Tien, PC
Estrella, MM
Parikh, CR
Butch, AW
Anastos, K
Cohen, MH
Nowicki, M
Sharma, A
Young, MA
Abraham, A
Shlipak, MG
AF Driver, Todd H.
Scherzer, Rebecca
Peralta, Carmen A.
Tien, Phyllis C.
Estrella, Michelle M.
Parikh, Chirag R.
Butch, Anthony W.
Anastos, Kathryn
Cohen, Mardge H.
Nowicki, Marek
Sharma, Anjali
Young, Mary A.
Abraham, Alison
Shlipak, Michael G.
TI Comparisons of creatinine and cystatin C for detection of kidney disease
and prediction of all-cause mortality in HIV-infected women
SO AIDS
LA English
DT Article
DE creatinine; cystatin C; glomerular filtration rate; HIV; kidney;
mortality; women
ID GLOMERULAR-FILTRATION-RATE; STAGE RENAL-DISEASE; ANTIRETROVIRAL THERAPY;
CARDIOVASCULAR EVENTS; SERUM CREATININE; HIV-1-INFECTED PATIENTS;
ELDERLY PERSONS; INTERAGENCY HIV; RISK; MUSCLE
AB Background:Cystatin C could improve chronic kidney disease (CKD) classification in HIV-infected women relative to serum creatinine.
Design:Retrospective cohort analysis.
Methods:Cystatin C and creatinine were measured from specimens taken and stored during the 1999-2000 examination among 908 HIV-infected participants in the Women's Interagency HIV study (WIHS). Mean follow-up was 10.2 years. Predictors of differential glomerular filtration rate (GFR) estimates were evaluated with multivariable linear regression. The associations of baseline categories (<60, 60-90, and >90ml/min per 1.73m(2)) of creatinine estimated GFR (eGFR(cr)), cystatin C eGFR (eGFR(cys)), and combined creatinine-cystatin C eGFR (eGFR(cr-cys)) with all-cause mortality were evaluated using multivariable Cox regression. The net reclassification index (NRI) was calculated to evaluate the effect of cystatin C on reclassification of CKD staging.
Results:CKD risk factors were associated with lower eGFR(cys) and eGFR(cr-cys) values compared with eGFR(cr). Relative to eGFR more than 90, the eGFR less than 60 category by eGFR(cys) (Adjusted hazard ratio: 2.56; 95% confidence interval: 1.63-4.02), eGFR(cr-cys) (3.11; 1.94-5.00), and eGFR(cr) (2.34; 1.44-3.79) was associated with increased mortality risk. However, the eGFR 60-90 category was associated with increased mortality risk for eGFR(cys) (1.80; 1.28-2.53) and eGFR(cr-cys) (1.91; 1.38-2.66) but not eGFR(cr) (1.20; 0.85-1.67). The overall NRI for mortality was 26% when reclassifying from eGFR(cr) to eGFR(cys) (P<0.001) and was 20% when reclassifying from eGFR(cr) to eGFR(cr-cys) (P<0.001).
Conclusion:The addition of cystatin C may improve mortality risk prediction by stages of kidney function relative to creatinine. CKD risk factors are associated with an overestimate of GFR by serum creatinine relative to cystatin C.
C1 [Driver, Todd H.] Univ Calif San Francisco, Sch Med, San Francisco Vet Affairs Med Ctr, San Francisco, CA USA.
[Scherzer, Rebecca; Peralta, Carmen A.; Tien, Phyllis C.; Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco Vet Affairs Med Ctr, San Francisco, CA USA.
[Peralta, Carmen A.; Tien, Phyllis C.; Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco Vet Affairs Med Ctr, San Francisco, CA USA.
[Estrella, Michelle M.; Abraham, Alison] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Parikh, Chirag R.] Yale Univ, Dept Med, Nephrol Sect, New Haven, CT 06520 USA.
[Parikh, Chirag R.] Yale Univ, Program Appl Translat Res, New Haven, CT USA.
[Butch, Anthony W.] Univ Calif Los Angeles, Clin Immunol Res Lab, Los Angeles, CA USA.
[Anastos, Kathryn] Albert Einstein Coll Med, Dept Med & Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
[Cohen, Mardge H.] Stroger Hosp, Dept Med, Chicago, IL USA.
[Cohen, Mardge H.] Rush Univ, Chicago, IL 60612 USA.
[Nowicki, Marek] Univ So Calif, Los Angeles, CA USA.
[Sharma, Anjali] Suny Downstate Med Ctr, Dept Med, Div Infect Dis, Brooklyn, NY 11203 USA.
[Young, Mary A.] Georgetown Univ, Med Ctr, Washington, DC 20007 USA.
RP Shlipak, MG (reprint author), San Francisco VA Med Ctr, 4150 Clement St,Box 111A1, San Francisco, CA 94121 USA.
EM michael.shlipak@ucsf.edu
FU UCSF-CTSI [TL1 TR000144]; [R01 AG034853-03]
FX Sources of Support: R01 AG034853-03 (Shlipak); UCSF-CTSI Grant Number
TL1 TR000144 (Driver).
NR 48
TC 12
Z9 13
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD SEP 10
PY 2013
VL 27
IS 14
BP 2291
EP 2299
DI 10.1097/QAD.0b013e328362e874
PG 9
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 248LZ
UT WOS:000326702700016
PM 23669156
ER
PT J
AU Hage, FG
Wackers, FJT
Bansal, S
Chyun, DA
Young, LH
Inzucchi, SE
Iskandrian, AE
AF Hage, Fadi G.
Wackers, Frans J. Th
Bansal, Shanti
Chyun, Deborah A.
Young, Lawrence H.
Inzucchi, Silvio E.
Iskandrian, Ami E.
TI The heart rate response to adenosine: A simple predictor of adverse
cardiac outcomes in asymptomatic patients with type 2 diabetes
SO INTERNATIONAL JOURNAL OF CARDIOLOGY
LA English
DT Article
DE Type 2 diabetes mellitus; Heart rate; Adenosine; Myocardial perfusion
imaging; Autonomic function
ID CARDIOVASCULAR AUTONOMIC NEUROPATHY; MYOCARDIAL-ISCHEMIA; DIAD;
REGADENOSON; MELLITUS; RISK; DIPYRIDAMOLE; ASSOCIATION; DYSFUNCTION;
MORTALITY
AB Background: The Detection of Ischemia in Asymptomatic Diabetics (DIAD) study demonstrated a low 5-year hard cardiac event rate. We hypothesized that a blunted heart rate response (HRR, maximum percent change) to adenosine, a simple marker of cardiac autonomic neuropathy, will identify a cohort at higher cardiac risk.
Methods: In DIAD, 518 participants were randomized to screening adenosine myocardial perfusion imaging (MPI) and had available data. HRR <20% was considered abnormal. The primary endpoint was a composite of nonfatal myocardial infarction and cardiac death.
Results: During 4.7+/-0.9 years of follow-up 15 (3%) participants experienced the primary outcome. Participants with lower HRR experienced more events than those with higher HRR (8%, 3%, 1%, for HRR <20% (n=79), 20-39% (n=182) and >= 40% (n=257), respectively, p=0.01). In a Cox proportional regression model that included MPI abnormalities and HRR, both were independently associated with cardiac events (p for model <0.001). HRR <20% was associated with 9-fold increased risk (p=0.007) and moderate/large abnormal MPI was associated with 6-fold increased risk (p=0.004). Participants with both abnormal MPI and HRR (n=8) were at highest risk for cardiac events (38%) whereas those with HRR >= 40%, irrespective of MPI abnormalities (n=234), were at extremely low risk (>= 1%, log-rank p<0.001).
Conclusions: In DIAD, abnormal HRR to adenosine infusion is an independent predictor of cardiac events. This easily obtained marker of cardiac autonomic neuropathy identifies asymptomatic patients with type 2 diabetes mellitus at increased risk, particularly when associated with abnormal MPI, who may warrant further testing and more aggressive cardiovascular risk factor management. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Hage, Fadi G.; Iskandrian, Ami E.] Univ Alabama Birmingham, Birmingham, AL USA.
[Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Wackers, Frans J. Th; Bansal, Shanti; Young, Lawrence H.; Inzucchi, Silvio E.] Yale Univ, Sch Med, New Haven, CT USA.
[Chyun, Deborah A.] NYU, New York, NY USA.
RP Hage, FG (reprint author), Zeigler Res Bldg 1024,703 19th St South, Birmingham, AL 35294 USA.
EM fadihage@uab.edu
OI Hage, Fadi/0000-0002-1397-4942
FU General Clinical Research Centers at Yale University (National
Institutes of Health) [M01-RR-00125]; University of Rochester [NIH
5M01-RR-00847]; Tulane University [NIH 6M01-RR-05096]
FX Financial disclosure: This work was performed with the support of the
General Clinical Research Centers at Yale University (National
Institutes of Health M01-RR-00125), University of Rochester (NIH
5M01-RR-00847), and Tulane University (NIH 6M01-RR-05096).
NR 21
TC 8
Z9 8
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0167-5273
J9 INT J CARDIOL
JI Int. J. Cardiol.
PD SEP 10
PY 2013
VL 167
IS 6
BP 2952
EP 2957
DI 10.1016/j.ijcard.2012.08.011
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 219BH
UT WOS:000324478400102
PM 22981277
ER
PT J
AU Korrapati, MC
Howell, LH
Shaner, BE
Megyesi, JK
Siskind, LJ
Schnellmann, RG
AF Korrapati, Midhun C.
Howell, Lauren H.
Shaner, Brooke E.
Megyesi, Judit K.
Siskind, Leah J.
Schnellmann, Rick G.
TI Suramin: A Potential Therapy for Diabetic Nephropathy
SO PLOS ONE
LA English
DT Article
ID TUBULAR EPITHELIAL-CELLS; KAPPA-B ACTIVATION; KIDNEY-DISEASE; RENAL
INJURY; DB/DB MOUSE; TGF-BETA; FIBROSIS; MECHANISMS; RATS; MICE
AB Objective: To determine whether delayed administration of a single dose of suramin, a drug that has been used extensively in humans to treat trypanosomiasis, attenuates renal injury in a leptin receptor deficient C57BLKS/J db/db type 2 diabetic nephropathy (T2DN) mouse model.
Research Design and Methods: Groups of female non-diabetic (control) db/m and diabetic db/db mice of 8 and 16 weeks of age, respectively, were treated with suramin (10 mg/kg) or saline i.v. All animals were euthanized one week later. Measurements in mice 1 week following treatment included the following: body weight; blood glucose; urinary protein excretion; pathological lesions in glomeruli and proximal tubules; changes in protein expression of pro-inflammatory transcription factor nuclear factor kappa B (NF-kappa B) and intracellular adhesion molecule-1 (ICAM-1), profibrotic transforming growth factor-beta 1 (TGF-beta 1), phospho-SMAD-3 and alpha-smooth muscle actin (alpha-SMA); and immunohistochemical analysis of leukocyte infiltration and collagen 1A2 (COL1A2) deposition.
Results: Immunoblot analysis revealed increased NF-kappa B, ICAM-1, TGF-beta 1, phospho-SMAD-3, and alpha-SMA proteins in both 9 and 17 week db/db mice as compared to db/m control mice. Immunohistochemical analysis revealed moderate leukocyte infiltration and collagen 1A2 (COL1A2) deposition in 9 week db/db mice that was increased in the 17 week db/db mice. Importantly, suramin significantly decreased expression of all these markers in 9 week db/db mice and partially decreased in 17 week db/db mice without altering body weight, blood glucose or urinary protein excretion. There was no difference in creatinine clearance between 9 week db/m and db/db mice +/- suramin. Importantly, in the 17 week db/db mice suramin intervention reversed the impaired creatinine clearance and overt histological damage.
Conclusions: Delayed administration of a single dose of suramin in a model of T2DN attenuated inflammation and fibrosis as well as improved renal function, supporting the use of suramin in T2DN.
C1 [Korrapati, Midhun C.; Howell, Lauren H.; Shaner, Brooke E.; Siskind, Leah J.; Schnellmann, Rick G.] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA.
[Megyesi, Judit K.] Univ Arkansas Med Sci, Div Nephrol, Coll Med, Dept Internal Med, Little Rock, AR 72205 USA.
[Siskind, Leah J.; Schnellmann, Rick G.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA.
RP Siskind, LJ (reprint author), Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA.
EM leah.siskind@louisville.edu
FU National Institute of Diabetes and Digestive and Kidney Diseases of the
National Institutes of Health [R01DK093462]; Cancer Center Support Grant
[P30 CA138313]; Centers of Biomedical Research Excellence in Lipidomics
and Pathobiology [NIH/NCRR P20 RR17677]; South Carolina Centers of
Biomedical Research Excellence in Oxidants, Redox Balance and Stress
Signaling [P20 GM103542]; National Institutes of Health [GM 084147, C06
RR-015455]; Biomedical Laboratory Research and Development Program of
the Department of Veterans Affairs; South Carolina Clinical &
Translational Research (SCTR) Institute; Medical University of South
Carolina CTSA, NIH/NCRR [UL1RR029882]
FX Research reported in this publication was supported in part by National
Institute of Diabetes and Digestive and Kidney Diseases of the National
Institutes of Health, [R01DK093462] (to L.J.S.), the Lipidomics Shared
Resource of the Hollings Cancer Center at the Medical University of
South Carolina supported by a Cancer Center Support Grant [P30
CA138313], pilot project from the [NIH/NCRR P20 RR17677] Centers of
Biomedical Research Excellence in Lipidomics and Pathobiology (to
L.J.S), South Carolina Centers of Biomedical Research Excellence in
Oxidants, Redox Balance and Stress Signaling [P20 GM103542], pilot
project from the [NIH/NCRR P20 RR17677], National Institutes of Health
Grant [GM 084147] and by the Biomedical Laboratory Research and
Development Program of the Department of Veterans Affairs. Animal
facilities were funded by National Institutes of Health grant [C06
RR-015455]. This reseach was supported in part by the South Carolina
Clinical & Translational Research (SCTR) Institute, with an academic
home at the Medical University of South Carolina CTSA, NIH/NCRR Grant
Number UL1RR029882. The contents are solely the responsibility of the
authors and do not necessarily represent the official views of the NIH,
VA, or National Center for Research Resources. The funders had no role
in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 48
TC 8
Z9 8
U1 1
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 9
PY 2013
VL 8
IS 9
AR e73655
DI 10.1371/journal.pone.0073655
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 244QV
UT WOS:000326405300104
PM 24040012
ER
PT J
AU Lam, KD
Miao, YH
Steinman, MA
AF Lam, Khoa D.
Miao, Yinghui
Steinman, Michael A.
TI Cumulative Changes in the Use of Long-term Medications: A Measure of
Prescribing Complexity
SO JAMA INTERNAL MEDICINE
LA English
DT Letter
ID REGIMEN
C1 [Lam, Khoa D.; Steinman, Michael A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Lam, Khoa D.; Miao, Yinghui; Steinman, Michael A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Miao, Yinghui; Steinman, Michael A.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA.
RP Steinman, MA (reprint author), San Francisco VA Med Ctr, 4150 Clement St,POB 181G, San Francisco, CA 94121 USA.
EM mike.steinman@ucsf.edu
FU NIA NIH HHS [RC1 AG036377, RC1-AG036377, 1K23-AG030999, K23 AG030999,
P30 AG044281]
NR 5
TC 3
Z9 3
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD SEP 9
PY 2013
VL 173
IS 16
BP 1546
EP 1547
DI 10.1001/jamainternmed.2013.7060
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 218VS
UT WOS:000324461200015
PM 23752793
ER
PT J
AU Bodhankar, S
Chen, YX
Vandenbark, AA
Murphy, SJ
Offner, H
AF Bodhankar, Sheetal
Chen, Yingxin
Vandenbark, Arthur A.
Murphy, Stephanie J.
Offner, Halina
TI PD-L1 enhances CNS inflammation and infarct volume following
experimental stroke in mice in opposition to PD-1
SO JOURNAL OF NEUROINFLAMMATION
LA English
DT Article
DE Co-inhibitory pathway; Inflammatory states; MCAO; Programmed death-1
ligand 1 and 2
ID REGULATORY T-CELLS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS;
ISCHEMIC-STROKE; PERIPHERAL TOLERANCE; DEFICIENT MICE; EXPRESSION;
RESPONSES; LIGANDS; PATHWAY; IMMUNITY
AB Background: Stroke severity is worsened by recruitment of inflammatory immune cells into the brain. This process depends in part on T cell activation, in which the B7 family of co-stimulatory molecules plays a pivotal role. Previous studies demonstrated more severe infarcts in mice lacking programmed death-1 (PD-1), a member of the B7 family, thus implicating PD-1 as a key factor in limiting stroke severity. The purpose of this study was to determine if this protective effect of PD-1 involves either of its ligands, PD-L1 or PD-L2.
Methods: Central nervous system (CNS) inflammation and infarct volume were evaluated in male PD-L1 and PD-L2 knockout ((-/-)) mice undergoing 60 minutes of middle cerebral artery occlusion (MCAO) followed by 96 hours of reperfusion and compared to wild-type (WT) C57BL/6J mice.
Results: PD-L1(-/-) and PD-L2(-/-) mice had smaller total infarct volumes compared to WT mice. The PD-L1-/-and to a lesser extent PD-L2(-/-) mice had reduced levels of proinflammatory activated microglia and/or infiltrating monocytes and CD4(+) T cells in the ischemic hemispheres. There was a reduction in ischemia-related splenic atrophy accompanied by lower activation status of splenic T cells and monocytes in the absence of PD-L1, suggesting a pathogenic rather than a regulatory role for both PD-1 ligands (PD-Ls). Suppressor T cells (IL-10-producing CD8(+) CD122(+) T cells) trafficked to the brain in PD-L1(-/-) mice and there was decreased expression of CD80 on splenic antigen-presenting cells (APCs) as compared to the WT and PD-L2(-/-) mice.
Conclusions: Our novel observations are the first to implicate PD-L1 involvement in worsening outcome of experimental stroke. The presence of suppressor T cells in the right MCAO-inflicted hemisphere in mice lacking PDL1 implicates these cells as possible key contributors for controlling adverse effects of ischemia. Increased expression of CD80 on APCs in WT and PD-L2(-/-) mice suggests an overriding interaction leading to T cell activation. Conversely, low CD80 expression by APCs, along with increased PD-1 and PD-L2 expression in PD-L1(-/-) mice suggests alternative T cell signaling pathways, leading to a suppressor phenotype. These results suggest that agents (for example antibodies) that can target and neutralize PD-L1/2 may have therapeutic potential for treatment of human stroke.
C1 [Bodhankar, Sheetal; Vandenbark, Arthur A.; Offner, Halina] Portland VA Med Ctr, R&D 31, Portland, OR 97239 USA.
[Bodhankar, Sheetal; Vandenbark, Arthur A.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA.
[Vandenbark, Arthur A.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA.
[Chen, Yingxin; Murphy, Stephanie J.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97239 USA.
[Murphy, Stephanie J.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA.
RP Offner, H (reprint author), Portland VA Med Ctr, R&D 31, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM offnerva@ohsu.edu
FU NIH/National Institute of Neurological Disorders and Stroke (NINDS)
[1RO1 NS075887]; Department of Veterans Affairs, Veterans Health
Administration, Office of Research and Development; Biomedical
Laboratory Research and Development
FX The authors wish to thank Melissa Barber for assistance with manuscript
submission. This work was supported by NIH/National Institute of
Neurological Disorders and Stroke (NINDS): 1RO1 NS075887. This material
is based upon work supported in part by the Department of Veterans
Affairs, Veterans Health Administration, Office of Research and
Development, and Biomedical Laboratory Research and Development. The
contents do not represent the views of the Department of Veterans
Affairs or the United States Government.
NR 47
TC 21
Z9 21
U1 0
U2 11
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-2094
J9 J NEUROINFLAMM
JI J. Neuroinflamm.
PD SEP 9
PY 2013
VL 10
AR 111
DI 10.1186/1742-2094-10-111
PG 15
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA 214OL
UT WOS:000324143300001
PM 24015822
ER
PT J
AU Tanner, RM
Calhoun, DA
Bell, EK
Bowling, CB
Gutierrez, OM
Irvin, MR
Lackland, DT
Oparil, S
Warnock, D
Muntner, P
AF Tanner, Rikki M.
Calhoun, David A.
Bell, Emmy K.
Bowling, C. Barrett
Gutierrez, Orlando M.
Irvin, Marguerite R.
Lackland, Daniel T.
Oparil, Suzanne
Warnock, David
Muntner, Paul
TI Prevalence of Apparent Treatment-Resistant Hypertension among
Individuals with CKD
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID CHRONIC KIDNEY-DISEASE; HIGH-BLOOD-PRESSURE; ENDOTHELIAL DYSFUNCTION;
UNITED-STATES; RISK; MICROALBUMINURIA; ATHEROSCLEROSIS; SPIRONOLACTONE;
PREVENTION; COMMITTEE
AB Background and objectivesApparent treatment-resistant hypertension is defined as systolic/diastolic BP140/90 mmHg with concurrent use of three or more antihypertensive medication classes or use of four or more antihypertensive medication classes regardless of BP level.Design, setting, participants, & measurementsThe prevalence of apparent treatment-resistant hypertension among Reasons for Geographic and Racial Differences in Stroke study participants treated for hypertension (n=10,700) was determined by level of estimated GFR and albumin-to-creatinine ratio, and correlates of apparent treatment-resistant hypertension among those participants with CKD were evaluated. CKD was defined as an albumin-to-creatinine ratio30 mg/g or estimated GFR<60 ml/min per 1.73 m(2).ResultsThe prevalence of apparent treatment-resistant hypertension was 15.8%, 24.9%, and 33.4% for those participants with estimated GFR60, 45-59, and <45 ml/min per 1.73 m(2), respectively, and 12.1%, 20.8%, 27.7%, and 48.3% for albumin-to-creatinine ratio<10, 10-29, 30-299, and 300 mg/g, respectively. The multivariable-adjusted prevalence ratios (95% confidence intervals) for apparent treatment-resistant hypertension were 1.25 (1.11 to 1.41) and 1.20 (1.04 to 1.37) for estimated GFR levels of 45-59 and <45 ml/min per 1.73 m(2), respectively, versus 60 ml/min per 1.73 m(2) and 1.54 (1.39 to 1.71), 1.76 (1.57 to 1.97), and 2.44 (2.12 to 2.81) for albumin-to-creatinine ratio levels of 10-29, 30-299, and 300 mg/g, respectively, versus albumin-to-creatinine ratio<10 mg/g. After multivariable adjustment, men, black race, larger waist circumference, diabetes, history of myocardial infarction or stroke, statin use, and lower estimated GFR and higher albumin-to-creatinine ratio levels were associated with apparent treatment-resistant hypertension among individuals with CKD.ConclusionsThis study highlights the high prevalence of apparent treatment-resistant hypertension among individuals with CKD.
C1 [Tanner, Rikki M.; Irvin, Marguerite R.; Muntner, Paul] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL 35294 USA.
[Calhoun, David A.; Oparil, Suzanne] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA.
[Bell, Emmy K.; Gutierrez, Orlando M.; Warnock, David] Univ Alabama Birmingham, Dept Med, Div Nephrol, Birmingham, AL 35294 USA.
[Bowling, C. Barrett] Univ Alabama Birmingham, Dept Med, Div Gerontol, Birmingham, AL 35294 USA.
[Bowling, C. Barrett] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Lackland, Daniel T.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
RP Muntner, P (reprint author), Univ Alabama Birmingham, Dept Epidemiol, 1665 Univ Blvd,Suite 230J, Birmingham, AL 35294 USA.
EM pmuntner@uab.edu
FU National Institute of Neurological Disorders and Stroke, National
Institutes of Health, Department of Health and Human Services [U01
NS041588]; Amgen Corporation
FX This research project is supported by Cooperative Agreement U01 NS041588
from the National Institute of Neurological Disorders and Stroke,
National Institutes of Health, Department of Health and Human Services.
Additional funding was provided by an investigator-initiated
grant-in-aid from Amgen Corporation.
NR 26
TC 33
Z9 39
U1 0
U2 8
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
EI 1555-905X
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD SEP 6
PY 2013
VL 8
IS 9
BP 1583
EP 1590
DI 10.2215/CJN.00550113
PG 8
WC Urology & Nephrology
SC Urology & Nephrology
GA 235GR
UT WOS:000325705500018
PM 23868902
ER
PT J
AU Weisbord, SD
Gallagher, M
Kaufman, J
Cass, A
Parikh, CR
Chertow, GM
Shunk, KA
McCullough, PA
Fine, MJ
Mor, MK
Lew, RA
Huang, GD
Conner, TA
Brophy, MT
Lee, J
Soliva, S
Palevsky, PM
AF Weisbord, Steven D.
Gallagher, Martin
Kaufman, James
Cass, Alan
Parikh, Chirag R.
Chertow, Glenn M.
Shunk, Kendrick A.
McCullough, Peter A.
Fine, Michael J.
Mor, Maria K.
Lew, Robert A.
Huang, Grant D.
Conner, Todd A.
Brophy, Mary T.
Lee, Joanne
Soliva, Susan
Palevsky, Paul M.
TI Prevention of Contrast-Induced AKI: A Review of Published Trials and the
Design of the Prevention of Serious Adverse Events following Angiography
(PRESERVE) Trial
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID ACUTE KIDNEY INJURY; RANDOMIZED CONTROLLED-TRIAL; PERCUTANEOUS CORONARY
INTERVENTION; RADIOCONTRAST-INDUCED NEPHROPATHY; ELEVATION
MYOCARDIAL-INFARCTION; INTRAVENOUS N-ACETYLCYSTEINE; ISOTONIC
SODIUM-BICARBONATE; ASSOCIATION TASK-FORCE; RENAL-INSUFFICIENCY; PRIMARY
ANGIOPLASTY
AB Contrast-induced AKI (CI-AKI) is a common condition associated with serious, adverse outcomes. CI-AKI may be preventable because its risk factors are well characterized and the timing of renal insult is commonly known in advance. Intravenous (IV) fluids and N-acetylcysteine (NAC) are two of the most widely studied preventive measures for CI-AKI. Despite a multitude of clinical trials and meta-analyses, the most effective type of IV fluid (sodium bicarbonate versus sodium chloride) and the benefit of NAC remain unclear. Careful review of published trials of these interventions reveals design limitations that contributed to their inconclusive findings. Such design limitations include the enrollment of small numbers of patients, increasing the risk for type I and type II statistical errors; the use of surrogate primary endpoints defined by small increments in serum creatinine, which are associated with, but not necessarily causally related to serious, adverse, patient-centered outcomes; and the inclusion of low-risk patients with intact baseline kidney function, yielding low event rates and reduced generalizability to a higher-risk population. The Prevention of Serious Adverse Events following Angiography (PRESERVE) trial is a randomized, double-blind, multicenter trial that will enroll 8680 high-risk patients undergoing coronary or noncoronary angiography to compare the effectiveness of IV isotonic sodium bicarbonate versus IV isotonic sodium chloride and oral NAC versus oral placebo for the prevention of serious, adverse outcomes associated with CI-AKI. This article discusses key methodological issues of past trials investigating IV fluids and NAC and how they informed the design of the PRESERVE trial.
C1 [Weisbord, Steven D.] Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15240 USA.
RP Weisbord, SD (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, 7E Room 120,111F-U, Pittsburgh, PA 15240 USA.
EM weisbordsd@upmc.edu
OI Palevsky, Paul/0000-0002-7334-5400
FU Department of Veterans Affairs Cooperative Studies Program
FX This work was supported by the Department of Veterans Affairs
Cooperative Studies Program.
NR 97
TC 35
Z9 35
U1 0
U2 7
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
EI 1555-905X
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD SEP 6
PY 2013
VL 8
IS 9
BP 1618
EP 1631
DI 10.2215/CJN.11161012
PG 14
WC Urology & Nephrology
SC Urology & Nephrology
GA 235GR
UT WOS:000325705500024
PM 23660180
ER
PT J
AU Million, M
Zhao, JF
Luckey, A
Czimmer, J
Maynard, GD
Kehne, J
Hoffman, DC
Tache, Y
AF Million, Mulugeta
Zhao, Jing-Fang
Luckey, Andrew
Czimmer, Jozsef
Maynard, George D.
Kehne, John
Hoffman, Diane C.
Tache, Yvette
TI The Newly Developed CRF1-Receptor Antagonists, NGD 98-2 and NGD 9002,
Suppress Acute Stress-Induced Stimulation of Colonic Motor Function and
Visceral Hypersensitivity in Rats
SO PLOS ONE
LA English
DT Article
ID CORTICOTROPIN-RELEASING-FACTOR; IRRITABLE-BOWEL-SYNDROME; CRF1 RECEPTOR
ANTAGONIST; FACTOR SIGNALING PATHWAYS; FACTOR TYPE-1 RECEPTOR;
COLORECTAL DISTENSION; NONPEPTIDE ANTAGONIST; RECTAL DISTENSION; MAJOR
DEPRESSION; PAIN
AB Corticotropin releasing factor receptor 1 (CRF1) is the key receptor that mediates stress-related body responses. However to date there are no CRF1 antagonists that have shown clinical efficacy in stress-related diseases. We investigated the inhibitory effects of a new generation, topology 2 selective CRF1 antagonists, NGD 98-2 and NGD 9002 on exogenous and endogenous CRF-induced stimulation of colonic function and visceral hypersensitivity to colorectal distension (CRD) in conscious rats. CRF1 antagonists or vehicle were administered orogastrically (og) or subcutaneously (sc) before either intracerebroventricular (icv) or intraperitoneal (ip) injection of CRF (10 mu g/kg), exposure to water avoidance stress (WAS, 60 min) or repeated CRD (60 mmHg twice, 10 min on/off at a 30 min interval). Fecal pellet output (FPO), diarrhea and visceromotor responses were monitored. In vehicle (og)-pretreated rats, icv CRF stimulated FPO and induced diarrhea in >50% of rats. NGD 98-2 or NGD 9002 (3, 10 and 30 mg/kg, og) reduced the CRF-induced FPO response with an inhibitory IC50 of 15.7 and 4.3 mg/kg respectively. At the highest dose, og NGD 98-2 or NGD 9002 blocked icv CRF-induced FPO by 67-87% and decreased WAS-induced-FPO by 23-53%. When administered sc, NGD 98-2 or NGD 9002 (30 mg/kg) inhibited icv and ip CRF-induced-FPO. The antagonists also prevented the development of nociceptive hyper-responsivity to repeated CRD. These data demonstrate that topology 2 CRF1 antagonists, NGD 98-2 and NGD 9002, administered orally, prevented icv CRF-induced colonic secretomotor stimulation, reduced acute WAS-induced defecation and blocked the induction of visceral sensitization to repeated CRD.
C1 [Million, Mulugeta; Zhao, Jing-Fang; Luckey, Andrew; Czimmer, Jozsef; Tache, Yvette] Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Div Digest Dis,Dept Med, Los Angeles, CA 90095 USA.
[Million, Mulugeta; Tache, Yvette] Univ Calif Los Angeles, David Geffen Sch Med, Oppenheimer Family Ctr Neurobiol Stress, Div Digest Dis,Dept Med, Los Angeles, CA 90095 USA.
[Million, Mulugeta; Zhao, Jing-Fang; Luckey, Andrew; Czimmer, Jozsef; Tache, Yvette] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Maynard, George D.; Kehne, John; Hoffman, Diane C.] Neurogen Corp, Branford, CT USA.
RP Million, M (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Div Digest Dis,Dept Med, Los Angeles, CA 90095 USA.
EM millionmulugeta@mednet.ucla.edu
FU Neurogen-Aventis CRF Collaboration, Branford, Connecticut, USA; Veterans
Administration Research Career Scientist Award; NIH [RO1 DK-078676, R01
DK-57238, P50 DK-64539, DK-41301]
FX This work was supported by an investigator initiated fund from the
Neurogen-Aventis CRF Collaboration, Branford, Connecticut, USA (YT, MM);
The Veterans Administration Research Career Scientist Award (YT), Center
Grant NIH DK-41301 (Animal Model Core, YT, MM); RO1 DK-078676 (MM); R01
DK-57238 (YT) and P50 DK-64539 (YT, MM). The funders had no decision
role in the study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
NR 61
TC 10
Z9 10
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 6
PY 2013
VL 8
IS 9
AR e73749
DI 10.1371/journal.pone.0073749
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 224BO
UT WOS:000324856500059
PM 24040053
ER
PT J
AU Sudore, RL
Stewart, AL
Knight, SJ
McMahan, RD
Feuz, M
Miao, YH
Barnes, DE
AF Sudore, Rebecca L.
Stewart, Anita L.
Knight, Sara J.
McMahan, Ryan D.
Feuz, Mariko
Miao, Yinghui
Barnes, Deborah E.
TI Development and Validation of a Questionnaire to Detect Behavior Change
in Multiple Advance Care Planning Behaviors
SO PLOS ONE
LA English
DT Article
ID DIVERSE OLDER-ADULTS
AB Introduction: Advance directives have traditionally been considered the gold standard for advance care planning. However, recent evidence suggests that advance care planning involves a series of multiple discrete behaviors for which people are in varying stages of behavior change. The goal of our study was to develop and validate a survey to measure the full advance care planning process.
Methods: The Advance Care Planning Engagement Survey assesses "Process Measures'' of factors known from Behavior Change Theory to affect behavior (knowledge, contemplation, self-efficacy, and readiness, using 5-point Likert scales) and "Action Measures'' (yes/no) of multiple behaviors related to surrogate decision makers, values and quality of life, flexibility for surrogate decision making, and informed decision making. We administered surveys at baseline and 1 week later to 50 diverse, older adults from San Francisco hospitals. Internal consistency reliability of Process Measures was assessed using Cronbach's alpha (only continuous variables) and test-retest reliability of Process and Action Measures was examined using intraclass correlations. For discriminant validity, we compared Process and Action Measure scores between this cohort and 20 healthy college students (mean age 23.2 years, SD 2.7).
Results: Mean age was 69.3 (SD 10.5) and 42% were non-White. The survey took a mean of 21.4 minutes (+/- 6.2) to administer. The survey had good internal consistency (Process Measures Cronbach's alpha, 0.94) and test-retest reliability (Process Measures intraclass correlation, 0.70; Action Measures, 0.87). Both Process and Action Measure scores were higher in the older than younger group, p<.001.
Conclusion: A new Advance Care Planning Engagement Survey that measures behavior change (knowledge, contemplation, self-efficacy, and readiness) and multiple advance care planning actions demonstrates good reliability and validity. Further research is needed to assess whether survey scores improve in response to advance care planning interventions and whether scores are associated with receipt of care consistent with one's wishes.
C1 [Sudore, Rebecca L.; McMahan, Ryan D.; Feuz, Mariko; Miao, Yinghui; Barnes, Deborah E.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Sudore, Rebecca L.; Feuz, Mariko; Miao, Yinghui] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA.
[Stewart, Anita L.] Univ Calif San Francisco, Inst Hlth & Aging, San Francisco, CA USA.
[Knight, Sara J.] Vet Adm, Hlth Serv Res & Dev Serv, Washington, DC USA.
[Knight, Sara J.; Barnes, Deborah E.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[Barnes, Deborah E.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
RP Sudore, RL (reprint author), San Francisco VA Med Ctr, San Francisco, CA USA.
EM rebecca.sudore@ucsf.edu
FU Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development, HSRD; National Palliative Care Research
Center; National Institute on Aging, National Institutes of Health
[P30-AG15272]
FX This study was funded in part by the Department of Veterans Affairs,
Veterans Health Administration, Office of Research and Development,
HSR&D, the National Palliative Care Research Center, and by Grant
P30-AG15272 under the Resource Centers for Minority Aging Research
program by the National Institute on Aging, National Institutes of
Health. The funders had no role in the design and conduct of the study;
collection, management, analysis, and interpretation of the data; and
preparation, review, or approval of the manuscript; or decision to
submit the manuscript for publication. The contents of this manuscript
do not represent the views of the Department of Veterans Affairs or the
United States Government.
NR 20
TC 11
Z9 11
U1 1
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 5
PY 2013
VL 8
IS 9
AR e72465
DI 10.1371/journal.pone.0072465
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 219CG
UT WOS:000324481600032
PM 24039772
ER
PT J
AU Huang, E
Ngo, M
Yee, S
Held, L
Norman, K
Scremin, AME
Scremin, O
AF Huang, Emerald
Ngo, Mai
Yee, Stuart
Held, Laura
Norman, Keith
Scremin, A. M. Erika
Scremin, Oscar
TI Repeated blast exposure alters open field behavior recorded under low
illumination
SO BRAIN RESEARCH
LA English
DT Article
DE Brain injury; Blast injury; Rat
ID TRAUMATIC BRAIN-INJURY; RAT; CONCUSSION; HEADACHE; MODEL; MICE; AGE
AB Blast-induced traumatic brain injury (bTBI) can have devastating behavioral consequences. This study was designed to evaluate the behavioral consequences of single or repeated bTBI, as evaluated by an open field (OF) test conducted in near-darkness to avoid confounding effects of illumination and photophobia. Sprague-Dawley rats under isoflurane anesthesia were exposed to a series of 3 sub-lethal blasts into a compressed air-driven blast chamber separated by 2 week intervals (n=11). Sham controls received anesthesia but without blast exposure (n=11). OF tests were performed 1 or 7 days after each blast using a computerized video tracking system in near-darkness to monitor spontaneous activity. Spatial and temporal variables calculated for both blast and sham groups were: Distance moved (cm) and time (s) spent in the center or periphery zones of the field, total distance traveled, speed in center and periphery zones, rearing events and non-linear regressions of distance moved and rearing events on time. Results showed that the sham group expressed the expected decrease (habituation) in total distance walked, and distance walked as well as speed in center and periphery in successive exposures to the OF while the blast group did not, a sign of impaired learning. The blast group also walked more and faster and demonstrated more rearing behavior, both considered OF signs of anxiety. These results indicate that OF outcomes of bTBI in animals have resemblance to alterations observed in human subjects with this condition and might be useful in evaluating the response of behavioral outcomes of bTBI to experimental treatments. Published by Elsevier B.V.
C1 [Huang, Emerald; Ngo, Mai; Yee, Stuart] Univ Calif Los Angeles, VA Multicampus Residency Program, Los Angeles, CA USA.
[Held, Laura; Scremin, A. M. Erika] Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA.
[Norman, Keith; Scremin, Oscar] Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA.
[Scremin, A. M. Erika] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Scremin, Oscar] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA.
RP Scremin, O (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Dept Res, 11301 Wilshire Blvd,Bldg 115,Room 319, Los Angeles, CA 90073 USA.
EM oscremin@ucla.edu
FU Department of Veterans Affairs Rehabilitation Research & Development
Merit Review (VARRD) [B5089R]; VA RR&D Research Career Scientist award
FX This work was supported by Department of Veterans Affairs Rehabilitation
Research & Development Merit Review (VARR&D) #B5089R, and a VA RR&D
Research Career Scientist award (to O.U.S.).
NR 29
TC 4
Z9 4
U1 0
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
J9 BRAIN RES
JI Brain Res.
PD SEP 5
PY 2013
VL 1529
BP 125
EP 133
DI 10.1016/j.brainres.2013.06.042
PG 9
WC Neurosciences
SC Neurosciences & Neurology
GA 221KQ
UT WOS:000324658200013
PM 23850767
ER
PT J
AU Proctor, EK
Landsverk, J
Baumann, AA
Mittman, BS
Aarons, GA
Brownson, RC
Glisson, C
Chambers, D
AF Proctor, Enola K.
Landsverk, John
Baumann, Ana A.
Mittman, Brian S.
Aarons, Gregory A.
Brownson, Ross C.
Glisson, Charles
Chambers, David
TI The implementation research institute: training mental health
implementation researchers in the United States
SO IMPLEMENTATION SCIENCE
LA English
DT Article
DE Dissemination research; Implementation research; Training; Translational
research
ID COMORBIDITY SURVEY REPLICATION; KNOWLEDGE TRANSLATION; DISSEMINATION;
SCIENCE; STRATEGIES; DISORDERS; FRAMEWORK; TRAINEES; SERVICES; QUALITY
AB Background: The Implementation Research Institute (IRI) provides two years of training in mental health implementation science for 10 new fellows each year. The IRI is supported by a National Institute of Mental Health (NIMH) R25 grant and the Department of Veterans Affairs (VA). Fellows attend two annual week-long trainings at Washington University in St. Louis. Training is provided through a rigorous curriculum, local and national mentoring, a 'learning site visit' to a federally funded implementation research project, pilot research, and grant writing.
Methods: This paper describes the rationale, components, outcomes to date, and participant experiences with IRI.
Results: IRI outcomes include 31 newly trained implementation researchers, their new grant proposals, contributions to other national dissemination and implementation research training, and publications in implementation science authored by the Core Faculty and fellows. Former fellows have obtained independent research funding in implementation science and are beginning to serve as mentors for more junior investigators.
Conclusions: Based on the number of implementation research grant proposals and papers produced by fellows to date, the IRI is proving successful in preparing new researchers who can inform the process of making evidence-based mental healthcare more available through real-world settings of care and who are advancing the field of implementation science.
C1 [Proctor, Enola K.; Baumann, Ana A.] Washington Univ, George Warren Brown Sch Social Work, Ctr Mental Hlth Serv Res, St Louis, MO 63130 USA.
[Landsverk, John] San Diego Childrens Hosp, Child & Adolescent Serv Res Ctr, San Diego, CA USA.
[Mittman, Brian S.] VA Greater Los Angeles Healthcare Syst, Sepulveda, CA USA.
[Aarons, Gregory A.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA.
[Brownson, Ross C.] Washington Univ, Sch Med, St Louis, MO 63130 USA.
[Glisson, Charles] Univ Tennessee, Childrens Mental Hlth Serv Res Ctr, Knoxville, TN USA.
[Chambers, David] NIMH, Div Serv & Intervent Res, Bethesda, MD 20892 USA.
RP Proctor, EK (reprint author), Washington Univ, George Warren Brown Sch Social Work, Ctr Mental Hlth Serv Res, 1 Brookings Dr Campus,Box 1196, St Louis, MO 63130 USA.
EM ekp@wustl.edu
OI Baumann, Ana/0000-0002-4523-0147; Mittman, Brian/0000-0003-3589-9178
FU National Institute of Mental Health through the Center for Mental Health
Services Research [NIMH P30 MH068579]; National Institute of Mental
Health through the Implementation Research Institute [NIMH R25
MH080916]; US Department of Veterans Affairs Quality Enhancement
Research Initiative (QUERI)
FX Preparation of this paper was supported by the National Institute of
Mental Health through the Center for Mental Health Services Research
(NIMH P30 MH068579) and the Implementation Research Institute (NIMH R25
MH080916) and the US Department of Veterans Affairs Quality Enhancement
Research Initiative (QUERI). We gratefully acknowledge learning site
hosts who make invaluable contribution to IRI training; administrative
support from the Brown School, Washington University in St. Louis; and
the volunteer research assistants who contribute to the Institute's
success.
NR 30
TC 11
Z9 11
U1 2
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1748-5908
J9 IMPLEMENT SCI
JI Implement. Sci.
PD SEP 5
PY 2013
VL 8
AR 105
DI 10.1186/1748-5908-8-105
PG 12
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 214JQ
UT WOS:000324129400001
PM 24007290
ER
PT J
AU Menees, DS
Peterson, ED
Wang, Y
Curtis, JP
Messenger, JC
Rumsfeld, JS
Gurm, HS
AF Menees, Daniel S.
Peterson, Eric D.
Wang, Yongfei
Curtis, Jeptha P.
Messenger, John C.
Rumsfeld, John S.
Gurm, Hitinder S.
TI Door-to-Balloon Time and Mortality among Patients Undergoing Primary PCI
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID ACUTE-MYOCARDIAL-INFARCTION; PERCUTANEOUS CORONARY INTERVENTION;
CARDIOVASCULAR DATA REGISTRY; PRIMARY ANGIOPLASTY; REPERFUSION;
STRATEGIES; OUTCOMES; QUALITY; TRENDS; ASSOCIATION
AB BACKGROUND
Current guidelines for the treatment of ST-segment elevation myocardial infarction recommend a door-to-balloon time of 90 minutes or less for patients undergoing primary percutaneous coronary intervention (PCI). Door-to-balloon time has become a performance measure and is the focus of regional and national quality-improvement initiatives. However, it is not known whether national improvements in door-to-balloon times have been accompanied by a decline in mortality.
METHODS
We analyzed annual trends in door-to-balloon times and in-hospital mortality using data from 96,738 admissions for patients undergoing primary PCI for ST-segment elevation myocardial infarction from July 2005 through June 2009 at 515 hospitals participating in the CathPCI Registry. In a subgroup analysis using a linked Medicare data set, we assessed 30-day mortality.
RESULTS
Median door-to-balloon times declined significantly, from 83 minutes in the 12 months from July 2005 through June 2006 to 67 minutes in the 12 months from July 2008 through June 2009 (P<0.001). Similarly, the percentage of patients for whom the door-to-balloon time was 90 minutes or less increased from 59.7% in the first year to 83.1% in the last year (P<0.001). Despite improvements in door-to-balloon times, there was no significant overall change in unadjusted in-hospital mortality (4.8% in 2005-2006 and 4.7% in 2008-2009, P=0.43 for trend) or in risk-adjusted in-hospital mortality (5.0% in 2005-2006 and 4.7% in 2008-2009, P=0.34), nor was a significant difference observed in unadjusted 30-day mortality (P=0.64).
CONCLUSIONS
Although national door-to-balloon times have improved significantly for patients undergoing primary PCI for ST-segment elevation myocardial infarction, in-hospital mortality has remained virtually unchanged. These data suggest that additional strategies are needed to reduce in-hospital mortality in this population.
C1 [Menees, Daniel S.; Gurm, Hitinder S.] Univ Michigan, Ann Arbor, MI 48109 USA.
[Menees, Daniel S.; Gurm, Hitinder S.] Vet Affairs VA Ann Arbor Hlth Care Syst, Ann Arbor, MI USA.
[Peterson, Eric D.] Duke Univ, Durham, NC USA.
[Wang, Yongfei; Curtis, Jeptha P.] Yale Univ, New Haven, CT USA.
[Messenger, John C.; Rumsfeld, John S.] Univ Colorado, Sch Med, Aurora, CO USA.
[Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA.
RP Menees, DS (reprint author), Univ Michigan, Dept Internal Med, Div Cardiovasc Med, 1500 East Med Ctr Dr,2A396, Ann Arbor, MI 48109 USA.
EM dmenees@umich.edu
OI Gurm, Hitinder/0000-0002-1646-0218
FU National Cardiovascular Data Registry of the American College of
Cardiology Foundation
FX Funded by the National Cardiovascular Data Registry of the American
College of Cardiology Foundation.
NR 23
TC 183
Z9 189
U1 0
U2 9
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD SEP 5
PY 2013
VL 369
IS 10
BP 901
EP 909
DI 10.1056/NEJMoa1208200
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 211KV
UT WOS:000323906900007
PM 24004117
ER
PT J
AU Shlipak, MG
Matsushita, K
Arnlov, J
Inker, LA
Katz, R
Polkinghorne, KR
Rothenbacher, D
Sarnak, MJ
Astor, BC
Coresh, J
Levey, AS
Gansevoort, RT
AF Shlipak, Michael G.
Matsushita, Kunihiro
Arnlov, Johan
Inker, Lesley A.
Katz, Ronit
Polkinghorne, Kevan R.
Rothenbacher, Dietrich
Sarnak, Mark J.
Astor, Brad C.
Coresh, Josef
Levey, Andrew S.
Gansevoort, Ron T.
CA CKD Prognosis Consortium
TI Cystatin C versus Creatinine in Determining Risk Based on Kidney
Function
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID GLOMERULAR-FILTRATION-RATE; STAGE RENAL-DISEASE; COLLABORATIVE
METAANALYSIS; POPULATION COHORTS; HIGHER ALBUMINURIA; ESTIMATED GFR;
ALL-CAUSE; GENERAL-POPULATION; HEART-FAILURE; CKD-EPI
AB BACKGROUND
Adding the measurement of cystatin C to that of serum creatinine to determine the estimated glomerular filtration rate (eGFR) improves accuracy, but the effect on detection, staging, and risk classification of chronic kidney disease across diverse populations has not been determined.
METHODS
We performed a meta-analysis of 11 general-population studies (with 90,750 participants) and 5 studies of cohorts with chronic kidney disease (2960 participants) for whom standardized measurements of serum creatinine and cystatin C were available. We compared the association of the eGFR, as calculated by the measurement of creatinine or cystatin C alone or in combination with creatinine, with the rates of death (13,202 deaths in 15 cohorts), death from cardiovascular causes (3471 in 12 cohorts), and end-stage renal disease (1654 cases in 7 cohorts) and assessed improvement in reclassification with the use of cystatin C.
RESULTS
In the general-population cohorts, the prevalence of an eGFR of less than 60 ml per minute per 1.73 m(2) of body-surface area was higher with the cystatin C-based eGFR than with the creatinine-based eGFR (13.7% vs. 9.7%). Across all eGFR categories, the reclassification of the eGFR to a higher value with the measurement of cystatin C, as compared with creatinine, was associated with a reduced risk of all three study outcomes, and reclassification to a lower eGFR was associated with an increased risk. The net reclassification improvement with the measurement of cystatin C, as compared with creatinine, was 0.23 (95% confidence interval [CI], 0.18 to 0.28) for death and 0.10 (95% CI, 0.00 to 0.21) for end-stage renal disease. Results were generally similar for the five cohorts with chronic kidney disease and when both creatinine and cystatin C were used to calculate the eGFR.
CONCLUSIONS
The use of cystatin C alone or in combination with creatinine strengthens the association between the eGFR and the risks of death and end-stage renal disease across diverse populations.
C1 [Shlipak, Michael G.] Univ Calif San Francisco, Div Gen Internal Med, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA.
[Shlipak, Michael G.] Univ Calif San Francisco, Dept Med Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Matsushita, Kunihiro; Coresh, Josef] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Arnlov, Johan] Geriatr Uppsala Univ, Dept Publ Hlth & Caring Sci, Uppsala, Sweden.
[Arnlov, Johan] Dalarna Univ, Sch Hlth & Social Studies, Falun, Sweden.
[Inker, Lesley A.; Sarnak, Mark J.; Levey, Andrew S.] Tufts Med Ctr, Div Nephrol, Boston, MA USA.
[Katz, Ronit] Univ Washington, Seattle, WA 98195 USA.
[Polkinghorne, Kevan R.] Monash Univ, Dept Nephrol, Monash Med Ctr, Melbourne, Vic 3004, Australia.
[Polkinghorne, Kevan R.] Monash Univ, Dept Med, Melbourne, Vic, Australia.
[Rothenbacher, Dietrich] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, Germany.
[Rothenbacher, Dietrich] Univ Ulm, Inst Epidemiol & Med Biometry, Ulm, Germany.
[Astor, Brad C.] Univ Wisconsin, Dept Populat Hlth Sci, Sch Med & Publ Hlth, Madison, WI 53706 USA.
[Gansevoort, Ron T.] Univ Groningen, Univ Med Ctr Groningen, Dept Nephrol, Groningen, Netherlands.
RP Coresh, J (reprint author), Chron Kidney Dis Prognosis Consortium Data Coordi, 615 Wolfe St, Baltimore, MD 21205 USA.
RI Arnlov, Johan/N-9886-2013; Schottker, Ben/F-8183-2014; Wetzels,
Jack/A-1720-2014; Kronenberg, Florian/B-1736-2008; Brenner,
Hermann/B-4627-2017
OI Schottker, Ben/0000-0002-1217-4521; Kronenberg,
Florian/0000-0003-2229-1120; Brenner, Hermann/0000-0002-6129-1572;
Klein, Ronald/0000-0002-4428-6237; Townend, Jonathan/0000-0002-5881-5806
FU National Kidney Foundation
FX Funded by the National Kidney Foundation and others.
NR 52
TC 225
Z9 240
U1 4
U2 29
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD SEP 5
PY 2013
VL 369
IS 10
BP 932
EP 943
DI 10.1056/NEJMoa1214234
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA 211KV
UT WOS:000323906900010
PM 24004120
ER
PT J
AU Peng, ZC
Zhang, NH
Wei, WZ
Huang, CS
Cetina, Y
Otis, TS
Houser, CR
AF Peng, Zechun
Zhang, Nianhui
Wei, Weizheng
Huang, Christine S.
Cetina, Yliana
Otis, Thomas S.
Houser, Carolyn R.
TI A Reorganized GABAergic Circuit in a Model of Epilepsy: Evidence from
Optogenetic Labeling and Stimulation of Somatostatin Interneurons
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID TEMPORAL-LOBE EPILEPSY; KAINATE-TREATED RATS; SPONTANEOUS RECURRENT
SEIZURES; FIBER SYNAPTIC REORGANIZATION; PILOCARPINE-INDUCED SEIZURES;
CA1 PYRAMIDAL CELLS; DENTATE GYRUS; MOUSE MODEL; GRANULE CELLS;
FASCIA-DENTATA
AB Axonal sprouting of excitatory neurons is frequently observed in temporal lobe epilepsy, but the extent to which inhibitory interneurons undergo similar axonal reorganization remains unclear. The goal of this study was to determine whether somatostatin (SOM)-expressing neurons in stratum (s.) oriens of the hippocampus exhibit axonal sprouting beyond their normal territory and innervate granule cells of the dentate gyrus in a pilocarpine model of epilepsy. To obtain selective labeling of SOM-expressing neurons in s. oriens, a Cre recombinase-dependent construct for channelrhodopsin2 fused to enhanced yellow fluorescent protein (ChR2-eYFP) was virally delivered to this region in SOM-Cre mice. In control mice, labeled axons were restricted primarily to s. lacunosum-moleculare. However, in pilocarpine-treated animals, a rich plexus of ChR2-eYFP-labeled fibers and boutons extended into the dentate molecular layer. Electron microscopy with immunogold labeling demonstrated labeled axon terminals that formed symmetric synapses on dendritic profiles in this region, consistent with innervation of granule cells. Patterned illumination of ChR2-labeled fibers in s. lacunosum-moleculare of CA1 and the dentate molecular layer elicited GABAergic inhibitory responses in dentate granule cells in pilocarpine-treated mice but not in controls. Similar optical stimulation in the dentate hilus evoked no significant responses in granule cells of either group of mice. These findings indicate that under pathological conditions, SOM/GABAergic neurons can undergo substantial axonal reorganization beyond their normal territory and establish aberrant synaptic connections. Such reorganized circuitry could contribute to functional deficits in inhibition in epilepsy, despite the presence of numerous GABAergic terminals in the region.
C1 [Peng, Zechun; Zhang, Nianhui; Huang, Christine S.; Cetina, Yliana; Otis, Thomas S.; Houser, Carolyn R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA.
[Wei, Weizheng] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
[Otis, Thomas S.; Houser, Carolyn R.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA.
Vet Adm Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA.
RP Houser, CR (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, CHS 73-235,10833 Le Conte Ave, Los Angeles, CA 90095 USA.
EM houser@mednet.ucla.edu
FU National Institutes of Health [NS075245, RR029267, NS068408]; Veterans
Affairs Medical Research Funds
FX This work was supported by National Institutes of Health Grants NS075245
(C. R. H.), RR029267 (T.S.O.), and NS068408 (T.S.O.) and Veterans
Affairs Medical Research Funds (C. R. H.). We gratefully acknowledge Dr.
Karl Deisseroth for making reagents available through Addgene and the
Penn Vector Core in the School of Medicine Gene Therapy Program at the
University of Pennsylvania for preparation of the viral vector. We thank
Dr. Istvan Mody for helpful discussions.
NR 61
TC 31
Z9 31
U1 1
U2 28
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD SEP 4
PY 2013
VL 33
IS 36
BP 14392
EP 14405
DI 10.1523/JNEUROSCI.2045-13.2013
PG 14
WC Neurosciences
SC Neurosciences & Neurology
GA 214VQ
UT WOS:000324165500013
PM 24005292
ER
PT J
AU Castiblanco, J
Arcos-Burgos, M
Anaya, JM
AF Castiblanco, John
Arcos-Burgos, Mauricio
Anaya, Juan-Manuel
TI What is next after the genes for autoimmunity?
SO BMC MEDICINE
LA English
DT Review
DE Autoimmunity; Common; Genetics; Genomics; Personalized; Predictive
medicine; Polyautoimmunity; Translational medicine
ID GENOME-WIDE ASSOCIATION; DISEASE GENETICS; MEDICINE; MECHANISMS;
BIOINFORMATICS; HERITABILITY; ENVIRONMENT; MICROBIOME; EXPRESSION;
DISORDERS
AB Clinical pathologies draw us to envisage disease as either an independent entity or a diverse set of traits governed by common physiopathological mechanisms, prompted by environmental assaults throughout life. Autoimmune diseases are not an exception, given they represent a diverse collection of diseases in terms of their demographic profile and primary clinical manifestations. Although they are pleiotropic outcomes of non-specific disease genes underlying similar immunogenetic mechanisms, research generally focuses on a single disease. Drastic technologic advances are leading research to organize clinical genomic multidisciplinary approaches to decipher the nature of human biological systems. Once the currently costly omic-based technologies become universally accessible, the way will be paved for a cleaner picture to risk quantification, prevention, prognosis and diagnosis, allowing us to clearly define better phenotypes always ensuring the integrity of the individuals studied. However, making accurate predictions for most autoimmune diseases is an ambitious challenge, since the understanding of these pathologies is far from complete. Herein, some pitfalls and challenges of the genetics of autoimmune diseases are reviewed, and an approximation to the future of research in this field is presented.
C1 [Castiblanco, John; Anaya, Juan-Manuel] Univ Rosario, Ctr Autoimmune Dis Res CREA, Sch Med & Hlth Sci, Bogota, Colombia.
[Castiblanco, John] Univ Rosario, Doctoral Program Biomed Sci, Bogota, Colombia.
[Castiblanco, John] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, Ctr Personalized Med, San Antonio, TX 78229 USA.
[Castiblanco, John] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Arcos-Burgos, Mauricio] Australian Natl Univ, John Curtin Sch Med Res, Genome Biol Dept, ANU Coll Med Biol & Environm, Canberra, ACT 2601, Australia.
RP Anaya, JM (reprint author), Univ Rosario, Ctr Autoimmune Dis Res CREA, Sch Med & Hlth Sci, Carrera 24 63-C-69, Bogota, Colombia.
EM juan.anaya@urosario.edu.co
RI CASTIBLANCO, JOHN/B-6599-2009; Anaya, Juan-Manuel/J-1960-2016
OI CASTIBLANCO, JOHN/0000-0002-7965-9822; Anaya,
Juan-Manuel/0000-0002-6444-1249; Universidad del Rosario,
Biblioteca/0000-0003-3491-9392
FU Universidad del Rosario; Colciencias, Bogota, Colombia [122254531722]
FX This work was supported by Universidad del Rosario and Colciencias
(122254531722), Bogota, Colombia.
NR 60
TC 10
Z9 10
U1 0
U2 19
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1741-7015
J9 BMC MED
JI BMC Med.
PD SEP 4
PY 2013
VL 11
AR 197
DI 10.1186/1741-7015-11-197
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 211KM
UT WOS:000323905900001
PM 24107170
ER
PT J
AU Deswal, A
Basra, SS
AF Deswal, Anita
Basra, Sukhdeep S.
TI Incident Cancer in Patients With Heart Failure Causation or Mere
Association?
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Editorial Material
DE cancer; epidemiology; follow-up studies; heart failure; risk
C1 [Deswal, Anita] Michael E DeBakey VAMC, Sect Cardiol, Houston, TX USA.
[Deswal, Anita; Basra, Sukhdeep S.] Baylor Coll Med, Cardiol Sect, Houston, TX 77030 USA.
RP Deswal, A (reprint author), Michael E DeBakey VA Med Ctr 111B, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM adeswal@bcm.edu
NR 10
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD SEP 3
PY 2013
VL 62
IS 10
BP 887
EP 888
DI 10.1016/j.jacc.2013.04.087
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 211IO
UT WOS:000323900300006
PM 23810872
ER
PT J
AU Beach, MC
Roter, D
Korthuis, PT
Epstein, RM
Sharp, V
Ratanawongsa, N
Cohn, J
Eggly, S
Sankar, A
Moore, RD
Saha, S
AF Beach, Mary Catherine
Roter, Debra
Korthuis, P. Todd
Epstein, Ronald M.
Sharp, Victoria
Ratanawongsa, Neda
Cohn, Jonathon
Eggly, Susan
Sankar, Andrea
Moore, Richard D.
Saha, Somnath
TI A Multicenter Study of Physician Mindfulness and Health Care Quality
SO ANNALS OF FAMILY MEDICINE
LA English
DT Article
DE patient-physician relations; patient-physician communication;
mindfulness; HIV; acquired immunodeficiency syndrome
ID PATIENT-PROVIDER COMMUNICATION; STRESS REDUCTION; CLINICAL-PRACTICE;
MEDICAL-STUDENTS; HIV; SATISFACTION; PROGRAM; PARTICIPATION;
CENTEREDNESS; ADHERENCE
AB PURPOSE Mindfulness (ie, purposeful and nonjudgmental attentiveness to one's own experience, thoughts, and feelings) is associated with physician well-being. We sought to assess whether clinician self-rated mindfulness is associated with the quality of patient care.
METHODS We conducted an observational study of 45 clinicians (34 physicians, 8 nurse practitioners, and 3 physician assistants) caring for patients infected with the human immunodeficiency virus (HIV) who completed the Mindful Attention Awareness Scale and 437 HIV-infected patients at 4 HIV specialty clinic sites across the United States. We measured patient-clinician communication quality with audio-recorded encounters coded using the Roter Interaction Analysis System (RIAS) and patient ratings of care.
RESULTS In adjusted analyses comparing clinicians with highest and lowest tertile mindfulness scores, patient visits with high-mindfulness clinicians were more likely to be characterized by a patient-centered pattern of communication (adjusted odds ratio of a patient-centered visit was 4.14; 95% CI, 1.58-10.86), in which both patients and clinicians engaged in more rapport building and discussion of psychosocial issues. Clinicians with high-mindfulness scores also displayed more positive emotional tone with patients (adjusted beta = 1.17; 95% CI, 0.46-1.9). Patients were more likely to give high ratings on clinician communication (adjusted prevalence ratio [APR] = 1.48; 95% CI, 1.17-1.86) and to report high overall satisfaction (APR = 1.45; 95 CI, 1.15-1.84) with high-mindfulness clinicians. There was no association between clinician mindfulness and the amount of conversation about biomedical issues.
CONCLUSIONS Clinicians rating themselves as more mindful engage in more patient-centered communication and have more satisfied patients. Interventions should determine whether improving clinician mindfulness can also improve patient health outcomes.
C1 [Beach, Mary Catherine; Roter, Debra; Moore, Richard D.] Johns Hopkins Univ, Baltimore, MD USA.
[Korthuis, P. Todd; Saha, Somnath] Oregon Hlth & Sci Univ, Portland, OR USA.
[Epstein, Ronald M.] Univ Rochester, Rochester, NY USA.
[Sharp, Victoria] St Lukes Roosevelt Hosp, New York, NY USA.
[Ratanawongsa, Neda] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Cohn, Jonathon; Eggly, Susan; Sankar, Andrea] Wayne State Univ, Detroit, MI USA.
[Saha, Somnath] Portland VA Med Ctr, Portland, OR USA.
RP Beach, MC (reprint author), Johns Hopkins Univ, Div Gen Internal Med, Room 2-511,2024 East Monument St, Baltimore, MD 21287 USA.
EM mcbeach@jhmi.edu
RI Roter, Debra/N-8830-2014
OI Eggly, Susan/0000-0002-8137-6098
FU Health Resources Service Administration; Agency for Healthcare Research
and Quality [AHRQ 290-01-0012, K08 HS013903-05]; National Institute of
Drug Abuse [K23 DA019809]; Department of Veterans Affairs; Robert Wood
Johnson Generalist Physician Faculty Scholars Awards
FX This research was supported by a contract from the Health Resources
Service Administration and the Agency for Healthcare Research and
Quality (AHRQ 290-01-0012). In addition, Dr Korthuis was supported by
the National Institute of Drug Abuse (K23 DA019809), Dr Saha was
supported by the Department of Veterans Affairs, Dr Beach was supported
by the Agency for Healthcare Research and Quality (K08 HS013903-05), and
both Drs Beach and Saha were supported by Robert Wood Johnson Generalist
Physician Faculty Scholars Awards.
NR 39
TC 34
Z9 34
U1 3
U2 11
PU ANNALS FAMILY MEDICINE
PI LEAWOOD
PA 11400 TOMAHAWK CREEK PARKWAY, LEAWOOD, KS 66211-2672 USA
SN 1544-1709
EI 1544-1717
J9 ANN FAM MED
JI Ann. Fam. Med.
PD SEP-OCT
PY 2013
VL 11
IS 5
BP 421
EP 428
DI 10.1370/afm.1507
PG 8
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA AI3XN
UT WOS:000336799100006
PM 24019273
ER
PT J
AU Dadu, RT
Dodge, R
Nambi, V
Virani, SS
Hoogeveen, RC
Smith, NL
Chen, FJ
Pankow, JS
Guild, C
Tang, WHW
Boerwinkle, E
Hazen, SL
Ballantyne, CM
AF Dadu, Razvan T.
Dodge, Rhiannon
Nambi, Vijay
Virani, Salim S.
Hoogeveen, Ron C.
Smith, Nicholas L.
Chen, Fengju
Pankow, James S.
Guild, Cameron
Tang, W. H. Wilson
Boerwinkle, Eric
Hazen, Stanley L.
Ballantyne, Christie M.
TI Ceruloplasmin and Heart Failure in the Atherosclerosis Risk in
Communities Study
SO CIRCULATION-HEART FAILURE
LA English
DT Article
DE cardiovascular diseases; ceruloplasmin; heart failure; polymorphism;
single nucleotide
ID SENSITIVE PLASMA-PROTEINS; ACUTE-PHASE PROTEINS; C-REACTIVE PROTEIN;
MYOCARDIAL-INFARCTION; SERUM CERULOPLASMIN; CARDIOVASCULAR RISK;
OXIDATIVE STRESS; NITRIC-OXIDE; DISEASE; ASSOCIATION
AB Background Ceruloplasmin (Cp) decreases nitric oxide bioavailability in blood and has been associated with cardiovascular disease (CVD) in clinical studies. We assessed the associations between Cp and incident heart failure (HF), death, and CVD in the Atherosclerosis Risk in Communities (ARIC) study.
Methods and Results Cp was measured at ARIC visit 4 (1996-1998). We studied 9240 individuals without HF or CVD at ARIC visit 4 and followed them for a mean of 10.5 years. Genome-wide association study was performed to identify genetic determinants of Cp levels and evaluate their association with incident HF in ARIC participants. Cp levels (meanSD) were higher in women versus men (335 +/- 79 versus 258 +/- 44 mg/L; P<0.0001), women on versus not on hormone-replacement therapy (398 +/- 89 versus 291 +/- 60 mg/L; P<0.0001), and African Americans versus whites (299 +/- 63 versus 293 +/- 74 mg/L; P=0.0005). After adjusting for traditional risk factors, high-sensitivity C-reactive protein, N-terminal pro-B-type natriuretic peptide, and high-sensitivity cardiac troponin T, higher levels of Cp were associated with HF (hazard ratio, 1.44; 95% confidence interval, 1.13-1.83) and mortality (hazard ratio, 1.38; 95% confidence interval, 1.11-1.63). A locus on the ceruloplasmin gene on chromosome 3 was significantly associated with Cp levels (normal 295.56 +/- 77.60 mg/L; heterozygote 316.72 +/- 88.02 mg/L; homozygote 331.04 +/- 85.40 mg/L; P=8.3x10(-13)) but not with incident HF. After adjustment for traditional risk factors, Cp levels were also weekly associated with CVD.
Conclusions Cp was associated with incident HF, mortality, and CVD in the ARIC population. A single locus on chromosome 3 was associated with Cp levels but not with HF.
C1 [Dadu, Razvan T.; Nambi, Vijay; Virani, Salim S.; Hoogeveen, Ron C.; Ballantyne, Christie M.] Baylor Coll Med, Dept Med, Sect Cardiovasc Res, Houston, TX 77030 USA.
[Virani, Salim S.] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA.
[Ballantyne, Christie M.] Baylor Coll Med, Dept Med, Cardiol Sect, Houston, TX 77030 USA.
[Dadu, Razvan T.; Nambi, Vijay; Virani, Salim S.; Hoogeveen, Ron C.; Ballantyne, Christie M.] Methodist DeBakey Heart & Vasc Ctr, Ctr Cardiovasc Dis Prevent, Houston, TX USA.
[Dodge, Rhiannon; Chen, Fengju; Boerwinkle, Eric] Univ Texas Hlth Sci Ctr Houston, Ctr Human Genet, Houston, TX 77030 USA.
[Virani, Salim S.] Michael E DeBakey VA Med Ctr Hlth Serv, Res & Dev Ctr Excellence, Hlth Policy & Qual Program, Houston, TX USA.
[Pankow, James S.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA.
[Guild, Cameron] Univ Mississippi, Med Ctr, Div Cardiovasc Dis, Jackson, MS 39216 USA.
[Tang, W. H. Wilson; Hazen, Stanley L.] Cleveland Clin Fdn, Cleveland, OH USA.
[Smith, Nicholas L.] Univ Washington, Dept Cardiovasc Res, Seattle, WA 98195 USA.
RP Ballantyne, CM (reprint author), Baylor Coll Med, 6565 Fannin St,MS A601, Houston, TX 77030 USA.
EM cmb@bcm.edu
OI Virani, Salim/0000-0001-9541-6954; Pankow, James/0000-0001-7076-483X
FU National Heart, Lung, and Blood Institute [HHSN268201100005C,
HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN26820110
0009C, HHSN268201100010C, HHSN268201100011C, HHSN 268201100012C,
R01HL087641, R01HL59367, R01HL 086694]; National Human Genome Research
Institute [U01HG004402]; National Institutes of Health (NIH)
[HHSN268200625226C]; NIH [UL1RR025005, 2P01HL076491, 1R01HL103931]; NIH
Roadmap for Medical Research
FX The Atherosclerosis Risk in Communities study is performed as a
collaborative study supported by National Heart, Lung, and Blood
Institute contracts (HHSN268201100005C, HHSN268201100006C,
HHSN268201100007C, HHSN268201100008C, HHSN26820110 0009C,
HHSN268201100010C, HHSN268201100011C, and HHSN 268201100012C),
R01HL087641, R01HL59367, and R01HL 086694; National Human Genome
Research Institute contract U01HG004402; and National Institutes of
Health (NIH) contract HHSN268200625226C. Infrastructure was partly
supported by Grant Number UL1RR025005, a component of the NIH and NIH
Roadmap for Medical Research. This work was also supported by NIH grants
2P01HL076491 (Dr Hazen) and 1R01HL103931 (Dr Tang).
NR 29
TC 12
Z9 13
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-3289
EI 1941-3297
J9 CIRC-HEART FAIL
JI Circ.-Heart Fail.
PD SEP
PY 2013
VL 6
IS 5
BP 936
EP 943
DI 10.1161/CIRCHEARTFAILURE.113.000270
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AG2GO
UT WOS:000335234500012
PM 23861484
ER
PT J
AU Homma, S
Thompson, JLP
Sanford, AR
Mann, DL
Sacco, RL
Levin, B
Pullicino, PM
Freudenberger, RS
Teerlink, JR
Graham, S
Mohr, JP
Massie, BM
Labovitz, AJ
Di Tullio, MR
Gabriel, AP
Lip, GYH
Estol, CJ
Lok, DJ
Ponikowski, P
Anker, SD
AF Homma, Shunichi
Thompson, John L. P.
Sanford, Alexandra R.
Mann, Douglas L.
Sacco, Ralph L.
Levin, Bruce
Pullicino, Patrick M.
Freudenberger, Ronald S.
Teerlink, John R.
Graham, Susan
Mohr, J. P.
Massie, Barry M.
Labovitz, Arthur J.
Di Tullio, Marco R.
Gabriel, Andre P.
Lip, Gregory Y. H.
Estol, Conrado J.
Lok, Dirk J.
Ponikowski, Piotr
Anker, Stefan D.
CA WARCEF Investigators
TI Benefit of Warfarin Compared With Aspirin in Patients With Heart Failure
in Sinus Rhythm A Subgroup Analysis of WARCEF, a Randomized Controlled
Trial
SO CIRCULATION-HEART FAILURE
LA English
DT Article
DE aspirin; heart failure; sinus rhythm; stroke; warfarin
ID ATRIAL-FIBRILLATION; SURVIVAL; THERAPY; DISEASE; STROKE
AB Background The Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial found no difference in the primary outcome between warfarin and aspirin in 2305 patients with reduced left ventricular ejection fraction in sinus rhythm. However, it is unknown whether any subgroups benefit from warfarin or aspirin.
Methods and Results We used a Cox model stepwise selection procedure to identify subgroups that may benefit from warfarin or aspirin on the WARCEF primary outcome. A secondary analysis added major hemorrhage to the outcome. The primary efficacy outcome was time to the first to occur of ischemic stroke, intracerebral hemorrhage, or death. Only age group was a significant treatment effect modifier (P for interaction, 0.003). Younger patients benefited from warfarin over aspirin on the primary outcome (4.81 versus 6.76 events per 100 patient-years: hazard ratio, 0.63; 95% confidence interval, 0.48-0.84; P=0.001). In older patients, therapies did not differ (9.91 versus 9.01 events per 100 patient-years: hazard ratio, 1.09; 95% confidence interval, 0.88-1.35; P=0.44). With major hemorrhage added, in younger patients the event rate remained lower for warfarin than aspirin (5.41 versus 7.25 per 100 patient-years: hazard ratio, 0.68; 95% confidence interval, 0.52-0.89; P=0.005), but in older patients it became significantly higher for warfarin (11.80 versus 9.35 per 100 patient-years: hazard ratio, 1.25; 95% confidence interval, 1.02-1.53; P=0.03).
Conclusions In patients <60 years, warfarin improved outcomes over aspirin with or without inclusion of major hemorrhage. In patients 60 years, there was no treatment difference, but the aspirin group had significantly better outcomes when major hemorrhage was included.
Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT00041938.
C1 [Homma, Shunichi; Di Tullio, Marco R.; Gabriel, Andre P.] Columbia Univ, Med Ctr, Dept Med, Div Cardiol, New York, NY 10032 USA.
[Mohr, J. P.] Columbia Univ, Med Ctr, Dept Neurol, New York, NY 10032 USA.
[Thompson, John L. P.; Sanford, Alexandra R.; Levin, Bruce] Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, New York, NY 10032 USA.
[Mann, Douglas L.] Washington Univ, Dept Med, St Louis, MO USA.
[Sacco, Ralph L.] Univ Miami, Miller Sch Med, Dept Neurol, Coral Gables, FL 33124 USA.
[Pullicino, Patrick M.] Univ Kent, Kent Inst Med & Hlth Sci, Canterbury, Kent, England.
[Freudenberger, Ronald S.] Lehigh Valley Hosp, Dept Med, Div Cardiol, Allentown, PA USA.
[Teerlink, John R.; Massie, Barry M.] Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Med, Cardiol Sect, San Francisco, CA USA.
[Graham, Susan] SUNY Upstate Med Univ, Dept Med, Div Cardiol, Buffalo, NY USA.
[Labovitz, Arthur J.] Univ S Florida, Dept Cardiovasc Med, Tampa, FL USA.
[Lip, Gregory Y. H.] Univ Birmingham, City Hosp, Ctr Cardiovasc Sci, Birmingham, W Midlands, England.
[Estol, Conrado J.] Ctr Neurol Tratamiento & Rehabil, Buenos Aires, DF, Argentina.
[Lok, Dirk J.] Deventer Hosp, Dept Cardiol, Deventer, Netherlands.
[Ponikowski, Piotr] Wroclaw Med Univ, Mil Hosp, Dept Heart Dis, Wroclaw, Poland.
[Anker, Stefan D.] Charite, Campus Virchow Klinikum, Dept Cardiol, D-13353 Berlin, Germany.
RP Homma, S (reprint author), Columbia Univ, Med Ctr, PH 3-342,622 W 168th St, New York, NY 10032 USA.
EM sh23@columbia.edu
RI Ponikowski, Piotr/O-6454-2015
OI Ponikowski, Piotr/0000-0002-3391-7064; Mann, Douglas
/0000-0002-2516-0145
FU National Institute of Neurological Diseases and Stroke [U01-NS-043975,
U01-NS-039143]
FX The WARCEF trial was supported by grant nos. U01-NS-043975 to Dr Homma
and U01-NS-039143 to Dr Thompson from the National Institute of
Neurological Diseases and Stroke. Warfarin and warfarin placebo were
provided by Taro Pharmaceuticals USA, and aspirin and aspirin placebo by
Bayer HealthCare.
NR 21
TC 13
Z9 15
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-3289
EI 1941-3297
J9 CIRC-HEART FAIL
JI Circ.-Heart Fail.
PD SEP
PY 2013
VL 6
IS 5
BP 988
EP 997
DI 10.1161/CIRCHEARTFAILURE.113.000372
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AG2GO
UT WOS:000335234500018
PM 23881846
ER
PT J
AU Platt, AB
Wick, LC
Hurley, S
Soto-Calderon, H
Wieland, W
Staley, B
Maislin, G
Gurubhagavatula, I
AF Platt, Alec B.
Wick, Lindsay C.
Hurley, Sharon
Soto-Calderon, Haideliza
Wieland, Will
Staley, Beth
Maislin, Greg
Gurubhagavatula, Indira
TI Hits and Misses Screening Commercial Drivers for Obstructive Sleep Apnea
Using Guidelines Recommended by a Joint Task Force
SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE
LA English
DT Article
ID MOTOR-VEHICLE CRASH; RISK; METAANALYSIS; ACCIDENTS; DIAGNOSIS; OBESITY;
ADULTS
AB Objective: To evaluate joint task force criteria-based screening for severe obstructive sleep apnea (s-OSA) in commercial drivers. Methods: Among a community-based cohort of licensed commercial vehicle drivers, we assessed utility of the joint task force criteria. We conducted full, 14-channel overnight polysomnography in all drivers, defining s-OSA as an apnea-hypopnea index of 30 or more per hour. Results: One hundred of 104 drivers with successful polysomnography studies were predominantly obese (median body mass index = 32.8 kg/m(2); interquartile range = 26.8 to 37.4) and had a median apnea-hypopnea index of 20.6 per hour (interquartile range = 10.0 to 34.2). Examination-based criteria were more effective (sensitivity = 80%; negative posttest probability [nPTP] = 17%) than symptom-based criteria (sensitivity = 63%; nPTP = 23%). Examination and symptom-based criteria combined had high sensitivity (97%) and low nPTP (7%), but poor specificity (19%). Conclusions: Examination-based criteria missed 20% of s-OSA cases. Combining examination with confidentially reported symptoms improved sensitivity but required confirmatory polysomnography in 86%, supporting universal screening of all drivers.
C1 [Platt, Alec B.] Resp Specialists, Wyomissing, PA USA.
[Platt, Alec B.; Gurubhagavatula, Indira] Univ Penn, Perelman Sch Med, Div Sleep Med, Philadelphia, PA 19104 USA.
[Wick, Lindsay C.; Hurley, Sharon; Soto-Calderon, Haideliza; Wieland, Will; Staley, Beth; Maislin, Greg; Gurubhagavatula, Indira] Univ Penn, Med Ctr, Ctr Sleep & Circadian Neurobiol, Philadelphia, PA 19104 USA.
[Gurubhagavatula, Indira] Philadelphia VA Med Ctr, Pulm Crit Care & Sleep Sect, Philadelphia, PA USA.
RP Platt, AB (reprint author), 2608 Keiser Blvd, Wyomissing, PA 19610 USA.
EM alecplatt@gmail.com
FU NIOSH/CDC [R01-OH009149]
FX The study was supported by NIOSH/CDC R01-OH009149. Embla Inc provided an
unrestricted loan of sleep diagnostic equipment.
NR 25
TC 8
Z9 8
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1076-2752
EI 1536-5948
J9 J OCCUP ENVIRON MED
JI J. Occup. Environ. Med.
PD SEP
PY 2013
VL 55
IS 9
BP 1035
EP 1040
DI 10.1097/JOM.0b013e318298fb0e
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 300EY
UT WOS:000330448400007
PM 23969501
ER
PT J
AU Lawson, EH
Hall, BL
Ko, CY
AF Lawson, Elise H.
Hall, Bruce Lee
Ko, Clifford Y.
TI Risk Factors for Superficial vs Deep/Organ-Space Surgical Site
Infections Implications for Quality Improvement Initiatives
SO JAMA SURGERY
LA English
DT Article
ID COLORECTAL SURGERY; WOUND-INFECTION; CARE; MORTALITY; PROGRAM;
HOSPITALIZATION; SURVEILLANCE; ASSOCIATION; RESECTION; COLON
AB IMPORTANCE Surgical site infections (SSIs) are the focus of numerous quality improvement initiatives because they are a common and costly cause of potentially preventable patient morbidity. Superficial and deep/organ-space SSIs differ in terms of anatomical location and clinical severity.
OBJECTIVE To identify risk factors that are uniquely predictive of superficial vs deep/organ-space SSIs occurring after colectomy procedures.
DESIGN Retrospective cohort study.
SETTING American College of Surgeons National Surgical Quality Improvement Program.
PARTICIPANTS Patients undergoing colectomy procedures in 2011 were identified by Current Procedural Terminology codes.
INTERVENTION Colectomy procedures.
MAIN OUTCOMES AND MEASURES We compared rates of superficial SSI and deep/organ-space SSI associated with perioperative variables of interest: demographics; preoperative clinical severity, risk factors, and comorbidities and variables related to the hospitalization or procedure. Hierarchical multivariable logistic regression models were developed to identify risk-adjusted predictors of each SSI type.
RESULTS Among 27 011 patients identified from 305 hospitals, 6.2% developed a superficial SSI and 4.7% developed a deep/organ-space SSI. Risk factors common to the occurrence of both SSI types were identified: open surgery (vs laparoscopic) and current smoker. Risk factors with differential effects on each SSI type included specific postoperative diagnoses, disseminated cancer, and irradiation therapy, which were all associated with increased odds of deep/organ-space SSI only. The graded relationship between increasing body mass index and SSI occurrence appeared to be stronger for superficial SSI.
CONCLUSIONS AND RELEVANCE Risk factors for superficial SSI and deep/organ-space SSI vary in terms of magnitude and significance, suggesting that these SSI types are somewhat different disease processes. Groups interested in preventing SSIs might improve success by considering these SSI types independently for root-cause analyses and development of best practices and interventions.
C1 [Lawson, Elise H.; Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA.
[Hall, Bruce Lee] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA.
[Hall, Bruce Lee] Barnes Jewish Hosp, St Louis, MO 63110 USA.
[Hall, Bruce Lee] St Louis Vet Affairs Med Ctr, Ctr Hlth Policy, St Louis, MO USA.
[Hall, Bruce Lee] Washington Univ, John M Olin Sch Business, St Louis, MO 63130 USA.
[Hall, Bruce Lee; Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA.
[Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Lawson, EH (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, 10833 Le Conte Ave,72-215 CHS, Los Angeles, CA 90095 USA.
EM elawson@mednet.ucla.edu
FU VA Health Services Research and Development program grant [RWJ 65-020];
ACS through the Robert Wood Johnson Foundation Clinical Scholars Program
FX Dr Lawson's time was supported by VA Health Services Research and
Development program grant RWJ 65-020 and the ACS through the Robert Wood
Johnson Foundation Clinical Scholars Program. Dr Hall is a consultant
for the ACS and Dr Ko is staff at the ACS.
NR 30
TC 30
Z9 31
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6254
EI 2168-6262
J9 JAMA SURG
JI JAMA Surg.
PD SEP
PY 2013
VL 148
IS 9
BP 849
EP 858
DI 10.1001/jamasurg.2013.2925
PG 10
WC Surgery
SC Surgery
GA 228TE
UT WOS:000325212300014
PM 23864108
ER
PT J
AU Cook, JM
Pilver, C
Dinnen, S
Schnurr, PP
Hoff, R
AF Cook, Joan M.
Pilver, Corey
Dinnen, Stephanie
Schnurr, Paula P.
Hoff, Rani
TI Prevalence of Physical and Sexual Assault and Mental Health Disorders in
Older Women: Findings From a Nationally Representative Sample
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE Geriatric; interpersonal violence; PTSD; women
ID POSTTRAUMATIC-STRESS-DISORDER; INTIMATE PARTNER VIOLENCE; TRAUMATIC
EVENTS; COMORBIDITY-SURVEY; DOMESTIC VIOLENCE; VERBAL ABUSE;
RISK-FACTORS; ADULTS; POPULATION; IMPACT
AB Objectives: This study presents prevalence and characteristics of physical and sexual assaults, and their relationship to posttraumatic stress disorder (PTSD), and mood and anxiety disorders in a nationally representative sample of older women. Design and Setting: Face-to-face interviews conducted with adult participants from wave 2 of the National Epidemiological Survey on Alcohol and Related Conditions. Participants: A total of 3,354 community-residing women of age 65 years and older. Measurement: Alcohol Use Disorder and Associated Disabilities Interview Schedule for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, current mood and anxiety disorders. Results: Almost 14% of participants reported a history of physical or sexual assault or both during their lifetimes. Assaults were often repeated rather than isolated events. Although the majority of participants did not identify interpersonal violence as their "worst" traumatic event, those who experienced interpersonal violence were generally more likely than those without such history to meet the criteria for past-year and lifetime PTSDs, depression, and anxiety. Conclusions: Some women who have been physically or sexually assaulted decades earlier continue to report significant levels of mood and anxiety disorders into late adulthood. Several ways to increase the identification and treatment of older female trauma survivors by healthcare providers are suggested.
C1 [Cook, Joan M.; Pilver, Corey; Dinnen, Stephanie; Hoff, Rani] Yale Univ, Sch Med, New Haven, CT USA.
[Cook, Joan M.; Schnurr, Paula P.] US Dept Vet Affairs, Natl Ctr PTSD, Washington, DC USA.
[Schnurr, Paula P.] Geisel Sch Med, Dartmouth Med Sch, Hanover, NH USA.
RP Cook, JM (reprint author), Yale Univ, Sch Med, Natl Ctr PTSD, NEPEC 182,950 Campbell Ave, West Haven, CT 06516 USA.
EM Joan.Cook@yale.edu
NR 41
TC 5
Z9 5
U1 7
U2 18
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD SEP
PY 2013
VL 21
IS 9
BP 877
EP 886
DI 10.1016/j.jagp.2013.01.016
PG 10
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 298YW
UT WOS:000330361900009
PM 23567392
ER
PT J
AU Chen, LX
Mao, JJ
Fernandes, S
Galantino, ML
Guo, WS
LaRiccia, P
Teal, VL
Bowman, MA
Schumacher, HR
Farrar, JT
AF Chen, Lan X.
Mao, Jun J.
Fernandes, Shawn
Galantino, Mary Lou
Guo, Wensheng
LaRiccia, Patrick
Teal, Valerie L.
Bowman, Marjorie A.
Schumacher, H. Ralph
Farrar, John T.
TI Integrating Acupuncture With Exercise-Based Physical Therapy for Knee
Osteoarthritis A Randomized Controlled Trial
SO JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
LA English
DT Article
DE acupuncture; physical therapy; osteoarthritis of the knee;
placebo-controlled randomized trial; obese patients; African American
ID CHRONIC PAIN; ALTERNATIVE MEDICINE; CLINICAL IMPORTANCE; PATIENT;
EXPECTATIONS; OUTCOMES; RECOMMENDATIONS; COMPLEMENTARY
AB Background: Knee osteoarthritis is a chronic disease associated with significant morbidity and economic cost. The efficacy of acupuncture in addition to traditional physical therapy has received little study.
Objective: The objective of this study was to compare the efficacy and safety of integrating a standardized true acupuncture protocol versus nonpenetrating acupuncture into exercise-based physical therapy (EPT).
Methods: This was a randomized, double-blind, controlled trial at 3 physical therapy centers in Philadelphia, PA. We studied 214 patients (66% African Americans) with at least 6 months of chronic knee pain and x-ray-confirmed Kellgren scores of 2 or 3. Patients received 12 sessions of acupuncture directly following EPT over 6 to 12 weeks. Acupuncture was performed at the same 9 points dictated by the traditional Chinese "Bi" syndrome approach to knee pain, using either standard needles or Streitberger non-skin-puncturing needles. The primary outcome was the proportion of patients with at least a 36% improvement in Western Ontario and McMaster Universities Osteoarthritis Index score at 12 weeks.
Results: Both treatment groups showed improvement from combined therapy with no difference between true (31.6%) and nonpenetrating acupuncture (30.3%) in Western Ontario and McMaster Universities Osteoarthritis Index response rate (P = 0.5) or report of minor adverse events. A multivariable logistic regression prediction model identified an association between a positive expectation of relief from acupuncture and reported improvement. No differences were noted by race, sex, or age.
Conclusions: Puncturing acupuncture needles did not perform any better than nonpuncturing needles integrated with EPT. Whether EPT, acupuncture, or other factors accounted for any improvement noted in both groups could not be determined in this study. Expectation for relief was a predictor of reported benefit.
C1 [Chen, Lan X.] Univ Penn, Penn Presbyterian Med Ctr, Philadelphia, PA 19104 USA.
[Mao, Jun J.; Fernandes, Shawn; Galantino, Mary Lou; Guo, Wensheng; LaRiccia, Patrick; Teal, Valerie L.; Bowman, Marjorie A.; Farrar, John T.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
[Mao, Jun J.] Univ Penn, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA.
[Galantino, Mary Lou] Univ Penn, Div Rheumatol, Philadelphia, PA 19104 USA.
[Schumacher, H. Ralph] Richard Stockton Coll New Jersey, Program Phys Therapy, Galloway, NJ USA.
[Schumacher, H. Ralph] Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
RP Farrar, JT (reprint author), Univ Penn, Sch Med, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Blockley Hall,Room 816,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM jfarrar@mail.med.upenn.edu
FU National Institutes of Health/National Center for Complementary and
Alternative Medicine (NCCAM) [R01-AT000304]; NCCAM [K23 AT004112]
FX This study is supported by a grant from the National Institutes of
Health/National Center for Complementary and Alternative Medicine
(NCCAM) R01-AT000304. Dr Mao is also supported by NCCAM K23 AT004112.
The funding agency had no role in the design and conduct of this study.
NR 37
TC 10
Z9 11
U1 3
U2 19
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1076-1608
EI 1536-7355
J9 JCR-J CLIN RHEUMATOL
JI JCR-J. Clin. Rheumatol.
PD SEP
PY 2013
VL 19
IS 6
BP 308
EP 316
DI 10.1097/RHU.0b013e3182a21848
PG 9
WC Rheumatology
SC Rheumatology
GA 300KC
UT WOS:000330461800002
PM 23965480
ER
PT J
AU Hawkins, EJ
Malte, CA
Grossbard, J
Saxon, AJ
Imel, ZE
Kivlahan, DR
AF Hawkins, Eric J.
Malte, Carol A.
Grossbard, Joel
Saxon, Andrew J.
Imel, Zac E.
Kivlahan, Daniel R.
TI Comparative Safety of Benzodiazepines and Opioids Among Veterans Affairs
Patients With Posttraumatic Stress Disorder
SO JOURNAL OF ADDICTION MEDICINE
LA English
DT Article
DE Posttraumatic stress disorder; antidepressants; opioids;
benzodiazepines; adverse events
ID PRESCRIPTION OPIOIDS; MILITARY SERVICE; NONCANCER PAIN; METAANALYSIS;
OVERDOSE; PTSD; MORTALITY; PATTERNS; TRENDS; FALLS
AB Objectives: Although Veterans Affairs (VA) patients with posttraumatic stress disorder (PTSD) are prescribed benzodiazepines and opioids in addition to recommended pharmacotherapies, little is known about the safety of these medications. This study compared the 2-year incidence of adverse events among VA patients with PTSD exposed to combinations of selective serotonin reuptake inhibitors (SSRIs) or serotonin/norepinephrine reuptake inhibitors (SNRIs), benzodiazepines, and opioids.
Methods: This retrospective cohort study used VA administrative data from 2004 to 2010 to identify and follow 5236 VA patients with PTSD with new episodes of (1) SSRIs/SNRIs only; (2) concurrent SSRIs/SNRIs and benzodiazepines; and (3) concurrent SSRIs/SNRIs, benzodiazepines, and opioids. Outcome measures were the 2-year incidence and adjusted hazard ratios (AHR) of mental health and medicine/surgery hospitalizations, emergency department visits, harmful events (eg, injuries and death), and any adverse event after adjustment for demographics, clinical covariates, and adverse event history.
Results: Comparedwith SSRIs/SNRIs only, the adjusted risk of mental health hospitalizations (AHR: 1.87; 95% confidence interval [CI]: 1.37-2.53) was greater among patients prescribed SSRIs/SNRIs and benzodiazepines concurrently. The AHR of mental health hospitalizations (AHR: 2.00; 95% CI: 1.35-2.98), medicine/surgery hospitalizations (AHR: 4.86; 95% CI: 3.30-7.14), emergency department visits (AHR: 2.01; 95% CI: 1.53-2.65), any harmful event (2.92; 95% CI: 2.21-3.84), and any adverse event (AHR: 2.65; 95% CI: 2.18-3.23) were all significantly greater among patients prescribed SSRIs/SNRIs, benzodiazepines, and opioids than among those prescribed SSRIs/SNRIs only.
Conclusions: Concurrently prescribing SSRIs/SNRIs, benzodiazepines, and opioids among patients with PTSD is associated with adverse events. Although efforts are warranted to monitor patients who are prescribed combinations of these medications to prevent adverse events, these results should be interpreted with caution until they are replicated.
C1 [Hawkins, Eric J.; Malte, Carol A.; Grossbard, Joel; Kivlahan, Daniel R.] Hlth Serv Res & Dev, Seattle, WA USA.
[Hawkins, Eric J.; Malte, Carol A.; Saxon, Andrew J.; Kivlahan, Daniel R.] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98108 USA.
[Hawkins, Eric J.; Saxon, Andrew J.; Kivlahan, Daniel R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Imel, Zac E.] Univ Utah, Dept Educ Psychol, Salt Lake City, UT 84112 USA.
RP Hawkins, EJ (reprint author), VA Puget Sound Hlth Care Syst, Seattle Div S116ATC, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM Eric.Hawkins@va.gov
OI imel, zachary/0000-0001-9645-7184
FU U.S. Department of Veterans Affairs, Veterans Health Administration;
Center of Excellence in Substance Abuse Treatment and Education
FX This material is based on the work supported by the U.S. Department of
Veterans Affairs, Veterans Health Administration, and Center of
Excellence in Substance Abuse Treatment and Education. Supporting
organizations had no further role in study design; in the collection,
analysis, and interpretation of data; in the writing of the report; or
in the decision to submit the article for publication.
NR 34
TC 1
Z9 1
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1932-0620
EI 1935-3227
J9 J ADDICT MED
JI J. Addict. Med.
PD SEP-OCT
PY 2013
VL 7
IS 5
BP 354
EP 362
DI 10.1097/ADM.0b013e31829e3957
PG 9
WC Substance Abuse
SC Substance Abuse
GA 300KR
UT WOS:000330463300008
PM 24091764
ER
PT J
AU Pompili, M
Sher, L
Serafini, G
Forte, A
Innamorati, M
Dominici, G
Lester, D
Amore, M
Girardi, P
AF Pompili, Maurizio
Sher, Leo
Serafini, Gianluca
Forte, Alberto
Innamorati, Marco
Dominici, Giovanni
Lester, David
Amore, Mario
Girardi, Paolo
TI Posttraumatic Stress Disorder and Suicide Risk Among Veterans A
Literature Review
SO JOURNAL OF NERVOUS AND MENTAL DISEASE
LA English
DT Review
DE Suicidal behavior; PTSD; veterans; risk factors; prevention
ID AFGHANISTAN WAR VETERANS; VIETNAM VETERANS; DEPRESSED-PATIENTS; PTSD;
IDEATION; COMORBIDITY; MILITARY; IRAQ; EXPOSURE; BEHAVIOR
AB Posttraumatic stress disorder (PTSD) is frequently associated with suicidal ideation and suicide attempts. Suicide is an important cause of death in veterans, and the risk for intentional death continues to be high many years after service. The aim of the present study was to investigate whether there is a relationship between PTSD and suicidal behavior among veterans. We also discussed the risk factors of suicide among war veterans with PTSD. A systematic review was conducted focusing on war-related PTSD and suicidal behavior. A total of 80 articles from peer-reviewed journals were identified, 34 were assessed for eligibility, and 16 were included. Having a history of PTSD is associated with higher rates of morbidity and mortality and increased the risk for suicidal behavior. The association between PTSD and suicidal behavior was confirmed by the presence of other risk factors and high rates of comorbidity. Current suicidal behavior should be adequately assessed in war veterans.
C1 [Pompili, Maurizio; Serafini, Gianluca; Forte, Alberto; Innamorati, Marco; Dominici, Giovanni; Girardi, Paolo] Univ Roma La Sapienza, Dept Neurosci Mental Hlth & Sensory Organs, Suicide Prevent Ctr, St Andrea Hosp, I-00185 Rome, Italy.
[Sher, Leo] James J Peters Vet Adm Med Ctr, New York, NY USA.
[Sher, Leo] Mt Sinai Sch Med, New York, NY USA.
[Lester, David] Richard Stockton Coll New Jersey, Galloway, NJ USA.
[Amore, Mario] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Sect Psychiat, Genoa, Italy.
RP Pompili, M (reprint author), Univ Roma La Sapienza, Dept Psychiat, St Andrea Hosp, 1035 Via Grottarossa, I-00189 Rome, Italy.
EM maurizio.pompili@uniroma1.it
OI Pompili, Maurizio/0000-0003-1886-4977
FU Italian Ministry of University Research-PRIN Project
FX This study was supported, in part, by a grant from the Italian Ministry
of University Research-PRIN Project (M. P., G. S., P. G.).
NR 54
TC 30
Z9 31
U1 5
U2 35
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0022-3018
EI 1539-736X
J9 J NERV MENT DIS
JI J. Nerv. Ment. Dis.
PD SEP
PY 2013
VL 201
IS 9
BP 802
EP 812
DI 10.1097/NMD.0b013e3182a21458
PG 11
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 299DM
UT WOS:000330375300012
PM 23995037
ER
PT J
AU McNichol, L
Lund, C
Rosen, T
Gray, M
AF McNichol, Laurie
Lund, Carolyn
Rosen, Ted
Gray, Mikel
TI Medical Adhesives and Patient Safety: State of the Science Consensus
Statements for the Assessment, Prevention, and Treatment of
Adhesive-Related Skin Injuries
SO ORTHOPAEDIC NURSING
LA English
DT Reprint
ID TAPE; INFECTION; OUTBREAK; BACTERIA; ZYGOMYCOSIS
AB Skin injury related to medical adhesive usage is a prevalent but underrecognized complication that occurs across all care settings and among all age groups. If proper technique for application and/or removal of adhesive products is not used, tissue trauma can occur, impacting patient safety and quality of life and increasing healthcare costs. Little guidance exists in the literature regarding appropriate selection and proper use of adhesive products to minimize medical adhesive-related skin injury, as well as best practices for skin care preventive strategies, application and removal techniques, and assessment and treatment of such injuries. In an effort to define best practices for prevention of such injury, a consensus panel of 23 recognized key opinion leaders convened to establish consensus statements on the assessment, prevention, and treatment of medical adhesive-related skin injury. The consensus summit was held in December 2012 and was made possible by an unrestricted educational grant from 3M. This document details the consensus definitions and statements and identifies research priorities for development of new adhesive technologies and protocols for skin protection. KEY WORDS: Bandages, Dressings, Medical adhesive, Skin integrity, Skin stripping, Skin tear, Surgical tape
C1 [McNichol, Laurie] Cone Hlth Syst, Greensboro, NC USA.
[Lund, Carolyn] Childrens Hosp, Oakland, CA 94609 USA.
[Lund, Carolyn] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA.
[Rosen, Ted] Baylor Coll Med, Houston, TX 77030 USA.
[Rosen, Ted] Houston Vet Affairs Med Ctr, Houston, TX USA.
[Gray, Mikel] Univ Virginia, Charlottesville, VA 22908 USA.
RP Gray, M (reprint author), Univ Virginia, Dept Urol, POB 800422, Charlottesville, VA 22908 USA.
EM MG5K@hscmail.mcc.virginia.edu
NR 79
TC 2
Z9 2
U1 2
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0744-6020
EI 1538-8654
J9 ORTHOP NURS
JI Orthop. Nurs.
PD SEP-OCT
PY 2013
VL 32
IS 5
BP 267
EP 281
DI 10.1097/NOR.0b013e3182a39caf
PG 15
WC Nursing; Orthopedics
SC Nursing; Orthopedics
GA 298VA
UT WOS:000330351400007
PM 24022422
ER
PT J
AU Sarraf, D
Chan, C
Rahimy, E
Abraham, P
AF Sarraf, David
Chan, Clement
Rahimy, Ehsan
Abraham, Prema
TI PROSPECTIVE EVALUATION OF THE INCIDENCE AND RISK FACTORS FOR THE
DEVELOPMENT OF RPE TEARS AFTER HIGH- AND LOW-DOSE RANIBIZUMAB THERAPY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; antivascular endothelial growth
factor; ranibizumab; retinal pigment epithelial tears; vascularized
pigment epithelial detachment
ID PIGMENT EPITHELIAL TEAR; INTRAVITREAL BEVACIZUMAB INJECTION; OPTICAL
COHERENCE TOMOGRAPHY; CHOROIDAL NEOVASCULARIZATION SECONDARY;
PROLIFERATIVE DIABETIC-RETINOPATHY; MACULAR DEGENERATION;
CLINICOPATHOLOGICAL CORRELATION; RETINAL-DETACHMENT; AVASTIN;
PATHOGENESIS
AB Purpose: To prospectively determine the incidence and risk factors for retinal pigment epithelial (RPE) tears in eyes with vascularized pigment epithelial detachments (PED) and exudative age-related macular degeneration receiving antivascular endothelial growth factor therapy.
Methods: Eyes were prospectively randomized into 1 of 4 arms: 1) 0.5 mg of ranibizumab monthly for 12 months; 2) 0.5 mg of ranibizumab monthly for 3 months and then pro re nata on the basis of clinical and optical coherence tomography-guided indications; 3) high-dose 2.0 mg of ranibizumab monthly for 12 months; or 4) 2.0 mg of ranibizumab monthly for 3 months and then pro re nata thereafter. All PEDs were measured for height, greatest linear diameter, and surface area at baseline. The incidence of RPE tears in the entire 4-arm cohort was determined at the end of 12 months. Eyes were divided into two groups (tear vs. nontear) and statistically compared to determine risk factors for the development of RPE tear.
Results: Of 37 eyes, a total of 5 developed postranibizumab RPE tears during the course of the study (incidence 14%). Four of the 5 tears occurred in the high-dose 2.0-mg groups. Baseline PED height, surface area, and greatest linear diameter were significantly greater in the group that developed RPE tears versus the nontear group (P = 0.018, 0.031, and 0.048, respectively). There were significantly more eyes with PED height >550 microns in the RPE tear group (4 of 5, 80%) compared with the nontear group (9 of 32, 18%) (P = 0.042). The presence of PED height >550 microns was associated with an increased tear rate from 14% to 31%. Furthermore, retrospective identification of a ring sign or Grade 1 tear at baseline, in addition to PED height >550 microns, was associated with a further increase in the tear rate to 67%.
Conclusion: In this study, the prospective incidence of RPE tears was similar to 14%. A baseline PED height >550 microns and presence of a Grade 1 tear, or positive ring sign, were identified as high-risk factors for the subsequent development of an RPE tear.
C1 [Sarraf, David; Rahimy, Ehsan] Univ Calif Los Angeles, Jules Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, Los Angeles, CA 90095 USA.
[Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA.
[Chan, Clement] Southern Calif Desert Retina Consultants, Med Grp, Palm Desert, CA USA.
[Chan, Clement] Loma Linda Univ, Dept Ophthalmol, Loma Linda, CA 92350 USA.
[Abraham, Prema] Black Hills Reg Eye Inst, Rapid City, SD USA.
RP Sarraf, D (reprint author), Univ Calif Los Angeles, Jules Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, 100 Stein Plaza, Los Angeles, CA 90095 USA.
EM dsarraf@ucla.edu
FU Genentech; Karl Kirchgessner Foundation at the Jules Stein Eye Institute
FX Supported by an Investigator-Supported Trial grant from Genentech and by
a grant (D. S.) from the Karl Kirchgessner Foundation at the Jules Stein
Eye Institute.
NR 51
TC 19
Z9 19
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2013
VL 33
IS 8
BP 1551
EP 1557
PG 7
WC Ophthalmology
SC Ophthalmology
GA 297CP
UT WOS:000330233200009
PM 23652578
ER
PT J
AU Dion, GR
Weitzel, EK
McMains, KC
AF Dion, Gregory Robert
Weitzel, Erik K.
McMains, Kevin C.
TI Current Approaches to Diagnosis and Management of Rhinitis
SO SOUTHERN MEDICAL JOURNAL
LA English
DT Review
DE allergic rhinitis; infectious rhinitis; nasal airway obstruction;
nonallergic rhinitis; nonallergic rhinitis with eosinophilia syndrome;
rhinitis; vasomotor rhinitis
ID AZELASTINE NASAL SPRAY; ALLERGIC RHINITIS; NONALLERGIC RHINITIS;
SUBLINGUAL IMMUNOTHERAPY; GUSTATORY RHINITIS; ATOPIC MARCH; ASTHMA;
MEDICAMENTOSA; SWIMMERS; EFFICACY
AB Rhinitis affects >20% of the population and is a common reason patients visit their primary care physician. Proper therapeutic intervention initially requires differentiating rhinitis from acute and chronic rhinosinusitis. After establishing rhinitis as the etiology of a patient's symptoms, a careful, thoughtful history and physical examination aids the cause. Rhinitis can be allergic, nonallergic, or mixed (having features of both allergic and nonallergic rhinitis). Therapeutic interventions vary, depending on the etiology of rhinitis. Symptoms that are refractory to avoidance and pharmacotherapy warrant referral to an allergist or otolaryngologist for consideration of immunotherapy or surgical intervention. In many cases, adhering to an evidence-based therapeutic treatment algorithm will allow physicians to effectively manage rhinitis.
C1 San Antonio Mil Med Ctr, Ft Sam Houston, TX USA.
Wilford Hall Ambulatory Surg Ctr, San Antonio, TX USA.
Audie L Murphy Vet Hosp, San Antonio, TX USA.
RP Dion, GR (reprint author), ATTN MCHE SDT Oto, Dept Otolaryngol, 3551 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA.
EM greg.r.dion@us.army.mil
OI Weitzel, Erik/0000-0001-9155-3556
NR 56
TC 1
Z9 1
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0038-4348
EI 1541-8243
J9 SOUTH MED J
JI South.Med.J.
PD SEP
PY 2013
VL 106
IS 9
BP 526
EP 531
DI 10.1097/SMJ.0b013e3182a5f0f6
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 298UE
UT WOS:000330349200010
PM 24002559
ER
PT J
AU Deyo, RA
Hickam, D
Duckart, JP
Piedra, M
AF Deyo, Richard A.
Hickam, David
Duckart, Jonathan P.
Piedra, Mark
TI Complications After Surgery for Lumbar Stenosis in a Veteran Population
SO SPINE
LA English
DT Article
DE spinal stenosis; lumbar stenosis; lumbar fusion; complications; surgical
complications; postoperative mortality; prediction rule; patient safety;
risk prediction; receiver operating characteristic (ROC)
ID SPINE SURGERY; RISK-FACTORS; WOUND INFECTIONS; FUSION SURGERY;
INSTRUMENTATION; RATES
AB Study Design. Secondary analysis of the prospectively collected Veterans Affairs National Surgical Quality Improvement Program database.
Objective. Determine rates of major medical complications, wound complications, and mortality among patients undergoing surgery for lumbar stenosis and examine risk factors for these complications.
Summary of Background Data. Surgery for spinal stenosis is concentrated among older adults, in whom complications are more frequent than among middle-aged patients. Many studies have focused on infections or device complications, but fewer studies have focused on major cardiopulmonary complications, using prospectively collected data.
Methods. We identified patients who underwent surgery for a primary diagnosis of lumbar stenosis between 1998 and 2009 from the Veterans Affairs National Surgical Quality Improvement Program database. We created a composite of major medical complications, including acute myocardial infarction, stroke, pulmonary embolism, pneumonia, systemic sepsis, coma, and cardiac arrest.
Results. Among 12,154 eligible patients, major medical complications occurred in 2.1%, wound complications in 3.2%, and 90-day mortality in 0.6%. Major medical complications, but not wound complications, were strongly associated with age. American Society of Anesthesiologists (ASA) class was a strong predictor of compli-cations. Insulin use, long-term corticosteroid use, and preoperative functional status were also significant predictors. Fusion procedures were associated with higher complication rates than with decompression alone. In logistic regressions, ASA class and age were the strongest predictors of major medical complications (odds ratio for ASA class 4 vs. class 1 or 2: 2.97; 95% confidence interval, 1.68-5.25; P = 0.0002). After adjustment for comorbidity, age, and functional status, fusion procedures remained associated with higher medical complication rates than were decompressions alone (odds ratio = 2.85; 95% confidence interval, 2.14-3.78; P < 0.0001).
Conclusion. ASA class, age, type of surgery, insulin or corticosteroid use, and functional status were independent risk factors for major medical complications. These factors may help in selecting patients and planning procedures, improving patient safety.
C1 [Deyo, Richard A.] Oregon Hlth & Sci Univ, Dept Family Med, Portland, OR 97239 USA.
[Deyo, Richard A.; Hickam, David] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA.
[Deyo, Richard A.] Oregon Hlth & Sci Univ, Dept Publ Hlth, Portland, OR 97239 USA.
[Deyo, Richard A.] Oregon Hlth & Sci Univ, Dept Prevent Med, Portland, OR 97239 USA.
[Deyo, Richard A.] Oregon Hlth & Sci Univ, Ctr Res Occupat & Environm Toxicol, Portland, OR 97239 USA.
[Piedra, Mark] Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR 97239 USA.
[Hickam, David; Duckart, Jonathan P.] Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Mental & Phys D, Portland, OR USA.
RP Deyo, RA (reprint author), Oregon Hlth & Sci Univ, Dept Family Med, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM deyor@ohsu.edu
FU National Institute for Arthritis, Musculoskeletal and Skin Diseases [R01
AR054912]; National Center for Research Resources grant [UL1 RR024140];
Research Enhancement Award Program of the Veterans Health Administration
FX National Institute for Arthritis, Musculoskeletal and Skin Diseases (R01
AR054912), National Center for Research Resources grant funds (UL1
RR024140), and the Research Enhancement Award Program of the Veterans
Health Administration funds were received to support this work. This
material is the result of work supported with resources and the use of
facilities at the Portland VA Medical Center, Portland, OR.
NR 18
TC 7
Z9 7
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0362-2436
EI 1528-1159
J9 SPINE
JI SPINE
PD SEP 1
PY 2013
VL 38
IS 19
BP 1695
EP 1702
DI 10.1097/BRS.0b013e31829f65c1
PG 8
WC Clinical Neurology; Orthopedics
SC Neurosciences & Neurology; Orthopedics
GA 299AN
UT WOS:000330366800020
PM 23778366
ER
PT J
AU Dick, AAS
Mercer, LD
Smith, JM
McDonald, RA
Young, B
Healey, PJ
AF Dick, Andre A. S.
Mercer, Laina D.
Smith, Jodi M.
McDonald, Ruth A.
Young, Bessie
Healey, Patrick J.
TI Donor and Recipient Size Mismatch in Adolescents Undergoing Living-Donor
Renal Transplantation Affect Long-Term Graft Survival
SO TRANSPLANTATION
LA English
DT Article
DE Body surface area; Renal transplantation; Pediatrics and living donor;
Size mismatch; Graft survival
ID KIDNEY-TRANSPLANTATION; RACIAL-DIFFERENCES; UNITED-STATES; DISPARITIES;
GENDER; OUTCOMES; OVERUSE; FAILURE; WEIGHT; ACCESS
AB Background. Controversies exist in the adult literature regarding the use of kidneys from small donors into larger recipients. Little is known regarding this issue in pediatric kidney transplantation. To assess the impact of donor/recipient size mismatch on long-term renal graft survival in pediatric patients undergoing living-donor renal transplantation.
Methods. We reviewed the United Network for Organ Sharing database from 1987 to 2010 for adolescent (11-18 years old) patients who underwent primary living-donor renal transplantation. According to donor/recipient body surface area (BSA) ratio, patients were stratified into two categories: BSA ratio <0.9 and >= 0.9. Graft survival rates were compared between these two groups using Kaplan-Meier survival curves and Cox proportional hazards models.
Results. Of the 1880 patients identified, 116 (6.2%) had a donor/recipient BSA ratio <0.9 and 1764 (93.8%) had a donor/recipient BSA ratio >= 0.9 group. BSA ratio <0.9 conferred an increased risk of graft loss (adjusted hazard ratio, 1.61; 95% confidence interval, 1.13-2.27; P=0.008). Patients with a donor/recipient BSA ratio >= 0.9 group had a significantly longer graft survival compared with those with a donor/recipient BSA ratio <0.9 after adjustment for donor age and gender, recipient age, gender, ethnicity, cause of renal failure, as well as clinical factors, such as cold and warm ischemia time and HLA mismatch.
Conclusion. We conclude that low donor/recipient BSA ratio was associated with an increased risk of graft loss. Appropriate size matching conferred better long-term graft survival in adolescents receiving live-donor kidney transplants.
C1 [Dick, Andre A. S.; Healey, Patrick J.] Seattle Childrens Hosp, Dept Surg, Div Pediat Transplantat, Seattle, WA 98105 USA.
[Dick, Andre A. S.; Healey, Patrick J.] Univ Washington, Med Ctr, Seattle, WA 98105 USA.
[Mercer, Laina D.] Seattle Childrens Res Inst, Core Biomed Stat, Seattle, WA USA.
[Smith, Jodi M.; McDonald, Ruth A.] Seattle Childrens, Dept Pediat, Div Nephrol, Seattle, WA USA.
[Young, Bessie] Univ Washington, Kidney Res Inst, VA Puget Sound Hlth Care Syst, Div Nephrol, Seattle, WA 98105 USA.
RP Dick, AAS (reprint author), Seattle Childrens Hosp, Dept Surg, Div Pediat Transplantat, 4800 Sand Point Way Northeast,M-S W-7800, Seattle, WA 98105 USA.
EM Andre.dick@seattlechildrens.org
FU Seattle Children's Center for Clinical and Translational Research
Faculty Research Support Fund; Center for Clinical and Translational
Research at the Seattle Children's Research Institute; National
Institutes of Health/National Center for Research Resources
[UL1RR025014]; VA Puget Sound; National Institutes of Health [DK079745]
FX This publication was funded by the Seattle Children's Center for
Clinical and Translational Research Faculty Research Support Fund. The
Seattle Children's Core for Biomedical Statistics is supported by the
Center for Clinical and Translational Research at the Seattle Children's
Research Institute and the National Institutes of Health/National Center
for Research Resources grant UL1RR025014. B.Y. is supported by the VA
Puget Sound and by the National Institutes of Health grant DK079745.
NR 24
TC 4
Z9 4
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
EI 1534-6080
J9 TRANSPLANTATION
JI Transplantation
PD SEP
PY 2013
VL 96
IS 6
BP 555
EP 559
DI 10.1097/TP.0b013e31829d672c
PG 5
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 299GK
UT WOS:000330383900013
PM 23838999
ER
PT J
AU Sun, HY
Cacciarelli, TV
Singh, N
AF Sun, Hsin-Yun
Cacciarelli, Thomas V.
Singh, Nina
TI Micafungin Versus Amphotericin B Lipid Complex for the Prevention of
Invasive Fungal Infections in High-Risk Liver Transplant Recipients
SO TRANSPLANTATION
LA English
DT Article
DE Fungal infections; Liver transplant; Antifungal prophylaxis
ID SOLID-ORGAN TRANSPLANTATION; ANTIFUNGAL PROPHYLAXIS; PREEMPTIVE THERAPY;
ASPERGILLOSIS; CYTOMEGALOVIRUS; VALGANCICLOVIR; FORMULATIONS;
CASPOFUNGIN; MANAGEMENT; MORTALITY
AB Background. Limited data exist regarding echinocandins as antifungal prophylaxis in liver transplant recipients.
Methods. The efficacy and safety of targeted prophylaxis with micafungin or amphotericin B lipid complex (ABLC) was assessed in a sequential cohort of high-risk patients (posttransplantation dialysis, retransplantation, or reoperation) and compared with those without high risk who did not receive prophylaxis. Outcomes were assessed at 90 days.
Results. Micafungin versus ABLC recipients were older (P=0.0065) and more likely to have hepatocellular carcinoma (P=0.025). High-risks, that is, dialysis (55.6% vs. 79.2%), retransplantation (5.6% vs. 12.5%), and reoperation (38.9% vs. 20.8%) did not differ between the two groups. Invasive fungal infections developed in 11.1% (2 of 18) of micafungin recipients, 8.3% (2 of 24) of ABLC recipients, and 3% (7 of 234) of patients without high risks (P=0.12). In nondialyzed patients, ABLC versus micafungin recipients had significantly higher serum creatinine on day 14 (P=0.04). However, renal and hepatic function, rejection, graft loss, and mortality did not differ for the two groups on day 90.
Conclusions. Targeted prophylaxis with micafungin or ABLC decreased the risk of mycoses in high-risk recipients compared with that in low-risk recipients. Compared with ABLC, however, micafungin appeared to be associated with lower early-renal dysfunction and no additional risk of hepatic dysfunction.
C1 [Sun, Hsin-Yun; Cacciarelli, Thomas V.; Singh, Nina] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Sun, Hsin-Yun] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan.
[Sun, Hsin-Yun] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan.
[Cacciarelli, Thomas V.; Singh, Nina] Univ Pittsburgh, Pittsburgh, PA USA.
RP Singh, N (reprint author), Vet Affairs Med Ctr, Infect Dis Sect, Univ Dr C, Pittsburgh, PA 15240 USA.
EM nis5@pitt.edu
OI SUN, HSIN-YUN/0000-0003-0074-7721
FU Astellas; Pfizer, Inc.; Astellas Pharma
FX This material is the result of work supported with resources and the use
of facilities at the Veterans Affairs Pittsburgh Healthcare System
(Pittsburgh, PA). The contents do not represent the views of the
Department of Veterans Affairs or the U.S. Government. The study was
supported through an investigator-initiated grant program of Astellas.
The sponsor had no role in study design, conduct, analyses, and
interpretation of the results. N.S. has received research support from
Pfizer, Inc., and Astellas Pharma.
NR 28
TC 16
Z9 18
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
EI 1534-6080
J9 TRANSPLANTATION
JI Transplantation
PD SEP
PY 2013
VL 96
IS 6
BP 573
EP 578
DI 10.1097/TP.0b013e31829d674f
PG 6
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 299GK
UT WOS:000330383900016
PM 23842191
ER
PT J
AU Sibila, O
Laserna, E
Mortensen, EM
Anzueto, A
Restrepo, MI
AF Sibila, Oriol
Laserna, Elena
Mortensen, Eric M.
Anzueto, Antonio
Restrepo, Marcos I.
TI Effects of Inhaled Corticosteroids on Pneumonia Severity and
Antimicrobial Resistance
SO RESPIRATORY CARE
LA English
DT Article
DE drug resistance; inhaled corticosteroids; pneumonia; severity of illness
index
ID OBSTRUCTIVE PULMONARY-DISEASE; COMMUNITY-ACQUIRED PNEUMONIA; LONG-TERM
USE; COPD PATIENTS; SALMETEROL/FLUTICASONE PROPIONATE; RISK-FACTORS;
METAANALYSIS; SALMETEROL; EXACERBATIONS; FLUTICASONE
AB BACKGROUND: Limited information is available regarding the impact of prior use of inhaled corticosteroids (ICS) in patients subsequently developing community-acquired pneumonia (CAP). We assessed the effects of prior ICS use on severity of illness and microbiology in CAP hospitalized patients. METHODS: A retrospective cohort study of subjects with CAP (by the International Classification of Diseases, 9th Revision, Clinical Modification) was conducted over a 4-year period at 2 tertiary teaching hospitals. Subjects were considered to be ICS users if they received ICS prior to admission. Primary outcomes were severity of illness and microbiology at admission. RESULTS: Data were abstracted on 664 subjects: 89 prior ICS users (13.4%) and 575 non-users (86.6%). Prior ICS users had higher severity of illness at admission: mean +/- SD Pneumonia Severity Index 100.8 +/- 31.4 vs 68.8 +/- 33.4, P = .001, and CURB-65 (confusion, urea nitrogen, respiratory rate, blood pressure, >= 65 years of age) score 1.56 +/- 1.02 vs 1.19 +/- 1.02, P = .002. Prior ICS use was independently associated with antimicrobial-resistant pathogens: 11.2% vs 5.9%, odds ratio 2.6, 95% CI 1.1-6.1, P = .04. CONCLUSIONS: Prior ICS use was associated with higher severity of illness at admission and higher incidence of antimicrobial-resistant pathogens in CAP hospitalized patients.
C1 [Sibila, Oriol; Laserna, Elena; Anzueto, Antonio; Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Mortensen, Eric M.] Vet Affairs North Texas Hlth Care Syst, San Antonio, TX 78229 USA.
[Mortensen, Eric M.] Univ Texas Sothwestern Med Ctr, San Antonio, TX USA.
[Sibila, Oriol] Hosp Santa Creu & Sant Pau, Serv Pneumol, Barcelona, Spain.
[Laserna, Elena] Hosp Comarcal Mollet, Mollet Del Valles, Spain.
[Anzueto, Antonio; Restrepo, Marcos I.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
RP Restrepo, MI (reprint author), South Texas Vet Hlth Care Syst, ALMD 7400,Merton Minter Blvd, San Antonio, TX 78229 USA.
EM restrepom@uthscsa.edu
RI Restrepo, Marcos/H-4442-2014
OI Mortensen, Eric/0000-0002-3880-5563
FU Howard Hughes Medical Institute [00378-001]; Department of Veteran
Affairs Veterans Integrated Service Network 17; Instituto de Salud
Carlos III [BAE11/00102]; Sociedad Espanola de Neumologia y Cirugia
Toracica (SEPAR); Societat Catalana de Pneumologia; Fundacio Catalana de
Pneumologia; National Heart, Lung, and Blood Institute [K23HL096054]
FX Dr Anzueto has disclosed a relationship with Boehringer Ingelheim,
GlaxoSmithKline, Forest Laboratories, Astra-Zeneca, Pfizer, Intermune,
Amgen, Bayer-Schering Pharma, Lilly, and the National Institutes of
Health. Dr Restrepo has disclosed relationships with Theravance, Forest
Laboratories, Johnson & Johnson, Trius, Novartis, and Pfizer. This
research was supported by Howard Hughes Medical Institute faculty
start-up grant 00378-001, and by a Department of Veteran Affairs
Veterans Integrated Service Network 17 new faculty grant. Dr Sibila was
supported by Instituto de Salud Carlos III (BAE11/00102). Drs Sibila and
Laserna were supported by Sociedad Espanola de Neumologia y Cirugia
Toracica (SEPAR), Societat Catalana de Pneumologia and Fundacio Catalana
de Pneumologia. Dr Restrepo was partly supported grant K23HL096054 from
the National Heart, Lung, and Blood Institute. The funding agencies had
no role in the preparation, review, or approval of the manuscript. The
views expressed in this report are those of the authors and do not
represent the views of the Department of Veterans Affairs.
NR 33
TC 5
Z9 5
U1 0
U2 0
PU DAEDALUS ENTERPRISES INC
PI IRVING
PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA
SN 0020-1324
EI 1943-3654
J9 RESP CARE
JI Respir. Care
PD SEP
PY 2013
VL 58
IS 9
BP 1489
EP 1494
DI 10.4187/respcare.02191
PG 6
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 295EP
UT WOS:000330099700011
PM 23345471
ER
PT J
AU Sabin, AT
Gallun, FJ
Souza, PE
AF Sabin, Andrew T.
Gallun, Frederick J.
Souza, Pamela E.
TI Acoustical correlates of performance on a dynamic range compression
discrimination task
SO JOURNAL OF THE ACOUSTICAL SOCIETY OF AMERICA
LA English
DT Article
ID MODULATION TRANSFER-FUNCTIONS; HEARING-AID; AMPLITUDE-MODULATION; GAP
DETECTION; SPECTROTEMPORAL MODULATION; SPEECH-INTELLIGIBILITY; RELEASE
TIME; NOISE; RECOGNITION; FREQUENCY
AB Dynamic range compression is widely used to reduce the difference between the most and least intense portions of a signal. Such compression distorts the shape of the amplitude envelope of a signal, but it is unclear to what extent such distortions are actually perceivable by listeners. Here, the ability to distinguish between compressed and uncompressed versions of a noise vocoded sentence was initially measured in listeners with normal hearing while varying the threshold, ratio, attack, and release parameters. This narrow condition was selected in order to characterize perception under the most favorable listening conditions. The average behavioral sensitivity to compression was highly correlated to several acoustical indices of modulation depth. In particular, performance was highly correlated to the Euclidean distance between the modulation spectra of the uncompressed and compressed signals. Suggesting that this relationship is not restricted to the initial test conditions, the correlation remained largely unchanged both (1) when listeners with normal hearing were tested using a time-compressed version of the original signal, and (2) when listeners with impaired hearing were tested using the original signal. If this relationship generalizes to more ecologically valid conditions, it will provide a straightforward method for predicting the detectability of compression-induced distortions. (C) 2013 Acoustical Society of America.
C1 [Sabin, Andrew T.; Souza, Pamela E.] Northwestern Univ, Dept Commun Sci & Disorders, Evanston, IL 60201 USA.
[Gallun, Frederick J.] Portland VA Med Ctr, VA RR&D Natl Ctr Rehabil Auditory Res NCRAR, Portland, OR 97239 USA.
[Gallun, Frederick J.] Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, Portland, OR 97239 USA.
RP Sabin, AT (reprint author), Northwestern Univ, Dept Commun Sci & Disorders, 2240 Campus Dr, Evanston, IL 60201 USA.
EM a-sabin@northwestern.edu
FU NIH [DC60014]; Department of Veterans Affairs, Veterans Health
Administration, Rehabilitation Research and Development Service (Center
of Excellence Award) [C4844C]
FX Efoe Nyatepe-Coo and Alex Evanoff helped with data collected. Morten
Jepsen, Eric Hoover and Richard Wright provided helpful conversations in
the development of this work. This work was funded by NIH grant DC60014
and by the Department of Veterans Affairs, Veterans Health
Administration, Rehabilitation Research and Development Service (Center
of Excellence Award C4844C).
NR 54
TC 3
Z9 3
U1 0
U2 3
PU ACOUSTICAL SOC AMER AMER INST PHYSICS
PI MELVILLE
PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA
SN 0001-4966
EI 1520-8524
J9 J ACOUST SOC AM
JI J. Acoust. Soc. Am.
PD SEP
PY 2013
VL 134
IS 3
BP 2136
EP 2147
DI 10.1121/1.4816410
PG 12
WC Acoustics; Audiology & Speech-Language Pathology
SC Acoustics; Audiology & Speech-Language Pathology
GA 294LG
UT WOS:000330047000041
PM 23967944
ER
PT J
AU Hosain, GMM
Latini, DM
Kauth, MR
Goltz, HH
Helmer, DA
AF Hosain, G. M. Monawar
Latini, David M.
Kauth, Michael R.
Goltz, Heather Honore
Helmer, Drew A.
TI Racial Differences in Sexual Dysfunction Among Postdeployed Iraq and
Afghanistan Veterans
SO AMERICAN JOURNAL OF MENS HEALTH
LA English
DT Article
DE race; ethnicity; sexual dysfunction; postdeployment; veterans
ID POSTTRAUMATIC-STRESS-DISORDER; ERECTILE DYSFUNCTION;
CARDIOVASCULAR-DISEASE; UNITED-STATES; RISK-FACTORS; PREVALENCE; MEN;
SYMPTOMS; HEALTH; SATISFACTION
AB This study examined the racial/ethnic differences in prevalence and risk factors of sexual dysfunction among postdeployed Iraqi/Afghanistan veterans. A total of 3,962 recently deployed veterans were recruited from Houston Veterans Affairs medical center. The authors examined sociodemographic, medical, mental-health, and lifestyle-related variables. Sexual dysfunction was diagnosed by ICD9-CM code and/or medicines prescribed for sexual dysfunction. Analyses included chi-square, analysis of variance, and multivariate logistic regression. Sexual dysfunction was observed 4.7% in Whites, 7.9% in African Americans, and 6.3% in Hispanics. Age, marital status, smoking, and hypertension were risk factors for Whites, whereas age, marital status, posttraumatic stress disorder and hypertension were significant for African Americans. For Hispanics, only age and posttraumatic stress disorder were significant. This study identified that risk factors of sexual dysfunction varied by race/ethnicity. All postdeployed veterans should be screened; and psychosocial support and educational materials should address race/ethnicity-specific risk factors.
C1 [Hosain, G. M. Monawar; Latini, David M.; Kauth, Michael R.; Goltz, Heather Honore] Houston VA HSR&D Ctr Excellence, Houston, TX 77030 USA.
[Hosain, G. M. Monawar; Latini, David M.; Kauth, Michael R.; Goltz, Heather Honore] Baylor Coll Med, Houston, TX 77030 USA.
[Kauth, Michael R.] VA South Cent Mental Illness Res Educ & Clin Ctr, Houston, TX USA.
[Goltz, Heather Honore] Univ Houston Downtown, Houston, TX USA.
[Helmer, Drew A.] VA RRD Ctr Excellence & PrimeCare, Houston, TX USA.
[Helmer, Drew A.] VA New Jersey Hlth Care Serv, E Orange, NJ USA.
[Helmer, Drew A.] Univ Med & Dent New Jersey, Newark, NJ 07103 USA.
RP Hosain, GMM (reprint author), Houston VA HSR&D Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM monawarhosain@gmail.com
OI Latini, David/0000-0002-6161-4861
FU NIDDK NIH HHS [K12 DK0083014, K12 DK083014]
NR 31
TC 0
Z9 0
U1 0
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1557-9883
EI 1557-9891
J9 AM J MENS HEALTH
JI Am. J. Mens Health
PD SEP
PY 2013
VL 7
IS 5
BP 374
EP 381
DI 10.1177/1557988312471842
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 287WY
UT WOS:000329574200003
PM 23300201
ER
PT J
AU Li, L
Sun, Z
Yang, J
Waldron, RT
Lugea, A
Pandol, SJ
AF Li, L.
Sun, Z.
Yang, J.
Waldron, R. T.
Lugea, A.
Pandol, S. J.
TI Hyperglycaemia and hyperinsulinaemia promote fibrogenesis: increased
risk of pancreatic cancer
SO DIABETOLOGIA
LA English
DT Meeting Abstract
CT 49th Annual Meeting of the
European-Association-for-the-Study-of-Diabetes (EASD)
CY SEP 23-27, 2013
CL Barcelona, SPAIN
SP European Assoc Study Diabet
C1 [Li, L.; Sun, Z.; Yang, J.] Southeast Univ, Zhongda Hosp, Nanjing, Jiangsu, Peoples R China.
[Li, L.; Waldron, R. T.; Lugea, A.; Pandol, S. J.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Waldron, R. T.; Pandol, S. J.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
EI 1432-0428
J9 DIABETOLOGIA
JI Diabetologia
PD SEP
PY 2013
VL 56
SU 1
MA 803
BP S321
EP S321
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 282TQ
UT WOS:000329196901460
ER
PT J
AU Marx, N
Rosenstock, J
Kahn, SE
Zinman, B
Kastelein, JJ
Lachin, J
Espeland, MA
Bluhmki, E
Mattheus, M
Patel, S
Johansen, O
Woerle, HJ
AF Marx, N.
Rosenstock, J.
Kahn, S. E.
Zinman, B.
Kastelein, J. J.
Lachin, J.
Espeland, M. A.
Bluhmki, E.
Mattheus, M.
Patel, S.
Johansen, O.
Woerle, H. -J.
TI Baseline characteristics of participants enrolled in the cardiovascular
outcome study of linagliptin versus glimepiride in early type 2 diabetes
(CAROLINA)
SO DIABETOLOGIA
LA English
DT Meeting Abstract
CT 49th Annual Meeting of the
European-Association-for-the-Study-of-Diabetes (EASD)
CY SEP 23-27, 2013
CL Barcelona, SPAIN
SP European Assoc Study Diabet
C1 [Marx, N.] Univ Hosp Aachen, Dept Internal Med 1, Aachen, Germany.
[Rosenstock, J.] Dallas Diabet & Endocrine Ctr, Dallas, TX USA.
[Kahn, S. E.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA.
[Kahn, S. E.] Univ Washington, Dept Med, Seattle, WA USA.
[Zinman, B.] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada.
[Zinman, B.] Univ Toronto, Div Endocrinol, Toronto, ON M5S 1A1, Canada.
[Kastelein, J. J.] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands.
[Lachin, J.] George Washington Univ, Biostat Ctr, Rockville, MD USA.
[Espeland, M. A.] Wake Forest Univ Hlth Sci, Dept Biostat Sci, Winston Salem, NC USA.
[Bluhmki, E.] Boehringer Ingelheim GmbH & Co KG, Biberach, Germany.
[Mattheus, M.; Johansen, O.; Woerle, H. -J.] Boehringer Ingelheim KG, Ingelheim, Germany.
[Patel, S.] Boehringer Ingelheim GmbH & Co KG, Bracknell, Berks, England.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
EI 1432-0428
J9 DIABETOLOGIA
JI Diabetologia
PD SEP
PY 2013
VL 56
SU 1
MA 73
BP S36
EP S37
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 282TQ
UT WOS:000329196900074
ER
PT J
AU Eknoyan, D
Hurley, RA
Taber, KH
AF Eknoyan, Donald
Hurley, Robin A.
Taber, Katherine H.
TI The Neurobiology of Placebo and Nocebo: How Expectations Influence
Treatment Outcomes
SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES
LA English
DT Article
ID PARKINSONS-DISEASE; DOPAMINE RELEASE; SPINAL-CORD; ANALGESIA; PAIN;
RESPONSES; SYSTEM; ACTIVATION; MECHANISMS; BRAIN
C1 [Eknoyan, Donald] Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Eknoyan, Donald] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
[Hurley, Robin A.] Vet Affairs Mid Atlantic Mental Illness Res Educ, Durham, NC 27701 USA.
[Hurley, Robin A.] WG Hefner Vet Affairs Med Ctr Salisbury, Salisbury, NC USA.
[Hurley, Robin A.] Wake Forest Sch Med Winston Salem, Dept Psychiat, Winston Salem, NC USA.
[Hurley, Robin A.] Wake Forest Sch Med Winston Salem, Dept Radiol, Winston Salem, NC USA.
[Hurley, Robin A.] Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
[Taber, Katherine H.] Via Coll Osteopath Med Blacksburg, Div Biomed Sci, Blacksburg, VA USA.
[Taber, Katherine H.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA.
RP Hurley, RA (reprint author), Vet Affairs Mid Atlantic Mental Illness Res Educ, Durham, NC 27701 USA.
EM Robin.Hurley@va.gov
NR 38
TC 0
Z9 0
U1 1
U2 6
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0895-0172
EI 1545-7222
J9 J NEUROPSYCH CLIN N
JI J. Neuropsychiatr. Clin. Neurosci.
PD FAL
PY 2013
VL 25
IS 4
BP 250
EP 254
PG 5
WC Clinical Neurology; Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 286TN
UT WOS:000329491700001
ER
PT J
AU Avidan, A
Hays, RD
Diaz, N
Bordelon, Y
Thompson, AW
Vassar, SD
Vickrey, BG
AF Avidan, Alon
Hays, Ron D.
Diaz, Natalie
Bordelon, Yvette
Thompson, Alexander W.
Vassar, Stefanie D.
Vickrey, Barbara G.
TI Associations of Sleep Disturbance Symptoms With Health-Related Quality
of Life in Parkinson's Disease
SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES
LA English
DT Article
ID MEDICAL OUTCOMES; DISORDERS; DEPRESSION; SCALE; RECOMMENDATIONS;
RESPIRATION; PROGRESSION; INSOMNIA; ONSET
AB The authors examined associations of various sleep-disturbance symptoms with health-related quality of life (HRQOL) in 153 adults with Parkinson's disease (PD). PD patients reported more snoring, sleep inadequacy, daytime somnolence, and sleep-maintenance problems than the general population. Symptoms having the broadest and strongest unique associations with generic HRQOL (eight scales; two composites of SF-36) were daytime somnolence (five scales; one composite), sleep initiation (eight scales; two composites), and awakening short of breath or with headache (six scales; two composites). Associations of selected sleep-disturbance symptoms-some unanticipated-suggest that assessing specific symptoms is worthwhile in clinical care.
C1 [Avidan, Alon] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA.
Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA.
Univ Calif Los Angeles, Dept Hlth Policy & Management, Los Angeles, CA 90024 USA.
Harbor UCLA, Dept Neurol, Los Angeles, CA USA.
Behav Hlth Serv, Grp Hlth Cooperat, Seattle, WA USA.
Parkinsons Dis Res Educ & Clin Ctr, Los Angeles, CA USA.
VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Avidan, A (reprint author), Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA.
EM avidan@mednet.ucla.edu
FU Parkinson Alliance; National Institute of Neurological Disorders and
Stroke [NS038367]; Veteran's Administration; National Institute of Aging
[P30AG021684]; National Center on Minority Health and Health Disparities
[P20MD000182]
FX Study support was provided by the Parkinson Alliance, by National
Institute of Neurological Disorders and Stroke NS038367, and by the
Veteran's Administration. Dr. Hays was supported in part by a National
Institute of Aging (P30AG021684) and National Center on Minority Health
and Health Disparities (P20MD000182) grants.
NR 41
TC 4
Z9 4
U1 0
U2 5
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0895-0172
EI 1545-7222
J9 J NEUROPSYCH CLIN N
JI J. Neuropsychiatr. Clin. Neurosci.
PD FAL
PY 2013
VL 25
IS 4
BP 319
EP 326
PG 8
WC Clinical Neurology; Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 286TN
UT WOS:000329491700040
PM 24247858
ER
PT J
AU Walker, RJ
Smalls, BL
Bonilha, HS
Campbell, JA
Egede, LE
AF Walker, Rebekah J.
Smalls, Brittany L.
Bonilha, Heather Shaw
Campbell, Jennifer A.
Egede, Leonard E.
TI BEHAVIORAL INTERVENTIONS TO IMPROVE GLYCEMIC CONTROL IN AFRICAN
AMERICANS WITH TYPE 2 DIABETES: A SYSTEMATIC REVIEW
SO ETHNICITY & DISEASE
LA English
DT Article
DE Diabetes; Glucose Control; African Americans; Ethnic Groups; Lifestyle
ID SELF-MANAGEMENT EDUCATION; HEALTH DISPARITIES; RACIAL-DIFFERENCES;
ADULTS; OLDER; METAANALYSIS; DISEASE; IMPACT; BLACK; TRIAL
AB Objective: The use of behavioral interventions has been shown to improve glycemic control, however, the effectiveness of different behavioral interventions in one of the most high risk populations, African Americans, remains unclear. Our systematic review identified and examined findings of published behavioral interventions targeted at African Americans to improve glycemic control. The goal of our study was to distinguish which interventions were effective and identify areas for future research.
Design: Medline, PsychInfo, and CINAHL were searched for articles published from January 2000 through January 2012 using a reproducible strategy. Study eligibility criteria included interventions aimed at changing behavior in adult African Americans with type 2 diabetes and measured glycemic control.
Results: Ten studies met the inclusion criteria, of which five showed a statistically significant change in HbA1c in the intervention group when compared to the control group. Summary information and characteristics of the reviewed studies are provided.
Conclusions: Characteristics of successful interventions included using problem solving with the patient, culturally tailoring the intervention, and using a nurse educator. Limitations include the limited number of intervention studies available using glycemic control as the outcome measure. Clinical trials are needed to determine how best to tailor interventions to this largely underserved population and studies should describe details of cultural tailoring to provide information for future programs.
C1 [Walker, Rebekah J.; Smalls, Brittany L.; Campbell, Jennifer A.; Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Disparities Res, Charleston, SC 29425 USA.
[Walker, Rebekah J.; Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Hlth Equ & Rural Outreach Innovat Ctr, Charleston, SC USA.
[Walker, Rebekah J.; Smalls, Brittany L.; Bonilha, Heather Shaw] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA.
[Egede, Leonard E.] Med Univ S Carolina, Dept Med, Div Gen Internal Med & Geriatr, Charleston, SC 29425 USA.
RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Disparities Res, 135 Rutledge Ave,Room 280G,POB 250593, Charleston, SC 29425 USA.
EM egedel@musc.edu
NR 34
TC 4
Z9 4
U1 4
U2 8
PU INT SOC HYPERTENSION BLACKS-ISHIB
PI ATLANTA
PA 100 AUBURN AVE NE STE 401, ATLANTA, GA 30303-2527 USA
SN 1049-510X
EI 1945-0826
J9 ETHNIC DIS
JI Ethn. Dis.
PD FAL
PY 2013
VL 23
IS 4
BP 401
EP 408
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 280HN
UT WOS:000329019400002
PM 24392600
ER
PT J
AU Betancourt, RM
Degnan, KO
Long, JA
AF Betancourt, Renee M.
Degnan, Kathleen O.
Long, Judith A.
TI RACIAL DIFFERENCES IN GLUCOSE CONTROL AMONG PATIENTS WITH TYPE 2
DIABETES: A SURVEY ON DIETARY TEMPTATIONS, COPING, AND TRUST IN
PHYSICIANS
SO ETHNICITY & DISEASE
LA English
DT Article
DE Disparities; Diabetes Mellitus; Glucose Control; Psychosocial Factors
ID AFRICAN-AMERICAN; GLYCEMIC CONTROL; CARE; DISPARITIES; SCALE; OUTCOMES;
BEHAVIORS; MORTALITY; ADHERENCE; QUALITY
AB Objective: A quantitative evaluation of self-care behaviors, psychosocial stressors, and patient relationships to health care to better understand racial disparities in these domains.
Research Design and Methods: A cross-sectional study of adult patients with type 2 diabetes in University of Pennsylvania Healthcare System who had a HbA1c test within one month of survey administration. The survey instrument included among other items, the Dieter's Inventory of Eating Temptations Self-Efficacy instrument (DIET-SE), the Jalowiec Coping Scale (JCS), and the Trust in Physician (TIP) scale.
Results: 332 individuals completed the survey. Poor glucose control was significantly associated with Black race, lower income level, other demographic variables, non-perfect medication adherence, and poorer diet quality. It was also associated with lower self-efficacy to resist social dietary temptations, and among White patients it was associated was decreased use of a confrontive coping style. However, these factors did not explain the racial differences in glucose control between Blacks and Whites.
Conclusions: Interventions aimed at dietary temptations, coping styles, or trust in physicians may not reduce racial disparities in glucose control. However, interventions that focus on dietary temptations may positively affect all diabetic patients.
C1 [Betancourt, Renee M.] Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA.
[Degnan, Kathleen O.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Long, Judith A.] Univ Penn, Div Gen Internal Med, Philadelphia VA Ctr Hlth Equ Res & Promot, Perelman Sch Med, Philadelphia, PA 19104 USA.
RP Betancourt, RM (reprint author), 995 Potrero Ave,Bldg 83, San Francisco, CA 94110 USA.
EM betancourtr@fcm.ucsf.edu
NR 33
TC 2
Z9 2
U1 1
U2 5
PU INT SOC HYPERTENSION BLACKS-ISHIB
PI ATLANTA
PA 100 AUBURN AVE NE STE 401, ATLANTA, GA 30303-2527 USA
SN 1049-510X
EI 1945-0826
J9 ETHNIC DIS
JI Ethn. Dis.
PD FAL
PY 2013
VL 23
IS 4
BP 409
EP 414
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 280HN
UT WOS:000329019400003
PM 24392601
ER
PT J
AU Doherty, JE
Woodard, LE
Bear, AS
Foster, AE
Wilson, MH
AF Doherty, Joseph E.
Woodard, Lauren E.
Bear, Adham S.
Foster, Aaron E.
Wilson, Matthew H.
TI An adaptable system for improving transposon-based gene expression in
vivo via transient transgene repression
SO FASEB JOURNAL
LA English
DT Article
DE piggyBac; inducible expression; gene transfer
ID IMMUNE-RESPONSE; MAMMALIAN-CELLS; HYDRODYNAMIC INJECTION; FIREFLY
LUCIFERASE; ADENOVIRAL VECTORS; THERAPY; LIVER; MICE; DELIVERY;
TETRACYCLINE
AB Transposons permit permanent cellular genome engineering in vivo. However, transgene expression falls rapidly postdelivery due to a variety of mechanisms, including immune responses. We hypothesized that delaying initial transgene expression would improve long-term transgene expression by using an engineered piggyBac transposon system that can regulate expression. We found that a 2-part nonviral Tet-KRAB inducible expression system repressed expression of a luciferase reporter in vitro. However, we also observed nonspecific promoter-independent repression. Thus, to achieve temporary transgene repression after gene delivery in vivo, we utilized a nonintegrating version of the repressor plasmid while the gene of interest was delivered in an integrating piggyBac transposon vector. When we delivered the luciferase transposon and repressor to immunocompetent mice by hydrodynamic injection, initial luciferase expression was repressed by 2 orders of magnitude. When luciferase expression was followed long term in vivo, we found that expression was increased >200-fold compared to mice that received only the luciferase transposon and piggyBac transposase. We found that repression of early transgene expression could prevent the priming of luciferase-specific T cells in vivo. Therefore, transient transgene repression postgene delivery is an effective strategy for inhibiting the antitransgene immune response and improving long-term expression in vivo without using immunosuppression.Doherty, J. E., Woodard, L. E., Bear, A. S., Foster, A. E., Wilson, M. H. An adaptable system for improving transposon-based gene expression in vivo via transient transgene repression.
C1 [Doherty, Joseph E.; Bear, Adham S.; Foster, Aaron E.; Wilson, Matthew H.] Baylor Coll Med, Med Scientist Training Program, Houston, TX 77030 USA.
[Doherty, Joseph E.; Wilson, Matthew H.] Baylor Coll Med, Interdept Program Cell & Mol Biol, Houston, TX 77030 USA.
[Doherty, Joseph E.; Woodard, Lauren E.; Wilson, Matthew H.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
[Bear, Adham S.; Foster, Aaron E.; Wilson, Matthew H.] Baylor Coll Med, Interdept Program Translat Biol & Mol Med, Houston, TX 77030 USA.
[Bear, Adham S.; Foster, Aaron E.; Wilson, Matthew H.] Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA.
[Wilson, Matthew H.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
RP Wilson, MH (reprint author), Baylor Coll Med, 1 Baylor Plaza,MS BCM395,ABBR R704, Houston, TX 77030 USA.
EM mhwilson@bcm.edu
FU U.S. National Institutes of Health (NIH) [T32GM007330]; NIH
[T32DK064717, T32DK062706, T32DK060445, R01 DK093660]; U.S. Department
of Veterans Affairs
FX J.E.D. was supported by U.S. National Institutes of Health (NIH) Medical
Scientist Training Program grant T32GM007330, and subsequently by NIH
Cell and Gene Therapy Training grant T32DK064717 and the generous
support of Bill and Mary Jo Robbins. L. E. W. was supported by NIH grant
T32DK062706 and subsequently by NIH grant T32DK060445. M. H. W. was
supported in part by a career development award from the U.S. Department
of Veterans Affairs and NIH grant R01 DK093660. This work was also made
possible by the generous support of Dr. and Mrs. Harold M. Selzman.
NR 53
TC 3
Z9 3
U1 1
U2 9
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD SEP
PY 2013
VL 27
IS 9
BP 3753
EP 3762
DI 10.1096/fj.13-232090
PG 10
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 277SV
UT WOS:000328840500033
PM 23752206
ER
PT J
AU Ioannou, GN
AF Ioannou, George N.
TI Chronic Hepatitis B Infection: A Global Disease Requiring Global
Strategies
SO HEPATOLOGY
LA English
DT Editorial Material
ID PUBLIC-HEALTH MANAGEMENT; UNITED-STATES; VIRUS INFECTION; LIVER-CANCER;
RECOMMENDATIONS; IDENTIFICATION; MODEL
C1 [Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Res & Dev, Seattle, WA 98108 USA.
[Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Gastroenterol, Seattle, WA 98108 USA.
[Ioannou, George N.] Univ Washington, Dept Med, Div Gastroenterol, Seattle, WA USA.
RP Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Gastroenterol, S-111 Gastro,1660 S Columbian Way, Seattle, WA 98108 USA.
EM georgei@medicine.washington.edu
NR 20
TC 11
Z9 11
U1 1
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD SEP
PY 2013
VL 58
IS 3
BP 839
EP 843
DI 10.1002/hep.26516
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 283YX
UT WOS:000329284000001
PM 23703788
ER
PT J
AU Lawson, CM
Daley, BJ
Sams, VG
Martindale, R
Kudsk, KA
Miller, KR
AF Lawson, Christy M.
Daley, Brian J.
Sams, Valerie G.
Martindale, Robert
Kudsk, Kenneth A.
Miller, Keith R.
TI Factors That Impact Patient Outcome: Nutrition Assessment
SO JOURNAL OF PARENTERAL AND ENTERAL NUTRITION
LA English
DT Article
DE nutrition assessment; body mass index; malnutrition; elective surgery
ID TOTAL PARENTERAL-NUTRITION; ENTERAL NUTRITION; MALNUTRITION;
UNDERNUTRITION; RISK
AB Defining malnutrition and nutrition risk has been a topic of many papers and discussions throughout the modern literature. Multiple definitions have been proposed, ranging from simple body weight measurements to a more all-encompassing concept looking at disease-specific inflammatory states. Biochemical markers, elements of a history examination, physical examination findings, calculations, and technical tests have all been proposed to help further characterize and delineate those who might be at risk for malnutrition, translating to an increased risk of adverse outcomes after major surgery. The purpose of this paper is to summarize some of the most utilized and most reliable ways to determine nutrition status within the scope of the North American Surgical Nutrition Summit (2012) and discuss how to incorporate these methods into the way that patients are screened preoperatively for elective surgery.
C1 [Lawson, Christy M.; Daley, Brian J.; Sams, Valerie G.] Univ Tennessee, Med Ctr, Dept Surg, Knoxville, TN 37920 USA.
[Martindale, Robert] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR USA.
[Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Veteran Adm Surg Serv, Madison, WI USA.
[Miller, Keith R.] Univ Louisville, Dept Surg, Louisville, KY 40292 USA.
RP Lawson, CM (reprint author), Univ Tennessee, Med Ctr, Dept Surg, 1924 Alcoa Highway,Box U-11, Knoxville, TN 37920 USA.
EM cmlawson@utmck.edu
FU Nestle Healthcare Nutrition
FX The publication of the supplement in which this article appears is
supported by an educational grant from Nestle Healthcare Nutrition.
Authors received an honorarium from the Nestle Nutrition Institute for
their participation in the North American Surgical Nutrition Summit.
NR 29
TC 3
Z9 4
U1 2
U2 6
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0148-6071
EI 1941-2444
J9 JPEN-PARENTER ENTER
JI J. Parenter. Enter. Nutr.
PD SEP
PY 2013
VL 37
IS 5
SU S
BP 30S
EP 38S
DI 10.1177/0148607113499372
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 276XL
UT WOS:000328782900003
PM 24009247
ER
PT J
AU Pierre, JF
Heneghan, AF
Lawson, CM
Wischmeyer, PE
Kozar, RA
Kudsk, KA
AF Pierre, Joseph F.
Heneghan, Aaron F.
Lawson, Christy M.
Wischmeyer, Paul E.
Kozar, Rosemary A.
Kudsk, Kenneth A.
TI Pharmaconutrition Review: Physiological Mechanisms
SO JOURNAL OF PARENTERAL AND ENTERAL NUTRITION
LA English
DT Review
DE immunonutrition; pharmaconutrition; immune modulation; nutrition therapy
ID CRITICALLY-ILL PATIENTS; GAMMA-LINOLENIC ACID; INTENSIVE-CARE-UNIT;
NITRIC-OXIDE SYNTHASE; ACUTE LUNG INJURY; RESPIRATORY-DISTRESS-SYNDROME;
TOTAL PARENTERAL-NUTRITION; DOUBLE-BLIND TRIAL; SEVERE BURN INJURY;
BACTERIAL-INFECTION RATES
AB The search to improve outcomes in critically ill patients through nutrition support has steadily progressed over the past 4 decades. One current approach to this problem is the addition of specific nutrients as primary therapy to improve host defenses and improve the outcome of critically ill patients. The field is referred to as pharmaconutrition, with the hope of focusing investigations on each nutrient to understand its pharmacological effects on immune and clinical outcomes. The purpose of this review is to describe some of the known physiological mechanisms of pharmaconutrients such as glutamine, arginine, -3 fatty acids, and selenium.
C1 [Pierre, Joseph F.; Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI USA.
[Pierre, Joseph F.; Heneghan, Aaron F.; Kudsk, Kenneth A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Madison, WI 53792 USA.
[Lawson, Christy M.] Univ Tennessee, Med Ctr, Dept Surg, Knoxville, TN 37920 USA.
[Wischmeyer, Paul E.] Univ Colorado, Dept Anesthesiol, Denver, CO 80202 USA.
[Kozar, Rosemary A.] Univ Texas Houston, Hlth Sci Ctr, Dept Surg, Houston, TX USA.
RP Kudsk, KA (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Nutr Sci, H4-736 Clin Sci Ctr,600 Highland Ave, Madison, WI 53792 USA.
EM kudsk@surgery.wisc.edu
FU Nestle Healthcare Nutrition
FX The publication of the supplement in which this article appears is
supported by an educational grant from Nestle Healthcare Nutrition.
Authors received an honorarium from the Nestle Nutrition Institute for
their participation in the North American Surgical Nutrition Summit.
NR 225
TC 17
Z9 17
U1 3
U2 13
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0148-6071
EI 1941-2444
J9 JPEN-PARENTER ENTER
JI J. Parenter. Enter. Nutr.
PD SEP
PY 2013
VL 37
IS 5
SU S
BP 51S
EP 65S
DI 10.1177/0148607113493326
PG 15
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 276XL
UT WOS:000328782900005
PM 24009249
ER
PT J
AU Hughes, J
Jouldjian, S
Washington, DL
Alessi, CA
Martin, JL
AF Hughes, Jaime
Jouldjian, Stella
Washington, Donna L.
Alessi, Cathy A.
Martin, Jennifer L.
TI Insomnia and Symptoms of Post-traumatic Stress Disorder Among Women
Veterans
SO BEHAVIORAL SLEEP MEDICINE
LA English
DT Article
ID COGNITIVE-BEHAVIORAL THERAPY; MAJOR DEPRESSIVE DISORDER; SLEEP QUALITY
INDEX; PSYCHIATRIC-DISORDERS; HEALTH-CARE; OF-LIFE; QUESTIONNAIRE;
DISTURBANCES; EPIDEMIOLOGY; AFGHANISTAN
AB Women will account for 10% of the Veteran population by 2020, yet there has been little focus on sleep issues among women Veterans. In a descriptive study of 107 women Veterans with insomnia (mean age = 49 years, 44% non-Hispanic white), 55% had probable post traumatic stress disorder (PTSD) (total score 33). Probable PTSD was related to more severe self-reported sleep disruption and greater psychological distress. In a regression model, higher PTSD Checklist-Civilian (PCL-C) total score was a significant independent predictor of worse insomnia severity index score while other factors were not. Women Veterans preferred behavioral treatments over pharmacotherapy in general, and efforts to increase the availability of such treatments should be undertaken. Further research is needed to better understand the complex relationship between insomnia and PTSD among women Veterans.
C1 [Hughes, Jaime; Jouldjian, Stella] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA.
[Washington, Donna L.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Ctr Excellence Study Healthcare Provider Behav, Los Angeles, CA 90095 USA.
[Alessi, Cathy A.; Martin, Jennifer L.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA 90095 USA.
RP Martin, JL (reprint author), 16111 Plummer St 11E, North Hills, CA 91343 USA.
EM Jennifer.Martin@va.gov
FU VA Health Services Research and Development [PPO 09-282-1]; VA
Rehabilitation Research and Development [1RX000135-01]; National
Institute on Aging [K23 AG028452]; VAGLAHS Geriatric Research,
Education, and Clinical Center (GRECC)
FX Supported by: VA Health Services Research and Development (PPO
09-282-1), VA Rehabilitation Research and Development (1RX000135-01),
National Institute on Aging (K23 AG028452), and the VAGLAHS Geriatric
Research, Education, and Clinical Center (GRECC).
NR 51
TC 7
Z9 7
U1 5
U2 16
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1540-2002
EI 1540-2010
J9 BEHAV SLEEP MED
JI Behav. Sleep Med.
PD SEP 1
PY 2013
VL 11
IS 4
BP 258
EP 274
DI 10.1080/15402002.2012.683903
PG 17
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 268QR
UT WOS:000328186100002
PM 23205531
ER
PT J
AU Fredericks, WJ
McGarvey, T
Wang, HY
Zheng, YM
Fredericks, NJ
Yin, HK
Wang, LP
Hsiao, W
Lee, R
Weiss, JS
Nickerson, ML
Kruth, HS
Rauscher, FJ
Malkowicz, SB
AF Fredericks, William J.
McGarvey, Terry
Wang, Huiyi
Zheng, Yongmu
Fredericks, Nathaniel J.
Yin, Hankun
Wang, Li-Ping
Hsiao, Wayland
Lee, Rob
Weiss, Jayne S.
Nickerson, Michael L.
Kruth, Howard S.
Rauscher, Frank J., III
Malkowicz, S. Bruce
TI The TERE1 Protein Interacts With Mitochondrial TBL2: Regulation of
Trans-Membrane Potential, ROS/RNS and SXR Target Genes
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE TERE1; TBL2; MITOCHONDRIA; LIPID METABOLISM; ROS; SXR TARGET GENES
ID BREAST-CANCER CELLS; CARCINOMA-CELLS; NITRIC-OXIDE; BLADDER; UBIAD1;
CHOLESTEROL; VITAMIN-K-2; ACTIVATION; RECEPTOR; INHIBITION
AB We originally discovered TERE1 as a potential tumor suppressor protein based upon reduced expression in bladder and prostate cancer specimens and growth inhibition of tumor cell lines/xenografts upon ectopic expression. Analysis of TERE1 (aka UBIAD1) has shown it is a prenyltransferase enzyme in the natural bio-synthetic pathways for both vitamin K-2 and COQ10 production and exhibits multiple subcellular localizations including mitochondria, endoplasmic reticulum, and golgi. Vitamin K-2 is involved in mitochondrial electron transport, SXR nuclear hormone receptor signaling and redox cycling: together these functions may form the basis for tumor suppressor function. To gain further insight into mechanisms of growth suppression and enzymatic regulation of TERE1 we isolated TERE1 associated proteins and identified the WD40 repeat, mitochondrial protein TBL2. We examined whether disease specific mutations in TERE1 affected interactions with TBL2 and the role of each protein in altering mitochondrial function, ROS/RNS production and SXR target gene regulation. Biochemical binding assays demonstrated a direct, high affinity interaction between TERE1 and TBL2 proteins; TERE1 was localized to both mitochondrial and non-mitochondrial membranes whereas TBL2 was predominantly mitochondrial; multiple independent single amino acid substitutions in TERE1 which cause a human hereditary corneal disease reduced binding to TBL2 strongly suggesting the relevance of this interaction. Ectopic TERE1 expression elevated mitochondrial trans-membrane potential, oxidative stress, NO production, and activated SXR targets. A TERE1-TBL2 complex likely functions in oxidative/nitrosative stress, lipid metabolism, and SXR signaling pathways in its role as a tumor suppressor. J. Cell. Biochem. 114: 2170-2187, 2013. (c) 2013 Wiley Periodicals, Inc.
C1 [Fredericks, William J.; Wang, Huiyi; Zheng, Yongmu; Fredericks, Nathaniel J.; Yin, Hankun; Malkowicz, S. Bruce] Univ Penn, Dept Surg, Div Urol, Philadelphia, PA 19104 USA.
[Fredericks, William J.; Wang, Huiyi; Zheng, Yongmu; Fredericks, Nathaniel J.; Yin, Hankun; Lee, Rob; Malkowicz, S. Bruce] Vet Affairs Med Ctr Philadelphia, Philadelphia, PA 19104 USA.
[McGarvey, Terry] Kirksville Osteopath Med Sch, Dept Anat, Kirksville, MO 63501 USA.
[Wang, Li-Ping] Univ Penn, Med Ctr, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
[Hsiao, Wayland] Weill Cornell Med Coll, Dept Urol, New York, NY USA.
[Lee, Rob] Univ Penn, Dept Otorhinolaryngol, Philadelphia, PA 19104 USA.
[Weiss, Jayne S.] Louisiana State Univ, Dept Ophthalmol, New Orleans, LA USA.
[Weiss, Jayne S.] Louisiana State Univ, Ctr Eye, New Orleans, LA 70112 USA.
[Nickerson, Michael L.] NCI, Canc & Inflammat Program, Ft Detrick, MD 21702 USA.
[Kruth, Howard S.] NIH, Sect Expt Atherosclerosis, Bethesda, MD 20892 USA.
[Rauscher, Frank J., III] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA.
RP Fredericks, WJ (reprint author), VA Med Ctr Philadelphia, Res Bldg 21,Room A418,Univ & Woodland Ave, Philadelphia, PA 19104 USA.
EM wjfredericks@verizon.net
OI Lee, Robert/0000-0001-5826-6686
FU Veterans Affairs Merit Review; Innisfree Foundation of Bryn Mawr, PA;
Castleman Family Fund
FX Grant sponsor: Veterans Affairs Merit Review; Grant sponsor: The
Innisfree Foundation of Bryn Mawr, PA; Grant sponsor: The Castleman
Family Fund.
NR 50
TC 11
Z9 11
U1 0
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
EI 1097-4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD SEP
PY 2013
VL 114
IS 9
BP 2170
EP 2187
DI 10.1002/jcb.24567
PG 18
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 261YA
UT WOS:000327699500024
PM 23564352
ER
PT J
AU Kilbourne, AM
Deeghan, T
Jones, KR
AF Kilbourne, Amy M.
Deeghan, Tisha
Jones, Kenneth R.
TI Serious Mental Illness and Weight Management Interventions
SO PSYCHIATRIC SERVICES
LA English
DT Letter
C1 [Kilbourne, Amy M.] US Dept Vet Affairs, Hlth Serv Res & Dev Serv, Ctr Clin Management Res, Ann Arbor, MI USA.
[Deeghan, Tisha] Genesee Hlth Syst, Flint, MI USA.
[Jones, Kenneth R.] VHA Natl Ctr Hlth Promot & Dis Prevent, Durham, NC USA.
RP Kilbourne, AM (reprint author), US Dept Vet Affairs, Hlth Serv Res & Dev Serv, Ctr Clin Management Res, Ann Arbor, MI USA.
NR 5
TC 0
Z9 0
U1 6
U2 7
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
EI 1557-9700
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD SEP
PY 2013
VL 64
IS 9
BP 931
EP 931
PG 1
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 255ZC
UT WOS:000327277600021
PM 24026842
ER
PT J
AU Okwemba, R
Medvedeva, E
Wang, A
AF Okwemba, Robert
Medvedeva, Elina
Wang, Andrew
TI Medication Adherence Among Patients With Comorbid Diabetes
SO PSYCHIATRIC SERVICES
LA English
DT Letter
ID SCHIZOPHRENIA
C1 [Okwemba, Robert; Medvedeva, Elina; Wang, Andrew] Ctr Hlth Equ Res & Promot, Dept Vet Affairs, Philadelphia, PA USA.
RP Okwemba, R (reprint author), Ctr Hlth Equ Res & Promot, Dept Vet Affairs, Philadelphia, PA USA.
NR 3
TC 1
Z9 1
U1 0
U2 1
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
EI 1557-9700
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD SEP
PY 2013
VL 64
IS 9
BP 934
EP 935
PG 3
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 255ZC
UT WOS:000327277600025
PM 24026846
ER
PT J
AU Aspinall, SL
Zhao, XH
Good, CB
Stone, RA
Smith, KJ
Cunningham, FE
AF Aspinall, Sherrie L.
Zhao, Xinhua
Good, Chester B.
Stone, Roslyn A.
Smith, Kenneth J.
Cunningham, Francesca E.
TI FDA Warning and Removal of Rosiglitazone From VA National Formulary
SO AMERICAN JOURNAL OF MANAGED CARE
LA English
DT Article
ID CARDIOVASCULAR EVENTS; DIABETES-MELLITUS; RISK; PIOGLITAZONE;
METAANALYSIS; OUTCOMES; IMPACT; CARE
AB Objectives: To describe changes in rosiglitazone prescribing following the US Food and Drug Administration (FDA) warning of potentially increased risk of myocardial infarction and removal from the Department of Veterans Affairs National Formulary (VANF), assess patient-level factors associated with rosiglitazone discontinuation, and evaluate changes in glucose control.
Study Design: Historical cohort.
Methods: Veterans with an active outpatient prescription for rosiglitazone on April 1, 2007, were followed until June 30, 2008. Incidence rate ratios (IRRs) of rosiglitazone discontinuation were compared over time using Poisson methods. We identified patient-level factors associated with stopping rosiglitazone using multivariable Poisson regression and compared glycated hemoglobin (A1C) values across time among patients who discontinued/continued rosiglitazone using linear mixed models.
Results: Of 95,539 veterans with an active outpatient rosiglitazone prescription, 86.7% discontinued rosiglitazone. Discontinuation rates increased significantly after the FDA warning, with IRRs from 1.6 to 1.8. After removal from the VANF, rosiglitazone discontinuation rates again increased significantly. Discontinuing rosiglitazone was associated with the FDA warning, removal from the VANF, female sex, black race, Hispanic ethnicity, comorbidity,A1C greater than 9%, and use of rosiglitazone as first- or second-line therapy. Among patients who did and did not receive a replacement medication, the mean changes in A1C from baseline were 0.12% and 0.46%, respectively. for those who continued rosiglitazone, the mean change in A1C was 0.02%.
Conclusion: The rosiglitazone discontinuation rate increased following the FDA warning and increased further following removal of rosiglitazone from the VANE Glucose control may have declined among those who discontinued rosiglitazone.
C1 [Aspinall, Sherrie L.; Zhao, Xinhua; Good, Chester B.; Cunningham, Francesca E.] VA Ctr Medicat Safety, Hines, IL USA.
[Aspinall, Sherrie L.; Zhao, Xinhua; Good, Chester B.; Stone, Roslyn A.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA.
[Aspinall, Sherrie L.; Good, Chester B.] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA.
[Good, Chester B.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
[Stone, Roslyn A.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA.
[Smith, Kenneth J.] Univ Pittsburgh, Div Clin Modeling & Decis Sci, Pittsburgh, PA USA.
RP Aspinall, SL (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 7180 Highland Dr 151C-H, Pittsburgh, PA 15206 USA.
EM sherrie.aspinall@va.gov
NR 21
TC 6
Z9 6
U1 0
U2 0
PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC
PI PLAINSBORO
PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA
SN 1088-0224
J9 AM J MANAG CARE
JI Am. J. Manag. Care
PD SEP
PY 2013
VL 19
IS 9
BP 748
EP 758
PG 11
WC Health Care Sciences & Services; Health Policy & Services; Medicine,
General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 244WF
UT WOS:000326420200005
PM 24304257
ER
PT J
AU Oyer, SL
Nagel, W
Mulligan, JK
AF Oyer, Samuel L.
Nagel, Whitney
Mulligan, Jennifer K.
TI Differential expression of adhesion molecules by sinonasal fibroblasts
among control and chronic rhinosinusitis patients
SO AMERICAN JOURNAL OF RHINOLOGY & ALLERGY
LA English
DT Article
ID NASAL POLYPOSIS; EOSINOPHIL INFILTRATION; TNF-ALPHA; ENDOTHELIAL-CELLS;
CHRONIC SINUSITIS; LUNG FIBROBLASTS; INFLAMMATION; BUDESONIDE; VCAM-1;
ICAM-1
AB Background: Chronic rhinosinusitis (CRS) is characterized by inflammatory cell migration into sinus tissue with resultant inflammation fueled by a milieu of cytokines. Fibroblasts may contribute to inflammation through expression of leukocyte adhesion molecules such as vascular cell adhesion molecule (VCAM) and intercellular adhesion molecule (ICAM). VCAM attracts eosinophils and mast cells contributing to Th2 skewing, and ICAM attracts neutrophils and to a lesser degree, eosinophils, and contributes to mixed Th1/Th2 skewing. The purpose of this study was to compare sinus fibroblast adhesion molecule expression ex vivo among CRS subtypes and in vitro after cytokine stimulation.
Methods: Sinus biopsy specimens were taken from control patients (n = 13), CRS without nasal polyposis (CRSsNP, n = 6), and CRS with nasal polyposis (CRSwNP, n = 15). Ex vivo levels of VCAM and ICAM were measured by flow cytometry from single cell suspensions of tissue biopsy specimens. Changes in VCAM and ICAM expression to cytokine exposure were assessed using in vitro cultured sinonasal fibroblasts treated with tumor necrosis factor (TNF)-alpha, interleukin (IL)-4, or interferon (IFN)-gamma.
Results: Ex vivo VCAM expression was lowest in controls, higher in CRSsNP, and highest in CRSwNP. In vitro stimulation with TNF-alpha and IL-4, but not IFN-gamma, increased VCAM among CRSsNP, while expression in CRSwNP remained elevated with all treatments except IFN-gamma. Ex vivo ICAM expression was elevated in both CRS subtypes. In vitro stimulation with TNF-alpha and IFN-gamma, but not IL-4, increased ICAM expression in all patients with the largest effects among the CRSsNP subgroup.
Conclusion: Sinonasal fibroblast expression of adhesion molecules in sinusitis varies by disease state and is selectively influenced by exposure to inflammatory cytokines.
C1 [Oyer, Samuel L.; Nagel, Whitney; Mulligan, Jennifer K.] Med Univ S Carolina, Div Rhinol & Sinus Surg, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA.
[Oyer, Samuel L.; Nagel, Whitney; Mulligan, Jennifer K.] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA.
[Mulligan, Jennifer K.] Ralph H Johnson Vet Affairs Med Ctr, Dept Surg, Res Serv, Charleston, SC USA.
RP Mulligan, JK (reprint author), MSC 550,135 Rutledge Ave, Charleston, SC 29425 USA.
EM konopa@musc.edu
FU American Rhinologic Society as part of the Centralized Otolaryngology
Research Efforts (CORE) Grants program; Flight Attendant Medical
Research Institutes
FX Funded by a grant to SL Oyer from the American Rhinologic Society as
part of the Centralized Otolaryngology Research Efforts (CORE) Grants
program, and a grant to JK Mulligan from the Flight Attendant Medical
Research Institutes. The remaining author has no conflicts of interest
to declare pertaining to this article
NR 28
TC 5
Z9 5
U1 0
U2 0
PU OCEAN SIDE PUBLICATIONS INC
PI PROVIDENCE
PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA
SN 1945-8924
EI 1945-8932
J9 AM J RHINOL ALLERGY
JI Am. J. Rhinol. Allergy
PD SEP-OCT
PY 2013
VL 27
IS 5
BP 381
EP 386
DI 10.2500/ajra.2013.27.3934
PG 6
WC Otorhinolaryngology
SC Otorhinolaryngology
GA 249EL
UT WOS:000326759700014
PM 24119601
ER
PT J
AU Privette, ED
Werth, VP
AF Privette, Emily D.
Werth, Victoria P.
TI Update on pathogenesis and treatment of CLE
SO CURRENT OPINION IN RHEUMATOLOGY
LA English
DT Review
DE Cutaneous Lupus Disease Area and Severity Index; Cutaneous Lupus
Erythematous; hydroxychloroquine; interferon
ID CUTANEOUS LUPUS-ERYTHEMATOSUS; AICARDI-GOUTIERES SYNDROME; BLOOD
MONONUCLEAR-CELLS; DISEASE-ACTIVITY; SEVERITY INDEX; RENAL-DISEASE;
EFFICACY; THERAPY; SMOKING; HYDROXYCHLOROQUINE
AB Purpose of review Cutaneous Lupus Erythematous (CLE) is an autoimmune disease in which patients may present with isolated skin findings or have CLE associated with underlying systemic disease. The most significant recent studies on its pathogenesis and therapeutic management are reviewed here.
Recent findings Patients with subacute and Discoid Lupus Erythematous had elevated Interferon score, about a third of all cases of SCLE could be attributed to previous drug exposure, and smoking may be more closely associated with CLE than Systemic Lupus Erythematous (SLE). An underlying genetic defect in some subsets of CLE patients may also be shared with SLE. Efficacy of antimalarial therapy is enhanced by increasing treatment duration or maintaining higher blood drug concentrations. Combination antimalarials that include quinacrine, thalidomide analogs, and Mycophenalate Mofetil may also be effective in refractory CLE.
Summary The pathogenesis of CLE remains unclear, and is likely multifactorial. Identified associations with subsets of CLE suggest future research questions in CLE pathogenesis. Subsets of CLE associated with interface dermatitis may share an underlying genetic defect in interferon signaling with SLE. The Cutaneous Lupus Disease Area and Severity Index is a valuable and widely used tool allowing standardized assessment and reporting of cutaneous disease activity and damage. More evidence is available to guide treatment of refractory CLE, but larger studies are needed.
Video abstract
http://links.lww.com/COR/A4.
C1 [Privette, Emily D.; Werth, Victoria P.] Univ Penn, Sch Med, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA.
[Privette, Emily D.; Werth, Victoria P.] Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA.
RP Werth, VP (reprint author), Perelman Ctr Adv Med, Dept Dermatol, Suite 1-330A,3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA.
EM werth@mail.med.upenn.edu
FU Department of Veterans Affairs (Veterans Health Administration, Office
of Research and Development, Biomedical Laboratory Research and
Development); National Institutes of Health [NIH K24-AR 02207]
FX This material is based upon work supported by a Merit Review Grant from
the Department of Veterans Affairs (Veterans Health Administration,
Office of Research and Development, Biomedical Laboratory Research and
Development) and by the National Institutes of Health (NIH K24-AR 02207)
to V.P.W.
NR 43
TC 7
Z9 8
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-8711
EI 1531-6963
J9 CURR OPIN RHEUMATOL
JI Curr. Opin. Rheumatol.
PD SEP
PY 2013
VL 25
IS 5
BP 584
EP 590
DI 10.1097/BOR.0b013e32836437ba
PG 7
WC Rheumatology
SC Rheumatology
GA 248KD
UT WOS:000326697400004
PM 23872903
ER
PT J
AU Jacobs, RL
Harper, N
He, W
Rather, CG
Castiblanco, J
Carrillo, A
Manoharan, M
Avadhanam, N
Liu, Y
Ingale, P
Andrews, CP
Ramirez, DA
Ahuja, SK
AF Jacobs, R. L.
Harper, N.
He, W.
Rather, C. G.
Castiblanco, J.
Carrillo, A.
Manoharan, M.
Avadhanam, N.
Liu, Y.
Ingale, P.
Andrews, C. P.
Ramirez, D. A.
Ahuja, S. K.
TI Evaluation of ultra-rush immunotherapy for Virginia live oak in a pollen
challenge chamber identifies cytokine and transcriptional correlates of
protection
SO ALLERGY
LA English
DT Meeting Abstract
CT World Allergy and Asthma Congress of the
European-Academy-of-Allergy-and-Clinical-Immunology and
World-Allergy-Organization
CY JUN 22-26, 2013
CL Milan, ITALY
SP European Acad Allergy & Clin Immunol, World Allergy Org
C1 [Jacobs, R. L.; Rather, C. G.; Andrews, C. P.; Ramirez, D. A.] Biogen Res Chamber, San Antonio, TX USA.
[Harper, N.; He, W.; Castiblanco, J.; Carrillo, A.; Manoharan, M.; Avadhanam, N.; Liu, Y.; Ingale, P.; Ahuja, S. K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Harper, N.; He, W.; Castiblanco, J.; Carrillo, A.; Manoharan, M.; Avadhanam, N.; Liu, Y.; Ingale, P.; Ahuja, S. K.] South Texas Vet Hlth Care Syst, Vet Adm Ctr Personalized Med, San Antonio, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD SEP
PY 2013
VL 68
SU 97
SI SI
BP 20
EP 20
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 227VH
UT WOS:000325142900044
ER
PT J
AU Land, AM
Nelson, GA
Bell, SG
Denby, KJ
Estrada, CA
Willett, LL
AF Land, Andrew M.
Nelson, George A.
Bell, Stephen G.
Denby, Kara J.
Estrada, Carlos A.
Willett, Lisa L.
TI Widening the Differential for Brain Masses in Human Immunodeficiency
Virus-Positive Patients: Syphilitic Cerebral Gummata
SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES
LA English
DT Article
DE Syphilis; HIV; Neurosyphilis; Gumma
ID HIV-INFECTION; NEUROSYPHILIS
AB A 39-year-old man with newly diagnosed human immunodeficiency virus (HIV) infection was admitted with right-sided weakness, right-sided vision loss and slurred speech, which worsened over several weeks. Brain imaging revealed bilateral intraparenchymal ring-enhancing lesions and enhancement of the right optic nerve. Serological findings were positive for venereal disease research laboratory test, whereas the cerebrospinal fluid venereal disease research laboratory test was nonreactive. Brain biopsy suggested a diagnosis of syphilitic cerebral gummata, and the patient's improvement with penicillin and dexamethasone further supported this etiology. Syphilitic cerebral gummata have rarely been reported in patients with HIV infection. This patient demonstrates that cerebral gummata should be considered in the differential diagnosis in immunocompromised patients with characteristic brain masses, that HIV and syphilis often coexist with early neurosyphilis appearing more frequently in this patient population and that normal cerebrospinal fluid studies may not represent a true lack of syphilitic activity in HIV patients.
C1 [Land, Andrew M.; Nelson, George A.; Bell, Stephen G.] Univ Alabama Birmingham, Tinsley Harrison Internal Med Residency Program, Birmingham, AL 35294 USA.
[Denby, Kara J.] Univ Alabama Birmingham, Sch Med, Birmingham, AL 35294 USA.
[Estrada, Carlos A.; Willett, Lisa L.] Univ Alabama Birmingham, Birmingham Hosp, Div Gen Internal Med, Birmingham, AL 35294 USA.
[Estrada, Carlos A.] Birmingham Vet Affairs Med Ctr, Vet Affairs Qual Scholars Fellowship Program, Birmingham, AL USA.
RP Land, AM (reprint author), Univ Alabama Birmingham, BDB 327,1720 2nd Ave South, Birmingham, AL 35294 USA.
EM amland@uab.edu
FU Department of Veterans Affairs National Quality Scholars Fellowship
(VAQS); Department of Veterans Affairs Office of Academic Affiliations
(OAA)
FX The Department of Veterans Affairs National Quality Scholars Fellowship
(VAQS) is funded by the Department of Veterans Affairs Office of
Academic Affiliations (OAA). The opinions expressed in this article are
those of the contributing authors alone and do not necessarily reflect
the views, opinions or policies of the Department of Veterans Affairs.
NR 13
TC 2
Z9 3
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0002-9629
EI 1538-2990
J9 AM J MED SCI
JI Am. J. Med. Sci.
PD SEP
PY 2013
VL 346
IS 3
BP 253
EP 255
DI 10.1097/MAJ.0b013e31828c9f22
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 242MX
UT WOS:000326247500020
PM 23588265
ER
PT J
AU Bersohn, MM
Turner, MP
Traiger, GL
Frost, AE
Shapiro, S
AF Bersohn, Malcolm M.
Turner, Michelle P.
Traiger, Glenna L.
Frost, Adaani E.
Shapiro, Shelley
TI Systemic BP and Heart Rate as Prognostic Indicators in Pulmonary
Arterial Hypertension
SO CHEST
LA English
DT Article
ID REVEAL REGISTRY; DISEASE MANAGEMENT; FAILURE; PREDICTORS; INSIGHTS;
OUTCOMES; ASSOCIATION; GUIDELINES; DIAGNOSIS; MORTALITY
AB Background: Heart rate (HR) and systolic BP (SBP) are significant multivariate predictors of survival in patients with pulmonary arterial hypertension (PAH) as part of a 19-element formula. To what extent HR and BP alone predict survival and future hospitalization in patients with PAH is unknown.
Methods: We analyzed data from the Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL Registry), a prospective, observational study of patients with PAH. Patients were analyzed by quintile (Q) according to values of HR, SBP, and SBP/HR. Kaplan-Meier curves were calculated by Q for survival and freedom from hospitalization.
Results: For patients in the worst Q, 1-year survival after enrollment was 85% +/- 2% for SBP, 86% +/- 2% for HR, and 84% +/- 2% for SBP/HR vs 91% +/- 1% for the middle three Qs (P < .001). Hospitalization occurred more frequently than mortality but with a similar pattern among Qs. One-year survival after first follow-up of patients in the worst Q for change (Delta) in SBP since enrollment was 85% +/- 2% (P = .004), 86% +/- 2% for Delta HR (P = .12), and 84% +/- 2% for Delta SBP/HR (P = .024) vs the middle three Qs (Delta SBP: 91% +/- 1%; Delta HR: 90% +/- 1%; Delta SBP/HR: 90% +/- 1%).
Conclusions: Changes in vital signs from enrollment to first follow-up were less predictive of mortality than the values of vital-sign parameters at either enrollment or first follow-up. HR, SBP, and SBP/HR at enrollment identified high-risk groups with survival differences of 5% to 7% and freedom from hospitalization differences of 9% to 11% vs lower-risk groups. SBP/HR defines the highest-risk group, including most of the high-risk patients defined by HR and SBP separately.
C1 [Bersohn, Malcolm M.; Shapiro, Shelley] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Bersohn, Malcolm M.; Shapiro, Shelley] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Turner, Michelle P.] ICON Late Phase & Outcomes Res, San Francisco, CA USA.
[Traiger, Glenna L.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Frost, Adaani E.] Baylor Coll Med, Houston, TX 77030 USA.
RP Bersohn, MM (reprint author), VA Greater Angeles Healthcare Syst, Cardiol 111E,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM mbersohn@ucla.edu
FU Cotherix Inc
FX Funding and support for the REVEAL Registry were provided by Cotherix
Inc, and its affiliate Actelion Pharmaceuticals US Inc.
NR 15
TC 3
Z9 3
U1 3
U2 4
PU AMER COLL CHEST PHYSICIANS
PI NORTHBROOK
PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA
SN 0012-3692
EI 1931-3543
J9 CHEST
JI Chest
PD SEP
PY 2013
VL 144
IS 3
BP 959
EP 965
DI 10.1378/chest.12-2572
PG 7
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 241JC
UT WOS:000326161700034
PM 23598723
ER
PT J
AU Yusin, JS
Klaustermeyer, W
Simmons, CW
Baum, M
AF Yusin, J. S.
Klaustermeyer, W.
Simmons, C. W.
Baum, M.
TI Desensitization in patients with beta-lactam drug allergy
SO ALLERGOLOGIA ET IMMUNOPATHOLOGIA
LA English
DT Article
DE Beta-lactam antibiotic; Hypersensitivity; Desensitization
ID PENICILLIN ALLERGY; IMMEDIATE HYPERSENSITIVITY; CLINICAL HISTORY;
CROSS-REACTIVITY; TOLERABILITY; EXPERIENCE; REAGENTS; IMIPENEM
AB Background: Patients with a history of beta-lactam antibiotic allergy are often admitted to the hospital with severe or life-threatening infections requiring beta-lactam antibiotics. Strict avoidance of beta lactams to such patients may prevent them from getting adequate coverage and can lead to an increase in the use of alternative antibiotics, which can predispose to antibiotic resistance. Past studies revealed a lower incidence of pen allergy then patients' histories suggest. Fortunately today, there are three options for patients presenting with a history of beta-lactam allergy. Penicillin skin testing, beta-lactam challenge or beta-lactam desensitization.
Recently Pre Pen has been FDA re-approved and when combined with Pen G is a valid way to determine if patients are able to tolerate beta-lactam antibiotic. When these agents are not available one must decide about desensitization or challenge. When a patient has a positive penicillin skin test, desensitization or beta-lactam avoidance are the only options.
This paper reviews the safety of beta-lactam desensitization.
Objective: To perform a chart review on patients desensitised with beta lactam to determine if desensitizations can be performed safely without minimal complications. Methods: A retrospective chart review was performed on allergy and immunology inpatient consultations for beta-lactam desensitization between September 2003 and August 2006 at the Cedars-Sinai Medical Centre in Los Angeles. Patient data and outcomes of desensitization were analysed.
Results: A total of 13 intravenous desensitizations were performed on 12 patients. The patients consisted of eight females and four males with an average age of 65 years. Age range was 36-92 years old. All 13 intravenous desensitizations were completed without complications. No patient required a slower rate of desensitization or discontinuance of the desensitization. Patients were able to tolerate the initial therapeutic dose of their beta-lactam antibiotic and were then able to complete full therapeutic courses of their antibiotic.
Conclusion: Beta-lactam antibiotic sensitivity continues to present a challenging problem for physicians. Patients with drug resistant infections who are unable to obtain skin testing or who test positive to skin tests may need either a challenge or desensitization. Desensitization, saved for those with a convincing beta-lactam hypersensitivity history is often the choice of last resort given the associated cost and risk of anaphylaxis. However, once desensitization is complete, patients are usually able to tolerate full doses of antibiotics for full treatment length with minimal side effects. Published by Elsevier Espana, S.L. on behalf of SEICAP.
C1 [Yusin, J. S.; Simmons, C. W.; Baum, M.] Greater Los Angeles VA Hlth Care Syst, Los Angeles, CA USA.
[Klaustermeyer, W.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA.
RP Yusin, JS (reprint author), Greater Los Angeles VA Hlth Care Syst, Los Angeles, CA USA.
EM Joseph.Yusin2@va.gov
FU Department of Veterans Affairs
FX This material is based upon work supported by the Department of Veterans
Affairs.
NR 23
TC 2
Z9 2
U1 0
U2 4
PU ELSEVIER DOYMA SL
PI BARCELONA
PA TRAVESERA DE GARCIA, 17-21, BARCELONA, 08021, SPAIN
SN 0301-0546
EI 1578-1267
J9 ALLERGOL IMMUNOPATH
JI Allergol. Immunopath.
PD SEP-OCT
PY 2013
VL 41
IS 5
BP 298
EP 303
DI 10.1016/j.aller.2012.06.003
PG 6
WC Allergy; Immunology
SC Allergy; Immunology
GA 237BL
UT WOS:000325843100004
PM 23177979
ER
PT J
AU Clark, KB
AF Clark, Kevin B.
TI New Therapeutic Bearings for Repositioned Drugs
SO CURRENT TOPICS IN MEDICINAL CHEMISTRY
LA English
DT Editorial Material
C1 Vet Affairs Greater Los Angeles Healthcare Syst, Res & Dev Serv, Los Angeles, CA 90073 USA.
RP Clark, KB (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Res & Dev Serv, 4229 SE Harney St, Los Angeles, CA 90073 USA.
NR 0
TC 3
Z9 3
U1 1
U2 6
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
EMIRATES
SN 1568-0266
EI 1873-4294
J9 CURR TOP MED CHEM
JI Curr. Top. Med. Chem.
PD SEP
PY 2013
VL 13
IS 18
BP 2281
EP 2282
PG 2
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 238EX
UT WOS:000325926500006
PM 24059466
ER
PT J
AU Clark, KB
Eisenstein, EM
Krahl, SE
AF Clark, Kevin B.
Eisenstein, Edward M.
Krahl, Scott E.
TI Calcium Antagonists: A Ready Prescription for Treating Infectious
Diseases?
SO CURRENT TOPICS IN MEDICINAL CHEMISTRY
LA English
DT Review
DE Antibiotic tolerance or resistance; antimicrobial drugs; biotechnology;
disease transmission and virulence; microbial pathogens and parasites;
pharmaceuticals
ID WORLD-HEALTH-ORGANIZATION; LEISHMANIA L. CHAGASI; ANTIMICROBIAL AGENTS;
ANTIBIOTIC-RESISTANCE; CA2+ CHANNEL; OLD DRUGS; IN-VITRO; PROTOZOAN
PARASITES; FILAMENTOUS FUNGUS; CANDIDA-ALBICANS
AB Emergence of new and medically resistant pathogenic microbes continues to escalate toward worldwide public health, wild habitat, and commercial crop and livestock catastrophes. Attempts at solving this problem with sophisticated modern biotechnologies, such as smart vaccines and microbicidal and microbistatic drugs that precisely target parasitic bacteria, fungi, and protozoa, remain promising without major clinical and industrial successes. However, discovery of a more immediate, broad spectrum prophylaxis beyond conventional epidemiological approaches might take no longer than the time required to fill a prescription at your neighborhood pharmacy. Findings from a growing body of research suggest calcium antagonists, long approved and marketed for various human cardiovascular and neurological indications, may produce safe, efficacious antimicrobial effects. As a general category of drugs, calcium antagonists include compounds that disrupt passage of Ca2+ molecules across cell membranes and walls, sequestration and mobilization of free intracellular Ca2+, and downstream binding proteins and sensors of Ca2+-dependent regulatory pathways important for proper cell function. Administration of calcium antagonists alone at current therapeutically relevant doses and schedules, or with synergistic compounds and additional antimicrobial medications, figures to enhance host immunoprotection by directly altering pathogen infection sequences, life cycles, homeostasis, antibiotic tolerances, and numerous other infective, survival, and reproductive processes. Short of being miracle drugs, calcium antagonists are welcome old drugs with new tricks capable of controlling some of the most virulent and pervasive global infectious diseases of plants, animals, and humans, including Chagas' disease, malaria, and tuberculosis.
C1 [Eisenstein, Edward M.; Krahl, Scott E.] Vet Affairs Greater Los Angeles Hlth Care Syst, Res & Dev Serv, Los Angeles, CA 90073 USA.
[Krahl, Scott E.] Univ Calif Los Angeles, Dept Neurosurg, Los Angeles, CA USA.
RP Clark, KB (reprint author), 4229 S E Harney St, Portland, OR 97206 USA.
EM kbclarkphd@yahoo.com
NR 143
TC 3
Z9 3
U1 1
U2 15
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
EMIRATES
SN 1568-0266
EI 1873-4294
J9 CURR TOP MED CHEM
JI Curr. Top. Med. Chem.
PD SEP
PY 2013
VL 13
IS 18
BP 2291
EP 2305
PG 15
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 238EX
UT WOS:000325926500008
PM 24059464
ER
PT J
AU Garvey, WT
AF Garvey, W. Timothy
TI NEW TOOLS FOR WEIGHT-LOSS THERAPY ENABLE A MORE ROBUST MEDICAL MODEL FOR
OBESITY TREATMENT: RATIONALE FOR A COMPLICATIONS-CENTRIC APPROACH
SO ENDOCRINE PRACTICE
LA English
DT Review
ID RANDOMIZED CONTROLLED-TRIAL; LIFE-STYLE INTERVENTION; BODY-MASS INDEX;
CONTROLLED-RELEASE PHENTERMINE/TOPIRAMATE; LIPOPROTEIN SUBCLASS PROFILE;
TOPIRAMATE EXTENDED-RELEASE; TYPE-2 DIABETES-MELLITUS; OBSTRUCTIVE
SLEEP-APNEA; CARDIOVASCULAR RISK; METABOLIC SYNDROME
AB Objective: Recent advances in lifestyle intervention programs, pharmacotherapy, and bariatric surgery have enabled the development of medical models for the treatment of obesity. Regarding pharmacotherapy, in 2012 the U.S. Food and Drug Administration approved two new effective and safe weight-loss medications, phentermine/topiramate extended release and lorcaserin, which has greatly augmented options for medically assisted weight loss.
Methods: The rationale for advantages of a complications- centric medical model over current body mass index (BMI)-centric indications for therapy is examined.
Results: Currently, the baseline BMI level is the principle determinant of indications for obesity treatment using medication and surgery. However, the BMI-centric approach fails to target therapy to those obese patients who will benefit most from weight loss. In contrast, a complications- centric medical model is proposed that will earmark the modality and intensity of the therapeutic intervention based on the presence and severity of complications that can be ameliorated by weight loss.
Conclusion: The complications-centric approach to "medicalizing" obesity care employs weight loss primarily as a tool to treat obesity-related complications and promotes the optimization of health outcomes, the benefit/ risk ratio, and the cost-effectiveness of therapy.
C1 [Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA.
[Garvey, W. Timothy] Birmingham VA Med Ctr, Birmingham, AL USA.
RP Garvey, WT (reprint author), Univ Alabama Birmingham, Dept Nutr Sci, Webb 232,1720 2nd Ave South, Birmingham, AL 35294 USA.
EM garveyt@uab.edu
FU Weight Watchers International Inc.; Amylin; Merck
FX Dr. Garvey is an advisor for Alkermes Plc, Daiichi-Sankyo Inc,
LipoScience, VIVUS Inc, Janssen Pharmaceuticals, Novo Nordisk, Eisai,
AstraZeneca/Bristol-Myers-Squibb, and Tethys. He is a speaker for Merck
& Company and Amylin Pharmaceuticals Inc and holds stock in
Bristol-Myers Squibb Company, Isis/Genzyme, Merck, Pfizer Inc, Eli Lilly
and Company, and VIVUS Inc. He has received research support from
Amylin, Merck, and Weight Watchers International Inc.
NR 77
TC 16
Z9 17
U1 0
U2 6
PU AMER ASSOC CLINICAL ENDOCRINOLOGISTS
PI JACKSONVILLE
PA 245 RIVERSIDE AVENUE, STE 200, JACKSONVILLE, FL 32202 USA
SN 1530-891X
EI 1934-2403
J9 ENDOCR PRACT
JI Endocr. Pract.
PD SEP-OCT
PY 2013
VL 19
IS 5
BP 864
EP 874
DI 10.4158/EP13263.RA
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 235WC
UT WOS:000325750800022
PM 24014010
ER
PT J
AU Loewenstein, G
Friedman, JY
McGill, B
Ahmad, S
Linck, S
Sinkula, S
Beshears, J
Choi, JJ
Kolstad, J
Laibson, D
Madrian, BC
List, JA
Volpp, KG
AF Loewenstein, George
Friedman, Joelle Y.
McGill, Barbara
Ahmad, Sarah
Linck, Suzanne
Sinkula, Stacey
Beshears, John
Choi, James J.
Kolstad, Jonathan
Laibson, David
Madrian, Brigitte C.
List, John A.
Volpp, Kevin G.
TI Consumers' misunderstanding of health insurance
SO JOURNAL OF HEALTH ECONOMICS
LA English
DT Article
DE Insurance; Behavioral economics; Simplification
ID INFORMATION; MARKETS; CHOICE; COVERAGE
AB We report results from two surveys of representative samples of Americans with private health insurance. The first examines how well Americans understand, and believe they understand, traditional health insurance coverage. The second examines whether those insured under a simplified all-copay insurance plan will be more likely to engage in cost-reducing behaviors relative to those insured under a traditional plan with deductibles and coinsurance, and measures consumer preferences between the two plans. The surveys provide strong evidence that consumers do not understand traditional plans and would better understand a simplified plan, but weaker evidence that a simplified plan would have strong appeal to consumers or change their healthcare choices. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Loewenstein, George] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA.
[Friedman, Joelle Y.] Univ Penn, Leonard Davis Inst, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA.
[McGill, Barbara] Colchester Consulting Grp, Glencoe, IL 60022 USA.
[Linck, Suzanne] Humana, Strateg Consultant Product Dev Small Business, Green Bay, WI 54344 USA.
[Sinkula, Stacey] Humana, Managing Actuary Small Business, Green Bay, WI 54344 USA.
[Beshears, John] Stanford Grad Sch Business, Stanford, CA 94305 USA.
[Choi, James J.] Yale Sch Management, New Haven, CT 06520 USA.
[Kolstad, Jonathan] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA.
[Laibson, David] Harvard Univ, Dept Econ, Cambridge, MA 02138 USA.
[Madrian, Brigitte C.] Harvard Univ, Cambridge, MA 02138 USA.
[List, John A.] Univ Chicago, Chicago, IL USA.
[Volpp, Kevin G.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Volpp, Kevin G.] Leonard Davis Inst, Ctr Hlth Incent & Behav Econ, Davis, CA USA.
[Volpp, Kevin G.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Volpp, Kevin G.] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA.
[Ahmad, Sarah] Dev Humana, Commercial Product, Louisville, KY 40202 USA.
RP Loewenstein, G (reprint author), Carnegie Mellon Univ, 5000 Forbes Ave,319 C Porter Hall, Pittsburgh, PA 15213 USA.
EM gl20@andrew.cmu.edu; bmcgill@colchesterconsultinggroup.com;
sahmad@humana.com; ssinkula@humana.com; beshears@stanford.edu;
james.choi@yale.edu; jkolstad@wharton.upenn.edu; Dlaibson@harvard.edu;
brigitte_madrian@harvard.edu; jlist@uchicago.edu
RI Choi, James/D-4706-2012
NR 29
TC 28
Z9 28
U1 2
U2 29
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-6296
EI 1879-1646
J9 J HEALTH ECON
JI J. Health Econ.
PD SEP
PY 2013
VL 32
IS 5
BP 850
EP 862
DI 10.1016/j.jhealeco.2013.04.004
PG 13
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA 239YD
UT WOS:000326061000008
PM 23872676
ER
PT J
AU Ganguly, K
Byl, NN
Abrams, GM
AF Ganguly, Karunesh
Byl, Nancy N.
Abrams, Gary M.
TI Neurorehabilitation: Motor Recovery After Stroke as an Example
SO ANNALS OF NEUROLOGY
LA English
DT Article
ID TRANSCRANIAL MAGNETIC STIMULATION; INDUCED MOVEMENT THERAPY; UPPER-LIMB
RECOVERY; SPINAL-CORD-INJURY; FUNCTIONAL RECOVERY; BRAIN-STIMULATION;
ISCHEMIC-STROKE; CORTICAL STIMULATION; CONTROLLED-TRIAL; CLINICAL-TRIALS
AB The field of neurorehabilitation aims to translate neuroscience research toward the goal of maximizing functional recovery after neurological injury. A growing body of research indicates that the fundamental principles of neurological rehabilitation are applicable to a broad range of congenital, degenerative, and acquired neurological disorders. In this perspective, we will focus on motor recovery after acquired brain injuries such as stroke. Over the past few decades, a large body of basic and clinical research has created an experimental and theoretical foundation for approaches to neurorehabilitation. Recent randomized clinical trials all emphasize the requirement for intense progressive rehabilitation programs to optimally enhance recovery. Moreover, advances in multimodal assessment of patients with neuroimaging and neurophysiological tools suggest the possibility of individualized treatment plans based on recovery potential. There are also promising indications for medical as well as noninvasive brain stimulation paradigms to facilitate recovery. Ongoing or planned clinical studies should provide more definitive evidence. We also highlight unmet needs and potential areas of research. Continued research built upon a robust experimental and theoretical foundation should help to develop novel treatments to improve recovery after neurological injury. Ann Neurol 2013;74:373-381
C1 [Ganguly, Karunesh; Abrams, Gary M.] Univ Calif San Francisco, San Francisco Vet Adm Med Ctr, Dept Neurol & Rehabil, San Francisco, CA 94143 USA.
[Ganguly, Karunesh; Abrams, Gary M.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
[Byl, Nancy N.] Univ Calif San Francisco, Dept Phys Therapy & Rehabil Sci, San Francisco, CA 94143 USA.
RP Ganguly, K (reprint author), 127 Neurol,4150 Clement St, San Francisco, CA 94121 USA.
EM Karunesh.Ganguly@ucsf.edu
FU Department of Veterans Affairs [B6674W]; American Heart Association
[0875016N]; Burroughs Wellcome Fund (CAMS); University of California,
California Institute for Technology, Research and Innovation Science
(CITRIS) [A115093, P0036258]
FX Supported by grants to K. G. and G. A. from the Department of Veterans
Affairs (B6674W) and to K. G. from the American Heart Association
(0875016N) and the Burroughs Wellcome Fund (CAMS). Also supported by
funding to N.N.B. from the University of California, California
Institute for Technology, Research and Innovation Science (CITRIS)
Award# A115093, P0036258 (PI Jacob Rosen).
NR 105
TC 4
Z9 4
U1 1
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0364-5134
EI 1531-8249
J9 ANN NEUROL
JI Ann. Neurol.
PD SEP
PY 2013
VL 74
IS 3
BP 373
EP 381
DI 10.1002/ana.23994
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 232BJ
UT WOS:000325463100013
PM 25813243
ER
PT J
AU Li, PY
Gan, Y
Sun, BL
Zhang, F
Lu, BF
Gao, YQ
Liang, WM
Thomson, AW
Chen, J
Hu, XM
AF Li, Peiying
Gan, Yu
Sun, Bao-Liang
Zhang, Feng
Lu, Binfeng
Gao, Yanqin
Liang, Weimin
Thomson, Angus W.
Chen, Jun
Hu, Xiaoming
TI Adoptive Regulatory T-Cell Therapy Protects Against Cerebral Ischemia
SO ANNALS OF NEUROLOGY
LA English
DT Article
ID BLOOD-BRAIN-BARRIER; EXPERIMENTAL STROKE; NEUTROPHIL INFILTRATION; REG
CELLS; IN-VIVO; MATRIX-METALLOPROTEINASE-9; DISEASE; INJURY; GAMMA;
VITRO
AB ObjectiveRecent evidence suggests that functional deficiency in regulatory T cells (Tregs), an innate immunomodulator, exacerbates brain damage after cerebral ischemia. We therefore evaluated the effect of Treg transfer in rodent models of ischemic stroke and further investigated the mechanism underlying Treg-afforded neuroprotection.
MethodsWe examined the therapeutic potential of Tregs and the mechanisms of neuroprotection in vivo in 2 rodent models of ischemic stroke and in vitro in Treg-neutrophil cocultures using a combined approach including cell-specific depletion, gene knockout mice, and bone marrow chimeras.
ResultsSystemic administration of purified Tregs at 2, 6, or even 24 hours after middle cerebral artery occlusion resulted in a marked reduction of brain infarct and prolonged improvement of neurological functions lasting out to 4 weeks. Treg-afforded neuroprotection was accompanied by attenuated blood-brain barrier (BBB) disruption during early stages of ischemia, decreased cerebral inflammation, and reduced infiltration of peripheral inflammatory cells into the lesioned brain. Surprisingly, Tregs exerted early neuroprotection without penetrating into the brain parenchyma or inhibiting the activation of residential microglia. Rather, both in vivo and in vitro studies demonstrated that Tregs suppressed peripheral neutrophil-derived matrix metallopeptidase-9 production, thus preventing proteolytic damage of the BBB. In addition to its potent central neuroprotection, Treg treatment was shown to ameliorate poststroke lymphopenia, suggesting a beneficial effect on immune status.
InterpretationOur study suggests that Treg adoptive therapy is a novel and potent cell-based therapy targeting poststroke inflammatory dysregulation and neurovascular disruption. Ann Neurol 2013;74:458-471
C1 [Li, Peiying; Zhang, Feng; Gao, Yanqin; Liang, Weimin; Chen, Jun; Hu, Xiaoming] Fudan Univ, Huashan Hosp, Dept Anesthesiol, State Key Lab Med Neurobiol, Shanghai 200433, Peoples R China.
[Li, Peiying; Zhang, Feng; Gao, Yanqin; Liang, Weimin; Chen, Jun; Hu, Xiaoming] Fudan Univ, Inst Brain Sci, Shanghai 200433, Peoples R China.
[Li, Peiying; Gan, Yu; Zhang, Feng; Chen, Jun; Hu, Xiaoming] Univ Pittsburgh, Sch Med, Ctr Cerebrovasc Dis Res, Pittsburgh, PA USA.
[Sun, Bao-Liang] Shandong Univ, Affiliated Hosp, Taishan Med Coll, Dept Neurol, Tai An, Shandong, Peoples R China.
[Sun, Bao-Liang] Shandong Univ, Affiliated Hosp, Taishan Med Coll, Key Lab Cerebral Microcirculat, Tai An, Shandong, Peoples R China.
[Lu, Binfeng; Thomson, Angus W.] Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA USA.
[Thomson, Angus W.] Univ Pittsburgh, Sch Med, Dept Surg, Starzl Transplantat Inst, Pittsburgh, PA USA.
[Chen, Jun; Hu, Xiaoming] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
RP Hu, XM (reprint author), Univ Pittsburgh, Med Ctr, Dept Neurol, Pittsburgh, PA 15213 USA.
EM chenj2@upmc.edu; hux2@upmc.edu
RI Gao, Yanqin/I-6790-2016
OI Gao, Yanqin/0000-0002-4915-9819
FU Veterans Health Administration (GRECC); NIH NINDS [NS36736, NS43802,
NS45048]; American Heart Association [10POST4150028, 10SDG2560122];
Chinese Natural Science Foundation [8107094]
FX This work was supported by the Veterans Health Administration (GRECC
pilot grant to J.C.), NIH NINDS grants (NS36736, NS43802, and NS45048 to
J.C.), and grants from the American Heart Association (10POST4150028 to
X. H., 10SDG2560122 to F.Z.). B.-L. S. was supported by Chinese Natural
Science Foundation grants (8107094).
NR 38
TC 49
Z9 52
U1 4
U2 30
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0364-5134
EI 1531-8249
J9 ANN NEUROL
JI Ann. Neurol.
PD SEP
PY 2013
VL 74
IS 3
BP 458
EP 471
DI 10.1002/ana.23815
PG 14
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 232BJ
UT WOS:000325463100024
PM 23674483
ER
PT J
AU Baruch, L
Sherman, O
AF Baruch, Lawrence
Sherman, Olga
TI Inaccuracy of Point-of-Care International Normalized Ratio in
Rivaroxaban-Treated Patients
SO ANNALS OF PHARMACOTHERAPY
LA English
DT Article
DE rivaroxaban; point-of-care INR; INR; anticoagulation; factor Xa
inhibitor; deep vein thrombosis
AB Objective: To report 2 cases in which point-of-care international normalized ratios (POC-INRs) measured using a Hemochron Jr. Signature Elite device (International Technidyne Corporation) were inaccurate in rivaroxaban-treated patients. Case Summaries: Therapy in an 86-year-old man with atrial fibrillation was converted from warfarin to rivaroxaban 15 mg twice daily because of a deep venous thrombotic event despite an INR of 2.4, which was within the therapeutic range. One week later a POC-INR was inadvertently measured, which was 6.3. In light of the POC-INR being markedly elevated, a laboratory test for INR was performed, which gave a result of 2.74. Therapy in a 66-year-old man was converted from war-farin to rivaroxaban 15 mg twice daily because of unstable INRs and a pulmonary embolism despite a therapeutic INR. Seven days after rivaroxaban was started, the patient's POC-INR was 9.2; simultaneously measured laboratory-determined INR was 2.0. For both patients, coagulation tests performed on follow-up visits revealed continued discordance between the POC and laboratory assays. Discussion: Rivaroxaban is an oral factor Xa inhibitor with a predictable pharmacokinetic profile, allowing for a fixed-dose regimen without the need for coagulation monitoring. When patients' therapy is switched from rivaroxaban to warfarin, it is recommended that the drugs be given concurrently until the INR is 2.0 or higher, to ensure adequate anticoagulation during this well-recognized vulnerable period for stroke. POC testing is a common method of INR assessment in clinical practice. During ROCKET-AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation), POC-INRs were measured exclusively with the INRatio device (Hemosense), and values above 4 were seen very rarely (0.25%), which indicates that the values determined in our patients were highly unusual. Conclusions: Our 2 patients receiving rivaroxaban had POC-INRs elevated beyond what was expected; these measurements were discordant from INRs simultaneously measured via the laboratory. A prospective evaluation assessing the accuracy of other commonly used POC-INR devices in patients receiving rivaroxaban would determine whether our findings extend to other devices. Until that time, laboratory measurement of INR or POC-INR using an INRatio device is recommended when patients' therapy is transitioned from rivaroxaban to warfarin.
C1 [Baruch, Lawrence] James J Peters VA Med Ctr, Program Med, Bronx, NY USA.
[Baruch, Lawrence] Mt Sinai Sch Med, Dept Cardiol, New York, NY USA.
[Sherman, Olga] James J Peters VA Med Ctr, Pharm Program, Bronx, NY USA.
RP Baruch, L (reprint author), James J Peters VA Med Ctr, Program Med, Bronx, NY USA.
EM lawrence.baruch@va.gov
NR 1
TC 0
Z9 0
U1 0
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1060-0280
EI 1542-6270
J9 ANN PHARMACOTHER
JI Ann. Pharmacother.
PD SEP
PY 2013
VL 47
IS 9
BP 1210
EP 1212
DI 10.1177/1060028013503129
PG 3
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 225UR
UT WOS:000324989700014
PM 24259738
ER
PT J
AU Groeneveld, PW
AF Groeneveld, Peter W.
TI Can Advanced Healthcare Technology Save Money?
SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES
LA English
DT Editorial Material
DE Editorials; chest pain diagnosis; computed tomographic angiography;
emergency medicine; health economics; hospital costs
ID CORONARY; ANGIOGRAPHY; PREDICTORS; IMPACT; TRIAL; SCORE; RISK
C1 [Groeneveld, Peter W.] Philadelphia Vet Affairs Med Ctr, Dept Vet Affairs, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
[Groeneveld, Peter W.] Univ Penn, Sch Med, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA.
[Groeneveld, Peter W.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
RP Groeneveld, PW (reprint author), Univ Penn, Sch Med, 1229 Blockley Hall,423 Serv Dr, Philadelphia, PA 19104 USA.
EM petergro@mail.med.upenn.edu
NR 13
TC 0
Z9 0
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-7705
EI 1941-7713
J9 CIRC-CARDIOVASC QUAL
JI Circ.-Cardiovasc. Qual. Outcomes
PD SEP
PY 2013
VL 6
IS 5
BP 509
EP 510
DI 10.1161/CIRCOUTCOMES.113.000533
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 219RM
UT WOS:000324526400003
PM 24021698
ER
PT J
AU Ulu, A
Harris, TR
Morisseau, C
Miyabe, C
Inoue, H
Schuster, G
Dong, H
Iosif, AM
Liu, JY
Weiss, RH
Chiamvimonvat, N
Imig, JD
Hammock, BD
AF Ulu, Arzu
Harris, Todd R.
Morisseau, Christophe
Miyabe, Christina
Inoue, Hiromi
Schuster, Gertrud
Dong, Hua
Iosif, Ana-Maria
Liu, Jun-Yan
Weiss, Robert H.
Chiamvimonvat, Nipavan
Imig, John D.
Hammock, Bruce D.
TI Anti-inflammatory Effects of omega-3 Polyunsaturated Fatty Acids and
Soluble Epoxide Hydrolase Inhibitors in Angiotensin-II-Dependent
Hypertension
SO JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
LA English
DT Article
DE omega-3 polyunsaturated fatty acids; EPA; DHA; soluble epoxide hydrolase
inhibitors; angiotensin-II-dependent hypertension
ID PLACEBO-CONTROLLED TRIAL; LONG-CHAIN OMEGA-3-FATTY-ACIDS;
BLOOD-PRESSURE; DOCOSAHEXAENOIC ACID; CARDIOVASCULAR-DISEASE;
CYTOCHROME-P450 EPOXYGENASES; KNOCKOUT MICE; DOUBLE-BLIND; FISH-OIL;
METABOLITES
AB The mechanisms underlying the anti-inflammatory and antihypertensive effects of long-chain -3 polyunsaturated fatty acids (-3 PUFAs) are still unclear. The epoxides of an -6 fatty acid, arachidonic acid epoxyeicosatrienoic acids also exhibit antihypertensive and anti-inflammatory effects. Thus, we hypothesized that the major -3 PUFAs, including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), may lower the blood pressure and attenuate renal markers of inflammation through their epoxide metabolites. Here, we supplemented mice with an -3 rich diet for 3 weeks in a murine model of angiotensin-II-dependent hypertension. Also, because EPA and DHA epoxides are metabolized by soluble epoxide hydrolase (sEH), we tested the combination of an sEH inhibitor and the -3 rich diet. Our results show that -3 rich diet in combination with the sEH inhibitor lowered Ang-II, increased the blood pressure, further increased the renal levels of EPA and DHA epoxides, reduced renal markers of inflammation (ie, prostaglandins and MCP-1), downregulated an epithelial sodium channel, and upregulated angiotensin-converting enzyme-2 message and significantly modulated cyclooxygenase and lipoxygenase metabolic pathways. Overall, our findings suggest that epoxides of the -3 PUFAs contribute to lowering systolic blood pressure and attenuating inflammation in part by reduced prostaglandins and MCP-1 and by upregulation of angiotensin-converting enzyme-2 in angiotensin-II-dependent hypertension.
C1 [Ulu, Arzu; Harris, Todd R.; Morisseau, Christophe; Miyabe, Christina; Dong, Hua; Liu, Jun-Yan; Hammock, Bruce D.] Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA.
[Ulu, Arzu; Harris, Todd R.; Morisseau, Christophe; Miyabe, Christina; Dong, Hua; Liu, Jun-Yan; Hammock, Bruce D.] Univ Calif Davis, UC Davis Comprehens Canc Ctr, Davis, CA 95616 USA.
[Inoue, Hiromi; Weiss, Robert H.] Univ Calif Davis, Sch Med, Div Nephrol, Davis, CA 95616 USA.
[Schuster, Gertrud] Univ Calif Davis, Sch Med, Dept Nutr, Davis, CA 95616 USA.
[Chiamvimonvat, Nipavan] Univ Calif Davis, Sch Med, Dept Internal Med, Div Cardiovasc Med, Davis, CA 95616 USA.
[Iosif, Ana-Maria] Univ Calif Davis, Sch Med, Dept Publ Hlth, Div Biostat, Davis, CA 95616 USA.
[Weiss, Robert H.; Chiamvimonvat, Nipavan] US Dept Vet Affairs, Med Ctr, Sacramento, CA USA.
[Imig, John D.] Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA.
RP Hammock, BD (reprint author), Univ Calif Davis, Dept Entomol, 1 Shields Ave, Davis, CA 95616 USA.
EM bdhammock@ucdavis.edu
RI Liu, Jun-Yan/D-8890-2014
OI Imig, John/0000-0002-9668-2899
FU NIEHS [R01 ES002710]; NIEHS Superfund Research Program [P42 ES004699];
NIH [5UO1CA86402, 1R01CA135401-01A1, 1R01DK082690-01A1, HL59699,
DK38226]; Medical Service of the US Department of Veterans' Affairs;
NIDDK [U24 DK097154]; National Center for Advancing Translational
Sciences, NIH [UL1 TR000002]; NIH T32 training grant in basic and
translational cardiovascular science [T32 HL86350]
FX Supported by NIEHS grant R01 ES002710 and NIEHS Superfund Research
Program grant P42 ES004699; NIH grants 5UO1CA86402 (Early Detection
Research Network), 1R01CA135401-01A1, and 1R01DK082690-01A1; and the
Medical Service of the US Department of Veterans' Affairs (all to R. H.
W.). Analytical work was partially supported by the NIH and NIDDK grant
U24 DK097154. Studies and analyses performed by J. D. Imig were
supported by NIH grants HL59699 and DK38226. Analyses performed by A.-M.
Iosif were supported by the National Center for Advancing Translational
Sciences, NIH, through grant UL1 TR000002. T. R. Harris is supported by
NIH T32 training grant in basic and translational cardiovascular science
(T32 HL86350). B. D. Hammock is a George and Judy Marcus senior fellow
of the American Asthma Foundation, and was supported by NIEHS grant R01
ES002710 and NIEHS Superfund Research Program grant P42 ES004699.
NR 65
TC 29
Z9 31
U1 4
U2 20
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0160-2446
EI 1533-4023
J9 J CARDIOVASC PHARM
JI J. Cardiovasc. Pharmacol.
PD SEP
PY 2013
VL 62
IS 3
BP 285
EP 297
DI 10.1097/FJC.0b013e318298e460
PG 13
WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy
SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy
GA 219WX
UT WOS:000324543400008
PM 23676336
ER
PT J
AU Choi, SY
Chacon-Heszele, MF
Huang, LW
McKenna, S
Wilson, FP
Zuo, XF
Lipschutz, JH
AF Choi, Soo Young
Chacon-Heszele, Maria F.
Huang, Liwei
McKenna, Sarah
Wilson, F. Perry
Zuo, Xiaofeng
Lipschutz, Joshua H.
TI Cdc42 Deficiency Causes Ciliary Abnormalities and Cystic Kidneys
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID IN-SITU HYBRIDIZATION; RAC1 SMALL GTPASES; CELL-POLARITY;
EPITHELIAL-CELLS; PRIMARY CILIOGENESIS; SPINDLE ORIENTATION; KUPFFERS
VESICLE; PRIMARY CILIUM; KIF3A SUBUNIT; KINESIN-II
AB Ciliogenesis and cystogenesis require the exocyst, a conserved eight-protein trafficking complex that traffics ciliary proteins. In culture, the small GTPase Cdc42 co-localizes with the exocyst at primary cilia and interacts with the exocyst component Sec10. The role of Cdc42 in vivo, however, is not well understood. Here, knockdown of cdc42 in zebrafish produced a phenotype similar to sec10 knockdown, including tail curvature, glomerular expansion, and mitogen-activated protein kinase (MAPK) activation, suggesting that cdc42 and sec10 cooperate in ciliogenesis. In addition, cdc42 knockdown led to hydrocephalus and loss of photoreceptor cilia. Furthermore, there was a synergistic genetic interaction between zebrafish cdc42 and sec10, suggesting that cdc42 and sec10 function in the same pathway. Mice lacking Cdc42 specifically in kidney tubular epithelial cells died of renal failure within weeks of birth. Histology revealed cystogenesis in distal tubules and collecting ducts, decreased ciliogenesis in cyst cells, increased tubular cell proliferation, increased apoptosis, increased fibrosis, and led to MAPK activation, all of which are features of polycystic kidney disease, especially nephronophthisis. Taken together, these results suggest that Cdc42 localizes the exocyst to primary cilia, whereupon the exocyst targets and docks vesicles carrying ciliary proteins. Abnormalities in this pathway result in deranged ciliogenesis and polycystic kidney disease.
C1 [Choi, Soo Young; Chacon-Heszele, Maria F.; Huang, Liwei; McKenna, Sarah; Wilson, F. Perry; Zuo, Xiaofeng; Lipschutz, Joshua H.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
[Wilson, F. Perry] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
[Lipschutz, Joshua H.] Philadelphia Vet Affairs Med Ctr, Dept Med, Philadelphia, PA USA.
RP Lipschutz, JH (reprint author), Room 405C,Clin Res Bldg,415 Curie Blvd, Philadelphia, PA 19104 USA.
EM jhlipsch@mail.med.upenn.edu
FU Department of Veterans Affairs [1L01BX00820]; National Institutes of
Health [DK069909, DK047757, DK093625]; Satellite Healthcare; NephHope
Postdoctoral Fellowship; University of Pennsylvania Translational
Medicine Institute
FX This work was supported in part by grants from the Department of
Veterans Affairs (VA Merit Award 1L01BX00820 to J.H.L.), National
Institutes of Health (DK069909 and DK047757 to J.H.L., and DK093625 to
L. H.), Satellite Healthcare (Norman S. Coplon Extramural Research Grant
to J.H.L), a NephHope Postdoctoral Fellowship (to M. F. C. H.), and the
University of Pennsylvania Translational Medicine Institute (pilot grant
to J.H.L).
NR 63
TC 20
Z9 20
U1 0
U2 7
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046-6673
EI 1533-3450
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD SEP
PY 2013
VL 24
IS 9
BP 1435
EP 1450
DI 10.1681/ASN.2012121236
PG 16
WC Urology & Nephrology
SC Urology & Nephrology
GA 227EO
UT WOS:000325092900015
PM 23766535
ER
PT J
AU Arterburn, D
Livingston, EH
Olsen, MK
Smith, VA
Kavee, AL
Kahwati, LC
Henderson, WG
Maciejewski, ML
AF Arterburn, David
Livingston, Edward H.
Olsen, Maren K.
Smith, Valerie A.
Kavee, Andrew L.
Kahwati, Leila C.
Henderson, William G.
Maciejewski, Matthew L.
TI Predictors of initial weight loss after gastric bypass surgery in twelve
veterans affairs medical centers
SO OBESITY RESEARCH & CLINICAL PRACTICE
LA English
DT Article
DE Gastric bypass surgery
ID LONG-TERM MORTALITY; BARIATRIC SURGERY; SURGICAL CARE; OUTCOMES;
QUALITY; IMPACT; IMPROVEMENT; OPERATIONS; FACILITIES; PROGRAM
AB The objective of this study was to identify determinants of significant weight loss one year after gastric bypass surgery among United States veterans. Using data from the Veterans Affairs (VA) Surgical Quality Improvement Program, we identified 516 veterans who had gastric bypass surgery (24% laparoscopic) in one of twelve VA bariatric centers in 2000-2006 and one or more postoperative weight measures. The probability of losing 30% or more of baseline weight at one year was estimated via logistic regression, examining the following potential predictor variables: age, gender, race, marital status, body mass index (BMI), American Society of Anesthesiologists class, comorbidity burden, smoking status, diabetes medications taken and surgical procedure (open or laparoscopic). The 516 cases had a mean BMI of 49 kg/m(2), mean age of 51.5 years, 74% were male, 77% were Caucasian, and 55% were married. The predicted mean weight loss was 76 (95% CI: 73-79) pounds (22%) at six months and 109 (95% CI: 104-114) pounds (32%) at one-year. Based upon estimated individual trajectories of 370 patients with adequate follow-up data, 58% of the sample lost 30% or more of their baseline weight at one year; and <1% lost <10% of their baseline weight at 1 year. In the logistic regression, patients were more likely to Lose 30% or more of their baseline weight if they were female (odds ratio (OR) = 2.5, p < 0.01) or Caucasian (OR = 2.3, p < 0.01). We conclude that gastric bypass surgery yields significant weight loss for most patients in Veterans Affairs Medical Centers, but is particularly effective for female and Caucasian patients. (C) 2012 Asian Oceanian Association for the Study of Obesity. Published by Elsevier Ltd. All rights reserved.
C1 [Arterburn, David] Grp Hlth Res Inst, Seattle, WA USA.
[Arterburn, David] Univ Washington, Dept Med, Div Gen Internal Med, Seattle, WA 98195 USA.
[Livingston, Edward H.] Univ Texas SW Med Ctr Dallas, Div Gastrointestinal & Endocrine Surg, Dallas, TX 75390 USA.
[Livingston, Edward H.] Vet Adm North Texas Hlth Care Syst, Dallas, TX USA.
[Livingston, Edward H.] Univ Texas Arlington, Dept Biomed Engn, Arlington, TX 76019 USA.
[Olsen, Maren K.; Smith, Valerie A.; Kavee, Andrew L.; Maciejewski, Matthew L.] Durham VA Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC 27705 USA.
[Olsen, Maren K.] Duke Univ, Dept Biostat & Bioinformat, Durham, NC 27706 USA.
[Henderson, William G.] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Henderson, William G.] Univ Colorado, Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO USA.
[Henderson, William G.] Univ Colorado, Hlth Sci Ctr, Colorado Hlth Outcomes Program, Aurora, CO USA.
[Maciejewski, Matthew L.] Duke Univ, Dept Med, Div Gen Internal Med, Durham, NC 27706 USA.
RP Maciejewski, ML (reprint author), Durham VA Med Ctr, Ctr Hlth Serv Res Primary Care 152, 411 West Chapel Hill St,Suite 600, Durham, NC 27705 USA.
EM arterburn.d@ghc.org; matthew.maciejewski@va.gov
FU Office of Research and Development, Health Services Research and
Development Service, Department of Veterans Affairs [IIR 05-201, SHP
08-137]; Takeda Pharmaceuticals; Novartis; Surgical Review Corporation
FX This work was supported by the Office of Research and Development,
Health Services Research and Development Service, Department of Veterans
Affairs (IIR 05-201, SHP 08-137). The authors also would like to
acknowledge the VA Surgical Quality Data Use Group (SQDUG) for its role
as scientific advisors and for the critical review of data use and
analysis presented in this manuscript. Dr. Arterburn was formerly with
the Cincinnati VA and Dr. Livingston was formerly with the Dallas VA.
Dr. Maciejewski has received consultation funds from Takeda
Pharmaceuticals, Novartis and the Surgical Review Corporation, and owns
stock in Amgen. The views expressed are those of the authors and do not
reflect the views of the Department of Veterans Affairs, the United
States Government, Duke University, the University of Texas Southwestern
Medical Center, the University of Texas, the University of Colorado, the
Group Health Research Institute, or the University of Washington.
NR 28
TC 7
Z9 7
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1871-403X
EI 1878-0318
J9 OBES RES CLIN PRACT
JI Obes. Res. Clin. Pract.
PD SEP-OCT
PY 2013
VL 7
IS 5
BP E367
EP E376
DI 10.1016/j.orcp.2012.02.009
PG 10
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 232EU
UT WOS:000325475100006
PM 24304479
ER
PT J
AU Aschbacher, K
O'Donovan, A
Wolkowitz, OM
Dhabhar, FS
Su, YL
Epel, E
AF Aschbacher, Kirstin
O'Donovan, Aoife
Wolkowitz, Owen M.
Dhabhar, Firdaus S.
Su, Yali
Epel, Elissa
TI Good stress, bad stress and oxidative stress: Insights from anticipatory
cortisol reactivity
SO PSYCHONEUROENDOCRINOLOGY
LA English
DT Article
DE Oxidative stress; Biological aging; Chronic stress; Acute stress;
DNA/RNA damage; Cortisol; Hypothalamic-pituitaryadrenal axis; Eustress;
Resilience; Reactive oxygen species
ID PSYCHOLOGICAL STRESS; IMMUNE FUNCTION; MEDIATION ANALYSIS; PERCEIVED
STRESS; TELOMERE LENGTH; FREE-RADICALS; DNA-DAMAGE; RESPONSES; DISEASE;
ALLOSTASIS
AB Chronic psychological stress appears to accelerate biological aging, and oxidative damage is an important potential mediator of this process. However, the mechanisms by which psychological stress promotes oxidative damage are poorly understood. This study investigates the theory that cortisol increases in response to an acutely stressful event have the potential to either enhance or undermine psychobiological resilience to oxidative damage, depending on the body's prior exposure to chronic psychological stress. In order to achieve a range of chronic stress exposure, forty-eight post-menopausal women were recruited in a case-control design that matched women caring for spouses with dementia (a chronic stress model) with similarly aged control women whose spouses were healthy. Participants completed a questionnaire assessing perceived stress over the previous month and provided fasting blood. Three markers of oxidative damage were assessed: 8-iso-prostaglandin F-2 alpha (IsoP), lipid peroxidation, 8-hydroxyguanosine (8-oxoG) and 8-hydroxy-2'-deoxyguanosine (8-OHdG), reflecting oxidative damage to RNA/DNA respectively. Within approximately one week, participants completed a standardized acute laboratory stress task while salivary cortisol responses were measured. The increase from 0 to 30 min was defined as "peak" cortisol reactivity, while the increase from 0 to 15 min was defined as "anticipatory" cortisol reactivity, representing a cortisol response that began while preparing for the stress task. Women under chronic stress had higher 8-oxoG, oxidative damage to RNA (p < .01). A moderated mediation model was tested, in which it was hypothesized that heightened anticipatory cortisol reactivity would mediate the relationship between perceived stress and elevated oxidative stress damage, but only among women under chronic stress. Consistent with this model, bootstrapped path analysis found significant indirect paths from perceived stress to 8-oxoG and IsoP (but not 8-OHdG) via anticipatory cortisol reactivity, showing the expected relations among chronically stressed participants ( p <= .01) Intriguingly, among those with low chronic stress exposure, moderate (compared to low) levels of perceived stress were associated with reduced levels of oxidative damage. Hence, this study supports the emerging model that chronic stress exposure promotes oxidative damage through frequent and sustained activation of the hypothalamic-pituitary-adrenal axis. It also supports the less studied model of 'eustress' - that manageable levels of life stress may enhance psychobiological resilience to oxidative damage. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Aschbacher, Kirstin; O'Donovan, Aoife; Wolkowitz, Owen M.; Epel, Elissa] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Aschbacher, Kirstin] Inst Integrat Hlth, Baltimore, MD USA.
[O'Donovan, Aoife] San Francisco VA Med Ctr, San Francisco, CA USA.
[Dhabhar, Firdaus S.] Stanford Univ, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA.
[Dhabhar, Firdaus S.] Stanford Univ, Stanford Inst Immun Transplantat & Infect, Palo Alto, CA 94304 USA.
[Su, Yali] SilverCreek Technol, Gilbert, AZ USA.
RP Aschbacher, K (reprint author), Univ Calif San Francisco, Sch Med, Dept Psychiat, 3333 Calif St,Suite 465, San Francisco, CA 94143 USA.
EM kirstin.aschbacher@ucsf.edu
FU NIH/NIA [R01 AG030424-01A2]; NIH/NHLBI [K23 HL112955]; Institute for
Integrative Health, Baltimore, MD; NIH/NCRR UCSF-CTSI [UL1 RR024131]
FX This research was supported in part by funding from the NIH/NIA grant
R01 AG030424-01A2, as well as support for the first author from the
NIH/NHLBI grant K23 HL112955 and The Institute for Integrative Health,
Baltimore, MD. The CTSI CCRC and the Core Immunology Lab were supported
by NIH/NCRR UCSF-CTSI Grant No. UL1 RR024131. The funders had no role in
study design, data collection and analysis, decision to publish or
preparation of the manuscript.
NR 54
TC 48
Z9 50
U1 8
U2 63
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4530
J9 PSYCHONEUROENDOCRINO
JI Psychoneuroendocrinology
PD SEP
PY 2013
VL 38
IS 9
BP 1698
EP 1708
DI 10.1016/j.psyneuen.2013.02.004
PG 11
WC Endocrinology & Metabolism; Neurosciences; Psychiatry
SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry
GA 228LM
UT WOS:000325188300024
PM 23490070
ER
PT J
AU Loftis, JM
AF Loftis, Jennifer M.
TI Indolamine 2,3-dioxygenase regulation and neuropsychiatric symptoms
SO PSYCHONEUROENDOCRINOLOGY
LA English
DT Letter
DE Anxiety; Depression; Cytokine; Inflammation; Tryptophan
ID DEPRESSION
C1 [Loftis, Jennifer M.] Portland VA Med Ctr, Res & Dev Serv, Portland, OR 97239 USA.
[Loftis, Jennifer M.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97239 USA.
RP Loftis, JM (reprint author), Portland VA Med Ctr, Res & Dev Serv, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM loftisj@ohsu.edu
FU BLRD VA [I01 BX002061]; NIDA NIH HHS [P50 DA018165]
NR 8
TC 1
Z9 1
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4530
J9 PSYCHONEUROENDOCRINO
JI Psychoneuroendocrinology
PD SEP
PY 2013
VL 38
IS 9
BP 1829
EP 1830
DI 10.1016/j.psyneuen.2013.05.020
PG 2
WC Endocrinology & Metabolism; Neurosciences; Psychiatry
SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry
GA 228LM
UT WOS:000325188300039
PM 23810316
ER
PT J
AU Yehuda, R
Hildebrandt, T
Spiegel, D
AF Yehuda, Rachel
Hildebrandt, Tom
Spiegel, David
TI Introduction to Special Issue of Psychoneuroendocrinology "Enduring
effects of Traumatic Stress: Molecular and Hormonal Mechanisms"
SO PSYCHONEUROENDOCRINOLOGY
LA English
DT Editorial Material
C1 [Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Psychiat, Traumat Stress Studies Div, New York, NY USA.
[Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, Mental Hlth Care Ctr, Bronx, NY 10468 USA.
[Yehuda, Rachel] Icahn Sch Med Mt Sinai, Fishberg Dept Neurosci, New York, NY USA.
[Hildebrandt, Tom] Icahn Sch Med Mt Sinai, Dept Psychiat, Eating & Weight Disorders Program, New York, NY USA.
[Spiegel, David] Stanford Univ, Sch Med, Dept Psychiat, Stanford, CA 94305 USA.
RP Yehuda, R (reprint author), James J Peters Vet Affairs Med Ctr, Mt Sinai Sch Med, Dept Psychiat, Traumat Stress Studies Div, 526 OOMH PTSD 116-A,130 West Kingsbridge Rd, Bronx, NY 10468 USA.
EM rachel.yehuda@va.gov
OI Hildebrandt, Thomas/0000-0001-7054-9590
NR 6
TC 0
Z9 0
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4530
J9 PSYCHONEUROENDOCRINO
JI Psychoneuroendocrinology
PD SEP
PY 2013
VL 38
IS 9
BP 1832
EP 1834
DI 10.1016/j.psyneuen.2013.06.018
PG 3
WC Endocrinology & Metabolism; Neurosciences; Psychiatry
SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry
GA 228LM
UT WOS:000325188300041
PM 23849599
ER
PT J
AU Daskalakis, NP
Bagot, RC
Parker, KJ
Vinkers, CH
de Kloet, ER
AF Daskalakis, Nikolaos P.
Bagot, Rosemary C.
Parker, Karen J.
Vinkers, Christiaan H.
de Kloet, E. R.
TI The three-hit concept of vulnerability and resilience: Toward
understanding adaptation to early-life adversity outcome
SO PSYCHONEUROENDOCRINOLOGY
LA English
DT Article
DE Vulnerability; Resilience; Stress adaptation; Three hit; HPA axis;
Developmental programming; Epigenetics Genetic predisposition; Early
life environment; Later life environment
ID PITUITARY-ADRENAL AXIS; CORTICOTROPIN-RELEASING-FACTOR;
GLUCOCORTICOID-RECEPTOR GENE; POSTTRAUMATIC-STRESS-DISORDER; MARMOSET
CALLITHRIX-JACCHUS; INFANT SQUIRREL-MONKEYS; EARLY SOCIAL ENRICHMENT;
MATERNAL-CARE; DIFFERENTIAL SUSCEPTIBILITY; ADRENOCORTICAL-RESPONSE
AB Stressful experiences during early-life can modulate the genetic programming of specific brain circuits underlying emotional and cognitive aspects of behavioral adaptation to stressful experiences later in life. Although this programming effect exerted by experience-related factors is an important determinant of mental health, its outcome depends on cognitive inputs and hence the valence an individual assigns to a given environmental context. From this perspective we will highlight, with studies in rodents, non-human primates and humans, the three-hit concept of vulnerability and resilience to stress-related mental disorders, which is based on gene environment interactions during critical phases of perinatal and juvenile brain development. The three-hit (i.e., hit-1: genetic predisposition, hit-2: early-life environment, and hit-3: later-life environment) concept accommodates the cumulative stress hypothesis stating that in a given context vulnerability is enhanced when failure to cope with adversity accumulates. Alternatively, the concept also points to the individual's predictive adaptive capacity, which underlies the stress inoculation and match/mismatch hypotheses. The latter hypotheses propose that the experience of relatively mild early-life adversity prepares for the future and promotes resilience to similar challenges in later-life; when a mismatch occurs between early and later-life experience, coping is compromised and vulnerability is enhanced. The three-hit concept is fundamental for understanding how individuals can either be prepared for coping with life to come and remain resilient or are unable to do so and succumb to a stress-related mental disorder, under seemingly identical circumstances. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Daskalakis, Nikolaos P.] Icahn Sch Med Mt Sinai, Dept Psychiat, Traumat Stress Studies Div, New York, NY USA.
[Daskalakis, Nikolaos P.] Icahn Sch Med Mt Sinai, Dept Psychiat, Lab Mol Neuropsychiat, New York, NY USA.
[Daskalakis, Nikolaos P.] James J Peters Vet Affairs Med Ctr, Mental Hlth Care Ctr, PTSD Clin Res Program, Bronx, NY USA.
[Daskalakis, Nikolaos P.] James J Peters Vet Affairs Med Ctr, Lab Clin Neuroendocrinol & Neurochem, Bronx, NY USA.
[Daskalakis, Nikolaos P.; de Kloet, E. R.] Leiden Univ, Leiden Acad, Ctr Drug Res, Div Med Pharmacol, Leiden, Netherlands.
[Daskalakis, Nikolaos P.; de Kloet, E. R.] Leiden Univ, Leiden Univ Med Ctr, Leiden, Netherlands.
[Bagot, Rosemary C.] Douglas Mental Hlth Univ Inst, Neurosci Div, Montreal, PQ, Canada.
[Bagot, Rosemary C.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, Fishberg Dept Neurosci, Lab Mol Psychiat, New York, NY USA.
[Parker, Karen J.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA.
[Vinkers, Christiaan H.] Univ Med Ctr Utrecht, Rudolf Magnus Inst Neurosci, Dept Psychiat, Utrecht, Netherlands.
[Vinkers, Christiaan H.] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Div Pharmacol, Utrecht, Netherlands.
[Vinkers, Christiaan H.] Univ Utrecht, Rudolf Magnus Inst Neurosci, Utrecht, Netherlands.
RP Daskalakis, NP (reprint author), Mt Sinai Sch Med, Lab Mol Neuropsychiat, 1 Gustave L Levy Pl,Box 1668, New York, NY 10029 USA.
EM Nikolaos.daskalakis@mssm.edu
RI Daskalakis, Nikolaos/B-7930-2014; Parker, Karen/G-1347-2012
OI Daskalakis, Nikolaos/0000-0003-1660-9112; Parker,
Karen/0000-0002-6836-6338
FU Dutch Top-Institute Pharma [T5-209]; Royal Netherlands Academy for
Sciences; [NIH-R01HD67175]
FX We would like to thank the organizers of 42nd ISPNE Conference for
choosing our proposal for a Symposium. We would like to thank Dr. Esther
Nederhof for participating as a speaker in the Symposium. ND and EdK
were supported by the Dutch Top-Institute Pharma T5-209, and KP by the
NIH-R01HD67175. EdK was also supported by the Royal Netherlands Academy
for Sciences.
NR 200
TC 75
Z9 75
U1 10
U2 74
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4530
J9 PSYCHONEUROENDOCRINO
JI Psychoneuroendocrinology
PD SEP
PY 2013
VL 38
IS 9
BP 1858
EP 1873
DI 10.1016/j.psyneuen.2013.06.008
PG 16
WC Endocrinology & Metabolism; Neurosciences; Psychiatry
SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry
GA 228LM
UT WOS:000325188300045
PM 23838101
ER
PT J
AU Daskalakis, NP
Yehuda, R
Diamond, DM
AF Daskalakis, Nikolaos P.
Yehuda, Rachel
Diamond, David M.
TI Animal models in translational studies of PTSD
SO PSYCHONEUROENDOCRINOLOGY
LA English
DT Article
DE Post-traumatic stress disorder; PTSD; Animal model; Translational;
Bionnarkers; Therapeutics; Individual differences
ID POSTTRAUMATIC-STRESS-DISORDER; HIPPOCAMPUS-DEPENDENT MEMORY; NATIONAL
COMORBIDITY SURVEY; BDNF VAL66MET POLYMORPHISM; MENSTRUAL-CYCLE
MODULATION; MEDIAL PREFRONTAL CORTEX; HIGH-DOSE CORTICOSTERONE;
LONG-TERM POTENTIATION; HEALTHY-YOUNG MEN; DSM-IV DISORDERS
AB Understanding the neurobiological mechanisms of post-traumatic stress disorder (PTSD) is of vital importance for developing biomarkers and more effective pharmacotherapy for this disorder. The design of bidirectional translational studies addressing all facets of PTSD is needed. Animal models of PTSD are needed not only to capture the complexity of PTSD behavioral characteristics, but also to address experimentally the influence of variety of factors which might determine an individual's vulnerability or resilience to trauma, e.g., genetic predisposition, early-life experience and social support. The current review covers recent translational approaches to bridge the gap between human and animal PTSD research and to create a framework for discovery of biomarkers and novel therapeutics. Published by Elsevier Ltd.
C1 [Daskalakis, Nikolaos P.; Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Psychiat, Traumat Stress Studies Div, New York, NY USA.
[Daskalakis, Nikolaos P.; Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Psychiat, Lab Mol Neuropsychiat, New York, NY USA.
[Daskalakis, Nikolaos P.; Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, Mental Hlth Care Ctr, PTSD Clin Res Program, Bronx, NY USA.
[Daskalakis, Nikolaos P.; Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, Lab Clin Neuroendocrinol & Neurochem, Bronx, NY USA.
[Diamond, David M.] Vet Affairs Hosp, Res & Dev Serv, Tampa, FL USA.
[Diamond, David M.] Univ S Florida, Dept Psychol, Ctr Preclin & Clin Res PTSD, Tampa, FL 33620 USA.
[Diamond, David M.] Univ S Florida, Dept Mol Pharmacol & Physiol, Ctr Preclin & Clin Res PTSD, Tampa, FL 33620 USA.
RP Diamond, DM (reprint author), Univ S Florida, Dept Psychol, 4202 E Fowler Ave,PCD 4118G, Tampa, FL 33620 USA.
EM ddiamond@usf.edu
RI Daskalakis, Nikolaos/B-7930-2014
OI Daskalakis, Nikolaos/0000-0003-1660-9112
FU Department of Defense grant; Veterans Affairs Department
FX We would like to thank the organizers of 42nd ISPNE Conference for
choosing our proposal for a Symposium. We would like to thank Dr. Israel
Liberzon and Dr. Joseph Rayman for participating as speakers in the
Symposium. DMD was supported by Career Scientist and Merit Review Awards
from the Veterans Affairs Department during the production of this
review. NPD and RY were supported by a Department of Defense grant. The
opinions expressed in this review are those of the authors and not of
the Department of Veterans Affairs, Department of Defense or the US
government.
NR 276
TC 38
Z9 39
U1 8
U2 43
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4530
J9 PSYCHONEUROENDOCRINO
JI Psychoneuroendocrinology
PD SEP
PY 2013
VL 38
IS 9
BP 1895
EP 1911
DI 10.1016/j.psyneuen.2013.06.006
PG 17
WC Endocrinology & Metabolism; Neurosciences; Psychiatry
SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry
GA 228LM
UT WOS:000325188300048
PM 23845512
ER
PT J
AU Yehuda, R
Neylan, TC
Flory, JD
McFarlane, AC
AF Yehuda, Rachel
Neylan, Thomas C.
Flory, Janine D.
McFarlane, Alexander C.
TI The use of biomarkers in the military: From theory to practice
SO PSYCHONEUROENDOCRINOLOGY
LA English
DT Article
DE Biomarker; PTSD; Trauma; Military; Risk; Resilience; Neurobiology;
Combat exposure
ID POSTTRAUMATIC-STRESS-DISORDER; RISK-FACTORS; TRAUMA; PTSD; RESILIENCE;
DEPRESSION; DEPLOYMENT; VETERANS; EXPOSURE; IDENTIFICATION
AB This paper provides a summary of relevant issues covered in the conference, "The Use of Biomarkers in the Military: Theory to Practice" held at the New York Academy of Science on September 14, 2012. The conference covered the state of the science in identification of PTSD biomarkers, including, the definition of different classes of biomarkers pertaining to PTSD. The aim of the satellite conference was to bring together researchers who have been supported by the Department of Defense, Veterans Administration, National Institutes of Health, and other agencies around the world, who are interested in the identification of biomarkers for PTSD risk, diagnosis, symptom severity and treatment response, for a discussion of salient issues regarding biomarker development for PTSD, as well as special considerations for the use of biomarkers in the military. (C) 2013 Published by Elsevier Ltd.
C1 [Yehuda, Rachel; Flory, Janine D.] James J Peters VAMC, Dept Psychiat, Bronx, NY 10468 USA.
[Yehuda, Rachel; Flory, Janine D.] Mt Sinai Sch Med, Dept Psychiat & Neurosci, New York, NY USA.
[Neylan, Thomas C.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[Neylan, Thomas C.] San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA USA.
[McFarlane, Alexander C.] Univ Adelaide, Dept Psychiat, Adelaide, SA, Australia.
RP Yehuda, R (reprint author), James J Peters VAMC, 526 OOMH,130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM rachel.yehuda@va.gov
FU DOD [W81XWH-10-2-0072, W81XWH-09-2-0044]
FX This work was supported by the following funding: DOD W81XWH-10-2-0072
(RY) and DOD W81XWH-09-2-0044 (RY)
NR 43
TC 13
Z9 13
U1 0
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4530
J9 PSYCHONEUROENDOCRINO
JI Psychoneuroendocrinology
PD SEP
PY 2013
VL 38
IS 9
BP 1912
EP 1922
DI 10.1016/j.psyneuen.2013.06.009
PG 11
WC Endocrinology & Metabolism; Neurosciences; Psychiatry
SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry
GA 228LM
UT WOS:000325188300049
PM 23927936
ER
PT J
AU Hula, WD
Cherney, LR
Worrall, LE
AF Hula, William D.
Cherney, Leora R.
Worrall, Linda E.
TI Setting a Research Agenda to Inform Intensive Comprehensive Aphasia
Programs
SO TOPICS IN STROKE REHABILITATION
LA English
DT Article
DE aphasia; cost-benefit analysis; rehabilitation; treatment efficacy;
treatment effectiveness; treatment outcome
ID CLINICAL-OUTCOME RESEARCH; INDUCED LANGUAGE THERAPY; RANDOMIZED-TRIALS;
CLUSTER RANDOMIZATION; CONSORT STATEMENT; BROCAS APHASIA; STROKE;
RECOVERY; EFFICACY; HEALTH
AB Research into intensive comprehensive aphasia programs (ICAPs) has yet to show that this service delivery model is efficacious, effective, has cost utility, or can be broadly implemented. This article describes a phased research approach to the study of ICAPs and sets out a research agenda that considers not only the specific issues surrounding ICAPs, but also the phase of the research. Current ICAP research is in the early phases, with dosing and outcome measurement as prime considerations as well as refinement of the best treatment protocol. Later phases of ICAP research are outlined, and the need for larger scale collaborative funded research is recognized. The need for more rapid translation into practice is also acknowledged, and the use of hybrid models of phased research is encouraged within the ICAP research agenda.
C1 [Hula, William D.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
[Hula, William D.] Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA 15260 USA.
[Cherney, Leora R.] Rehabil Inst Chicago, Ctr Aphasia Res & Treatment, Chicago, IL USA.
[Cherney, Leora R.] Northwestern Univ, Chicago, IL 60611 USA.
[Worrall, Linda E.] Univ Queensland, Sch Hlth & Rehabil Sci, Brisbane, Qld, Australia.
RP Hula, WD (reprint author), VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
RI Worrall, Linda/D-2579-2010
OI Worrall, Linda/0000-0002-3283-7038
FU Veterans Affairs Rehabilitation Research and Development Career
Development Award [C6210M]; NHMRC [569935]
FX We acknowledge the Veterans Affairs Rehabilitation Research and
Development Career Development Award C6210M and NHMRC grant 569935 to
the Centre for Clinical Research Excellence in Aphasia Rehabilitation.
NR 69
TC 4
Z9 4
U1 2
U2 13
PU THOMAS LAND PUBLISHERS, INC
PI ST LOUIS
PA 255 JEFFERSON RD, ST LOUIS, MO 63119-3627 USA
SN 1074-9357
J9 TOP STROKE REHABIL
JI Top. Stroke Rehabil.
PD SEP-OCT
PY 2013
VL 20
IS 5
BP 409
EP 420
DI 10.1310/tsr2005-409
PG 12
WC Rehabilitation
SC Rehabilitation
GA 231WE
UT WOS:000325448300005
PM 24091283
ER
PT J
AU Juan, J
Hind, J
Jones, C
McCulloch, T
Gangnon, R
Robbins, J
AF Juan, Junerose
Hind, Jacqueline
Jones, Corinne
McCulloch, Timothy
Gangnon, Ron
Robbins, JoAnne
TI Case Study: Application of Isometric Progressive Resistance
Oropharyngeal Therapy Using the Madison Oral Strengthening Therapeutic
Device
SO TOPICS IN STROKE REHABILITATION
LA English
DT Article
DE deglutition; dysphagia; rehabilitation; strengthening; stroke
ID NECK-CANCER PATIENTS; PENETRATION-ASPIRATION SCALE; QOL OUTCOMES TOOL;
SWAL-QOL; DYSPHAGIA; STROKE; ADULTS; PNEUMONIA; EXERCISE; MUSCLE
AB Purpose: Isometric progressive resistance oropharyngeal (I-PRO) therapy improves swallowing function; however, current devices utilize a single sensor that provides limited information or are prohibitively expensive. This single-subject study presents results of I-PRO therapy, detraining, and maintenance using the 5-sensor Madison Oral Strengthening Therapeutic (MOST) device combined with upper esophageal sphincter (UES) dilatation. Methods: A 56-year-old female nurse who was 27 months post stroke and subsequent to traditional behavioral interventions and UES dilatations presented limited to gastrostomy tube intake only and expectorating all saliva. She completed 8 weeks of I-PRO therapy, 5 weeks of detraining, and 9 weeks of I-PRO maintenance (reduced frequency) followed by a third UES dilatation post intervention. Data included diet inventory, lingual pressures (MOST), lingual volume (magnetic resonance imaging), postswallow residue (videofluoroscopy), UES and pharyngeal pressures (high-resolution manometry), and quality of life (QOL). Results: Findings after 8 weeks of I-PRO therapy were progression to general oral diet, 15 lb weight gain, increased isometric pressures (Delta > 16 kPa) with transference to swallowing pressures, increased lingual volume (8.3%), reduced pharyngeal wall residue (P = .03), increased pharyngeal pressures (Delta > 43 mm Hg) and increased UES opening (nadir) pressures(Delta > 9 mm Hg) with improved temporopressure coordination across the pharynx, and improved QOL. After detraining, decreased isometric pressures and reduced UES opening were noted. After I-PRO maintenance, isometric anterior lingual pressures returned to levels noted after the 8 weeks of intervention. Conclusion: I-PRO therapy, facilitated by the MOST device combined with instrumental UES dilatation, improved swallow safety, increased oropharyngeal intake, and facilitated UES opening while enriching QOL.
C1 [Juan, Junerose; Hind, Jacqueline; Robbins, JoAnne] Univ Wisconsin, Dept Med, Madison, WI USA.
[Juan, Junerose; Hind, Jacqueline; Robbins, JoAnne] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ Clin Ctr, Madison, WI USA.
[Jones, Corinne; McCulloch, Timothy] Univ Wisconsin, Dept Surg, Madison, WI USA.
[Gangnon, Ron] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA.
RP Juan, J (reprint author), Univ Wisconsin, Dept Med, Madison, WI USA.
FU VA Merit Grant [C4796R]
FX This article is the result of work supported by VA Merit Grant C4796R
and resources at the Geriatric Research, Education, and Clinical Center
(GRECC) in the William S. Middleton Memorial Veterans Hospital. This is
GRECC manuscript #09. The senior author, Dr. Robbins, serves in a
leadership position for Swallow Solutions, LLC, and is an equity holder.
NR 31
TC 1
Z9 1
U1 2
U2 11
PU THOMAS LAND PUBLISHERS, INC
PI ST LOUIS
PA 255 JEFFERSON RD, ST LOUIS, MO 63119-3627 USA
SN 1074-9357
J9 TOP STROKE REHABIL
JI Top. Stroke Rehabil.
PD SEP-OCT
PY 2013
VL 20
IS 5
BP 450
EP 470
DI 10.1310/tsr2005-450
PG 21
WC Rehabilitation
SC Rehabilitation
GA 231WE
UT WOS:000325448300009
PM 24091287
ER
PT J
AU Bowles, DW
Weickhardt, A
Jimeno, A
AF Bowles, D. W.
Weickhardt, A.
Jimeno, A.
TI AFATINIB FOR THE TREATMENT OF PATIENTS WITH EGFR-POSITIVE NON-SMALL CELL
LUNG CANCER
SO DRUGS OF TODAY
LA English
DT Article
DE Afatinib; EGFR; Non-small cell lung cancer; BIBW-2992; Dual inhibitor
ID GROWTH-FACTOR RECEPTOR; ADVANCED SOLID TUMORS; ERBB FAMILY BLOCKER;
TYROSINE KINASE INHIBITOR; METASTATIC BREAST-CANCER; I DOSE-ESCALATION;
PHASE-I; OPEN-LABEL; ACQUIRED-RESISTANCE; BIBW 2992
AB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are valuable treatments for EGFR-mutated non-small cell lung cancer (NSCLC). Anti-EGFR anti-bodies are widely used in the treatment of head and neck squamous cell carcinomas (HNSCC) and in KRAS wildtype colorectal cancer. The first-generation, reversible EGFR inhibitors erlotinib and gefitinib in the first-line setting provide superior progression-free survival and quality of life compared to conventional chemotherapy in NSCLC harboring activating EGFR mutations. However, these therapies eventually fail and new options are needed. Afatinib is a novel irreversible inhibitor of the ErbB family members EGFR, tyrosine kinase-type cell surface receptors HER2 and HER4. It shows preclinical efficacy in NSCLC with common EGFR-activating mutations and the T790M mutation typically associated with EGFR TKI resistance. Preclinical activity is seen in other tumor types as well, including HNSCC. Clinically, afatinib has been evaluated in the broad-reaching LUX Lung trial program, with significant activity seen in the first and later-line settings. It is also under investigation in multiple other tumor types. This review will stress on afatinib's preclinical pharmacology, pharmacokinetics and clinical activity with a focus on NSCLC.
C1 [Bowles, D. W.; Jimeno, A.] Univ Colorado, Sch Med, Div Med Oncol, Denver, CO USA.
[Bowles, D. W.] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Weickhardt, A.] Austin Hosp, Olivia Newton John Canc & Wellness Ctr, Melbourne, Vic 3084, Australia.
RP Jimeno, A (reprint author), Univ Colorado Denver, Div Med Oncol, 12801 East 17th Ave,MS 8117, Aurora, CO 80045 USA.
EM antonio.jimeno@ucdenver.edu
NR 73
TC 7
Z9 8
U1 0
U2 18
PU PROUS SCIENCE, SAU-THOMSON REUTERS
PI BARCELONA
PA 398 PROVENCA, 08025 BARCELONA, SPAIN
SN 1699-3993
J9 DRUG TODAY
JI Drugs Today
PD SEP
PY 2013
VL 49
IS 9
BP 523
EP 535
DI 10.1358/dot.2013.49.9.2016610
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 225SO
UT WOS:000324982800001
PM 24086949
ER
PT J
AU Daskalakis, NP
Lehrner, A
Yehuda, R
AF Daskalakis, Nikolaos P.
Lehrner, Amy
Yehuda, Rachel
TI Endocrine Aspects of Post-traumatic Stress Disorder and Implications for
Diagnosis and Treatment
SO ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
LA English
DT Article
DE Stress; Sympathetic; Hypothalamic-pituitary-adrenal axis; Cortisol;
Post-traumatic stress disorder
ID GLUCOCORTICOID-RECEPTOR EXPRESSION; NATIONAL COMORBIDITY SURVEY; COMBAT
VETERANS; RISK-FACTORS; LOW CORTISOL; HOLOCAUST SURVIVORS; MAJOR
DEPRESSION; ANIMAL-MODEL; HPA AXIS; PTSD
AB Post-traumatic stress disorder (PTSD) is a serious, multisystem disorder with multiple medical comorbidities. This article reviews the current literature on the endocrine aspects of PTSD, specifically hypothalamic-pituitary-adrenal axis alterations indicative of low cortisol and increased glucocorticoid sensitivity, and the proposed mechanisms whereby these alterations increase risk or reflect pathophysiology. Discussion includes novel treatment innovations and directions for future research.
C1 [Daskalakis, Nikolaos P.; Lehrner, Amy; Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Psychiat, Traumat Stress Studies Div, New York, NY 10029 USA.
[Daskalakis, Nikolaos P.; Lehrner, Amy; Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Psychiat, Lab Mol Neuropsychiat, New York, NY 10029 USA.
[Daskalakis, Nikolaos P.; Lehrner, Amy; Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, PTSD Program, Mental Hlth Care Ctr, Bronx, NY 10468 USA.
[Daskalakis, Nikolaos P.; Lehrner, Amy; Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, Lab Clin Neuroendocrinol & Neurochem, Bronx, NY 10468 USA.
[Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA.
RP Daskalakis, NP (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, Lab Mol Neuropsychiat, Gustave L Levy Pl,Box 1668, New York, NY 10029 USA.
EM nikolaos.daskalakis@mssm.edu
RI Daskalakis, Nikolaos/B-7930-2014
OI Daskalakis, Nikolaos/0000-0003-1660-9112
NR 68
TC 38
Z9 42
U1 6
U2 34
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8529
J9 ENDOCRIN METAB CLIN
JI Endocrinol. Metabol. Clin. North Amer.
PD SEP
PY 2013
VL 42
IS 3
BP 503
EP +
DI 10.1016/j.ecl.2013.05.004
PG 12
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 228MO
UT WOS:000325191100007
PM 24011883
ER
PT J
AU Thomas, WW
Harvey, RJ
Rudmik, L
Hwang, PH
Schlosser, RJ
AF Thomas, W. Walsh, III
Harvey, Richard J.
Rudmik, Luke
Hwang, Peter H.
Schlosser, Rodney J.
TI Distribution of topical agents to the paranasal sinuses: an
evidence-based review with recommendations
SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY
LA English
DT Article
DE sinusitis; topical; spray; irrigation; nebulizer; therapies; anatomy;
surgery
ID CLINICAL-PRACTICE GUIDELINES; NASAL IRRIGATION; MIDDLE MEATUS; HEAD
POSITION; CHRONIC RHINOSINUSITIS; SINONASAL IRRIGATION; INTRANASAL
DELIVERY; PULSATING AEROSOLS; CONTROLLED-TRIAL; NOSE DROPS
AB BackgroundThe objective of this work was to review the literature concerning the distribution of topical therapeutics to the sinuses versus nasal cavity regarding: surgical state, delivery device, head position, and nasal anatomy and to provide evidence-based recommendations.
MethodsA systematic review was conducted using Medline, EMBASE, and Cochrane databases to perform a Medical Subject Heading search of the literature from 1946 until the last week of May 2012. Articles were independently reviewed and graded for level of evidence. All authors came to consensus on recommendations through an iterative process.
ResultsRecommendations were made for: improved sinus delivery with high-volume devices and after standard sinus surgery. Recommendations were made against low-volume delivery devices, such as drops, sprays, or simple nebulizers as they do not reliably reach the sinuses. If large-volume devices are not tolerated, low-volume devices are recommended using the lying head back or lateral head low positions to improve nasal cavity distribution to the middle meatus or olfactory cleft.
ConclusionSurgery, volume of device, head position, and nasal anatomy were shown to impact distribution to the sinuses. Recommendations are made based upon this evidence as to how to best maximize therapeutic distribution to the sinuses.
C1 [Thomas, W. Walsh, III; Schlosser, Rodney J.] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Charleston, SC 29403 USA.
[Thomas, W. Walsh, III; Schlosser, Rodney J.] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29403 USA.
[Harvey, Richard J.] Univ New S Wales, Div Rhinol & Endoscop Skull Base Surg, Sydney, NSW, Australia.
[Harvey, Richard J.] St Vincents Hosp, Sydney, NSW 2010, Australia.
[Rudmik, Luke] Univ Calgary, Div Otolaryngol Head & Neck Surg, Calgary, AB T2N 1N4, Canada.
[Hwang, Peter H.] Stanford Univ, Dept Otolaryngol Head & Neck Surg, Palo Alto, CA 94304 USA.
RP Schlosser, RJ (reprint author), Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, 135 Rutledge Ave,MSC 550, Charleston, SC 29403 USA.
EM schlossr@musc.edu
NR 42
TC 28
Z9 28
U1 1
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2042-6976
J9 INT FORUM ALLERGY RH
JI Int. Forum Allergy Rhinol.
PD SEP
PY 2013
VL 3
IS 9
BP 691
EP 703
DI 10.1002/alr.21172
PG 13
WC Otorhinolaryngology
SC Otorhinolaryngology
GA 227KL
UT WOS:000325111500002
PM 23729216
ER
PT J
AU Jenkins, AJ
Yu, J
Alaupovic, P
Basu, A
Klein, RL
Lopes-Virella, M
Baker, NL
Hunt, KJ
Lackland, DT
Garvey, WT
Lyons, TJ
AF Jenkins, Alicia J.
Yu, Jeremy
Alaupovic, Petar
Basu, Arpita
Klein, Richard L.
Lopes-Virella, Maria
Baker, Nathaniel L.
Hunt, Kelly J.
Lackland, Daniel T.
Garvey, W. Timothy
Lyons, Timothy J.
CA DCCT EDIC Res Grp
TI Apolipoprotein-defined lipoproteins and apolipoproteins: Associations
with abnormal albuminuria in type 1 diabetes in the diabetes control and
complications trial/epidemiology of diabetes interventions and
complications cohort
SO JOURNAL OF DIABETES AND ITS COMPLICATIONS
LA English
DT Article
DE Type 1 diabetes; Nephropathy; Albuminuria; Lipoproteins; Apolipoproteins
ID CARDIOVASCULAR RISK-FACTOR; B-CONTAINING LIPOPROTEINS; VASCULAR-DISEASE
RISK; DCCT/EDIC COHORT; RENAL-INSUFFICIENCY; INSULIN-RESISTANCE; C-III;
DENSITY-LIPOPROTEIN; CENTRAL OBESITY; NEPHROPATHY
AB Aims: Dyslipoproteinemia has been associated with nephropathy in diabetes, with stronger correlations in men than in women. We aimed to characterize and compare plasma lipoprotein profiles associated with normal and increased albuminuria in men and women using apolipoprotein-defined lipoprotein subclasses and simple apolipoprotein measures.
Methods: This is a cross-sectional study in a subset (154 women and 282 men) of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort, using samples obtained in 1997-9. Immunochemical methods were used to quantify plasma apolipoprotein-based lipoprotein subclasses and individual apolipoprotein levels.
Results: In adjusted analyses, elevated Lipoprotein-B (Lp-B) was significantly associated with macroalbuminuria in men [odds ratios (OR) and 95% confidence interval (CI): 2.13 (1.15-3.97)] and women [3.01 (1.11-8.12)], while association with Lp-B:C was observed only in men [1.84 (1.19-2.86)]. For individual apolipoproteins the following significant associations with macroalbuminuria were observed in men only: Apolipoprotein B (ApoB) [1.97 (1.20-3.25)], Apo-AII [0.52 (0.29-0.93)], ApoC-III [1.95 (1.16-3.30)], "ApoC-III in VLDL" (heparin-manganese precipitate) [1.88 (1.16-3.04)1, and "ApoCIII in HDL" (heparin-manganese supernatant) [2.03 (1.27-3.26)], all P < 0.05).
Conclusions: Atherogenic apolipoprotein-based profiles are associated with nephropathy in Type 1 diabetic men and to a lesser extent in women. The difference could result from the greater prevalence and severity of dyslipoproteinemia, and from the greater prevalence of renal dysfunction, in men vs women. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Jenkins, Alicia J.; Yu, Jeremy; Lyons, Timothy J.] Univ Oklahoma, Harold Hamm Diabet Ctr, Hlth Sci Ctr, Oklahoma City, OK 73104 USA.
[Jenkins, Alicia J.; Yu, Jeremy; Lyons, Timothy J.] Univ Oklahoma, Hlth Sci Ctr, Sect Endocrinol & Diabet, Oklahoma City, OK 73104 USA.
[Alaupovic, Petar] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA.
[Basu, Arpita] Oklahoma State Univ, Dept Nutr Sci, Stillwater, OK 74078 USA.
[Klein, Richard L.; Lopes-Virella, Maria] Med Univ S Carolina, Div Endocrinol, Charleston, SC 29425 USA.
[Klein, Richard L.; Lopes-Virella, Maria] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA.
[Baker, Nathaniel L.; Hunt, Kelly J.] Med Univ S Carolina, Div Biostat & Epidemiol, Charleston, SC 29425 USA.
[Lackland, Daniel T.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
[Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr, Birmingham, AL 35294 USA.
RP Lyons, TJ (reprint author), Harold Hamm Diabet Ctr, 1000 North Lincoln Blvd,Suite 2900, Oklahoma City, OK 73104 USA.
EM t.lyons@qub.ac.uk
FU American Diabetes Association, the National Institutes of Health NIH
[PO1 HL55782]; Juvenile Diabetes Research Foundation [4-1998-272,
996001, 197028]; Diabetes Research and Wellness Foundation, Inc.
(Fairfax, Virginia); Presbyterian Health Foundation of Oklahoma City;
Division of Diabetes, Endocrinology and Metabolic Diseases of the
National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK); NIH (NCRR) [M01-RR-1070, M01 RR-14467]; OUHSC; Genentech, Inc.;
NIDDK
FX Grants were provided by: the American Diabetes Association, the National
Institutes of Health NIH (PO1 HL55782), Juvenile Diabetes Research
Foundation (# 4-1998-272, 996001, and 197028), the Diabetes Research and
Wellness Foundation, Inc. (Fairfax, Virginia), and the Presbyterian
Health Foundation of Oklahoma City. The DCCT/EDIC is sponsored through
research contracts from the Division of Diabetes, Endocrinology and
Metabolic Diseases of the National Institute of Diabetes and Digestive
and Kidney Diseases (NIDDK). Additional support was provided by the NIH
(NCRR) Grants M01-RR-1070 and M01 RR-14467 to the General Clinical
Research Centers at MUSC and OUHSC, and by Genentech, Inc. through a
Cooperative Research and Development Agreement with the NIDDK.
NR 48
TC 2
Z9 4
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1056-8727
J9 J DIABETES COMPLICAT
JI J. Diabetes Complications
PD SEP-OCT
PY 2013
VL 27
IS 5
BP 447
EP 453
DI 10.1016/j.jdiacomp.2013.06.002
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 229WX
UT WOS:000325299700007
PM 23850262
ER
PT J
AU Henry, RR
Chilton, R
Garvey, WT
AF Henry, Robert R.
Chilton, Robert
Garvey, W. Timothy
TI New options for the treatment of obesity and type 2 diabetes mellitus
(narrative review)
SO JOURNAL OF DIABETES AND ITS COMPLICATIONS
LA English
DT Review
DE Phentermine; Topiramate extended-release; Obesity; Type 2 diabetes;
Cardiovascular
ID CARDIOVASCULAR RISK-FACTORS; CONTROLLED-RELEASE PHENTERMINE/TOPIRAMATE;
RANDOMIZED CONTROLLED-TRIAL; LIFE-STYLE INTERVENTION; HIGH
BLOOD-PRESSURE; BODY-MASS INDEX; FREE FATTY-ACID; WEIGHT-LOSS;
INSULIN-RESISTANCE; BARIATRIC SURGERY
AB Moderate weight loss (>5%), which has been associated with improvements in glycemic parameters in patients with dysglycemia, also reduces the presence of other comorbidities, including dyslipidemia and hypertension, culminating in a reduced risk of cardiovascular disease. Lifestyle changes are the recommended preliminary approach to weight loss, with an initial weight-loss goal of 10% of body weight achieved over 6 months at a rate of 1-2 pounds per week selected as an appropriate target to decrease the severity of obesity-related risk factors. Implementing and maintaining the lifestyle changes associated with weight loss can, however, be challenging for many patients. Therefore, additional interventions sometimes may be necessary. Bariatric surgery can also be a highly effective option for weight loss and comorbidity reduction, but surgery carries considerable risks and is still applicable only to selected patients with type 2 diabetes. Thus, attention is turning to the use of weight-loss medications, including 2 recently approved compounds: twice-daily lorcaserin and a once-daily combination of phentermine and topiramate extended-release, both shown to be safe and effective therapies in the management of obesity in patients with type 2 diabetes. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Henry, Robert R.] VA San Diego Healthcare Syst, Ctr Metab Res, San Diego, CA USA.
[Henry, Robert R.] Univ Calif San Diego, San Diego, CA 92103 USA.
[Chilton, Robert] Cardiovasc Dis & Intervent Cardiol Univ Hosp, San Antonio, TX USA.
[Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA.
[Garvey, W. Timothy] Birmingham VA Med Ctr, Birmingham, AL USA.
RP Henry, RR (reprint author), VA San Diego Healthcare Syst, Ctr Metab Res, San Diego, CA USA.
EM rrhenry@vapop.ucsd.edu
FU VIVUS, Inc.
FX We would like to acknowledge and thank The Lockwood Group for editorial
assistance (funding was provided by VIVUS, Inc.), and VIVUS, Inc.
internal contributors.
NR 66
TC 14
Z9 17
U1 1
U2 26
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1056-8727
J9 J DIABETES COMPLICAT
JI J. Diabetes Complications
PD SEP-OCT
PY 2013
VL 27
IS 5
BP 508
EP 518
DI 10.1016/j.jdiacomp.2013.04.011
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 229WX
UT WOS:000325299700017
PM 23726071
ER
PT J
AU Erickson, CS
Barlow, AJ
Pierre, JF
Heneghan, AF
Epstein, ML
Kudsk, KA
Gosain, A
AF Erickson, Christopher S.
Barlow, Amanda J.
Pierre, Joseph F.
Heneghan, Aaron F.
Epstein, Miles L.
Kudsk, Kenneth A.
Gosain, Ankush
TI Colonic enteric nervous system analysis during parenteral nutrition
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Article
DE Enteric nervous system; nNOS; Neurotransmitter; Motility; TPN;
Parenteral nutrition; Bombesin
ID MOUSE MODEL; HIRSCHSPRUNGS-DISEASE; BARRIER FUNCTION; NEUROTRANSMITTER
EXPRESSION; GASTROINTESTINAL-TRACT; LYMPHOID-TISSUE; BOMBESIN; MOTILITY;
MICE; IMMUNITY
AB Introduction: Parenteral nutrition (PN) is a necessary therapy used to feed patients with gastrointestinal dysfunction. Unfortunately, PN results in intestinal atrophy and changes to host immune function. PN may also induce additional effects on gut motility that we hypothesized would result from changes in the enteric nervous system.
Methods: Mice received an intravenous (IV) catheter and were randomized to chow (n = 5), IV PN (n = 6), or IV PN + bombesin (BBS, 15 mu g/kg, 3 x/d) (n = 6) for 5 d. Colons were removed and dissected to measure the length and circumference. Enteric neuronal density and neurotransmitter expression were determined by co-immunostaining whole-mount tissue with Hu and neuronal nitric oxide synthase (nNOS).
Results: The number of myenteric neurons expressing Hu and nNOS increased per unit length in the mid-colon during PN treatment compared with chow. This increase was abrogated by the addition of BBS to the PN regimen. However, the percentage of nNOS-expressing neurons was not significantly altered by PN. Morphometric analysis revealed a decrease in the length and circumference of the colon during PN administration that was partially normalized by supplementation of PN with BBS. A significant reduction in total fecal output was observed in PN animals compared with chow and was increased by mice receiving BBS in addition to PN.
Conclusions: PN causes a constriction of the bowel wall, reducing not only the length but also the circumference of the colon. These changes cause a condensation of enteric neurons but no difference in neurotransmitter expression. BBS supplementation partially restores the constriction and increases the fecal output during PN treatment compared with PN treatment alone. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Erickson, Christopher S.; Epstein, Miles L.] Univ Wisconsin, Madison Sch Med & Publ Hlth, Dept Neurosci, Madison, WI 53792 USA.
[Barlow, Amanda J.; Pierre, Joseph F.; Heneghan, Aaron F.; Kudsk, Kenneth A.; Gosain, Ankush] Univ Wisconsin, Madison Sch Med & Publ Hlth, Dept Surg, Madison, WI 53792 USA.
[Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI USA.
RP Gosain, A (reprint author), Univ Wisconsin, Dept Surg, 600 Highland Ave,K4-752 CSC, Madison, WI 53792 USA.
EM gosain@surgery.wisc.edu
OI Gosain, Ankush/0000-0002-0428-1503
FU Central Surgical Association Foundation Turcotte Award; NIH-NIDDK
[RO1DK081634]; Biomedical Laboratory Research & Development Service of
the VA Office of Research and Development [I01BX001672]
FX This research is supported by a Central Surgical Association Foundation
Turcotte Award (AG), NIH-NIDDK RO1DK081634 grant (MLE), and grant
I01BX001672 from the Biomedical Laboratory Research & Development
Service of the VA Office of Research and Development (KAK). The contents
of this article do not represent the views of the Department of Veterans
Affairs or the United States Government.
NR 27
TC 3
Z9 3
U1 0
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-4804
J9 J SURG RES
JI J. Surg. Res.
PD SEP
PY 2013
VL 184
IS 1
BP 132
EP 137
DI 10.1016/j.jss.2013.02.044
PG 6
WC Surgery
SC Surgery
GA 207NX
UT WOS:000323609400022
PM 23601532
ER
PT J
AU Gracz, AD
Fuller, MK
Wang, FC
Li, LH
Stelzner, M
Dunn, JCY
Martin, MG
Magness, ST
AF Gracz, Adam D.
Fuller, Megan K.
Wang, Fengchao
Li, Linheng
Stelzner, Matthias
Dunn, James C. Y.
Martin, Martin G.
Magness, Scott T.
TI Brief Report: CD24 and CD44 Mark Human Intestinal Epithelial Cell
Populations with Characteristics of Active and Facultative Stem Cells
SO STEM CELLS
LA English
DT Article
DE Tissue-specific stem cells; Cell surface markers; Fluorescence-activated
cell sorting; Flow cytometry; Cell culture
ID EXPRESSION MARKS; IN-VITRO; LGR5; EXPANSION; ORGANOIDS; COLON
AB Recent seminal studies have rapidly advanced the understanding of intestinal epithelial stem cell (IESC) biology in murine models. However, the lack of techniques suitable for isolation and subsequent downstream analysis of IESCs from human tissue has hindered the application of these findings toward the development of novel diagnostics and therapies with direct clinical relevance. This study demonstrates that the cluster of differentiation genes CD24 and CD44 are differentially expressed across LGR5 positive active stem cells as well as HOPX positive facultative stem cells. Fluorescence-activated cell sorting enables differential enrichment of LGR5 (CD24-/CD44+) and HOPX (CD24+/CD44+) cells for gene expression analysis and culture. These findings provide the fundamental methodology and basic cell surface signature necessary for isolating and studying intestinal stem cell populations in human physiology and disease. STEM Cells2013;31:2024-2030
C1 [Gracz, Adam D.; Magness, Scott T.] Univ N Carolina, Dept Med, Div Gastroenterol & Hepatol, Chapel Hill, NC 27599 USA.
[Gracz, Adam D.; Magness, Scott T.] Univ N Carolina, Dept Cell Biol & Physiol, Chapel Hill, NC 27599 USA.
[Fuller, Megan K.] Univ N Carolina, Dept Surg, Chapel Hill, NC 27599 USA.
[Magness, Scott T.] Univ N Carolina, Chapel Hill, NC 27599 USA.
[Wang, Fengchao; Li, Linheng] Stowers Inst Med Res, Kansas City, MO USA.
[Fuller, Megan K.] VA Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA.
[Stelzner, Matthias; Dunn, James C. Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA.
[Martin, Martin G.] Univ Calif Los Angeles, Dept Pediat, Div Gastroenterol, Los Angeles, CA 90024 USA.
RP Magness, ST (reprint author), Univ N Carolina, 111 Mason Farm Rd,CB 7032,MBRB Rm 4337, Chapel Hill, NC 27599 USA.
EM magness@med.unc.edu
FU NC TraCS Institute Pilot Grant Program [2KR271103, 2KR381202]; Center
for Gastrointestinal Biology and Disease [5P30DK034987-27]; University
Cancer Research Fund Innovation Award; NIH National Center for Research
Resources; National Center for Advancing Translational Sciences,
National Institutes of Health
FX We thank the UNC flow cytometry facility (P30CA06086) and the
neuroscience confocal facility, which is cofunded by the National
Institute of Neurological Disorders and Stroke and the National
Institute of Child Health and Human Development (P30NS045892). Drs.
Timothy Farrell and Wayne Overby, and Myra Jones, Karen Colton, and Lisa
Prestia, for coordinating the collection of deidentified remnant jejunal
tissue from gastric-bypass operations. The Duke Human Vaccine Institute
flow cytometry core, and Dr. John Whitesides and Ian Cumming, for
technical assistance. Drs. Tope Keku and Robert Sandler for unpublished
data regarding mucosal biopsy weight. Drs. P. Kay Lund, Susan Henning
(SJH), and Christopher Dekaney for useful discussions and critical
review of the manuscript. This work was funded by the NC TraCS Institute
Pilot Grant Program, 2KR271103 (Gracz/Fuller) and 2KR381202 (Gracz), the
Center for Gastrointestinal Biology and Disease, 5P30DK034987-27
(Magness), and a University Cancer Research Fund Innovation Award
(Magness). The NC TraCS Institute is supported by Grants UL1RR025747,
KL2RR025746, and TLRR025745 from the NIH National Center for Research
Resources and the National Center for Advancing Translational Sciences,
National Institutes of Health. The National Institute of Diabetes and
Digestive and Kidney Diseases/National Institute of Allergy and
Infectious Disease Intestinal Stem Cell Consortium (U01DK085541-SJH;
U01DK85507-LL/FW; U01DK85535-MGM/JCYD/MS). The content is solely the
responsibility of the authors and does not necessarily represent the
official views of the National Center for Research Resources or the
National Institutes of Health.
NR 19
TC 29
Z9 29
U1 0
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1066-5099
J9 STEM CELLS
JI Stem Cells
PD SEP
PY 2013
VL 31
IS 9
BP 2024
EP 2030
DI 10.1002/stem.1391
PG 7
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
Oncology; Cell Biology; Hematology
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA 229II
UT WOS:000325255700027
PM 23553902
ER
PT J
AU Li, G
Bekris, LM
Leong, L
Steinbart, EJ
Shofer, JB
Crane, PK
Larson, EB
Peskind, ER
Bird, TD
Yu, CE
AF Li, Ge
Bekris, Lynn M.
Leong, Lesley
Steinbart, Ellen J.
Shofer, Jane B.
Crane, Paul K.
Larson, Eric B.
Peskind, Elaine R.
Bird, Thomas D.
Yu, Chang-En
TI TOMM40 intron 6 poly-T length, age at onset, and neuropathology of AD in
individuals with APOE epsilon 3/epsilon 3
SO ALZHEIMERS & DEMENTIA
LA English
DT Article
DE Alzheimer's disease; Age at onset; Genetic; APOE; TOMM40; PSEN1
mutation; PSEN2 mutation; Neuropathology
ID FAMILIAL ALZHEIMERS-DISEASE; GENOME-WIDE ASSOCIATION; APOLIPOPROTEIN-E;
PROTEIN-LEVELS; DIAGNOSIS; DEMENTIA; COHORT; LOCI; PRESENILIN-1;
SENSITIVITY
AB Background: This study investigates the association between TOMM40 poly-T length, age at onset, and neuropathology in individuals with Alzheimer's disease (AD) with the apolipoprotein E (APOE) epsilon 3/epsilon 3 allele.
Methods: Thirty-two presenilin 1 (PSEN1) mutation carriers with AD, 27 presenilin 2 (PSEN2) mutation carriers with AD, 59 participants with late-onset AD (LOAD), and 168 autopsied subjects from a community-based cohort were genotyped for TOMM40 intron 6 poly-T (rs10524523) length using short tandem repeat assays.
Results: Among AD individuals with PSEN2 mutations, the presence of a long poly-T was associated with an earlier age at onset, whereas there were no such associations for subjects with PSEN1 mutations or LOAD. In community-based participants, the presence of a long poly-T was associated with increased neuritic tangles and a greater likelihood of pathologically diagnosed AD.
Conclusion: TOMM40 intron 6 poly-T length may explain some of the variation in age at onset in PSEN2 familial AD and may be associated with AD neuropathology in persons with APOE epsilon 3/epsilon 3. (C) 2013 The Alzheimer's Association. All rights reserved.
C1 [Li, Ge; Shofer, Jane B.; Peskind, Elaine R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Bekris, Lynn M.; Crane, Paul K.; Larson, Eric B.; Yu, Chang-En] Univ Washington, Dept Med, Seattle, WA USA.
[Bekris, Lynn M.; Leong, Lesley; Steinbart, Ellen J.; Bird, Thomas D.; Yu, Chang-En] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA.
[Steinbart, Ellen J.; Bird, Thomas D.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA.
[Larson, Eric B.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA.
[Peskind, Elaine R.] VA Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA.
RP Li, G (reprint author), Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
EM gli@u.washington.edu
RI Crane, Paul/C-8623-2014
FU National Institute of Aging [AG033693, AG006781, AG05136, AG034214];
U.S. Department of Veterans Affairs, Office of Research and Development,
Biomedical Laboratory Research Program
FX This study was supported by grants AG033693, AG006781, AG05136, and
AG034214 from the National Institute of Aging and by the U.S. Department
of Veterans Affairs, Office of Research and Development, Biomedical
Laboratory Research Program. The study sponsors had no role in the
design and conduct of the study; collection, management, analysis, and
interpretation of the data; or preparation, review, and approval of the
manuscript.
NR 43
TC 5
Z9 5
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1552-5260
J9 ALZHEIMERS DEMENT
JI Alzheimers. Dement.
PD SEP
PY 2013
VL 9
IS 5
BP 554
EP 561
DI 10.1016/j.jalz.2012.06.009
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA 222IN
UT WOS:000324724500009
PM 23183136
ER
PT J
AU Geda, YE
Schneider, LS
Gitlin, LN
Miller, DS
Smith, GS
Bell, J
Evans, J
Lee, M
Porsteinsson, A
Lanctot, KL
Rosenberg, PB
Sultzer, DL
Francis, PT
Brodaty, H
Padala, PP
Onyike, CU
Ortiz, LA
Ancoli-Israel, S
Bliwise, DL
Martin, JL
Vitiello, MV
Yaffe, K
Zee, PC
Herrmann, N
Sweet, RA
Ballard, C
Khin, NA
Alfaro, C
Murray, PS
Schultz, S
Lyketsos, CG
AF Geda, Yonas E.
Schneider, Lon S.
Gitlin, Laura N.
Miller, David S.
Smith, Gwenn S.
Bell, Joanne
Evans, Jovier
Lee, Michael
Porsteinsson, Anton
Lanctot, Krista L.
Rosenberg, Paul B.
Sultzer, David L.
Francis, Paul T.
Brodaty, Henry
Padala, Prasad P.
Onyike, Chiadikaobi U.
Ortiz, Luis Agueera
Ancoli-Israel, Sonia
Bliwise, Donald L.
Martin, Jennifer L.
Vitiello, Michael V.
Yaffe, Kristine
Zee, Phyllis C.
Herrmann, Nathan
Sweet, Robert A.
Ballard, Clive
Khin, Ni A.
Alfaro, Cara
Murray, Patrick S.
Schultz, Susan
Lyketsos, Constantine G.
CA Neuropsychiat Syndromes
TI Neuropsychiatric symptoms in Alzheimer's disease: Past progress and
anticipation of the future
SO ALZHEIMERS & DEMENTIA
LA English
DT Article
DE Neuropsychiatric symptoms; Behavioral and psychological symptoms of
dementia; Agitation/aggression; Sleep disorders; Depression; Apathy;
Psychosis; Delusions; Hallucinations; Dementia; Alzheimer's disease;
Mild cognitive impairment; Mild behavioral impairment
ID MILD COGNITIVE IMPAIRMENT; VASCULAR DEPRESSION HYPOTHESIS; PITTSBURGH
COMPOUND-B; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; BEHAVIORAL
SYMPTOMS; NATIONAL INSTITUTE; RANDOMIZED-TRIAL; RATING-SCALE;
DOUBLE-BLIND
AB Neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) are widespread and disabling. This has been known since Dr. Alois Alzheimer's first case, Frau Auguste D., presented with emotional distress and delusions of infidelity/excessive jealousy, followed by cognitive symptoms. Being cognizant of this, in 2010 the Alzheimer's Association convened a research roundtable on the topic of NPS in AD. A major outcome of the roundtable was the founding of a Professional Interest Area (PIA) within the International Society to Advance Alzheimer's Research and Treatment (ISTAART). The NPS-PIA has prepared a series of documents that are intended to summarize the literature and provide more detailed specific recommendations for NPS research. This overview paper is the first of these living documents that will be updated periodically as the science advances. The overview is followed by syndrome-specific synthetic reviews and recommendations prepared by NPS-PIA workgroups on depression, apathy, sleep, agitation, and psychosis. (C) 2013 The Alzheimer's Association. All rights reserved.
C1 [Geda, Yonas E.] Mayo Clin, Coll Med, Dept Psychiat, Scottsdale, AZ USA.
[Geda, Yonas E.] Mayo Clin, Coll Med, Dept Neurol, Scottsdale, AZ USA.
[Schneider, Lon S.] Univ So Calif, Los Angeles, CA USA.
[Gitlin, Laura N.] Johns Hopkins Univ, Sch Nursing, Baltimore, MD USA.
[Miller, David S.] Bracket, Wayne, PA USA.
[Smith, Gwenn S.; Rosenberg, Paul B.; Onyike, Chiadikaobi U.; Lyketsos, Constantine G.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Div Geriatr Psychiat & Neuropsychiat, Baltimore, MD 21218 USA.
[Evans, Jovier] NIMH, Geriatr Res Branch, Geriatr Translat Neurosci & MultiModal Interv Pro, Geriatr Pharmacol Intervent, Bethesda, MD 20892 USA.
[Lee, Michael] Univ Minnesota, Inst Translat Neurosci, Dept Neurosci, Minneapolis, MN USA.
[Lee, Michael] Univ Minnesota, Inst Translat Neurosci, Ctr Neurodegenerat Dis, Minneapolis, MN USA.
[Porsteinsson, Anton] Univ Rochester, Sch Med & Dent Rochester, Dept Psychiat, Rochester, NY USA.
[Lanctot, Krista L.] Sunnybrook Res Inst, Brain Sci Program, Toronto, ON, Canada.
[Lanctot, Krista L.] Univ Toronto, Dept Psychiat, Toronto, ON, Canada.
[Lanctot, Krista L.] Univ Toronto, Dept Pharmacol, Toronto, ON, Canada.
[Lanctot, Krista L.] Univ Toronto, Dept Toxicol, Toronto, ON, Canada.
[Sultzer, David L.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, David Geffen Sch Med, Los Angeles, CA 90024 USA.
[Sultzer, David L.] VA Greater Angeles Healthcare Syst, Psychiat Serv, Los Angeles, CA USA.
[Francis, Paul T.] Kings Coll London, Wolfson Ctr Age Related Dis, London, England.
[Brodaty, Henry] Univ New S Wales, Dementia Collaborat Res Ctr, Sydney, NSW, Australia.
[Padala, Prasad P.] Cent Arkansas Vet Healthcare Syst, Geriatr Res Educ & Clin Ctr, Little Rock, AR USA.
[Padala, Prasad P.] Univ Arkansas Med Sci, Dept Psychiat, Little Rock, AR 72205 USA.
[Ortiz, Luis Agueera] C1BERSAM, Madrid, Spain.
[Ortiz, Luis Agueera] Univ Hosp Doce Octubre, Madrid, Spain.
[Ancoli-Israel, Sonia] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.
[Ancoli-Israel, Sonia] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
[Bliwise, Donald L.] Emory Univ, Sch Med, Wesley Woods Hlth Ctr, Dept Neurol, Atlanta, GA USA.
[Martin, Jennifer L.] Univ Calif Los Angeles, Educ & Clin Ctr, VA Greater Angeles Healthcare Geriatr Res, Los Angeles, CA USA.
[Martin, Jennifer L.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Vitiello, Michael V.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Zee, Phyllis C.] Northwestern Univ, Feinberg Sch Med, Dept Neurol, Chicago, IL 60611 USA.
[Sweet, Robert A.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA.
[Sweet, Robert A.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA.
[Sweet, Robert A.; Murray, Patrick S.] VA Pittsburgh Healthcare Syst, VISN 4 Mental Illness Res Educ & Clin Ctr MIRECC, Pittsburgh, PA USA.
[Ballard, Clive] Kings Coll London, Wolfson Ctr Age Related Dis, Biomed Res Unit, Inst Psychiat & Alzheimers Soc, London WC2R 2LS, England.
[Khin, Ni A.; Alfaro, Cara] US FDA, Ctr Drug Evaluat & Res, Off Drug Evaluat 1 OND, Div Psychiat Prod, Silver Spring, MD USA.
[Schultz, Susan] Univ Iowa, Carver Coll Med, Dept Psychiat, Iowa City, IA USA.
RP Lyketsos, CG (reprint author), Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Div Geriatr Psychiat & Neuropsychiat, Baltimore, MD 21218 USA.
RI Lee, Michael/D-9491-2013; Francis, Paul/A-9199-2008
OI Lee, Michael/0000-0001-5865-9682; Murray, Patrick/0000-0002-6525-2888;
Vitiello, Michael/0000-0002-9776-0473; Lanctot, Krista
L./0000-0001-7024-6637
FU NIMH [K01-MH68351, R24-MH074779, R01-MH079814, RC1-MH090770-01]; NIA
[U01-AG006786]; National Center for Research Resources [RR024150];
Robert Wood Johnson Foundation; European Union Regional Development Fund
[FNUSA-ICRC: CZ.1.05/1.1.00/02.0123]; Baxter; Elan Pharmaceuticals;
Johnson Johnson; Eli Lilly; Myriad; Novartis; Pfizer; Abbott
Laboratories; AC Immune; Allergan; Allon; Alzheimer Drug Discovery
Foundation; AstraZeneca; Bristol-Myers Squibb; Elan; Exonhit; Forest;
GlaxoSmithKline; Ipsen Pharmaceuticals; Lundbeck; Medavante; Medivation;
Merck; Merz; Roche; Sanofi-Aventis; Schering-Plough; Schwabe; Toyama;
Transition Therapeutics; Alzheimer's Association [IIRG-07-28686]; Johns
Hopkins Alzheimer's Disease Research Center [P50-AG005146]; NIMH, MA;
Associated Jewish Federation of Baltimore; Weinberg Foundation; Eisai;
Lilly; Ortho-McNeil; Bristol-Myers; National Football League; Functional
Neuromodulation Inc.
FX The authors thank Dr. Michelle M. Mielke for her helpful comments and
feedback on early drafts of this manuscript. Dr. Geda was supported by
NIMH grant K01-MH68351, NIA grant U01-AG006786 (the Mayo Clinic Study of
Aging), National Center for Research Resources grant RR024150 (Mayo
Clinic CTSA [Career Transition Award]), the Robert Wood Johnson
Foundation (Harold Amos Scholar), and the European Union Regional
Development Fund (Project FNUSA-ICRC: CZ.1.05/1.1.00/02.0123). Dr.
Schneider reports being an editor on the Cochrane Collaboration Dementia
and Cognitive Improvement Group, which oversees systematic reviews of
drugs for cognitive impairment and dementia. He received a grant from
the Alzheimer's Association for a registry for dementia and cognitive
impairment trials; he is also in receipt of grant or research support
from Baxter, Elan Pharmaceuticals, Johnson & Johnson, Eli Lilly, Myriad,
Novartis, and Pfizer. He has served as a consultant for or received
consulting fees from Abbott Laboratories, AC Immune, Allergan, Allon,
the Alzheimer Drug Discovery Foundation, AstraZeneca, Bristol-Myers
Squibb, Elan, Eli Lilly, Exonhit, Forest, GlaxoSmithKline, Ipsen
Pharmaceuticals, Johnson & Johnson, Lundbeck, Myriad, Medavante,
Medivation, Merck, Merz, Novartis, Pfizer, Roche, Sanofi-Aventis,
Schering-Plough, Schwabe, Toyama, and Transition Therapeutics. Dr.
Gitlin was supported by NIMH grants R24-MH074779, R01-MH079814, and
RC1-MH090770-01 and Alzheimer's Association grant IIRG-07-28686 and
served on the Phillips Life Line Falls Advisory Board. Dr. Miller is a
full-time employee of Bracket. Dr. Lyketsos was supported by the Johns
Hopkins Alzheimer's Disease Research Center (P50-AG005146). He has
received grant support (research or CME) from NIMH, MA, the Associated
Jewish Federation of Baltimore, the Weinberg Foundation, Forest,
GlaxoSmithKline, Eisai, Pfizer, AstraZeneca, Lilly, Ortho-McNeil,
Bristol-Myers, Novartis, the National Football League, Elan, and
Functional Neuromodulation Inc. He has served as consultant/advisor for
AstraZeneca, GlaxoSmithKline, Eisai, Novartis, Forest, Supernus, Adlyfe,
Takeda, Wyeth, Lundbeck, Merz, Lilly, Pfizer, Genentech, Elan, the NFL
Players Association, the NFL Benefits Office, Avanir, and Zinfandel. He
has also received honorarium or travel support from Pfizer, Forest,
GlaxoSmithKline, and Health Monitor.
NR 68
TC 76
Z9 77
U1 6
U2 43
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1552-5260
J9 ALZHEIMERS DEMENT
JI Alzheimers. Dement.
PD SEP
PY 2013
VL 9
IS 5
BP 602
EP 608
DI 10.1016/j.jalz.2012.12.001
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 222IN
UT WOS:000324724500015
PM 23562430
ER
PT J
AU Watson, GS
Cholerton, BA
Gross, RG
Weintraub, D
Zabetian, CP
Trojanowski, JQ
Montine, TJ
Siderowf, A
Leverenz, JB
AF Watson, G. Stennis
Cholerton, Brenna A.
Gross, Rachel G.
Weintraub, Daniel
Zabetian, Cyrus P.
Trojanowski, John Q.
Montine, Thomas J.
Siderowf, Andrew
Leverenz, James B.
TI Neuropsychologic assessment in collaborative Parkinson's disease
research: A proposal from the National Institute of Neurological
Disorders and Stroke Morris K. Udall Centers of Excellence for
Parkinson's Disease Research at the University of Pennsylvania and the
University of Washington
SO ALZHEIMERS & DEMENTIA
LA English
DT Article
ID MONTREAL COGNITIVE ASSESSMENT; DEMENTIA; MOCA; IMPAIRMENT; SYMPTOMS;
VALIDITY; COHORT; MMSE; MCI
AB Cognitive impairment (CI) and behavioral disturbances can be the earliest symptoms of Parkinson's disease (PD), ultimately afflict the vast majority of PD patients, and increase caregiver burden. Our two Morris K. Udall Centers of Excellence for Parkinson's Disease Research were supported by the National Institute of Neurological Disorders and Stroke (NINDS) in an effort to recommend a comprehensive yet practical approach to cognitive and behavioral assessment to further collaborative research. We recommend a stepwise approach with two levels of standardized evaluation to establish a common battery, as well as an alternative testing recommendation for severely impaired subjects, and review supplemental tests that may be useful in specific research settings. Our flexible approach may be applied to studies with varying emphasis on cognition and behavior, does not place undue burden on participants or resources, and has a high degree of compatibility with existing test batteries to promote collaboration. (C) 2013 The Alzheimer's Association. All rights reserved.
C1 [Watson, G. Stennis; Cholerton, Brenna A.; Leverenz, James B.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Gross, Rachel G.; Weintraub, Daniel; Siderowf, Andrew] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA.
[Gross, Rachel G.; Weintraub, Daniel; Siderowf, Andrew] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
[Zabetian, Cyrus P.] Vet AffairsPuget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA.
[Zabetian, Cyrus P.; Leverenz, James B.] Vet Affairs Puget Sound Hlth Care Syst, Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA USA.
[Zabetian, Cyrus P.; Leverenz, James B.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA.
[Trojanowski, John Q.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA.
[Trojanowski, John Q.] Univ Penn, Inst Aging, Philadelphia, PA 19104 USA.
[Trojanowski, John Q.] Univ Penn, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA.
[Montine, Thomas J.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
[Leverenz, James B.] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA.
RP Leverenz, JB (reprint author), Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
EM leverenz@uw.edu
FU NINDS [NS062684, NS053488]; Nancy and Buster Alvord Endowment
FX This study was funded by NINDS (NS062684, NS053488) and the Nancy and
Buster Alvord Endowment. The authors thank Dr Kathy Montine for
editorial assistance.
NR 27
TC 4
Z9 4
U1 4
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1552-5260
J9 ALZHEIMERS DEMENT
JI Alzheimers. Dement.
PD SEP
PY 2013
VL 9
IS 5
BP 609
EP 614
DI 10.1016/j.jalz.2012.07.006
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA 222IN
UT WOS:000324724500016
PM 23164549
ER
PT J
AU Lysack, C
Leach, C
Russo, T
Paulson, D
Lichtenberg, PA
AF Lysack, Cathy
Leach, Carrie
Russo, Theresa
Paulson, Daniel
Lichtenberg, Peter A.
TI DVD Training for Depression Identification and Treatment in Older
Adults: A Two-Group, Randomized, Wait-List Control Study
SO AMERICAN JOURNAL OF OCCUPATIONAL THERAPY
LA English
DT Article
DE depression; education, continuing; geriatric assessment; staff
development; teaching
ID LATE-LIFE DEPRESSION; HOME-CARE; OCCUPATIONAL-THERAPY; TREATING
DEPRESSION; CONTROLLED-TRIAL; HEALTH-STATUS; INTERVENTION; RECOGNITION;
SCALE; MOOD
AB OBJECTIVE. To test the effectiveness of an educational intervention aimed at improving mental health. knowledge and skills in occupational therapists working with older rehabilitation patients.
METHOD. The DVD-format educational intervention was evaluated using a two-group randomized wait-list control design. Occupational therapists (n = 75) completed a 32-item knowledge questionnaire at three time points. Patient charts were reviewed (n = 960) at 3 months before and 3 and 6 months after DVD training to evaluate clinical practice change.
RESULTS. A two-way analysis of variance showed knowledge scores increased significantly for both groups after DVD training. A significant Group x Time interaction and significant main effects for time and group were found. Chart review data also showed significant increases in desired clinical behaviors in both groups after training. The greatest single item of clinical practice change was use of a standardized depression screen.
CONCLUSION. DVD-based training can significantly improve mental health practice.
C1 [Lysack, Cathy; Leach, Carrie; Lichtenberg, Peter A.] Wayne State Univ, Inst Gerontol, Detroit, MI 48202 USA.
[Russo, Theresa] Alzheimers Assoc Greater Michigan Chapter, Southfield, MI USA.
[Paulson, Daniel] Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA.
[Paulson, Daniel] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
[Lichtenberg, Peter A.] Wayne State Univ, Dept Psychiat & Behav Neurosci, Detroit, MI 48202 USA.
RP Lysack, C (reprint author), Wayne State Univ, Inst Gerontol, Room 231,Knapp Bldg,87 East Ferry St, Detroit, MI 48202 USA.
EM c.lysack@wayne.edu
NR 30
TC 1
Z9 1
U1 1
U2 7
PU AMER OCCUPATIONAL THERAPY ASSOC, INC
PI BETHESDA
PA 4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA
SN 0272-9490
J9 AM J OCCUP THER
JI Am. J. Occup. Ther.
PD SEP-OCT
PY 2013
VL 67
IS 5
BP 584
EP 593
DI 10.5014/ajot.2013.008060
PG 10
WC Rehabilitation
SC Rehabilitation
GA 220EQ
UT WOS:000324565400012
PM 23968797
ER
PT J
AU Stengel, A
Goebel-Stengel, M
Wang, L
Hu, E
Karasawa, H
Pisegna, JR
Tache, Y
AF Stengel, Andreas
Goebel-Stengel, Miriam
Wang, Lixin
Hu, Eugenia
Karasawa, Hiroshi
Pisegna, Joseph R.
Tache, Yvette
TI High-protein diet selectively reduces fat mass and improves glucose
tolerance in Western-type diet-induced obese rats
SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE
PHYSIOLOGY
LA English
DT Article
DE diet-induced obesity; food intake; high-protein diet; gut hormones
ID CONDITIONED TASTE-AVERSION; WEIGHT-LOSS DIETS; FOOD-INTAKE; BODY-WEIGHT;
INDUCED THERMOGENESIS; RESPIRATION CHAMBER; CEREBROSPINAL-FLUID; ENERGY
RESTRICTION; METABOLIC SYNDROME; INSULIN-SECRETION
AB Obesity is an increasing health problem. Because drug treatments are limited, diets remain popular. High-protein diets (HPD) reduce body weight (BW), although the mechanisms are unclear. We investigated physiological mechanisms altered by switching diet induced obesity (DIO) rats from Western-type diet (WTD) to HPD. Male rats were fed standard (SD) or WTD (45% calories from fat). After developing DIO (50% of rats), they were switched to SD (15% calories from protein) or HPD (52% calories from protein) for up to 4 weeks. Food intake (FI), BW, body composition, glucose tolerance, insulin sensitivity, and intestinal hormone plasma levels were monitored. Rats fed WTD showed an increased FI and had a 25% greater BW gain after 9 wk compared with SD (P < 0.05). Diet-induced obese rats switched from WTD to HPD reduced daily FI by 30% on day 1, which lasted to day 9 (-9%) and decreased BW during the 2-wk period compared with SD/SD (P < 0.05). During these 2 wk, WTD/HPD rats lost 72% more fat mass than WTD/SD (P < 0.05), whereas lean mass was unaltered. WTD/HPD rats had lower blood glucose than WTD/SD at 30 min postglucose gavage (P < 0.05). The increase of pancreatic polypeptide and peptide YY during the 2-h dark-phase feeding was higher in WTD/HPD compared with WTD/SD (P < 0.05). These data indicate that HPD reduces BW in WTD rats, which may be related to decreased FI and the selective reduction of fat mass accompanied by improved glucose tolerance, suggesting relevant benefits of HPD in the treatment of obesity.
C1 [Stengel, Andreas; Goebel-Stengel, Miriam; Wang, Lixin; Hu, Eugenia; Karasawa, Hiroshi; Pisegna, Joseph R.; Tache, Yvette] Univ Calif Los Angeles, Dept Med, Ctr Neurobiol Stress, CURE,Digest Dis Res Ctr,Digest Dis Div, Los Angeles, CA 90024 USA.
[Stengel, Andreas; Goebel-Stengel, Miriam; Wang, Lixin; Hu, Eugenia; Karasawa, Hiroshi; Pisegna, Joseph R.; Tache, Yvette] VA Greater Angeles Hlth Care Syst, Los Angeles, CA USA.
[Stengel, Andreas] Charite Ctr Internal Med & Dermatol, Obes Ctr Berlin, D-13353 Berlin, Germany.
[Stengel, Andreas] Charite, D-13353 Berlin, Germany.
[Goebel-Stengel, Miriam] Inst Neurogastroenterol & Motility, Dept Internal Med, Berlin, Germany.
[Goebel-Stengel, Miriam] Martin Luther Hosp, Berlin, Germany.
RP Tache, Y (reprint author), CURE, VA GLA Healthcare Syst, Bldg 115,Rm 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM ytache@mednet.ucla.edu
RI Biguzzi, Felipe/E-4724-2015
FU VA Merit award; National Institute of Health center grant [DK-41301]; VA
Career Scientist Award; [5 RC1 DK-086150-02]
FX This article was supported by VA Merit award (to Y. Tache and J. R.
Pisegna), National Institute of Health center grant DK-41301 (Animal
Core, to Y. Tache), VA Career Scientist Award (to Y. Tache) and 5 RC1
DK-086150-02 (S. B., C.P.).
NR 62
TC 8
Z9 8
U1 0
U2 4
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6119
J9 AM J PHYSIOL-REG I
JI Am. J. Physiol.-Regul. Integr. Comp. Physiol.
PD SEP
PY 2013
VL 305
IS 6
BP R582
EP R591
DI 10.1152/ajpregu.00598.2012
PG 10
WC Physiology
SC Physiology
GA 222TA
UT WOS:000324753200003
PM 23883680
ER
PT J
AU Sonne, SC
Andrews, JO
Gentilin, SM
Oppenheimer, S
Obeid, J
Brady, K
Wolf, S
Davis, R
Magruder, K
AF Sonne, Susan C.
Andrews, Jeannette O.
Gentilin, Stephanie M.
Oppenheimer, Stephanie
Obeid, Jihad
Brady, Kathleen
Wolf, Sharon
Davis, Randal
Magruder, Kathryn
TI Development and pilot testing of a video-assisted informed consent
process
SO CONTEMPORARY CLINICAL TRIALS
LA English
DT Article
DE Informed consent process; Videos; Electronic forms; Tablet computing
ID RANDOMIZED CONTROLLED-TRIAL; COMPREHENSION; INFORMATION; MULTIMEDIA;
LITERACY
AB The informed consent process for research has come under scrutiny, as consent documents are increasingly long and difficult to understand. Innovations are needed to improve comprehension in order to make the consent process truly informed. We report on the development and pilot testing of video clips that could be used during the consent process to better explain research procedures to potential participants. Based on input from researchers and community partners, 15 videos of common research procedures/concepts were produced. The utility of the videos was then tested by embedding them in mock-informed consent documents that were presented via an online electronic consent system designed for delivery via iPad. Three mock consents were developed, each containing five videos. All participants (n = 61) read both a paper version and the video-assisted iPad version of the same mock consent and were randomized to which format they reviewed first. Participants were given a competency quiz that posed specific questions about the information in the consent after reviewing the first consent document to which they were exposed. Most participants (78.7%) preferred the video-assisted format compared to paper (12.9%). Nearly all (96.7%) reported that the videos improved their understanding of the procedures described in the consent document; however, the comprehension of material did not significantly differ by consent format. Results suggest videos may be helpful in providing participants with information about study procedures in a way that is easy to understand. Additional testing of video consents for complex protocols and with subjects of lower literacy is warranted. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Sonne, Susan C.; Andrews, Jeannette O.; Gentilin, Stephanie M.; Oppenheimer, Stephanie; Obeid, Jihad; Brady, Kathleen; Wolf, Sharon; Davis, Randal; Magruder, Kathryn] Med Univ S Carolina, Charleston, SC 29425 USA.
[Brady, Kathleen; Magruder, Kathryn] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA.
RP Sonne, SC (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, 125 Doughty St,Suite 190, Charleston, SC 29425 USA.
EM sonnesc@musc.edu
OI Obeid, Jihad/0000-0002-7193-7779
FU South Carolina Clinical and Translational Research (SCTR) Institute;
Medical University of South Carolina, through NIH [UL1 RR029882, UL1
TR000062]; [RC2 LM010796]
FX This publication was supported by the South Carolina Clinical and
Translational Research (SCTR) Institute, with an academic home at the
Medical University of South Carolina, through NIH grant numbers UL1
RR029882 and UL1 TR000062 as well as RC2 LM010796.
NR 18
TC 10
Z9 10
U1 1
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1551-7144
J9 CONTEMP CLIN TRIALS
JI Contemp. Clin. Trials
PD SEP
PY 2013
VL 36
IS 1
BP 25
EP 31
DI 10.1016/j.cct.2013.05.011
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 225KH
UT WOS:000324961300003
PM 23747986
ER
PT J
AU Trivedi, RB
Szarka, JG
Beaver, K
Brousseau, K
Nevins, E
Yancy, WS
Slade, A
Voils, CI
AF Trivedi, Ranak B.
Szarka, Jackie G.
Beaver, Kristine
Brousseau, Koriann
Nevins, Elaine
Yancy, William S., Jr.
Slade, Alecia
Voils, Corrine I.
TI Recruitment and retention rates in behavioral trials involving patients
and a support person: A systematic review
SO CONTEMPORARY CLINICAL TRIALS
LA English
DT Review
DE Dyad; Caregiver; Couple; Intervention; Recruitment; Retention
ID RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; CANCER PAIN MANAGEMENT;
BREAST-CANCER; FAMILY CAREGIVERS; ALZHEIMER-DISEASE; CLINICAL-TRIAL;
BRAIN-INJURY; STROKE PATIENTS; INTERVENTION
AB Background: Recruitment and retention challenges impede the study of behavioral interventions among patient-support person dyads.
Purpose: The aim of the study was to characterize recruitment and retention rates of behavioral interventions involving dyads.
Methods: Using PRISMA guidelines and with the guidance of a medical librarian, we searched Medline, EMBASE, Cochrane Controlled Trials, PsycInfo, and CINAHL from inception until July 2011. Eligible articles involved RCTs of behavioral interventions targeting adult patients with a non-psychiatric illness and a support person. Sample and study characteristics, recruitment and retention strategies, and recruitment and retention rates were abstracted in duplicate. Quality of reporting was determined on a 5-point scale. Due to the heterogeneity in data reporting and missing data, a narrative synthesis was undertaken
Results: 53 unique studies involving 8081 dyads were included. 9 studies were ascertained to have a "high quality" of reporting. A majority of the studies did not report target sample size, time to complete recruitment, and sample sizes at each follow-up time point. Strategies employed to recruit support persons were rarely reported. 16 studies did not report the number of dyads screened. The mean recruitment rate was 51.2% (range: 4.3%-95.4%), and mean retention rate was 77.5% (range: 36%-100%).
Conclusions: Details regarding recruitment and retention methodology were sparse in these interventions. Where available, data suggests that resources need to be devoted towards recruitment of sample but that retention rates are generally adequate. Published by Elsevier Inc.
C1 [Trivedi, Ranak B.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Trivedi, Ranak B.; Szarka, Jackie G.; Beaver, Kristine; Brousseau, Koriann; Nevins, Elaine] VA Puget Sound Hlth Care Syst, Northwest HSR&D Ctr Excellence, Seattle, WA 98101 USA.
[Yancy, William S., Jr.; Slade, Alecia; Voils, Corrine I.] Ctr Hlth Serv Res Primary Care, Dept Vet Affairs, Durham, NC 27705 USA.
[Yancy, William S., Jr.; Voils, Corrine I.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
RP Trivedi, RB (reprint author), VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat MPD 152, 795 Willow Rd, Menlo Pk, CA 94025 USA.
EM ranak.trivedi@va.gov; Jackie.szarka@va.gov; kaakullia@gmail.com;
Koriann.brousseau@va.gov; Elaine.nevins@va.gov; Yancy006@mc.duke.edu;
Alecia.slade@gmail.com; voils001@mc.duke.edu
OI Voils, Corrine/0000-0003-1913-663X
FU Department of Veterans Affairs (VA); Veterans Health Administration
Health Services Research and Development (HSRD) Service, IHI [IHI
02-062]; VA HSR&D Career Development Award [CDA-09-206]
FX This work was supported by the Department of Veterans Affairs (VA),
Veterans Health Administration Health Services Research and Development
(HSR&D) Service, IHI 02-062. Dr. Trivedi was supported by a VA HSR&D
Career Development Award, CDA-09-206. VA Puget Sound Health Care System
and the VA Palo Alto Health Care System provided resources to support
this research. The authors had full access to all of the data in the
study and take responsibility for the integrity of the data and the
accuracy of the data analysis. Views expressed in this article are those
of the authors and do not necessarily reflect the position or policy of
the Department of Veterans Affairs.
NR 68
TC 8
Z9 8
U1 3
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1551-7144
J9 CONTEMP CLIN TRIALS
JI Contemp. Clin. Trials
PD SEP
PY 2013
VL 36
IS 1
BP 307
EP 318
DI 10.1016/j.cct.2013.07.009
PG 12
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 225KH
UT WOS:000324961300034
PM 23916918
ER
PT J
AU Fisher, V
Fernandez, MP
Krejci-Manwaring, J
AF Fisher, Valerie
Fernandez, Martin P.
Krejci-Manwaring, Jennifer
TI Lichen Planus Mimicking Recalcitrant Ulcerative Psoriasis: When Is It
Time to Biopsy?
SO CUTIS
LA English
DT Article
ID EFFICACY
AB LP verrucosus, is a rare disorder that presents as verrucous plaques, typically on the lower extremities and ankles. This variant differs from the common presentation of LP, which appears as flat, polygonal, pink-purple papules spread diffusely on the flexor wrists, trunk, shins, and dorsal aspects of the feet, frequently involving the oral mucosa. Clinically, hypertrophic LP can be confused with psoriasis and usually does not respond to therapy with biologics. We present a case of hypertrophic LP in a 42-year-old woman who had been treated extensively for psoriasis. Although the morphology and location of the hyperkeratotic plaques mimicked psoriasis, biopsy results exhibited characteristic features of hypertrophic LP, and the lesions responded to treatment with acitretin,. clobetasol propionate ointment, hydroxychloroquine, and simple wound care. The hypertrophic variant of LP can be extremely challenging to differentiate from psoriasis. Physicians who treat patients with scaly plaques should think beyond psoriasis and consider the hypertrophic variant of LP as a potential diagnosis.
C1 [Fisher, Valerie; Fernandez, Martin P.; Krejci-Manwaring, Jennifer] Univ Texas Hlth Sci Ctr San Antonio, Div Dermatol & Cutaneous Surg, San Antonio, TX 78229 USA.
[Krejci-Manwaring, Jennifer] Audie L Murphy Mem Vet Adm Med Ctr, Div Dermatol, San Antonio, TX 78229 USA.
RP Krejci-Manwaring, J (reprint author), Audie L Murphy Mem Vet Adm Med Ctr, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.
EM krejcimanwar@uthscsa.edu
NR 9
TC 1
Z9 1
U1 0
U2 0
PU QUADRANT HEALTHCOM INC
PI PARSIPPANY
PA 7 CENTURY DRIVE, STE 302, PARSIPPANY, NJ 07054-4603 USA
SN 0011-4162
J9 CUTIS
JI Cutis
PD SEP
PY 2013
VL 92
IS 3
BP 136
EP 139
PG 4
WC Dermatology
SC Dermatology
GA 223FW
UT WOS:000324791100010
PM 24153142
ER
PT J
AU Ghose, T
Fiellin, DA
Gordon, AJ
Metraux, S
Goetz, MB
Blackstock, O
McInnes, K
Rodriguez-Barradas, MC
Justice, AC
AF Ghose, T.
Fiellin, D. A.
Gordon, A. J.
Metraux, S.
Goetz, M. B.
Blackstock, O.
McInnes, K.
Rodriguez-Barradas, M. C.
Justice, A. C.
TI Hazardous drinking and its association with homelessness among veterans
in care
SO DRUG AND ALCOHOL DEPENDENCE
LA English
DT Article
DE Hazardous drinking; Homelessness; Veteran care; Alcohol use;
Longitudinal analysis; Veterans Aging Cohort Study
ID DSM-III-R; ALCOHOL-USE; SUBSTANCE-ABUSE; MENTAL-ILLNESS; HEALTH-CARE;
GENERAL-POPULATION; SUICIDAL IDEATION; WAR VETERANS; DRUG-ABUSE;
DRINKERS
AB Background: While scholarship on alcohol use and homelessness has focused on the impact of alcohol abuse and dependence, little is known about the effects of lower levels of misuse such as hazardous use. Veterans receiving care in the Department of Veterans Affairs Health Care System (VA) constitute a population that is vulnerable to alcohol misuse and homelessness. This research examines the effects of hazardous drinking on homelessness in the Veterans Aging Cohort Study, a sample of 2898 older veterans (mean age=50.2), receiving care in 8 VAs across the country.
Methods: Logistic regression models examined the associations between (1) hazardous drinking at baseline and homelessness at 1-year follow-up, (2) transitions into and out of hazardous drinking from baseline to follow-up and homelessness at follow-up, and (3) transitioning to hazardous drinking and transitioning to homelessness from baseline to follow-up during that same time-period.
Results: After controlling for other correlates including alcohol dependence, hazardous drinking at baseline increased the risk of homelessness at follow-up (adjusted odds ratio [AOR] = 1.39, 95% confidence interval [CI] = 1.02, 1.88). Transitioning to hazardous drinking more than doubled the risk of homelessness at follow-up (AOR=2.42,95% CI=1.41, 4.15), while more than doubling the risk of transitioning from being housed at baseline to being homeless at follow-up (AOR=2.49, 95% CI=1.30, 4.79).
Conclusions: Early intervention that seeks to prevent transitioning into hazardous drinking could increase housing stability among veterans. Brief interventions which have been shown to be effective at lower levels of alcohol use should be implemented with veterans in VA care. Published by Elsevier Ireland Ltd.
C1 [Ghose, T.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19130 USA.
[Fiellin, D. A.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA.
[Fiellin, D. A.] Yale Univ, Sch Med, Ctr Interdisciplinary Res AIDS, New Haven, CT 06510 USA.
[Gordon, A. J.] Univ Pittsburgh, Sch Med, VA Pittsburgh HealthCare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA.
[Metraux, S.] Univ Sci, Dept Hlth Policy & Publ Hlth, Philadelphia, PA 19104 USA.
[Goetz, M. B.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Blackstock, O.; Justice, A. C.] VA Connecticut Healthcare Syst, West Haven, CT 06516 USA.
[Blackstock, O.; Justice, A. C.] Yale Univ, Sch Med, New Haven, CT 06510 USA.
[McInnes, K.] ENRM VA Med Ctr, VA QUERI Program, Bedford, MA 01730 USA.
[McInnes, K.] ENRM VA Med Ctr, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA 01730 USA.
[McInnes, K.] Boston Univ, Sch Publ Hlth, Boston, MA 02215 USA.
[Rodriguez-Barradas, M. C.] Michael E DeBakey VAMC, Houston, TX 77030 USA.
[Rodriguez-Barradas, M. C.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
RP Ghose, T (reprint author), Univ Penn, Sch Social Policy & Practice, D17 Caster Bldg,3701 Locust Walk, Philadelphia, PA 19130 USA.
EM toorjo@sp2.upenn.edu
OI Goetz, Matthew/0000-0003-4542-992X; Fiellin, David/0000-0002-4006-010X
FU National Institutes of Health: NIAAA [U10-AA13566]; NHLBI [R01-HL095136,
R01-HL090342, RCI-HL100347]; NIA [R01-AG029154, K23 AG024896]
FX This work was financially supported by National Institutes of Health:
NIAAA (U10-AA13566), NHLBI (R01-HL095136; R01-HL090342; RCI-HL100347),
and NIA (R01-AG029154; K23 AG024896). The funding helped support the
implementation of the study, i.e., the implementation of the study
design, the data collection process and preparation of the data for
analysis. The funders played no role in the analysis of the data, the
preparation of the manuscript or decisions regarding where to submit it.
NR 45
TC 3
Z9 3
U1 0
U2 12
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0376-8716
J9 DRUG ALCOHOL DEPEN
JI Drug Alcohol Depend.
PD SEP 1
PY 2013
VL 132
IS 1-2
BP 202
EP 206
DI 10.1016/j.drugalcdep.2013.02.004
PG 5
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA 216KE
UT WOS:000324281400028
PM 23474200
ER
PT J
AU Hoef, LWV
Paige, AL
Riley, KO
Cure, J
Soltani, M
Williams, FB
Kennedy, RE
Szaflarski, JP
Knowlton, RC
AF Hoef, Lawrence W. Ver
Paige, A. LeBron
Riley, Kristen O.
Cure, Joel
Soltani, Mehdi
Williams, Frank B.
Kennedy, Richard E.
Szaflarski, Jerzy P.
Knowlton, Robert C.
TI Evaluating hippocampal internal architecture on MRI: Inter-rater
reliability of a proposed scoring system
SO EPILEPSY RESEARCH
LA English
DT Article
DE Hippocampus; Temporal lobe epilepsy; MRI; Ammon's horn; Inter-rater
reliability; Internal architecture
ID SCLEROSIS; EPILEPSY; ATROPHY
AB Background: Asymmetry of hippocampal internal architecture (HIA) has been reported to be a frequent imaging finding in epilepsy patients with temporal lobe epilepsy (TLE) who exhibit other signs of hippocampal sclerosis. HIA asymmetry may also be an independent predictor of the side of seizure onset in patients with otherwise normal MRI scans. The study of HIA asymmetry and its relationship to the laterality of TLE would benefit from a reliable method of assessing the clarity of HIA in MRI scans. We propose a visual scoring system that rates HIA clarity from 1 (imperceptible) to 4 (excellent) and report the inter-rater reliability (IRR) of this system.
Methods: In the initial preliminary phase of this study we examined IRR using a kappa statistic (K) among a mixed group of expert and non-expert reviewers using only a brief description of the scoring system to score single images from a series of patients. In the second phase we explored the effect of training on the use of our HIA scoring system by assessing IRR among neuroimaging experts before and after a brief interactive training session. In this phase, multiple slices from each patient were scored. Separate K values and intraclass correlation coefficients (ICC) were calculated from the scores given to each hippocampal image and from the asymmetry of scores between left and right for each slice. In the third phase the effect of training on non-expert reviewers was explored using a similar approach as with the expert reviewers.
Results: In the preliminary phase of the study, HIA scoring of single images showed substantial agreement among expert reviewers (kappa(HIA) = 0.65), fair agreement among non-expert reviewers (kappa(HIA) = 0.27), and a fair to moderate degree of agreement among all the reviewers as a whole (kappa(HIA) = 0.40). In the second phase, prior to training there was substantial agreement among expert reviewers in regard to the individual HIA scores (kappa(HIA) = 0.62; ICCHIA = 0.81) but only moderate agreement on the degree of asymmetry (kappa(Asym) = 0.47; ICCAsym = 0.71). Training improved agreement on the individual HIA scores (kappa(HIA) = 0.58-0.72; ICCHIA = 0.76-0.84) and on the degree of asymmetry (kappa(Asym) = 0.61-0.67; ICCAsym = 081-0.85). Among non-expert reviewers, scores improved from only a fair degree of agreement pre-training (kappa(HIA) = 0.25, kappa(Asym) = 0.25; ICCHIA = 0.68, ICCAsym = 0.66) to a moderate level of agreement after training (kappa(HIA) = 0.54, kappa(Asym) = 0.52; ICCHIA = 0.78, ICCAsym = 0.81).
Conclusions: The proposed HIA scoring system has a substantial degree of inter-rater reliability among experienced neuroimaging reviewers. Training improves the detection of asymmetries in HIA score in particular. Non-expert reviewers can employ the system with a moderate degree of reliability, and training has an even greater impact on the improvement of scoring reliability. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Hoef, Lawrence W. Ver; Soltani, Mehdi; Szaflarski, Jerzy P.] Univ Alabama Birmingham, Dept Neurol, UAB Epilepsy Ctr, Birmingham, AL 35294 USA.
[Hoef, Lawrence W. Ver; Soltani, Mehdi] Birmingham VA Med Ctr, Neurol Serv, Birmingham, AL USA.
[Paige, A. LeBron; Soltani, Mehdi] Univ Iowa, Dept Neurol, Iowa Comprehens Epilepsy Program, Iowa City, IA 52242 USA.
[Riley, Kristen O.; Soltani, Mehdi] Univ Alabama Birmingham, Div Neurosurg, Birmingham, AL USA.
[Cure, Joel; Soltani, Mehdi] Univ Alabama Birmingham, Dept Radiol, Birmingham, AL USA.
[Soltani, Mehdi; Williams, Frank B.; Kennedy, Richard E.] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA.
[Soltani, Mehdi; Knowlton, Robert C.] Univ Texas Houston, Texas Comprehens Epilepsy Program, Dept Neurol, Houston, TX USA.
RP Hoef, LWV (reprint author), Suite 312 CIRC,1719 6th Ave South, Birmingham, AL 35205 USA.
EM LVERHOEF@UAB.EDU; LeBron-Paige@uiowa.edu; KRILEY@UAB.EDU; CUREJ@UAB.EDU;
soltanim_20@yahoo.com; FBW@UAB.EDU; RKennedy@ms.soph.uab.edu;
SZAFLAJ@UAB.EDU; Robert.C.Knowlton@uth.tmc.edu
RI Williams, Frank/H-2220-2016
OI Williams, Frank/0000-0001-7507-4870; Riley, Kristen/0000-0001-5895-6855
FU National Institute of Biomedical Imaging and Bioengineering of the
National Institutes of Health [1K23EB008452-01A1]
FX Research reported in this publication was supported by the National
Institute of Biomedical Imaging and Bioengineering of the National
Institutes of Health under Award Number 1K23EB008452-01A1. The content
is solely the responsibility of the authors and does not necessarily
represent the official views of the National Institutes of Health.
NR 18
TC 1
Z9 1
U1 1
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-1211
EI 1872-6844
J9 EPILEPSY RES
JI Epilepsy Res.
PD SEP
PY 2013
VL 106
IS 1-2
BP 146
EP 154
DI 10.1016/j.eplepsyres.2013.05.009
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA 221NM
UT WOS:000324665600016
ER
PT J
AU Hoef, LWV
Williams, FB
Kennedy, RE
Szaflarski, JP
Knowlton, RC
AF Hoef, Lawrence W. Ver
Williams, Frank B.
Kennedy, Richard E.
Szaflarski, Jerzy P.
Knowlton, Robert C.
TI Predictive value of hippocampal internal architecture asymmetry in
temporal lobe epilepsy
SO EPILEPSY RESEARCH
LA English
DT Article
DE Hippocampus; Temporal lobe epilepsy; MRI; Ammon's horn; Hippcampal
internal architecture; Imaging
ID HIGH-RESOLUTION MRI; SCLEROSIS; ATROPHY; SUBFIELDS; AGE
AB Background: Asymmetry of hippocampal internal architecture (HIA) clarity has been suggested to be a sign of hippocampal sclerosis (HS) and is frequently associated with other MRI findings of HS. The goal of this work is to use a previously developed HIA visual scoring system (Ver Hoef et al., 2013) to quantify HIA asymmetry in a retrospective series of consecutive temporal lobe epilepsy (TLE) patients and evaluate its value in predicting laterality of seizure onset both in patients with other signs of HS (HS+) and those without (HS-).
Methods: The HIA scoring system was used to rate hippocampal asymmetry and to assess the agreement between HIA and seizure lateralization. The median values of the average HIA scores for each hippocampus were compared for HS+ epileptogenic hippocampi, HS- epileptogenic hippocampi, and non-epileptogenic hippocampi with a Kruskal Wallis one-way analysis of variance by ranks. Pair-wise differences between groups were evaluated with the two-tailed Mann Whitney U test. A logistic regression model examined the utility of average HIA asymmetry score in predicting the true laterality of seizure onset as determined by video-EEG. Sensitivity and specificity are calculated using various asymmetry thresholds in each patient group.
Results: Fifty-five patients were identified who met inclusion criteria. Thirteen patients (24%) were found to have hippocampal atrophy and/or signal abnormality indicative of HS (HS+) and 42 did not (HS-). Significant differences were observed in the distribution of individual and average HIA scores between each of the groups of hippocampi, with HS+ hippocampi having the lowest HIA scores and non-epileptogenic hippocampi having the highest. Logistic regression analysis showed that the average HIA asymmetry score was a strong predictor of the laterality of seizure onset (beta = 3.93508, p < 0.001). HIA asymmetry remained significant even after adjustment for HS+/HS- status (beta = 3.8854, p < 0.001). Among HS- patients, when the average HIA asymmetry score was equal to or exceeded a threshold value of 0.5, the specificity for correctly predicting the side of seizure onset was between 95% and 100% with a sensitivity of 40-45%. Among HS+ patients, a threshold of 0.3 yielded a sensitivity of 85% and specificity of 100%.
Conclusions: In this report we show for the first time that HIA asymmetry is a significant predictor of the laterality of seizure onset in TLE patients with otherwise normal MRI findings, and that the proposed HIA scoring system has high specificity and moderate sensitivity for lateralizing seizure onset in patients with TLE. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Hoef, Lawrence W. Ver; Szaflarski, Jerzy P.] Univ Alabama Birmingham, Dept Neurol, UAB Epilepsy Ctr, Birmingham, AL 35294 USA.
[Hoef, Lawrence W. Ver] Birmingham VA Med Ctr, Neurol Serv, Birmingham, AL USA.
[Williams, Frank B.; Kennedy, Richard E.] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA.
[Knowlton, Robert C.] Univ Texas Houston, Texas Comprehens Epilepsy Program, Dept Neurol, Houston, TX USA.
RP Hoef, LWV (reprint author), Suite 312 CIRC,1719 6th Ave South, Birmingham, AL 35205 USA.
EM LVERHOEF@UAB.EDU; FBW@UAB.EDU; RKennedy@ms.soph.uab.edu;
SZAFLAJ@UAB.EDU; Robert.C.Knowlton@uth.tmc.edu
RI Williams, Frank/H-2220-2016
OI Williams, Frank/0000-0001-7507-4870
FU National Institute of Biomedical Imaging and Bioengineering of the
National Institutes of Health [1K23EB008452-01A1]
FX Research reported in this publication was supported by the National
Institute of Biomedical Imaging and Bioengineering of the National
Institutes of Health under Award Number 1K23EB008452-01A1.
NR 19
TC 3
Z9 3
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-1211
EI 1872-6844
J9 EPILEPSY RES
JI Epilepsy Res.
PD SEP
PY 2013
VL 106
IS 1-2
BP 155
EP 163
DI 10.1016/j.eplepsyres.2013.05.008
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA 221NM
UT WOS:000324665600017
ER
PT J
AU Ponticorvo, A
Cardenas, D
Dunn, AK
Ts'o, D
Duong, TQ
AF Ponticorvo, Adrien
Cardenas, Damon
Dunn, Andrew K.
Ts'o, Daniel
Duong, Timothy Q.
TI Laser speckle contrast imaging of blood flow in rat retinas using an
endoscope
SO JOURNAL OF BIOMEDICAL OPTICS
LA English
DT Article
DE laser speckle imaging; retinal imaging; gas challenge; flicker
stimulation
ID OPTIC-NERVE; PHOTOGRAPHY; RESOLUTION; IMAGES; FUNDUS
AB Laser speckle contrast imaging (LSCI) offers a cost-effective means to image blood flow in vivo. However, it is not commonly used to image rodent retinas because of the challenges associated with imaging through the curved cornea and delivering light through the highly scattering lens. A solution to overcome these problems by using LSCI in conjunction with an endoscope to obtain high spatiotemporal blood flow images is described. Its utility is demonstrated by imaging blood flow changes in rat retinas using hyperoxic, hypercapnic, and visual (flicker) stimulations. Hypercapnia increases blood flow, hyperoxia decreases blood flow, and visual stimulation increases blood flow in the retina relative to basal conditions. The time-to-peak of the LSCI response to visual stimulation is also measured. This approach may prove useful to investigate dysregulation in blood flow-evoked responses in retinal diseases and to evaluate treatment strategies in rodents. (C) The Authors. Published by SPIE under a Creative Commons Attribution 3.0 Unported License. Distribution or reproduction of this work in whole or in part requires full attribution of the original publication, including its DOI.
C1 [Ponticorvo, Adrien; Cardenas, Damon; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA.
[Dunn, Andrew K.] Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA.
[Ts'o, Daniel] SUNY Upstate Med Univ, Dept Neurosurg & Neurosci, Syracuse, NY 13210 USA.
[Duong, Timothy Q.] South Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX 78229 USA.
RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA.
EM duongt@uthscsa.edu
RI Duong, Timothy/B-8525-2008; Dunn, Andrew/I-9527-2014
FU Department of Veterans Affairs (VA MERIT Award); NIH [R01 EY018855, R01
EY014211]
FX This work was supported in part by the Department of Veterans Affairs
(VA MERIT Award) and NIH (R01 EY018855 and R01 EY014211).
NR 22
TC 9
Z9 9
U1 0
U2 7
PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA
SN 1083-3668
J9 J BIOMED OPT
JI J. Biomed. Opt.
PD SEP
PY 2013
VL 18
IS 9
AR 090501
DI 10.1117/1.JBO.18.9.090501
PG 3
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
Medical Imaging
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
Medical Imaging
GA 222QX
UT WOS:000324747300001
PM 24064947
ER
PT J
AU Iyer, RS
Bhargava, P
Sandstrom, CK
Dicks, DL
Reddy, GP
AF Iyer, Ramesh S.
Bhargava, Puneet
Sandstrom, Claire K.
Dicks, Demetrius L.
Reddy, Gautham P.
TI Establishing a Fellowship Education Committee
SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY
LA English
DT Editorial Material
ID DIAGNOSTIC-RADIOLOGY; RESIDENTS; PROGRAMS
C1 [Iyer, Ramesh S.] Seattle Childrens Hosp, Dept Radiol, Seattle, WA USA.
[Bhargava, Puneet] VA Puget Sound Hlth Care Syst, Dept Radiol, Seattle, WA USA.
[Sandstrom, Claire K.; Dicks, Demetrius L.; Reddy, Gautham P.] Univ Washington, Med Ctr, Dept Radiol, Seattle, WA 98105 USA.
RP Iyer, RS (reprint author), Univ Washington, Sch Med, Seattle Childrens Hosp, 4800 Sand Point Way NE, Seattle, WA 98105 USA.
EM riyer@uw.edu
OI Bhargava, Puneet/0000-0002-3849-9666
NR 16
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1546-1440
J9 J AM COLL RADIOL
JI J. Am. Coll. Radiol.
PD SEP
PY 2013
VL 10
IS 9
BP 718
EP 720
DI 10.1016/j.jacr.2012.07.024
PG 3
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 222IB
UT WOS:000324723300018
PM 23332609
ER
PT J
AU Banks, WA
AF Banks, William A.
TI Artificial Emotions: Robots Caring for the Elderly
SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION
LA English
DT Editorial Material
ID ANIMAL-ASSISTED THERAPY; LONELINESS; DOGS
C1 [Banks, William A.] Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA.
[Banks, William A.] Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA.
RP Banks, WA (reprint author), VA PSH CSI GRECC S-182,Bldg 1,Rm 810A,1600 S Colu, Seattle, WA 98108 USA.
EM wabanks1@u.washington.edu
NR 8
TC 3
Z9 3
U1 3
U2 29
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1525-8610
J9 J AM MED DIR ASSOC
JI J. Am. Med. Dir. Assoc.
PD SEP
PY 2013
VL 14
IS 9
BP 635
EP 636
DI 10.1016/j.jamda.2013.04.011
PG 2
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 217AS
UT WOS:000324329500003
PM 23764538
ER
PT J
AU Boockvar, K
Signor, D
Ramaswamy, R
Hung, W
AF Boockvar, Kenneth
Signor, Daniel
Ramaswamy, Ravishankar
Hung, William
TI Delirium During Acute Illness in Nursing Home Residents
SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION
LA English
DT Article
DE Nursing homes; delirium; nosocomial infection; activities of daily
living
ID CONFUSION ASSESSMENT METHOD; ELDERLY MEDICAL PATIENTS; PREDICTIVE MODEL;
SYMPTOMS; PREVALENCE; PERSISTENT; MORTALITY; SCALE; RISK; CARE
AB Objectives: To ascertain the incidence of delirium during acute illness in nursing home residents, describe the timing of delirium after acute illness onset, describe risk factors for delirium, and explore the relationship between delirium and complications of acute illness.
Design: Prospective observational cohort study.
Setting: Three nursing homes in metropolitan New York.
Participants: Individuals who were expected to remain in the nursing home for at least 2 months, who, as part of a parent study, were receiving opioids, antidepressants, or antipsychotics on a routine basis, and who did not have an acute medical illness at the time of screening. Acute illness surveillance was performed twice weekly through communication with nursing home nursing staff and medical providers using established clinical criteria for incipient cases.
Measurements: We followed patients for 14 days after illness onset, and, if applicable, an additional 14 days each after hospital admission and hospital discharge. Delirium was assessed 3 times weekly using the Confusion Assessment Method (CAM). Physical function decline was calculated using change in the Minimum Data Set Activities of Daily Living Scale (MDS-ADL) and cognitive function decline using change in the Minimum Data Set Cognitive performance scale (MDS-CPS). Falls were ascertained by record review.
Results: Among 136 nursing home patients followed for a mean of 11.7 months, 78 experienced 232 acute illnesses, of which 162 (71%) were managed in the nursing home. The most common diagnoses were urinary tract infection (20%), cellulitis (15%), and lower respiratory tract infection (9%). Subjects experienced delirium during 41 (17.7%) of 232 acute illnesses. Female sex was associated with a greater risk of delirium (odds ratio 2.59; 95% confidence interval [CI] 1.04-6.43) but there were no other risk factors identified. Delirium was a risk factor for cognitive function decline (odds ratio 4.59; 95% CI 1.99-10.59; P = .0004), but not ADL function decline or falling.
Conclusion: Delirium occurred frequently as a complication of acute illness in the nursing home, and was a risk factor for cognitive function decline. This finding supports the rationale to target individuals at the onset of an acute medical problem in the design of interventions to prevent delirium in the nursing home setting. Published by Elsevier Inc. on behalf of the American Medical Directors Association, Inc.
C1 [Boockvar, Kenneth; Signor, Daniel; Hung, William] James J Peters VA Med Ctr, Bronx, NY USA.
[Boockvar, Kenneth] Jewish Home Lifecare, New York, NY 10025 USA.
[Boockvar, Kenneth; Ramaswamy, Ravishankar; Hung, William] Mt Sinai, Icahn Sch Med, New York, NY USA.
RP Boockvar, K (reprint author), Jewish Home Lifecare, 120 West 106th St, New York, NY 10025 USA.
EM kenneth.boockvar@mssm.edu
OI Boockvar, Kenneth/0000-0003-1165-5558
FU VA Health Services Research and Development Grants [ARCD 03-027-1, REA
08-260]; Greenwall Foundation
FX This study was funded by VA Health Services Research and Development
Grants ARCD 03-027-1 and REA 08-260. Dr. Boockvar was supported by the
Greenwall Foundation.
NR 34
TC 15
Z9 15
U1 1
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1525-8610
J9 J AM MED DIR ASSOC
JI J. Am. Med. Dir. Assoc.
PD SEP
PY 2013
VL 14
IS 9
BP 656
EP 660
DI 10.1016/j.jamda.2013.06.004
PG 5
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 217AS
UT WOS:000324329500008
PM 23896369
ER
PT J
AU Yoo, JW
Choi, JB
Kim, SJ
Shin, HP
Kim, K
Ryu, WS
Min, TJ
Kim, S
Nakagawa, S
AF Yoo, Ji Won
Choi, Jong Bum
Kim, Sun Jung
Shin, Hyun P.
Kim, Kyudam
Ryu, Woo Sang
Min, Too Jae
Kim, Sulgi
Nakagawa, Shunichi
TI Factors Associated With Remaining in a Skilled Nursing Facility for Over
90 Days from Admission: Residents' Participation in Therapy and Desire
to Return to the Community
SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION
LA English
DT Article
DE Nursing home; patient participation; skilled nursing facility
ID MINIMUM DATA SET; HOME RESIDENTS; DETERMINANTS; TRANSITIONS; POSTACUTE;
DELIRIUM
AB Background: To identify the factors associated with stay in a skilled nursing facility (SNF) among new enrollees who did not fully participate in therapy sessions.
Methods: Data (n = 36,133) were obtained from the Minimum Data Set version 2.0 in the state of Michigan in 2009. Study participants were new SNF enrollees (n = 699) who did not fully participate in therapy sessions despite their desire to return to the community. Multivariate logistic regressions were performed to identify factors contributing to remaining in a nursing home for 91 days or longer.
Results: New SNF enrollees were more likely to remain in nursing home when they were depressed (odds ratio [OR] 1.41; 95% confidence interval [CI], 1.09-2.08; P = .01), experiencing delirium (OR = 3.20; 95% CI, 1.48-5.92; P < .001), were not in pain (OR = 0.83; 95% CI, 0.60-0.95; P = .03), or in less complex care (OR = 0.57; 95% CI, 0.44-0.81; P < .01).
Conclusions: A higher number of new SNF enrollees than previously reported were likely to stay in nursing homes (28.0%). Depression and delirium were associated with stay in an SNF, while pain and higher complexity of care were associated with returning to the community. Copyright (C) 2013 - American Medical Directors Association, Inc.
C1 [Yoo, Ji Won] Aurora Hlth Care, Ctr Senior Hlth & Longev, Milwaukee, WI USA.
[Yoo, Ji Won] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA.
[Choi, Jong Bum] Yonsei Univ, Coll Med, Dept Pain Med & Anesthesia, Seoul, South Korea.
[Kim, Sun Jung] Yonsei Univ, Coll Med, Dept Publ Hlth, Seoul, South Korea.
[Kim, Sun Jung] Yonsei Univ, Coll Med, Inst Hlth Serv Res, Seoul, South Korea.
[Shin, Hyun P.] Kyung Hee Univ, Coll Med, East West Neo Med Ctr, Dept Internal Med, Seoul, South Korea.
[Kim, Kyudam] Korea Adv Inst Sci & Technol, Taejon 305701, South Korea.
[Ryu, Woo Sang] Korea Univ, Coll Med, Clin Res Ctr, Seoul 136705, South Korea.
[Min, Too Jae] Korea Univ, Coll Med, Dept Pain Med & Anesthesia, Seoul 136705, South Korea.
[Kim, Sulgi] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
[Nakagawa, Shunichi] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY USA.
[Nakagawa, Shunichi] James J Peters Vet Affairs Med Ctr, Ctr Clin, Bronx, NY USA.
RP Yoo, JW (reprint author), Univ Michigan, Sch Med, Dept Internal Med, 300 North Ingalls Bldg,Room 932, Ann Arbor, MI 48109 USA.
EM yoojiw@trinity-health.org
NR 20
TC 1
Z9 1
U1 10
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1525-8610
J9 J AM MED DIR ASSOC
JI J. Am. Med. Dir. Assoc.
PD SEP
PY 2013
VL 14
IS 9
AR UNSP 710.e1
DI 10.1016/j.jamda.2013.05.022
PG 4
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 217AS
UT WOS:000324329500020
PM 23860264
ER
PT J
AU Cotofana, S
Wyman, BT
Benichou, O
Dreher, D
Nevitt, M
Gardiner, J
Wirth, W
Hitzl, W
Kwoh, CK
Eckstein, F
Frobell, RB
AF Cotofana, S.
Wyman, B. T.
Benichou, O.
Dreher, D.
Nevitt, M.
Gardiner, J.
Wirth, W.
Hitzl, W.
Kwoh, C. K.
Eckstein, F.
Frobell, R. B.
CA OAI Investigators Grp
TI Relationship between knee pain and the presence, location, size and
phenotype of femorotibial denuded areas of subchondral bone as
visualized by MRI
SO OSTEOARTHRITIS AND CARTILAGE
LA English
DT Article
DE Pain; Cartilage; MRI; Denuded area of subchondral bone
ID INITIATIVE PROGRESSION SUBCOHORT; ARTICULAR-CARTILAGE; IMAGING FINDINGS;
OSTEOCHONDRAL JUNCTION; RADIOGRAPHIC FEATURES; SENSORY INNERVATION;
REGIONAL-ANALYSIS; OSTEOARTHRITIS; ASSOCIATION; JOINT
AB Objective: Conflicting associations between imaging biomarkers and pain in knee osteoarthritis (OA) have been reported. A relation between pain and denuded areas of subchondral bone (dABs) has been suggested and this study explores this relationship further by relating the presence, phenotype, location and size of dABs to different measures of knee pain.
Methods: 633 right knees from the Osteoarthritis Initiative (OAI) (250 men, age 61.7 +/- 9.6 yrs, BMI 29.4 +/- 4.7 kg/m(2)) were included. Manual segmentation of the femorotibial cartilage plates was performed on 3 T coronal fast low angle shot with water excitation (FLASHwe) images. dABs were defined as areas where the subchondral bone was uncovered by cartilage. The following measures of pain were used: weightbearing-, non-weightbearing-, moderate-to-severe-, infrequent- and frequent knee pain.
Results: Using pain measures from subjects without dABs as a reference, those with at least one dAB had a 1.64-fold higher prevalence ratio [PR, 95% confidence interval (CI) 1.24-2.18] to have frequent and 1.45-fold higher for moderate-to-severe knee pain (95% CI 1.13-1.85). Subjects with dABs in central subregions had a 1.53-fold increased prevalence of having weightbearing pain (95% Cl 1.20-1.97), especially when the central subregion was moderately (>10%) denuded (PR 1.81, 95% CI 135-2.42). Individuals with cartilage-loss-type dABs had a slightly higher prevalence (PR 1.13, 95% CI 1.00-1.27) of having frequent knee pain compared to individuals with intra-chondral-osteophyte-type dABs.
Conclusion: This study supports a positive relation between femorotibial dABs and knee pain, especially when the dABs are located centrally (i.e., in weightbearing regions) or when the respective central subregion is moderately denuded. (C) 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
C1 [Cotofana, S.; Wirth, W.; Hitzl, W.; Eckstein, F.; Frobell, R. B.] Paracelsus Med Univ, Salzburg, Austria.
[Cotofana, S.; Wirth, W.; Eckstein, F.] Chondrometr GmbH, Ainring, Germany.
[Wyman, B. T.; Gardiner, J.] Pfizer Inc, Groton, CT 06340 USA.
[Benichou, O.] Eli Lilly & Co, Indianapolis, IN 46285 USA.
[Dreher, D.] Merck Serono, Geneva, Switzerland.
[Nevitt, M.] UCSF, San Francisco, CA USA.
[Kwoh, C. K.] Univ Pittsburgh, Pittsburgh, PA 15260 USA.
[Kwoh, C. K.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Frobell, R. B.] Lund Univ, Dept Orthoped, Clin Sci Lund, Lund, Sweden.
RP Cotofana, S (reprint author), PMU, Inst Anat & Musculoskeletal Res, Strubergasse 21, A-5020 Salzburg, Austria.
EM sebastian.cotofana@pmu.ac.at
RI Wirth, Wolfgang/C-8724-2011
OI Wirth, Wolfgang/0000-0002-2297-8283
FU Pfizer Inc.; Eli Lilly Co; Merck Serono SA - Geneva, Switzerland;
GlaxoSmithKline; Centocor Inc.; National Institutes of Health, a branch
of the Department of Health and Human Services [N01-AR-2-2258,
N01-AR-2-2259, N01-AR-2-2260, N01-AR-2-2261, N01-AR-2-2262]; Novartis
Pharmaceuticals Corporation; Merck Research Laboratories
FX The image analysis of this study was funded by an industry consortium
consisting of Pfizer Inc., Eli Lilly & Co, Merck Serono SA - Geneva,
Switzerland, GlaxoSmithKline, and Centocor Inc.; The OAI is a
public-private partnership comprised five contracts (N01-AR-2-2258;
N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by
the National Institutes of Health, a branch of the Department of Health
and Human Services, and conducted by the OAI Study Investigators.
Private funding partners include Pfizer Inc.; Novartis Pharmaceuticals
Corporation; Merck Research Laboratories; and GlaxoSmithKline. Private
sector funding for the OAI is managed by the Foundation for the National
Institutes of Health. This manuscript has received the approval of the
OAI Publications Committee based on a review of its scientific content
and data interpretation.
NR 48
TC 11
Z9 11
U1 1
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1063-4584
J9 OSTEOARTHR CARTILAGE
JI Osteoarthritis Cartilage
PD SEP
PY 2013
VL 21
IS 9
SI SI
BP 1214
EP 1222
DI 10.1016/j.joca.2013.04.001
PG 9
WC Orthopedics; Rheumatology
SC Orthopedics; Rheumatology
GA 225KQ
UT WOS:000324962200011
PM 23973133
ER
PT J
AU Switzer, GE
Robinson, GFWB
Rubio, DM
Fowler, NR
Kapoor, WN
AF Switzer, Galen E.
Robinson, Georgeanna F. W. B.
Rubio, Doris M.
Fowler, Nicole R.
Kapoor, Wishwa N.
TI Doctoral Programs to Train Future Leaders in Clinical and Translational
Science
SO ACADEMIC MEDICINE
LA English
DT Article
ID AWARDS
AB Purpose
Although the National Institutes of Health (NIH) has made extensive investments in educational programs related to clinical and translational science (CTS), there has been no systematic investigation of the number and characteristics of PhD programs providing training to future leaders in CTS. The authors undertook to determine the number of institutions that, having had received NIH-funded Clinical and Translational Science Awards (CTSAs), currently had or were developing PhD programs in CTS; to examine differences between programs developed before and after CTSA funding; and to provide detailed characteristics of new programs.
Method
In 2012, CTS program leaders at the 60 CTSA-funded institutions completed a cross-sectional survey focusing on four key domains related to PhD programs in CTS: program development and oversight; students; curriculum and research; and milestones.
Results
Twenty-two institutions had fully developed PhD programs in CTS, and 268 students were earning PhDs in this new field; 13 institutions were planning PhD programs. New programs were more likely to have fully developed PhD competencies and more likely to include students in medical school, students working only on their PhD, students working on a first doctoral degree, and students working in T1 translational research. They were less likely to include physicians and students working in clinical or T2 research.
Conclusions
Although CTS PhD programs have similarities, they also vary in their characteristics and management of students. This may be due to diversity in translational science itself or to the relative infancy of CTS as a discipline.
C1 [Switzer, Galen E.] Univ Pittsburgh, Pittsburgh, PA USA.
[Switzer, Galen E.; Fowler, Nicole R.] Univ Pittsburgh, Dept Med, PhD Program Clin & Translat Sci, Pittsburgh, PA USA.
[Switzer, Galen E.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Robinson, Georgeanna F. W. B.; Rubio, Doris M.] Univ Pittsburgh, Sch Med, Inst Clin Res Educ, Pittsburgh, PA USA.
[Rubio, Doris M.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
[Rubio, Doris M.] Univ Pittsburgh, Sch Med, Ctr Data, Ctr Res Hlth, Pittsburgh, PA USA.
[Rubio, Doris M.] Univ Pittsburgh, Sch Med, Off Evaluat, Pittsburgh, PA USA.
[Rubio, Doris M.] Univ Pittsburgh, Sch Med, Dept Med, Off Lifelong Learning, Pittsburgh, PA 15213 USA.
[Kapoor, Wishwa N.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA.
[Kapoor, Wishwa N.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.
[Kapoor, Wishwa N.] Univ Pittsburgh, Inst Clin Res Educ, Pittsburgh, PA USA.
[Kapoor, Wishwa N.] Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA USA.
[Kapoor, Wishwa N.] Univ Pittsburgh, RAND Univ Pittsburgh Hlth Inst, Pittsburgh, PA USA.
[Kapoor, Wishwa N.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA USA.
RP Switzer, GE (reprint author), Iroquois Bldg 502,3600 Forbes Ave, Pittsburgh, PA 15213 USA.
EM switzerge@upmc.edu
OI Robinson, Georgeanna/0000-0001-6205-2867
FU National Institutes of Health (NIH) [UL1 RR024153, UL1TR000005]
FX The project described was supported by the National Institutes of Health
(NIH) through grant numbers UL1 RR024153 and UL1TR000005.
NR 10
TC 3
Z9 3
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-2446
J9 ACAD MED
JI Acad. Med.
PD SEP
PY 2013
VL 88
IS 9
BP 1332
EP 1339
DI 10.1097/ACM.0b013e31829e7bce
PG 8
WC Education, Scientific Disciplines; Health Care Sciences & Services
SC Education & Educational Research; Health Care Sciences & Services
GA 208AN
UT WOS:000323647300040
PM 23899901
ER
PT J
AU Robinson, GFWB
Switzer, GE
Cohen, ED
Primack, BA
Kapoor, WN
Seltzer, DL
Bakken, LL
Rubio, DM
AF Robinson, Georgeanna F. W. B.
Switzer, Galen E.
Cohen, Elan D.
Primack, Brian A.
Kapoor, Wishwa N.
Seltzer, Deborah L.
Bakken, Lori L.
Rubio, Doris McGartland
TI A Shortened Version of the Clinical Research Appraisal Inventory:
CRAI-12
SO ACADEMIC MEDICINE
LA English
DT Article
ID PHYSICIAN-SCIENTISTS; SELF-EFFICACY; CAREER
AB Purpose
The original Clinical Research Appraisal Inventory (CRAI), which assesses the self-confidence of trainees in performing different aspects of clinical research, comprises 92 items. Completing the lengthy CRAI is time-consuming and represents a considerable burden to respondents, yet the CRAI provides useful data for evaluating research training programs. The purpose of this study is to develop a shortened version of the CRAI and to test its validity and reliability.
Method
Trainees in clinical research degree and career development programs at the University of Pittsburgh's Institute for Clinical Research Education completed the 92-item CRAI between 2007 and 2012, inclusive. The authors conducted, first, exploratory factor analysis on a training dataset (2007-2010) to reduce the number of items and, then, confirmatory factor analyses on a testing dataset (2011-2012) to test the psychometric properties of the shortened version.
Results
Of 546 trainees, 394 (72%) provided study data. Exploratory factor analysis revealed six distinct factors, and confirmatory factor analysis identified the two items with the highest loadings per factor, for a total of 12 items. Cronbach alpha for the six new factors ranged from 0.80 to 0.94. Factors in the 12-item CRAI were strongly and significantly associated with factors in the 92-item CRAI; correlations ranged from 0.82 to0.96 (P < .001 for each).
Conclusions
The 12-item CRAI is faster and less burdensome to complete but retains the strong psychometric properties of the original CRAI.
C1 [Robinson, Georgeanna F. W. B.] Univ Pittsburgh, Sch Med, Inst Clin Res Educ, Pittsburgh, PA USA.
[Switzer, Galen E.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Switzer, Galen E.; Primack, Brian A.; Rubio, Doris McGartland] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
[Cohen, Elan D.; Rubio, Doris McGartland] Univ Pittsburgh, Sch Med, Ctr Res Hlth Care Data Ctr, Pittsburgh, PA USA.
[Kapoor, Wishwa N.; Seltzer, Deborah L.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA.
[Kapoor, Wishwa N.; Seltzer, Deborah L.] Univ Pittsburgh, Sch Med, Ctr Res Hlth Care, Pittsburgh, PA USA.
[Kapoor, Wishwa N.; Seltzer, Deborah L.; Rubio, Doris McGartland] Univ Pittsburgh, Sch Med, Inst Clin Res Educ, Pittsburgh, PA USA.
[Kapoor, Wishwa N.] Univ Pittsburgh, Sch Med, Clin & Translat Sci Inst, Pittsburgh, PA USA.
[Bakken, Lori L.] Univ Wisconsin, Sch Human Ecol, Dept Interdisciplinary Studies, Madison, WI USA.
RP Robinson, GFWB (reprint author), Inst Clin Res Educ, 200 Meyran Ave,Suite 200, Pittsburgh, PA 15213 USA.
EM gwrobins@pitt.edu
OI Robinson, Georgeanna/0000-0001-6205-2867
FU National Institutes of Health [UL1 RR024153, UL1TR000005]
FX The National Institutes of Health supported this study through grant
numbers UL1 RR024153 and UL1TR000005.
NR 11
TC 2
Z9 2
U1 4
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-2446
EI 1938-808X
J9 ACAD MED
JI Acad. Med.
PD SEP
PY 2013
VL 88
IS 9
BP 1340
EP 1345
DI 10.1097/ACM.0b013e31829e75e5
PG 6
WC Education, Scientific Disciplines; Health Care Sciences & Services
SC Education & Educational Research; Health Care Sciences & Services
GA 208AN
UT WOS:000323647300041
PM 23886999
ER
PT J
AU Campbell, KH
Huang, ES
Dale, W
Parker, MM
John, PM
Young, BA
Moffet, HH
Laiteerapong, N
Karter, AJ
AF Campbell, Kellie Hunter
Huang, Elbert S.
Dale, William
Parker, Melissa M.
John, Priya M.
Young, Bessie A.
Moffet, Howard H.
Laiteerapong, Neda
Karter, Andrew J.
TI Association Between Estimated GFR, Health-Related Quality of Life, and
Depression Among Older Adults With Diabetes: The Diabetes and Aging
Study
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Article
DE Aging; chronic kidney disease (CKD); depression; quality of life
ID CHRONIC KIDNEY-DISEASE; NORTHERN CALIFORNIA DISTANCE;
GLOMERULAR-FILTRATION-RATE; RENAL-DISEASE; DIALYSIS; HOSPITALIZATION;
INITIATION; EQUATION; PROFILE; COHORT
AB Background: Although chronic kidney disease (CKD) is a highly prevalent condition among older adults with diabetes, the associations between health-related quality of life (HRQoL) and severity of CKD in this population are not well understood. The objective of this study was to assess HRQoL and depressive symptoms across estimated glomerular filtration rate (eGFR) stages.
Study Design: Cross-sectional.
Setting & Participants: 5,805 members of Kaiser Permanente Northern California, 60 years or older with diabetes, from the 2005-2006 Diabetes Study of Northern California (DISTANCE) survey.
Predictor: eGFR categories were defined as >= 90 (referent category), 75-89, 60-74, 45-59, 30-44, or <= 29 mL/min/1.73 m(2).
Outcomes: HRQoL was measured using the modified Short Form -8 Physical Component Summary (PCS) and Mental Component Summary (MCS) scores. Depressive symptoms were measured using the Patient Health Questionnaire -8.
Results: In unadjusted linear regression analyses, physical (PCS) and mental (MCS) HRQoL scores were significantly lower with worsening eGFR level. However, after adjustment for sociodemographics, diabetes duration, obesity, and cardiovascular comorbid conditions and taking into account interactions with proteinuria, none of the eGFR categories was significantly or substantively associated with PCS or MCS score. In both unadjusted and adjusted analyses, higher risk of depressive symptoms was observed in respondents with eGFR <= 29 mL/min/1.73 m(2) (relative risk, 2.02; 95% CI, 1.10-3.71; P < 0.05) compared with the referent group. However, this eGFR-depression relationship was no longer significant after adjusting for hemoglobin level.
Limitations: Participants are part of a single health care delivery system.
Conclusions: Our findings suggest the need for greater attention to and potential interventions for depression in patients with reduced eGFR. (C) 2013 by the National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
C1 [Campbell, Kellie Hunter; Huang, Elbert S.; Dale, William; John, Priya M.; Laiteerapong, Neda] Univ Chicago, Dept Med, Chicago, IL 60637 USA.
[Parker, Melissa M.; Moffet, Howard H.; Karter, Andrew J.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA.
[Young, Bessie A.] Univ Washington, Div Nephrol, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
[Young, Bessie A.] Kidney Res Inst, Seattle, WA USA.
RP Campbell, KH (reprint author), Univ Chicago, Sect Geriatr & Palliat Med, 5841 S Maryland Ave,MC 6098, Chicago, IL 60637 USA.
EM kcampbel@medicine.bsd.uchicago.edu
FU T. Franklin Williams Scholars Award; Atlantic Philanthropies, Inc;
American Geriatrics Society Foundation for Health in Aging; John A.
Hartford Foundation; Association of Specialty Professors; National
Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
[R01DK081796, R01DK080726, R01DK65664]; Centers for Diabetes Translation
Research at Kaiser Permanente; University of California, San Francisco
[P30 DK092924]; University of Chicago [P30 DK092949]; VA Puget Sound
Health Care System, Seattle, WA; National Institutes of Health, NIDDK
[DK079745]
FX Dr Campbell is supported by a T. Franklin Williams Scholars Award.
Funding was provided by Atlantic Philanthropies, Inc; the American
Geriatrics Society Foundation for Health in Aging; the John A. Hartford
Foundation; and the Association of Specialty Professors. The Diabetes
and Aging Study was supported by funding from the National Institute of
Diabetes and Digestive and Kidney Diseases (NIDDK; grants R01DK081796,
R01DK080726, and R01DK65664). Investigators also were supported by the
Centers for Diabetes Translation Research at Kaiser Permanente and
University of California, San Francisco (P30 DK092924) and the
University of Chicago (P30 DK092949). The sponsors played no role in the
design or interpretation of the study. Dr Young's contribution is
supported by resources from the VA Puget Sound Health Care System,
Seattle, WA, and by the National Institutes of Health, NIDDK (DK079745).
None of the mentioned funders had input into the content of this
manuscript and did not report any potential conflicts of interest
relevant to this article.
NR 36
TC 5
Z9 5
U1 1
U2 10
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD SEP
PY 2013
VL 62
IS 3
BP 541
EP 548
DI 10.1053/j.ajkd.2013.03.039
PG 8
WC Urology & Nephrology
SC Urology & Nephrology
GA 212ZZ
UT WOS:000324023700015
PM 23746376
ER
PT J
AU Shlipak, MG
Mattes, MD
Peralta, CA
AF Shlipak, Michael G.
Mattes, Monica D.
Peralta, Carmen A.
TI Update on Cystatin C: Incorporation Into Clinical Practice
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Review
DE Cystatin C; glomerular filtration rate (GFR) estimation; chronic kidney
disease
ID GLOMERULAR-FILTRATION-RATE; CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE;
SERUM CREATININE; FUNCTION DECLINE; ELDERLY PERSONS; OLDER-ADULTS;
RISK-FACTOR; US ADULTS; ALL-CAUSE
AB Kidney function monitoring using creatinine-based glomerular filtration rate estimation is a routine part of clinical practice. Emerging evidence has shown that cystatin C may improve classification of glomerular filtration rate for defining chronic kidney disease in certain clinical populations and assist in understanding the complications of chronic kidney disease. In this review and update, we summarize the overall literature on cystatin C, critically evaluate recent high-impact studies, highlight the role of cystatin C in recent kidney disease guidelines, and suggest a practical approach for clinicians to incorporate cystatin C into practice. We conclude by addressing frequently asked questions related to implementing cystatin C use in a clinical setting. (C) 2013 by the National Kidney Foundation, Inc.
C1 [Shlipak, Michael G.; Mattes, Monica D.; Peralta, Carmen A.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Shlipak, Michael G.; Mattes, Monica D.; Peralta, Carmen A.] Univ Calif San Francisco, San Francisco, CA 94121 USA.
RP Shlipak, MG (reprint author), Univ Calif San Francisco, Vet Affairs Med Ctr 111A1, 4150 Clement St, San Francisco, CA 94121 USA.
EM michael.shlipak@ucsf.edu
FU National Institute of Health (NIH)/National Institute on Aging
[5R01AG034853-03, 5R01AG027002-06]; NIH/National Institute of Diabetes
and Digestive and Kidney Diseases [1R01DK087961-01A1, K23 DK082793]
FX Dr Shlipak was supported by National Institute of Health (NIH)/National
Institute on Aging grants 5R01AG034853-03 and 5R01AG027002-06, and
NIH/National Institute of Diabetes and Digestive and Kidney Diseases
grant 1R01DK087961-01A1. Dr Peralta was supported by NIH/National
Institute of Diabetes and Digestive and Kidney Diseases grant K23
DK082793.
NR 52
TC 48
Z9 51
U1 4
U2 10
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD SEP
PY 2013
VL 62
IS 3
BP 595
EP 603
DI 10.1053/j.ajkd.2013.03.027
PG 9
WC Urology & Nephrology
SC Urology & Nephrology
GA 212ZZ
UT WOS:000324023700022
PM 23701892
ER
PT J
AU Baxter, SL
Pistilli, M
Pujari, SS
Liesegang, TL
Suhler, EB
Thorne, JE
Foster, CS
Jabs, DA
Levy-Clarke, GA
Nussenblatt, RB
Rosenbaum, JT
Kempen, JH
AF Baxter, Sally L.
Pistilli, Maxwell
Pujari, Siddharth S.
Liesegang, Teresa L.
Suhler, Eric B.
Thorne, Jennifer E.
Foster, C. Stephen
Jabs, Douglas A.
Levy-Clarke, Grace A.
Nussenblatt, Robert B.
Rosenbaum, James T.
Kempen, John H.
TI Risk of Choroidal Neovascularization among the Uveitides
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PUNCTATE INNER CHOROIDOPATHY; INTRAVITREAL BEVACIZUMAB; MULTIFOCAL
CHOROIDITIS; REGRESSION-ANALYSIS; DISEASES; VEGF; COMPLICATIONS;
NOMENCLATURE; PANUVEITIS; SECONDARY
AB PURPOSE: To evaluate the risk, risk factors, and visual impact of choroidal neovascularization (CNV) in uveitis cases.
DESIGN: Retrospective cohort study.
METHODS: Standardized medical record review at 5 tertiary centers.
RESULTS: Among 15 137 uveitic eyes (8868 patients), CNV was rare in the cases of anterior or intermediate uveitis. Among the 4041 eyes (2307 patients) with posterior uveitis or panuveitis, 81(2.0%) had CNV at presentation. Risk factors included posterior uveitis in general and specific uveitis syndromes affecting the outer retina retinal pigment epithelium choroid interface. Among the 2364 eyes (1357 patients) with posterior uveitis or panuveitis and free of CNV at the time of cohort entry, the cumulative 2-year incidence of CNV was 2.7% (95% confidence interval [CI], 1.8% to 3.5%). Risk factors for incident CNV included currently active inflammation (adjusted hazard ratio [aHR], 2.13; 95% CI, 1.26 to 3.60), preretinal neovascularization (aHR, 3.19; 95% CI, 1.30 to 7.80), and prior diagnosis of CNV in the contralateral eye (aHR, 5.79; 95% CI, 2.77 to 12.09). Among specific syndromes, the incidence was greater in Vogt-Koyanagi-Harada syndrome (aHR, 3.37; 95% CI, 1.52 to 7.46) and punctate inner choroiditis (aHR, 8.67; 95% CI, 2.83 to 26.54). Incident CNV was associated with a 2-line loss of visual acuity (+0.19 logarithm of the minimal angle of resolution units; 95% CI, 0.079 to 0.29) from the preceding visit.
CONCLUSIONS: CNV is an uncommon complication Of uveitis associated with visual impairment that occurs more commonly in forms affecting the outer retina retinal pigment epithelium choroid interface, during periods of inflammatory activity, in association with preretinal neovascularization, and in second eyes of patients with unilateral CNV. Because CNV is treatable, a systematic approach to early detection in high-risk patients may be appropriate. ((C) 2013 by Elsevier Inc. All rights reserved.)
C1 [Baxter, Sally L.; Kempen, John H.] Univ Penn, Perelman Sch Med, Scheie Eye Inst, Philadelphia, PA 19104 USA.
[Pistilli, Maxwell; Kempen, John H.] Univ Penn, Perelman Sch Med, Ctr Prevent Ophthalmol & Biostat, Dept Ophthalmol, Philadelphia, PA 19104 USA.
[Pujari, Siddharth S.; Foster, C. Stephen] Massachusetts Eye Res & Surg Inst, Cambridge, MA USA.
[Pujari, Siddharth S.] Vasan Eye Care Hosp, Belgaum, Karnataka, India.
[Liesegang, Teresa L.; Suhler, Eric B.; Rosenbaum, James T.] Oregon Hlth & Sci Univ, Dept Ophthalmol, Portland, OR 97201 USA.
[Suhler, Eric B.; Rosenbaum, James T.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA.
[Suhler, Eric B.] Portland VA Med Ctr, Portland, OR USA.
[Thorne, Jennifer E.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA.
[Thorne, Jennifer E.; Jabs, Douglas A.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Foster, C. Stephen] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA.
[Jabs, Douglas A.] Icahn Sch Med Mt Sinai, Dept Ophthalmol, New York, NY USA.
[Jabs, Douglas A.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY USA.
[Levy-Clarke, Grace A.; Nussenblatt, Robert B.] NEI, Immunol Lab, Bethesda, MD 20892 USA.
[Levy-Clarke, Grace A.] Johnson & Johnson, New Brunswick, NJ USA.
[Rosenbaum, James T.] Legacy Hlth Syst, Devers Eye Inst, Portland, OR USA.
[Kempen, John H.] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
RP Kempen, JH (reprint author), Univ Penn, Dept Ophthalmol, Ctr Prevent Ophthalmol & Biostat, 3535 Market St,Suite 700, Philadelphia, PA 19104 USA.
EM john.kempen@uphs.upenn.edu
OI Pistilli, Maxwell/0000-0002-4266-4150
FU Research to Prevent Blindness, Inc, New York, New York; Paul and Evanina
Mackall Foundation; National Eye Institute; Department of Veterans'
Affairs
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
OF POTENTIAL CONFLICTS OF INTEREST and the following were reported.
Jennifer E. Thome serves a consultant for Allergan and XOMA. C. Stephen
Foster serves as a lecturer for Alcon, Inspire, Ista, and Centocor; as a
Consultant for Sirion; as a consultant and lecturer for Allergan and
Bausch & Lomb; and as an equity owner for EyeGate. Douglas A. Jabs
serves a consultant for Abbott Laboratories, Alcon Laboratories,
Allergan Pharmaceutical Corporation, Corcept Therapeutics, Genentech,
Genzyme Corporation, GlaxoSmith Kline, and Roche Pharmaceuticals and is
a member of the Data and Safety Monitoring Board for Applied Genetic
Technologies Corporation and Novartis Pharmaceutical Corporation. Grace
A. Levy-Clarke is employed by Johnson & Johnson Vision Care. James T.
Rosenbaum serves or has served as a consultant for Abbott Laboratories,
Amgen, Allergan, Genentech, Novartis, and UCB and has been involved in
clinical trials for Abbott Laboratories, Genentech, Lux Biosciences, and
Eyegate Pharma. John H. Kempen serves or has served as a consultant for
Alcon, Allergan, Can-Fite, Clearside, Lux Biosciences, Sanofi-Pasteur,
and Xoma. Supported primarily by Grant EY014943 from the National Eye
Institute, National Institutes of Health, Bethesda, Maryland (J.H.K.).
Additional support was provided by Research to Prevent Blindness, Inc,
New York, New York, and the Paul and Evanina Mackall Foundation. Dr
Kempen was a Research to Prevent Blindness James S Adams Special Scholar
Award recipient, Dr Thome was a Research to Prevent Blindness Harrington
Special Scholar Award recipient, and Drs Jabs and Rosenbaum were
Research to Prevent Blindness Senior Scientific Investigator Award
recipients during the course of the study. Dr Levy-Clarke was previously
supported by and Dr Nussenblatt continues to be supported by intramural
funds from the National Eye Institute. Dr Suhler receives support from
the Department of Veterans' Affairs. None of the sponsors had any role
in the design and conduct of the report; collection, management,
analysis, and interpretation of the data; or in the preparation, review,
and approval of this manuscript. Involved in Design and conduct of study
(S.L.B., M.P., J.H.K.); Collection, management, analysis, and
interpretation of data (all authors); Preparation of manuscript (S.L.B.,
M.P., J.H.K.); and review and approval of manuscript (all authors).
NR 28
TC 16
Z9 16
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD SEP
PY 2013
VL 156
IS 3
BP 468
EP 477
DI 10.1016/j.ajo.2013.04.040
PG 10
WC Ophthalmology
SC Ophthalmology
GA 214RM
UT WOS:000324153500009
PM 23795984
ER
PT J
AU Khazim, K
Gorin, Y
Cavaglieri, RC
Abboud, HE
Fanti, P
AF Khazim, Khaled
Gorin, Yves
Cavaglieri, Rita Cassia
Abboud, Hanna E.
Fanti, Paolo
TI The antioxidant silybin prevents high glucose-induced oxidative stress
and podocyte injury in vitro and in vivo
SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY
LA English
DT Article
DE albuminuria; apoptosis; diabetic nephropathy; NADPH oxidase;
phytochemicals
ID TYPE-2 DIABETIC-NEPHROPATHY; NADPH OXIDASE ACTIVITY; STAGE
RENAL-DISEASE; INDUCED NEPHROTOXICITY; SUPEROXIDE-PRODUCTION; SIGNALING
PATHWAYS; OVERT NEPHROPATHY; KIDNEY-DISEASE; SILIBININ; SILYMARIN
AB Podocyte injury, a major contributor to the pathogenesis of diabetic nephropathy, is caused at least in part by the excessive generation of reactive oxygen species (ROS). Overproduction of superoxide by the NADPH oxidase isoform Nox4 plays an important role in podocyte injury. The plant extract silymarin is attributed antioxidant and antiproteinuric effects in humans and in animal models of diabetic nephropathy. We investigated the effect of silybin, the active constituent of silymarin, in cultures of mouse podocytes and in the OVE26 mouse, a model of type 1 diabetes mellitus and diabetic nephropathy. Exposure of podocytes to high glucose (HG) increased 60% the intracellular superoxide production, 90% the NADPH oxidase activity, 100% the Nox4 expression, and 150% the number of apoptotic cells, effects that were completely blocked by 10 mu M silybin. These in vitro observations were confirmed by similar in vivo findings. The kidney cortex of vehicle-treated control OVE26 mice displayed greater Nox4 expression and twice as much superoxide production than cortex of silybin-treated mice. The glomeruli of control OVE26 mice displayed 35% podocyte drop out that was not present in the silybin-treated mice. Finally, the OVE26 mice experienced 54% more pronounced albuminuria than the silybin-treated animals. In conclusion, this study demonstrates a protective effect of silybin against HG-induced podocyte injury and extends this finding to an animal model of diabetic nephropathy.
C1 [Abboud, Hanna E.; Fanti, Paolo] Audie L Murphy Mem Hosp Div, South Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Khazim, Khaled; Gorin, Yves; Cavaglieri, Rita Cassia; Abboud, Hanna E.; Fanti, Paolo] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Khazim, Khaled] Western Galilee Hosp, Nephrol & Hypertens Unit, Nahariyya, Israel.
RP Fanti, P (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Nephrol, Dept Med, MC 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM fanti@uthscsa.edu
FU National Center for Complementary and Alternative Medicine [AT-004490];
Merit Review Grant [1I01CX000264]; Juvenile Diabetes Research Foundation
Multiproject Grants; National Institute of Diabetes and Digestive and
Kidney Diseases [RO1 DK 079996]; American Physicians Fellowship for
Medicine in Israel
FX This work was supported in part through National Center for
Complementary and Alternative Medicine Grant AT-004490 (P. Fanti), Merit
Review Grant 1I01CX000264 (P. Fanti), Juvenile Diabetes Research
Foundation Multiproject Grants (Y. Gorin and H. E. Abboud), National
Institute of Diabetes and Digestive and Kidney Diseases Grant RO1 DK
079996 (Y. Gorin), and American Physicians Fellowship for Medicine in
Israel (K. Khazim).
NR 63
TC 28
Z9 30
U1 1
U2 13
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1931-857X
J9 AM J PHYSIOL-RENAL
JI Am. J. Physiol.-Renal Physiol.
PD SEP
PY 2013
VL 305
IS 5
BP F691
EP F700
DI 10.1152/ajprenal.00028.2013
PG 10
WC Physiology; Urology & Nephrology
SC Physiology; Urology & Nephrology
GA 214AA
UT WOS:000324101000011
PM 23804455
ER
PT J
AU Friedman, MJ
AF Friedman, Matthew J.
TI Toward Rational Pharmacotherapy for Posttraumatic Stress Disorder:
Reprise
SO AMERICAN JOURNAL OF PSYCHIATRY
LA English
DT Editorial Material
C1 [Friedman, Matthew J.] Geisel Sch Med Dartmouth, US Dept Vet Affairs, Natl Ctr PTSD, Hanover, NH 03755 USA.
[Friedman, Matthew J.] Geisel Sch Med Dartmouth, Dept Psychiat, Hanover, NH USA.
[Friedman, Matthew J.] Geisel Sch Med Dartmouth, Dept Pharmacol, Hanover, NH USA.
[Friedman, Matthew J.] Geisel Sch Med Dartmouth, Dept Toxicol, Hanover, NH USA.
RP Friedman, MJ (reprint author), Geisel Sch Med Dartmouth, US Dept Vet Affairs, Natl Ctr PTSD, Hanover, NH 03755 USA.
EM matthew.j.friedman@dartmouth.edu
NR 10
TC 4
Z9 4
U1 0
U2 4
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0002-953X
J9 AM J PSYCHIAT
JI Am. J. Psychiat.
PD SEP
PY 2013
VL 170
IS 9
BP 944
EP 946
DI 10.1176/appi.ajp.2013.13060768
PG 3
WC Psychiatry
SC Psychiatry
GA 212VK
UT WOS:000324010700003
PM 24030605
ER
PT J
AU Wortzel, HS
AF Wortzel, Hal S.
TI Clinical Manual of Neuropsychiatry
SO AMERICAN JOURNAL OF PSYCHIATRY
LA English
DT Book Review
C1 [Wortzel, Hal S.] Denver VA Med Ctr, Educ & Clin Ctr, VISN Mental Illness Res 19, Denver, CO USA.
[Wortzel, Hal S.] Univ Colorado, Sch Med, Denver, CO USA.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0002-953X
J9 AM J PSYCHIAT
JI Am. J. Psychiat.
PD SEP
PY 2013
VL 170
IS 9
BP 1063
EP 1064
DI 10.1176/appi.ajp.2013.13020193
PG 2
WC Psychiatry
SC Psychiatry
GA 212VK
UT WOS:000324010700023
ER
PT J
AU Weathington, NM
Sznajder, JI
Mallampalli, RK
AF Weathington, Nathaniel M.
Sznajder, Jacob I.
Mallampalli, Rama K.
TI The Emerging Role of the Ubiquitin Proteasome in Pulmonary Biology and
Disease
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article
DE ubiquitin; proteasome; pulmonary disease; drug development; E3 ligase
ID SURFACTANT PROTEIN-C; TRANSMEMBRANE CONDUCTANCE REGULATOR; ACUTE LUNG
INJURY; NF-KAPPA-B; F-BOX PROTEINS; ALLOSTERIC INHIBITOR; MITOTIC
ARREST; BETA-TRCP; DEGRADATION; LIGASE
AB Derangements in normal cellular homeostasis at the protein level can cause or be the consequence of initiation and progression of pulmonary diseases related to genotype, infection, injury, smoking, toxin exposure, or neoplasm. We discuss one of the fundamental mechanisms of protein homeostasis, the ubiquitin proteasome system (UPS), as it relates to lung disease. The UPS effects selective degradation of ubiquitinated target proteins via ubiquitin ligase activity. Important pathobiological mechanisms relating to the UPS and lung disease have been the focus of research, with inappropriate cellular proteolysis now a validated therapeutic target. We review the contributions of this system in various lung diseases, and discuss the exciting area of UPS-targeting drug development for pulmonary disease.
C1 [Weathington, Nathaniel M.; Mallampalli, Rama K.] Univ Pittsburgh, Acute Lung Injury Ctr Excellence Pulm Allergy & C, Dept Med, Pittsburgh, PA 15213 USA.
[Sznajder, Jacob I.] Northwestern Univ, Chicago, IL 60611 USA.
[Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Dept Cell Biol & Physiol, Pittsburgh, PA USA.
RP Mallampalli, RK (reprint author), Univ Pittsburgh, UPMC Montefiore, Dept Med, NW 628, Pittsburgh, PA 15213 USA.
EM mallampallirk@upmc.edu
FU U.S. Department of Veterans Affairs, Veterans Health Administration,
Office of Research and Development, Biomedical Laboratory Research and
Development; U.S. Department of Veterans Affairs; National Institutes of
Health [HL096376, HL097376, HL098174, HL-R37-48129, HL-PO1-71643];
Department of Veterans Affairs, Veterans Health Administration, VA
Pittsburgh Healthcare System
FX The authors thank Bill Chen and Yutong Zhao for careful review of this
manuscript. This material is based on work supported, in part, by the
U.S. Department of Veterans Affairs, Veterans Health Administration,
Office of Research and Development, Biomedical Laboratory Research and
Development. This work was supported by a Merit Review Award from the
U.S. Department of Veterans Affairs and National Institutes of Health
R01 grants HL096376, HL097376, and HL098174 (to R. K. M.) and
HL-R37-48129 and HL-PO1-71643 (to J.I.S.). N.M.W. is supported by a
research fellowship through the U.S. Department of Veterans Affairs,
Veterans Health Administration, VA Pittsburgh Healthcare System.
NR 72
TC 13
Z9 14
U1 0
U2 8
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD SEP 1
PY 2013
VL 188
IS 5
BP 530
EP 537
DI 10.1164/rccm.201304-0754PP
PG 8
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 214BU
UT WOS:000324106200007
PM 23713962
ER
PT J
AU Shah, FA
Pike, F
Alvarez, K
Angus, D
Newman, AB
Lopez, O
Tate, J
Kapur, V
Wilsdon, A
Krishnan, JA
Hansel, N
Au, D
Avdalovic, M
Fan, VS
Barr, G
Yende, S
AF Shah, Faraaz Ali
Pike, Francis
Alvarez, Karina
Angus, Derek
Newman, Anne B.
Lopez, Oscar
Tate, Judith
Kapur, Vishesh
Wilsdon, Anthony
Krishnan, Jerry A.
Hansel, Nadia
Au, David
Avdalovic, Mark
Fan, Vincent S.
Barr, Graham
Yende, Sachin
TI Bidirectional Relationship between Cognitive Function and Pneumonia
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article
DE pneumonia; dementia; cognitive function
ID RESPIRATORY-DISTRESS-SYNDROME; COMMUNITY-ACQUIRED PNEUMONIA; LONG-TERM
MORTALITY; INFLAMMATORY MARKERS; CARDIOVASCULAR HEALTH; CRITICAL
ILLNESS; GLOBAL BURDEN; UNITED-STATES; SEVERE SEPSIS; OLDER-PEOPLE
AB Rationale: Relationships between chronic health conditions and acute infections remain poorly understood. Preclinical studies suggest crosstalk between nervous and immune systems.
Objectives: To determine bidirectional relationships between cognition and pneumonia.
Methods: We conducted longitudinal analyses of a population-based cohort over 10 years. We determined whether changes in cognition increase risk of pneumonia hospitalization by trajectory analyses and joint modeling. We then determined whether pneumonia hospitalization increased risk of subsequent dementia using a Cox model with pneumonia as a time-varying covariate.
Measurements and Main Results: Of the 5,888 participants, 639 (10.9%) were hospitalized with pneumonia at least once. Most participants had normal cognition before pneumonia. Three cognition trajectories were identified: no, minimal, and severe rapid decline. A greater proportion of participants hospitalized with pneumonia were on trajectories of minimal or severe decline before occurrence of pneumonia compared with those never hospitalized with pneumonia( proportion with no, minimal, and severe decline were 67.1%, 22.8%, and 10.0% vs. 76.0%, 19.3%, and 4.6% for participants with
[GRAPHICS]
and without pneumonia, respectively; P<0.001). Small subclinical changes in cognition increased risk of pneumonia, even in those with normal cognition and physical function before pneumonia (beta = -0.02; P < 0.001). Participants with pneumonia were subsequently at an increased risk of dementia (hazard ratio, 2.24 [95% confidence interval, 1.62-3.11]; P = 0.01). Associations were independent of demographics, health behaviors, other chronic conditions, and physical function. Bidirectional relationship did not vary based on severity of disease, and similar associations were noted for those with severe sepsis and other infections.
Conclusions: A bidirectional relationship exists between pneumonia and cognition and may explain how a single episode of infection in well-appearing older individuals accelerates decline in chronic health conditions and loss of functional independence.
C1 [Shah, Faraaz Ali] Univ Pittsburgh, Med Ctr, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15261 USA.
[Pike, Francis; Alvarez, Karina; Angus, Derek; Tate, Judith; Yende, Sachin] Univ Pittsburgh, Clin Res Invest & Syst Modeling Acute Illness Ctr, Pittsburgh, PA 15261 USA.
[Angus, Derek; Yende, Sachin] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15261 USA.
[Newman, Anne B.] Univ Pittsburgh, Div Geriatr, Dept Epidemiol, Pittsburgh, PA 15261 USA.
[Lopez, Oscar] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15261 USA.
[Kapur, Vishesh; Wilsdon, Anthony; Au, David; Fan, Vincent S.] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA.
[Krishnan, Jerry A.] Univ Illinois, Sect Pulm Crit Care Sleep & Allergy, Chicago, IL USA.
[Krishnan, Jerry A.] Univ Illinois Hosp & Hlth Sci Syst, Chicago, IL USA.
[Hansel, Nadia] Johns Hopkins Univ, Div Pulm & Crit Care Med, Baltimore, MD USA.
[Au, David; Fan, Vincent S.] VA Puget Sound, HSR&D, Seattle, WA USA.
[Avdalovic, Mark] Univ Calif Davis, Div Pulm & Crit Care Med, Davis, CA USA.
[Barr, Graham] Columbia Univ, Dept Med, Med Ctr, New York, NY USA.
[Barr, Graham] Columbia Univ, Dept Epidemiol, Med Ctr, New York, NY USA.
RP Yende, S (reprint author), Univ Pittsburgh, 606D Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.
EM yendes@upmc.edu
RI Kapur, Vishesh/K-1054-2014; Tate, Judith/C-7447-2015; Newman,
Anne/C-6408-2013; Angus, Derek/E-9671-2012
OI Kapur, Vishesh/0000-0002-5417-1097; Newman, Anne/0000-0002-0106-1150;
FU NHLBI [HL080295]; National Institute on Aging [AG-023629, AG-15928,
AG-20098, AG-027058]; Department of Veterans Affairs;
[HHSN268201200036C]; [HHSN268200800007C]; [N01-HC-85079];
[N01-HC-85080]; [N01-HC-85081]; [N01-HC-85082]; [N01-HC-85083];
[N01-HC-85084]; [N01-HC-85085]; [N01-HC-85086]; [N01-HC-35129];
[N01-HC-15103]; [N01-HC-55222]; [N01-HC-75150]; [N01-HC-45133]; [K23
GM083215]; [R01GM097471]
FX Supported by contracts HHSN268201200036C, HHSN268200800007C,
N01-HC-85079 through N01-HC-85086, N01-HC-35129, N01-HC-15103,
N01-HC-55222, N01-HC-75150, N01-HC-45133, and grant HL080295 from the
NHLBI, with additional contribution from the National Institute of
Neurological Disorders and Stroke. Additional support was provided
through AG-023629, AG-15928, AG-20098, and AG-027058 from the National
Institute on Aging. Dr. Au is funded through the Department of Veterans
Affairs. A full list of principal CHS investigators and institutions can
be found at http://www.chs-nhlbi.org/pi.htm. Dr. Yende is supported by
K23 GM083215 and R01GM097471.
NR 43
TC 39
Z9 39
U1 1
U2 5
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD SEP 1
PY 2013
VL 188
IS 5
BP 586
EP 592
DI 10.1164/rccm.201212-2154OC
PG 7
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 214BU
UT WOS:000324106200014
PM 23848267
ER
PT J
AU Johannesmeyer, D
Smith, V
Cole, DJ
Esnaola, NF
Camp, ER
AF Johannesmeyer, David
Smith, Valerie
Cole, David J.
Esnaola, Nestor F.
Camp, E. Ramsay
TI The impact of lymph node disease in extremity soft-tissue sarcomas: a
population-based analysis
SO AMERICAN JOURNAL OF SURGERY
LA English
DT Article
DE Lymph node; Sarcoma; Extremity; Prognosis
ID METASTASIS; EPIDEMIOLOGY; SURVEILLANCE; SURVIVAL; DATABASE; REGISTRY;
BIOPSY
AB BACKGROUND: Because of the low incidence of regional lymph node metastasis, node-positive soft-tissue sarcoma patients remain poorly characterized. Our objective was to assess regional lymph node metastasis in extremity sarcoma patients using a large population database.
METHODS: The Surveillance, Epidemiology, and End Results database was queried for extremity sarcoma patients. Clinicopathologic data and outcomes were examined to evaluate the significance of regional lymph node metastasis.
RESULTS: Of 7,159 patients without distant metastasis, 64 patients had identified regional lymph node metastasis (.9%). Regional lymph node metastasis was associated with younger age, tumor grade, size, invasion, and tumor subtype. Excluding distant metastasis, lymph node status was the strongest prognostic factor (hazards ratio = 5.1, P < .001).
CONCLUSIONS: Isolated regional lymph node metastasis is rare in extremity sarcoma patients. However, in the absence of distant metastasis, lymph node status is the most important prognostic factor. The management of positive lymph nodes remains uncertain although diagnosing lymph node metastasis may identify early biologically aggressive disease. Published by Elsevier Inc.
C1 [Camp, E. Ramsay] Med Univ S Carolina, Dept Surg, Div Surg Oncol, Charleston, SC 29425 USA.
Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA.
RP Camp, ER (reprint author), Med Univ S Carolina, Dept Surg, Div Surg Oncol, 25 Courtenay Dr, Charleston, SC 29425 USA.
EM campe@musc.edu
NR 19
TC 2
Z9 2
U1 0
U2 0
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9610
J9 AM J SURG
JI Am. J. Surg.
PD SEP
PY 2013
VL 206
IS 3
BP 289
EP 295
DI 10.1016/j.amjsurg.2012.10.043
PG 7
WC Surgery
SC Surgery
GA 213YK
UT WOS:000324096400001
PM 23806824
ER
PT J
AU Baker, RR
AF Baker, Rodney R.
TI Robert Spurlin Waldrop (1912-2012) OBITUARY
SO AMERICAN PSYCHOLOGIST
LA English
DT Biographical-Item
C1 [Baker, Rodney R.] Dept Vet Affairs, San Antonio, TX USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0003-066X
J9 AM PSYCHOL
JI Am. Psychol.
PD SEP
PY 2013
VL 68
IS 6
BP 473
EP 473
DI 10.1037/a0033585
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 217FP
UT WOS:000324342800010
PM 24016122
ER
PT J
AU Carlozzi, NE
Fyffe, D
Morin, KG
Byrne, R
Tulsky, DS
Victorson, D
Lai, JS
Wecht, JM
AF Carlozzi, Noelle E.
Fyffe, Denise
Morin, Kel G.
Byrne, Rachel
Tulsky, David S.
Victorson, David
Lai, Jin-Shei
Wecht, Jill M.
TI Impact of Blood Pressure Dysregulation on Health-Related Quality of Life
in Persons With Spinal Cord Injury: Development of a Conceptual Model
SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION
LA English
DT Article; Proceedings Paper
CT Meeting of the Academy-of-Spinal-Cord-Injury-Professionals
CY SEP 03-05, 2012
CL Las Vegas, NV
SP Acad Spinal Cord Injury Profess
DE Blood pressure; Outcome assessment (health care); Quality of life;
Rehabilitation; Spinal cord injuries
ID PATIENT-REPORTED OUTCOMES; CARDIOVASCULAR-DISEASE RISK; ORTHOSTATIC
HYPOTENSION; AUTONOMIC DYSREFLEXIA; COGNITIVE PERFORMANCE; NEUROLOGICAL
LEVEL; FUNCTIONAL INDEX; TETRAPLEGIA; PARAPLEGIA; ASSOCIATION
AB Objectives: To identify medically relevant aspects of blood pressure dysregulation (BPD) related to quality of life in individuals with spinal cord injury (SCI), and to propose an integrated conceptual framework based on input from both individuals with SCI and their clinical providers. This framework will serve as a guide for the development of a patient-reported outcome (PRO) measure specifically related to BPD.
Design: Three focus groups with individuals with SCI and 3 groups with SCI providers were analyzed using grounded-theory based qualitative analysis to ascertain how blood pressure impacts health-related quality of life (HRQOL) in individuals with SCI.
Setting: Focus groups were conducted at 2 Veterans Affairs medical centers and a research center.
Participants: Individuals with SCI (n=27) in 3 focus groups and clinical providers (n=25) in 3 focus groups.
Interventions: Not applicable.
Main Outcome Measures: Not applicable.
Results: Qualitative analysis indicated that all focus groups spent the highest percentage of time discussing symptoms of BPD (39%), followed by precipitators/causes of BPD (16%), preventative actions (15%), corrective actions (12%), and the impact that BPD has on social or emotional functioning (8%). While patient/consumer focus groups and provider focus groups raised similar issues, providers spent more time discussing precipitators/causes of BPD and preventative actions (38%) than patient/consumer groups (24%).
Conclusions: These results suggest that BPD uniquely and adversely impacts HRQOL in persons with SCI. While both individuals with SCI and their providers highlighted the relevant symptoms of BPD, the SCI providers offered additional detailed information regarding the precipitators/causes and what can be done to prevent/treat BPD. Further, the results suggest that persons with SCI are aware of how BPD impacts their HRQOL and are able to distinguish between subtle signs and symptoms. These findings exemplify the need for a validated and sensitive clinical measurement tool that can assess the extent to which BPD impacts HRQOL in patients with SCI. (C) 2013 by the American Congress of Rehabilitation Medicine
C1 [Carlozzi, Noelle E.; Tulsky, David S.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA.
[Fyffe, Denise; Byrne, Rachel] Kessler Fdn Res Ctr, Spinal Cord Injury Outcomes & Assessment Lab, W Orange, NJ USA.
[Fyffe, Denise] Univ Med & Dent New Jersey, Dept Phys Med & Rehabil, Newark, NJ 07103 USA.
[Morin, Kel G.; Wecht, Jill M.] James J Peters Vet Affairs Med Ctr, Rehabil Res & Dev Serv, Bronx, NY USA.
[Victorson, David; Lai, Jin-Shei] Northwestern Univ, Dept Med & Social Sci, Chicago, IL 60611 USA.
[Wecht, Jill M.] Mt Sinai Sch Med, Dept Med, New York, NY USA.
[Wecht, Jill M.] Mt Sinai Sch Med, New York, NY USA.
RP Carlozzi, NE (reprint author), Univ Michigan, Ctr Rehabil Outcomes & Assessment Res, Dept Phys Med & Rehabil, North Campus Res Complex,2800 Plymouth Rd,Bldg NC, Ann Arbor, MI 48109 USA.
EM carlozzi@med.umich.edu
FU RRD VA [I01 RX000405]
NR 58
TC 7
Z9 7
U1 1
U2 8
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0003-9993
J9 ARCH PHYS MED REHAB
JI Arch. Phys. Med. Rehabil.
PD SEP
PY 2013
VL 94
IS 9
BP 1721
EP 1730
DI 10.1016/j.apmr.2013.02.024
PG 10
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 214QZ
UT WOS:000324151900011
PM 23499779
ER
PT J
AU Yuan, KY
Sun, Y
Zhou, T
McDonald, J
Chen, YB
AF Yuan, Kaiyu
Sun, Yong
Zhou, Tong
McDonald, Jay
Chen, Yabing
TI PARP-1 Regulates Resistance of Pancreatic Cancer to TRAIL Therapy
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID LIGAND-INDUCED APOPTOSIS; FAS-MEDIATED APOPTOSIS; NF-KAPPA-B;
POLY(ADP-RIBOSE) POLYMERASE; IN-VITRO; MONOCLONAL-ANTIBODY; INHIBITORY
PROTEIN; DNA-DAMAGE; CELL-LINES; MECHANISMS
AB Purpose: Activating extrinsic apoptotic pathways targeting death receptors (DR) using agonistic antibodies or TNF-related apoptosis-inducing ligand (TRAIL) is promising for cancer therapy. However, most pancreatic cancers are resistant to TRAIL therapy. The present studies aimed to identify combination therapies that enhance the efficacy of TRAIL therapy and to investigate the underlying mechanisms.
Experimental Design: A xenograft model in nude mice was used to determine pancreatic cancer tumorigenesis and therapeutic efficacy of TRA-8, a monoclonal agonistic antibody for DR5. Pancreatic cancer cells were used to characterize mechanisms underlying PARP-1 regulation of TRA-8-induced apoptosis in vitro.
Results: PARP-1 was found highly expressed in the TRA-8-resistant PANC-1 and Suit-2 cells, compared with TRA-8-sensitive BxPc-3 and MiaPaca-2. Inhibition of PARP-1 with a pharmacologic inhibitor sensitized PANC-1 and Suit2 cells to TRA-8-induced apoptosis in a dose-dependent manner. Furthermore, siRNAs specifically knocking down PARP-1 markedly enhanced TRA-8-induced apoptosis in vitro and augmented the efficacy of TRA-8 therapy on tumorigenesis in vivo. PARP-1 knockdown increased TRA-8-induced activation of caspase-8 in the death-induced signaling complex (DISC). Immunoprecipitation with DR5 antibody identified the recruitment of PARP-1 and PARP-1-mediated protein poly-ADP-ribosylation (pADPr) modification in the DR5-associated DISC. Further characterization revealed that PARP-1-mediated pADPr modification of caspase-8 inhibited caspase-8 activation, which may contribute to its function in regulating TRA-8 resistance.
Conclusions: Our studies provide molecular insights into a novel function of PARP-1 in regulating the extrinsic apoptosis machinery and also support interventions combining PARP-1 inhibitors with DR agonists for pancreatic cancer therapy. (C)2013 AACR.
C1 [Yuan, Kaiyu; Sun, Yong; McDonald, Jay; Chen, Yabing] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
[Zhou, Tong] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
[McDonald, Jay; Chen, Yabing] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
RP Chen, YB (reprint author), Univ Alabama Birmingham, Dept Pathol, 614 Shelby Res Bldg,1825 Univ Blvd, Birmingham, AL 35294 USA.
EM ybchen@uab.edu
FU UAB Department of Pathology; VA Merit Review Award; NIH [P50CA101955]
FX This work was supported in part by UAB Department of Pathology start-up
funds (to Y. Chen) and a VA Merit Review Award (to J.M. McDonald). T.
Zhou was support by a NIH grant P50CA101955.
NR 49
TC 22
Z9 22
U1 2
U2 11
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD SEP 1
PY 2013
VL 19
IS 17
BP 4750
EP 4759
DI 10.1158/1078-0432.CCR-13-0516
PG 10
WC Oncology
SC Oncology
GA 213ZE
UT WOS:000324098400023
PM 23833311
ER
PT J
AU Brooks-Worrell, B
Narla, R
Palmer, JP
AF Brooks-Worrell, B.
Narla, R.
Palmer, J. P.
TI Islet autoimmunity in phenotypic type 2 diabetes patients
SO DIABETES OBESITY & METABOLISM
LA English
DT Review
DE autoimmune disease; autoimmunity; inflammation; islet-reactive T cells;
T cells; type 1 diabetes; type 2 diabetes
ID GLUTAMIC-ACID DECARBOXYLASE; T-CELL RESPONSES; INSULIN-RESISTANCE;
CHRONIC INFLAMMATION; CLINICAL PHENOTYPE; ADULTS LADA; OLDER AGE;
LATENT; ANTIBODIES; PROTEINS
AB Historically, type 2 diabetes (T2D) was considered a metabolic disease of ageing. However, recent discoveries have demonstrated the role of chronic systemic inflammation in the development of insulin resistance and subsequent progression to T2D. Over the years, investigations into the pathophysiology of T2D have identified the presence of islet-specific T cells and islet autoimmune disease in T2D patients. Moreover, the cell-mediated islet autoimmunity has also been correlated with the progressive loss of beta-cell function associated with T2D disease pathogenesis. In this manuscript, the involvement of cell-mediated islet autoimmune disease in the progression of T2D disease and the similarities in islet-specific T-cell reactivity between type 1 diabetes (T1D) and T2D are discussed.
C1 [Brooks-Worrell, B.; Palmer, J. P.] Univ Washington, Dept Med, Seattle, WA USA.
[Narla, R.; Palmer, J. P.] VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA 98108 USA.
RP Brooks-Worrell, B (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM bbrooks@u.washington.edu
FU NIDDK NIH HHS [R01 DK083471, P30 DK017047]
NR 34
TC 14
Z9 15
U1 1
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1462-8902
J9 DIABETES OBES METAB
JI Diabetes Obes. Metab.
PD SEP
PY 2013
VL 15
SU 3
SI SI
BP 137
EP 140
DI 10.1111/dom.12167
PG 4
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 211DV
UT WOS:000323885900016
PM 24003930
ER
PT J
AU McMillan, GP
Reavis, KM
Konrad-Martin, D
Dille, MF
AF McMillan, Garnett P.
Reavis, Kelly M.
Konrad-Martin, Dawn
Dille, Marilyn F.
TI The Statistical Basis for Serial Monitoring in Audiology
SO EAR AND HEARING
LA English
DT Article
ID PRODUCT OTOACOUSTIC EMISSIONS; TEST-RETEST RELIABILITY; SAMPLE-SIZE;
SOUND-LEVEL; CALIBRATION
AB Objectives: Audiologists regularly use serial monitoring to evaluate changes in a patient's auditory function over time. Observed changes are compared with reference standards to determine whether further clinical action is necessary. Reference standards are established in a control sample of otherwise healthy subjects to identify the range of auditory shifts that one might reasonably expect to occur in the absence of any pathological insult. Statistical approaches to this seemingly mundane problem typically invoke 1 of 3 approaches: percentiles of the cumulative distribution, the variance of observed shifts, and the standard error of measurement. In this article, the authors describe the statistical foundation for these approaches, along with a mixed model-based alternative, and identify several necessary, although typically unacknowledged assumptions. Regression to the mean, the phenomenon of an unusual measurement typically followed by a more common one, can seriously bias observed changes in auditory function and clinical expectations. An approach that adjusts for this important effect is also described.
Design: Distortion product otoacoustic emissions (DPOAEs) elicited at a single primary frequency, f(2) of 3175 Hz, were collected from 32 healthy subjects at baseline and 19 to 29 days later. Ninety percent test-retest reference limits were computed from these data using each statistical approach. DPOAE shifts were also collected from a sample of 18 cisplatin patients tested after 120 to 200mg of cisplatin. Reference limits established according to each of the statistical approaches in the healthy sample were used to identify clinically alarming DPOAE shifts in the cisplatin patient sample.
Results: Reference limits established with any of the parametric methods were similar. The percentile-based approach gave the widest and least precisely estimated intervals. The highest sensitivity for detecting clinically alarming DPOAE shifts was based on a mixed model approach that adjusts for regression to the mean.
Conclusions: Parametric methods give similar serial monitoring criteria as long as certain critical assumptions are met by the data. The most flexible method for estimating test-retest limits is based on the linear mixed model. Clinical sensitivity may be further enhanced by adjusting for regression to the mean.
C1 [McMillan, Garnett P.; Reavis, Kelly M.; Konrad-Martin, Dawn; Dille, Marilyn F.] Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, Vet Affairs Rehabil Res & Dev Serv VA RR&D, Portland, OR USA.
[McMillan, Garnett P.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA.
[Konrad-Martin, Dawn; Dille, Marilyn F.] Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, Portland, OR 97201 USA.
RP McMillan, GP (reprint author), Portland VA Med Ctr, NCRAR, 3710 US Vet Hosp Rd P5, Portland, OR USA.
EM garnett.mcmillan@va.gov
OI Reavis, Kelly/0000-0002-4906-1010
FU Department of Veterans Affairs Rehabilitation Research and Development
Service [C4183R, C7113N]; VA RR&D National Center for Rehabilitative
Auditory Research, Portland, Oregon
FX This work was supported by the Department of Veterans Affairs
Rehabilitation Research and Development Service (grants C4183R and
C7113N) and the VA RR&D National Center for Rehabilitative Auditory
Research, Portland, Oregon.
NR 22
TC 7
Z9 7
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0196-0202
J9 EAR HEARING
JI Ear Hear.
PD SEP
PY 2013
VL 34
IS 5
BP 610
EP 618
DI 10.1097/AUD.0b013e31828a21b3
PG 9
WC Audiology & Speech-Language Pathology; Otorhinolaryngology
SC Audiology & Speech-Language Pathology; Otorhinolaryngology
GA 213JL
UT WOS:000324052800010
PM 23563060
ER
PT J
AU Wasterlain, CG
Naylor, DE
Liu, H
Niquet, J
Baldwin, R
AF Wasterlain, Claude G.
Naylor, David E.
Liu, Hantao
Niquet, Jerome
Baldwin, Roger
TI Trafficking of NMDA receptors during status epilepticus: Therapeutic
implications
SO EPILEPSIA
LA English
DT Article
DE NMDA receptor; Receptor trafficking; Status epilepticus; Acute seizures;
Cholinergic seizures; Epilepsy; Monotherapy; Hippocampus
ID SUSTAINING STATUS EPILEPTICUS; EPILEPTOGENESIS; ANTAGONISTS
AB We used two models of status epilepticus (SE) to study trafficking of N-methyl-d-aspartate (NMDA) receptors. SE is associated with increased surface expression of NR1 subunits of NMDA receptors, and with an increase of NMDA synaptic and extrasynaptic currents suggesting an increase in number of functional NMDA receptors on dentate granule cells. The therapeutic implications of these results are discussed.
C1 [Wasterlain, Claude G.; Naylor, David E.; Liu, Hantao; Niquet, Jerome; Baldwin, Roger] Vet Adm Greater Los Angeles Healthcare Syst, Dept Neurol, West Los Angeles, CA USA.
[Wasterlain, Claude G.; Naylor, David E.; Liu, Hantao; Niquet, Jerome] UCLA Brain Res Inst, West Los Angeles, CA USA.
[Wasterlain, Claude G.] Univ Calif Los Angeles, David Geffen Sch Med, West Los Angeles, CA USA.
[Naylor, David E.] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, West Los Angeles, CA USA.
RP Wasterlain, CG (reprint author), West LA VA Med Ctr, Dept Neurol 127, 11301 Wilshire Blvd, West Los Angeles, CA 90073 USA.
EM wasterla@ucla.edu
FU Research Service of the Veterans Health Administration; NINDS [NS13515,
NS074926]; James and Debbie Cho Foundation; VHA (Career Development
Award); Los Angeles Biomedical Research Institute
FX Supported by the Research Service of the Veterans Health Administration
(Merit Review C.W.), by NINDS (NS13515 and NS074926 to C.W.), by the
James and Debbie Cho Foundation and by the VHA (Career Development Award
to D.N.) and the Los Angeles Biomedical Research Institute (to D.N.).
NR 13
TC 18
Z9 18
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0013-9580
J9 EPILEPSIA
JI Epilepsia
PD SEP
PY 2013
VL 54
SU 6
SI SI
BP 78
EP 80
DI 10.1111/epi.12285
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA 210JA
UT WOS:000323826600023
PM 24001081
ER
PT J
AU Leung, FW
AF Leung, Felix W.
TI Water-aided Colonoscopy
SO GASTROENTEROLOGY CLINICS OF NORTH AMERICA
LA English
DT Article
DE Colonoscopy; Water-aided method; Discomfort; Pain; Adenoma detection
rate; Water immersion; Water exchange
ID UNSEDATED COLONOSCOPY; WARM WATER; SEDATED COLONOSCOPY; AIR
INSUFFLATION; PATIENT TOLERANCE; CECAL INTUBATION; MINIMAL SEDATION;
CONTROLLED-TRIAL; US VETERANS; INFUSION
AB Water-aided methods for colonoscopy include the established water immersion and the recent novel modification of water exchange. Water immersion entails the use of water as an adjunct to air insufflations to facilitate insertion. Water exchange evolved from water immersion to facilitate completion of colonoscopy without discomfort in unsedated patients. Infused water is removed predominantly during insertion rather than withdrawal. A higher adenoma detection rate has been reported with water exchange. Aggregate data of randomized controlled trials suggest that water exchange may be superior to water immersion in attenuating colonoscopy discomfort and optimizing adenoma detection, particularly in the proximal colon.
C1 [Leung, Felix W.] Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, Dept Med, Div Gastroenterol, North Hills, CA 91343 USA.
[Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Leung, FW (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, Dept Med, Div Gastroenterol, 111G,16111 Plummer St, North Hills, CA 91343 USA.
EM felix.leung@va.gov
FU Veterans Affairs Medical Research Funds at Veterans Affairs Greater Los
Angeles Healthcare System; American College of Gastroenterology Clinical
Research Award
FX The study is supported in part by Veterans Affairs Medical Research
Funds at Veterans Affairs Greater Los Angeles Healthcare System and an
American College of Gastroenterology Clinical Research Award (FWL).
NR 50
TC 5
Z9 5
U1 1
U2 4
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8553
J9 GASTROENTEROL CLIN N
JI Gastroenterol. Clin. North Am.
PD SEP
PY 2013
VL 42
IS 3
BP 507
EP +
DI 10.1016/j.gtc.2013.05.006
PG 14
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 215PA
UT WOS:000324221500007
PM 23931857
ER
PT J
AU Jayadev, S
Bird, TD
AF Jayadev, Suman
Bird, Thomas D.
TI Hereditary ataxias: overview
SO GENETICS IN MEDICINE
LA English
DT Review
DE ataxia; cerebellum; neurogenetics
ID ONSET SPINOCEREBELLAR ATAXIA; RECESSIVE CEREBELLAR-ATAXIA; GENETICALLY
DEFINED SUBTYPES; MARINESCO-SJOGREN-SYNDROME; OCULAR MOTOR APRAXIA;
ADULT-ONSET; COENZYME-Q10 DEFICIENCY; POLYGLUTAMINE EXPANSIONS;
TREMOR/ATAXIA SYNDROME; MOLECULAR DIAGNOSIS
AB The hereditary ataxias are a highly heterogeneous group of disorders phenotypically characterized by gait ataxia, incoordination of eye movements, speech, and hand movements, and usually associated with atrophy of the cerebellum. There are more than 35 autosomal dominant types frequently termed spinocerebellar ataxia and typically having adult onset. The most common subtypes are spinocerebellar ataxia 1, 2, 3, 6, and 7, all of which are nucleotide repeat expansion disorders. Autosomal recessive ataxias usually have onset in childhood; the most common subtypes are Friedreich, ataxia-telangiectasia, ataxia with oculomotor apraxia type 1, and ataxia with oculomotor apraxia type 2. Four autosomal recessive types have dietary or biochemical treatment modalities (ataxia with vitamin E deficiency, cerebrotendinous xanthomatosis, Refsum, and coenzyme Q10 deficiency), whereas there are no specific treatments for other ataxias. Diagnostic genetic testing is complicated because of the large number of relatively uncommon subtypes with extensive phenotypic overlap. However, the best testing strategy is based on assessing relative frequencies, ethnic predilections, and recognition of associated phenotypic features such as seizures, visual loss, or associated movement abnormalities.
C1 [Jayadev, Suman; Bird, Thomas D.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA.
[Bird, Thomas D.] Univ Washington, Dept Med Med Genet, Seattle, WA 98195 USA.
[Bird, Thomas D.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA.
RP Bird, TD (reprint author), Univ Washington, Dept Neurol, Seattle, WA 98195 USA.
EM tomnroz@uw.edu
FU Veterans Affairs Research; National Center for Biotechnology Information
FX This study was supported by funding from Veterans Affairs Research and
the National Center for Biotechnology Information. This overview
represents a revised and updated version of Thomas D. Bird's Hereditary
Ataxia in GeneReviews at GeneTests: Medical Genetics Information
Resource (online resource). Copyright University of Washington, Seattle,
Washington, 1998-2012. http://www.genetests.org.
NR 80
TC 25
Z9 26
U1 3
U2 22
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1098-3600
J9 GENET MED
JI Genet. Med.
PD SEP
PY 2013
VL 15
IS 9
BP 673
EP 683
DI 10.1038/gim.2013.28
PG 11
WC Genetics & Heredity
SC Genetics & Heredity
GA 214XN
UT WOS:000324172000002
PM 23538602
ER
PT J
AU Makarov, DV
Loeb, S
Ulmert, D
Drevin, L
Lambe, M
Stattin, P
AF Makarov, Danil V.
Loeb, Stacy
Ulmert, David
Drevin, Linda
Lambe, Mats
Stattin, Par
TI Prostate Cancer Imaging Trends After a Nationwide Effort to Discourage
Inappropriate Prostate Cancer Imaging
SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article
ID STAGING EVALUATION; BONE-SCAN; APPROPRIATE; ANTIGEN; RISK; PREVALENCE;
GUIDELINES; PARAMETERS; SURVIVAL; OVERUSE
AB Background Reducing inappropriate use of imaging to stage incident prostate cancer is a challenging problem highlighted recently as a Physician Quality Reporting System quality measure and by the American Society of Clinical Oncology and the American Urological Association in the Choosing Wisely campaign. Since 2000, the National Prostate Cancer Register (NPCR) of Sweden has led an effort to decrease national rates of inappropriate prostate cancer imaging by disseminating utilization data along with the latest imaging guidelines to urologists in Sweden. We sought to determine the temporal and regional effects of this effort on prostate cancer imaging rates.
Methods We performed a retrospective cohort study among men diagnosed with prostate cancer from the NPCR from 1998 to 2009 (n = 99 879). We analyzed imaging use over time stratified by clinical risk category (low, intermediate, high) and geographic region. Generalized linear models with a logit link were used to test for time trend.
Results Thirty-six percent of men underwent imaging within 6 months of prostate cancer diagnosis. Overall, imaging use decreased over time, particularly in the low-risk category, among whom the imaging rate decreased from 45% to 3% (P < .001), but also in the high-risk category, among whom the rate decreased from 63% to 47% (P < .001). Despite substantial regional variation, all regions experienced clinically and statistically (P < .001) significant decreases in prostate cancer imaging.
Conclusions A Swedish effort to provide data on prostate cancer imaging use and imaging guidelines to clinicians was associated with a reduction in inappropriate imaging over a 10-year period, as well as slightly decreased appropriate imaging in high-risk patients. These results may inform current efforts to promote guideline-concordant imaging in the United States and internationally.
C1 [Makarov, Danil V.; Loeb, Stacy] US Dept Vet Affairs, New York, NY USA.
[Makarov, Danil V.; Loeb, Stacy] NYU, Dept Urol, New York, NY USA.
[Makarov, Danil V.; Loeb, Stacy] NYU, Dept Populat Hlth, New York, NY USA.
[Makarov, Danil V.; Loeb, Stacy] NYU, Inst Canc, New York, NY USA.
[Drevin, Linda; Lambe, Mats] Univ Uppsala Hosp, Reg Canc Ctr, Uppsala, Sweden.
[Ulmert, David; Stattin, Par] Mem Sloan Kettering Canc Ctr, Dept Surg, Urol Serv, New York, NY 10021 USA.
[Stattin, Par] Umea Univ, Dept Surg & Perioperat Sci Urol & Androl, SE-90187 Umea, Sweden.
[Lambe, Mats] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.
RP Stattin, P (reprint author), Umea Univ, Dept Surg & Perioperat Sci Urol & Androl, SE-90187 Umea, Sweden.
EM par.stattin@urologi.umu.se
OI Lambe, Mats/0000-0002-4624-3767; Makarov, Danil/0000-0002-0565-9272;
Loeb, Stacy/0000-0003-3933-9207
FU Swedish Research Council [825-2012-5047]; Swedish Cancer Foundation [11
0471]; United States Department of Veterans Affairs, Health Services
Research and Development Service; Louis Feil Charitable Lead Trust
FX This work was supported by the Swedish Research Council (825-2012-5047)
and The Swedish Cancer Foundation (11 0471). SL and DVM (VA HSR&D CDA &
CDP 11-257) are supported by the United States Department of Veterans
Affairs, Health Services Research and Development Service and the Louis
Feil Charitable Lead Trust.
NR 32
TC 14
Z9 14
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
J9 JNCI-J NATL CANCER I
JI JNCI-. Natl. Cancer Inst.
PD SEP
PY 2013
VL 105
IS 17
BP 1306
EP 1313
DI 10.1093/jnci/djt175
PG 8
WC Oncology
SC Oncology
GA 213EW
UT WOS:000324038500011
PM 23853055
ER
PT J
AU Yarar-Fisher, C
Bickel, CS
Windham, ST
McLain, AB
Bamman, MM
AF Yarar-Fisher, Ceren
Bickel, C. Scott
Windham, Samuel T.
McLain, Amie B.
Bamman, Marcas M.
TI Skeletal muscle signaling associated with impaired glucose tolerance in
spinal cord-injured men and the effects of contractile activity
SO JOURNAL OF APPLIED PHYSIOLOGY
LA English
DT Article
DE spinal cord injury; skeletal muscle; glucose uptake signaling;
neuromuscular electrical stimulation; resistance exercise
ID ACTIVATED PROTEIN-KINASE; RESISTANCE EXERCISE; INSULIN SENSITIVITY;
LIPID-METABOLISM; OLDER-ADULTS; MOLECULAR RESPONSES; AKT SUBSTRATE;
TIME-COURSE; AMPK; PHOSPHORYLATION
AB The mechanisms underlying poor glucose tolerance in persons with spinal cord injury (SCI), along with its improvement after several weeks of neuromuscular electrical stimulation-induced resistance exercise (NMES-RE) training, remain unclear, but presumably involve the affected skeletal musculature. We, therefore, investigated skeletal muscle signaling pathways associated with glucose transporter 4 (GLUT-4) translocation at rest and shortly after a single bout of NMES-RE in SCI (n = 12) vs. able-bodied (AB, n = 12) men. Subjects completed an oral glucose tolerance test during visit 1 and approximate to 90 NMES-RE isometric contractions of the quadriceps during visit 2. Muscle biopsies were collected before, and 10 and 60 min after, NMES-RE. We assessed transcript levels of GLUT-4 by quantitative PCR and protein levels of GLUT-4 and phosphorylated-and total AMP-activated protein kinase (AMPK)-alpha, CaMKII, Akt, and AS160 by immunoblotting. Impaired glucose tolerance in SCI was confirmed by higher (P < 0.05) plasma glucose concentrations than AB at all time points after glucose ingestion, despite equivalent insulin responses to the glucose load. GLUT-4 protein content was lower (P < 0.05) in SCI vs. AB at baseline. Main group effects revealed higher phosphorylation in SCI of AMPK-alpha, CaMKII, and Akt (P < 0.05), and Akt phosphorylation increased robustly (P < 0.05) following NMES-RE in SCI only. In SCI, low skeletal muscle GLUT-4 protein concentration may, in part, explain poor glucose tolerance, whereas heightened phosphorylation of relevant signaling proteins (AMPK-alpha, CaMKII) suggests a compensatory effort. Finally, it is encouraging to find (based on Akt) that SCI muscle remains both sensitive and responsive to mechanical loading (NMES-RE) even approximate to 22 yr after injury.
C1 [Yarar-Fisher, Ceren; Bamman, Marcas M.] Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Birmingham, AL 35294 USA.
[Bickel, C. Scott] Univ Alabama Birmingham, Dept Phys Therapy, Birmingham, AL 35294 USA.
[Windham, Samuel T.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA.
[McLain, Amie B.] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL 35294 USA.
[Yarar-Fisher, Ceren; Bickel, C. Scott; Windham, Samuel T.; McLain, Amie B.; Bamman, Marcas M.] Univ Alabama Birmingham, UAB Ctr Exercise Med, Birmingham, AL 35294 USA.
[Bamman, Marcas M.] Birmingham VA Med Ctr, Birmingham, AL USA.
RP Bamman, MM (reprint author), Univ Alabama Birmingham, UAB Ctr Exercise Med, 966 McCallum Basic Hlth Sci Bldg,1720 2nd Ave Sou, Birmingham, AL 35294 USA.
EM mbamman@uab.edu
FU VA Merit Award; University of Alabama Birmingham (UAB) Center for
Exercise Medicine, Department of Physical Medicine and Rehabilitation
[5T32 DK-62710]; UAB Center for Clinical and Translational Science [UL1
TR000165]
FX This work was supported by VA Merit Award (M. M. Bamman), University of
Alabama Birmingham (UAB) Center for Exercise Medicine, Department of
Physical Medicine and Rehabilitation, 5T32 DK-62710, and the UAB Center
for Clinical and Translational Science (UL1 TR000165).
NR 52
TC 3
Z9 3
U1 0
U2 6
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 8750-7587
J9 J APPL PHYSIOL
JI J. Appl. Physiol.
PD SEP
PY 2013
VL 115
IS 5
BP 756
EP 764
DI 10.1152/japplphysiol.00122.2013
PG 9
WC Physiology; Sport Sciences
SC Physiology; Sport Sciences
GA 212YZ
UT WOS:000324020600023
PM 23766505
ER
PT J
AU Lin, AL
Zheng, W
Halloran, JJ
Burbank, RR
Hussong, SA
Hart, MJ
Javors, M
Shih, YYI
Muir, E
Fonseca, RS
Strong, R
Richardson, AG
Lechleiter, JD
Fox, PT
Galvan, V
AF Lin, Ai-Ling
Zheng, Wei
Halloran, Jonathan J.
Burbank, Raquel R.
Hussong, Stacy A.
Hart, Matthew J.
Javors, Martin
Shih, Yen-Yu Ian
Muir, Eric
Fonseca, Rene Solano
Strong, Randy
Richardson, Arlan G.
Lechleiter, James D.
Fox, Peter T.
Galvan, Veronica
TI Chronic rapamycin restores brain vascular integrity and function through
NO synthase activation and improves memory in symptomatic mice modeling
Alzheimer's disease
SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
LA English
DT Article
DE age-associated; Alzheimer's disease; cerebral amyloid angiopathy; nitric
oxide synthase; rapamycin; target-of-rapamycin (TOR); vascular
dysfunction
ID CEREBRAL AMYLOID ANGIOPATHY; GENETICALLY HETEROGENEOUS MICE;
SIROLIMUS-ELUTING STENTS; EXTENDS LIFE-SPAN; TRANSGENIC MICE; MAMMALIAN
TARGET; COGNITIVE DEFICITS; PLAQUE-FORMATION; BETA CLEARANCE; MOUSE
MODEL
AB Vascular pathology is a major feature of Alzheimer's disease (AD) and other dementias. We recently showed that chronic administration of the target-of-rapamycin (TOR) inhibitor rapamycin, which extends lifespan and delays aging, halts the progression of AD-like disease in transgenic human (h) APP mice modeling AD when administered before disease onset. Here we demonstrate that chronic reduction of TOR activity by rapamycin treatment started after disease onset restored cerebral blood flow (CBF) and brain vascular density, reduced cerebral amyloid angiopathy and microhemorrhages, decreased amyloid burden, and improved cognitive function in symptomatic hAPP (AD) mice. Like acetylcholine (ACh), a potent vasodilator, acute rapamycin treatment induced the phosphorylation of endothelial nitric oxide (NO) synthase (eNOS) and NO release in brain endothelium. Administration of the NOS inhibitor L-NG-Nitroarginine methyl ester reversed vasodilation as well as the protective effects of rapamycin on CBF and vasculature integrity, indicating that rapamycin preserves vascular density and CBF in AD mouse brains through NOS activation. Taken together, our data suggest that chronic reduction of TOR activity by rapamycin blocked the progression of AD-like cognitive and histopathological deficits by preserving brain vascular integrity and function. Drugs that inhibit the TOR pathway may have promise as a therapy for AD and possibly for vascular dementias.
C1 [Lin, Ai-Ling; Muir, Eric; Fox, Peter T.] Res Imaging Inst, San Antonio, TX USA.
[Zheng, Wei; Richardson, Arlan G.; Lechleiter, James D.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78245 USA.
[Halloran, Jonathan J.; Burbank, Raquel R.; Hussong, Stacy A.; Fonseca, Rene Solano; Galvan, Veronica] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78245 USA.
[Halloran, Jonathan J.; Burbank, Raquel R.; Hussong, Stacy A.; Hart, Matthew J.; Fonseca, Rene Solano; Strong, Randy; Richardson, Arlan G.; Galvan, Veronica] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA.
[Hart, Matthew J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78245 USA.
[Javors, Martin] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78245 USA.
[Shih, Yen-Yu Ian] Univ N Carolina, Dept Neurol, Chapel Hill, NC USA.
[Shih, Yen-Yu Ian] Univ N Carolina, Biomed Res Imaging Ctr, Chapel Hill, NC USA.
[Strong, Randy; Richardson, Arlan G.] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA.
[Strong, Randy; Richardson, Arlan G.] South Texas Vet Hlth Care Syst, Res Serv, San Antonio, TX USA.
[Strong, Randy] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78245 USA.
RP Galvan, V (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, 15355 Lambda Dr, San Antonio, TX 78245 USA.
EM galvanv@uthscsa.edu
RI Fox, Peter/B-4725-2010
OI Fox, Peter/0000-0002-0465-2028; Shih, Yen-Yu Ian/0000-0001-6529-911X
FU Ellison Medical Foundation; William & Ella Owens Medical Research
Foundation; UTHSCSA University Research Council; UTHSCSA Institute for
Integration of Medicine and Science; NIA Interventions Testing Center
[U01AG022307]; NIH [RC2AG036613]; NIA [5T32AG021890]; UTHSCSA; CTRC at
UTHSCSA [NIH-NCI P30 CA54174]; San Antonio Nathan Shock Aging Center
[P30AG-13319]; Neurodegeneration Research Center (REAP) from the
Research and Development Service of the Department of Veterans Affairs
FX This work was supported by an Ellison Medical Foundation New Scholar
Award in Aging, a William & Ella Owens Medical Research Foundation Grant
and a UTHSCSA University Research Council Award to VG, an UTHSCSA
Institute for Integration of Medicine and Science Award to ALL, the NIA
Interventions Testing Center (U01AG022307) to RS, RC2AG036613 NIH
Recovery Act Grand Opportunities "GO'' grant to AR, and by 5T32AG021890
NIA Biology of Aging Training Grant Fellowship to SH. Images were
generated in the Core Optical Imaging Facility, which is supported by
UTHSCSA and NIH-NCI P30 CA54174 (CTRC at UTHSCSA). We recognize the
support of the San Antonio Nathan Shock Aging Center (P30AG-13319, AR)
and the VA Neurodegeneration Research Center (REAP) from the Research
and Development Service of the Department of Veterans Affairs to AR and
RS.
NR 68
TC 42
Z9 43
U1 1
U2 12
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0271-678X
J9 J CEREBR BLOOD F MET
JI J. Cereb. Blood Flow Metab.
PD SEP
PY 2013
VL 33
IS 9
BP 1412
EP 1421
DI 10.1038/jcbfm.2013.82
PG 10
WC Endocrinology & Metabolism; Hematology; Neurosciences
SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology
GA 214IQ
UT WOS:000324126400013
PM 23801246
ER
PT J
AU Pu, HJ
Guo, YL
Zhang, WT
Huang, LT
Wang, GH
Liou, AK
Zhang, J
Zhang, PY
Leak, RK
Wang, Y
Chen, J
Gao, YQ
AF Pu, Hongjian
Guo, Yanling
Zhang, Wenting
Huang, Lanting
Wang, Guohua
Liou, Anthony K.
Zhang, Jia
Zhang, Pengyue
Leak, Rehana K.
Wang, Yun
Chen, Jun
Gao, Yanqin
TI Omega-3 polyunsaturated fatty acid supplementation improves neurologic
recovery and attenuates white matter injury after experimental traumatic
brain injury
SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
LA English
DT Article
DE behavior (rodent); brain trauma; inflammation; neurodegeneration; white
matter/oligodendrocytes
ID SPINAL-CORD-INJURY; DOCOSAHEXAENOIC ACID; PARKINSONS-DISEASE; MODEL;
RAT; OMEGA-3-FATTY-ACIDS; EXCITOTOXICITY; MECHANISMS; GLUTAMATE;
VULNERABILITY
AB Dietary supplementation with omega-3 (omega-3) fatty acids is a safe, economical mean of preventive medicine that has shown protection against several neurologic disorders. The present study tested the hypothesis that this method is protective against controlled cortical impact (CCI). Indeed, mice fed with omega-3 polyunsaturated fatty acid (PUFA)-enriched diet for 2 months exhibited attenuated short and long-term behavioral deficits due to CCI. Although omega-3 PUFAs did not decrease cortical lesion volume, these fatty acids did protect against hippocampal neuronal loss after CCI and reduced pro-inflammatory response. Interestingly, omega-3 PUFAs prevented the loss of myelin basic protein (MPB), preserved the integrity of the myelin sheath, and maintained the nerve fiber conductivity in the CCI model. omega-3 PUFAs also directly protected oligodendrocyte cultures from excitotoxicity and blunted the microglial activation-induced death of oligodendrocytes in microglia/oligodendrocyte cocultures. In sum, omega-3 PUFAs elicit multifaceted protection against behavioral dysfunction, hippocampal neuronal loss, inflammation, and loss of myelination and impulse conductivity. The present report is the first demonstration that omega-3 PUFAs protect against white matter injury in vivo and in vitro. The protective impact of omega-3 PUFAs supports the clinical use of this dietary supplement as a prophylaxis against traumatic brain injury and other nervous system disorders.
C1 [Pu, Hongjian; Guo, Yanling; Zhang, Wenting; Huang, Lanting; Wang, Guohua; Zhang, Jia; Zhang, Pengyue; Wang, Yun; Chen, Jun; Gao, Yanqin] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China.
[Pu, Hongjian; Guo, Yanling; Zhang, Wenting; Huang, Lanting; Wang, Guohua; Zhang, Jia; Zhang, Pengyue; Wang, Yun; Chen, Jun; Gao, Yanqin] Fudan Univ, Inst Brain Sci, Shanghai 200032, Peoples R China.
[Liou, Anthony K.; Chen, Jun; Gao, Yanqin] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA.
[Liou, Anthony K.; Chen, Jun; Gao, Yanqin] Univ Pittsburgh, Ctr Cerebrovasc Dis Res, Pittsburgh, PA USA.
[Liou, Anthony K.; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
[Leak, Rehana K.] Duquesne Univ, Mylan Sch Pharm, Div Pharmaceut Sci, Pittsburgh, PA 15219 USA.
RP Gao, YQ (reprint author), Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China.
EM chenj2@upmc.edu; yqgao@shmu.edu.cn
RI Gao, Yanqin/I-6790-2016
OI Gao, Yanqin/0000-0002-4915-9819; Leak, Rehana/0000-0003-2817-7417
FU Chinese Ministry of Science and Technology; National Institutes of
Health/NINDS [NS36736, NS43802, NS45048, NS056118]; Chinese Natural
Science Foundation [30870794, 81020108021, 81171149, 81150110494,
81000497]; VA Research Career Scientist Award; VA Merit Review grant;
UPMC
FX This research is supported in part by the Special Research Funds from
Chinese Ministry of Science and Technology to State Key laboratories (to
YG and JC), National Institutes of Health/NINDS grants NS36736, NS43802,
NS45048 and NS056118 (to JC), and Chinese Natural Science Foundation
grants No 30870794, No 81020108021, No 81171149, No 81150110494, and No
81000497 (to YG). JC is a recipient of the VA Research Career Scientist
Award, VA Merit Review grant, and the RK Mellon Endowed Chair from UPMC.
NR 40
TC 25
Z9 26
U1 2
U2 24
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0271-678X
J9 J CEREBR BLOOD F MET
JI J. Cereb. Blood Flow Metab.
PD SEP
PY 2013
VL 33
IS 9
BP 1474
EP 1484
DI 10.1038/jcbfm.2013.108
PG 11
WC Endocrinology & Metabolism; Hematology; Neurosciences
SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology
GA 214IQ
UT WOS:000324126400020
PM 23801244
ER
PT J
AU Sacks, HS
Fain, JN
Bahouth, SW
Ojha, S
Frontini, A
Budge, H
Cinti, S
Symonds, ME
AF Sacks, Harold S.
Fain, John N.
Bahouth, Suleiman W.
Ojha, Shalini
Frontini, Andrea
Budge, Helen
Cinti, Saverio
Symonds, Michael E.
TI Adult Epicardial Fat Exhibits Beige Features
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID BROWN ADIPOSE-TISSUE; WHITE ADIPOCYTES; COLD-EXPOSURE; PPAR-GAMMA;
OBESITY; EXPRESSION; DISTINCT; HUMANS; MOUSE; IDENTIFICATION
AB Context: Human epicardial fat has been designated previously as brown-like fat. The supraclavicular fat depot in man has been defined as beige coexistent with classical brown based on its gene expression profile.
Objective: The aim of the study was to establish the gene expression profile and morphology of human epicardial and visceral paracardial fat compared with sc fat.
Setting: The study was conducted at a tertiary care hospital cardiac center.
Patients: Epicardial, visceral paracardial, and sc fat samples had been taken from middle-aged patients with severe coronary atherosclerosis or valvular heart disease.
Interventions: Gene expression was determined by reverse transcription-quantitative PCR and relative abundance of the mitochondrial uncoupling protein-1 (UCP-1) by Western blotting. Epicardial tissue sections from patients were examined by light microscopy, UCP-1 immunohistochemistry, and cell morphometry.
Main Outcome Measures: We hypothesized that epicardial fat has a mixed phenotype with a gene expression profile similar to that described for beige cell lineage.
Results: Immunoreactive UCP-1 was clearly measurable in each epicardial sample analyzed but was undetectable in each of the 4 other visceral and sc depots. Epicardial fat exhibited high expression of genes for UCP-1, PRDM16, PGC-1 alpha, PPAR gamma, and the beige adipocyte-specific marker CD137, which were also expressed in visceral paracardial fat but only weakly in sternal, upper abdominal, and lower extremity sc fat. Histology of epicardial fat showed small unilocular adipocytes without UCP-1 immunostaining.
Conclusion: UCP-1 is relatively abundant in epicardial fat, and this depot possesses molecular features characteristic of those found in vitro in beige lineage adipocytes.
C1 [Sacks, Harold S.] VA Greater Angeles Healthcare Syst, Endocrinol & Diabet Div, Los Angeles, CA 90073 USA.
[Sacks, Harold S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Fain, John N.] Univ Tennessee, Hlth Sci Ctr, Coll Med, Dept Microbiol Immunol & Biochem, Memphis, TN 38163 USA.
[Bahouth, Suleiman W.] Univ Tennessee, Hlth Sci Ctr, Coll Med, Dept Pharmacol, Memphis, TN 38163 USA.
[Ojha, Shalini; Budge, Helen; Symonds, Michael E.] Univ Nottingham Hosp, Sch Clin Sci, Acad Div Child Hlth, Early Life Nutr Res Unit, Nottingham NG7 2UH, England.
[Frontini, Andrea; Cinti, Saverio] Univ Ancona, United Hosp, Politecn Marche,Obes Ctr, Dept Expt & Clin Med, I-60020 Ancona, Italy.
RP Sacks, HS (reprint author), VA Greater Angeles Healthcare Syst, Endocrinol & Diabet Div 111D,11310 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM hsacks@hotmail.com
OI Ojha, Shalini/0000-0001-5668-4227; Symonds, Michael/0000-0001-9649-8963
FU European Union FP7 Project DIABAT [HEALTH F2-2011-278373];
Cardiometabolic Disease Research Foundation, Los Angeles, California
FX This work was supported by European Union FP7 Project DIABAT (HEALTH
F2-2011-278373) (to S.C.), and the Cardiometabolic Disease Research
Foundation, Los Angeles, California (to H.S.).
NR 41
TC 30
Z9 34
U1 2
U2 11
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD SEP
PY 2013
VL 98
IS 9
BP E1448
EP E1455
DI 10.1210/jc.2013-1265
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 214YJ
UT WOS:000324175200002
PM 23824424
ER
PT J
AU Del Rossi, G
Rechtine, GR
Conrad, BP
Horodyski, M
AF Del Rossi, Gianluca
Rechtine, Glenn R.
Conrad, Bryan P.
Horodyski, MaryBeth
TI IS SUB-OCCIPITAL PADDING NECESSARY TO MAINTAIN OPTIMAL ALIGNMENT OF THE
UNSTABLE SPINE IN THE PREHOSPITAL SETTING? A PRELIMINARY REPORT
SO JOURNAL OF EMERGENCY MEDICINE
LA English
DT Article
DE prehospital care; spinal immobilization; cervical spine
ID CERVICAL-SPINE; ANKYLOSING-SPONDYLITIS; IMMOBILIZATION; POSITION;
INTACT; INJURY; MODEL
AB Background: As prehospital emergency rescuers prepare cervical spine-injured adult patients for immobilization and transport to hospital, it is essential that patients be placed in a favorable position. Previously, it was recommended that patients with cervical spine injuries be immobilized in a slightly flexed position using pads placed beneath the head. However, it is unknown how neck flexion created with pad placement affects the unstable spine. Objective: To determine the effects of three different head positions on the alignment of unstable vertebral segments. Methods: Five cadavers with a complete segmental instability at the C5 and C6 level were included in the study. The head was either placed directly on the ground (or spine board) or on foam pads. Three conditions were tested: no pad; pads 2.84 cm thick; and pads 4.26 cm thick. Pads were positioned beneath the head to determine their effect on spinal alignment. Anterior-posterior translation, flexion-extension motion, and axial displacement across the unstable segment were compared between conditions. Results: Although statistical tests failed to identify any significant differences between pad conditions, some meaningful results were noted. In general, the "no pad" condition aligned the spine in a position that best replicated the intact spine. Conclusions: Because the goal of emergency rescuers is to conserve whatever physiologic or structural integrity of the spinal cord and spinal column that remains, the outcome of this study suggests that this goal may be best achieved using the "no pad" condition. However, it is recommended that more research be conducted to confirm these preliminary findings. (C) 2013 Elsevier Inc.
C1 [Del Rossi, Gianluca] Univ S Florida, Dept Orthopaed & Sports Med, Tampa, FL 33612 USA.
[Rechtine, Glenn R.] US Dept Vet Affairs, St Petersburg, FL USA.
[Conrad, Bryan P.; Horodyski, MaryBeth] Univ Florida, Dept Orthopaed & Rehabil, Gainesville, FL USA.
RP Del Rossi, G (reprint author), Univ S Florida, Dept Orthopaed & Sports Med, 13220 USF Laurel Dr,MDF 5111,Mail Code MDC106, Tampa, FL 33612 USA.
NR 16
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0736-4679
J9 J EMERG MED
JI J. Emerg. Med.
PD SEP
PY 2013
VL 45
IS 3
BP 366
EP 370
DI 10.1016/j.jemermed.2013.01.042
PG 5
WC Emergency Medicine
SC Emergency Medicine
GA 213IC
UT WOS:000324048400022
PM 23849357
ER
PT J
AU Douglas, VC
Hessler, CS
Dhaliwal, G
Betjemann, JP
Fukuda, KA
Alameddine, LR
Lucatorto, R
Johnston, SC
Josephson, SA
AF Douglas, Vanja C.
Hessler, Christine S.
Dhaliwal, Gurpreet
Betjemann, John P.
Fukuda, Keiko A.
Alameddine, Lama R.
Lucatorto, Rachael
Johnston, S. Claiborne
Josephson, S. Andrew
TI The AWOL tool: Derivation and validation of a delirium prediction rule
SO JOURNAL OF HOSPITAL MEDICINE
LA English
DT Article
ID INTENSIVE-CARE PATIENTS; OLDER PATIENTS; MEDICAL INPATIENTS; CLINICAL
JUDGMENT; MINI-COG; OUTCOMES; MODEL; SURGERY; DEMENTIA; ILLNESS
AB BACKGROUND: Risk factors for delirium are well-described, yet there is no widely used tool to predict the development of delirium upon admission in hospitalized medical patients.
OBJECTIVE: To develop and validate a tool to predict the likelihood of developing delirium during hospitalization.
DESIGN: Prospective cohort study with derivation (May 2010-November 2010) and validation (October 2011-March 2012) cohorts.
SETTING: Two academic medical centers and 1 Veterans Affairs medical center.
PATIENTS: Consecutive medical inpatients (209 in the derivation and 165 in the validation cohort) over age 50 years without delirium at the time of admission.
MEASUREMENTS: Delirium assessed daily for up to 6 days using the Confusion Assessment Method.
RESULTS: The AWOL prediction rule was derived by assigning 1 point to each of 4 items assessed upon enrollment that were independently associated with the development of delirium (Age80 years, failure to spell World backward, disOrientation to place, and higher nurse-rated iLlness severity). Higher scores were associated with higher rates of delirium in the derivation and validation cohorts (P for trend<0.001 and 0.025, respectively). Rates of delirium according to score in the combined population were: 0(1/50, 2%), 1(5/141, 4%), 2(15/107, 14%), 3(10/50, 20%), and 4(7/11, 64%) (P for trend<0.001). Area under the receiver operating characteristic curve for the derivation and validation cohorts was 0.81 (0.73-0.90) and 0.69 (0.54-0.83) respectively.
CONCLUSIONS: The AWOL prediction rule characterizes medical patients' risk for delirium at the time of hospital admission and could be used for clinical stratification and in trials of delirium prevention. Journal of Hospital Medicine 2013;8:493-499. (c) 2013 Society of Hospital Medicine
C1 [Douglas, Vanja C.; Hessler, Christine S.; Betjemann, John P.; Fukuda, Keiko A.; Alameddine, Lama R.; Johnston, S. Claiborne; Josephson, S. Andrew] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
[Dhaliwal, Gurpreet; Lucatorto, Rachael] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Dhaliwal, Gurpreet; Lucatorto, Rachael] San Francisco VA Med Ctr, Med Serv, San Francisco, CA USA.
[Alameddine, Lama R.] San Francisco VA Med Ctr, Dept Psychol, San Francisco, CA USA.
[Johnston, S. Claiborne] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
RP Douglas, VC (reprint author), UCSF Dept Neurol, Parnassus Ave,M798,San Francisco, San Francisco, CA 94143 USA.
EM Vanja.Douglas@ucsf.edu
FU University of California, San Francisco
FX The following University of California, San Francisco neurology
residents provided follow-up of study subjects on weekends and were
financially compensated: Amar Dhand, MD, DPhil; Tim West, MD; Sarah
Shalev, MD; Karen DaSilva, MD; Mark Burish, MD, PhD; Maggie Waung, MD,
PhD; Raquel Gardner, MD; Molly Burnett, MD; Adam Ziemann, MD, PhD;
Kathryn Kvam, MD; Neel Singhal, MD, PhD; James Orengo, MD, PhD; Kelly
Mills, MD; and Joanna Hellmuth, MD, MHS. The authors are grateful to Dr.
Douglas Bauer for assisting with the study design.
NR 41
TC 6
Z9 7
U1 1
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1553-5592
J9 J HOSP MED
JI J. Hosp. Med.
PD SEP
PY 2013
VL 8
IS 9
BP 493
EP 499
DI 10.1002/jhm.2062
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 212ZL
UT WOS:000324022200003
PM 23922253
ER
PT J
AU Reddy, AT
Lakshmi, SP
Dornadula, S
Pinni, S
Rampa, DR
Reddy, RC
AF Reddy, Aravind T.
Lakshmi, Sowmya P.
Dornadula, Sireesh
Pinni, Sudheer
Rampa, Dileep R.
Reddy, Raju C.
TI The Nitrated Fatty Acid 10-Nitro-Oleate Attenuates Allergic Airway
Disease
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID ACTIVATED-RECEPTOR-GAMMA; KAPPA-B KINASE; PPAR-GAMMA; SEVERE ASTHMA;
ALVEOLAR MACROPHAGES; MURINE MODEL; HUMAN NEUTROPHILS; INFLAMMATION;
CORTICOSTEROIDS; INHIBITION
AB Asthma is a serious, growing problem worldwide. Inhaled steroids, the current standard therapy, are not always effective in this chronic inflammatory disease and can cause adverse effects. We tested the hypothesis that nitrated fatty acids (NFAs) may provide an effective alternative treatment. NFAs are endogenously produced by nonenzymatic reaction of NO with unsaturated fatty acids and exert anti-inflammatory actions both by activating the nuclear hormone receptor peroxisome proliferator-activated receptor (PPAR)gamma and via PPAR-independent mechanisms, but whether they might ameliorate allergic airway disease was previously untested. We found that pulmonary delivery of the NFA 10-nitro-oleic acid (OA-NO2) reduced the severity of murine allergic airway disease, as assessed by various pathological and molecular markers. Fluticasone, an inhaled steroid commonly used to treat asthma, produced similar effects on most end points, but only OA-NO2 induced robust apoptosis of neutrophils and their phagocytosis by alveolar macrophages. This suggests that OA-NO2 may be particularly effective in neutrophil-rich, steroid-resistant severe asthma. In primary human bronchial epithelial cells, OA-NO2 blocked phosphorylation and degradation of I kappa B and enhanced inhibitory binding of PPAR gamma to NF-kappa B. Our results indicate that the NFA OA-NO2 is efficacious in preclinical models of allergic airway disease and may have potential for treating asthma patients.
C1 Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, Dept Med, Sch Med, Pittsburgh, PA 15213 USA.
Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA.
RP Reddy, RC (reprint author), Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA.
EM reddyrc@upmc.edu
FU National Institutes of Health [HL093196]
FX This work was supported by National Institutes of Health Grant HL093196
(to R.C.R.).
NR 46
TC 16
Z9 16
U1 0
U2 2
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD SEP 1
PY 2013
VL 191
IS 5
BP 2053
EP 2063
DI 10.4049/jimmunol.1300730
PG 11
WC Immunology
SC Immunology
GA 204TU
UT WOS:000323393300005
PM 23913958
ER
PT J
AU McMahan, RD
Knight, SJ
Fried, TR
Sudore, RL
AF McMahan, Ryan D.
Knight, Sara J.
Fried, Terri R.
Sudore, Rebecca L.
TI Advance Care Planning Beyond Advance Directives: Perspectives From
Patients and Surrogates
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Article
DE Advance directives; decision making; aging; qualitative research
ID LIFE DECISION-MAKING; OF-LIFE; MEDICAL-CARE; LIVING WILL; HEALTH; DEATH;
PREFERENCES; DISAGREE; FAMILY; OTHERS
AB Context. Advance care planning (ACP) has focused on documenting life-sustaining treatment preferences in advance directives (ADs). The ADs alone may be insufficient to prepare diverse patients and surrogates for complex medical decisions.
Objectives. To understand what steps best prepare patients and surrogates for decision making. Methods. We conducted 13 English/Spanish focus groups with participants from a Veterans Affairs and county hospital and the community. Seven groups included patients (n = 38), aged >= 65 years, who reported making serious medical decisions. Six separate groups included surrogates (n = 31), aged >= 18 years, who made decisions for others. Semistructured focus groups asked what activities best prepared the participants for decision making. Two investigators independently coded data and performed thematic content analysis. Disputes were resolved by consensus.
Results. The mean +/- SD patient age was 78 +/- 8 years, and 61% were nonwhite. The mean +/- SD surrogate age was 57 +/- 10 years, and 91% were nonwhite. Qualitative analysis identified four overarching themes about how to best prepare for decision making: 1) identify values based on past experiences and quality of life, 2) choose surrogates wisely and verify that they understand their role, 3) decide whether to grant leeway in surrogate decision making, and 4) inform other family and friends of one's wishes to prevent conflict.
Conclusion. Beyond ADs, patients and surrogates recommend several additional steps to prepare for medical decision making including using past experiences to identify values, verifying that the surrogate understands their role, deciding whether to grant surrogates leeway, and informing other family and friends of one's wishes. Future ACP interventions should consider incorporating these additional ACP activities. Published by Elsevier Inc. on behalf of U. S. Cancer Pain Relief Committee.
C1 [McMahan, Ryan D.; Knight, Sara J.; Sudore, Rebecca L.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA.
[McMahan, Ryan D.; Sudore, Rebecca L.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94121 USA.
[Knight, Sara J.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA.
[Knight, Sara J.] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94121 USA.
[Knight, Sara J.] Vet Hlth Adm, Hlth Serv Res & Dev Serv, Washington, DC USA.
[Fried, Terri R.] Vet Affairs Connecticut Healthcare Syst, New Haven, CT USA.
[Fried, Terri R.] Yale Univ, Sch Med, New Haven, CT USA.
RP Sudore, RL (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Div Geriatr, 4150 Clement St,151R, San Francisco, CA 94121 USA.
EM rebecca.sudore@ucsf.edu
FU U.S. Department of Veterans Affairs; National Palliative Care Research
Center
FX This study was supported by the U.S. Department of Veterans Affairs and
the National Palliative Care Research Center. The funding sources had no
role in the creation of study materials, data collection, analysis, or
interpretation of the data. No authors report any conflict of interest.
NR 46
TC 25
Z9 25
U1 2
U2 24
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD SEP
PY 2013
VL 46
IS 3
BP 355
EP 365
DI 10.1016/j.jpainsymman.2012.09.006
PG 11
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA 213BA
UT WOS:000324026700005
PM 23200188
ER
PT J
AU Sanders, DS
Lattin, DJ
Read-Brown, S
Tu, DC
Wilson, DJ
Hwang, TS
Morrison, JC
Yackel, TR
Chiang, MF
AF Sanders, David S.
Lattin, Daniel J.
Read-Brown, Sarah
Tu, Daniel C.
Wilson, David J.
Hwang, Thomas S.
Morrison, John C.
Yackel, Thomas R.
Chiang, Michael F.
TI Electronic Health Record Systems in Ophthalmology Impact on Clinical
Documentation
SO OPHTHALMOLOGY
LA English
DT Article
ID INTENSIVE-CARE-UNIT; INFORMATION-TECHNOLOGY; VENOUS THROMBOEMBOLISM;
DIABETIC-RETINOPATHY; MEDICAL INFORMATICS; TIME UTILIZATION;
DATA-COLLECTION; PHYSICIANS; ERRORS; REPRESENTATION
AB Objective: To evaluate quantitative and qualitative differences in documentation of the ophthalmic examination between paper and electronic health record (EHR) systems.
Design: Comparative case series.
Participants: One hundred fifty consecutive pairs of matched paper and EHR notes, documented by 3 attending ophthalmologist providers.
Methods: An academic ophthalmology department implemented an EHR system in 2006. Database queries were performed to identify cases in which the same problems were documented by the same provider on different dates, using paper versus EHR methods. This was done for 50 consecutive pairs of examinations in 3 different diseases: age-related macular degeneration (AMD), glaucoma, and pigmented choroidal lesions (PCLs). Quantitative measures were used to compare completeness of documenting the complete ophthalmologic examination, as well as disease-specific critical findings using paper versus an EHR system. Qualitative differences in paper versus EHR documentation were illustrated by selecting representative paired examples.
Main Outcome Measures: (1) Documentation score, defined as the number of examination elements recorded for the slit-lamp examination, fundus examination, and complete ophthalmologic examination and for critical clinical findings for each disease. (2) Paired comparison of qualitative differences in paper versus EHR documentation.
Results: For all 3 diseases (AMD, glaucoma, PCL), the number of complete examination findings recorded was significantly lower with paper than the EHR system (P < 0.004). Among the 3 individual examination sections (general, slit lamp, fundus) for the 3 diseases, 5 of the 9 possible combinations had significantly lower mean documentation scores with paper than EHR notes. For 2 of the 3 diseases, the number of critical clinical findings recorded was significantly lower using paper versus EHR notes (P <= 0.022). All (150/150) paper notes relied on graphical representations using annotated hand-drawn sketches, whereas no (0/150) EHR notes contained drawings. Instead, the EHR systems documented clinical findings using textual descriptions and interpretations.
Conclusions: There were quantitative and qualitative differences in the nature of paper versus EHR documentation of ophthalmic findings in this study. The EHR notes included more complete documentation of examination elements using structured textual descriptions and interpretations, whereas paper notes used graphical representations of findings.
C1 [Sanders, David S.; Lattin, Daniel J.; Read-Brown, Sarah; Tu, Daniel C.; Wilson, David J.; Hwang, Thomas S.; Morrison, John C.; Chiang, Michael F.] Oregon Hlth & Sci Univ, Casey Eye Inst, Dept Ophthalmol, Portland, OR 97239 USA.
[Tu, Daniel C.] Portland VA Med Ctr, Ophthalmol Operat Care Div, Portland, OR USA.
[Yackel, Thomas R.; Chiang, Michael F.] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97239 USA.
RP Chiang, MF (reprint author), Oregon Hlth & Sci Univ, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA.
EM chiangm@ohsu.edu
OI Read-Brown, Sarah/0000-0002-6526-2939
FU Research to Prevent Blindness, Inc, New York, New York
FX Supported by unrestricted departmental funding from Research to Prevent
Blindness, Inc, New York, New York (D.S.S., S.R.B., D.C.T., D.J.W.,
T.S.H., J.C.M., and M.F.C.). The funding organization had no role in the
design or conduct of this research.
NR 39
TC 8
Z9 8
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2013
VL 120
IS 9
BP 1745
EP 1755
DI 10.1016/j.ophtha.2013.02.017
PG 11
WC Ophthalmology
SC Ophthalmology
GA 213HG
UT WOS:000324045800025
PM 23683945
ER
PT J
AU Tucker, RP
Wingate, LR
O'Keefe, VM
Mills, AC
Rasmussen, K
Davidson, CL
Grant, DM
AF Tucker, Raymond P.
Wingate, LaRicka R.
O'Keefe, Victoria M.
Mills, Adam C.
Rasmussen, Kathy
Davidson, Collin L.
Grant, DeMond M.
TI Rumination and suicidal ideation: The moderating roles of hope and
optimism
SO PERSONALITY AND INDIVIDUAL DIFFERENCES
LA English
DT Article
DE Rumination; Hope; Optimism; Suicide; Suicidal ideation; Brooding;
Reflection
ID COLLEGE-STUDENTS; DEPRESSED MOOD; RISK; HOPELESSNESS; REFLECTION;
SYMPTOMS; HISTORY; LIFE
AB The current study aimed to investigate whether the correlation between rumination and suicidal ideation is moderated by the presence of hope and optimism. It was hypothesized that both hope and optimism would moderate (weaken) the relationship between rumination and suicidal ideation. Two hundred and ninety-eight participants completed self-report measures of hope, optimism, rumination (brooding and reflection), and depression. Results demonstrated that both hope and optimism weakened the relationship between rumination and suicidal ideation, as well as the relationships between both subscales of rumination and suicidal thinking. These results were found when controlling for symptoms of depression. Results suggest that a ruminative thinking style may be most harmful when an absence of hope or optimism is also present. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Tucker, Raymond P.; Wingate, LaRicka R.; O'Keefe, Victoria M.; Mills, Adam C.; Rasmussen, Kathy; Grant, DeMond M.] Oklahoma State Univ, Dept Psychol, Stillwater, OK 74078 USA.
[Davidson, Collin L.] Denver VA Med Ctr, VA VISN MIRECC 19, Denver, CO USA.
RP Wingate, LR (reprint author), Oklahoma State Univ, Dept Psychol, 116 North Murray Hall, Stillwater, OK 74078 USA.
EM laricka.wingate@okstate.edu
OI Grant, DeMond/0000-0002-5231-6563
NR 38
TC 14
Z9 16
U1 0
U2 16
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0191-8869
J9 PERS INDIV DIFFER
JI Pers. Individ. Differ.
PD SEP
PY 2013
VL 55
IS 5
BP 606
EP 611
DI 10.1016/j.paid.2013.05.013
PG 6
WC Psychology, Social
SC Psychology
GA 191JZ
UT WOS:000322410500028
ER
PT J
AU Bentley, JP
Brown, CJ
McGwin, G
Sawyer, P
Allman, RM
Roth, DL
AF Bentley, John P.
Brown, Cynthia J.
McGwin, Gerald, Jr.
Sawyer, Patricia
Allman, Richard M.
Roth, David L.
TI Functional status, life-space mobility, and quality of life: a
longitudinal mediation analysis
SO QUALITY OF LIFE RESEARCH
LA English
DT Article
DE Wilson-Cleary model; Activities of daily living; Mobility; SF-12;
Longitudinal mediation; Autoregressive mediation modeling
ID STRUCTURAL EQUATION MODEL; DWELLING OLDER-ADULTS; CONCEPTUAL-MODEL;
PREDICTORS; DEPRESSION; VARIABLES; SURVIVORS; DECLINES; SURGERY; PANEL
AB Using the Wilson-Cleary model of patient outcomes as a conceptual framework, the impact of functional status on health-related quality of life (HRQoL) among older adults was examined, including tests of the mediation provided by life-space mobility.
Participants were enrollees in a population-based, longitudinal study of mobility among community-dwelling older adults. Data from four waves of the study equally spaced approximately 18 months apart (baseline, 18, 36, and 54 months) were used for participants who survived at least 1 year beyond the 54-month assessment (n = 677). Autoregressive mediation models using longitudinal data and cross-sectional mediation models using baseline data were evaluated and compared using structural equation modeling.
The longitudinal autoregressive models supported the mediating role of life-space mobility and suggested that this effect is larger for the mental component summary score than the physical component summary score of the SF-12. Evidence for a reciprocal relationship over time between functional status, measured by ADL difficulty, and life-space mobility was suggested by modification indices; these model elaborations did not alter the substantive meaning of the mediation effects. Mediated effect estimates from longitudinal autoregressive models were generally larger than those from cross-sectional models, suggesting that mediating relationships would have been missed or were potentially underestimated in cross-sectional models.
These results support a mediating role for life-space mobility in the relationship between functional status and HRQoL. Functional status limitations might cause diminished HRQoL in part by limiting mobility. Mobility limitations may precede functional status limitations in addition to being a consequence thereof.
C1 [Bentley, John P.] Univ Mississippi, Sch Pharm, University, MS 38677 USA.
[Brown, Cynthia J.] Univ Alabama Birmingham, Birmingham VA Med Ctr, Birmingham, AL 35294 USA.
[Brown, Cynthia J.; Sawyer, Patricia] Univ Alabama Birmingham, Div Gerontol Geriatr & Palliat Care, Birmingham, AL 35294 USA.
[McGwin, Gerald, Jr.] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL 35294 USA.
[Allman, Richard M.] Univ Alabama Birmingham, Atlanta VA Geriatr Res Educ & Clin Ctr, Ctr Aging, Birmingham, AL 35294 USA.
[Allman, Richard M.] Univ Alabama Birmingham, Div Gerontol Geriatr & Palliat Care, Birmingham, AL 35294 USA.
[Roth, David L.] Johns Hopkins Univ, Ctr Aging & Hlth, Baltimore, MD 21205 USA.
RP Bentley, JP (reprint author), Univ Mississippi, Sch Pharm, Faser Hall 235, University, MS 38677 USA.
EM phjpb@olemiss.edu
FU National Institute on Aging [R01 AG015062]
FX The UAB Study of Aging is funded through a grant from the National
Institute on Aging (R01 AG015062).
NR 59
TC 15
Z9 16
U1 6
U2 32
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0962-9343
J9 QUAL LIFE RES
JI Qual. Life Res.
PD SEP
PY 2013
VL 22
IS 7
BP 1621
EP 1632
DI 10.1007/s11136-012-0315-3
PG 12
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 214BL
UT WOS:000324105100011
PM 23161329
ER
PT J
AU Moyer, CE
Delevich, KM
Fish, KN
Asafu-Adjei, JK
Sampson, AR
Dorph-Petersen, KA
Lewis, DA
Sweet, RA
AF Moyer, Caitlin E.
Delevich, Kristen M.
Fish, Kenneth N.
Asafu-Adjei, Josephine K.
Sampson, Allan R.
Dorph-Petersen, Karl-Anton
Lewis, David A.
Sweet, Robert A.
TI Intracortical excitatory and thalamocortical boutons are intact in
primary auditory cortex in schizophrenia
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE VGluT1; VGluT2; Primary auditory cortex; Quantitative microscopy;
Stereology; Postmortem human tissue
ID VESICULAR GLUTAMATE TRANSPORTERS; MISMATCH NEGATIVITY GENERATION;
MESSENGER-RNA EXPRESSION; DENDRITIC SPINE DENSITY; SUPERIOR TEMPORAL
GYRUS; RAT HIPPOCAMPAL SLICES; PREFRONTAL CORTEX; PLANUM TEMPORALE;
HESCHL GYRUS; IN-VIVO
AB Schizophrenia is associated with auditory processing impairments that could arise as a result of primary auditory cortex excitatory circuit pathology. We have previously reported a deficit in dendritic spine density in deep layer 3 of primary auditory cortex in subjects with schizophrenia. As boutons and spines can be structurally and functionally co-regulated, we asked whether the densities of intracortical excitatory or thalamocortical presynaptic boutons are also reduced. We studied 2 cohorts of subjects with schizophrenia and matched controls, comprising 27 subject pairs, and assessed the density, number, and within-bouton vesicular glutamate transporter (VGluT) protein level of intracortical excitatory (VGluT1-immunoreactive) and thalamocortical (VGluT2-immunoreactive) boutons in deep layer 3 of primary auditory cortex using quantitative confocal microscopy and stereologic sampling methods. We found that VGluT1- and VGluT2-immunoreactive puncta densities and numbers were not altered in deep layer 3 of primary auditory cortex of subjects with schizophrenia. Our results indicate that reduced dendritic spine density in primary auditory cortex of subjects with schizophrenia is not matched by a corresponding reduction in excitatory bouton density. This suggests excitatory boutons in primary auditory cortex in schizophrenia may synapse with structures other than spines, such as dendritic shafts, with greater frequency. The discrepancy between dendritic spine reduction and excitatory bouton preservation may contribute to functional impairments of the primary auditory cortex in subjects with schizophrenia. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Moyer, Caitlin E.; Fish, Kenneth N.; Lewis, David A.; Sweet, Robert A.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA.
[Moyer, Caitlin E.; Delevich, Kristen M.; Fish, Kenneth N.; Dorph-Petersen, Karl-Anton; Lewis, David A.; Sweet, Robert A.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15213 USA.
[Asafu-Adjei, Josephine K.; Sampson, Allan R.] Univ Pittsburgh, Dept Stat, Pittsburgh, PA 15213 USA.
[Dorph-Petersen, Karl-Anton] Aarhus Univ Hosp, Ctr Psychiat Res, Risskov, Denmark.
[Dorph-Petersen, Karl-Anton] Aarhus Univ, Ctr Stochast Geometry & Adv Bioimaging, Aarhus, Denmark.
[Lewis, David A.] Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA 15213 USA.
[Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA.
[Sweet, Robert A.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Pittsburgh, PA 15213 USA.
RP Sweet, RA (reprint author), Biomed Sci Tower,Rm W1645,3811 OHara St, Pittsburgh, PA 15213 USA.
EM SweetRA@upmc.edu
RI Lewis, David/G-4053-2014; Dorph-Petersen, Karl-Anton/A-9039-2015
OI Lewis, David/0000-0002-3225-6778; Dorph-Petersen,
Karl-Anton/0000-0002-6676-034X; Moyer, Caitlin/0000-0002-2571-2595;
Delevich, Kristen/0000-0001-5698-0093
FU [MH071533]; [MH084053]; [MH085108]
FX This work was supported by Grants MH071533 (RAS), MH084053 (DAL), and
MH085108 (KNF).
NR 57
TC 8
Z9 8
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD SEP
PY 2013
VL 149
IS 1-3
BP 127
EP 134
DI 10.1016/j.schres.2013.06.024
PG 8
WC Psychiatry
SC Psychiatry
GA 211UQ
UT WOS:000323937200020
PM 23830684
ER
PT J
AU Hiremath, SV
Ding, D
Farringdon, J
Vyas, N
Cooper, RA
AF Hiremath, S. V.
Ding, D.
Farringdon, J.
Vyas, N.
Cooper, R. A.
TI Physical activity classification utilizing SenseWear activity monitor in
manual wheelchair users with spinal cord injury
SO SPINAL CORD
LA English
DT Article
DE spinal cord injury; physical activity; manual wheelchair users; machine
learning; energy expenditure; multisensor activity monitor
ID ENERGY-EXPENDITURE
AB Study design: Validation.
Objectives: The primary aim of this study was to develop and evaluate activity classification algorithms for a multisensor-based SenseWear (SW) activity monitor that can recognize wheelchair-related activities performed by manual wheelchair users (MWUs) with spinal cord injury (SCI). The secondary aim was to evaluate how the accuracy in activity classification affects the estimation of energy expenditure (EE) in MWUs with SCI.
Setting: University-based laboratory.
Methods: Forty-five MWUs with SCI wore a SW on their upper arm and participated in resting, wheelchair propulsion, arm-ergometery and deskwork activities. The investigators annotated the start and end of each activity trial while the SW collected multisensor data and a portable metabolic cart collected criterion EE. Three methods including linear discriminant analysis, quadratic discriminant analysis (QDA), and Naive Bayes (NB) were used to develop classification algorithms for four activities based on the training data set from 36 subjects.
Results: The classification accuracy was 96.3% for QDA and 94.8% for NB when the classification algorithms were tested on the validation data set from nine subjects. The average EE estimation errors using the activity-specific EE prediction model were 5.3 +/- 21.5% and 4.6 +/- 22.8% when the QDA and NB classification algorithms were applied, respectively, as opposed to 4.9 +/- 20.7% when 100% classification accuracy was assumed.
Conclusion: The high classification accuracy and low EE estimation errors suggest that the SW can be used by researchers and clinicians to classify and estimate the EE for the four activities tested in this study among MWUs with SCI.
C1 [Hiremath, S. V.; Ding, D.; Cooper, R. A.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Dept Vet Affairs, Pittsburgh, PA 15206 USA.
[Hiremath, S. V.; Ding, D.; Cooper, R. A.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA.
[Ding, D.; Cooper, R. A.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA.
[Farringdon, J.; Vyas, N.] BodyMedia Inc, Pittsburgh, PA USA.
RP Ding, D (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Dept Vet Affairs, 6425 Penn Ave,Suite 400, Pittsburgh, PA 15206 USA.
EM dad5@pitt.edu
OI Farringdon, Jonathan/0000-0001-5977-3700
FU Rehabilitation Engineering Research Center on Interactive Exercise &
Recreation Technologies & Exercise Physiology benefitting Persons with
Disabilities [H133E120005]; National Institute on Disability and
Rehabilitation Research (NIDRR); Switzer Research Fellowship
[H133Fl10032]; NIDRR; VA Center of Excellence for Wheelchairs and
Associated Rehabilitation Engineering [B3142C]
FX The work is supported by the Rehabilitation Engineering Research Center
on Interactive Exercise & Recreation Technologies & Exercise Physiology
benefitting Persons with Disabilities (H133E120005) funded by the
National Institute on Disability and Rehabilitation Research (NIDRR).
Mr. Hiremath's work on this article was also funded through the Switzer
Research Fellowship (H133Fl10032) awarded by the NIDRR. The work is also
supported by the VA Center of Excellence for Wheelchairs and Associated
Rehabilitation Engineering (B3142C). The contents do not represent the
views of the Department of Veterans Affairs or the United States
Government.
NR 18
TC 7
Z9 7
U1 1
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1362-4393
J9 SPINAL CORD
JI Spinal Cord
PD SEP
PY 2013
VL 51
IS 9
BP 705
EP 709
DI 10.1038/sc.2013.39
PG 5
WC Clinical Neurology; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA 216UB
UT WOS:000324309000011
PM 23689386
ER
PT J
AU Krautkramer, KA
Linnemann, AK
Fontaine, DA
Whillock, AL
Harris, TW
Schleis, GJ
Truchan, NA
Marty-Santos, L
Lavine, JA
Cleaver, O
Kimple, ME
Davis, DB
AF Krautkramer, Kimberly A.
Linnemann, Amelia K.
Fontaine, Danielle A.
Whillock, Amy L.
Harris, Ted W.
Schleis, Gregory J.
Truchan, Nathan A.
Marty-Santos, Leilani
Lavine, Jeremy A.
Cleaver, Ondine
Kimple, Michelle E.
Davis, Dawn Belt
TI Tcf19 is a novel islet factor necessary for proliferation and survival
in the INS-1 beta-cell line
SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
LA English
DT Article
DE diabetes; beta-cell; islet; proliferation; apoptosis; transcription
factor 19; transcription; endoplasmic reticulum stress
ID ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE;
DIABETES-MELLITUS; ER STRESS; MISFOLDED GLYCOPROTEINS; DEVELOPING
PANCREAS; FHA DOMAIN; EXPRESSION; APOPTOSIS; MASS
AB Recently, a novel type 1 diabetes association locus was identified at human chromosome 6p31.3, and transcription factor 19 (TCF19) is a likely causal gene. Little is known about Tcf19, and we now show that it plays a role in both proliferation and apoptosis in insulinoma cells. Tcf19 is expressed in mouse and human islets, with increasing mRNA expression in nondiabetic obesity. The expression of Tcf19 is correlated with beta-cell mass expansion, suggesting that it may be a transcriptional regulator of beta-cell mass. Increasing proliferation and decreasing apoptotic cell death are two strategies to increase pancreatic beta-cell mass and prevent or delay diabetes. siRNA-mediated knockdown of Tcf19 in the INS-1 insulinoma cell line, a beta-cell model, results in a decrease in proliferation and an increase in apoptosis. There was a significant reduction in the expression of numerous cell cycle genes from the late G1 phase through the M phase, and cells were arrested at the G1/S checkpoint. We also observed increased apoptosis and susceptibility to endoplasmic reticulum (ER) stress after Tcf19 knockdown. There was a reduction in expression of genes important for the maintenance of ER homeostasis (Bip, p58(IPK), Edem1, and calreticulin) and an increase in proapoptotic genes (Bim, Bid, Nix, Gadd34, and Pdia2). Therefore, Tcf19 is necessary for both proliferation and survival and is a novel regulator of these pathways.
C1 [Krautkramer, Kimberly A.; Linnemann, Amelia K.; Fontaine, Danielle A.; Whillock, Amy L.; Harris, Ted W.; Schleis, Gregory J.; Truchan, Nathan A.; Kimple, Michelle E.; Davis, Dawn Belt] Univ Wisconsin, Dept Med, Div Endocrinol Diabet & Metab, Madison, WI USA.
[Lavine, Jeremy A.; Davis, Dawn Belt] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA.
[Marty-Santos, Leilani; Cleaver, Ondine] Univ Texas Southwestern, Dept Mol Biol, Dallas, TX USA.
[Davis, Dawn Belt] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
RP Davis, DB (reprint author), 4148 MFCB,MC 5148,1685 Highland Ave, Madison, WI 53705 USA.
EM dbd@medicine.wisc.edu
RI Davis, Dawn/B-1624-2013
OI Cleaver, Ondine/0000-0003-2454-6641
FU NIDDK [K08-DK-083442, 3R01-DK-079862-S1, F31-DK-092098,
5-R01-DK-079862]; William and Judith Busse Women in Research Foundation;
University of Wisconsin School of Medicine and Public Health and
Department of Medicine, Division of Endocrinology; Wisconsin Alumni
Research Foundation; Central Society for Clinical Research; Pilot Award
from the Integrated Islet Distribution Program; JDRF [17-2011-608];
Medical Scientist Training Program [T32GM08692]; National Center for
Advancing Translational Sciences [UL1TR0000427]
FX D. B. Davis acknowledges research support from the NIDDK
(K08-DK-083442), the William and Judith Busse Women in Research
Foundation, the University of Wisconsin School of Medicine and Public
Health and Department of Medicine, Division of Endocrinology, the
Wisconsin Alumni Research Foundation, and the Central Society for
Clinical Research. D. B. Davis was also the recipient of a Pilot Award
from the Integrated Islet Distribution Program that provided an
allotment of human islets. M. E. Kimple has received research support
from JDRF (17-2011-608). J. A. Lavine and K. A. Krautkramer have been
supported by the Medical Scientist Training Program (T32GM08692). O.
Cleaver and L. Marty-Santos have also been supported by the NIDDK
[3R01-DK-079862-S1 (L. Marty-Santos), F31-DK-092098 (L. Marty-Santos),
and 5-R01-DK-079862 (O. Cleaver)]. We also acknowledge statistical
consultation through the Clinical and Translational Science Award
program through National Center for Advancing Translational Sciences
Grant UL1TR0000427.
NR 55
TC 5
Z9 5
U1 3
U2 8
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0193-1849
J9 AM J PHYSIOL-ENDOC M
JI Am. J. Physiol.-Endocrinol. Metab.
PD SEP
PY 2013
VL 305
IS 5
BP E600
EP E610
DI 10.1152/ajpendo.00147.2013
PG 11
WC Endocrinology & Metabolism; Physiology
SC Endocrinology & Metabolism; Physiology
GA 211WH
UT WOS:000323941900004
PM 23860123
ER
PT J
AU Mitchell, T
Johnson, MS
Ouyang, XS
Chacko, BK
Mitra, K
Lei, XY
Gai, Y
Moore, DR
Barnes, S
Zhang, JH
Koizumi, A
Ramanadham, S
Darley-Usmar, VM
AF Mitchell, Tanecia
Johnson, Michelle S.
Ouyang, Xiaosen
Chacko, Balu K.
Mitra, Kasturi
Lei, Xiaoyong
Gai, Ying
Moore, D. Ray
Barnes, Stephen
Zhang, Jianhua
Koizumi, Akio
Ramanadham, Sasanka
Darley-Usmar, Victor M.
TI Dysfunctional mitochondrial bioenergetics and oxidative stress in
Akita(+/Ins2)-derived beta-cells
SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
LA English
DT Article
DE diabetes mellitus; beta-cell; mitochondrial respiration; endoplasmic
reticulum stress; mitochondrial quality control
ID ENDOPLASMIC-RETICULUM STRESS; DIABETES-MELLITUS; INSULIN GENE;
SUPEROXIDE-DISMUTASE; MUTANT MICE; AUTOPHAGY; MUTATIONS; EXPRESSION;
MECHANISM; MOUSE
AB Insulin release from pancreatic beta-cells plays a critical role in blood glucose homeostasis, and beta-cell dysfunction leads to the development of diabetes mellitus. In cases of monogenic type 1 diabetes mellitus (T1DM) that involve mutations in the insulin gene, we hypothesized that misfolding of insulin could result in endoplasmic reticulum (ER) stress, oxidant production, and mitochondrial damage. To address this, we used the Akita(+/Ins2) T1DM model in which misfolding of the insulin 2 gene leads to ER stress-mediated beta-cell death and thapsigargin to induce ER stress in two different beta-cell lines and in intact mouse islets. Using transformed pancreatic beta-cell lines generated from wild-type Ins2(-/-) (WT) and Akita(+/Ins2) mice, we evaluated cellular bioenergetics, oxidative stress, mitochondrial protein levels, and autophagic flux to determine whether changes in these processes contribute to beta-cell dysfunction. In addition, we induced ER stress pharmacologically using thapsigargin in WT beta-cells, INS-1 cells, and intact mouse islets to examine the effects of ER stress on mitochondrial function. Our data reveal that Akita(+/Ins2)-derived beta-cells have increased mitochondrial dysfunction, oxidant production, mtDNA damage, and alterations in mitochondrial protein levels that are not corrected by autophagy. Together, these findings suggest that deterioration in mitochondrial function due to an oxidative environment and ER stress contributes to beta-cell dysfunction and could contribute to T1DM in which mutations in insulin occur.
C1 [Mitchell, Tanecia; Johnson, Michelle S.; Ouyang, Xiaosen; Chacko, Balu K.; Zhang, Jianhua; Darley-Usmar, Victor M.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
[Mitchell, Tanecia; Johnson, Michelle S.; Ouyang, Xiaosen; Chacko, Balu K.; Barnes, Stephen; Zhang, Jianhua; Darley-Usmar, Victor M.] Univ Alabama Birmingham, Ctr Free Radical Biol, Birmingham, AL 35294 USA.
[Mitra, Kasturi] Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA.
[Lei, Xiaoyong; Gai, Ying; Ramanadham, Sasanka] Univ Alabama Birmingham, Dept Cell, Birmingham, AL 35294 USA.
[Barnes, Stephen] Univ Alabama Birmingham, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA.
[Ouyang, Xiaosen; Zhang, Jianhua] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Moore, D. Ray; Barnes, Stephen] Univ Alabama Birmingham, Targeted Metabol & Prote Lab, Birmingham, AL 35294 USA.
[Koizumi, Akio] Kyoto Grad Sch Med, Dept Hlth & Environm Sci, Kyoto, Japan.
RP Darley-Usmar, VM (reprint author), Univ Alabama Birmingham, Dept Pathol, Biomed Res Bldg 2,901 19th St South, Birmingham, AL 35294 USA.
EM darley@uab.edu
FU Veterans Affairs Merit Award [AA-13395, DK-075865]; O'Brien Center
[P30-DK-079337]; University of Alabama at Birmingham Health Services
Foundation General Endowment Fund; [T32-DK-007545]; [DK-69455];
[NS-064090]
FX We appreciate support from the following: T32-DK-007545 (T. Mitchell),
DK-69455 (S. Ramanadham), NS-064090 and a Veterans Affairs Merit Award
(J. Zhang), AA-13395 and DK-075865 (V. M. Darley-Usmar), and the O'Brien
Center P30-DK-079337 (S. Barnes and V. M. Darley-Usmar). Funds for the
mass spectrometer used in this study were provided by a grant from the
University of Alabama at Birmingham Health Services Foundation General
Endowment Fund.
NR 62
TC 16
Z9 17
U1 0
U2 6
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0193-1849
J9 AM J PHYSIOL-ENDOC M
JI Am. J. Physiol.-Endocrinol. Metab.
PD SEP
PY 2013
VL 305
IS 5
BP E585
EP E599
DI 10.1152/ajpendo.00093.2013
PG 15
WC Endocrinology & Metabolism; Physiology
SC Endocrinology & Metabolism; Physiology
GA 211WH
UT WOS:000323941900003
PM 23820623
ER
PT J
AU Kornblit, B
Maloney, DG
Storb, R
Storek, J
Hari, P
Vucinic, V
Maziarz, RT
Chauncey, TR
Pulsipher, MA
Bruno, B
Petersen, FB
Bethge, WA
Hubel, K
Bouvier, ME
Fukuda, T
Storer, BE
Sandmaier, BM
AF Kornblit, Brian
Maloney, David G.
Storb, Rainer
Storek, Jan
Hari, Parameswaran
Vucinic, Vladan
Maziarz, Richard T.
Chauncey, Thomas R.
Pulsipher, Michael A.
Bruno, Benedetto
Petersen, Finn B.
Bethge, Wolfgang A.
Huebel, Kai
Bouvier, Michelle E.
Fukuda, Takahiro
Storer, Barry E.
Sandmaier, Brenda M.
TI Fludarabine and 2-Gy TBI is Superior to 2 Gy TBI as Conditioning for
HLA-Matched Related Hematopoietic Cell Transplantation: A Phase III
Randomized Trial
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Article
DE Nonmyeloablative conditioning; Fludarabine/low dose total body
irradiation; HLA-matched related hematopoietic cell transplantation
randomized trial
ID TOTAL-BODY IRRADIATION; CHRONIC LYMPHOCYTIC-LEUKEMIA; HEMATOLOGIC
MALIGNANCIES; MARROW TRANSPLANTATION; FOLLICULAR LYMPHOMA;
RISK-ASSESSMENT; KILLER-CELLS; CHIMERISM; DONOR; INTENSITY
AB The risks and benefits of adding fludarabine to a 2-Gy total body irradiation (TBI) nonmyeloablative regimen are unknown. For this reason, we conducted a prospective randomized trial comparing 2-Gy TBI alone, or in combination with 90 mg/m(2) fludarabine (FLU/TBI), before transplantation of peripheral blood stem cells from HLA-matched related donors. Eighty-five patients with hematological malignancies were randomized to be conditioned with TBI alone (n = 44) or FLU/TBI (n = 41). All patients had initial engraftment. Two graft rejections were observed, both in the TBI group. Infection rates, nonrelapse mortality, and graft-versus-host disease (GVHD) were similar between groups. Three-year overall survival was lower in the TBI group (54% versus 65%; hazard ratio [HR], .57; P = .09), with higher incidences of relapse/progression (55% versus 40%; HR, .55; P = .06), relapse-related mortality (37% versus 28%; HR, .53; P = .09), and a lower progression-free survival (36% versus 53%; HR, .56; P = .05). Median donor T cell chimerism levels were significantly lower in the TBI group at days 28 (61% versus 90%; P < .0001) and 84 (68% versus 92%; P < .0001), as was NK cell chimerism on day 28 (75% versus 96%; P = .0005). In conclusion, this randomized trial demonstrates the importance of fludarabine in augmenting the graft-versus-tumor effect by ensuring prompt and durable high-level donor engraftment early after transplantation. (C) 2013 American Society for Blood and Marrow Transplantation.
C1 [Kornblit, Brian; Maloney, David G.; Storb, Rainer; Chauncey, Thomas R.; Bouvier, Michelle E.; Storer, Barry E.; Sandmaier, Brenda M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA.
[Maloney, David G.; Storb, Rainer; Sandmaier, Brenda M.] Univ Washington, Dept Med, Div Oncol, Seattle, WA 98195 USA.
[Storek, Jan] Univ Calgary, Dept Med, Calgary, AB, Canada.
[Storek, Jan] Univ Calgary, Dept Oncol & Microbiol, Calgary, AB, Canada.
[Storek, Jan] Univ Calgary, Dept Immunol, Calgary, AB, Canada.
[Storek, Jan] Univ Calgary, Dept Infect Dis, Calgary, AB, Canada.
[Hari, Parameswaran] Med Coll Wisconsin, Div Hematol & Oncol, Milwaukee, WI 53226 USA.
[Vucinic, Vladan] Univ Leipzig, Dept Hematol & Oncol, D-04109 Leipzig, Germany.
[Maziarz, Richard T.] Oregon Hlth & Sci Univ, Ctr Hematol Malignancies, Portland, OR 97201 USA.
[Chauncey, Thomas R.] VA Puget Sound Hlth Care Syst, Marrow Transplant Unit, Seattle, WA USA.
[Pulsipher, Michael A.] Univ Utah, Sch Med, Huntsman Canc Inst, Div Hematol & Hematol Malignancies, Salt Lake City, UT USA.
[Bruno, Benedetto] Univ Turin, Sch Med, Div Hematol, Turin, Italy.
[Petersen, Finn B.] LDS Hosp, Intermt Blood & Marrow Transplant Acutr Leukemia, Salt Lake City, UT USA.
[Bethge, Wolfgang A.] Univ Tubingen, Med Ctr, Dept Med, Tubingen, Germany.
[Huebel, Kai] Univ Cologne, Ctr Integrated Oncol Cologne Bonn, Dept Med 1, D-50931 Cologne, Germany.
[Fukuda, Takahiro] Natl Canc Ctr, Stem Cell Transplantat Div, Tokyo, Japan.
[Storer, Barry E.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
RP Sandmaier, BM (reprint author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,D1-100,POB 19024, Seattle, WA 98109 USA.
EM bsandmai@fhcrc.org
OI Hari, Parameswaran/0000-0002-8800-297X
FU National Institutes of Health, Bethesda, MD [CA078902, HL036444,
CA015704]; Danish Cancer Society [DP08135]; Froken Amalie Jorgensens
Mindelegat; Anders Hasselbalchs Fond; Ricerca Sanitaria Finalizzata
[RF-PIE-2008-1206999, RF-PIE-2009-1491359]
FX Financial disclosure: Research funding was provided by the National
Institutes of Health, Bethesda, MD, grants, CA078902, HL036444, and
CA015704. The content is solely the responsibility of the authors and
does not necessarily represent the official views of the National
Institutes of Health nor its subsidiary Institutes and Centers. B.K. was
supported by a fellowship from the Danish Cancer Society (DP08135),
Froken Amalie Jorgensens Mindelegat and Anders Hasselbalchs Fond. B.B.
was supported by Ricerca Sanitaria Finalizzata RF-PIE-2008-1206999 and
RF-PIE-2009-1491359.
NR 36
TC 10
Z9 10
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD SEP
PY 2013
VL 19
IS 9
BP 1340
EP 1347
DI 10.1016/j.bbmt.2013.06.002
PG 8
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 212WT
UT WOS:000324014200009
PM 23769990
ER
PT J
AU Cassaday, RD
Guthrie, KA
Budde, EL
Thompson, L
Till, BG
Press, OW
Chauncey, TR
Pagel, JM
Petersdorf, SH
Palanca-Wessels, MC
Philip, M
Bensinger, WI
Holmberg, LA
Shustov, A
Green, DJ
Libby, EN
Maloney, DG
Gopal, AK
AF Cassaday, Ryan D.
Guthrie, Katherine A.
Budde, Elizabeth L.
Thompson, Leslie
Till, Brian G.
Press, Oliver W.
Chauncey, Thomas R.
Pagel, John M.
Petersdorf, Stephen H.
Palanca-Wessels, Maria Corinna
Philip, Mary
Bensinger, William I.
Holmberg, Leona A.
Shustov, Andrei
Green, Damian J.
Libby, Edward N.
Maloney, David G.
Gopal, Ajay K.
TI Specific Features Identify Patients with Relapsed or Refractory Mantle
Cell Lymphoma Benefitting from Autologous Hematopoietic Cell
Transplantation
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Article
DE Mantle cell lymphoma; Autologous transplantation
ID PROGRESSION-FREE SURVIVAL; PLUS RITUXIMAB; REMISSION; MULTICENTER;
PHASE-2; REGIMEN; TRIAL; CHOP
AB Outcomes with autologous hematopoietic cell transplantation (auto HCT) for relapsed and/or refractory mantle cell lymphoma (MCL) are typically poor. We hypothesized that certain factors could predict which patients experience a favorable outcome with this approach. We thus developed a predictive score from a cohort of 67 such patients using 3 factors independently associated with progression-free survival (PFS): (1) simplified Mantle Cell Lymphoma International Prognostic Index score before auto HCT (hazard ratio MR], 2.9; P = .002); (2) B symptoms at diagnosis (HR, 2.7; P = .005); and (3) remission quotient, calculated by dividing the time, in months, from diagnosis to auto HCT by the number of prior treatments (HR, 1.4; P = .02). The estimated 5-year PFS for favorable-risk patients (n = 23) and unfavorable-risk patients (n = 44) were 58% (95% confidence interval [CI], 34% to 75%) and 15% (95% Cl, 6% to 28%), respectively. These factors also independently predicted overall survival. In summary, we have defined 3 simple factors that can identify patients with relapsed/refractory MCL who derive a durable benefit from salvage auto HCT. (C) 2013 American Society for Blood and Marrow Transplantation.
C1 [Cassaday, Ryan D.; Guthrie, Katherine A.; Budde, Elizabeth L.; Thompson, Leslie; Till, Brian G.; Press, Oliver W.; Chauncey, Thomas R.; Pagel, John M.; Petersdorf, Stephen H.; Palanca-Wessels, Maria Corinna; Philip, Mary; Bensinger, William I.; Holmberg, Leona A.; Shustov, Andrei; Green, Damian J.; Libby, Edward N.; Maloney, David G.; Gopal, Ajay K.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA.
[Cassaday, Ryan D.; Budde, Elizabeth L.; Thompson, Leslie; Till, Brian G.; Press, Oliver W.; Chauncey, Thomas R.; Pagel, John M.; Petersdorf, Stephen H.; Bensinger, William I.; Holmberg, Leona A.; Green, Damian J.; Libby, Edward N.; Maloney, David G.; Gopal, Ajay K.] Univ Washington, Dept Med, Div Med Oncol, Seattle, WA USA.
[Chauncey, Thomas R.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
[Palanca-Wessels, Maria Corinna; Philip, Mary; Shustov, Andrei] Univ Washington, Dept Med, Div Hematol, Seattle, WA 98195 USA.
RP Gopal, AK (reprint author), 825 Eastlake Ave E,Mailstop G3-200, Seattle, WA 98109 USA.
EM agopal@u.washington.edu
FU Lymphoma Research Foundation MCL Initiative; Leukemia and Lymphoma
Society; NIH [T32 CA009515-27, P01 CA044991]; NCI [K08 CA163603, K08
CA151682]; Mary Wright Memorial Fund
FX This work was supported by The Lymphoma Research Foundation MCL
Initiative, a Clinical Scholar Award by the Leukemia and Lymphoma
Society (A.K.G.), NIH T32 CA009515-27 (R.D.C.), NCI K08 CA163603
(M.C.P.W.), NCI K08 CA151682 (N.G.), NIH P01 CA044991, the Mary Wright
Memorial Fund, and gifts from David and Patricia Giuliani, Frank and
Betty Vandermeer, and Don and Debbie Hunkins.
NR 19
TC 8
Z9 9
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD SEP
PY 2013
VL 19
IS 9
BP 1403
EP 1406
DI 10.1016/j.bbmt.2013.07.005
PG 4
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 212WT
UT WOS:000324014200020
PM 23871782
ER
PT J
AU Pasinetti, GM
Bilski, AE
Zhao, W
AF Pasinetti, Giulio Maria
Bilski, Amanda E.
Zhao, Wei
TI Sirtuins as therapeutic targets of ALS
SO CELL RESEARCH
LA English
DT Editorial Material
ID AMYOTROPHIC-LATERAL-SCLEROSIS; SURVIVAL
C1 [Pasinetti, Giulio Maria; Bilski, Amanda E.; Zhao, Wei] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA.
[Pasinetti, Giulio Maria; Zhao, Wei] James J Peters Vet Affairs Med Ctr, GRECC, Bronx, NY USA.
RP Pasinetti, GM (reprint author), Mt Sinai Sch Med, Dept Neurol, 1468 Madison Ave,Annenberg Bldg,Room 20-02, New York, NY 10029 USA.
EM Giulio.Pasinetti@mssm.edu
NR 10
TC 5
Z9 5
U1 1
U2 10
PU INST BIOCHEMISTRY & CELL BIOLOGY
PI SHANGHAI
PA SIBS, CAS, 319 YUEYANG ROAD, SHANGHAI, 200031, PEOPLES R CHINA
SN 1001-0602
J9 CELL RES
JI Cell Res.
PD SEP
PY 2013
VL 23
IS 9
BP 1073
EP 1074
DI 10.1038/cr.2013.94
PG 2
WC Cell Biology
SC Cell Biology
GA 211SH
UT WOS:000323930200006
PM 23856645
ER
PT J
AU Huynh, AK
Kinsler, JJ
Cunningham, WE
Sayles, JN
AF Huynh, Alexis K.
Kinsler, Janni J.
Cunningham, William E.
Sayles, Jennifer N.
TI The role of mental health in mediating the relationship between social
support and optimal ART adherence
SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV
LA English
DT Article
DE HIV; AIDS; ART adherence; social support; mental health; mediation
analyses
ID ACTIVE ANTIRETROVIRAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; HIV-POSITIVE
MEN; MEDICATION ADHERENCE; DEPRESSION; WOMEN; INTERVENTION; ADULTS
AB Optimal adherence to antiretroviral therapy (ART) is essential for reducing mortality and morbidity in persons living with HIV/AIDS (PLWHA), as well as for reducing the risk of further HIV transmission. While studies have identified psychosocial factors such as lack of social support and poor mental health status as important barriers to optimal ART adherence, few studies have explored the potential of a mediation effect of psychosocial factors on the relationship between social support and optimal ART adherence. This paper assessed whether mental health status mediated the relationship between social support and optimal ART adherence among a cross-sectional sample of 202 persons living with HIV who were recruited from HIV clinical care sites and community-based organizations in Los Angeles County (LAC). Participants completed a survey that included social support items from the Medical Outcome Study: Social Support Survey (MOS-SSS) Instrument, mental health measures from the Medical Outcomes Study Short Form (SF-12), and ART adherence based on self-report. Among those currently taking ART, 61.7% reported having optimal adherence. Social support was significantly associated with a high score on the mental health status scale (AOR =2.90; 95% CI=1.14-5.78) and optimal ART adherence (AOR=1.81; 95% CI=1.81; 95% CI=1.18-2.79). When mental health status was introduced into the model, the association between social support and optimal ART adherence was no longer significant. Our findings suggest the HIV interventions targeting social support to improve ART adherence will likely be most successful if the support bolsters the mental health of the participants. Clearly, better understanding the relationships among social support, mental health, and ART adherence will be critical for development and implementation of future ART adherence interventions.
C1 [Huynh, Alexis K.; Cunningham, William E.; Sayles, Jennifer N.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA.
[Huynh, Alexis K.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Kinsler, Janni J.] Univ Calif Los Angeles, Dept Community Hlth Sci, Los Angeles, CA USA.
[Cunningham, William E.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA.
RP Kinsler, JJ (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA.
EM jkinsler@ucla.edu
FU NIA NIH HHS [P30 AG021684]; NIMH NIH HHS [K23 MH083535]; NIMHD NIH HHS
[P20 MD000182]
NR 17
TC 8
Z9 8
U1 0
U2 12
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 0954-0121
J9 AIDS CARE
JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv
PD SEP 1
PY 2013
VL 25
IS 9
BP 1179
EP 1184
DI 10.1080/09540121.2012.752787
PG 6
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychology, Multidisciplinary; Respiratory System; Social Sciences,
Biomedical
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychology; Respiratory System; Biomedical Social Sciences
GA 207VQ
UT WOS:000323633200016
PM 23320407
ER
PT J
AU Jonassaint, CR
Haywood, C
Korthuis, PT
Cooper, LA
Saha, S
Sharp, V
Cohn, J
Moore, RD
Beach, MC
AF Jonassaint, Charles R.
Haywood, Carlton, Jr.
Korthuis, Philip Todd
Cooper, Lisa A.
Saha, Somnath
Sharp, Victoria
Cohn, Jonathon
Moore, Richard D.
Beach, Mary Catherine
TI The impact of depressive symptoms on patient-provider communication in
HIV care
SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV
LA English
DT Article
DE depression; communication; quality of health care; patient satisfaction;
HIV
ID MEDICAL-CARE; PHYSICIAN; ADHERENCE; SATISFACTION; HEALTH; INDIVIDUALS;
PREDICTORS; INFECTION; VETERANS; OUTCOMES
AB Persons with HIV who develop depression have worse medical adherence and outcomes. Poor patient-provider communication may play a role in these outcomes. This cross-sectional study evaluated the influence of patient depression on the quality of patient-provider communication. Patient-provider visits (n=406) at four HIV care sites were audio-recorded and coded with the Roter Interaction Analysis System (RIAS). Negative binomial and linear regressions using generalized estimating equations tested the association of depressive symptoms, as measured by the Center for Epidemiology Studies Depression scale (CES-D), with RIAS measures and postvisit patient-rated quality of care and provider-reported regard for his or her patient. The patients, averaged 45 years of age (range =20-77), were predominately male (n=286, 68.5%), of black race (n=250, 60%), and on antiretroviral medications (n=334, 80%). Women had greater mean CES-D depression scores (12.0) than men (10.6; p=0.03). There were no age, race, or education differences in depression scores. Visits with patients reporting severe depressive symptoms compared to those reporting none/mild depressive symptoms were longer and speech speed was slower. Patients with severe depressive symptoms did more emotional rapport building but less social rapport building, and their providers did more data gathering/counseling (ps<0.05). In postvisit questionnaires, providers reported lower levels of positive regard for, and rated more negatively patients reporting more depressive symptoms (p<0.01). In turn, patients reporting more depressive symptoms felt less respected and were less likely to report that their provider knows them as a person than none/mild depressive symptoms patients (ps<0.05). Greater psychosocial needs of patients presenting with depressive symptoms and limited time/resources to address these needs may partially contribute to providers' negative attitudes regarding their patients with depressive symptoms. These negative attitudes may ultimately serve to adversely impact patient-provider communication and quality of HIV care.
C1 [Jonassaint, Charles R.; Cooper, Lisa A.; Moore, Richard D.; Beach, Mary Catherine] Johns Hopkins Univ, Div Gen Internal Med, Baltimore, MD 21218 USA.
[Haywood, Carlton, Jr.] Johns Hopkins Univ, Berman Inst Bioeth, Baltimore, MD USA.
[Haywood, Carlton, Jr.; Cooper, Lisa A.; Beach, Mary Catherine] Johns Hopkins Univ, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD USA.
[Korthuis, Philip Todd; Saha, Somnath] Oregon Hlth & Sci Univ, Dept Med, Gen Internal Med Sect, Portland VA Med Ctr, Portland, OR 97201 USA.
[Sharp, Victoria] St Lukes Roosevelt Hosp, Dept Med, New York, NY 10025 USA.
[Cohn, Jonathon] Wayne State Univ, Sch Med, Detroit, MI USA.
RP Jonassaint, CR (reprint author), Johns Hopkins Univ, Div Gen Internal Med, Baltimore, MD 21218 USA.
EM charles.jonassaint@jhmi.edu
RI Jonassaint, Charles/I-2772-2014
OI Jonassaint, Charles/0000-0002-5662-5806; Haywood Jr.,
Carlton/0000-0002-3574-7871
FU NHLBI NIH HHS [K24 HL083113]; NIAAA NIH HHS [R01 AA016893, R21
AA015032]; NIAID NIH HHS [P30 AI094189, U01 AI069918]; NIDA NIH HHS [R01
DA011602]; PHS HHS [AHRQ 290-01-0012]
NR 32
TC 1
Z9 1
U1 4
U2 5
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 0954-0121
J9 AIDS CARE
JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv
PD SEP 1
PY 2013
VL 25
IS 9
BP 1185
EP 1192
DI 10.1080/09540121.2012.752788
PG 8
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychology, Multidisciplinary; Respiratory System; Social Sciences,
Biomedical
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychology; Respiratory System; Biomedical Social Sciences
GA 207VQ
UT WOS:000323633200017
PM 23320529
ER
PT J
AU Froehlich, JC
Hausauer, BJ
Federoff, DL
Fischer, SM
Rasmussen, DD
AF Froehlich, Janice C.
Hausauer, Brett J.
Federoff, David L.
Fischer, Stephen M.
Rasmussen, Dennis D.
TI Prazosin Reduces Alcohol Drinking Throughout Prolonged Treatment and
Blocks the Initiation of Drinking in Rats Selectively Bred for High
Alcohol Intake
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
DE Prazosin; Alcohol; Alcohol-Preferring (P) Rats; Noradrenergic System;
Alcohol Relapse; Alcoholism Pharmacotherapies
ID ALPHA(1)-ADRENERGIC RECEPTOR ANTAGONIST; PREFERRING P RATS; ANXIETY
DISORDERS; BLOOD-PRESSURE; ETHANOL; STRESS; DEPENDENCE; NEOPHOBIA;
BRAIN; RENIN
AB Background This study examined whether prazosin reduces alcohol drinking over the course of prolonged treatment and whether it blocks the initiation of alcohol drinking in rats with a genetic predisposition toward high alcohol drinking, that is alcohol-preferring (P) rats.
Methods In study one, alcohol-experienced P rats that had been drinking alcohol for 2 h/d for several months were treated daily with prazosin (0, 0.5, 1.0, or 2.0mg/kg body weight [BW]) for 7weeks. In study two, alcohol-naive P rats were treated daily with prazosin (0, 1.0, or 2.0mg/kg BW) for 2weeks prior to, or concomitantly with, the initiation of alcohol access and throughout 3weeks of alcohol availability. Prazosin treatment and alcohol access were then discontinued for 2weeks followed by reinstatement of alcohol access without prazosin treatment for 4weeks, followed by resumption of daily prazosin treatment (2.0mg/kg BW) for 3weeks.
Results Prazosin reduced alcohol drinking throughout 7weeks of treatment in P rats accustomed to drinking alcohol. Following termination of prazosin treatment, alcohol drinking slowly returned to pretreatment baseline. Reduced alcohol intake was accompanied by increased water intake. In alcohol-naive P rats, prazosin administration prior to the first opportunity to drink alcohol and throughout 3weeks of alcohol access retarded acquisition of alcohol drinking and reduced the amount of alcohol consumed. When prazosin was administered concomitantly with the first opportunity to drink alcohol, it abolished acquisition of alcohol drinking. Discontinuation of prazosin treatment allowed expression of a genetic predisposition toward high alcohol drinking to gradually emerge. Prazosin retained the ability to reduce alcohol intake with repeated treatments.
Conclusions Prazosin decreased alcohol drinking during prolonged treatment and may be useful for treating alcoholism and alcohol-use disorders. Prazosin may also be useful for deterring the initiation of drinking in individuals with a family history of alcoholism.
C1 [Froehlich, Janice C.; Hausauer, Brett J.; Federoff, David L.; Fischer, Stephen M.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA.
[Rasmussen, Dennis D.] VA Puget Sound Hlth Care Syst, VISN Mental Illness Res Educ & Clin Ctr 20, Seattle, WA USA.
Univ Washington, Seattle, WA 98195 USA.
RP Froehlich, JC (reprint author), Indiana Univ Sch Med, 975 West Walnut St IB 448, Indianapolis, IN 46202 USA.
EM jcfroehl@iupui.edu
FU NIH [AA018604, AA07611, AA13881]
FX We thank Dr. Ting-Kai Li and the Indiana Alcohol Research Center for
supplying the selectively bred rats used in this study. This work was
supported by NIH grants AA018604 (JCF and DDR), AA07611 (JCF), and
AA13881 (DDR). The content is solely the responsibility of the authors
and does not necessarily represent the official views of the National
Institute on Alcohol Abuse and Alcoholism or the National Institutes of
Health.
NR 56
TC 16
Z9 16
U1 0
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD SEP
PY 2013
VL 37
IS 9
BP 1552
EP 1560
DI 10.1111/acer.12116
PG 9
WC Substance Abuse
SC Substance Abuse
GA 208KE
UT WOS:000323676600014
PM 23731093
ER
PT J
AU Saliminejad, M
Bemanian, S
Ho, A
Spiegel, B
Laine, L
AF Saliminejad, M.
Bemanian, S.
Ho, A.
Spiegel, B.
Laine, L.
TI The yield and cost of colonoscopy in patients with metastatic cancer of
unknown primary
SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS
LA English
DT Article
ID PRIMARY TUMORS; PRIMARY SITE; CARCINOMA; EPIDEMIOLOGY; PROFILE
AB Background Although gastroenterologists are asked to perform colonoscopy in patients with metastatic cancer of unknown primary (MCUP), studies evaluating this practice are lacking.
Aim To determine the yield and cost of colonoscopy in patients referred for colonoscopy with an indication of MCUP.
Methods We prospectively and retrospectively assessed colonoscopies performed from 2000 to 2011 at a county, a university, and a Veterans Administration medical centre to identify patients referred for colonoscopy for the indication of MCUP. Exclusion criteria included overt or occult bleeding, iron-deficiency anaemia, familial-colon-cancer syndrome, prior colon cancer, imaging suggesting colorectal lesion, and palpable rectal mass. Outcomes were the number of primary colon cancers and costs based on 2012 Medicare reimbursements.
Results Two (1%) of the 160 patients meeting enrollment criteria had a primary colon cancer identified, and both died within 1month after diagnosis without receiving therapy targeted at colon cancer. One patient without colon cancer had a perforation because of colonoscopy, which required surgery and colostomy. The cost of a strategy of routinely performing colonoscopy in patients referred with MCUP was $84736 per colon primary identified.
Conclusions Primary colon cancer was rarely identified at colonoscopy in patients with MCUP and no standard indications for diagnostic colonoscopy. Furthermore, the cost to diagnose one additional colon primary was very high. Those with colon cancer had advanced disease and were unable to benefit from targeted therapy. Routine colonoscopy for MCUP cannot be recommended at present.
C1 [Saliminejad, M.; Bemanian, S.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
[Ho, A.; Spiegel, B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Ho, A.; Spiegel, B.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Laine, L.] Yale Univ, Sch Med, New Haven, CT 06520 USA.
[Laine, L.] VA Connecticut Healthcare Syst, West Haven, CT USA.
RP Laine, L (reprint author), Yale Univ, Sect Digest Dis, Sch Med, POB 208019, New Haven, CT 06520 USA.
EM loren.laine@yale.edu
NR 15
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0269-2813
J9 ALIMENT PHARM THER
JI Aliment. Pharmacol. Ther.
PD SEP
PY 2013
VL 38
IS 6
BP 628
EP 633
DI 10.1111/apt.12429
PG 6
WC Gastroenterology & Hepatology; Pharmacology & Pharmacy
SC Gastroenterology & Hepatology; Pharmacology & Pharmacy
GA 204OC
UT WOS:000323375800008
PM 23869398
ER
PT J
AU Sabodash, V
Mendez, MF
Fong, S
Hsiao, JJ
AF Sabodash, Valeriy
Mendez, Mario F.
Fong, Sylvia
Hsiao, Julia J.
TI Suicidal Behavior in Dementia: A Special Risk in Semantic Dementia
SO AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS
LA English
DT Article
DE dementia; semantic dementia; Alzheimer's disease; suicide; suicidal;
depression; primary progressive aphasia
ID ALZHEIMERS-DISEASE; FRONTOTEMPORAL DEMENTIA; DEGENERATION; DYSFUNCTION;
CONSENSUS; IDEATION; FEATURES; PEOPLE; MILD; LIFE
AB Background:
Some studies report a low suicide risk in general dementia and in Alzheimer's disease (AD).
Objective:
To evaluate suicidal behavior among patients with semantic dementia (SD), a disorder that impairs semantic knowledge.
Methods:
We reviewed the presence of active suicidal behavior and related factors among 25 patients with SD compared to 111 age-matched patients with early-onset AD.
Results:
In all, 5 (20%) patients with SD had suicidal behavior (2 successfully killed themselves) compared to 1 (0.9%) with AD (P < .001). There was significantly more depression and greater premorbid history of suicidal behavior among the patients with SD compared to those with AD. Among the patients with SD, those with suicidal behavior, compared to those without, had more depression and greater insight into their deficits.
Conclusions:
Patients with SD are at special risk of committing suicide, particularly if they have depression and preserved insight. Possible mechanisms include an impaired sense of semantic competence with increased impulsivity.
C1 [Sabodash, Valeriy; Mendez, Mario F.; Hsiao, Julia J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
[Sabodash, Valeriy; Mendez, Mario F.; Fong, Sylvia; Hsiao, Julia J.] VA Greater Los Angeles Healthcare Ctr, Neurobehav Unit 691 116AF, Los Angeles, CA 90073 USA.
[Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
RP Sabodash, V (reprint author), VA Greater Los Angeles Healthcare Ctr, Neurobehav Unit 691 116AF, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM mmendez@UCLA.edu
FU National Institute on Aging [R01 AG034499]
FX The authors disclosed receipt of the following financial support for the
research, authorship, and/or publication of this article: National
Institute on Aging R01 AG034499 (MFM).
NR 38
TC 7
Z9 8
U1 3
U2 20
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1533-3175
J9 AM J ALZHEIMERS DIS
JI Am. J. Alzheimers Dis. Other Dement.
PD SEP
PY 2013
VL 28
IS 6
BP 592
EP 599
DI 10.1177/1533317513494447
PG 8
WC Geriatrics & Gerontology; Clinical Neurology
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 207YS
UT WOS:000323641500007
PM 23821774
ER
PT J
AU Sher, L
AF Sher, Leo
TI Psychological autopsy studies: Past, present, and future
SO AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY
LA English
DT Letter
ID SUICIDE
C1 [Sher, Leo] James J Peters Vet Adm Med Ctr, Bronx, NY 10468 USA.
[Sher, Leo] Mt Sinai Sch Med, New York, NY USA.
RP Sher, L (reprint author), James J Peters Vet Adm Med Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA.
EM Leo.Sher@mssm.edu
NR 5
TC 4
Z9 4
U1 1
U2 11
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0004-8674
J9 AUST NZ J PSYCHIAT
JI Aust. N. Z. J. Psych.
PD SEP
PY 2013
VL 47
IS 9
BP 884
EP 884
DI 10.1177/0004867413479071
PG 1
WC Psychiatry
SC Psychiatry
GA 208GS
UT WOS:000323666500021
PM 23411093
ER
PT J
AU Turner, EH
AF Turner, Erick H.
TI Author's Reply to Shrier: "Publication Bias, With a Focus on Psychiatry:
Causes and Solutions"
SO CNS DRUGS
LA English
DT Letter
ID TRIALS; PROTOCOLS; OUTCOMES
C1 [Turner, Erick H.] Behav Hlth & Neurosci Div, Portland, ME USA.
[Turner, Erick H.] Portland VA Med Ctr, Portland, OR 97239 USA.
[Turner, Erick H.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA.
[Turner, Erick H.] Oregon Hlth & Sci Univ, Dept Pharmacol, Portland, OR 97201 USA.
[Turner, Erick H.] Oregon Hlth & Sci Univ, Ctr Eth Hlth Care, Portland, OR 97201 USA.
RP Turner, EH (reprint author), Behav Hlth & Neurosci Div, Portland, ME USA.
EM turnere@ohsu.edu
RI Turner, Erick/A-4848-2008
OI Turner, Erick/0000-0002-3522-3357
NR 7
TC 0
Z9 0
U1 0
U2 2
PU ADIS INT LTD
PI AUCKLAND
PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW
ZEALAND
SN 1172-7047
J9 CNS DRUGS
JI CNS Drugs
PD SEP
PY 2013
VL 27
IS 9
BP 775
EP 776
DI 10.1007/s40263-013-0099-1
PG 2
WC Clinical Neurology; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 207RJ
UT WOS:000323620900009
PM 23907702
ER
PT J
AU Sosenko, JM
Skyler, JS
Palmer, JP
Krischer, JP
Yu, LP
Mahon, J
Beam, CA
Boulware, DC
Rafkin, L
Schatz, D
Eisenbarth, G
AF Sosenko, Jay M.
Skyler, Jay S.
Palmer, Jerry P.
Krischer, Jeffrey P.
Yu, Liping
Mahon, Jeffrey
Beam, Craig A.
Boulware, David C.
Rafkin, Lisa
Schatz, Desmond
Eisenbarth, George
CA Type 1 Diabetes TrialNet Grp
Diabet Prevention Trial-Type 1 Stu
TI The Prediction of Type 1 Diabetes by Multiple Autoantibody Levels and
Their Incorporation Into an Autoantibody Risk Score in Relatives of Type
1 Diabetic Patients
SO DIABETES CARE
LA English
DT Article
ID ANTIBODY-POSITIVE RELATIVES; PREVENTION TRIAL-TYPE-1; 1ST-DEGREE
RELATIVES; METABOLIC MARKERS; GLUCOSE-TOLERANCE; INSULIN-SECRETION;
NATURAL-HISTORY; CHILDREN; MELLITUS; VALIDATION
AB OBJECTIVE We assessed whether a risk score that incorporates levels of multiple islet autoantibodies could enhance the prediction of type 1 diabetes (T1D).RESEARCH DESIGN AND METHODS TrialNet Natural History Study participants (n = 784) were tested for three autoantibodies (GADA, IA-2A, and mIAA) at their initial screening. Samples from those positive for at least one autoantibody were subsequently tested for ICA and ZnT8A. An autoantibody risk score (ABRS) was developed from a proportional hazards model that combined autoantibody levels from each autoantibody along with their designations of positivity and negativity.RESULTS The ABRS was strongly predictive of T1D (hazard ratio [with 95% CI] 2.72 [2.23-3.31], P < 0.001). Receiver operating characteristic curve areas (with 95% CI) for the ABRS revealed good predictability (0.84 [0.78-0.90] at 2 years, 0.81 [0.74-0.89] at 3 years, P < 0.001 for both). The composite of levels from the five autoantibodies was predictive of T1D before and after an adjustment for the positivity or negativity of autoantibodies (P < 0.001). The findings were almost identical when ICA was excluded from the risk score model. The combination of the ABRS and the previously validated Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) predicted T1D more accurately (0.93 [0.88-0.98] at 2 years, 0.91 [0.83-0.99] at 3 years) than either the DPTRS or the ABRS alone (P 0.01 for all comparisons).CONCLUSIONS These findings show the importance of considering autoantibody levels in assessing the risk of T1D. Moreover, levels of multiple autoantibodies can be incorporated into an ABRS that accurately predicts T1D.
C1 [Sosenko, Jay M.; Skyler, Jay S.; Rafkin, Lisa] Univ Miami, Div Endocrinol, Miami, FL 33152 USA.
[Palmer, Jerry P.] Univ Washington, Div Endocrinol Metab & Nutr, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
[Krischer, Jeffrey P.; Beam, Craig A.; Boulware, David C.] Univ S Florida, Div Informat & Biostat, Tampa, FL USA.
[Yu, Liping; Eisenbarth, George] Univ Colorado, Hlth Sci Ctr, Barbara Davis Ctr Childhood Diabet, HLA DNA Lab, Denver, CO 80262 USA.
[Mahon, Jeffrey] Univ Western Ontario, Dept Epidemiol & Biostat, London, ON, Canada.
[Schatz, Desmond] Univ Florida, Div Endocrinol, Gainesville, FL USA.
RP Sosenko, JM (reprint author), Univ Miami, Div Endocrinol, Miami, FL 33152 USA.
EM jsosenko@med.miami.edu
RI Moore, Daniel/A-4924-2008; Skyler, Jay/F-4211-2016
OI Moore, Daniel/0000-0002-6889-9345;
FU National Institutes of Health (NIH) through the National Institute of
Diabetes and Digestive and Kidney Diseases; National Institute of
Allergy and Infectious Diseases; Eunice Kennedy Shriver National
Institute of Child Health and Human Development [U01-DK-061010,
U01-DK-061016, U01-DK-061034, U01-DK-061036, U01-DK-061040,
U01-DK-061041, U01-DK-061042, U01-DK-061055, U01-DK-061058,
U01-DK-084565, U01-DK-085453, U01-DK-085461, U01-DK-085463,
U01-DK-085466, U01-DK-085499, U01-DK-085505, U01-DK-085509,
HHSN267200800019C]; National Center for Research Resources through
Clinical Translational Science Awards [UL1-RR-024131, UL1-RR-024139,
UL1-RR-024153, UL1-RR-024975, UL1-RR-024982, UL1-RR-025744,
UL1-RR-025761, UL1-RR-025780, UL1-RR-029890, UL1-RR-031986,
P30-DK-017047]; General Clinical Research Center Award [M01-RR-00400];
JDRF; American Diabetes Association (ADA)
FX The sponsor of the trial was the Type 1 Diabetes TrialNet Study Group.
The Type 1 Diabetes TrialNet Study Group is a clinical trials network
funded by the National Institutes of Health (NIH) through the National
Institute of Diabetes and Digestive and Kidney Diseases, the National
Institute of Allergy and Infectious Diseases, and the Eunice Kennedy
Shriver National Institute of Child Health and Human Development through
cooperative agreements U01-DK-061010, U01-DK-061016, U01-DK-061034,
U01-DK-061036, U01-DK-061040, U01-DK-061041, U01-DK-061042,
U01-DK-061055, U01-DK-061058, U01-DK-084565, U01-DK-085453,
U01-DK-085461, U01-DK-085463, U01-DK-085466, U01-DK-085499,
U01-DK-085505, and U01-DK-085509 and contract HHSN267200800019C; the
National Center for Research Resources through Clinical Translational
Science Awards UL1-RR-024131, UL1-RR-024139, UL1-RR-024153,
UL1-RR-024975, UL1-RR-024982, UL1-RR-025744, UL1-RR-025761,
UL1-RR-025780, UL1-RR-029890, UL1-RR-031986, and P30-DK-017047 and
General Clinical Research Center Award M01-RR-00400; the JDRF; and the
American Diabetes Association (ADA).
NR 30
TC 38
Z9 38
U1 4
U2 41
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
J9 DIABETES CARE
JI Diabetes Care
PD SEP
PY 2013
VL 36
IS 9
BP 2615
EP 2620
DI 10.2337/dc13-0425
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 205CZ
UT WOS:000323420200048
PM 23818528
ER
PT J
AU Meek, TH
Matsen, ME
Dorfman, MD
Guyenet, SJ
Damian, V
Nguyen, HT
Taborsky, GJ
Morton, GJ
AF Meek, Thomas H.
Matsen, Miles E.
Dorfman, Mauricio D.
Guyenet, Stephan J.
Damian, Vincent
Nguyen, Hong T.
Taborsky, Gerald J., Jr.
Morton, Gregory J.
TI Leptin Action in the Ventromedial Hypothalamic Nucleus Is Sufficient,
But Not Necessary, to Normalize Diabetic Hyperglycemia
SO ENDOCRINOLOGY
LA English
DT Article
ID GLUCOSE-UPTAKE; CARDIOVASCULAR ACTIONS; PERIPHERAL-TISSUES; WEIGHT
HOMEOSTASIS; INSULIN-RESISTANCE; NERVOUS-SYSTEM; FOOD-INTAKE; RATS;
NEURONS; CNS
AB In rodent models of type 1 diabetes, leptin administration into brain ventricles normalizes blood glucose at doses that have no effect when given peripherally. The ventromedial nucleus of the hypothalamus (VMN) is a potential target for leptin's antidiabetic effects because leptin-sensitive neurons in this brain area are implicated in glucose homeostasis. To test this hypothesis, we injected leptin directly into the bilateral VMN of rats with streptozotocin-induced uncontrolled diabetes mellitus. This intervention completely normalized both hyperglycemia and the elevated rates of hepatic glucose production and plasma glucagon levels but had no effect on tissue glucose uptake in the skeletal muscle or brown adipose tissue as measured using tracer dilution techniques during a basal clamp. To determine whether VMN leptin signaling is required for leptin-mediated normalization of diabetic hyperglycemia, we studied mice in which the leptin receptor gene was deleted in VMN steroidogenic factor 1 neurons using cre-loxP technology. Our findings indicate leptin action within these neurons is not required for the correction of diabetic hyperglycemia by central leptin infusion. We conclude that leptin signaling in the VMN is sufficient to mediate leptin's antidiabetic action but may not be necessary for this effect. Leptin action within a distributed neuronal network may mediate its effects on glucose homeostasis.
C1 [Meek, Thomas H.; Matsen, Miles E.; Dorfman, Mauricio D.; Guyenet, Stephan J.; Damian, Vincent; Nguyen, Hong T.; Morton, Gregory J.] Univ Washington, Diabet & Obes Ctr Excellence, Dept Med, Seattle, WA 98109 USA.
[Taborsky, Gerald J., Jr.] Vet Affairs Puget Sound Hlth Care Syst, Dept Vet Affairs Med Ctr, Seattle, WA 98108 USA.
RP Morton, GJ (reprint author), Univ Washington South Lake Union, Dept Med, 850 Republican St,N334,Box 358055, Seattle, WA 98195 USA.
EM gjmorton@u.washington.edu
FU Novo Nordisk Proof-of-Principle Award; National Institutes of Health
[DK089053, DK050154]; Nutrition Obesity Research Center [DK035816];
Diabetes and Metabolism Training Grants [F32 DK097859, T32 DK0007247]
FX This work was supported by a Novo Nordisk Proof-of-Principle Award (to
G.J.M.), National Institutes of Health Grants DK089053 (to G.J.M.), and
DK050154 (to G.J.T.), the Nutrition Obesity Research Center Grant
DK035816, and the Diabetes and Metabolism Training Grants F32 DK097859
and T32 DK0007247.
NR 33
TC 14
Z9 14
U1 0
U2 2
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0013-7227
J9 ENDOCRINOLOGY
JI Endocrinology
PD SEP
PY 2013
VL 154
IS 9
BP 3067
EP 3076
DI 10.1210/en.2013-1328
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 207RE
UT WOS:000323620100012
PM 23782941
ER
PT J
AU Garcia, JM
Scherer, T
Chen, JA
Guillory, B
Nassif, A
Papusha, V
Smiechowska, J
Asnicar, M
Buettner, C
Smith, RG
AF Garcia, Jose M.
Scherer, Thomas
Chen, Ji-an
Guillory, Bobby
Nassif, Anriada
Papusha, Victor
Smiechowska, Joanna
Asnicar, Mark
Buettner, Christoph
Smith, Roy G.
TI Inhibition of Cisplatin-Induced Lipid Catabolism and Weight Loss by
Ghrelin in Male Mice
SO ENDOCRINOLOGY
LA English
DT Article
ID HORMONE-SENSITIVE LIPASE; FATTY-ACID OXIDATION; SKELETAL-MUSCLE;
ADIPOSE-TISSUE; CANCER CACHEXIA; METABOLISM; LIPOLYSIS; ANOREXIA; RATS;
IDENTIFICATION
AB Cachexia, defined as an involuntary weight loss >= 5%, is a serious and dose-limiting side effect of chemotherapy that decreases survival in cancer patients. Alterations in lipid metabolism are thought to cause the lipodystrophy commonly associated with cachexia. Ghrelin has been proposed to ameliorate the alterations in lipid metabolism due to its orexigenic and anabolic properties. However, the mechanisms of action through which ghrelin could potentially ameliorate chemotherapy-associated cachexia have not been elucidated. The objectives of this study were to identify mechanisms by which the chemotherapeutic agent cisplatin alters lipid metabolism and to establish the role of ghrelin in reversing cachexia. Cisplatin-induced weight and fat loss were prevented by ghrelin. Cisplatin increased markers of lipolysis in white adipose tissue (WAT) and of beta-oxidation in liver and WAT and suppressed lipogenesis in liver, WAT, and muscle. Ghrelin prevented the imbalance between lipolysis, beta-oxidation, and lipogenesis in WAT and muscle. Pair-feeding experiments demonstrated that the effects of cisplatin and ghrelin on lipogenesis, but not on lipolysis and beta-oxidation, were due to a reduction in food intake. Thus, ghrelin prevents cisplatin-induced weight and fat loss by restoring adipose tissue functionality. An increase in caloric intake further enhances the anabolic effects of ghrelin.
C1 [Garcia, Jose M.; Chen, Ji-an; Guillory, Bobby; Papusha, Victor; Smiechowska, Joanna] Baylor Coll Med, Dept Med & Mol & Cell Biol, Ctr Translat Res Inflammatory Dis, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Garcia, Jose M.; Papusha, Victor; Smiechowska, Joanna; Asnicar, Mark; Smith, Roy G.] Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA.
[Scherer, Thomas; Buettner, Christoph] Mt Sinai Sch Med, Dept Med & Neurosci, New York, NY 10029 USA.
[Nassif, Anriada] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15261 USA.
RP Garcia, JM (reprint author), Michael E DeBakey VA Med Ctr, Div Endocrinol Diabet & Metab, 2002 Holcombe Blvd,Bldg 109,Room 210, Houston, TX 77584 USA.
EM jgarcia1@bcm.edu
FU US Department of Veterans Affairs (MERIT) [I01-BX000507, I01 CX000174];
US Department of Veterans Affairs (MREP); US Department of Veterans
Affairs (SHCNCDA); Caroline Wiess Law Fund for Molecular Medicine; NIH
[AG040583, T32AG000183, DK083658, DK082724, DK059637, DK020593]; Irma T.
Hirschl Scholar Award; University of Virginia [DK076037]; Baylor
Diabetes and Endocrinology Research Center [P30 DK079638]; University of
Pittsburgh School of Medicine Dean's Summer Research Program [DK
065521]; [U24 DK59637]
FX This work was supported by the US Department of Veterans Affairs (MERIT
grants I01-BX000507 and I01 CX000174, MREP, and a SHCNCDA); the Caroline
Wiess Law Fund for Molecular Medicine (to J.M.G.) and NIH Grants
AG040583 (to J.M.G.), T32AG000183 (to J.M.G. and B. G.), and DK083658
and DK082724 (to C. B.) C. B. is the recipient of an Irma T. Hirschl
Scholar Award. The Vanderbilt MMPC was supported in part by U24 DK59637;
Vanderbilt University Medical Center Hormone Assay and Analytical
Services Core was supported by NIH Grants DK059637 and DK020593;
University of Virginia and Baylor Diabetes and Endocrinology Research
Center received grants (DK076037 and P30 DK079638, respectively). A.N.
received support from the University of Pittsburgh School of Medicine
Dean's Summer Research Program T35 Grant DK 065521.
NR 41
TC 20
Z9 20
U1 0
U2 12
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0013-7227
J9 ENDOCRINOLOGY
JI Endocrinology
PD SEP
PY 2013
VL 154
IS 9
BP 3118
EP 3129
DI 10.1210/en.2013-1179
PG 12
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 207RE
UT WOS:000323620100017
PM 23832960
ER
PT J
AU Dyer, CA
AF Dyer, Christopher A.
TI Safety and tolerability of paricalcitol in patients with chronic kidney
disease
SO EXPERT OPINION ON DRUG SAFETY
LA English
DT Review
DE chronic kidney disease; hyperparathyroidism; paricalcitol; proteinuria;
vitamin D
ID RANDOMIZED CONTROLLED-TRIAL; DOSE VITAMIN-D; PATIENTS RECEIVING
HEMODIALYSIS; SECONDARY HYPERPARATHYROIDISM; PARATHYROID-HORMONE;
RENAL-FAILURE; CARDIOVASCULAR-DISEASE; DIALYSIS PATIENTS;
19-NOR-1-ALPHA,25-DIHYDROXYVITAMIN D-2; ORAL PARICALCITOL
AB Introduction: Secondary hyperparathyroidism (SHPT) is a complication of chronic kidney disease (CKD). Beyond skeletal complications, uncontrolled SHPT is associated with cardiovascular mortality. Vitamin D receptor activators (VDRAs) are a mainstay of therapy for SHPT; however, use is limited by hypercalcemia, though less so with calcitriol analogs such as paricalcitol and there is emerging experience with oral formulations for non-SHPT indications. The role of VDRAs in the treatment of SHPT becomes a complex question as alternative strategies have developed.
Areas covered: This review summarizes trials that established the safety and efficacy of paricalcitol for SHPT. Comparative experience with paricalcitol as against other VDRAs will be reviewed as will the experience with paricalcitol in non-dialysis CKD and comparative experience with non-VDRA-based therapy.
Expert opinion: VDRA therapy is considered first-line therapy for treatment of SHPT. Paricalcitol has demonstrated superiority to calcitriol with respect to parathyroid hormone suppression and calcium-phosphorus balance. Oral formulations of paricalcitol appear to be similarly effective for SHPT. While there is evidence to suggest adjunctive antiproteinuria benefit with the use of VDRAs, efficacy of these agents to slow the progression of CKD or to reduce cardiovascular risk has not yet been demonstrated.
C1 Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
RP Dyer, CA (reprint author), Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, 7703 Floyd Curl Dr,MC 7882, San Antonio, TX 78229 USA.
EM DyerCA@uthscsa.edu
NR 56
TC 4
Z9 4
U1 0
U2 7
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1474-0338
J9 EXPERT OPIN DRUG SAF
JI Expert Opin. Drug Saf.
PD SEP
PY 2013
VL 12
IS 5
BP 717
EP 728
DI 10.1517/14740338.2013.791675
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 206AW
UT WOS:000323488900012
PM 23621417
ER
PT J
AU Husain, N
Chen, TC
Hou, JK
AF Husain, Nisreen
Chen, Tien-Chun
Hou, Jason K.
TI An Unusual Cause of Diarrhea in an Immunocompromised Patient
Scedosporium apiospermum Colitis and Brain Abscess
SO GASTROENTEROLOGY
LA English
DT Editorial Material
C1 [Husain, Nisreen; Chen, Tien-Chun; Hou, Jason K.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Husain, Nisreen; Hou, Jason K.] Baylor Coll Med, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA.
[Chen, Tien-Chun] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
RP Husain, N (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
NR 3
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD SEP
PY 2013
VL 145
IS 3
BP 519
EP +
DI 10.1053/j.gastro.2013.06.006
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 207PG
UT WOS:000323613700017
PM 23896373
ER
PT J
AU Ather, S
Bavishi, C
McCauley, MD
Dhaliwal, A
Deswal, A
Johnson, S
Chan, W
Aguilar, D
Pritchett, AM
Ramasubbu, K
Wehrens, XHT
Bozkurt, B
AF Ather, Sameer
Bavishi, Chirag
McCauley, Mark D.
Dhaliwal, Amandeep
Deswal, Anita
Johnson, Sarah
Chan, Wenyaw
Aguilar, David
Pritchett, Allison M.
Ramasubbu, Kumudha
Wehrens, Xander H. T.
Bozkurt, Biykem
TI Worsening renal function is not associated with response to treatment in
acute heart failure
SO INTERNATIONAL JOURNAL OF CARDIOLOGY
LA English
DT Article
DE BNP; Renal function; Heart failure
ID BRAIN NATRIURETIC PEPTIDE; SERUM CREATININE; CARDIORENAL INTERACTIONS;
HOSPITALIZED-PATIENTS; OUTCOMES; IMPACT; ADMISSION
AB Background: About a fourth of acute decompensated heart failure (ADHF) patients develop renal dysfunction during their admission. To date, the association of ADHF treatment with the development of worsening renal function (WRF) remains contentious. Thus, we examined the association of WRF with changes in BNP levels and with mortality.
Methods: We performed retrospective chart review of patients admitted with ADHF who had BNP, eGFR, creatinine and blood urea nitrogen (BUN) values measured both on admission and discharge. Survival analysis was conducted using Cox proportional hazards model and correlation was measured using Spearman's rank correlation test.
Results: 358 patients admitted for ADHF were evaluated. WRF was defined as >20% reduction in eGFR from admission to discharge and response to treatment was assessed by Delta BNP. There was a statistically significant reduction in BNP and increase in BUN during the admission. Delta BNP did not correlate with either Delta GFR or Delta BUN. Patients who developed WRF and those who did not, had a similar reduction in BNP. On univariate survival analysis, Delta BUN, but not Delta eGFR, was associated with 1-year mortality. In multivariate Cox proportional hazards model, BUN at discharge was associated with 1-year mortality (HR: 1.02, p<0.001), but Delta eGFR and Delta BUN were not associated with the primary endpoint.
Conclusion: During ADHF treatment, Delta BNP was not associated with changes in renal function. Development of WRF during ADHF treatment was not associated with mortality. Our study suggests that development of WRF should not preclude diuresis in ADHF patients in the absence of volume depletion. (C) 2012 Published by Elsevier Ireland Ltd.
C1 [Ather, Sameer; McCauley, Mark D.; Deswal, Anita; Aguilar, David; Pritchett, Allison M.; Ramasubbu, Kumudha; Wehrens, Xander H. T.; Bozkurt, Biykem] Baylor Coll Med, Dept Med, Cardiol Sect, Houston, TX 77030 USA.
[Bavishi, Chirag; Chan, Wenyaw] Univ Texas Houston, Sch Publ Hlth, Houston, TX USA.
[Dhaliwal, Amandeep] Univ Iowa, Dept Med, Cardiol Sect, Iowa City, IA 52242 USA.
[Deswal, Anita; Johnson, Sarah; Bozkurt, Biykem] Baylor Coll Med, DeBakey VA Med Ctr, Winters Ctr Heart Failure Res, Houston, TX 77030 USA.
RP Bozkurt, B (reprint author), Michael E DeBakey VA Med Ctr, Div Cardiol, Winters Ctr Heart Failure, 3C-310 F,2002 Holcombe Blvd, Houston, TX 77030 USA.
EM bbozkurt@bcm.edu
OI ather, sameer/0000-0002-5579-0658
FU American Heart Association SCA predoctoral fellowship; Alkek foundation
fellowship
FX S.A. is supported by American Heart Association SCA predoctoral
fellowship (2010-2012) and Alkek foundation fellowship (2009-2012).
NR 22
TC 8
Z9 8
U1 0
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0167-5273
J9 INT J CARDIOL
JI Int. J. Cardiol.
PD SEP 1
PY 2013
VL 167
IS 5
BP 1912
EP 1917
DI 10.1016/j.ijcard.2012.05.004
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 207AU
UT WOS:000323569600048
PM 22633437
ER
PT J
AU Harbaugh, MP
Manuck, SB
Jennings, JR
Conklin, SM
Yao, JK
Muldoon, MF
AF Harbaugh, Matthew P.
Manuck, Stephen B.
Jennings, J. Richard
Conklin, Sarah M.
Yao, Jeffrey K.
Muldoon, Matthew F.
TI Long-chain, n-3 fatty acids and physical activity - Independent and
interactive associations with cardiac autonomic control
SO INTERNATIONAL JOURNAL OF CARDIOLOGY
LA English
DT Article
DE n-3 fatty acids; Exercise; HRV
ID HEART-RATE-VARIABILITY; MYOCARDIAL-INFARCTION; FISH-OIL;
HEALTHY-VOLUNTEERS; COLLEGE ALUMNI; EXERCISE; BLOOD; MORTALITY; RISK;
OMEGA-3-FATTY-ACIDS
AB Background/objectives: Intake of the marine-based, n-3 fatty acids and engagement in physical activity are inversely related to cardiac morbidity and mortality. Among putative mechanisms, both n-3 fatty acids and physical activity may act through modulation of autonomic control of the cardiovascular system. This investigation examined the independent and interactive associations of n-3 fatty acids (eicosapentaenoic and docosahexanenoic acid; EPA, DHA) and physical activity with heart rate variability (HRV).
Methods: Subjects were 259 healthy 30-54 year-old adults. Serum phospholipid fatty acid composition was employed as a biomarker of dietary n-3 fatty acid exposure. Physical activity based on the Paffenbarger questionnaire was coded as < or >= 2000 kcal/week. Standard time-domain (standard deviation of normal-to-normal intervals and root-mean squared of successive differences; SDNN, RMSSD) and frequency domain (high frequency and low frequency power) measures of HRV were derived from resting electrocardiographic recordings.
Results: In linear regression models with covariate adjustment for age, gender and race, greater n-3 fatty acid exposure was associated with greater SDNN and RMSSD, and high physical activity was associated with greater RMSSD. n-3 fatty acid exposure also predicted variation in SDNN, RMSSD, and high-frequency power in interaction with physical activity. Specifically, n-3 fatty acid exposure covaried positively with these three HRV indices only among participants expending 2000 kcal per week or more in physical activity. These latter findings were noted for DHA but not EPA.
Conclusions: These results suggest that the cardiovascular benefits of n-3 fatty acid consumption may be mediated, in part, by effects on cardiac autonomic control and may be dependent upon concomitant habitual exercise. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Harbaugh, Matthew P.] UPMC St Margarets, Pittsburgh, PA USA.
[Manuck, Stephen B.] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA.
[Jennings, J. Richard] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA.
[Conklin, Sarah M.] Allegheny Coll, Dept Psychol, Meadville, PA 16335 USA.
[Yao, Jeffrey K.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Muldoon, Matthew F.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA.
RP Muldoon, MF (reprint author), Univ Pittsburgh, Old Engn Hall,Room 506, Pittsburgh, PA 15260 USA.
EM mfm10@pitt.edu
FU US Public Health Service Awards [T32 HL07560, P01 HL40962, R21 HL081282]
FX US Public Health Service Awards T32 HL07560, P01 HL40962, and R21
HL081282.
NR 44
TC 1
Z9 1
U1 0
U2 11
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0167-5273
J9 INT J CARDIOL
JI Int. J. Cardiol.
PD SEP 1
PY 2013
VL 167
IS 5
BP 2102
EP 2107
DI 10.1016/j.ijcard.2012.05.110
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 207AU
UT WOS:000323569600078
PM 22704872
ER
PT J
AU Suffoletto, B
Akers, A
McGinnis, KA
Calabria, J
Wiesenfeld, HC
Clark, DB
AF Suffoletto, Brian
Akers, Aletha
McGinnis, Kathleen A.
Calabria, Jaclyn
Wiesenfeld, Harold C.
Clark, Duncan B.
TI A Sex Risk Reduction Text-Message Program for Young Adult Females
Discharged From the Emergency Department
SO JOURNAL OF ADOLESCENT HEALTH
LA English
DT Article
DE Young adult; Health promotion; Sexual health; Text messaging
ID RANDOMIZED CONTROLLED-TRIAL; SEXUALLY-TRANSMITTED-DISEASES;
UNITED-STATES; HEALTH-CARE; BEHAVIOR; ADOLESCENTS; SERVICE; PEOPLE; SMS;
INTERVENTIONS
AB Purpose: To pilot test a text message (SMS) sex risk reduction program among at-risk young adult female patients discharged from an emergency department (ED).
Methods: A convenience sample of 52 female patients with hazardous drinking behavior and recent risky sexual encounters were recruited from an urban ED and randomized to the SMS program (n = 23) or a control group (n = 29). All participants completed a web-based questionnaire in the ED and at 3-month follow-up. For 12 weeks, SMS participants were asked to report whether they had a risky sexual encounter in the past week, received theory-based feedback, and were asked if they were willing set a goal to refrain from having another risky encounter.
Results: Thirty-nine percent of SMS participants completed all weeks of SMS reports, and non-completion increasing from 12% on week 1 to a 33% by week 12. Three-month follow-up was completed in 56% of participants. In the intervention group, there was an increase in the proportion with condom use with last vaginal sex from 20% (95% CI 4%-48%) to 53% (95% CI 27%-79%) and an increase in always condom use over the past 28 days from 0% (95% CI 0%-22%) to 33% (95% CI 12%-62%). These changes were not statistically different from control participants.
Conclusions: SMS programs may be useful to reduce risk for sexually transmitted diseases among at-risk young adults being discharged from the ED. Future trials should examine ways to improve adherence to SMS dialog over time and measure objective outcomes in a larger sample. (C) 2013 Society for Adolescent Health and Medicine. All rights reserved.
C1 [Suffoletto, Brian; Calabria, Jaclyn] Univ Pittsburgh, Sch Med, Dept Emergency Med, Pittsburgh, PA 15221 USA.
[Akers, Aletha; Wiesenfeld, Harold C.] Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15221 USA.
[McGinnis, Kathleen A.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Clark, Duncan B.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15221 USA.
RP Suffoletto, B (reprint author), Univ Pittsburgh, 3600 Forbes Ave,Iroquois Bldg,Suite 400A, Pittsburgh, PA 15221 USA.
EM suffbp@upmc.edu
FU EMF-Century Council; Robert Wood Johnson Foundation Harold Amos Medical
Faculty Development Program; [R01AA016482]; [P50DA05605]
FX The authors thank Jack Doman in the Office of Academic Computing at the
Western Psychiatric Institute at the University of Pittsburgh for all
computer programming support. B. S. is supported by an EMF-Century
Council grant, A. A. is supported by the Robert Wood Johnson Foundation
Harold Amos Medical Faculty Development Program, and D.B.C. is supported
by R01AA016482 and P50DA05605.
NR 38
TC 17
Z9 17
U1 3
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1054-139X
J9 J ADOLESCENT HEALTH
JI J. Adolesc. Health
PD SEP
PY 2013
VL 53
IS 3
BP 387
EP 393
DI 10.1016/j.jadohealth.2013.04.006
PG 7
WC Psychology, Developmental; Public, Environmental & Occupational Health;
Pediatrics
SC Psychology; Public, Environmental & Occupational Health; Pediatrics
GA 207MA
UT WOS:000323602900014
PM 23707402
ER
PT J
AU Muldoon, MF
Erickson, KI
Goodpaster, BH
Jakicic, JM
Conklin, SM
Sekikawa, A
Yao, JK
Manuck, SB
AF Muldoon, Matthew F.
Erickson, Kirk I.
Goodpaster, Bret H.
Jakicic, John M.
Conklin, Sarah M.
Sekikawa, Akira
Yao, Jeffrey K.
Manuck, Stephen B.
TI Concurrent Physical Activity Modifies the Association between n3
Long-Chain Fatty Acids and Cardiometabolic Risk in Mid life Adults
SO JOURNAL OF NUTRITION
LA English
DT Article
ID EXERCISE-INDUCED ALTERATIONS; CARDIOVASCULAR-DISEASE;
INSULIN-RESISTANCE; FISH-OIL; METABOLIC SYNDROME; WEIGHT-LOSS;
YOUNG-ADULTS; N-3; FITNESS; GLUCOSE
AB Greater consumption of n3 (omega 3) polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) can reduce risk for cardiovascular disease events, yet their effects on metabolic risk factors and diabetes remain unclear. This cross-sectional study used a community volunteer sample to test whether the associations between n3 fatty acids and cardiometabolic risk vary as a function of physical activity. Participants were 344 generally healthy adults, 30-54 y of age, not taking fish oil supplements or confounding medications. Serum phospholipid EPA and DHA were used together (EPA+DHA) as a biomarker of n3 fatty acid exposure. Cardiometabolic risk was calculated as a continuous measure based on standardized distributions of blood pressure, waist circumference, HDL cholesterol, triglycerides, glucose, and a simple count of risk factors. Insulin resistance was estimated from the homeostatic model assessment. Physical activity was found to predict cardiometabolic risk (P <= 0.02) and insulin resistance (P <= 0.02) and to moderate the association between EPA+DHA and both cardiometabolic risk (P-interaction <= 0.02) and insulin resistance (P-interaction <= 0.02). Specifically, higher EPA+DHA was associated with lower cardiometabolic risk and insulin resistance in persons engaged in regular physical activity but not in relatively inactive individuals. These findings were noted in several components of cardiometabolic risk, in men and women separately, and in models adjusted for overall diet quality. In midlife adults, habitual physical activity may be necessary to unmask the salutary effects of n3 fatty acids on cardiometabolic risk and insulin resistance.
C1 [Muldoon, Matthew F.] Univ Pittsburgh, Sch Med, Heart & Vasc Inst, Pittsburgh, PA 15213 USA.
[Erickson, Kirk I.; Manuck, Stephen B.] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA.
[Goodpaster, Bret H.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.
[Jakicic, John M.] Univ Pittsburgh, Sch Educ, Dept Hlth & Phys Act, Pittsburgh, PA 15260 USA.
[Conklin, Sarah M.] Allegheny Coll, Dept Psychol & Neurosci, Meadville, PA 16335 USA.
[Sekikawa, Akira] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA.
[Yao, Jeffrey K.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Muldoon, MF (reprint author), Univ Pittsburgh, Sch Med, Heart & Vasc Inst, Pittsburgh, PA 15213 USA.
EM mfm10@pitt.edu
OI Sekikawa, Akira/0000-0002-7197-6321
FU U.S. Public Health Service Awards [P01 HL40962, R21 HL081282]
FX Supported by U.S. Public Health Service Awards P01 HL40962 and R21
HL081282.
NR 40
TC 2
Z9 2
U1 1
U2 22
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-3166
J9 J NUTR
JI J. Nutr.
PD SEP
PY 2013
VL 143
IS 9
BP 1414
EP 1420
DI 10.3945/jn.113.174078
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 205SX
UT WOS:000323466200008
PM 23884386
ER
PT J
AU Polack, PO
Friedman, J
Golshani, P
AF Polack, Pierre-Olivier
Friedman, Jonathan
Golshani, Peyman
TI Cellular mechanisms of brain state-dependent gain modulation in visual
cortex
SO NATURE NEUROSCIENCE
LA English
DT Article
ID BARREL CORTEX; CORTICAL NETWORKS; IN-VIVO; GABAERGIC NEURONS; BEHAVIORAL
STATE; BASAL FOREBRAIN; ACETYLCHOLINE; NOREPINEPHRINE; ACTIVATION;
NEOCORTEX
AB Visual cortical neurons fire at higher rates to visual stimuli during locomotion than during immobility, while maintaining orientation selectivity. The mechanisms underlying this change in gain are not understood. We performed whole-cell recordings from layer 2/3 and layer 4 visual cortical excitatory neurons and from parvalbumin-positive and somatostatin-positive inhibitory neurons in mice that were free to rest or run on a spherical treadmill. We found that the membrane potential of all cell types became more depolarized and (with the exception of somatostatin-positive interneurons) less variable during locomotion. Cholinergic input was essential for maintaining the unimodal membrane potential distribution during immobility, whereas noradrenergic input was necessary for the tonic depolarization associated with locomotion. Our results provide a mechanism for how neuromodulation controls the gain and signal-to-noise ratio of visual cortical neurons during changes in the state of vigilance.
C1 [Polack, Pierre-Olivier; Friedman, Jonathan; Golshani, Peyman] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
[Polack, Pierre-Olivier; Golshani, Peyman] W Los Angeles Vet Affairs Med Ctr, Dept Neurol, Los Angeles, CA 90073 USA.
RP Golshani, P (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
EM pgolshani@mednet.ucla.edu
OI Polack, Pierre-Olivier/0000-0003-1716-6595
FU US National Institutes of Health [KO8 NS0562101]; Whitehall Foundation
[2012-05-83]; Veterans Affairs Merit Review Award [1I01BX001524-01A1]
FX We acknowledge R. Gruver for technical assistance on visual stimulation,
Z. Peng and C. Houser for histology, and D. Contreras, M. Einstein, T.
Indersmitten, M. Javaherian, C. Kaba, S. Mahon, A. Silva and S. Singh
for their thoughtful comments on the manuscript. This work was supported
by the US National Institutes of Health (KO8 NS0562101), the Whitehall
Foundation (grant 2012-05-83) and a Veterans Affairs Merit Review Award
(1I01BX001524-01A1).
NR 53
TC 128
Z9 128
U1 0
U2 35
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1097-6256
J9 NAT NEUROSCI
JI Nat. Neurosci.
PD SEP
PY 2013
VL 16
IS 9
BP 1331
EP U227
DI 10.1038/nn.3464
PG 11
WC Neurosciences
SC Neurosciences & Neurology
GA 207KN
UT WOS:000323597500026
PM 23872595
ER
PT J
AU Oursler, KK
Tate, JP
Gill, TM
Crothers, K
Brown, TT
Crystal, S
Womack, J
Leaf, DA
Sorkin, JD
Justice, AC
AF Oursler, Krisann K.
Tate, Janet P.
Gill, Thomas M.
Crothers, Kristina
Brown, Todd T.
Crystal, Stephen
Womack, Julie
Leaf, David A.
Sorkin, John D.
Justice, Amy C.
TI Association of the Veterans Aging Cohort Study Index with Exercise
Capacity in HIV-Infected Adults
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ADVANCED HEART-FAILURE; 6-MINUTE WALK
TEST; PEAK OXYGEN-UPTAKE; ANTIRETROVIRAL THERAPY; FUNCTIONAL STATUS;
PHYSICAL FUNCTION; AEROBIC CAPACITY; SKELETAL-MUSCLE; MORTALITY
AB Physical disability is a major priority in aging, affecting morbidity, mortality, and quality of life. Despite the large number of adults aging with HIV, our understanding of the physiologic and clinical risk factors for disability is limited. Our goal is to determine whether the Veterans Aging Cohort Study (VACS) Index, based on routine clinical blood tests, could serve as a point of care screening tool to identify HIV-infected adults at high risk for physical disability. HIV-infected adults enrolled in the VACS participated in a cross-sectional exercise study with established measures of strength and endurance. The VACS Index was calculated using recent clinical laboratory values and age; a higher score reflects greater mortality risk. Statistical analyses included correlation and linear regression models adjusted for muscle mass. Fifty-five HIV-infected adults, predominantly African-American men, were included with age mean +/- SD of 52 +/- 7 years. Median (IQR) CD4 cell count was 356 cells/mm(3) (212-527). The VACS Index was inversely correlated with quadriceps strength (r = -0.45, p < 0.01), grip strength (r = -0.28, p = 0.04), and 6-min walk distance (r = -0.27, p = 0.05). A 20-point increase in VACS Index score was associated with a 10% lower leg strength (p < 0.01), which remained significant after adjustment for muscle cross-sectional area (p = 0.02). The VACS Index explained 31% of the variance in specific leg strength. In this group of middle-aged adults with well-controlled HIV infection the VACS Index was significantly associated with upper and lower extremity strength. The VACS Index may be valuable for identification of patients at high risk for disability due to muscle weakness.
C1 [Oursler, Krisann K.; Sorkin, John D.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
[Oursler, Krisann K.; Sorkin, John D.] Baltimore VA Med Ctr, Geriatr Res Educ & Clin Ctr, Baltimore, MD 21201 USA.
[Tate, Janet P.; Justice, Amy C.] Yale Univ, Sch Med & Publ Hlth, New Haven, CT USA.
[Tate, Janet P.; Justice, Amy C.] VA Connecticut Healthcare Syst, New Haven, CT USA.
[Gill, Thomas M.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA.
[Crothers, Kristina] Univ Washington, Seattle, WA 98195 USA.
[Brown, Todd T.] Johns Hopkins Sch Med, Baltimore, MD USA.
[Crystal, Stephen] Rutgers State Univ, Ctr Hlth Serv Res Pharmacotherapy Chron Dis Manag, Inst Hlth, New Brunswick, NJ 08903 USA.
[Womack, Julie] Yale Univ, Sch Nursing, New Haven, CT 06536 USA.
[Leaf, David A.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA.
[Leaf, David A.] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA.
RP Oursler, KK (reprint author), Baltimore VA Med Ctr, BT GRECC 18, 10 North Greene St, Baltimore, MD 21201 USA.
EM koursler@grecc.umaryland.edu
OI Crothers, Kristina/0000-0001-9702-0371
FU National Institute on Aging (NIA) [K23 AG024896]; NIA University of
Maryland Claude D. Pepper Older Americans Independence Center
[P60-AG12583]; Baltimore VA Geriatric Research, Clinical and Education
Center; NIA [K24AG021507, P30AG021342]; NHLBI [R01 HL090342]; NINR [K01
NR013437]; CTSA NCRR [UL1 RR024139]; NIAAA [U10-AA13566, U24-AA020794];
U.S. Department of Veterans Affairs
FX Disclosure of Funding: National Institute on Aging (NIA) K23 AG024896
(Dr. Oursler), NIA University of Maryland Claude D. Pepper Older
Americans Independence Center P60-AG12583 (Drs. Oursler and Sorkin),
Baltimore VA Geriatric Research, Clinical and Education Center (Drs.
Oursler and Sorkin), NIA K24AG021507 and P30AG021342 (Dr. Gill), NHLBI
R01 HL090342 (Dr. Crothers), NINR K01 NR013437 and CTSA NCRR UL1
RR024139 (Dr. Womack), and NIAAA U10-AA13566 and U24-AA020794 and in
kind by the U.S. Department of Veterans Affairs (Dr. Justice).
NR 44
TC 10
Z9 10
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD SEP
PY 2013
VL 29
IS 9
BP 1218
EP 1223
DI 10.1089/aid.2012.0388
PG 6
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 204NL
UT WOS:000323372600007
PM 23705911
ER
PT J
AU Berger, D
Williams, EC
Bryson, CL
Rubinsky, AD
Bradley, KA
AF Berger, Douglas
Williams, Emily C.
Bryson, Chris L.
Rubinsky, Anna D.
Bradley, Katharine A.
TI Alcohol questionnaires and HDL: Screening scores as scaled markers of
alcohol consumption
SO ALCOHOL
LA English
DT Article
DE HDL cholesterol; Alcohol; Alcohol screening questionnaire
ID PRIMARY-CARE PATIENTS; IDENTIFICATION TEST AUDIT; USE DISORDERS; PROBLEM
DRINKING; RISK-FACTORS; HEALTH; DEPRESSION; VALIDATION; DEPENDENCE;
SEVERITY
AB Improving the quality of alcohol-related care requires practical approaches to assessing alcohol consumption to guide management and monitor outcomes. Given the increasing use of alcohol screening questionnaires to identify alcohol misuse it would be ideal if scores on screening questionnaires were also indicators of average alcohol consumption. However, the questionnaires were not designed for this purpose and include dimensions of drinking that may not reflect average consumption (e.g. heavy episodic drinking, alcohol-related problems). In a general population sample, scores on the AUDIT-C screen correlated with reports of alcohol consumption in detailed interviews, but the relationship is unknown for clinical populations and other questionnaires. Serum high-density lipoprotein cholesterol (HDL) is a biomarker routinely obtained in clinical care and is known to rise with average alcohol consumption. This cross-sectional study of 11,175 male U.S. Veterans Affairs patients enrolled in a primary care study used HDL as an objective biomarker to evaluate whether average alcohol consumption increased as scores increased on 3 brief alcohol screens - the AUDIT-C, AUDIT Question #3 (a single-item screen), and the CAGE questionnaire. Mean HDL progressively increased as screening scores increased for the AUDIT-C and AUDIT Question #3: about 12 mg/dL from the lowest to the highest scores. The association was much weaker for the CAGE questionnaire. Results were minimally affected by adjustment for covariates (e.g. age, race, medical comorbidity, smoking, medication count, and depression) but the association was modified (p = 0.008) and mildly attenuated by adherent use of lipid-lowering medications. This study using HDL as a biomarker of average alcohol consumption adds to evidence that some alcohol screening scores may also serve as scaled markers of average alcohol consumption. Published by Elsevier Inc.
C1 [Berger, Douglas; Bryson, Chris L.] Dept Vet Affairs VA Puget Sound Hlth Care Syst, Gen Med Serv, Seattle, WA USA.
[Berger, Douglas; Bryson, Chris L.; Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA USA.
[Williams, Emily C.; Bryson, Chris L.; Rubinsky, Anna D.; Bradley, Katharine A.] Dept Vet Affairs VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Northwest Ctr Excellence, Seattle, WA USA.
[Williams, Emily C.; Bradley, Katharine A.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Rubinsky, Anna D.; Bradley, Katharine A.] Vet Affairs VA Puget Sound Hlth Care Syst, Ctr Excellence Substance Abuse Treatment & Educ, Seattle, WA USA.
[Bradley, Katharine A.] Grp Hlth Res Inst, Seattle, WA USA.
RP Berger, D (reprint author), VA Puget Sound, Gen Internal Med Sect, 1660 S Columbian Way,S-123 PCC, Seattle, WA 98108 USA.
EM douglas.berger@va.gov
FU VA HSRD IAC [05-206]
FX This project was funded by VA HSR&D IAC Grant 05-206. The funding
organization had no role in design and conduct of the study; collection,
management, analysis, and interpretation of the data; or preparation,
review, or approval of the manuscript.
NR 45
TC 4
Z9 4
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-8329
J9 ALCOHOL
JI Alcohol
PD SEP
PY 2013
VL 47
IS 6
BP 439
EP 445
DI 10.1016/j.alcohol.2013.07.001
PG 7
WC Substance Abuse; Pharmacology & Pharmacy; Toxicology
SC Substance Abuse; Pharmacology & Pharmacy; Toxicology
GA 204IY
UT WOS:000323360200003
PM 23886863
ER
PT J
AU LaRowe, SD
Kalivas, PW
Nicholas, JS
Randall, PK
Mardikian, PN
Malcolm, RJ
AF LaRowe, Steven D.
Kalivas, Peter W.
Nicholas, Joyce S.
Randall, Patrick K.
Mardikian, Pascale N.
Malcolm, Robert. J.
TI A double-blind placebo-controlled trial of N-acetylcysteine in the
treatment of cocaine dependence
SO AMERICAN JOURNAL ON ADDICTIONS
LA English
DT Article
ID NUCLEUS-ACCUMBENS; RECEPTOR AGONIST; SEEKING BEHAVIOR; RELAPSE;
REINSTATEMENT; INDIVIDUALS; VALIDITY; LY379268
AB Background: There remains no FDA approved medication for the treatment of cocaine dependence. Preclinical studies and early pilot clinical investigations have suggested that N-acetylcysteine (NAC) may be useful in the treatment of the disorder.
Objective: The present report assessed the efficacy of NAC in the treatment of cocaine dependence.
Methods: Cocaine-dependent volunteers (n = 111) were randomized to receive daily doses of 1,200 mg of NAC, 2,400 mg of NAC, or placebo. Participants were followed for 8 weeks (up to three visits weekly). At each of these visits, urine samples were collected, along with self-reports of cocaine use. Urine samples were assessed for quantitative levels of benzoylecognine (ie, cocaine metabolite).
Results: Overall, the primary results for the clinical trial were negative. However, when considering only subjects who entered the trial having already achieved abstinence, results favored the 2,400 mg NAC group relative to placebo, with the 2,400 mg group having longer times to relapse and lower craving ratings.
Conclusion: While the present trial failed to demonstrate that NAC reduces cocaine use in cocaine-dependent individuals actively using, there was some evidence it prevented return to cocaine use in individuals who had already achieved abstinence from cocaine.
Scientific Significance: N-acetylcysteine may be useful as a relapse prevention agent in abstinent cocaine-dependent individuals.
C1 [LaRowe, Steven D.] Ralph H Johnson VAMC, Charleston, SC USA.
[LaRowe, Steven D.; Randall, Patrick K.; Mardikian, Pascale N.; Malcolm, Robert. J.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Kalivas, Peter W.; Nicholas, Joyce S.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
[Nicholas, Joyce S.] Med Univ S Carolina, Dept Med, Div Biostat & Epidemiol, Charleston, SC 29425 USA.
RP LaRowe, SD (reprint author), Med Univ S Carolina, Dept Psychiat, Ctr Drug & Alcohol Programs, Charleston, SC 29425 USA.
EM larowe@musc.edu
OI LaRowe, Steven/0000-0002-7664-2451
FU NIDA NIH HHS [DA0199903, P50 DA015369, R01 DA003906, R01 DA012513]
NR 32
TC 32
Z9 34
U1 0
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1055-0496
J9 AM J ADDICTION
JI Am. J. Addict.
PD SEP
PY 2013
VL 22
IS 5
BP 443
EP 452
DI 10.1111/j.1521-0391.2013.12034.x
PG 10
WC Substance Abuse
SC Substance Abuse
GA 202DV
UT WOS:000323194600004
PM 23952889
ER
PT J
AU Collins, E
Gilkeson, G
AF Collins, Erin
Gilkeson, Gary
TI Hematopoetic and mesenchymal stem cell transplantation in the treatment
of refractory systemic lupus erythematosus - Where are we now?
SO CLINICAL IMMUNOLOGY
LA English
DT Review
DE Lupus; Stem cell transplantation
ID VERSUS-HOST-DISEASE; BONE-MARROW-TRANSPLANTATION; COLLAGEN-INDUCED
ARTHRITIS; AUTOIMMUNE-DISEASES; T-CELLS; INDOLEAMINE 2,3-DIOXYGENASE;
HEALTHY DONORS; IN-VITRO; MECHANISMS; MICE
AB Cell based therapies are of increasing interest in the treatment of systemic lupus due to their potential for long term suppression or cure of disease. Two methods for stem cell transplantation are currently being investigated/performed for treatment of lupus. Autologous hematopoetic stem cell transplantation is used in patients refractory to standard therapy. The morbidity and mortality of the procedure limit its use to select patients. Results indicate 50% long term disease free survival. The technical difficulty of the procedure requires it to be performed only in experienced centers. Mesenchymal stem cell transplants are a new emerging therapy for the treatment of lupus. Studies in murine models of lupus provide evidence of efficacy with safety. Limited uncontrolled trials in humans provide evidence of efficacy as well. Controlled trials are needed to assess the efficacy of both these therapies compared to standard therapy. Published by Elsevier Inc.
C1 Med Univ S Carolina, Div Rheumatol, Charleston, SC 29425 USA.
Ralph H Johnson VAMC, Med Res Serv, Charleston, SC USA.
RP Gilkeson, G (reprint author), 96 Jonathan Lucas St,Suite 912, Charleston, SC 29425 USA.
EM Gilkeson@musc.edu
NR 58
TC 6
Z9 7
U1 0
U2 17
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
J9 CLIN IMMUNOL
JI Clin. Immunol.
PD SEP
PY 2013
VL 148
IS 3
BP 328
EP 334
DI 10.1016/j.clim.2013.01.009
PG 7
WC Immunology
SC Immunology
GA 202CX
UT WOS:000323192200005
PM 23411031
ER
PT J
AU Arbizu, J
Prieto, E
Martinez-Lage, P
Marti-Climent, JM
Garcia-Granero, M
Lamet, I
Pastor, P
Riverol, M
Gomez-Isla, MT
Penuelas, I
Richter, JA
Weiner, MW
AF Arbizu, Javier
Prieto, E.
Martinez-Lage, P.
Marti-Climent, J. M.
Garcia-Granero, M.
Lamet, I.
Pastor, P.
Riverol, M.
Gomez-Isla, M. T.
Penuelas, I.
Richter, J. A.
Weiner, M. W.
CA Alzheimer's Dis Neuroimaging
TI Automated analysis of FDG PET as a tool for single-subject probabilistic
prediction and detection of Alzheimer's disease dementia
SO EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
LA English
DT Article
DE FDG; PET; Alzheimer's disease; Mild cognitive impairment; Dementia;
Prediction
ID MILD COGNITIVE IMPAIRMENT; BRAIN GLUCOSE-METABOLISM; GRAY-MATTER VOLUME;
F-18-FDG PET; APOE GENOTYPE; ASSOCIATION WORKGROUPS; DIAGNOSTIC
GUIDELINES; NATIONAL INSTITUTE; MRI; MCI
AB To introduce, evaluate and validate a voxel-based analysis method of F-18-FDG PET imaging for determining the probability of Alzheimer's disease (AD) in a particular individual.
The subject groups for model derivation comprised 80 healthy subjects (HS), 36 patients with mild cognitive impairment (MCI) who converted to AD dementia within 18 months, 85 non-converter MCI patients who did not convert within 24 months, and 67 AD dementia patients with baseline FDG PET scan were recruited from the AD Neuroimaging Initiative (ADNI) database. Additionally, baseline FDG PET scans from 20 HS, 27 MCI and 21 AD dementia patients from our institutional cohort were included for model validation. The analysis technique was designed on the basis of the AD-related hypometabolic convergence index adapted for our laboratory-specific context (AD-PET index), and combined in a multivariable model with age and gender for AD dementia detection (AD score). A logistic regression analysis of different cortical PET indexes and clinical variables was applied to search for relevant predictive factors to include in the multivariable model for the prediction of MCI conversion to AD dementia (AD-Conv score). The resultant scores were stratified into sixtiles for probabilistic diagnosis.
The area under the receiver operating characteristic curve (AUC) for the AD score detecting AD dementia in the ADNI database was 0.879, and the observed probability of AD dementia in the six defined groups ranged from 8 % to 100 % in a monotonic trend. For predicting MCI conversion to AD dementia, only the posterior cingulate index, Mini-Mental State Examination (MMSE) score and apolipoprotein E4 genotype (ApoE4) exhibited significant independent effects in the univariable and multivariable models. When only the latter two clinical variables were included in the model, the AUC was 0.742 (95 % CI 0.646 - 0.838), but this increased to 0.804 (95 % CI 0.714 - 0.894, bootstrap p = 0.027) with the addition of the posterior cingulate index (AD-Conv score). Baseline clinical diagnosis of MCI showed 29.7 % of converters after 18 months. The observed probability of conversion in relation to baseline AD-Conv score was 75 % in the high probability group (sixtile 6), 34 % in the medium probability group (merged sixtiles 4 and 5), 20 % in the low probability group (sixtile 3) and 7.5 % in the very low probability group (merged sixtiles 1 and 2). In the validation population, the AD score reached an AUC of 0.948 (95 % CI 0.625 - 0.969) and the AD-Conv score reached 0.968 (95 % CI 0.908 - 1.000), with AD patients and MCI converters included in the highest probability categories.
Posterior cingulate hypometabolism, when combined in a multivariable model with age and gender as well as MMSE score and ApoE4 data, improved the determination of the likelihood of patients with MCI converting to AD dementia compared with clinical variables alone. The probabilistic model described here provides a new tool that may aid in the clinical diagnosis of AD and MCI conversion.
C1 [Arbizu, Javier; Prieto, E.; Marti-Climent, J. M.; Penuelas, I.; Richter, J. A.] Univ Navarra Clin, Dept Nucl Med, Pamplona 31008, Spain.
[Martinez-Lage, P.; Lamet, I.; Pastor, P.; Riverol, M.; Gomez-Isla, M. T.] Univ Navarra Clin, Dept Neurol, Pamplona 31008, Spain.
[Garcia-Granero, M.] Univ Navarra, Sch Sci, Dept Biochem & Genet, Pamplona 31008, Spain.
[Weiner, M. W.] San Francisco VA Med Ctr, CIND, San Francisco, CA 94121 USA.
RP Arbizu, J (reprint author), Univ Navarra Clin, Dept Nucl Med, Ave Pio 12 36, Pamplona 31008, Spain.
EM jarbizu@unav.es
RI Saykin, Andrew/A-1318-2007; Pastor, Pau/C-9834-2009; Prieto,
Elena/N-2142-2014; Jack, Clifford/F-2508-2010
OI Saykin, Andrew/0000-0002-1376-8532; Pastor, Pau/0000-0002-7493-8777;
Prieto, Elena/0000-0002-3609-1210; Jack, Clifford/0000-0001-7916-622X
FU Government of Spain, Institute of Health Carlos III, the Ministry of
Health [01/0809]; Ministry of Science and Innovation CIBERNED (Centro de
Investigacion Biomedica en Red de Enfermedades Neurodegenerativas) [ADE
10/00028, CB06/05/0077]; Alzheimer's Disease Neuroimaging Initiative
(ADNI; National Institutes of Health) [U01 AG024904]; National Institute
on Aging; National Institute of Biomedical Imaging and Bioengineering;
Abbott; Alzheimer's Association; Alzheimer's Drug Discovery Foundation;
Amorfix Life Sciences Ltd.; AstraZeneca; Bayer HealthCare; BioClinica,
Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan
Pharmaceuticals Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd;
Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; IXICO Ltd.; Janssen
Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson
Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck Co.,
Inc.; Meso Scale Diagnostics, LLC.; Novartis Pharmaceuticals
Corporation; Pfizer Inc.; Servier; Synarc Inc.; Takeda Pharmaceutical
Company; Canadian Institutes of Health Research; NIH [P30 AG010129, K01
AG030514]
FX This work was supported in part by the Government of Spain, Institute of
Health Carlos III, the Ministry of Health grant 01/0809, and the
Ministry of Science and Innovation grant ADE 10/00028, and CB06/05/0077
CIBERNED (Centro de Investigacion Biomedica en Red de Enfermedades
Neurodegenerativas).; Data collection and sharing for this project was
funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI;
National Institutes of Health grant U01 AG024904). ADNI is funded by the
National Institute on Aging, the National Institute of Biomedical
Imaging and Bioengineering, and through generous contributions from the
following: Abbott; Alzheimer's Association; Alzheimer's Drug Discovery
Foundation; Amorfix Life Sciences Ltd.; AstraZeneca; Bayer HealthCare;
BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai
Inc.; Elan Pharmaceuticals Inc.; Eli Lilly and Company; F. Hoffmann-La
Roche Ltd and its affiliated company Genentech, Inc.; GE Healthcare;
Innogenetics, N.V.; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research
& Development, LLC.; Johnson & Johnson Pharmaceutical Research &
Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale
Diagnostics, LLC.; Novartis Pharmaceuticals Corporation; Pfizer Inc.;
Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian
Institutes of Health Research provides funds to support ADNI clinical
sites in Canada. Private sector contributions are facilitated by the
Foundation for the National Institutes of Health (www.fnih.org). The
grantee organization is the Northern California Institute for Research
and Education, and the study was coordinated by the Alzheimer's Disease
Cooperative Study at the University of California, San Diego. ADNI data
are disseminated by the Laboratory for Neuroimaging at the University of
California, Los Angeles. This research was also supported by NIH grants
P30 AG010129 and K01 AG030514.
NR 40
TC 16
Z9 17
U1 0
U2 13
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1619-7070
J9 EUR J NUCL MED MOL I
JI Eur. J. Nucl. Med. Mol. Imaging
PD SEP
PY 2013
VL 40
IS 9
BP 1394
EP 1405
DI 10.1007/s00259-013-2458-z
PG 12
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 200GO
UT WOS:000323056300014
PM 23715905
ER
PT J
AU Goldberger, JJ
Schliamser, JE
Kadish, AH
Subacius, H
Shalaby, A
Schaechter, A
Levine, J
AF Goldberger, Jeffrey J.
Schliamser, Jorge E.
Kadish, Alan H.
Subacius, Haris
Shalaby, Alaa
Schaechter, Andi
Levine, Joseph
TI Should an Improvement in Left Ventricular Systolic Function Preclude ICD
Generator Replacement? Reply
SO HEART RHYTHM
LA English
DT Letter
ID CARDIOMYOPATHY
C1 [Goldberger, Jeffrey J.; Schliamser, Jorge E.; Kadish, Alan H.; Subacius, Haris; Schaechter, Andi] Northwestern Univ, Feinberg Sch Med, Ctr Cardiovasc Innovat, Chicago, IL 60611 USA.
[Goldberger, Jeffrey J.; Schliamser, Jorge E.; Kadish, Alan H.; Subacius, Haris; Schaechter, Andi] Northwestern Univ, Feinberg Sch Med, Div Cardiol, Chicago, IL USA.
[Kadish, Alan H.] Touro Coll, Brooklyn, NY USA.
[Kadish, Alan H.] New York Med Coll, Valhalla, NY 10595 USA.
[Shalaby, Alaa] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Levine, Joseph] St Francis Hosp, Ctr Heart, Roslyn, NY USA.
RP Goldberger, JJ (reprint author), Northwestern Univ, Feinberg Sch Med, Ctr Cardiovasc Innovat, Chicago, IL 60611 USA.
EM j-goldberger@northwestern.edu
NR 2
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1547-5271
J9 HEART RHYTHM
JI Heart Rhythm
PD SEP
PY 2013
VL 10
IS 9
BP E77
EP E78
PG 3
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 206CQ
UT WOS:000323494600004
PM 23872694
ER
PT J
AU Krebs, CE
Karkheiran, S
Powell, JC
Cao, M
Makarov, V
Darvish, H
Di Paolo, G
Walker, RH
Shahidi, GA
Buxbaum, JD
De Camilli, P
Yue, ZY
Paisan-Ruiz, C
AF Krebs, Catharine E.
Karkheiran, Siamak
Powell, James C.
Cao, Mian
Makarov, Vladimir
Darvish, Hossein
Di Paolo, Gilbert
Walker, Ruth H.
Shahidi, Gholam Ali
Buxbaum, Joseph D.
De Camilli, Pietro
Yue, Zhenyu
Paisan-Ruiz, Coro
TI The Sac1 Domain of SYNJ1 Identified Mutated in a Family with Early-Onset
Progressive Parkinsonism with Generalized Seizures
SO HUMAN MUTATION
LA English
DT Article
DE homozygosity mapping; whole-exome sequencing; SYNJ1; autosomal recessive
Parkinsonism
AB This study aimed to elucidate the genetic causes underlying early-onset Parkinsonism (EOP) in a consanguineous Iranian family. To attain this, homozygosity mapping and whole-exome sequencing were performed. As a result, a homozygous mutation (c.773G>A; p.Arg258Gln) lying within the NH2-terminal Sac1-like inositol phosphatase domain of polyphosphoinositide phosphatase synaptojanin 1 (SYNJ1), which has been implicated in the regulation of endocytic traffic at synapses, was identified as the disease-segregating mutation. This mutation impaired the phosphatase activity of SYNJ1 against its Sac1 domain substrates in vitro. We concluded that the SYNJ1 mutation identified here is responsible for the EOP phenotype seen in our patients probably due to deficiencies in its phosphatase activity and consequent impairment of its synaptic functions. Our finding not only opens new avenues of investigation in the synaptic dysfunction mechanisms associated with Parkinsonism, but also suggests phosphoinositide metabolism as a novel therapeutic target for Parkinsonism.(C) 2013 Wiley Periodicals, Inc.
C1 [Krebs, Catharine E.; Powell, James C.; Walker, Ruth H.; Yue, Zhenyu; Paisan-Ruiz, Coro] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY USA.
[Karkheiran, Siamak] Univ Tehran Med Sci, Hazrat Rasool Hosp, Movement Disorders Clin, Tehran, Iran.
[Cao, Mian; De Camilli, Pietro] Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Cell Biol, New Haven, CT 06510 USA.
[Cao, Mian; De Camilli, Pietro] Yale Univ, Sch Med, Program Cellular Neurosci Neurodegenerat & Repair, New Haven, CT USA.
[Makarov, Vladimir] Columbia Univ, Dept Biostat, Mailman Sch Publ Hlth, New York, NY USA.
[Darvish, Hossein] Shahid Beheshti Univ Med Sci, Dept Med Genet, Tehran, Iran.
[Di Paolo, Gilbert] Columbia Univ, Taub Inst Res Alzheimers Dis & Aging Brain, Med Ctr, Dept Pathol & Cell Biol, New York, NY USA.
[Walker, Ruth H.] James J Peters Vet Affairs Med Ctr, Dept Neurol, Bronx, NY USA.
[Shahidi, Gholam Ali] Univ Tehran Med Sci, Hazrat Rasool Hosp, Dept Neurol, Tehran, Iran.
[Buxbaum, Joseph D.] Mt Sinai Schoool Med, Seaver Autism Ctr Res & Treatment, New York, NY USA.
[Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY USA.
[Buxbaum, Joseph D.; Yue, Zhenyu] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY USA.
[Buxbaum, Joseph D.; Paisan-Ruiz, Coro] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY USA.
[Buxbaum, Joseph D.; Paisan-Ruiz, Coro] Icahn Sch Med Mt Sinai, Mindich Child Hlth & Dev Inst, New York, NY USA.
[Buxbaum, Joseph D.; Yue, Zhenyu; Paisan-Ruiz, Coro] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY USA.
RP Paisan-Ruiz, C (reprint author), Icahn Sch Med Mt Sinai, Dept Neurol, 1 Gustave L Levy Pl, New York, NY USA.
EM coro.paisan-ruiz@mssm.edu
RI Paisan-Ruiz, Coro/C-2912-2009
OI Buxbaum, Joseph/0000-0001-8898-8313
FU Parkinson's Disease Foundation; Ellison Foundation; Michael J. Fox
Foundation; NIH/NINDS [R01NS060809, R01NS072359, R37NS036251,
R01NS079388]; NIMH [R01MH095797]
FX Contract grant sponsors: The Parkinson's Disease Foundation; Ellison
Foundation; Michael J. Fox Foundation; NIH/NINDS (R01NS060809,
R01NS072359, R37NS036251, R01NS079388); NIMH (R01MH095797).
NR 53
TC 74
Z9 76
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1059-7794
J9 HUM MUTAT
JI Hum. Mutat.
PD SEP
PY 2013
VL 34
IS 9
BP 1200
EP 1207
DI 10.1002/humu.22372
PG 8
WC Genetics & Heredity
SC Genetics & Heredity
GA 200YZ
UT WOS:000323109200004
PM 23804563
ER
PT J
AU Smith, KJ
Wateska, A
Nowalk, MP
Raymund, M
Lee, BY
Zimmerman, RK
Fine, MJ
AF Smith, Kenneth J.
Wateska, Angela
Nowalk, M. Patricia
Raymund, Mahlon
Lee, Bruce Y.
Zimmerman, Richard K.
Fine, Michael J.
TI Cost-Effectiveness of Procalcitonin-Guided Antibiotic Use in Community
Acquired Pneumonia
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE cost-effectiveness analysis; procalcitonin; community-acquired pneumonia
ID RANDOMIZED-CONTROLLED-TRIAL; LOW-RISK PATIENTS; LENGTH-OF-STAY; CRITICAL
PATHWAY; REDUCE DURATION; CARE; THERAPY; IMPLEMENTATION; METAANALYSIS;
COHORT
AB Although prior randomized trials have demonstrated that procalcitonin-guided antibiotic therapy effectively reduces antibiotic use in patients with community-acquired pneumonia (CAP), uncertainties remain regarding use of procalcitonin protocols in practice.
To estimate the cost-effectiveness of procalcitonin protocols in CAP.
Decision analysis using published observational and clinical trial data, with variation of all parameter values in sensitivity analyses.
Hypothetical patient cohorts who were hospitalized for CAP.
Procalcitonin protocols vs. usual care.
Costs and cost per quality adjusted life year gained.
When no differences in clinical outcomes were assumed, consistent with clinical trials and observational data, procalcitonin protocols cost $10-$54 more per patient than usual care in CAP patients. Under these assumptions, results were most sensitive to variations in: antibiotic cost, the likelihood that antibiotic therapy was initiated less frequently or over shorter durations, and the likelihood that physicians were nonadherent to procalcitonin protocols. Probabilistic sensitivity analyses, incorporating procalcitonin protocol-related changes in quality of life, found that protocol use was unlikely to be economically reasonable if physician protocol nonadherence was high, as observational study data suggest. However, procalcitonin protocols were favored if they decreased hospital length of stay.
Procalcitonin protocol use in hospitalized CAP patients, although promising, lacks physician nonadherence and resource use data in routine care settings, which are needed to evaluate its potential role in patient care. (C) Society of General Internal Medicine 2013
C1 [Smith, Kenneth J.; Wateska, Angela; Lee, Bruce Y.; Fine, Michael J.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA.
[Nowalk, M. Patricia; Raymund, Mahlon; Zimmerman, Richard K.] Univ Pittsburgh, Sch Med, Dept Family Med, Pittsburgh, PA 15213 USA.
[Fine, Michael J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ & Promot, Pittsburgh, PA USA.
RP Smith, KJ (reprint author), Univ Pittsburgh, Sch Med, Dept Med, 200 Meyran Ave,Suite 200, Pittsburgh, PA 15213 USA.
EM smithkj2@upmc.edu
OI Smith, Kenneth J/0000-0001-8088-566X; Zimmerman,
Richard/0000-0001-5941-6092
FU NIAID [R01AI 076256]
FX Supported by the NIAID (R01AI 076256)
NR 29
TC 13
Z9 13
U1 1
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD SEP
PY 2013
VL 28
IS 9
BP 1157
EP 1164
DI 10.1007/s11606-013-2400-x
PG 8
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 202XR
UT WOS:000323254700015
PM 23463457
ER
PT J
AU Yoon, J
Rose, DE
Canelo, I
Upadhyay, AS
Schectman, G
Stark, R
Rubenstein, LV
Yano, EM
AF Yoon, Jean
Rose, Danielle E.
Canelo, Ismelda
Upadhyay, Anjali S.
Schectman, Gordon
Stark, Richard
Rubenstein, Lisa V.
Yano, Elizabeth M.
TI Medical Home Features of VHA Primary Care Clinics and Avoidable
Hospitalizations
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE medical home; avoidable hospitalizations; access; care coordination
ID HEALTH-CARE; SENSITIVE CONDITIONS; ILLNESS; ACCESS; RATES
AB As the Veterans Health Administration (VHA) reorganizes providers into the patient-centered medical home, questions remain whether this model of care can demonstrate improved patient outcomes and cost savings.
We measured adoption of medical home features by VHA primary care clinics prior to widespread implementation of the patient-centered medical home and examined if they were associated with lower risk and costs of potentially avoidable hospitalizations.
Secondary patient data was linked to clinic administrative and survey data. Patient and clinic factors in the baseline year (FY2009) were used to predict patient outcomes in the follow-up year.
2,853,030 patients from 814 VHA primary care clinics
Patient outcomes were measured by hospitalizations for an ambulatory care sensitive condition (ACSC) and their costs and identified through diagnosis and procedure codes from inpatient records. Clinic adoption of medical home features was obtained from the American College of Physicians Medical Home BuilderA (R).
The overall mean home builder score in the study clinics was 88 (SD = 13) or 69 %. In adjusted analyses an increase of 10 points in the medical home adoption score in a clinic decreased the odds of an ACSC hospitalization for patients by 3 % (P = 0.032). By component, higher access and scheduling (P = 0.004) and care coordination and transitions (P = 0.020) component scores were related to lower risk of an ACSC hospitalization, and higher population management was related to higher risk (P = 0.023). Total medical home features was not related to ACSC hospitalization costs among patients with at least one (P = 0.074).
Greater adoption of medical home features by VHA primary care clinics was found to be significantly associated with lower risk of avoidable hospitalizations with access and scheduling and care coordination/transitions in care as key factors. (C) Society of General Internal Medicine 2013
C1 [Yoon, Jean; Upadhyay, Anjali S.] VA Palo Alto Hlth Care Syst, Hlth Econ Resource Ctr, Menlo Pk, CA 94025 USA.
[Yoon, Jean] VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk, CA USA.
[Rose, Danielle E.; Canelo, Ismelda; Rubenstein, Lisa V.; Yano, Elizabeth M.] VA Greater Los Angeles, Ctr Ctr Excellence Study Healthcare Provider Beha, Sepulveda, CA USA.
[Rubenstein, Lisa V.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA.
[Rubenstein, Lisa V.] RAND Corp, Santa Monica, CA USA.
[Yano, Elizabeth M.] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA.
[Schectman, Gordon; Stark, Richard] Vet Hlth Adm, Patient Care Serv, Washington, DC USA.
RP Yoon, J (reprint author), VA Palo Alto Hlth Care Syst, Hlth Econ Resource Ctr, 795 Willow Rd 152 MPD, Menlo Pk, CA 94025 USA.
EM jean.yoon@va.gov
FU Department of Veterans Affairs, Veterans Health Administration Office of
Research and Development, Health Services Research and Development [IIR
09-082]; VA HSR&D Senior Research Career Scientist Award [RCS 05-195]
FX This work was supported by the Department of Veterans Affairs, Veterans
Health Administration Office of Research and Development, Health
Services Research and Development (grant #: IIR 09-082). Dr. Yano's
effort was covered by a VA HSR&D Senior Research Career Scientist Award
(Project #RCS 05-195). The authors wish to acknowledge Belinda Black
MSPH, Office of Patient Care Services, Veterans Health Administration
for administering the clinic survey and Michael Barr MD, MBA, FACP,
American College of Physicians for providing valuable comments.
Preliminary results from this study were presented at the Academy Health
Annual Research Meeting, June 24-26, 2012, in Orlando, FL and the VA
Health Services Research and Development Meeting, July 17-19, in
Washington, DC.
NR 21
TC 15
Z9 15
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD SEP
PY 2013
VL 28
IS 9
BP 1188
EP 1194
DI 10.1007/s11606-013-2405-5
PG 7
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 202XR
UT WOS:000323254700019
PM 23529710
ER
PT J
AU Cronholm, PF
Shea, JA
Werner, RM
Miller-Day, M
Tufano, J
Crabtree, BF
Gabbay, R
AF Cronholm, Peter F.
Shea, Judy A.
Werner, Rachel M.
Miller-Day, Michelle
Tufano, Jim
Crabtree, Benjamin F.
Gabbay, Robert
TI The Patient Centered Medical Home: Mental Models and Practice Culture
Driving the Transformation Process
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE patient-centered care; primary health care; delivery of health care;
workplace; program evaluation
ID PRIMARY-CARE; HEALTH-CARE; IMPROVEMENT; QUALITY
AB The Patient-Centered Medical Home (PCMH) has become a dominant model of primary care re-design. The PCMH model is a departure from more traditional models of healthcare delivery and requires significant transformation to be realized.
To describe factors shaping mental models and practice culture driving the PCMH transformation process in a large multi-payer PCMH demonstration project.
Individual interviews were conducted at 17 primary care practices in South Eastern Pennsylvania.
A total of 118 individual interviews were conducted with clinicians (N = 47), patient educators (N = 4), office administrators (N = 12), medical assistants (N = 26), front office staff (N = 7), nurses (N = 4), care managers (N = 11), social workers (N = 4), and other stakeholders (N = 3). A multi-disciplinary research team used a grounded theory approach to develop the key constructs describing factors shaping successful practice transformation.
Three central themes emerged from the data related to changes in practice culture and mental models necessary for PCMH practice transformation: 1) shifting practice perspectives towards proactive, population-oriented care based in practice-patient partnerships; 2) creating a culture of self-examination; and 3) challenges to developing new roles within the practice through distribution of responsibilities and team-based care. The most tension in shifting the required mental models was displayed between clinician and medical assistant participants, revealing significant barriers towards moving away from clinician-centric care.
Key factors driving the PCMH transformation process require shifting mental models at the individual level and culture change at the practice level. Transformation is based upon structural and process changes that support orientation of practice mental models towards perceptions of population health, self-assessment, and the development of shared decision-making. Staff buy-in to the new roles and responsibilities driving PCMH transformation was described as central to making sustainable change at the practice level; however, key barriers related to clinician autonomy appeared to interfere with the formation of team-based care. (C) Society of General Internal Medicine 2013
C1 [Cronholm, Peter F.] Univ Penn, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA.
[Cronholm, Peter F.] Univ Penn, Ctr Publ Hlth Initiat, Philadelphia, PA 19104 USA.
[Cronholm, Peter F.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
[Shea, Judy A.; Werner, Rachel M.] Univ Penn, Div Gen Internal Med, Philadelphia, PA 19104 USA.
[Werner, Rachel M.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Miller-Day, Michelle] Chapman Univ, Dept Commun Studies, Orange, CA USA.
[Tufano, Jim] Univ Washington, Sch Med, Dept Biomed Informat & Med Educ, Seattle, WA USA.
[Crabtree, Benjamin F.] UMDNJ Robert Wood Johnson Med Sch, Dept Family Med & Community Hlth, New Brunswick, NJ USA.
[Gabbay, Robert] Penn State Coll Med, Penn State Milton S Hershey Med Ctr, Penn State Hershey Diabet Inst, Diabet Program, Hershey, PA USA.
RP Cronholm, PF (reprint author), Univ Penn, Dept Family Med & Community Hlth, 141 Anat & Chem Bldg,3620 Hamilton Walk, Philadelphia, PA 19104 USA.
EM peter.cronholm@uphs.upenn.edu
FU Agency for Healthcare Research and Quality [5R18HS019150]; Aetna
Foundation
FX This project was supported by a grant from the Agency for Healthcare
Research and Quality (5R18HS019150) and funds from Aetna Foundation.
NR 30
TC 26
Z9 26
U1 5
U2 30
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD SEP
PY 2013
VL 28
IS 9
BP 1195
EP 1201
DI 10.1007/s11606-013-2415-3
PG 7
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 202XR
UT WOS:000323254700020
PM 23539283
ER
PT J
AU Ganzini, L
Denneson, LM
Press, N
Bair, MJ
Helmer, DA
Poat, J
Dobscha, SK
AF Ganzini, Linda
Denneson, Lauren M.
Press, Nancy
Bair, Matthew J.
Helmer, Drew A.
Poat, Jennifer
Dobscha, Steven K.
TI Trust is the Basis for Effective Suicide Risk Screening and Assessment
in Veterans
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE depression; post-traumatic stress disorder; qualitative methods;
screening; suicide; veterans
ID CARE
AB To reduce suicides among Veterans, the Department of Veterans Affairs (VA) has designated suicide risk assessments for Veterans who screen positive for depression or post-traumatic stress disorder as a national performance goal. Many VA Medical Centers (VAMCs) are using brief suicidal ideation screens, administered in non-mental health ambulatory care settings, as the first step in the assessment process.
To explore Veterans' perceptions of the suicide screening and risk assessment process, the barriers and facilitators to disclosing suicidal thoughts, and perceptions of possible consequences of revealing suicidal thoughts.
Investigators recorded one semi-structured interview with each Veteran. Transcripts were analyzed using a modified grounded theory approach.
Thirty-four Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF) Veterans who screened positive for suicidal ideation in non-mental health ambulatory care settings in 2009 and 2010.
Veterans accepted the need to assess suicide risk. They increasingly experienced attempts to suppress and avoid thoughts of suicide as burdensome and exhausting. Despite this, Veterans often failed to disclose severe and pervasive suicidal thoughts when screened because: (1) they considered suicidal thoughts as shameful and a sign of weakness; (2) they believed suicidal thoughts were private and not to be divulged to strangers; (3) they worried that disclosure would lead to unwanted hospitalization or medication recommendations; and (4) the templated computer reminder process was perceived as perfunctory and disrespectful. In contrast, admitting and discussing thoughts of suicide with a health provider who focused on building a relationship, demonstrated genuineness and empathy, offered information on the rationale for suicide risk assessment, and used straightforward and understandable language, all promoted trust that resulted in more honest disclosure of suicidal thoughts.
In ambulatory care settings, both provider behaviors and system modifications may lead to more honest disclosure of suicidal thoughts. (C) Society of General Internal Medicine 2013
C1 [Ganzini, Linda; Denneson, Lauren M.; Dobscha, Steven K.] Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Phys & Mental D, Portland, OR 97207 USA.
[Ganzini, Linda; Denneson, Lauren M.; Dobscha, Steven K.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA.
[Press, Nancy] Oregon Hlth & Sci Univ, Dept Publ Hlth, Portland, OR 97201 USA.
[Press, Nancy; Poat, Jennifer] Oregon Hlth & Sci Univ, Dept Nursing, Portland, OR 97201 USA.
[Bair, Matthew J.] Richard L Roudebush Vet Adm Med Ctr, Indianapolis, IN 46202 USA.
[Helmer, Drew A.] W Haven Vet Affairs Med Ctr, West Haven, CT USA.
[Helmer, Drew A.] VA New Jersey Hlth Care Syst, War Related Illness & Injury Study Ctr, E Orange, NJ USA.
RP Ganzini, L (reprint author), Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Phys & Mental D, POB 1034 RD 66, Portland, OR 97207 USA.
EM linda.ganzini@va.gov
FU Department of Veterans Affairs, Veterans Health Administration, and
Health Services Research and Development Service [DHI-08-096]
FX We gratefully acknowledge the assistance of Michael Martin; Megan
Crutchfield, MPH; and Monica Huffman, BS. This material is based upon
work supported by the Department of Veterans Affairs, Veterans Health
Administration, and Health Services Research and Development Service
Project DHI-08-096. The views expressed in this article are those of the
authors and do not necessarily reflect the position or policy of the
Department of Veterans Affairs or the United States government.
NR 17
TC 21
Z9 21
U1 0
U2 12
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD SEP
PY 2013
VL 28
IS 9
BP 1215
EP 1221
DI 10.1007/s11606-013-2412-6
PG 7
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 202XR
UT WOS:000323254700023
PM 23580131
ER
PT J
AU Cassese, T
Kaplan, E
Douglas, V
Dhaliwal, G
AF Cassese, Todd
Kaplan, Elizabeth
Douglas, Vanja
Dhaliwal, Gurpreet
TI Getting to the Right Question
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Editorial Material
DE diagnostic reasoning; clinical problem solving; history-taking; weakness
ID PRIMARY SJOGRENS-SYNDROME; HYPOKALEMIC PERIODIC PARALYSIS; RESPIRATORY
ARREST; PHYSICIANS; DIAGNOSIS; ACIDOSIS
C1 [Cassese, Todd] Quinnipiac Univ, Dept Med Sci, Frank H Netter MD Sch Med, Hamden, CT 06518 USA.
[Kaplan, Elizabeth] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
[Douglas, Vanja] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
[Dhaliwal, Gurpreet] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Dhaliwal, Gurpreet] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Cassese, T (reprint author), Quinnipiac Univ, Dept Med Sci, Frank H Netter MD Sch Med, 275 Mt Carmel Ave, Hamden, CT 06518 USA.
EM todd.cassese@quinnipiac.edu
NR 15
TC 1
Z9 1
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD SEP
PY 2013
VL 28
IS 9
BP 1242
EP 1246
DI 10.1007/s11606-012-2254-7
PG 5
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 202XR
UT WOS:000323254700030
PM 23184311
ER
PT J
AU Cahill, ME
Remmers, C
Jones, KA
Xie, Z
Sweet, RA
Penzes, P
AF Cahill, Michael E.
Remmers, Christine
Jones, Kelly A.
Xie, Zhong
Sweet, Robert A.
Penzes, Peter
TI Neuregulin1 signaling promotes dendritic spine growth through kalirin
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Article
DE environmental enrichment; ERBB4; NRG1; plasticity; schizophrenia;
synapse
ID CENTRAL-NERVOUS-SYSTEM; PARVALBUMIN-POSITIVE INTERNEURONS; GDP/GTP
EXCHANGE FACTOR; LONG-TERM POTENTIATION; DEVELOPMENTAL PROFILE;
BEHAVIORAL PHENOTYPES; SURFACE EXPRESSION; PREFRONTAL CORTEX; TYROSINE
KINASE; RECEPTOR ERBB4
AB The biological functions of the neuregulin 1 (NRG1) and ERBB4 genes have received much recent attention due to several studies showing associations between these genes and schizophrenia. Moreover, reduced forebrain dendritic spine density is a consistent feature of schizophrenia. It is thus important to understand the mechanisms whereby NRG1 and erbB4 modulate spine morphogenesis. Here, we show that long-term incubation with NRG1 increases both spine size and density in cortical pyramidal neurons. NRG1 also enhances the content of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptors in spines. Knockdown of ERBB4 expression prevented the effects of NRG1 on spine size, but not on spine density. The effects of NRG1 and erbB4 on spines were mediated by the RacGEF kalirin, a well-characterized regulator of dendritic spines. Finally, we show that environmental enrichment, known to promote spine growth, robustly enhances the levels of erbB4 protein in the forebrain. These findings provide a mechanistic link between NRG1 signaling and spine morphogenesis.
C1 [Cahill, Michael E.; Remmers, Christine; Jones, Kelly A.; Xie, Zhong; Penzes, Peter] Northwestern Univ, Feinberg Sch Med, Dept Physiol, Chicago, IL 60611 USA.
[Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Psychiat, Translat Neurosci Program, Pittsburgh, PA USA.
[Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA.
[Sweet, Robert A.] VA Pittsburgh Healthcare Syst, Educ & Clin Ctr, VISN Mental Illness Res 4, Pittsburgh, PA USA.
[Penzes, Peter] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA.
RP Penzes, P (reprint author), 303 E Chicago Ave, Chicago, IL 60611 USA.
EM p-penzes@northwestern.edu
RI Xie, Zhong/B-6829-2011; Penzes, Peter/L-3987-2016
OI Xie, Zhong/0000-0002-8348-4455; Penzes, Peter/0000-0001-5449-1640
FU NIH-NIMH [R01MH071316, R01MH097216]; National Alliance for Research on
Schizophrenia and Depression (NARSAD); Ruth L. Kirschstein National
Research Service Awards [1F31AG031621-01A2, 1F31MH085362]; NIH [R01 MH
071533, R01 AG027224]; VHA [I01 BX000452]
FX This study was supported by grants from NIH-NIMH (R01MH071316,
R01MH097216), National Alliance for Research on Schizophrenia and
Depression (NARSAD) to P. P., Ruth L. Kirschstein National Research
Service Awards 1F31AG031621-01A2 to M. E. C and 1F31MH085362 to K.A.J,
and research grants from NIH (R01 MH 071533, R01 AG027224) and from the
VHA (I01 BX000452) to RAS. All experiments involving animals were done
according to the Institutional Animal Care and Use Committee of
Northwestern University. M. E. C, C. R, K.A.J., Z.X. performed research
and analyzed results. M. E. C., C. R., and P. P. wrote the manuscript,
and P. P. and R. A. S. contributed resources necessary to complete this
study.
NR 54
TC 15
Z9 15
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3042
J9 J NEUROCHEM
JI J. Neurochem.
PD SEP
PY 2013
VL 126
IS 5
BP 625
EP 635
DI 10.1111/jnc.12330
PG 11
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 204TV
UT WOS:000323393400008
PM 23742124
ER
PT J
AU Cirnigliaro, CM
Fountaine, MF
Emmons, R
Kirshblum, SC
Asselin, P
Spungen, AM
Bauman, WA
AF Cirnigliaro, Christopher M.
La Fountaine, Michael F.
Emmons, Racine
Kirshblum, Steven C.
Asselin, Pierre
Spungen, Ann M.
Bauman, William A.
TI Prediction of limb lean tissue mass from bioimpedance spectroscopy in
persons with chronic spinal cord injury
SO JOURNAL OF SPINAL CORD MEDICINE
LA English
DT Article
DE Spinal cord injury; Bioimpedance spectroscopy; Lean tissue mass;
Extracellular volume; Intracellular volume; Dual-energy X-ray
absorptiometry
ID X-RAY ABSORPTIOMETRY; SKELETAL-MUSCLE MASS; FAT-FREE MASS; RESTING
ENERGY-EXPENDITURE; BODY-COMPOSITION; BIOELECTRICAL-IMPEDANCE;
HEMODIALYSIS-PATIENTS; MEN; WATER; MODEL
AB Background: Bioimpedance spectroscopy (BIS) is a non-invasive, simple, and inexpensive modality that uses 256 frequencies to determine the extracellular volume impedance (ECVRe) and intracellular volume impedance (ICVRi) in the total body and regional compartments. As such, it may have utility as a surrogate measure to assess lean tissue mass (LTM).
Objective: To compare the relationship between LTM from dual-energy X-ray absorptiometry (DXA) and BIS impedance values in spinal cord injury (SCI) and able-bodied (AB) control subjects using a cross-sectional research design.
Methods: In 60 subjects (30 AB and 30 SCI), a total body DXA scan was used to obtain total body and leg LTM. BIS was performed to measure the impedance quotient of the ECVRe and ICVRi in the total body and limbs.
Results: BIS-derived ECVRe yielded a model for LTM in paraplegia, tetraplegia, and control for the right leg (RL) (R-2 = 0.75, standard errors of estimation (SEE) = 1.02 kg, P < 0.0001; R-2 = 0.65, SEE = 0.91 kg, P = 0.0006; and R-2 = 0.54, SEE = 1.31 kg, P < 0.0001, respectively) and left leg (LL) (R-2 = 0.76, SEE = 1.06 kg, P < 0.0001; R-2 = 0.64, SEE = 0.83 kg, P = 0.0006; and R-2 = 0.54, SEE = 1.34 kg, P < 0.0001, respectively). The ICVRi was similarly predictive of LTM in paraplegia, tetraplegia, and AB controls for the RL (R-2 = 0.85, SEE = 1.31 kg, P < 0.0001; R-2 = 0.52, SEE = 0.95 kg, P = 0.003; and R-2 = 0.398, SEE = 1.46 kg, P = 0.0003, respectively) and LL (R-2 = 0.62, SEE = 1.32 kg, P = 0.0003; R-2 = 0.57, SEE = 0.91 kg, P = 0.002; and R-2 = 0.42, SEE = 1.31 kg, P = 0.0001, respectively).
Conclusion: Findings demonstrate that the BIS-derived impedance quotients for ECVRe and ICVRi may be used as surrogate markers to track changes in leg LTM in persons with SCI.
C1 [Cirnigliaro, Christopher M.; La Fountaine, Michael F.; Asselin, Pierre; Spungen, Ann M.; Bauman, William A.] James J Peters VA Med Ctr, Natl Ctr Excellence Med Consequences Spinal Cord, Bronx, NY USA.
[La Fountaine, Michael F.; Spungen, Ann M.; Bauman, William A.] James J Peters VA Med Ctr, Med & Spinal Cord Injury Serv, Bronx, NY USA.
[La Fountaine, Michael F.] Seton Hall Univ, S Orange, NJ 07079 USA.
[La Fountaine, Michael F.; Spungen, Ann M.; Bauman, William A.] Icahn Sch Med Mt Sinai, New York, NY USA.
[Emmons, Racine] William Paterson Univ, Wayne, NJ USA.
[Kirshblum, Steven C.] Kessler Inst Rehabilitat, W Orange, NJ 07052 USA.
[Kirshblum, Steven C.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA.
RP Cirnigliaro, CM (reprint author), Kessler Inst Rehabilitat, Rm L052m,1199 Pleasant Valley Way, W Orange, NJ 07052 USA.
EM christopher.cirnigliaro@va.gov
FU James J. Peters VA Medical Center, Bronx, NY; Department of Veterans
Affairs Rehabilitation Research & Development (RRD) Service; Kessler
Institute for Rehabilitation, West Orange, NJ; RR&D National Center of
Excellence for the Medical Consequences of Spinal Cord Injury [B2648C,
B4162C]
FX The authors thank the James J. Peters VA Medical Center, Bronx, NY, the
Department of Veterans Affairs Rehabilitation Research & Development
(RR&D) Service, and the Kessler Institute for Rehabilitation, West
Orange, NJ for their support. This work was funded by a RR&D National
Center of Excellence for the Medical Consequences of Spinal Cord Injury
(#B2648C & B4162C).
NR 45
TC 1
Z9 1
U1 1
U2 6
PU MANEY PUBLISHING
PI LEEDS
PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND
SN 1079-0268
J9 J SPINAL CORD MED
JI J. Spinal Cord. Med.
PD SEP
PY 2013
VL 36
IS 5
SI SI
BP 443
EP 453
DI 10.1179/2045772313Y.0000000108
PG 11
WC Clinical Neurology
SC Neurosciences & Neurology
GA 203YL
UT WOS:000323330700006
PM 23941792
ER
PT J
AU Wecht, JM
Zhu, C
Weir, JP
Yen, C
Renzi, C
Galea, M
AF Wecht, Jill M.
Zhu, Carolyn
Weir, Joseph P.
Yen, Christina
Renzi, Christopher
Galea, Marinella
TI A prospective report on the prevalence of heart rate and blood pressure
abnormalities in veterans with spinal cord injuries
SO JOURNAL OF SPINAL CORD MEDICINE
LA English
DT Article
DE Spinal cord injuries; Bradycardia; Tachycardia; Hypotension;
Hypertension; Tetraplegia; Paraplegia; Autonomic function;
Cardiovascular disease; Veterans
ID REMAINING AUTONOMIC FUNCTION; PULSE-WAVE VELOCITY; INTERNATIONAL
STANDARDS; ARTERIAL STIFFNESS; CHRONIC HYPOTENSION; ORTHOSTATIC
HYPOTENSION; CARDIOVASCULAR-DISEASE; COGNITIVE PERFORMANCE; NEUROLOGICAL
LEVEL; PHYSICAL-ACTIVITY
AB Objective: Decentralized autonomic cardiovascular regulation may lead to increased prevalence of heart rate (HR) and blood pressure (BP) abnormalities in veterans with SCI. In addition, comorbid medical conditions and prescription medication use may increase HR and BP abnormalities. These abnormalities include bradycardia, and tachycardia, hypotension, hypertension as well as autonomic dysreflexia and orthostatic hypotension; the prevalence of which is unknown.
Design: HR and BP data were measured during a routine annual physical examination in 64 veterans with SCI. Measurements of HR and BP were recorded in the seated and supine positions to document the influence of body position and to document intra-subject variability in these assessments.
Results: All subjects were chronically injured (20 +/- 14 years), 33 subjects were tetraplegic (T: C3-C8), nine had high paraplegia (HP: T1-T6), and 22 had low paraplegia (LP: T7-L2). Regardless of position, the prevalence of bradycardia was increased in the T group, whereas prevalence of tachycardia was increased in the HP and LP groups. Systolic hypotension was more common in the T and HP groups than the LP group and positional effects were most evident in the T group. Systolic hypertension was comparable in the T and HP groups but was twice as prevalent in the LP group. Increased prevalence of individuals with three or more medical conditions and prescribed three or more medications which might influence HR and BP was observed.
Conclusion: Decentralized autonomic regulation, comorbid medical conditions, and prescription medication use in veterans with SCI result in HR and BP abnormalities; our data suggest that these abnormalities vary depending on the level of injury and orthostatic positioning.
C1 [Wecht, Jill M.; Yen, Christina; Renzi, Christopher] James J Peters VAMC, Ctr Excellence, Bronx, NY USA.
[Wecht, Jill M.; Galea, Marinella] James J Peters VAMC, Med Serv, Bronx, NY USA.
Mt Sinai Sch Med, Dept Med, New York, NY USA.
[Wecht, Jill M.; Galea, Marinella] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA.
[Zhu, Carolyn] Mt Sinai Sch Med, Dept Geriatr & Palliat Care, New York, NY USA.
[Zhu, Carolyn; Weir, Joseph P.] Univ Kansas, Dept Hlth Sport & Exercise Sci, Lawrence, KS 66045 USA.
RP Wecht, JM (reprint author), James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Rm 7A 13,130 West Kingsbridge Rd, Bronx, NY 10468 USA.
EM JM.Wecht@va.gov
FU Veterans Affairs Rehabilitation Research and Development Service
[B6999R]
FX This research was supported by the Veterans Affairs Rehabilitation
Research and Development Service (Grant no. B6999R).
NR 45
TC 5
Z9 5
U1 1
U2 10
PU MANEY PUBLISHING
PI LEEDS
PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND
SN 1079-0268
J9 J SPINAL CORD MED
JI J. Spinal Cord. Med.
PD SEP
PY 2013
VL 36
IS 5
SI SI
BP 454
EP 462
DI 10.1179/2045772313Y.0000000109
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA 203YL
UT WOS:000323330700007
PM 23941793
ER
PT J
AU Zhu, C
Galea, M
Livote, E
Signor, D
Wecht, JM
AF Zhu, Carolyn
Galea, Marinella
Livote, Elayne
Signor, Dan
Wecht, Jill M.
TI A retrospective chart review of heart rate and blood pressure
abnormalities in veterans with spinal cord injury
SO JOURNAL OF SPINAL CORD MEDICINE
LA English
DT Review
DE Spinal cord injuries; Cardiac arrhythmias; Hypotension; Hypertension;
Orthostatic hypotension; Autonomic dysreflexia; Tetraplegia; Paraplegia
ID CARDIOVASCULAR-DISEASE RISK; CONTINGENT NEGATIVE-VARIATION;
INTERNATIONAL STANDARDS; DEPRESSIVE SYMPTOMS; ARTERIAL STIFFNESS;
AUTONOMIC DYSREFLEXIA; COGNITIVE PERFORMANCE; HYPERTENSIVE SUBJECTS;
NEUROLOGICAL LEVEL; FOLLOW-UP
AB Objective: Autonomic impairment may lead to increased prevalence of heart rate (HR) and blood pressure (BP) abnormalities in veterans with spinal cord injury (SCI). In addition, comorbid medical conditions and prescription medication use may influence these abnormalities, including bradycardia, and tachycardia, hypotension, hypertension as well as autonomic dysreflexia (AD), and orthostatic hypotension (OH).
Design: A retrospective review of clinical and administrative datasets in veterans with SCI and compared the prevalence rates between clinical values and ICD-9 diagnostic codes in individuals with tetraplegia (T: C1-C8), high paraplegia (HP: T1-T6), and low paraplegia (LP: T7 and below).
Results: The prevalence of clinical values indicative of a HR >= 80 beats per minute was higher in the HP compared to the LP and T groups. A systolic BP (SBP) <= 110 mmHg was more common in the T compared to the HP and LP groups, whereas the prevalence of a SBP >= 140 mmHg was increased in the LP compared to the HP and T groups. Diagnosis of hypertension was 39-60% whereas the diagnosis of hypotension was less than 1%. Diagnosis of AD and OH was highest in the T group, but remained below 10%, regardless of categorical lesion level. Antihypertensive medications were commonly prescribed (55%), and patients on these medications were less likely to have high BP. The odds ratio of higher SBP and DBP increased with age and body mass index (BMI).
Conclusion: In veterans with SCI, the prevalence of HR and BP abnormalities varied depending on level of lesion, age, BMI, and prescription medication use.
C1 [Zhu, Carolyn; Livote, Elayne; Signor, Dan] James J Peters VAMC, Dept Geriatr & Palliat Med, Bronx, NY USA.
[Galea, Marinella; Wecht, Jill M.] James J Peters VAMC, Med Serv, Bronx, NY USA.
[Wecht, Jill M.] James J Peters VAMC, Ctr Excellence, Bronx, NY USA.
[Wecht, Jill M.] Mt Sinai Sch Med, Dept Med, New York, NY USA.
[Galea, Marinella; Wecht, Jill M.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA.
RP Wecht, JM (reprint author), James J Peters VA Med Ctr, Room 1E-02,130 West Kingsbridge Rd, Bronx, NY 10468 USA.
EM JM.Wecht@va.gov
FU Veterans Affairs Rehabilitation Research and Development Service
[B6999R]
FX This research was supported by the Veterans Affairs Rehabilitation
Research and Development Service (Grant # B6999R).
NR 59
TC 7
Z9 7
U1 2
U2 10
PU MANEY PUBLISHING
PI LEEDS
PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND
SN 1079-0268
J9 J SPINAL CORD MED
JI J. Spinal Cord. Med.
PD SEP
PY 2013
VL 36
IS 5
SI SI
BP 463
EP 475
DI 10.1179/2045772313Y.0000000145
PG 13
WC Clinical Neurology
SC Neurosciences & Neurology
GA 203YL
UT WOS:000323330700008
PM 23941794
ER
PT J
AU Bauman, WA
La Fountaine, MF
Cirnigliaro, CM
Kirshblum, SC
Spungen, AM
AF Bauman, William A.
La Fountaine, Michael F.
Cirnigliaro, Christopher M.
Kirshblum, Steven C.
Spungen, Ann M.
TI Low-dose baclofen therapy raised plasma insulin-like growth factor-1
concentrations, but not into the normal range in a predictable and
sustained manner in men with chronic spinal cord injury
SO JOURNAL OF SPINAL CORD MEDICINE
LA English
DT Article
DE Baclofen; Gamma-aminobutyric acid; Insulin-like growth factor-1;
Testosterone; Spinal cord injuries; Paraplegia; Tetraplegia; Spasticity
ID GAMMA-AMINOBUTYRIC-ACID; RESTING ENERGY-EXPENDITURE; HORMONE-SECRETION;
BODY-COMPOSITION; TESTOSTERONE; STIMULATION; INDIVIDUALS; INVOLVEMENT;
DISCORDANT; FAILURE
AB Objective: To evaluate, whether once-daily oral baclofen administration increases and/or sustains plasma insulin-like growth factor-1 (IGF-1) concentration in 11 men with chronic spinal cord injury (SCI) and IGF-1 deficiency (i.e. <250 ng/ml).
Design: Prospective, open-label, dose titration study. Baclofen was administered at 20 mg/day for 8 weeks; then increased to 40 mg/day for another 8 weeks. Plasma IGF-1 and self-reported side effects were measured at baseline and every other week for the duration of the study.
Results: The subjects were 43 +/- 12 years old, had duration of injury of 20 +/- 12 years; eight subjects had a complete motor injury, and eight had paraplegia. Nine of 11 subjects completed the 20 mg/day treatment and 5 subjects completed the 40 mg/day treatment. Plasma IGF-1 levels improved with each baclofen dose; however, only one subject increased from baseline and remained above the targeted physiological range of 250 ng/ml throughout treatment. A significant increase in IGF-1concentration was observed between baseline and week 2 (154 +/- 63 vs. 217 +/- 69 ng/ml; P < 0.05), weeks 8 and 10 (188 +/- 95 vs. 228 +/- 93 ng/ml; P < 0.05), and weeks 8 and 16 (188 +/- 95 vs. 259 +/- 92 ng/ml; P < 0.05). No serious side effects were observed at 20 mg/day; the 40 mg/day dose was less well tolerated.
Conclusion: Baclofen was not effective at sustaining plasma IGF-1 concentrations in the physiological range in men with chronic SCI.
C1 [Bauman, William A.; La Fountaine, Michael F.; Cirnigliaro, Christopher M.; Spungen, Ann M.] James J Peters VA Med Ctr, VA RR&D Natl Ctr Excellence Med Consequences Spin, Bronx, NY 10468 USA.
[Bauman, William A.; Spungen, Ann M.] James J Peters VA Med Ctr, Med Serv, Bronx, NY 10468 USA.
[Bauman, William A.; Spungen, Ann M.] Mt Sinai Sch Med, Dept Med, New York, NY USA.
[Bauman, William A.; Spungen, Ann M.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA.
[La Fountaine, Michael F.] Seton Hall Univ, Sch Hlth & Med Sci, Dept Phys Therapy, S Orange, NJ 07079 USA.
[Kirshblum, Steven C.] Kessler Inst Rehabil, W Orange, NJ USA.
[Kirshblum, Steven C.] Univ Med & Dent New Jersey, Dept Phys Med & Rehabil, Newark, NJ 07103 USA.
RP Bauman, WA (reprint author), James J Peters VA Med Ctr, Natl Ctr Excellence Med Consequences Spinal Cord, 130 West Kingsbridge Rd, Bronx, NY 10468 USA.
EM william.bauman@va.gov
FU James J. Peters VA Medical Center, Bronx, NY; Department of Veterans
Affairs Rehabilitation Research & Development Service; Kessler Institute
for Rehabilitation, West Orange, NJ; Veteran Affairs Rehabilitation
Research & Development National Center of Excellence for the Medical
Consequences of Spinal Cord Injury [B4162-C, B9212-C]
FX The authors thank the James J. Peters VA Medical Center, Bronx, NY, the
Department of Veterans Affairs Rehabilitation Research & Development
Service, and Kessler Institute for Rehabilitation, West Orange, NJ for
their support. This work was funded by the Veteran Affairs
Rehabilitation Research & Development National Center of Excellence for
the Medical Consequences of Spinal Cord Injury (No.'s B4162-C &
B9212-C).
NR 37
TC 3
Z9 3
U1 0
U2 1
PU MANEY PUBLISHING
PI LEEDS
PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND
SN 1079-0268
J9 J SPINAL CORD MED
JI J. Spinal Cord. Med.
PD SEP
PY 2013
VL 36
IS 5
SI SI
BP 476
EP 482
DI 10.1179/2045772312Y.0000000061
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 203YL
UT WOS:000323330700009
PM 23941795
ER
PT J
AU Evans, CT
Rogers, TJ
Chin, A
Johnson, S
Smith, B
Weaver, FM
Burns, SP
AF Evans, Charlesnika T.
Rogers, Thea J.
Chin, Amy
Johnson, Stuart
Smith, Bridget
Weaver, Frances M.
Burns, Stephen P.
TI Antibiotic prescribing trends in the emergency department for veterans
with spinal cord injury and disorder 2002-2007
SO JOURNAL OF SPINAL CORD MEDICINE
LA English
DT Article
DE Physician's practice patterns; Spinal cord injuries; Antibiotic
prescribing patterns; Antibiotic resistance; Veterans; Clinical
guidelines
ID RESPIRATORY-TRACT INFECTIONS; UNITED-STATES; ADULTS; RESISTANCE;
BRONCHITIS; PROVIDERS; SETTINGS
AB Objective: Clinical guidelines exist to promote antibiotic stewardship, particularly in ambulatory care settings such as the emergency department (ED). However, there is limited evidence on prescribing practice for persons with spinal cord injury and disorder (SCI/D). The goal of this study was to assess trends in antibiotic prescribing in the ED setting for persons with SCI/D.
Design: A retrospective dynamic cohort study design.
Setting: ED visits that did not result in same day hospitalization over 6 years (fiscal year (FY) 2002-FY2007) in Department of Veterans Affairs (VA) facilities
Participants: Veterans with SCI/D.
Outcome measures: VA clinical and administrative databases were used to identify the cohort and to obtain demographics, diagnoses, and medications. The rate of antibiotic prescribing for ED visits was defined as the number of antibiotics/total ED visits.
Results: Veterans with SCI/D had 21 934 ED visits and 5887 antibiotics prescribed over the study period (rate of 268.4 prescriptions/1000 visits). The antibiotic prescribing rate increased from 238.8/1000 visits in FY2002 to 310.8/1000 visits in FY2007 (P < 0.0001). This increase in the rate of prescribing was seen across all patient demographics and factors assessed.
Conclusion: Although clinical guidelines for judicious use of antibiotics in persons with SCI/D have been disseminated to providers, antibiotic prescribing in an ED setting is high and continuing to rise in this population.
C1 [Evans, Charlesnika T.; Rogers, Thea J.; Chin, Amy; Smith, Bridget; Weaver, Frances M.] Northwestern Univ, Feinberg Sch Med, Dept Vet Affairs VA, Ctr Management Complex Chron Care, Chicago, IL 60611 USA.
[Evans, Charlesnika T.; Rogers, Thea J.; Chin, Amy; Smith, Bridget; Weaver, Frances M.; Burns, Stephen P.] Northwestern Univ, Feinberg Sch Med, Spinal Cord Injury Qual Enhancement Res Initiat S, Chicago, IL 60611 USA.
[Evans, Charlesnika T.] Northwestern Univ, Feinberg Sch Med, Inst Healthcare Studies, Chicago, IL 60611 USA.
[Johnson, Stuart; Smith, Bridget; Weaver, Frances M.] Loyola Univ, Med Ctr, Dept Med, Maywood, IL 60153 USA.
[Burns, Stephen P.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Burns, Stephen P.] Univ Washington, Seattle, WA 98195 USA.
RP Evans, CT (reprint author), Edward J Hines Jr VA Hosp 151H, 5th Ave & Roosevelt Rd,POB 5000,Room D302, Hines, IL 60141 USA.
EM Charlesnika.Evans@va.gov
NR 23
TC 3
Z9 3
U1 0
U2 8
PU MANEY PUBLISHING
PI LEEDS
PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND
SN 1079-0268
J9 J SPINAL CORD MED
JI J. Spinal Cord. Med.
PD SEP
PY 2013
VL 36
IS 5
SI SI
BP 492
EP 498
DI 10.1179/2045772312Y.0000000076
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 203YL
UT WOS:000323330700011
PM 23941797
ER
PT J
AU Doran, KM
Ragins, KT
Iacomacci, AL
Cunningham, A
Jubanyik, KJ
Jenq, GY
AF Doran, Kelly M.
Ragins, Kyle T.
Iacomacci, Andrea L.
Cunningham, Alison
Jubanyik, Karen J.
Jenq, Grace Y.
TI The Revolving Hospital Door Hospital Readmissions Among Patients Who Are
Homeless
SO MEDICAL CARE
LA English
DT Article
DE homelessness; readmissions; hospital quality
ID CASE-MANAGEMENT PROGRAM; HEART-FAILURE; RESPITE CARE; HEALTH-CARE;
COSTS; ADULTS
AB Background: National attention is increasingly focused on hospital readmissions. Little prior research has examined readmissions among patients who are homeless.Objective: The aim of the study was to determine 30-day hospital readmission rates among patients who are homeless and examine factors associated with hospital readmissions in this population.Methods: We conducted a retrospective chart review of patients who were homeless and hospitalized at a single urban hospital from May-August 2012. Homelessness was identified by an electronic medical record flag and confirmed by manual chart review. The primary outcome was all-cause hospital readmission to the study hospital within 30 days of hospital discharge. Patient-level and hospitalization-level factors associated with risk for readmission were examined using generalized estimating equations.Results: There were 113 unique patients who were homeless and admitted to the hospital a total of 266 times during the study period. The mean age was 49 years, 27.4% of patients were women, and 75.2% had Medicaid. Half (50.8%) of all hospitalizations resulted in a 30-day hospital inpatient readmission and 70.3% resulted in either an inpatient readmission, observation status stay, or emergency department visit within 30 days of hospital discharge. Most readmissions occurred early after hospital discharge (53.9% within 1 week, 74.8% within 2 weeks). Discharge to the streets or shelter versus other living situations was associated with increased risk for readmission in multivariable analyses.Conclusions: Patients who were homeless had strikingly high 30-day hospital readmission rates. These findings suggest the urgent need for further research and interventions to improve postdischarge care for patients who are homeless.
C1 [Doran, Kelly M.] Yale Univ, Sch Med, Robert Wood Johnson Fdn, Clin Scholars Program, New Haven, CT USA.
[Doran, Kelly M.] US Dept Vet Affairs, New Haven, CT USA.
[Doran, Kelly M.; Jubanyik, Karen J.] Yale Univ, Sch Med, Dept Emergency Med, New Haven, CT USA.
[Ragins, Kyle T.] Yale Univ, Sch Med, New Haven, CT USA.
[Iacomacci, Andrea L.] Yale New Haven Med Ctr, Dept Clin Effectiveness, New Haven, CT 06504 USA.
[Cunningham, Alison] Columbus House Inc, New Haven, CT USA.
[Jenq, Grace Y.] Yale Univ, Sch Med, Dept Med, Sect Geriatr, New Haven, CT 06510 USA.
RP Doran, KM (reprint author), Bellevue Hosp Ctr, Dept Emergency Med, 1st Ave & 27th St,Room A345, New York, NY 10016 USA.
EM kmdoran@gmail.com
NR 24
TC 11
Z9 11
U1 2
U2 25
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
J9 MED CARE
JI Med. Care
PD SEP
PY 2013
VL 51
IS 9
BP 767
EP 773
DI 10.1097/MLR.0b013e31829fafbb
PG 7
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 205AE
UT WOS:000323411600004
PM 23929401
ER
PT J
AU Brent, GA
Kogai, T
AF Brent, Gregory A.
Kogai, Takahiko
TI CANCER Novel target to enhance radioiodine uptake in thyroid cancer
SO NATURE REVIEWS ENDOCRINOLOGY
LA English
DT Editorial Material
AB The sodium-iodide symporter mediates iodide uptake, but its activity is reduced by the overexpression of pituitary tumour-transforming gene 1 protein-binding factor (PBF) in thyroid tumours. A recent study shows that inhibiting PBF phosphorylation enhances radioiodine uptake in thyroid cancer models.
C1 [Brent, Gregory A.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA 90073 USA.
[Kogai, Takahiko] Dokkyo Med Univ, Dept Infect Control & Clin Lab Med, Mibu, Tochigi 3210293, Japan.
RP Brent, GA (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM gbrent@ucla.edu
FU NCI NIH HHS [R01 CA89364]
NR 10
TC 3
Z9 4
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-5029
J9 NAT REV ENDOCRINOL
JI Nat. Rev. Endocrinol.
PD SEP
PY 2013
VL 9
IS 9
BP 508
EP 509
DI 10.1038/nrendo.2013.132
PG 3
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 202LQ
UT WOS:000323218200003
PM 23817292
ER
PT J
AU Blomberg, BA
Akers, SR
Saboury, B
Mehta, NN
Cheng, G
Torigian, DA
Lim, E
Del Bello, C
Werner, TJ
Alavi, A
AF Blomberg, Bjoern A.
Akers, Scott R.
Saboury, Babak
Mehta, Nehal N.
Cheng, Gang
Torigian, Drew A.
Lim, Esther
Del Bello, Catherine
Werner, Thomas J.
Alavi, Abass
TI Delayed time-point F-18-FDG PET CT imaging enhances assessment of
atherosclerotic plaque inflammation
SO NUCLEAR MEDICINE COMMUNICATIONS
LA English
DT Article
DE atherosclerosis; fluorine-18 fluorodeoxyglucose; multiple time-point
imaging; positron emission tomography
ID POSITRON-EMISSION-TOMOGRAPHY; VASCULAR INFLAMMATION; FLUORODEOXYGLUCOSE
UPTAKE; LARGE ARTERIES; FDG-PET; RISK; RESOLUTION; WALL
AB Objective The aim of this study was to determine the ideal circulation time of fluorine-18 fluorodeoxyglucose (F-18-FDG) in order to detect and quantify atherosclerotic plaque inflammation with PET computed tomography (CT) imaging.Methods Fifteen patients underwent multiple time-point imaging at approximate to 60, 120, and 180 min after F-18-FDG administration. For each time point, global assessment of aortic and carotid F-18-FDG uptake was determined qualitatively by visual assessment and semiquantitatively by calculation of the mean and maximum standardized uptake values (SUV) and the corresponding target-to-background ratio (TBR).Results Delayed imaging achieved significant improvement in visualization of atherosclerotic plaque inflammation [Friedman's (2) statistic (d.f.=2, n=15)=24.13, P<0.001, Kendall's W=0.80]. This observation was confirmed by semiquantitative image analysis. At 1 h, the aortic and carotid SUVmean-calculated TBR was 1.05 [95% confidence interval (CI)=0.98, 1.11] and 0.88 (95% CI=0.81, 0.96), respectively. At 3 h, the TBR significantly increased to 1.57 (95% CI=1.28, 1.86; P=0.001) for the aorta and to 1.61 (95% CI=1.36, 1.87; P<0.001) for the carotid arteries. SUVmax-calculated TBRs showed a similar increase over time.Conclusion One- and 2-h F-18-FDG PET CT imaging is suboptimal for global assessment of atherosclerotic plaque inflammation compared with imaging at 3 h. Our data support the utilization of 3-h delayed imaging to obtain optimal data for the detection and quantification of atherosclerotic plaque inflammation in human arteries.
C1 [Blomberg, Bjoern A.; Saboury, Babak; Torigian, Drew A.; Alavi, Abass] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Blomberg, Bjoern A.; Saboury, Babak; Torigian, Drew A.; Werner, Thomas J.; Alavi, Abass] Hosp Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA.
[Akers, Scott R.; Cheng, Gang; Lim, Esther; Del Bello, Catherine] Philadelphia VA Med Ctr, Dept Radiol, Philadelphia, PA USA.
[Mehta, Nehal N.] NHLBI, Bethesda, MD 20892 USA.
[Blomberg, Bjoern A.] Univ Utrecht, Sch Med, Univ Med Ctr Utrecht, Utrecht, Netherlands.
RP Alavi, A (reprint author), 3400 Spruce St, Philadelphia, PA 19104 USA.
EM abass.alavi@uphs.upenn.edu
FU United States Department of Veterans Affairs (VISN 4 CPPF Grant)
FX This study was supported in part by a grant from the United States
Department of Veterans Affairs (VISN 4 CPPF Grant).
NR 29
TC 11
Z9 12
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0143-3636
J9 NUCL MED COMMUN
JI Nucl. Med. Commun.
PD SEP
PY 2013
VL 34
IS 9
BP 860
EP 867
DI 10.1097/MNM.0b013e3283637512
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 202QA
UT WOS:000323232000004
PM 23799532
ER
PT J
AU Gandhi, NR
Tate, JP
Rodriguez-Barradas, MC
Rimland, D
Goetz, MB
Gibert, C
Brown, ST
Mattocks, K
Justice, AC
AF Gandhi, Neel R.
Tate, Janet P.
Rodriguez-Barradas, Maria C.
Rimland, David
Goetz, Matthew Bidwell
Gibert, Cynthia
Brown, Sheldon T.
Mattocks, Kristin
Justice, Amy C.
TI Validation of an algorithm to identify antiretroviral-naive status at
time of entry into a large, observational cohort of HIV-infected
patients
SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
LA English
DT Article
DE HIV-1; antiretroviral therapy; cohort studies; HIV infections;
epidemiology; HIV infections/drug therapy; pharmacoepidemiology
ID IMMUNODEFICIENCY-VIRUS-INFECTION; FRENCH-HOSPITAL-DATABASE;
MYOCARDIAL-INFARCTION; HIV-1-INFECTED PATIENTS; THERAPY; RISK;
MORTALITY; AIDS; AGE; COLLABORATION
AB Purpose Large, observational HIV cohorts play an important role in answering questions which are difficult to study in randomized trials; however, they often lack detailed information regarding previous antiretroviral treatment (ART). Knowledge of ART treatment history is important when ascertaining the long-term impact of medications, co-morbidities, or adverse reactions on HIV outcomes.
Methods We performed a retrospective study to validate a prediction algorithm for identifying ART-naive patients using the Veterans Aging Cohort Study's Virtual Cohortan observational cohort of 40594 HIV-infected veterans nationwide. Medical records for 3070 HIV-infected patients were reviewed to determine history of combination ART treatment. An algorithm using Virtual Cohort laboratory data was used to predict ART treatment status and compared to medical record review.
Results Among 3070 patients' medical records reviewed, 1223 were eligible for analysis. Of these, 990 (81%) were ART naive at cohort entry based on medical record review. The prediction algorithm's sensitivity was 86%, specificity 47%, positive predictive value (PPV) 87%, and negative predictive value 45%, using a viral load threshold of <400 copies/ml. Sensitivity analysis revealed that PPV would be maximized by increasing the viral load threshold, whereas sensitivity would be maximized by lowering the viral load threshold.
Conclusions A prediction algorithm using available laboratory data can be used to accurately identify ART-naive patients in large, observational HIV cohorts. Use of this algorithm will allow investigators to accurately limit analyses to ART-naive patients when studying the contribution of ART to outcomes and adverse events. Copyright (c) 2013 John Wiley & Sons, Ltd.
C1 [Gandhi, Neel R.] Albert Einstein Coll Med, Div Gen Internal Med, Bronx, NY 10467 USA.
[Gandhi, Neel R.] Montefiore Med Ctr, Bronx, NY 10467 USA.
[Gandhi, Neel R.] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA.
[Gandhi, Neel R.] Emory Univ, Rollins Sch Publ Hlth, Dept Global Hlth, Atlanta, GA 30322 USA.
[Gandhi, Neel R.] Emory Univ, Rollins Sch Publ Hlth, Dept Infect Dis, Atlanta, GA 30322 USA.
[Tate, Janet P.; Justice, Amy C.] Yale Univ, Sch Med, Dept Med, Gen Internal Med Sect, New Haven, CT 06510 USA.
[Tate, Janet P.; Justice, Amy C.] VA Connecticut Healthcare Syst, New Haven, CT USA.
[Rodriguez-Barradas, Maria C.] Michael E DeBakey VA Med Ctr, Infect Dis Sect, Houston, TX USA.
[Rodriguez-Barradas, Maria C.] Michael E DeBakey VA Med Ctr, Dept Med, Houston, TX USA.
[Rodriguez-Barradas, Maria C.] Baylor Coll Med, Houston, TX 77030 USA.
[Rimland, David] Emory Univ, Sch Med, Dept Med, Infect Dis Sect, Atlanta, GA 30322 USA.
[Rimland, David] Atlanta VA Med Ctr, Atlanta, GA USA.
[Goetz, Matthew Bidwell] VA Greater Los Angeles Healthcare Syst, Infect Dis Sect, Los Angeles, CA USA.
[Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Gibert, Cynthia] Washington DC VA Med Ctr, Infect Dis Sect, Washington, DC USA.
[Gibert, Cynthia] George Washington Univ, Med Ctr, Washington, DC 20037 USA.
[Brown, Sheldon T.] James J Peters VA Med Ctr, Dept Med, Infect Dis Sect, New York, NY USA.
[Brown, Sheldon T.] Mt Sinai Sch Med, New York, NY USA.
[Mattocks, Kristin] VA Cent Western Massachusetts Hlth Care Syst, Quantitat Hlth Sci & Psychiat, Leeds, MA USA.
[Mattocks, Kristin] Univ Massachusetts, Med Ctr, Worcester, MA USA.
RP Gandhi, NR (reprint author), Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, 1518 Clifton Rd NE,CNR 3031, Atlanta, GA 30322 USA.
EM neelgandhi@alumni.williams.edu
OI Goetz, Matthew/0000-0003-4542-992X
FU National Institutes of Health: NIAAA [U10-AA13566]; NIA [R01-AG029154,
K23 AG024896]; Doris Duke Charitable Foundation Clinical Scientist
Development Award [2007070]; Training Program in Environmental
Epidemiology [T32 ES07069]; Centers for AIDS Research at Albert
Einstein/Montefiore [AI-51519]; Emory University [P30 AI050409]
FX This work was financially supported by National Institutes of Health:
NIAAA (U10-AA13566), and NIA (R01-AG029154; K23 AG024896). Dr. Gandhi is
the recipient of the Doris Duke Charitable Foundation Clinical Scientist
Development Award (2007070). Dr. Tate was supported by the Training
Program in Environmental Epidemiology funded under grant no. T32
ES07069. This work was also facilitated by the Centers for AIDS Research
at Albert Einstein/Montefiore (AI-51519) and at Emory University (P30
AI050409).
NR 24
TC 6
Z9 6
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1053-8569
J9 PHARMACOEPIDEM DR S
JI Pharmacoepidemiol. Drug Saf.
PD SEP
PY 2013
VL 22
IS 9
BP 1019
EP 1025
DI 10.1002/pds.3476
PG 7
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
GA 202WF
UT WOS:000323250600013
PM 23836591
ER
PT J
AU Davidson, TM
Price, M
McCauley, JL
Ruggiero, KJ
AF Davidson, Tatiana M.
Price, Matthew
McCauley, Jenna L.
Ruggiero, Kenneth J.
TI Disaster Impact Across Cultural Groups: Comparison of Whites, African
Americans, and Latinos
SO AMERICAN JOURNAL OF COMMUNITY PSYCHOLOGY
LA English
DT Article
DE Disaster impact; Cultural groups; PTSD; Depression
ID STRESSFUL LIFE EVENTS; HURRICANE-KATRINA; PSYCHOLOGICAL DISTRESS; PTSD;
RACE; RESOURCES; ETHNICITY; COMMUNICATION; RESILIENCE; CHECKLIST
AB The current study extends knowledge regarding the differential impact of natural disasters among White, African American, and Latino survivors of Hurricane Ike through its use of a large, regional sample recruited via representative sampling procedures to examine the associations between cultural identification and disaster impact, including loss, damage, and negative mental health outcomes. Consistent with previous research, results indicated disparities between cultural groups with regard to disaster exposure. Additionally, type of disaster impact was differentially associated with PTSD and depression status dependent on cultural group. Specifically, the extent of personal disaster exposure, property damage, and loss of services made significant contributions to PTSD status among White survivors. African-Americans were more likely than White and Latino Ike survivors to endorse post-disaster PTSD and depression and endorsement of depression was predicted by severity of property damage. With respect to Latino respondents, only the extent of personal disaster exposure significantly contributed to both PTSD and depression status. Implications of the current findings are discussed with regard to future disaster preparedness and response efforts and the implementation and evaluation of community-based disaster resources.
C1 [Davidson, Tatiana M.; Price, Matthew; McCauley, Jenna L.] Med Univ S Carolina, Natl Crime Victims Res & Treatment Ctr, Charleston, SC 29425 USA.
[Ruggiero, Kenneth J.] Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA.
RP Davidson, TM (reprint author), Med Univ S Carolina, Natl Crime Victims Res & Treatment Ctr, 67 President St IOP 2 South,MSC 861, Charleston, SC 29425 USA.
EM davidst@musc.edu
FU NIMH NIH HHS [R34 MH077149, R34 MH77149]
NR 50
TC 6
Z9 6
U1 4
U2 28
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0091-0562
J9 AM J COMMUN PSYCHOL
JI Am. J. Community Psychol.
PD SEP
PY 2013
VL 52
IS 1-2
BP 97
EP 105
DI 10.1007/s10464-013-9579-1
PG 9
WC Public, Environmental & Occupational Health; Psychology,
Multidisciplinary; Social Work
SC Public, Environmental & Occupational Health; Psychology; Social Work
GA 194QE
UT WOS:000322647000008
PM 23709270
ER
PT J
AU Kazamel, M
Cutter, G
Claussen, G
Alsharabati, M
Oh, SJ
Lu, L
King, PH
AF Kazamel, Mohamed
Cutter, Gary
Claussen, Gwendolyn
Alsharabati, Mohammad
Oh, Shin J.
Lu, Liang
King, Peter H.
TI Epidemiological features of amyotrophic lateral sclerosis in a large
clinic-based African American population
SO AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION
LA English
DT Article
DE Motor neuron disease; race; phenotype; gender effect
ID MOTOR-NEURON DISEASE; PROGNOSIS; ALS
AB Our objective was to identify the main clinical and epidemiological features of ALS in a large cohort of African American (AA) patients and compare them to Caucasian (CA) patients in a clinic-based population. We retrospectively identified 207 patients who were diagnosed with ALS based on the revised El Escorial criteria (60 AA and 147 CA subjects). Patients were seen in the Neuromuscular Division at the University Medical Center. We compared epidemiological and clinical features of these two groups, focusing on age of onset and diagnosis, clinical presentation and survival. Results showed that AA patients had a significantly younger age of disease onset (55 years vs. 61 years for CA, p = 0.011) and were diagnosed at an earlier age (56 years vs. 62 years, p = 0.012). In younger ALS patients (< 45 years of age), there was a significant difference in gender frequency, with females predominating in the AA population and males in the CA population (p = 0.025). In a multivariable Cox proportional hazard model, survival rates were not different between the groups. In both groups, survival significantly increased with younger age. In conclusion, AA patients presented at an earlier age, but there was no difference in survival compared to CA patients. A gender reversal occurred in younger ALS patients, with AA patients more likely to be female and CA patients more likely to be male.
C1 [Kazamel, Mohamed; Claussen, Gwendolyn; Alsharabati, Mohammad; Oh, Shin J.; Lu, Liang; King, Peter H.] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL USA.
[Cutter, Gary] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL USA.
[King, Peter H.] Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Birmingham, AL USA.
[King, Peter H.] Univ Alabama Birmingham, Dept Genet, Birmingham, AL USA.
[Oh, Shin J.; Lu, Liang; King, Peter H.] Birmingham VA Med Ctr, Birmingham, AL USA.
RP King, PH (reprint author), 1720 7th Ave S,SC 260, Birmingham, AL 35294 USA.
EM pking@uab.edu
FU National Institutes of Health; Department of Veterans Affairs
FX Funding was provided by the National Institutes of Health (PHK and LL),
and Department of Veterans Affairs (PHK).
NR 16
TC 7
Z9 8
U1 0
U2 0
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 2167-8421
J9 AMYOTROPH LA SCL FR
JI Amyotroph. Lateral Scher. Frontotemp. Degenerat.
PD SEP
PY 2013
VL 14
IS 5-6
BP 334
EP 337
DI 10.3109/21678421.2013.770030
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA 196NR
UT WOS:000322782800002
PM 23458155
ER
PT J
AU Liang, QL
Benavides, GA
Vassilopoulos, A
Gius, D
Darley-Usmar, V
Zhang, JH
AF Liang, Qiuli
Benavides, Gloria A.
Vassilopoulos, Athanassios
Gius, David
Darley-Usmar, Victor
Zhang, Jianhua
TI Bioenergetic and autophagic control by Sirt3 in response to nutrient
deprivation in mouse embryonic fibroblasts
SO BIOCHEMICAL JOURNAL
LA English
DT Article
DE apoptosis; autophagy; c-Jun; c-Jun N-terminal kinase (JNK); sirtuin 3
ID OXIDATIVE STRESS; DEPENDENT DEACETYLASE; LYSINE ACETYLATION; CELLULAR
BIOENERGETICS; MONITORING AUTOPHAGY; CALORIE RESTRICTION;
SKELETAL-MUSCLE; SIRTUINS; LC3; PROTEIN
AB Sirt3 (sirtuin 3) is an NAD-dependent deacetylase localized to mitochondria. Sirt3 expression is increased in mouse muscle and liver by starvation, which could protect against the starvation-dependent increase in oxidative stress and protein damage. Damaged proteins and organelles depend on autophagy for removal and this is critical for cell survival, but the role of Sirt3 is unclear. To examine this, we used Sirt3-KO (knockout) mouse embryonic fibroblast cells, and found that, under basal conditions, Sirt3-KO cells exhibited increased autophagy flux compared with WT (wild-type) cells. In response to nutrient deprivation, both WT and KO cells exhibited increased basal and ATP-linked mitochondrial respiration, indicating an increased energy demand. Both cells exhibited lower levels of phosphorylated mTOR (mammalian target of rapamycin) and higher autophagy flux, with KO cells exhibiting lower maximal mitochondrial respiration and reserve capacity, and higher levels of autophagy than WT cells. KO cells exhibit higher phospho-JNK (c-Jun N-terminal kinase) and phospho-c-Jun than WT cells under starvation conditions. However, inhibition of JNK activity in Sirt3-KO cells did not affect LC3-I (light chain 3-I) and LC3-II levels, indicating that Sirt3-regulated autophagy is independent of the JNK pathway. Caspase 3 activation and cell death are significantly higher in Sirt3-KO cells compared with WT cells in response to nutrient deprivation. Inhibition of autophagy by chloroquine exacerbated cell death in both WT and Sirt3-KO cells, and by 3-methyadenine exacerbated cell death in Sirt3-KO cells. These data suggest that nutrient deprivation-induced autophagy plays a protective role in cell survival, and Sirt3 decreases the requirement for enhanced autophagy and improves cellular bioenergetics.
C1 [Liang, Qiuli; Benavides, Gloria A.; Darley-Usmar, Victor; Zhang, Jianhua] Univ Alabama Birmingham, Ctr Free Rad Biol, Birmingham, AL 35294 USA.
[Liang, Qiuli; Benavides, Gloria A.; Darley-Usmar, Victor; Zhang, Jianhua] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
[Liang, Qiuli; Zhang, Jianhua] Birmingham VA Med Ctr, Dept Vet Affairs, Birmingham, AL 35233 USA.
[Vassilopoulos, Athanassios; Gius, David] Northwestern Univ, Feinberg Sch Med, Dept Radiat Oncol, Chicago, IL 60611 USA.
RP Zhang, JH (reprint author), Univ Alabama Birmingham, Ctr Free Rad Biol, Birmingham, AL 35294 USA.
EM zhanja@uab.edu
OI Zhang, Jianhua/0000-0002-2128-9574
FU National Institutes of Health [NIHR01-NS064090]; Veterans Affairs merit
award
FX This work was supported by the National Institutes of Health [grant
number NIHR01-NS064090] and a Veterans Affairs merit award (to J.Z.).
NR 52
TC 18
Z9 19
U1 0
U2 11
PU PORTLAND PRESS LTD
PI LONDON
PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND
SN 0264-6021
J9 BIOCHEM J
JI Biochem. J.
PD SEP 1
PY 2013
VL 454
BP 249
EP 257
DI 10.1042/BJ20130414
PN 2
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 202CL
UT WOS:000323191000009
PM 23767918
ER
PT J
AU Wheeler, S
Moore, K
Forsberg, CW
Riley, K
Floyd, JS
Smith, NL
Boyko, EJ
AF Wheeler, S.
Moore, K.
Forsberg, C. W.
Riley, K.
Floyd, J. S.
Smith, N. L.
Boyko, E. J.
TI Mortality among veterans with type 2 diabetes initiating metformin,
sulfonylurea or rosiglitazone monotherapy
SO DIABETOLOGIA
LA English
DT Article
DE Cohort study; Diabetes mellitus; Monotherapy; Mortality; Oral
hypoglycaemic medication; Pharmacoepidemiology; Veterans
ID ALL-CAUSE MORTALITY; ADVERSE CARDIOVASCULAR OUTCOMES; PROPENSITY SCORE
METHODS; POPULATION-BASED COHORT; MYOCARDIAL-INFARCTION;
PHARMACOLOGICAL-TREATMENT; CLINICAL-TRIALS; HEART-FAILURE; RISK;
MELLITUS
AB Despite oral hypoglycaemic medications being the most commonly used pharmacological treatments for type 2 diabetes, research is limited on their comparative safety, particularly their effects on overall mortality. We compared mortality risk with monotherapy initiation of four oral hypoglycaemic medications in a nationwide cohort of US veterans with type 2 diabetes.
We identified new users of oral hypoglycaemic medication monotherapy between 2004 and 2009 who received care for at least 1 year from the Veterans Health Administration. Patients were followed until initial monotherapy discontinuation, addition of another diabetes pharmacotherapy, death or end of follow-up. Mortality HRs were estimated using Cox regression adjusted for potential confounding factors.
Among new users of metformin, sulfonylureas and rosiglitazone (185,360 men, 7,812 women), 4,256 (2.2%) died during follow-up. Average duration of medication use ranged from 1.4 to 1.7 years. Significantly higher mortality risk was seen for glibenclamide (known as glyburide in the USA and Canada) (HR 1.38, 95% CI 1.27, 1.50) or glipizide (HR 1.55, 95% CI 1.43, 1.67) compared with metformin monotherapy, and for glipizide compared with rosiglitazone (HR 1.27, 95% CI 1.01, 1.59) or glibenclamide monotherapy (HR 1.12, 95% CI 1.02, 1.23). A significant sex-rosiglitazone interaction was seen (p = 0.034) compared with metformin monotherapy, with women having a higher HR (HR 4.36, 95% CI 1.34, 14.20) than men (HR 1.19, 95% CI 0.95, 1.49).
Significantly higher mortality was associated with glibenclamide, glipizide and rosiglitazone use compared with metformin, and with glipizide use compared with rosiglitazone or glibenclamide. The potential for residual confounding by indication should be considered in interpreting these results.
C1 [Wheeler, S.; Boyko, E. J.] VA Puget Sound Hlth Care Syst, Gen Med Serv, Seattle, WA 98108 USA.
[Moore, K.; Forsberg, C. W.; Riley, K.; Smith, N. L.; Boyko, E. J.] VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA 98108 USA.
[Floyd, J. S.] Univ Washington, Dept Med, Seattle, WA USA.
[Smith, N. L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Smith, N. L.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA.
[Boyko, E. J.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
RP Boyko, EJ (reprint author), VA Puget Sound Hlth Care Syst, 1660 South Columbian Way, Seattle, WA 98108 USA.
EM eboyko@uw.edu
RI Floyd, James/G-7563-2015
OI Boyko, Edward/0000-0002-3695-192X
FU ERIC of VA Puget Sound in Seattle; National Heart, Lung and Blood
Institute [T32 HL007902]
FX This work was supported by the ERIC of VA Puget Sound in Seattle, and by
facilities and services provided by the Diabetes Research Center
(DK-17047) at the University of Washington. VA Puget Sound Health Care
System provided support for the involvement of E. J. Boyko, N. L. Smith
and S. Wheeler in this research. J. S. Floyd was supported by National
Heart, Lung and Blood Institute training grant T32 HL007902.
NR 42
TC 18
Z9 18
U1 0
U2 11
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
J9 DIABETOLOGIA
JI Diabetologia
PD SEP
PY 2013
VL 56
IS 9
BP 1934
EP 1943
DI 10.1007/s00125-013-2958-1
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 200HV
UT WOS:000323059800011
PM 23797633
ER
PT J
AU Geng, T
Hu, W
Broadwater, MH
Snider, JM
Bielawski, J
Russo, SB
Schwacke, JH
Ross, J
Cowart, LA
AF Geng, T.
Hu, W.
Broadwater, M. H.
Snider, J. M.
Bielawski, J.
Russo, S. B.
Schwacke, J. H.
Ross, J.
Cowart, L. A.
TI Fatty acids differentially regulate insulin resistance through endoplasm
reticulum stress-mediated induction of tribbles homologue 3: a potential
link between dietary fat composition and the pathophysiological outcomes
of obesity
SO DIABETOLOGIA
LA English
DT Article
DE Animal model; Diet-induced obesity; ER stress; Insulin resistance; NEFA;
Trib3
ID COA DEHYDROGENASE-DEFICIENCY; PALMITATE-INDUCED APOPTOSIS;
SKELETAL-MUSCLE CELLS; METABOLICALLY HEALTHY; GLUCOSE-HOMEOSTASIS;
LIPID-METABOLISM; SATURATED-FAT; TRB3; ACTIVATION; CERAMIDE
AB Previous studies have shown that saturated fatty acids cause insulin resistance (IR) that is prevented by unsaturated fatty acids. Tribbles homologue 3 (TRIB3) is a putative endogenous inhibitor of insulin signalling, but its role in insulin signalling is controversial. This study aimed to determine whether fatty acids regulate IR via TRIB3.
We treated HepG2 cells with saturated and unsaturated fatty acids and evaluated TRIB3 expression. We then tested whether regulation of TRIB3 occurred through endoplasmic reticulum (ER) stress, and whether modulating TRIB3 and ER stress marker genes was necessary and/or sufficient for regulation of insulin signalling. To test the in vivo significance of this mechanism, we fed mice obesogenic diets with different fatty acid profiles and assessed physiological variables of diabetes, ER stress markers and Trib3 expression in the liver.
Our data show that fatty acids differentially regulate IR through ER stress-mediated induction of TRIB3. Intriguingly, a standard and widely used obesogenic diet high in unsaturated fats failed to induce ER stress, TRIB3 or IR. However, an alternative obesogenic diet with lower unsaturated fat recapitulated the cell studies by causing ER stress, TRIB3 induction and IR.
This study revealed a novel mechanism linking dietary fat composition to IR. Given the emerging roles for ER stress in non-alcoholic liver disease, we conclude that dietary fat composition rather than total amount may mediate hepatic pathology associated with obesity.
C1 [Geng, T.; Hu, W.; Broadwater, M. H.; Snider, J. M.; Bielawski, J.; Russo, S. B.; Schwacke, J. H.; Ross, J.; Cowart, L. A.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
[Broadwater, M. H.] NOAA, Ctr Coastal Environm Hlth & Biomol Res, Charleston, SC 29412 USA.
[Cowart, L. A.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29403 USA.
RP Cowart, LA (reprint author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave, Charleston, SC 29425 USA.
EM cowartl@musc.edu
FU VA Merit award; COBRE in Lipidomics in Pathobiology
FX This work was supported by a VA Merit award and the COBRE in Lipidomics
in Pathobiology, both to L. A. Cowart
NR 48
TC 13
Z9 15
U1 0
U2 23
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
J9 DIABETOLOGIA
JI Diabetologia
PD SEP
PY 2013
VL 56
IS 9
BP 2078
EP 2087
DI 10.1007/s00125-013-2973-2
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 200HV
UT WOS:000323059800027
PM 23820633
ER
PT J
AU Golden-Mason, L
Rosen, HR
AF Golden-Mason, Lucy
Rosen, Hugo R.
TI Natural killer cells: multifaceted players with key roles in hepatitis C
immunity
SO IMMUNOLOGICAL REVIEWS
LA English
DT Review
DE innate immunity; liver; human; interferon
ID HUMAN NK-CELLS; PLASMACYTOID-DENDRITIC-CELLS; ACTIVATED STELLATE CELLS;
INHIBITORY RECEPTOR GENES; B-ASSOCIATED TRANSCRIPT-3; VIRUS ENVELOPE
PROTEIN; INDUCED LIVER-INJURY; HLA-E EXPRESSION; COMPLEX CLASS-I;
T-CELLS
AB Natural killer cells (NKs) are involved in every stage of hepatitis C viral (HCV) infection, from protection against HCV acquisition and resolution in the acute phase to treatment-induced clearance. In addition to their direct antiviral actions, NKs are involved in the induction and priming of appropriate downstream T-cell responses. In the setting of chronic HCV, overall NK cell levels are decreased, subset distribution is altered, and changes in NK receptor (NKR) expression have been demonstrated, although the contribution of individual NKRs to viral clearance or persistence remains to be clarified. Enhanced NK cell cytotoxicity accompanied by insufficient interferon- production may promote liver damage in the setting of chronic infection. Treatment-induced clearance is associated with activation of NK cells, and it will be of interest to monitor NK cell responses to triple therapy. Activated NK cells also have anti-fibrotic properties, and the same hepatic NK cell populations that are actively involved in control of HCV may also be involved in control of HCV-associated liver damage. We still have much to learn, in particular: how do liver-derived NKs influence the outcome of HCV infection? Do NK receptors recognize HCV-specific components? And, are HCV-specific memory NK populations generated?
C1 [Golden-Mason, Lucy; Rosen, Hugo R.] UCD, Dept Med, Hepatitis Ctr C, Div Gastroenterol & Hepatol, Aurora, CO USA.
[Golden-Mason, Lucy; Rosen, Hugo R.] UCD, Integrated Program Immunol, Denver, CO USA.
[Golden-Mason, Lucy; Rosen, Hugo R.] NJH, Denver, CO USA.
[Rosen, Hugo R.] Denver VA Med Ctr, Denver, CO USA.
RP Rosen, HR (reprint author), Div GI Hepatol B 158, Acad Off Bldg 1,12631 E 17th Ave,Rm 7614,POB 6511, Aurora, CO 80045 USA.
EM hugo.rosen@ucdenver.edu
FU HCV Center Grant [U19 AI 1066328]; VA Merit Review [RO1 DK60590, RO1
DK071560]
FX This work was supported by the following grants to H. R. R.: U19 AI
1066328 (HCV Center Grant); VA Merit Review; RO1 DK60590 and RO1
DK071560. The authors declare no conflicts of interest.
NR 187
TC 27
Z9 29
U1 2
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-2896
J9 IMMUNOL REV
JI Immunol. Rev.
PD SEP
PY 2013
VL 255
IS 1
SI SI
BP 68
EP 81
DI 10.1111/imr.12090
PG 14
WC Immunology
SC Immunology
GA 201OM
UT WOS:000323150900006
PM 23947348
ER
PT J
AU Clark, RB
Cervantes, JL
Maciejewski, MW
Farrokhi, V
Nemati, R
Yao, XD
Anstadt, E
Fujiwara, M
Wright, KT
Riddle, C
La Vake, CJ
Salazar, JC
Finegold, S
Nichols, FC
AF Clark, Robert B.
Cervantes, Jorge L.
Maciejewski, Mark W.
Farrokhi, Vahid
Nemati, Reza
Yao, Xudong
Anstadt, Emily
Fujiwara, Mai
Wright, Kyle T.
Riddle, Caroline
La Vake, Carson J.
Salazar, Juan C.
Finegold, Sydney
Nichols, Frank C.
TI Serine Lipids of Porphyromonas gingivalis Are Human and Mouse Toll-Like
Receptor 2 Ligands
SO INFECTION AND IMMUNITY
LA English
DT Article
ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; BIOLOGICAL-ACTIVITIES;
MULTIPLE-SCLEROSIS; BONE LOSS; LIPOPOLYSACCHARIDE; ATHEROSCLEROSIS;
RECOGNITION; ACTIVATION; FLAVOLIPIN; FIMBRIAE
AB The total cellular lipids of Porphyromas gingivalis, a known periodontal pathogen, were previously shown to promote dendritic cell activation and inhibition of osteoblasts through engagement of Toll-like receptor 2 (TLR2). The purpose of the present investigation was to fractionate all lipids of P. gingivalis and define which lipid classes account for the TLR2 engagement, based on both in vitro human cell assays and in vivo studies in mice. Specific serine-containing lipids of P. gingivalis, called lipid 654 and lipid 430, were identified in specific high-performance liquid chromatography fractions as the TLR2-activating lipids. The structures of these lipids were defined using tandem mass spectrometry and nuclear magnetic resonance methods. In vitro, both lipid 654 and lipid 430 activated TLR2-expressing HEK cells, and this activation was inhibited by anti-TLR2 antibody. In contrast, TLR4-expressing HEK cells failed to be activated by either lipid 654 or lipid 430. Wild-type (WT) or TLR2-deficient (TLR2(-/-)) mice were injected with either lipid 654 or lipid 430, and the effects on serum levels of the chemokine CCL2 were measured 4 h later. Administration of either lipid 654 or lipid 430 to WT mice resulted in a significant increase in serum CCL2 levels; in contrast, the administration of lipid 654 or lipid 430 to TLR2(-/-) mice resulted in no increase in serum CCL2. These results thus identify a new class of TLR2 ligands that are produced by P. gingivalis that likely play a significant role in mediating inflammatory responses both at periodontal sites and, potentially, in other tissues where these lipids might accumulate.
C1 [Clark, Robert B.; Cervantes, Jorge L.; Anstadt, Emily; Fujiwara, Mai; Wright, Kyle T.; Riddle, Caroline; La Vake, Carson J.; Salazar, Juan C.] Univ Connecticut, Sch Med, Dept Pediat, Dept Immunol, Farmington, CT 06032 USA.
[Clark, Robert B.; Cervantes, Jorge L.; Anstadt, Emily; Fujiwara, Mai; Wright, Kyle T.; Riddle, Caroline; La Vake, Carson J.; Salazar, Juan C.] Univ Connecticut, Sch Med, Dept Med, Farmington, CT USA.
[Maciejewski, Mark W.] Univ Connecticut, Ctr Hlth, Dept Mol Microbial & Struct Biol, Farmington, CT USA.
[Farrokhi, Vahid; Nemati, Reza; Yao, Xudong] Univ Connecticut, Dept Chem, Storrs, CT USA.
[Finegold, Sydney] VA Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA USA.
[Nichols, Frank C.] Univ Connecticut, Sch Dent Med, Dept Oral Hlth & Diagnost Sci, Farmington, CT 06032 USA.
RP Nichols, FC (reprint author), Univ Connecticut, Sch Dent Med, Dept Oral Hlth & Diagnost Sci, Farmington, CT 06032 USA.
EM Nichols@nso.uchc.edu
FU NIH [1 R01 DE021055-01A1]; National MS Society [RG4070-A-6]; NIAID
[AI090166]
FX This work was supported by NIH 1 R01 DE021055-01A1 (F.C.N.), National MS
Society RG4070-A-6 (R.B.C.), and NIAID AI090166 (J.C.S.).
NR 53
TC 11
Z9 12
U1 0
U2 8
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD SEP
PY 2013
VL 81
IS 9
BP 3479
EP 3489
DI 10.1128/IAI.00803-13
PG 11
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 201NM
UT WOS:000323148300042
PM 23836823
ER
PT J
AU Salgado, CD
Sepkowitz, KA
John, JF
Cantey, JR
Attaway, HH
Freeman, KD
Sharpe, PA
Michels, HT
Schmidt, MG
AF Salgado, Cassandra D.
Sepkowitz, Kent A.
John, Joseph F.
Cantey, J. Robert
Attaway, Hubert H.
Freeman, Katherine D.
Sharpe, Peter A.
Michels, Harold T.
Schmidt, Michael G.
TI The Environment and Healthcare-Acquired Infections: Why Accurate
Reporting and Evaluation of Biological Plausibility Are Important Reply
SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
LA English
DT Letter
ID COPPER; SURFACES; UNIT
C1 [Salgado, Cassandra D.; Cantey, J. Robert] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
[Sepkowitz, Kent A.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA.
[John, Joseph F.] Ralph H Johnson VA, Dept Med, Charleston, SC USA.
[Attaway, Hubert H.; Schmidt, Michael G.] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA.
[Freeman, Katherine D.] Extrapolate, Delray Beach, FL USA.
[Sharpe, Peter A.] Sharpe & Associates, W Orange, NJ USA.
[Michels, Harold T.] Copper Dev Assoc, New York, NY USA.
RP Salgado, CD (reprint author), Med Univ S Carolina, Div Infect Dis, 135 Rutledge Ave, Charleston, SC 29425 USA.
EM salgado@musc.edu
NR 8
TC 1
Z9 2
U1 0
U2 1
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0899-823X
J9 INFECT CONT HOSP EP
JI Infect. Control Hosp. Epidemiol.
PD SEP 1
PY 2013
VL 34
IS 9
BP 997
EP 999
DI 10.1086/671938
PG 3
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 195LD
UT WOS:000322702900020
PM 23917920
ER
PT J
AU Fitz-Gibbon, S
Tomida, S
Chiu, BH
Nguyen, L
Du, C
Liu, MH
Elashoff, D
Erfe, MC
Loncaric, A
Kim, J
Modlin, RL
Miller, JF
Sodergren, E
Craft, N
Weinstock, GM
Li, HY
AF Fitz-Gibbon, Sorel
Tomida, Shuta
Chiu, Bor-Han
Lin Nguyen
Du, Christine
Liu, Minghsun
Elashoff, David
Erfe, Marie C.
Loncaric, Anya
Kim, Jenny
Modlin, Robert L.
Miller, Jeff F.
Sodergren, Erica
Craft, Noah
Weinstock, George M.
Li, Huiying
TI Propionibacterium acnes Strain Populations in the Human Skin Microbiome
Associated with Acne
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Article
ID STREPTOLYSIN-S; STAPHYLOCOCCUS-AUREUS; ESCHERICHIA-COLI; BODY HABITATS;
BACTERIA; SEQUENCE; STREPTOCOCCUS; RESISTANCE; DIVERSITY; GENES
AB The human skin microbiome has important roles in skin health and disease. However, bacterial population structure and diversity at the strain level is poorly understood. We compared the skin microbiome at the strain level and genome level of Propionibacterium acnes, a dominant skin commensal, between 49 acne patients and 52 healthy individuals by sampling the pilosebaceous units on their noses. Metagenomic analysis demonstrated that although the relative abundances of P. acnes were similar, the strain population structures were significantly different in the two cohorts. Certain strains were highly associated with acne, and other strains were enriched in healthy skin. By sequencing 66 previously unreported P. acnes strains and comparing 71 P. acnes genomes, we identified potential genetic determinants of various P. acnes strains in association with acne or health. Our analysis suggests that acquired DNA sequences and bacterial immune elements may have roles in determining virulence properties of P. acnes strains, and some could be future targets for therapeutic interventions. This study demonstrates a previously unreported paradigm of commensal strain populations that could explain the pathogenesis of human diseases. It underscores the importance of strain-level analysis of the human microbiome to define the role of commensals in health and disease.
C1 [Fitz-Gibbon, Sorel; Tomida, Shuta; Chiu, Bor-Han; Lin Nguyen; Du, Christine; Li, Huiying] Univ Calif Los Angeles, David Geffen Sch Med, Crump Inst Mol Imaging, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA.
[Du, Christine; Elashoff, David; Loncaric, Anya; Kim, Jenny; Modlin, Robert L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Liu, Minghsun; Modlin, Robert L.; Miller, Jeff F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA.
[Erfe, Marie C.; Craft, Noah] Univ Calif Los Angeles, David Geffen Sch Med, Harbor UCLA Med Ctr, Ctr Immunotherapeut Res,Los Angeles Biomed Res In, Los Angeles, CA 90095 USA.
[Kim, Jenny; Sodergren, Erica; Weinstock, George M.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Dermatol, Los Angeles, CA USA.
[Li, Huiying] Washington Univ, Genome Inst, St Louis, MO USA.
[Fitz-Gibbon, Sorel; Tomida, Shuta] UCLA DOE Inst Genom & Prote, Los Angeles, CA USA.
RP Li, HY (reprint author), Univ Calif Los Angeles, 4339 CNSI,570 Westwood Plaza,Bldg 114, Los Angeles, CA 90095 USA.
EM huiying@mednet.ucla.edu
OI Modlin, Robert/0000-0003-4720-031X
FU NIH [U54HG004968]; NIH/NIAMS [UH2AR057503]
FX We thank G Kasimatis, B Shi, EE Curd, R Yan, M Wong, and J Liu for
comments and technical support. We thank C Lee for performing
statistical analyses in the initial phase. We also thank Z Guo and CS
Miller for critical reading of the manuscript. This research was funded
as one of the Demonstration Projects by the NIH Human Microbiome Project
(HMP). It was supported by grant UH2AR057503 from NIH/NIAMS and grant
U54HG004968 from NIH.
NR 43
TC 106
Z9 112
U1 5
U2 78
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD SEP
PY 2013
VL 133
IS 9
BP 2152
EP 2160
DI 10.1038/jid.2013.21
PG 9
WC Dermatology
SC Dermatology
GA 202GY
UT WOS:000323203300013
PM 23337890
ER
PT J
AU Park, SH
Wang, DJJ
Duong, TQ
AF Park, Sung-Hong
Wang, Danny J. J.
Duong, Timothy Q.
TI Balanced steady state free precession for arterial spin labeling MRI:
Initial experience for blood flow mapping in human brain, retina, and
kidney
SO MAGNETIC RESONANCE IMAGING
LA English
DT Article
DE Blood flow; Arterial spin labeling; Pseudo-continuous arterial spin
labeling; Balanced steady state free precession; fMRI; Retina; Kidney
ID SINGLE-SHOT RARE; RADIO-FREQUENCY; DYNAMIC MRI; MOUSE MODEL; SSFP FMRI;
PERFUSION; RESOLUTION; INVERSION; QUANTIFICATION; QUANTITATION
AB We implemented pseudo-continuous ASL (pCASL) with 2D and 3D balanced steady state free precession (bSSFP) readout for mapping blood flow in the human brain, retina, and kidney, free of distortion and signal dropout, which are typically observed in the most commonly used echo-planar imaging acquisition. High resolution functional brain imaging in the human visual cortex was feasible with 3D bSSFP pCASL. Blood flow of the human retina could be imaged with pCASL and bSSFP in conjunction with a phase cycling approach to suppress the banding artifacts associated with bSSFP. Furthermore, bSSFP based pCASL enabled us to map renal blood flow within a single breath hold. Control and test-retest experiments suggested that the measured blood flow values in retina and kidney were reliable. Because there is no specific imaging tool for mapping human retina blood flow and the standard contrast agent technique for mapping renal blood flow can cause problems for patients with kidney dysfunction, bSSFP based pCASL may provide a useful tool for the diagnosis of retinal and renal diseases and can complement existing imaging techniques. (c) 2013 Elsevier Inc. All rights reserved.
C1 [Park, Sung-Hong] Korea Adv Inst Sci & Technol, Dept Bio & Brain Engn, Taejon 305701, South Korea.
[Park, Sung-Hong; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA.
[Wang, Danny J. J.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Park, SH (reprint author), Korea Adv Inst Sci & Technol, Dept Bio & Brain Engn, 291 Daehak Ro, Taejon 305701, South Korea.
EM sunghongpark@kaist.ac.kr; duongt@uthscsa.edu
RI Duong, Timothy/B-8525-2008; Park, Sung-Hong/B-3393-2012
OI Park, Sung-Hong/0000-0002-1731-0668
FU VA MERIT; KUSTAR-KAIST Institute; [R01 EY014211]; [R01 EY018855];
[R01 MH080892]; [R01-EB014922]; [R01 NS081077]
FX This work is supported in part by R01 EY014211, R01 EY018855, and VA
MERIT to TQD, by R01 MH080892, R01-EB014922 and R01 NS081077 to DJW, and
by KUSTAR-KAIST Institute to SHP.
NR 44
TC 15
Z9 15
U1 0
U2 18
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0730-725X
J9 MAGN RESON IMAGING
JI Magn. Reson. Imaging
PD SEP
PY 2013
VL 31
IS 7
BP 1044
EP 1050
DI 10.1016/j.mri.2013.03.024
PG 7
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 198TG
UT WOS:000322944600002
PM 23664680
ER
PT J
AU Wallace, GC
Dixon-Mah, YN
Vandergrift, WA
Ray, SK
Haar, CP
Mittendorf, AM
Patel, SJ
Banik, NL
Giglio, P
Das, A
AF Wallace, Gerald C.
Dixon-Mah, Yaenette N.
Vandergrift, W. Alex, III
Ray, Swapan K.
Haar, Catherine P.
Mittendorf, Amber M.
Patel, Sunil J.
Banik, Naren L.
Giglio, Pierre
Das, Arabinda
TI Targeting oncogenic ALK and MET: a promising therapeutic strategy for
glioblastoma
SO METABOLIC BRAIN DISEASE
LA English
DT Review
DE Glioblastoma; ALK; MET; AKT
ID ANAPLASTIC LYMPHOMA KINASE; HEPATOCYTE GROWTH-FACTOR; C-MET; MALIGNANT
GLIOMAS; TYROSINE KINASE; STEM-CELLS; RECURRENT GLIOBLASTOMA;
FACTOR/SCATTER FACTOR; TRANSCRIPTION FACTOR; GENETIC PATHWAYS
AB Glioblastoma is the most common aggressive, highly glycolytic, and lethal brain tumor. In fact, it is among the most commonly diagnosed lethal malignancies, with thousands of new cases reported in the United States each year. Glioblastoma's lethality is derived from a number of factors including highly active pro-mitotic and pro-metastatic pathways. Two factors increasingly associated with the intracellular signaling and transcriptional machinery required for such changes are anaplastic lymphoma kinase (ALK) and the hepatocyte growth factor receptor (HGFR or, more commonly MET). Both receptors are members of the receptor tyrosine kinase (RTK) family, which has itself gained much attention for its role in modulating mitosis, migration, and survival in cancer cells. ALK was first described as a vital oncogene in lymphoma studies, but it has since been connected to many carcinomas, including non-small cell lung cancer and glioblastoma. As the receptor for HGF, MET has also been highly characterized and regulates numerous developmental and wound healing events which, when upregulated in cancer, can promote tumor progression. The wealth of information gathered over the last 30 years regarding these RTKs suggests three downstream cascades that depend upon activation of STAT3, Ras, and AKT. This review outlines the significance of ALK and MET as they relate to glioblastoma, explores the significance of STAT3, Ras, and AKT downstream of ALK/MET, and touches on the potential for new chemotherapeutics targeting ALK and MET to improve glioblastoma patient prognosis.
C1 [Wallace, Gerald C.; Dixon-Mah, Yaenette N.; Vandergrift, W. Alex, III; Haar, Catherine P.; Mittendorf, Amber M.; Patel, Sunil J.; Banik, Naren L.; Giglio, Pierre; Das, Arabinda] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
[Wallace, Gerald C.; Dixon-Mah, Yaenette N.; Vandergrift, W. Alex, III; Haar, Catherine P.; Mittendorf, Amber M.; Patel, Sunil J.; Banik, Naren L.; Giglio, Pierre; Das, Arabinda] Med Univ S Carolina, MUSC Brain & Spine Tumor Program, Charleston, SC 29425 USA.
[Ray, Swapan K.] Univ S Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC 29208 USA.
[Banik, Naren L.] Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA.
RP Das, A (reprint author), Med Univ S Carolina, Dept Neurosci, 96 Jonathan Lucas St, Charleston, SC 29425 USA.
EM dasa@musc.edu
FU National Institutes of Health (NIH); National Institute of Neurological
Disorders and Stroke (NINDS) [NS31622, NS-38146, NS-57811, NS-41088];
State of South Carolina Spinal Cord Injury Research Project (SCSCIRF);
VA [1I01BX001262-01A2]; Pfizer, Inc.; Jerry Zucker Fund for Brain Tumor
Research of the MUSC Foundation
FX Completion of this project was made possible by funding from the
National Institutes of Health (NIH) and National Institute of
Neurological Disorders and Stroke (NINDS): (NS31622, NS-38146, NS-57811,
and NS-41088), the State of South Carolina Spinal Cord Injury Research
Project (SCSCIRF), VA (1I01BX001262-01A2), Pfizer, Inc., and the Jerry
Zucker Fund for Brain Tumor Research of the MUSC Foundation.
NR 92
TC 3
Z9 3
U1 1
U2 19
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0885-7490
J9 METAB BRAIN DIS
JI Metab. Brain Dis.
PD SEP
PY 2013
VL 28
IS 3
BP 355
EP 366
DI 10.1007/s11011-013-9401-7
PG 12
WC Endocrinology & Metabolism; Neurosciences
SC Endocrinology & Metabolism; Neurosciences & Neurology
GA 197XK
UT WOS:000322885700003
PM 23543207
ER
PT J
AU Bodhankar, S
Chen, YX
Vandenbark, AA
Murphy, SJ
Offner, H
AF Bodhankar, Sheetal
Chen, Yingxin
Vandenbark, Arthur A.
Murphy, Stephanie J.
Offner, Halina
TI IL-10-producing B-cells limit CNS inflammation and infarct volume in
experimental stroke
SO METABOLIC BRAIN DISEASE
LA English
DT Article
DE MCAO; Inflammatory cells; Regulatory B-cells; IL-10
ID REGULATORY T-CELLS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; ACUTE
ISCHEMIC-STROKE; MURINE EXPERIMENTAL STROKE; BRAIN-INJURY; B10 CELLS;
NEUROLOGIC DEFICITS; RAT-BRAIN; IN-VIVO; IL-10
AB Clinical stroke induces inflammatory processes leading to cerebral injury. IL-10 expression is elevated during major CNS diseases and limits inflammation in the brain. Recent evidence demonstrated that absence of B-cells led to larger infarct volumes and increased numbers of activated T-cells, monocytes and microglial cells in the brain, thus implicating a regulatory role of B-cell subpopulations in limiting CNS damage from stroke. The aim of this study was to determine whether the IL-10-producing regulatory B-cell subset can limit CNS inflammation and reduce infarct volume following ischemic stroke in B-cell deficient (mu MT-/-) mice. Five million IL-10-producing B-cells were obtained from IL-10-GFP reporter mice and transferred i.v. to mu MT(-/-)mice. After 24 h following this transfer, recipients were subjected to 60 min of middle cerebral artery occlusion (MCAO) followed by 48 h of reperfusion. Compared to vehicle-treated controls, the IL-10(+) B-cell-replenished mu MT(-/-)mice had reduced infarct volume and fewer infiltrating activated T-cells and monocytes in the affected brain hemisphere. These effects in CNS were accompanied by significant increases in regulatory T-cells and expression of the co-inhibitory receptor, PD-1, with a significant reduction in the proinflammatory milieu in the periphery. These novel observations provide the first proof of both immunoregulatory and protective functions of IL-10-secreting B-cells in MCAO that potentially could impart significant benefit for stroke patients in the clinic.
C1 [Bodhankar, Sheetal; Vandenbark, Arthur A.; Offner, Halina] Portland VA Med Ctr, VA Med Ctr, Portland, OR 97239 USA.
[Bodhankar, Sheetal; Vandenbark, Arthur A.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA.
[Vandenbark, Arthur A.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA.
[Chen, Yingxin; Murphy, Stephanie J.; Offner, Halina] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
RP Offner, H (reprint author), Portland VA Med Ctr, VA Med Ctr, R&D-31,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM offnerva@ohsu.edu
FU NIH/NINDS [1RO1 NS075887]; Department of Veterans Affairs, Veterans
Health Administration, Office of Research and Development, Biomedical
Laboratory Research and Development
FX The authors wish to thank Melissa Barber for assistance with manuscript
preparation. This work was supported by NIH/NINDS 1RO1 NS075887. This
material is based upon work supported in part by the Department of
Veterans Affairs, Veterans Health Administration, Office of Research and
Development, Biomedical Laboratory Research and Development. The
contents do not represent the views of the Department of Veterans
Affairs or the United States Government.
NR 63
TC 31
Z9 34
U1 0
U2 7
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0885-7490
J9 METAB BRAIN DIS
JI Metab. Brain Dis.
PD SEP
PY 2013
VL 28
IS 3
BP 375
EP 386
DI 10.1007/s11011-013-9413-3
PG 12
WC Endocrinology & Metabolism; Neurosciences
SC Endocrinology & Metabolism; Neurosciences & Neurology
GA 197XK
UT WOS:000322885700005
PM 23640015
ER
PT J
AU Crist, RC
Clarke, TK
Ang, A
Ambrose-Lanci, LM
Lohoff, FW
Saxon, AJ
Ling, W
Hillhouse, MP
Bruce, RD
Woody, G
Berrettini, WH
AF Crist, Richard C.
Clarke, Toni-Kim
Ang, Alfonso
Ambrose-Lanci, Lisa M.
Lohoff, Falk W.
Saxon, Andrew J.
Ling, Walter
Hillhouse, Maureen P.
Bruce, R. Douglas
Woody, George
Berrettini, Wade H.
TI An Intronic Variant in OPRD1 Predicts Treatment Outcome for Opioid
Dependence in African-Americans
SO NEUROPSYCHOPHARMACOLOGY
LA English
DT Article
DE pharmacogenetics; methadone; buprenorphine; treatment outcome
ID METHADONE-MAINTENANCE; RANDOMIZED-TRIAL; RECEPTOR GENE; ALCOHOL
DEPENDENCE; HEROIN-ADDICTION; DRUG-DEPENDENCE; RHESUS-MONKEYS;
CLINICAL-TRIAL; DELTA; BUPRENORPHINE
AB Although buprenorphine and methadone are both effective treatments for opioid dependence, their efficacy can vary significantly among patients. Genetic differences may explain some of the variability in treatment outcome. Understanding the interactions between genetic background and pharmacotherapy may result in more informed treatment decisions. This study is a pharmacogenetic analysis of the effects of genetic variants in OPRD1, the gene encoding the delta-opioid receptor, on the prevalence of opioid-positive urine tests in African-Americans (n = 77) or European-Americans (n = 566) undergoing treatment for opioid dependence. Patients were randomly assigned to treatment with either methadone or buprenorphine/naloxone (Suboxone) over a 24-week open-label clinical trial, in which illicit opioid use was measured by weekly urinalysis. In African-Americans, the intronic SNP rs678849 predicted treatment outcome for both medications. Methadone patients with the CC genotype were less likely to have opioid-positive urine tests than those in the combined CT and TT genotypes group (relative risk (RR) = 0.52, 95% confidence interval (CI) = 0.44-0.60, p = 0.001). In the buprenorphine treatment group, however, individuals with the CC genotype were more likely to have positive opioid drug screens than individuals in the combined CT and TT genotypes group (RR = 2.17, 95% CI = 1.95-2.68, p = 0.008). These findings indicate that the genotype at rs678849 predicts African-American patient response to two common treatments for opioid dependence, suggesting that matching patients to treatment type based on the genotype at this locus may improve overall treatment efficacy. This observation requires confirmation in an independent population.
C1 [Crist, Richard C.; Clarke, Toni-Kim; Ambrose-Lanci, Lisa M.; Lohoff, Falk W.; Berrettini, Wade H.] Univ Penn, Sch Med, Ctr Neurobiol & Behav, Dept Psychiat, Philadelphia, PA 19104 USA.
[Ang, Alfonso; Ling, Walter; Hillhouse, Maureen P.] Univ Calif Los Angeles, Integrated Subst Abuse Programs, Los Angeles, CA USA.
[Saxon, Andrew J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
[Bruce, R. Douglas] Yale Univ, Sch Med, New Haven, CT USA.
[Woody, George] Univ Penn, Perelman Sch Med, Treatment Res Inst, Philadelphia, PA 19104 USA.
RP Crist, RC (reprint author), Univ Penn, Sch Med, Ctr Neurobiol & Behav, Translat Res Labs,Dept Psychiat, 125 South 31st St,Room 2109, Philadelphia, PA 19104 USA.
EM crist@mail.med.upenn.edu
RI Lohoff, Falk/M-7951-2016
OI Clarke, Toni-Kim/0000-0002-7745-6351
FU Pfizer; Pamlab; Guidepoint Global LLC; Genome Canada; Genome Quebec;
Reckitt Benckiser Pharmaceuticals; Gilead Sciences; Merck Co.; Bristol
Myers Squibb; Boehringer Ingelheim; Abbott Laboratories; Pfizer, Inc.
FX Falk Lohoff received research grant support from Pfizer. Issued to
University of Pennsylvania and also scientific advisor or paid
consultant to Pamlab. Guidepoint Global LLC, Genome Canada, and Genome
Quebec. Andrew Saxon is a paid consultant to Reckitt Benckiser
Pharmaceuticals; Walter Ling is a paid consultant to Reckitt Benckiser
Pharmaceuticals; R Douglas Bruce received research grant support from
Gilead Sciences, Merck & Co., Bristol Myers Squibb, Boehringer
Ingelheim, Reckitt Benckiser Pharmaceuticals, Abbott Laboratories,
Pfizer, Inc., and honorarium from Reckitt Benckiser Pharmaceuticals; the
remaining authors declare no conflict of interest.
NR 54
TC 14
Z9 14
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0893-133X
J9 NEUROPSYCHOPHARMACOL
JI Neuropsychopharmacology
PD SEP
PY 2013
VL 38
IS 10
BP 2003
EP 2010
DI 10.1038/npp.2013.99
PG 8
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 201TI
UT WOS:000323165500019
PM 23612435
ER
PT J
AU Ovrutsky, AR
Merkel, PA
Schonteich, E
Bai, XY
Kinney, W
Iseman, MD
Kartalija, M
Knight, V
Chan, ED
AF Ovrutsky, Alida R.
Merkel, Patricia A.
Schonteich, Eric
Bai, Xiyuan
Kinney, William
Iseman, Michael D.
Kartalija, Marinka
Knight, Vijaya
Chan, Edward D.
TI Patients with non-tuberculous mycobacterial lung disease have elevated
transforming growth factor-beta following ex vivo stimulation of blood
with live Mycobacterium intracellulare
SO SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Non-tuberculous mycobacteria; Mycobacterium avium complex; Marfan
syndrome; interferon-gamma; fibrillin-1
ID INTERFERON-GAMMA; MARFANS-SYNDROME; CYTOKINE PRODUCTION; AVIUM
INFECTION; TGF-BETA; EXPRESSION; COMPLEX; ALPHA
AB We previously found that a subset of patients with pulmonary non-tuberculous mycobacterial (pNTM) disease were taller, leaner, and had a higher prevalence of pectus excavatum and scoliosis than uninfected controls. Additionally, whole blood of pNTM patients stimulated ex vivo with live Mycobacterium intracellulare produced significantly less interferon-gamma (IFN gamma) compared to that of uninfected controls. Since IFN. production can be suppressed by transforming growth factor-beta (TGF beta), an immunosuppressive cytokine, we measured basal and M. intracellulare-stimulated blood levels of TGF beta in a group of 20 pNTM patients and 20 uninfected controls. In contrast to the IFN. findings, we found that stimulated blood from pNTM patients produced significantly higher levels of TGF beta compared to controls. Since pNTM patients frequently possess body features that overlap with Marfan syndrome (MFS), and increased TGF beta expression is important in the pathogenesis of MFS, we posit that a yet-to-be-identified syndrome related to MFS predisposes certain individuals to develop pNTM disease.
C1 [Ovrutsky, Alida R.; Bai, Xiyuan; Kinney, William; Kartalija, Marinka; Chan, Edward D.] Denver Vet Affairs Med Ctr, Aurora, CO USA.
[Ovrutsky, Alida R.; Merkel, Patricia A.; Bai, Xiyuan; Kinney, William; Iseman, Michael D.; Knight, Vijaya; Chan, Edward D.] Natl Jewish Hlth, Dept Med, Aurora, CO USA.
[Ovrutsky, Alida R.; Merkel, Patricia A.; Bai, Xiyuan; Kinney, William; Iseman, Michael D.; Knight, Vijaya; Chan, Edward D.] Natl Jewish Hlth, Dept Acad Affairs, Aurora, CO USA.
[Schonteich, Eric] Natl Jewish Hlth, Complement Lab, Aurora, CO USA.
[Iseman, Michael D.; Chan, Edward D.] Univ Colorado Denver, Div Pulm Sci & Crit Care Med, Aurora, CO USA.
RP Chan, ED (reprint author), Natl Jewish Hlth, D509,Neustadt Bldg,1400 Jackson St, Denver, CO 80206 USA.
EM chane@njhealth.org
FU NCRR NIH HHS [UL1 RR025780]
NR 29
TC 4
Z9 4
U1 0
U2 3
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0036-5548
EI 1651-1980
J9 SCAND J INFECT DIS
JI Scand. J. Infect. Dis.
PD SEP
PY 2013
VL 45
IS 9
BP 711
EP 714
DI 10.3109/00365548.2013.800947
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA 202TP
UT WOS:000323242800009
PM 23808720
ER
PT J
AU Lai, A
Tran, T
Nguyen, HM
Fleischmann, J
Beenhouwer, DO
Graber, CJ
AF Lai, Andrew
Thuong Tran
Nguyen, Hien M.
Fleischmann, Jacob
Beenhouwer, David O.
Graber, Christopher J.
TI Outpatient Parenteral Antimicrobial Therapy at Large Veterans
Administration Medical Center
SO AMERICAN JOURNAL OF MANAGED CARE
LA English
DT Article
AB Objectives: To evaluate our outpatient parenteral antimicrobial therapy (OPAT) program to determine its impact on infection management in a facility notable for high patient comorbidity and a large catchment area that includes most of Southern California.
Study Design: Retrospective chart review.
Methods: We reviewed all episodes of patients receiving OPAT from our institution from 2006 through 2009 for patient utilization characteristics and assessment of complications.
Results: A total of 333 patients received 393 courses of OPAT for a mean of 21.1 days. Diabetes mellitus (53.5%), psychiatric disease (39%), and chronic kidney disease (31%) were common; more than half the patients lived more than 20 miles from our medical center. Osteomyelitis (39.7%) and bacteremia (19.3%) accounted for the majority of OPAT indications. Staphylococcus aureus (36.4%) was the most frequent infecting organism, and vancomycin (37.4%) was the most frequently prescribed medication. Complications including hospital readmission, adverse drug reactions, or line- related complications were noted in 96 of 393 (24.4%) episodes, but most were minor, reversible, or not directly related to the OPAT given. Serious line- related complications that required hospital readmission were noted in only 6 (1.5%) episodes. OPAT was completed as planned in 313 (79.6%) episodes; end-stage renal disease was associated with OPAT noncompletion in multivariable analysis (odds ratio = 2.20, P = .047). We estimated that OPAT saved our medical center $4 million per year.
Conclusions: Despite our patients' high level of comorbidity and our facility's large catchment area, we were able to deliver OPAT successfully and safely with significant cost savings.
C1 [Lai, Andrew] Huntington Hosp, Dept Med, Pasadena, CA USA.
[Thuong Tran; Fleischmann, Jacob; Beenhouwer, David O.; Graber, Christopher J.] VA Greater Los Angeles Healthcare Syst, Infect Dis Sect, 11301 Wilshire Blvd,111-F, Los Angeles, CA 90073 USA.
[Thuong Tran] VA Greater Los Angeles Healthcare Syst, Serv Pharm, Los Angeles, CA 90073 USA.
[Nguyen, Hien M.] Kaiser Permanente Northwest, Portland, OR USA.
[Fleischmann, Jacob; Beenhouwer, David O.; Graber, Christopher J.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Graber, CJ (reprint author), VA Greater Los Angeles Healthcare Syst, Infect Dis Sect, 11301 Wilshire Blvd,111-F, Los Angeles, CA 90073 USA.
EM christopher.graber@va.gov
NR 14
TC 0
Z9 0
U1 0
U2 0
PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC
PI PLAINSBORO
PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA
SN 1088-0224
J9 AM J MANAG CARE
JI Am. J. Manag. Care
PD SEP
PY 2013
VL 19
IS 9
PG 8
WC Health Care Sciences & Services; Health Policy & Services; Medicine,
General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA V44PB
UT WOS:000209759800003
ER
PT J
AU Selby, VN
Teerlink, JR
AF Selby, Van N.
Teerlink, John R.
TI What's New in the Treatment of Acute Heart Failure?
SO CURRENT CARDIOLOGY REPORTS
LA English
DT Article
DE Acute heart failure; Drug therapy; Clinical trials; Vasodilators;
Inotropes; Ultrafiltration; Diuretics; Nitroglycerin; Sodium
nitroprusside; Nesiritide; Dobutamine; Milrinone; Levosimendan;
Omecamtiv mecarbil; Serelaxin; Istaroxime; Ularitide; Cenderitide;
Aliskiren; Rolofylline; Tezosentan; Cinaciguat
ID ACUTE MYOCARDIAL-INFARCTION; NATIONAL REGISTRY ADHERE; RANDOMIZED
CONTROLLED-TRIALS; CARDIAC MYOSIN ACTIVATOR; SODIUM-NITROPRUSSIDE;
NATRIURETIC PEPTIDE; INTRAVENOUS NESIRITIDE; OMECAMTIV MECARBIL; RENAL
IMPAIRMENT; DOUBLE-BLIND
AB Acute heart failure is associated with substantial morbidity and mortality. Goals of treatment are decongestion, correction of hemodynamic abnormalities, symptom relief, and reducing long-term morbidity and mortality. Loop diuretics are a first-line agent for treatment of volume overload, with ultrafiltration reserved for those who do not respond to pharmacologic therapy. In patients with normal or elevated blood pressure, vasodilators are used to correct hemodynamics and reverse central volume redistribution, although no currently available agent has been shown to improve outcomes. Intravenous inotropes and inodilators are associated with frequent adverse effects and are reserved for patients with hypotension and evidence of inadequate perfusion. Novel drugs designed to maximize hemodynamic benefits while minimizing adverse effects are under investigation, with several agents showing promise in clinical studies.
C1 [Selby, Van N.] Univ Calif San Francisco, Div Cardiol, San Francisco, CA 94143 USA.
[Teerlink, John R.] San Francisco VA Med Ctr, Cardiol Sect, San Francisco, CA 94121 USA.
RP Teerlink, JR (reprint author), San Francisco VA Med Ctr, Cardiol Sect, 4150 Clement St,Cardiol 111C, San Francisco, CA 94121 USA.
EM john.teerlink@ucsf.edu
FU Amgen; Cytokinetics; Corthera; Novartis
FX John R. Teerlink has been consultant for Amgen, Cytokinetics, Corthera,
Novartis, and St. Jude, and has received grant support from Amgen,
Cytokinetics, Corthera, and Novartis.
NR 56
TC 5
Z9 5
U1 4
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523-3782
EI 1534-3170
J9 CURR CARDIOL REP
JI Curr. Cardiol. Rep.
PD SEP
PY 2013
VL 15
IS 9
AR 393
DI 10.1007/s11886-013-0393-z
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AT6YQ
UT WOS:000345083400002
PM 23881577
ER
PT J
AU Arnardottir, ES
Janson, C
Bjornsdottir, E
Benediktsdottir, B
Juliusson, S
Kuna, SK
Pack, AI
Gislason, T
AF Arnardottir, Erna Sif
Janson, Christer
Bjornsdottir, Erla
Benediktsdottir, Bryndis
Juliusson, Sigurdur
Kuna, Sam K.
Pack, Allan I.
Gislason, Thorarinn
TI Is frequent nocturnal sweating a symptom of obstructive sleep apnea?
SO EUROPEAN RESPIRATORY JOURNAL
LA English
DT Meeting Abstract
DE Sleep disorders; Sleep studies; Apnoea / Hypopnea
C1 [Arnardottir, Erna Sif; Bjornsdottir, Erla; Benediktsdottir, Bryndis; Gislason, Thorarinn] Landspitali, Dept Resp Med & Sleep, Reykjavik, Iceland.
[Arnardottir, Erna Sif; Bjornsdottir, Erla; Benediktsdottir, Bryndis; Gislason, Thorarinn] Univ Iceland, Fac Med, Reykjavik, Iceland.
[Arnardottir, Erna Sif; Kuna, Sam K.; Pack, Allan I.] Univ Penn, Sch Med, Dept Med, Div Sleep Med, Philadelphia, PA 19104 USA.
[Janson, Christer] Uppsala Univ, Dept Med Sci Resp Med & Allergol, Uppsala, Sweden.
[Juliusson, Sigurdur] Landspitali, Dept Otolaryngol, Reykjavik, Iceland.
[Kuna, Sam K.] Philadelphia Vet Affairs Med Ctr, Pulm Crit Care & Sleep Sect, Philadelphia, PA USA.
EM ernasif@landspitali.is; christer.janson@medsci.uu.se; erlabjo@gmail.com;
brynben@hi.is; sjul@landspitali.is; Samuel.Kuna@va.gov;
Allan.Pack@uphs.upenn.edu; thorarig@landspitali.is
NR 0
TC 0
Z9 0
U1 0
U2 0
PU EUROPEAN RESPIRATORY SOC JOURNALS LTD
PI SHEFFIELD
PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND
SN 0903-1936
EI 1399-3003
J9 EUR RESPIR J
JI Eur. Resp. J.
PD SEP 1
PY 2013
VL 42
SU 57
MA 4672
PG 1
WC Respiratory System
SC Respiratory System
GA V38VH
UT WOS:000209370403316
ER
PT J
AU Riaz, H
Riaz, I
Abir, T
Badshah, M
Milton, A
AF Riaz, Hans
Riaz, Irbaz
Abir, Tanvir
Badshah, Maaz
Milton, Abul
TI Vitamin D as a supplementary agent in the treatment of pulmonary
tuberculosis: A systematic review and meta-analysis of randomized
controlled trials
SO EUROPEAN RESPIRATORY JOURNAL
LA English
DT Meeting Abstract
DE Tuberculosis - management
C1 [Riaz, Hans] Dow Univ Hlth Sci, Internal Med, Karachi, Sindh, Pakistan.
[Riaz, Irbaz] Univ Arizona, Internal Med, Tucson, AZ USA.
[Abir, Tanvir] Univ Western Sydney, Sch Med, Sydney, NSW, Australia.
[Badshah, Maaz] Mt Sinai Sch Med, James J Peters VA Med Ctr, Internal Med, New York, NY USA.
[Milton, Abul] Univ Newcastle, Ctr Clin Epidemiol & Biostat, Newcastle, NJ USA.
EM harisriaz73@yahoo.com; sipra.irbaz@gmail.com;
abir_tanvir100@yahoo.com.au; maazbadshah501@hotmail.com;
milton.hasnat@newcastle.edu.au
NR 0
TC 0
Z9 0
U1 0
U2 0
PU EUROPEAN RESPIRATORY SOC JOURNALS LTD
PI SHEFFIELD
PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND
SN 0903-1936
EI 1399-3003
J9 EUR RESPIR J
JI Eur. Resp. J.
PD SEP 1
PY 2013
VL 42
SU 57
MA 567
PG 1
WC Respiratory System
SC Respiratory System
GA V38VH
UT WOS:000209370400438
ER
PT J
AU Akopians, AL
Rosales, M
Janzen, D
Memarzadeh, S
AF Akopians, A. L.
Rosales, M.
Janzen, D.
Memarzadeh, S.
TI DISTRIBUTION OF CD44 (CLUSTER OF DIFFERENTIATION-44) POSITIVE
ENDOMETRIAL EPITHELIAL PROGENITORS IN HUMAN ENDOMETRIOSIS
SO FERTILITY AND STERILITY
LA English
DT Meeting Abstract
CT International-Federation-of-Fertility-Societies 21st World Congress on
Fertility and Sterility / 69th Annual Meeting of the
American-Society-for-Reproductive-Medicine
CY OCT 12-17, 2013
CL Boston, MA
SP Int Federat Fertil Soc, Amer Soc Reprod Med
C1 [Akopians, A. L.; Rosales, M.; Janzen, D.; Memarzadeh, S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA.
[Memarzadeh, S.] Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, Los Angeles, CA USA.
[Memarzadeh, S.] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
EI 1556-5653
J9 FERTIL STERIL
JI Fertil. Steril.
PD SEP
PY 2013
VL 100
IS 3
SU S
MA P-745
BP S363
EP S364
PG 2
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA AQ1PY
UT WOS:000342554501520
ER
PT J
AU Orellana, G
Alvarado, L
Munoz-Neira, C
Avila, R
Mendez, MF
Slachevsky, A
AF Orellana, Gricel
Alvarado, Luis
Munoz-Neira, Carlos
Avila, Rodrigo
Mendez, Mario F.
Slachevsky, Andrea
TI Psychosis-Related Matricide Associated With a Lesion of the Ventromedial
Prefrontal Cortex
SO JOURNAL OF THE AMERICAN ACADEMY OF PSYCHIATRY AND THE LAW
LA English
DT Article
ID LATE-ONSET SCHIZOPHRENIA; PSYCHOPATHY; DELUSIONS; BRAIN;
NEUROPSYCHIATRY; CONFABULATION; VIOLATIONS; RETRIEVAL; JUDGMENT; INJURY
AB Matricide, the killing of a mother by her biological child, is a rare event. We report a case of matricide associated with a woman who sustained a right ventromedial prefrontal lesion during surgery for nasal polyposis that was performed when she was 40 years old. After her surgery, she developed psychotic symptoms associated with the emergence of antisocial behavior. She committed matricide 22 years later. Neuropsychological evaluation showed decreased frontal-executive deficits, and magnetic resonance imaging revealed a lesion in the right gyrus rectus area of the ventromedial prefrontal region. This case suggests that a secondary psychotic syndrome associated with a lesion in the frontal neural network, which is disturbed in psychopathy, could facilitate homicidal behavior. Furthermore, this case has legal implications for the prosecution of murder associated with a brain lesion.
C1 [Orellana, Gricel] Univ Chile, Fac Med, Dept Psiquiatria Oriente, Santiago, Chile.
[Alvarado, Luis] Univ Chile, Fac Ciencias Sociales, Dept Psicol, Santiago, Chile.
[Alvarado, Luis] Univ Chile, Fac Med, Dept Psiquiatria Oriente, Santiago, Chile.
[Munoz-Neira, Carlos; Slachevsky, Andrea] Hosp Salvador, Unidad Neurol Cognit & Demencias, Serv Neurol, Santiago, Chile.
[Avila, Rodrigo] Hosp Salvador, Serv Psiquiatria, Santiago, Chile.
[Mendez, Mario F.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA.
[Mendez, Mario F.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
[Mendez, Mario F.] VA Greater Los Angeles Healthcare Ctr, Los Angeles, CA USA.
[Slachevsky, Andrea] Univ Chile, Dept Neurol Oriente, Santiago, Chile.
[Slachevsky, Andrea] Univ Chile, Programa Farmacol Mol & Clin, ICBM, Fac Med, Santiago, Chile.
[Slachevsky, Andrea] Clin Alemana, Santiago, Chile.
RP Slachevsky, A (reprint author), Univ Chile, Ctr Invest Avanzada Educ, Periodista Jose Carrasco Tapia 75, Santiago, Chile.
EM aslachevsky@me.com
RI Alvarado, L./F-7134-2014
OI Alvarado, L./0000-0002-8219-9476
FU NIA NIH HHS [R01AG034499-03]
NR 42
TC 1
Z9 1
U1 4
U2 11
PU AMER ACAD PSYCHIATRY & LAW
PI BLOOMFIELD
PA ONE REGENCY DR, PO BOX 30, BLOOMFIELD, CT 06002 USA
SN 1093-6793
EI 1943-3662
J9 J AM ACAD PSYCHIATRY
JI J. Am. Acad. Psychiatry Law
PD SEP 1
PY 2013
VL 41
IS 3
BP 401
EP 406
PG 6
WC Law; Psychiatry
SC Government & Law; Psychiatry
GA AN8LT
UT WOS:000340856400010
PM 24051593
ER
PT J
AU Greysen, SR
Horwitz, LI
Covinsky, KE
Gordon, K
Ohl, ME
Justice, AC
AF Greysen, S. Ryan
Horwitz, Leora I.
Covinsky, Kenneth E.
Gordon, Kirsha
Ohl, Michael E.
Justice, Amy C.
TI Does Social Isolation Predict Hospitalization and Mortality Among HIV+
and Uninfected Older Veterans?
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE social isolation; outcomes of care; mortality; aging; hospitalization;
HIV/AIDS
ID LONG-TERM-CARE; ALCOHOL-CONSUMPTION; AFRICAN-AMERICANS; FOLLOW-UP;
ADULTS; SUPPORT; HEALTH; COHORT; WOMEN; RISK
AB Objectives
To compare levels of social isolation in aging veterans with and without the human immunodeficiency virus (HIV) and determine associations with hospital admission and mortality.
Design
Longitudinal data analysis.
Setting
The Veterans Aging Cohort Study (VACS), at eight VA Medical Centers nationally.
Participants
Veterans aged 55 and older enrolled in VACS from 2002 to 2008 (N = 1,836).
Measurements
A Social Isolation Score (SIS) was created using baseline survey responses about relationship status; number of friends and family and frequency of visits; and involvement in volunteer work, religious or self-help groups, and other community activities. Scores were compared according to age and HIV status, and multivariable regression was used to assess effects of SIS on hospital admission and all-cause mortality.
Results
Mean SIS was higher for HIV-positive (HIV+) individuals, with increasing difference according to age (P = .01 for trend). Social isolation was also more prevalent for HIV+ (59%) than uninfected participants (51%, P < .001). In multivariable regression analysis of HIV+ and uninfected groups combined, adjusted for demographic and clinical features, isolation was independently associated with greater risk of incident hospitalization (hazard rate (HR) = 1.25, 95% confidence interval (CI) = 1.09-1.42) and risk of all-cause mortality (HR=1.28, 95% CI = 1.06-1.54). Risk estimates calculated for HIV+ and uninfected groups separately were not significantly different.
Conclusion
Social isolation is associated with greater risk of hospitalization and death in HIV+ and uninfected older veterans. Despite similar effects in both groups, the population-level effect of social isolation may be greater in those who are HIV+ because of the higher prevalence of social isolation, particularly in the oldest individuals.
C1 [Greysen, S. Ryan] Univ Calif San Francisco, Div Hosp Med, San Francisco, CA 94113 USA.
[Horwitz, Leora I.; Justice, Amy C.] Yale Univ, Sch Med, Div Gen Internal Med, New Haven, CT USA.
[Covinsky, Kenneth E.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94113 USA.
[Covinsky, Kenneth E.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Gordon, Kirsha; Justice, Amy C.] W Haven Vet Affairs Med Ctr, West Haven, CT USA.
[Ohl, Michael E.] Univ Iowa, Sch Med, Div Infect Dis, Iowa City, IA 52242 USA.
RP Greysen, SR (reprint author), Univ Calif San Francisco, Div Hosp Med, 533 Parnassus Ave,Box 0131, San Francisco, CA 94113 USA.
EM Ryan.Greysen@ucsf.edu
OI Horwitz, Leora/0000-0003-1800-6040
FU Robert Wood Johnson Foundation; U.S. Department of Veterans Affairs;
National Institute on Aging [K08 AG038336]; American Federation for
Aging
FX The authors would like to thank the Robert Wood Johnson Foundation
Clinical Scholars program and U.S. Department of Veterans Affairs for
funding support. Dr. Horwitz is supported by the National Institute on
Aging (K08 AG038336) and the American Federation for Aging Research
through the Paul B. Beeson Career Development Award Program.
NR 57
TC 10
Z9 11
U1 1
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD SEP
PY 2013
VL 61
IS 9
BP 1456
EP 1463
DI 10.1111/jgs.12410
PG 8
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 216TL
UT WOS:000324307200003
PM 23927911
ER
PT J
AU Bouchard, R
Chong, T
Pugazhenthi, S
AF Bouchard, Ron
Chong, Thomas
Pugazhenthi, Subbiah
TI Laser Capture Microdissection of Neurons from Differentiated Human
Neuroprogenitor Cells in Culture
SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
DE Neuroscience; Issue 79; Neurobiology; Cellular Biology; Cells; Cultured;
Neurons; Central Nervous System; Neurodegenerative Diseases; Human
neuroprogenitor cells; neuronal differentiation; neuronal markers;
astrocytes; laser capture microdissection; PEN membrane slides; cell
culture
AB Neuroprogenitor cells (NPCs) isolated from the human fetal brain were expanded under proliferative conditions in the presence of epidermal growth factor (EGF) and fibroblast growth factor (FGF) to provide an abundant supply of cells. NPCs were differentiated in the presence of a new combination of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), dibutyryl cAMP (DBC) and retinoic acid on dishes coated with poly-L-lysine and mouse laminin to obtain neuron-rich cultures. NPCs were also differentiated in the absence of neurotrophins, DBC and retinoic acid and in the presence of ciliary neurotrophic factor (CNTF) to yield astrocyte-rich cultures. Differentiated NPCs were characterized by immunofluorescence staining for a panel of neuronal markers including NeuN, synapsin, acetylcholinesterase, synaptophysin and GAP43. Glial fibrillary acidic protein (GFAP) and STAT3, astrocyte markers, were detected in 10-15% of differentiated NPCs. To facilitate cell-type specific molecular characterization, laser capture microdissection was performed to isolate neurons cultured on polyethylene naphthalate (PEN) membrane slides. The methods described in this study provide valuable tools to advance our understanding of the molecular mechanism of neurodegeneration.
C1 [Bouchard, Ron; Chong, Thomas; Pugazhenthi, Subbiah] Denver VA Med Ctr, Endocrinol Sect, Denver, CO 80220 USA.
[Bouchard, Ron; Chong, Thomas; Pugazhenthi, Subbiah] Univ Colorado Denver Sch Med, Dept Med, Denver, CO 80204 USA.
RP Pugazhenthi, S (reprint author), Denver VA Med Ctr, Endocrinol Sect, Denver, CO 80220 USA.
EM Subbiah.Pugazhenthi@ucdenver.edu
FU Merit Review grant from the Veterans Administration [NEUD-004-07F]
FX This work was supported by Merit Review grant (NEUD-004-07F) from the
Veterans Administration (to S.P).
NR 15
TC 0
Z9 0
U1 0
U2 1
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940-087X
J9 JOVE-J VIS EXP
JI J. Vis. Exp.
PD SEP
PY 2013
IS 79
AR UNSP e50487
DI 10.3791/50487
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA V36RI
UT WOS:000209228100011
PM 24084642
ER
PT J
AU Kalapatapu, RK
Delucchi, KL
Lasher, BA
Vinogradov, S
Batki, SL
AF Kalapatapu, Raj K.
Delucchi, Kevin L.
Lasher, Brooke A.
Vinogradov, Sophia
Batki, Steven L.
TI Alcohol Use Biomarkers Predicting Cognitive Performance: A Secondary
Analysis in Veterans With Alcohol Dependence and Posttraumatic Stress
Disorder
SO MILITARY MEDICINE
LA English
DT Article
ID SUBSTANCE USE DISORDERS; GAMMA-GLUTAMYL-TRANSFERASE; LIVER-FUNCTION;
NEUROPSYCHOLOGICAL IMPAIRMENT; ABUSING PATIENTS; TREATMENT ENTRY;
DEPRESSION; ABUSERS; DICHOTOMIZATION; ABILITIES
AB Objective: We conducted a secondary analysis of baseline data from a recently completed pharmacological pilot clinical trial among 30 veterans with alcohol dependence and posttraumatic stress disorder (PTSD). This trial included baseline measures of alcohol use biomarkers, both indirect (carbohydrate-deficient transferrin, GGT [gamma-glutamyltransferase], mean corpuscular volume, AST [aspartate aminotransferase], alanine aminotransferase) and direct (ethyl glucuronide, ethyl sulfate), as well as neurocognitive measures (Trail Making Test parts A and B, Hopkins Verbal Learning Test-Revised, Balloon Analogue Risk Task, Delay Discounting Task). Methods: Two regression models were estimated and tested for each neurocognitive measure (dependent measure). The first model included the alcohol use biomarker alone as the predictor. The second model included the alcohol use biomarker along with the following 3 additional predictors: Beck Depression Inventory, Clinician-Administered PTSD Scale, and receiving medications. Results: In both models, the indirect biomarkers, such as GGT and AST, significantly predicted performance on the Hopkins Verbal Learning Test-Revised %Retention. GGT alone significantly predicted performance on the Trail Making Test part A. Conclusions: Indirect alcohol use biomarkers may have a specific role in identifying those veterans with alcohol dependence and PTSD who have impaired cognitive performance. However, direct alcohol use biomarkers may not share such a role.
C1 [Kalapatapu, Raj K.; Delucchi, Kevin L.; Vinogradov, Sophia; Batki, Steven L.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Kalapatapu, Raj K.; Lasher, Brooke A.; Vinogradov, Sophia; Batki, Steven L.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Lasher, Brooke A.; Vinogradov, Sophia; Batki, Steven L.] Northern Calif Inst Res & Educ, San Francisco, CA 94121 USA.
RP Kalapatapu, RK (reprint author), Univ Calif San Francisco, Dept Psychiat, 401 Parnassus Ave, San Francisco, CA 94143 USA.
FU Department of Defense [W81XWH-05-2-0094]; National Center for Research
Resources; National Center for Advancing Translational Sciences,
National Institutes of Health, through UCSF-CTSI [UL1 RR024131];
[K23DA034883]
FX This study was supported by the Department of Defense Grant Number
W81XWH-05-2-0094 (PI: Batki), which was given by the Northern California
Institute for Research and Education, and with resources of the Veterans
Affairs Medical Center, San Francisco, California. Dr. Kalapatapu is
currently funded by K23DA034883. This project was also supported by the
National Center for Research Resources and the National Center for
Advancing Translational Sciences, National Institutes of Health, through
UCSF-CTSI Grant Number UL1 RR024131.
NR 62
TC 2
Z9 2
U1 4
U2 10
PU ASSOC MILITARY SURG US
PI BETHESDA
PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA
SN 0026-4075
EI 1930-613X
J9 MIL MED
JI Milit. Med.
PD SEP
PY 2013
VL 178
IS 9
BP 974
EP 980
DI 10.7205/MILMED-D-13-00097
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA AN7UC
UT WOS:000340805500013
PM 24005546
ER
EF